U.S. patent application number 14/887764 was filed with the patent office on 2016-07-07 for irak inhibitors and uses thereof.
The applicant listed for this patent is Nimbus Iris, Inc.. Invention is credited to Jeremy Robert Greenwood, Geraldine C. Harriman, Rosana Kapeller-Libermann, Craig E. Masse, Shaughnessy Robinson, Donna L. Romero, Mee Shelley, Matthew David Wessel, Ronald T. Wester.
Application Number | 20160193216 14/887764 |
Document ID | / |
Family ID | 48781892 |
Filed Date | 2016-07-07 |
United States Patent
Application |
20160193216 |
Kind Code |
A1 |
Harriman; Geraldine C. ; et
al. |
July 7, 2016 |
IRAK INHIBITORS AND USES THEREOF
Abstract
The present invention provides compounds, compositions thereof,
and methods of using the same.
Inventors: |
Harriman; Geraldine C.;
(Charlestown, RI) ; Wester; Ronald T.; (Ledyard,
CT) ; Romero; Donna L.; (Chesterfield, MO) ;
Robinson; Shaughnessy; (Westerly, RI) ; Shelley;
Mee; (Tigard, OR) ; Wessel; Matthew David;
(Sisters, OR) ; Greenwood; Jeremy Robert;
(Brooklyn, NY) ; Masse; Craig E.; (Cambridge,
MA) ; Kapeller-Libermann; Rosana; (Chestnut Hill,
MA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Nimbus Iris, Inc. |
Cambridge |
MA |
US |
|
|
Family ID: |
48781892 |
Appl. No.: |
14/887764 |
Filed: |
October 20, 2015 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
13738410 |
Jan 10, 2013 |
9212190 |
|
|
14887764 |
|
|
|
|
61734133 |
Dec 6, 2012 |
|
|
|
61724695 |
Nov 9, 2012 |
|
|
|
61682637 |
Aug 13, 2012 |
|
|
|
61663227 |
Jun 22, 2012 |
|
|
|
61585194 |
Jan 10, 2012 |
|
|
|
Current U.S.
Class: |
514/210.21 ;
435/184; 514/232.8; 514/252.16; 514/267 |
Current CPC
Class: |
A61P 17/06 20180101;
A61P 7/00 20180101; A61P 31/00 20180101; Y02A 50/30 20180101; A61K
31/5377 20130101; A61P 9/04 20180101; A61P 35/02 20180101; A61P
1/18 20180101; A61P 3/00 20180101; A61P 9/10 20180101; A61P 35/00
20180101; A61P 37/02 20180101; A61P 1/16 20180101; A61P 13/10
20180101; A61P 27/06 20180101; A61P 21/02 20180101; A61P 3/04
20180101; A61P 11/00 20180101; A61P 13/08 20180101; A61P 19/06
20180101; A61P 37/00 20180101; A61P 9/00 20180101; A61P 11/06
20180101; A61P 25/14 20180101; A61P 29/00 20180101; A61P 9/12
20180101; A61P 21/04 20180101; A61P 3/10 20180101; A61P 13/02
20180101; A61P 19/02 20180101; A61P 31/12 20180101; A61P 25/04
20180101; A61P 43/00 20180101; A61P 19/00 20180101; C07D 495/04
20130101; A61P 11/02 20180101; A61P 13/12 20180101; A61P 3/06
20180101; A61P 5/00 20180101; A61P 17/14 20180101; A61K 31/4365
20130101; A61P 1/02 20180101; A61P 37/08 20180101; A61P 27/12
20180101; C07D 495/14 20130101; A61P 7/02 20180101; A61P 11/04
20180101; A61P 21/00 20180101; A61P 37/04 20180101; Y02A 50/479
20180101; A61P 1/04 20180101; A61P 25/16 20180101; A61P 25/00
20180101; A61P 25/08 20180101; A61P 15/00 20180101; A61P 17/00
20180101; A61P 37/06 20180101; A61P 27/02 20180101; A61P 27/16
20180101; A61P 25/28 20180101; A61P 27/14 20180101; A61K 31/519
20130101; A61P 7/06 20180101 |
International
Class: |
A61K 31/5377 20060101
A61K031/5377; A61K 31/519 20060101 A61K031/519 |
Claims
1-29. (canceled)
30. A method of inhibiting an IRAK protein kinase in a patient or
biological sample comprising administering to said patient, or
contacting said biological sample, with a compound or a
pharmaceutical composition thereof, wherein the compound is of
formula I: ##STR00648## or a pharmaceutically acceptable salt
thereof, wherein: Ring A is a 3-7 membered saturated or partially
unsaturated carbocyclic ring or a 4-7 membered saturated or
partially unsaturated heterocyclic ring having 1-3 heteroatoms
independently selected from nitrogen, oxygen, or sulfur; n is 0-4;
each R.sup.1 is independently --R, halogen, --CN, --NO.sub.2, --OR,
--CH.sub.2OR, --SR, --N(R).sub.2, --SO.sub.2R,
--SO.sub.2N(R).sub.2, --SOR, --C(O)R, --CO.sub.2R,
--C(O)N(R).sub.2, --C(O)N(R)--OR, --NRC(O)OR, --NRC(O)N(R).sub.2,
Cy, or --NRSO.sub.2R; or R.sup.1 is selected from one of the
following formulas: ##STR00649## two R.sup.1 groups are taken
together with their intervening atoms to form an optionally
substituted 4-7 membered fused, spiro-fused, or bridged bicyclic
ring having 0-2 heteroatoms independently selected from nitrogen,
oxygen, or sulfur; each Cy is an optionally substituted ring
selected from a 3-7 membered saturated or partially unsaturated
carbocyclic ring or a 4-7 membered saturated or partially
unsaturated heterocyclic ring having 1-3 heteroatoms independently
selected from nitrogen, oxygen, or sulfur; each R is independently
hydrogen, or an optionally substituted group selected from
C.sub.1-6 aliphatic, phenyl, 4-7 membered saturated or partially
unsaturated heterocyclic having 1-2 heteroatoms independently
selected from nitrogen, oxygen, or sulfur, or 5-6 membered
heteroaryl ring having 1-4 heteroatoms independently selected from
nitrogen, oxygen, or sulfur, or: two R groups on the same nitrogen
are taken together with their intervening atoms to form a 4-7
membered saturated, partially unsaturated, or heteroaryl ring
having 0-3 heteroatoms, in addition to the nitrogen, independently
selected from nitrogen, oxygen, or sulfur; Ring B is a 4-8 membered
partially unsaturated carbocyclic fused ring; or a 4-7 membered
partially unsaturated heterocyclic fused ring having 1-2
heteroatoms selected from nitrogen, oxygen, or sulfur; wherein said
Ring B may be optionally substituted by one or more oxo, thiono, or
imino groups; m is 1-4; p is 0-2; W is N or --C(R.sup.3)--; R.sup.z
is R, CN, NO.sub.2, halogen, --C(O)N(R).sub.2, --C(O)OR, --C(O)R,
--N(R).sub.2, --NH--[Ar], --N(R)C(O)OR, --NRC(O)N(R).sub.2, --OR,
or --SO.sub.2N(R).sub.2; [Ar] is an optionally substituted phenyl
or heteroaromatic ring: R.sup.3 is hydrogen, halogen, --CN,
C.sub.1-4 aliphatic, C.sub.1-4 haloaliphatic, --OR, --C(O)R, or
--C(O)N(R).sub.2; L.sup.1 is a covalent bond or a C.sub.1-6
bivalent hydrocarbon chain wherein one or two methylene units of
the chain are optionally and independently replaced by --NR--,
--N(R)C(O)--, --C(O)N(R)--, --N(R)SO.sub.2--, --SO.sub.2N(R)--,
--O--, --C(O)--, --OC(O)--, --C(O)O--, --S--, --SO-- or
--SO.sub.2--; each L.sup.2 is independently a covalent bond or a
C.sub.1-6 bivalent hydrocarbon chain wherein one or two methylene
units of the chain are optionally and independently replaced by
--NR--, --N(R)C(O)--, --C(O)N(R)--, --N(R)SO.sub.2--,
--SO.sub.2N(R)--, --O--, --C(O)--, --OC(O)--, --C(O)O--, --S--,
--SO-- or --SO.sub.2--; each R.sup.4 is independently halogen,
--CN, --NO.sub.2, --OR, --SR, --N(R).sub.2, --SO.sub.2R,
--SO.sub.2N(R).sub.2, --SOR, --C(O)R, --CO.sub.2R,
--C(O)N(R).sub.2, --NRC(O)R, --NRC(O)N(R).sub.2, --C(O)N(R)OR,
--N(R)C(O)OR, --N(R)S(O).sub.2N(R).sub.2, --NRSO.sub.2R, or an
optionally substituted group selected from C.sub.1-6 aliphatic,
phenyl, 4-7 membered saturated or partially unsaturated
heterocyclic having 1-2 heteroatoms independently selected from
nitrogen, oxygen, or sulfur, or 5-6 membered heteroaryl ring having
1-4 heteroatoms independently selected from nitrogen, oxygen, or
sulfur, or: two -L.sup.2(R.sup.4).sub.p--R.sup.4 groups are taken
together with their intervening atoms to form an optionally
substituted 4-7 membered fused, spiro-fused, or bridged bicyclic
ring having 0-2 heteroatoms independently selected from nitrogen,
oxygen, or sulfur; wherein said compound is not selected from the
group consisting of: ##STR00650## ##STR00651## ##STR00652##
##STR00653## ##STR00654## ##STR00655## ##STR00656## ##STR00657##
##STR00658## ##STR00659## ##STR00660## ##STR00661##
##STR00662##
31. The method of claim 30, wherein the IRAK protein kinase is an
IRAK-4 protein kinase.
32. The method of claim 30, wherein the IRAK protein kinase is an
IRAK-1 protein kinase.
33. A method of treating an IRAK-mediated disorder, disease, or
condition in a patient comprising administering to said patient a
compound, or a pharmaceutical composition thereof, wherein the
compound is of formula I: ##STR00663## or a pharmaceutically
acceptable salt thereof, wherein: Ring A is a 3-7 membered
saturated or partially unsaturated carbocyclic ring or a 4-7
membered saturated or partially unsaturated heterocyclic ring
having 1-3 heteroatoms independently selected from nitrogen,
oxygen, or sulfur; n is 0-4; each R.sup.1 is independently --R,
halogen, --CN, --NO.sub.2, --OR, --CH.sub.2OR, --SR, --N(R).sub.2,
--SO.sub.2R, --SO.sub.2N(R).sub.2, --SOR, --C(O)R, --CO.sub.2R,
--C(O)N(R).sub.2, --C(O)N(R)--OR, --NRC(O)OR, --NRC(O)N(R).sub.2,
Cy, or --NRSO.sub.2R; or R.sup.1 is selected from one of the
following formulas: ##STR00664## two R.sup.1 groups are taken
together with their intervening atoms to form an optionally
substituted 4-7 membered fused, spiro-fused, or bridged bicyclic
ring having 0-2 heteroatoms independently selected from nitrogen,
oxygen, or sulfur; each Cy is an optionally substituted ring
selected from a 3-7 membered saturated or partially unsaturated
carbocyclic ring or a 4-7 membered saturated or partially
unsaturated heterocyclic ring having 1-3 heteroatoms independently
selected from nitrogen, oxygen, or sulfur; each R is independently
hydrogen, or an optionally substituted group selected from
C.sub.1-6 aliphatic, phenyl, 4-7 membered saturated or partially
unsaturated heterocyclic having 1-2 heteroatoms independently
selected from nitrogen, oxygen, or sulfur, or 5-6 membered
heteroaryl ring having 1-4 heteroatoms independently selected from
nitrogen, oxygen, or sulfur, or: two R groups on the same nitrogen
are taken together with their intervening atoms to form a 4-7
membered saturated, partially unsaturated, or heteroaryl ring
having 0-3 heteroatoms, in addition to the nitrogen, independently
selected from nitrogen, oxygen, or sulfur; Ring B is a 4-8 membered
partially unsaturated carbocyclic fused ring; or a 4-7 membered
partially unsaturated heterocyclic fused ring having 1-2
heteroatoms selected from nitrogen, oxygen, or sulfur; wherein said
Ring B may be optionally substituted by one or more oxo, thiono, or
imino groups; m is 1-4; p is 0-2; W is N or --C(R.sup.3)--; R.sup.z
is R, CN, NO.sub.2, halogen, --C(O)N(R).sub.2, --C(O)OR, --C(O)R,
--N(R).sub.2, --NH--[Ar], --N(R)C(O)OR, --NRC(O)N(R).sub.2, --OR,
or --SO.sub.2N(R).sub.2; [Ar] is an optionally substituted phenyl
or heteroaromatic ring; R.sup.3 is hydrogen, halogen, --CN,
C.sub.1-4 aliphatic, C.sub.1-4 haloaliphatic, --OR, --C(O)R, or
--C(O)N(R).sub.2; L.sup.1 is a covalent bond or a C.sub.1-6
bivalent hydrocarbon chain wherein one or two methylene units of
the chain are optionally and independently replaced by --NR--,
--N(R)C(O)--, --C(O)N(R)--, --N(R)SO.sub.2--, --SO.sub.2N(R)--,
--O--, --C(O)--, --OC(O)--, --C(O)O--, --S--, --SO-- or
--SO.sub.2--; each L.sup.2 is independently a covalent bond or a
C.sub.1-6 bivalent hydrocarbon chain wherein one or two methylene
units of the chain are optionally and independently replaced by
--NR--, --N(R)C(O)--, --C(O)N(R)--, --N(R)S.sub.2--,
--SO.sub.2N(R)--, --O--, --C(O)--, --OC(O)--, --C(O)O--, --S--,
--SO-- or --SO.sub.2--; each R.sup.4 is independently halogen,
--CN, --NO.sub.2, --OR, --SR, --N(R).sub.2, --SO.sub.2R,
--SO.sub.2N(R).sub.2, --SOR, --C(O)R, --CO.sub.2R,
--C(O)N(R).sub.2, --NRC(O)R, --NRC(O)N(R).sub.2, --C(O)N(R)OR,
--N(R)C(O)OR, --N(R)S(O).sub.2N(R).sub.2, --NRSO.sub.2R, or an
optionally substituted group selected from C.sub.1-6 aliphatic,
phenyl, 4-7 membered saturated or partially unsaturated
heterocyclic having 1-2 heteroatoms independently selected from
nitrogen, oxygen, or sulfur, or 5-6 membered heteroaryl ring having
1-4 heteroatoms independently selected from nitrogen, oxygen, or
sulfur, or: two -L.sup.2(R.sup.4).sub.p--R.sup.4 groups are taken
together with their intervening atoms to form an optionally
substituted 4-7 membered fused, spiro-fused, or bridged bicyclic
ring having 0-2 heteroatoms independently selected from nitrogen,
oxygen, or sulfur; wherein said compound is not selected from the
group consisting of: ##STR00665## ##STR00666## ##STR00667##
##STR00668## ##STR00669## ##STR00670## ##STR00671## ##STR00672##
##STR00673## ##STR00674## ##STR00675## ##STR00676##
##STR00677##
34. The method of claim 33, wherein the IRAK-mediated disorder,
disease or condition is selected from the group consisting of a
cancer, a neurodegenerative disorder, a viral disease, an
autoimmune disease, an inflammatory disorder, a hereditary
disorder, a hormone-related disease, a metabolic disorder,
conditions associated with organ transplantation, immunodeficiency
disorders, a destructive bone disorder, a proliferative disorder,
an infectious disease, a condition associated with cell death,
thrombin-induced platelet aggregation, liver disease, pathologic
immune conditions involving T cell activation, a cardiovascular
disorder, and a CNS disorder.
35. The method of claim 34, wherein the cancer or proliferative
disorder is selected the group consisting of a benign or malignant
tumor, solid tumor, carcinoma of the brain, kidney, liver, adrenal
gland, bladder, breast, stomach, gastric tumors, ovaries, colon,
rectum, prostate, pancreas, lung, vagina, cervix, testis,
genitourinary tract, esophagus, larynx, skin, bone or thyroid,
sarcoma, glioblastomas, neuroblastomas, multiple myeloma,
gastrointestinal cancer, especially colon carcinoma or colorectal
adenoma, a tumor of the neck and head, an epidermal
hyperproliferation, psoriasis, prostate hyperplasia, a neoplasia, a
neoplasia of epithelial character, adenoma, adenocarcinoma,
keratoacanthoma, epidermoid carcinoma, large cell carcinoma,
non-small-cell lung carcinoma, lymphomas, Hodgkins and
Non-Hodgkins, a mammary carcinoma, follicular carcinoma,
undifferentiated carcinoma, papillary carcinoma, seminoma,
melanoma, an IL-1 driven disorder, an MyD88 driven disorder,
Smoldering or indolent multiple myeloma, or hematological
malignancies (including leukemia, diffuse large B-cell lymphoma
(DLBCL), ABC DLBCL, chronic lymphocytic leukemia (CLL), chronic
lymphocytic lymphoma, primary effusion lymphoma, Burkitt
lymphoma/leukemia, acute lymphocytic leukemia, B-cell
prolymphocytic leukemia, lymphoplasmacytic lymphoma, Waldenstrom's
macroglobulinemia (WM), splenic marginal zone lymphoma, multiple
myeloma, plasmacytoma, and intravascular large B-cell
lymphoma).
36. The method of claim 35, wherein the MyD88 driven disorder is
selected from the group consisting of ABC DLBCL, Waldenstrom's
macroglobulinemia, Hodgkin's lymphoma, primary cutaneous T-cell
lymphoma and chronic lymphocytic leukemia.
37. The method of claim 35, wherein the IL-1 driven disorder is
Smoldering or indolent multiple myeloma.
38. The method of claim 34, wherein the neurodegenerative disease
is selected from the group consisting of Alzheimer's disease,
Parkinson's disease, amyotrophic lateral sclerosis, Huntington's
disease, cerebral ischemia, and neurodegenerative disease caused by
traumatic injury, glutamate neurotoxicity, hypoxia, epilepsy,
treatment of diabetes, metabolic syndrome, obesity, organ
transplantation and graft versus host disease.
39. The method of claim 34, wherein the inflammatory disorder is
selected from the group consisting of conditions of the eye such as
ocular allergy, conjunctivitis, keratoconjunctivitis sicca, and
vernal conjunctivitis; diseases affecting the nose including
allergic rhinitis; and inflammatory disease in which autoimmune
reactions are implicated or having an autoimmune component or
etiology, including autoimmune hematological disorders (e.g.
hemolytic anemia, aplastic anemia, pure red cell anemia and
idiopathic thrombocytopenia), systemic lupus erythematosus,
rheumatoid arthritis, polychondritis, scleroderma, Wegener
granulamatosis, dermatomyositis, chronic active hepatitis,
myasthenia gravis, Steven-Johnson syndrome, idiopathic sprue,
autoimmune inflammatory bowel disease (e.g. ulcerative colitis and
Crohn's disease), irritable bowel syndrome, celiac disease,
periodontitis, hyaline membrane disease, kidney disease, glomerular
disease, alcoholic liver disease, multiple sclerosis, endocrine
opthalmopathy, Grave's disease, sarcoidosis, alveolitis, chronic
hypersensitivity pneumonitis, multiple sclerosis, primary biliary
cirrhosis, uveitis (anterior and posterior), Sjogren's syndrome,
keratoconjunctivitis sicca and vernal keratoconjunctivitis,
interstitial lung fibrosis, psoriatic arthritis, systemic juvenile
idiopathic arthritis, nephritis, vasculitis, diverticulitis,
interstitial cystitis, glomerulonephritis (with and without
nephrotic syndrome, e.g. including idiopathic nephrotic syndrome or
minal change nephropathy), chronic granulomatous disease,
endometriosis, leptospiriosis renal disease, glaucoma, retinal
disease, ageing, headache, pain, complex regional pain syndrome,
cardiac hypertrophy, musclewasting, catabolic disorders, obesity,
fetal growth retardation, hyperchlolesterolemia, heart disease,
chronic heart failure, mesothelioma, anhidrotic ecodermal
dysplasia, Behcet's disease, incontinentia pigmenti, Paget's
disease, pancreatitis, hereditary periodic fever syndrome, asthma
(allergic and non-allergic, mild, moderate, severe, bronchitic, and
exercise-induced), acute lung injury, acute respiratory distress
syndrome, eosinophilia, hypersensitivities, anaphylaxis, nasal
sinusitis, ocular allergy, silica induced diseases, COPD (reduction
of damage, airways inflammation, bronchial hyperreactivity,
remodeling or disease progression), pulmonary disease, cystic
fibrosis, acid-induced lung injury, pulmonary hypertension,
polyneuropathy, cataracts, muscle inflammation in conjunction with
systemic sclerosis, inclusion body myositis, myasthenia gravis,
thyroiditis, Addison's disease, lichen planus, Type 1 diabetes, or
Type 2 diabetes, appendicitis, atopic dermatitis, asthma, allergy,
blepharitis, bronchiolitis, bronchitis, bursitis, cervicitis,
cholangitis, cholecystitis, chronic graft rejection, colitis,
conjunctivitis, cystitis, dacryoadenitis, dermatitis,
dermatomyositis, encephalitis, endocarditis, endometritis,
enteritis, enterocolitis, epicondylitis, epididymitis, fasciitis,
fibrositis, gastritis, gastroenteritis, Henoch-Schonlein purpura,
hepatitis, hidradenitis suppurativa, immunoglobulin A nephropathy,
interstitial lung disease, laryngitis, mastitis, meningitis,
myelitis myocarditis, myositis, nephritis, oophoritis, orchitis,
osteitis, otitis, pancreatitis, parotitis, pericarditis,
peritonitis, pharyngitis, pleuritis, phlebitis, pneumonitis,
pneumonia, polymyositis, proctitis, prostatitis, pyelonephritis,
rhinitis, salpingitis, sinusitis, stomatitis, synovitis,
tendonitis, tonsillitis, ulcerative colitis, uveitis, vaginitis,
vasculitis, vulvitis, alopecia areata, erythema multiforma,
dermatitis herpetiformis, scleroderma, vitiligo, hypersensitivity
angiitis, urticaria, bullous pemphigoid, pemphigus vulgaris,
pemphigus foliaceus, paraneoplastic pemphigus, epidermolysis
bullosa acquisita, acute and chronic gout, chronic gouty arthritis,
psoriasis, psoriatic arthritis, rheumatoid arthritis, Juvenile
rheumatoid arthritis, Cryopyrin Associated Periodic Syndrome
(CAPS), and osteoarthritis.
40. The method of claim 30, wherein the compound is of formula II:
##STR00678## or a pharmaceutically acceptable salt thereof.
41. The method of claim 40, wherein the compound is of formula III:
##STR00679## or a pharmaceutically acceptable salt thereof.
42. The method of claim 41, wherein the compound is of formula IV:
##STR00680## or a pharmaceutically acceptable salt thereof.
43. The method of claim 42, wherein the compound is of formula V:
##STR00681## or a pharmaceutically acceptable salt thereof.
44. The method of claim 30, wherein the compound is of formulae VII
or VIII: ##STR00682## wherein each of W.sup.1, W.sup.2, X.sup.1,
X.sup.2, Y.sup.1, Y.sup.2, Z.sup.1, and Z.sup.2 are each
independently hydrogen or deuterium; or a pharmaceutically
acceptable salt thereof.
45. The method of claim 30, wherein the compound is of formula IX:
##STR00683## or a pharmaceutically acceptable salt thereof.
46. The method of claim 45, wherein the compound is of formulae X
or XI: ##STR00684## or a pharmaceutically acceptable salt
thereof.
47. The method of claim 41, wherein the compound is of formula XII:
##STR00685## or a pharmaceutically acceptable salt thereof.
48. The method of claim 47, wherein the compound is of formula
XIII: ##STR00686## or a pharmaceutically acceptable salt
thereof.
49. The method of claim 48, wherein the compound is of formula XIV:
##STR00687## or a pharmaceutically acceptable salt thereof.
50. The method of claim 49, wherein R.sup.4 is --OH or F, or a
pharmaceutically acceptable salt thereof.
51. The method of claim 41, wherein the compound is of formula
XVII: ##STR00688## or a pharmaceutically acceptable salt
thereof.
52. The method of claim 51, wherein the compound is of formula
XVIII: ##STR00689## or a pharmaceutically acceptable salt
thereof.
53. The method of claim 52, wherein the compound is of formula XIX:
##STR00690## or a pharmaceutically acceptable salt thereof.
54. The method of claim 30, wherein the compound is of formula
XXII: ##STR00691## or a pharmaceutically acceptable salt
thereof.
55. The method of claim 54, wherein the compound is of formula
XXIII: ##STR00692## or a pharmaceutically acceptable salt
thereof.
56. The method of claim 40, wherein the compound is of formula
XXIV: ##STR00693## or a pharmaceutically acceptable salt
thereof.
57. The method of claim 56, wherein the compound is of formula XXV:
##STR00694## or a pharmaceutically acceptable salt thereof.
58. The method of claim 57, wherein the compound is of formula
XXVI: ##STR00695## or a pharmaceutically acceptable salt
thereof.
59. The method of claim 30, wherein n is 1 and R.sup.1 is
--N(R).sub.2 or Cy, or a pharmaceutically acceptable salt
thereof.
60. The method of claim 30, wherein n is 1 and R.sup.1 is
morpholino, or a pharmaceutically acceptable salt thereof.
61. The method of claim 30, wherein n is 1 and R.sup.1 is
--N(CH.sub.3).sub.2, or a pharmaceutically acceptable salt
thereof.
62. The method of claim 30, wherein n is 1 and Ring A is a
1,4-trans-substituted cyclohexyl ring, or a pharmaceutically
acceptable salt thereof.
63. The method of claim 30, wherein R.sup.z is hydrogen, or a
pharmaceutically acceptable salt thereof.
64. The method of claim 30, wherein L.sup.1 is --O--, or a
pharmaceutically acceptable salt thereof.
65. The method of claim 30, wherein L.sup.1 is --NH--, or a
pharmaceutically acceptable salt thereof.
66. The method of claim 30, wherein said compound is selected from
any one of the compounds depicted in Table 1, or a pharmaceutically
acceptable salt thereof.
67. The method of claim 30, wherein a pharmaceutical composition
comprising the compound and a pharmaceutically acceptable carrier,
adjuvant, or vehicle is administered to the patient.
68. The method of claim 33, wherein the compound is of formula II:
##STR00696## or a pharmaceutically acceptable salt thereof.
69. The method of claim 68, wherein the compound is of formula III:
##STR00697## or a pharmaceutically acceptable salt thereof.
70. The method of claim 69, wherein the compound is of formula IV:
##STR00698## or a pharmaceutically acceptable salt thereof.
71. The method of claim 70, wherein the compound is of formula V:
##STR00699## or a pharmaceutically acceptable salt thereof.
72. The method of claim 33, wherein the compound is of formulae VII
or VIII: ##STR00700## wherein each of W.sup.1, W.sup.2, X.sup.1,
X.sup.2, Y.sup.1, Y.sup.2, Z.sup.1, and Z.sup.2 are each
independently hydrogen or deuterium; or a pharmaceutically
acceptable salt thereof.
73. The method of claim 33, wherein the compound is of formula IX:
##STR00701## or a pharmaceutically acceptable salt thereof.
74. The method of claim 73, wherein the compound is of formulae X
or XI: ##STR00702## or a pharmaceutically acceptable salt
thereof.
75. The method of claim 69, wherein the compound is of formula XII:
##STR00703## or a pharmaceutically acceptable salt thereof.
76. The method of claim 75, wherein the compound is of formula
XIII: ##STR00704## or a pharmaceutically acceptable salt
thereof.
77. The method of claim 76, wherein the compound is of formula XIV:
##STR00705## or a pharmaceutically acceptable salt thereof.
78. The method of claim 77, wherein R.sup.4 is --OH or F, or a
pharmaceutically acceptable salt thereof.
79. The method of claim 69, wherein the compound is of formula
XVII: ##STR00706## or a pharmaceutically acceptable salt
thereof.
80. The method of claim 79, wherein the compound is of formula
XVIII: ##STR00707## or a pharmaceutically acceptable salt
thereof.
81. The method of claim 80, wherein the compound is of formula XIX:
##STR00708## or a pharmaceutically acceptable salt thereof.
82. The method of claim 33, wherein the compound is of formula
XXII: ##STR00709## or a pharmaceutically acceptable salt
thereof.
83. The method of claim 82, wherein the compound is of formula
XXIII: ##STR00710## or a pharmaceutically acceptable salt
thereof.
84. The method of claim 68, wherein the compound is of formula
XXIV: ##STR00711## or a pharmaceutically acceptable salt
thereof.
85. The method of claim 84, wherein the compound is of formula XXV:
##STR00712## or a pharmaceutically acceptable salt thereof.
86. The method of claim 85, wherein the compound is of formula
XXVI: ##STR00713## or a pharmaceutically acceptable salt
thereof.
87. The method of claim 33, wherein n is 1 and R.sup.1 is
--N(R).sub.2 or Cy, or a pharmaceutically acceptable salt
thereof.
88. The method of claim 33, wherein n is 1 and R.sup.1 is
morpholino, or a pharmaceutically acceptable salt thereof.
89. The method of claim 33, wherein n is 1 and R.sup.1 is
--N(CH.sub.3).sub.2, or a pharmaceutically acceptable salt
thereof.
90. The method of claim 33, wherein n is 1 and Ring A is a
1,4-trans-substituted cyclohexyl ring, or a pharmaceutically
acceptable salt thereof.
91. The method of claim 33, wherein R.sup.z is hydrogen, or a
pharmaceutically acceptable salt thereof.
92. The method of claim 33, wherein L.sup.1 is --O--, or a
pharmaceutically acceptable salt thereof.
93. The method of claim 33, wherein L.sup.1 is --NH--, or a
pharmaceutically acceptable salt thereof.
94. The method of claim 33, wherein said compound is selected from
any one of the compounds depicted in Table 1, or a pharmaceutically
acceptable salt thereof.
95. The method of claim 33, wherein a pharmaceutical composition
comprising the compound and a pharmaceutically acceptable carrier,
adjuvant, or vehicle is administered to the patient.
Description
TECHNICAL FIELD OF THE INVENTION
[0001] The present invention relates to compounds and methods
useful for inhibiting one or more interleukin-1 receptor-associated
kinases ("IRAK"). The invention also provides pharmaceutically
acceptable compositions comprising compounds of the present
invention and methods of using said compositions in the treatment
of various disorders.
BACKGROUND OF THE INVENTION
[0002] The search for new therapeutic agents has been greatly aided
in recent years by a better understanding of the structure of
enzymes and other biomolecules associated with diseases. One
important class of enzymes that has been the subject of extensive
study is the protein kinase family.
[0003] Protein kinases constitute a large family of structurally
related enzymes that are responsible for the control of a variety
of signal transduction processes within the cell. Protein kinases
are thought to have evolved from a common ancestral gene due to the
conservation of their structure and catalytic function. Almost all
kinases contain a similar 250-300 amino acid catalytic domain. The
kinases may be categorized into families by the substrates they
phosphorylate (e.g., protein-tyrosine, protein-serine/threonine,
lipids, etc.).
[0004] In general, protein kinases mediate intracellular signaling
by effecting a phosphoryl transfer from a nucleoside triphosphate
to a protein acceptor that is involved in a signaling pathway.
These phosphorylation events act as molecular on/off switches that
can modulate or regulate the target protein biological function.
These phosphorylation events are ultimately triggered in response
to a variety of extracellular and other stimuli. Examples of such
stimuli include environmental and chemical stress signals (e.g.,
osmotic shock, heat shock, ultraviolet radiation, bacterial
endotoxin, and H.sub.2O.sub.2), cytokines (e.g., interleukin-1
(IL-1), interleukin-8 (IL-8) and tumor necrosis factor .alpha.
(TNF-.alpha.)), and growth factors (e.g., granulocyte
macrophage-colony-stimulating factor (GM-CSF), and fibroblast
growth factor (FGF)). An extracellular stimulus may affect one or
more cellular responses related to cell growth, migration,
differentiation, secretion of hormones, activation of transcription
factors, muscle contraction, glucose metabolism, control of protein
synthesis, and regulation of the cell cycle.
[0005] Many diseases are associated with abnormal cellular
responses triggered by kinase-mediated events. These diseases
include, but are not limited to, autoimmune diseases, inflammatory
diseases, bone diseases, metabolic diseases, neurological and
neurodegenerative diseases, cancer, cardiovascular diseases,
allergies and asthma, Alzheimer's disease, and hormone-related
diseases. Accordingly, there remains a need to find protein kinase
inhibitors useful as therapeutic agents.
SUMMARY OF THE INVENTION
[0006] It has now been found that compounds of this invention, and
pharmaceutically acceptable compositions thereof, are effective as
inhibitors of IRAK kinases. Such compounds have the general formula
I:
##STR00001##
or a pharmaceutically acceptable salt thereof, wherein each
variable is as defined and described herein.
[0007] Compounds of the present invention, and pharmaceutically
acceptable compositions thereof, are useful for treating a variety
of diseases, disorders or conditions, associated with regulation of
signaling pathways implicating IRAK kinases. Such diseases,
disorders, or conditions include those described herein.
[0008] Compounds provided by this invention are also useful for the
study of IRAK enzymes in biological and pathological phenomena; the
study of intracellular signal transduction pathways occurring in
bodily tissues; and the comparative evaluation of new IRAK
inhibitors or other regulators of kinases, signaling pathways, and
cytokine levels in vitro or in vivo.
BRIEF DESCRIPTION OF THE DRAWINGS
[0009] FIG. 1A depicts the results of the cell proliferation assay
for the negative control and compound I-73.
[0010] FIG. 1B depicts the results of the cell proliferation assay
for compounds I-74 and I-92.
[0011] FIG. 2 depicts the results of the cell proliferation assay
for compound I-67 against various DLBCL cell lines.
[0012] FIG. 3 depicts the results of the cell proliferation assay
for compound I-73 against various DLBCL cell lines.
[0013] FIG. 4 depicts the results of the cell proliferation assay
for compound I-92 against various DLBCL cell lines.
[0014] FIG. 5 depicts the results of the cell proliferation assay
for compound I-74 against various DLBCL cell lines.
[0015] FIG. 6 depicts the results of the NFkB Inhibition Assay for
compounds I-67, I-73. I-74, and I-92 in HBL1 cells.
[0016] FIG. 7 depicts the results of the Inhibition of
I.kappa.B.alpha. Phosphorylation and Degradation assay for
compounds I-67, I-73, I-74, and I-92.
[0017] FIG. 8 depicts the sensitization of ABC DLBCL Cells to IRAK
Inhibitors by BTK knockdown.
[0018] FIG. 9 depicts the sensitization of ABC DLBCL Cells to
compounds I-67 and I-92 by BTK knockdown.
[0019] FIG. 10 depicts the lack of sensitization of GCB DLBCL Cells
to compounds I-67 and I-92 by BTK Knockdown.
[0020] FIG. 11 depicts results of an in vivo murine IMQ-induced
psoriasis study. Representative mice were photographed to show the
degree of skin scaling. Compounds I-67 or I-92 were administered at
doses of 3, 10 and 30 mg/kg.
[0021] FIG. 12 depicts results of an in vivo murine IMQ-induced
psoriasis study. Mice were scored daily and the average scores of
mice dosed at 30 mg/kg with either I-67 or I-92 are shown for days
5, 8 and 10.
[0022] FIG. 13 depicts results of an in vivo murine air pouch model
of MSU-induced gout. The number of white blood cells in air pouch
exudate were measured in rats treated with I-67 twice a day at
doses of 10, 30 or 100 mg/kg for six days.
[0023] FIG. 14A depicts results of an in vivo murine
collagen-induced arthritis model for the groups dosed
intraperitoneally (IP) with I-67 or I-92 at 30 mg/kg twice a day
and the group dosed intraperitoneally with dexamethasone at 0.1
mg/kg twice a day. The left panel shows the average clinical scores
for each group of mice up to day 11. The middle panel shows the
average clinical scores calculated as the area under the curve, and
% inhibition relative to the vehicle is indicated in the bar graph.
The right panel shows the average body weight changes from day 1 to
day 11. FIG. 14B depicts the results of an in vivo murine
collagen-induced arthritis model for groups dosed orally (PO) with
I-67 at 30 mg/kg either once a day (QD) or twice a day (BID). The
left panel shows the average clinical scores for each group of mice
up to day 11. The middle panel shows the average clinical scores
calculated as the area under the curve, and % inhibition relative
to the vehicle is indicated in the bar graph. The right panel shows
the average body weight changes from day 1 to day 11.
[0024] FIG. 15 depicts a western blot of the indicated proteins in
HBL1 cells treated with vector alone, wild-type MyD88, mutant
MyD88-L265P with DMSO, mutant MyD88-L265P with a negative control
(5 .mu.m), mutant MyD88-L265P with either 5 .mu.m or 2.5 .mu.m I-67
and mutant MyD88-L265P with either 5 .mu.m or 2.5 .mu.m I-92.
[0025] FIG. 16 depicts results of an NF-.kappa..beta. activity
inhibition assay. ABC DLBCL and GCB DLBCL cell lines were created
with an NF-.kappa..beta. transcriptional reporter by transduction
with lentiviral particles containing an inducible NF-4-responsive
luciferase reporter construct following the method of Staudt et al.
(2012) and Ngo et al. (2011). Luciferase activity was then
measured.
[0026] FIG. 17 depicts results of a cytokine secretion inhibition
assay. Cells transduced with inducible shRNAs were placed in medium
containing doxycycline and the concentrations of IL-6 and IL-10
were measured by ELISA, following the method of Ngo et al. (2011).
Alternatively, unmanipulated lymphoma cells were placed into fresh
media with the addition of I-67 or I-92 and assessed for cytokines
as above.
[0027] FIG. 18A depicts the effects on tumor growth of treatment
with either vehicle alone or I-92 in an in vivo murine xenograft
tumor model of human ABC DLBCL lymphoma. Tumor growth was monitored
by measuring tumor size in two orthogonal dimensions. The tumor
volume was calculated by using the formula (1/2)(long
dimension).times.(short dimension).sup.2.
[0028] FIG. 18B depicts the effects on animal weight of treatment
with either vehicle alone or I-92 in an in vivo murine xenograft
tumor model of human ABC DLBCL lymphoma.
[0029] FIG. 19 depicts the viability of ABC DLBCL cell lines
treated at the concentrations indicated with ibrutinib, I-67, I-92
or a combination of ibrutinib with either I-67 or I-92. Assay
conditions were as reported in Staudt et al. (2012). Ibrutinib is
shown in closed circles; I-67 in upper panels is shown in closed
squares; I-92 in lower panels is shown in closed squares; combined
I-67 (upper panel) and I-92 (lower panel) treatments at a constant
ibrutinib concentration of 0.5 nM are shown in closed
triangles.
DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS
1. General Description of Certain Embodiments of the Invention
[0030] Compounds of the present invention, and compositions
thereof, are useful as inhibitors of one or more IRAK protein
kinases. In some embodiments, a provided compound inhibits IRAK-1
and IRAK-4.
[0031] The binding pocket of IRAK-4 contains a plurality of
hydration sites, each of which is occupied by a single molecule of
water. Each of these water molecules has a stability rating
associated with it. As used herein, the term "stability rating"
refers to a numerical calculation which incorporates the enthalpy,
entropy, and free energy values associated with each water
molecule. This stability rating allows for a measurable
determination of the relative stability of water molecules that
occupy hydration sites in the binding pocket of IRAK-4.
[0032] Water molecules occupying hydration sites in the binding
pocket of IRAK-4 having a stability rating of >2.5 kcal/mol are
referred to as "unstable waters."
[0033] Without wishing to be bound by any particular theory, it is
believed that displacement or disruption of an unstable water
molecule (i.e., a water molecule having a stability rating of
>2.5 kcal/mol), or replacement of a stable water (i.e., a water
molecule having a stability rating of <1 kcal/mol), by an
inhibitor results in tighter binding of that inhibitor.
Accordingly, inhibitors designed to displace one or more unstable
water molecules (i.e., those unstable water molecules not displaced
by any known inhibitor) will be a tighter binder and, therefore,
more potent inhibitor as compared to an inhibitor that does not
displace unstable water molecules.
[0034] It was surprisingly found that provided compounds displace
or disrupt one or more unstable water molecules. In some
embodiments, a provided compound displaces or disrupts at least two
unstable water molecules.
[0035] In certain embodiments, the present invention provides a
compound of formula I:
##STR00002##
or a pharmaceutically acceptable salt thereof, wherein: [0036] Ring
A is a 3-7 membered saturated or partially unsaturated carbocyclic
ring or a 4-7 membered saturated or partially unsaturated
heterocyclic ring having 1-3 heteroatoms independently selected
from nitrogen, oxygen, or sulfur; [0037] n is 0-4; [0038] each
R.sup.1 is independently --R, halogen, --CN, --NO.sub.2, --OR,
--CH.sub.2OR, --SR, --N(R).sub.2, --SO.sub.2R,
--SO.sub.2N(R).sub.2, --SOR, --C(O)R, --CO.sub.2R,
--C(O)N(R).sub.2, --C(O)N(R)--OR, --NRC(O)OR, --NRC(O)N(R).sub.2,
Cy, or --NRSO.sub.2R; or R.sup.1 is selected from one of the
following formulas:
##STR00003##
[0038] or [0039] two R.sup.1 groups are taken together with their
intervening atoms to form an optionally substituted 4-7 membered
fused, spiro-fused, or bridged bicyclic ring having 0-2 heteroatoms
independently selected from nitrogen, oxygen, or sulfur; [0040]
each Cy is an optionally substituted ring selected from a 3-7
membered saturated or partially unsaturated carbocyclic ring or a
4-7 membered saturated or partially unsaturated heterocyclic ring
having 1-3 heteroatoms independently selected from nitrogen,
oxygen, or sulfur; [0041] each R is independently hydrogen, or an
optionally substituted group selected from C.sub.1-6 aliphatic,
phenyl, 4-7 membered saturated or partially unsaturated
heterocyclic having 1-2 heteroatoms independently selected from
nitrogen, oxygen, or sulfur, or 5-6 membered heteroaryl ring having
1-4 heteroatoms independently selected from nitrogen, oxygen, or
sulfur, or: [0042] two R groups on the same nitrogen are taken
together with their intervening atoms to form a 4-7 membered
saturated, partially unsaturated, or heteroaryl ring having 0-3
heteroatoms, in addition to the nitrogen, independently selected
from nitrogen, oxygen, or sulfur; [0043] Ring B is a 4-8 membered
partially unsaturated carbocyclic fused ring; or a 4-7 membered
partially unsaturated heterocyclic fused ring having 1-2
heteroatoms selected from nitrogen, oxygen, or sulfur; wherein said
Ring B may be optionally substituted by one or more oxo, thiono, or
imino groups; [0044] m is 1-4; [0045] p is 0-2; [0046] W is N or
C(R.sup.3)--; [0047] R.sup.z is R, CN, NO.sup.2, halogen,
--C(O)N(R).sub.2, --C(O)OR, --C(O)R, --N(R).sub.2, --NH--[Ar],
--N(R)C(O)OR, --NRC(O)N(R).sub.2, --OR, or --SO.sup.2N(R).sub.2;
[0048] R.sup.3 is hydrogen, halogen, --CN, C.sub.1-4 aliphatic,
C.sub.1-4 haloaliphatic, --OR, --C(O)R, or C(O)N(R).sub.2; [0049]
[Ar] is an optionally substituted phenyl or heteroaromatic ring;
[0050] L.sup.1 is a covalent bond or a C.sub.1-6 bivalent
hydrocarbon chain wherein one or two methylene units of the chain
are optionally and independently replaced by --NR--, --N(R)C(O)--,
--C(O)N(R)--, --N(R)SO.sub.2--, --SO.sub.2N(R)--, --O--, --C(O)--,
--OC(O)--, --C(O)O--, --S--, --SO-- or --SO.sub.2--; [0051] each
L.sup.2 is independently a covalent bond or a C.sub.1-6 bivalent
hydrocarbon chain wherein one or two methylene units of the chain
are optionally and independently replaced by --NR--, --N(R)C(O)--,
--C(O)N(R)--, --N(R)SO.sub.2--, --SO.sub.2N(R)--, --O--, --C(O)--,
--OC(O)--, --C(O)O--, --S--, --SO-- or --SO.sub.2--; [0052] each
R.sup.4 is independently halogen, --CN, --NO.sub.2, --OR, --SR,
--N(R).sub.2, --SO.sub.2R, --SO.sub.2N(R).sub.2, --SOR, --C(O)R,
--CO.sub.2R, C(O)N(R).sub.2, --NRC(O)R, --NRC(O)N(R).sub.2,
--C(O)N(R)OR, --N(R)C(O)OR, --N(R)S(O).sub.2N(R).sub.2,
--NRSO.sub.2R, or an optionally substituted group selected from
C.sub.1-6 aliphatic, phenyl, 4-7 membered saturated or partially
unsaturated heterocyclic having 1-2 heteroatoms independently
selected from nitrogen, oxygen, or sulfur, or 5-6 membered
heteroaryl ring having 1-4 heteroatoms independently selected from
nitrogen, oxygen, or sulfur, or: [0053] two
-L.sup.2(R.sup.4).sub.p--R.sup.4 groups are taken together with
their intervening atoms to form an optionally substituted 4-7
membered fused, spiro-fused, or bridged bicyclic ring having 0-2
heteroatoms independently selected from nitrogen, oxygen, or
sulfur.
2. Compounds and Definitions
[0054] Compounds of the present invention include those described
generally herein, and are further illustrated by the classes,
subclasses, and species disclosed herein. As used herein, the
following definitions shall apply unless otherwise indicated. For
purposes of this invention, the chemical elements are identified in
accordance with the Periodic Table of the Elements, CAS version,
Handbook of Chemistry and Physics, 75.sup.th Ed. Additionally,
general principles of organic chemistry are described in "Organic
Chemistry", Thomas Sorrell, University Science Books, Sausalito:
1999, and "March's Advanced Organic Chemistry", 5.sup.th Ed., Ed.:
Smith, M. B. and March, J., John Wiley & Sons, New York: 2001,
the entire contents of which are hereby incorporated by
reference.
[0055] The term "aliphatic" or "aliphatic group", as used herein,
means a straight-chain (i.e., unbranched) or branched, substituted
or unsubstituted hydrocarbon chain that is completely saturated or
that contains one or more units of unsaturation, or a monocyclic
hydrocarbon or bicyclic hydrocarbon that is completely saturated or
that contains one or more units of unsaturation, but which is not
aromatic (also referred to herein as "carbocycle," "cycloaliphatic"
or "cycloalkyl"), that has a single point of attachment to the rest
of the molecule. Unless otherwise specified, aliphatic groups
contain 1-6 aliphatic carbon atoms. In some embodiments, aliphatic
groups contain 1-5 aliphatic carbon atoms. In other embodiments,
aliphatic groups contain 1-4 aliphatic carbon atoms. In still other
embodiments, aliphatic groups contain 1-3 aliphatic carbon atoms,
and in yet other embodiments, aliphatic groups contain 1-2
aliphatic carbon atoms. In some embodiments, "cycloaliphatic" (or
"carbocycle" or "cycloalkyl") refers to a monocyclic
C.sub.3-C.sub.6 hydrocarbon that is completely saturated or that
contains one or more units of unsaturation, but which is not
aromatic, that has a single point of attachment to the rest of the
molecule. Suitable aliphatic groups include, but are not limited
to, linear or branched, substituted or unsubstituted alkyl,
alkenyl, alkynyl groups and hybrids thereof such as
(cycloalkyl)alkyl, (cycloalkenyl)alkyl or (cycloalkyl)alkenyl.
[0056] As used herein, the term "bridged bicyclic" refers to any
bicyclic ring system, i.e. carbocyclic or heterocyclic, saturated
or partially unsaturated, having at least one bridge. As defined by
IUPAC, a "bridge" is an unbranched chain of atoms or an atom or a
valence bond connecting two bridgeheads, where a "bridgehead" is
any skeletal atom of the ring system which is bonded to three or
more skeletal atoms (excluding hydrogen). In some embodiments, a
bridged bicyclic group has 7-12 ring members and 0-4 heteroatoms
independently selected from nitrogen, oxygen, or sulfur. Such
bridged bicyclic groups are well known in the art and include those
groups set forth below where each group is attached to the rest of
the molecule at any substitutable carbon or nitrogen atom. Unless
otherwise specified, a bridged bicyclic group is optionally
substituted with one or more substituents as set forth for
aliphatic groups. Additionally or alternatively, any substitutable
nitrogen of a bridged bicyclic group is optionally substituted.
Exemplary bridged bicyclics include:
##STR00004##
[0057] The term "lower alkyl" refers to a C.sub.1-4 straight or
branched alkyl group. Exemplary lower alkyl groups are methyl,
ethyl, propyl, isopropyl, butyl, isobutyl, and tert-butyl.
[0058] The term "lower haloalkyl" refers to a C.sub.1-4 straight or
branched alkyl group that is substituted with one or more halogen
atoms.
[0059] The term "heteroatom" means one or more of oxygen, sulfur,
nitrogen, phosphorus, or silicon (including, any oxidized form of
nitrogen, sulfur, phosphorus, or silicon; the quaternized form of
any basic nitrogen or; a substitutable nitrogen of a heterocyclic
ring, for example N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in
pyrrolidinyl) or NR.sup.+ (as in N-substituted pyrrolidinyl)).
[0060] The term "unsaturated," as used herein, means that a moiety
has one or more units of unsaturation.
[0061] As used herein, the term "bivalent C.sub.1-8 (or C.sub.1-6)
saturated or unsaturated, straight or branched, hydrocarbon chain",
refers to bivalent alkylene, alkenylene, and alkynylene chains that
are straight or branched as defined herein.
[0062] The term "alkylene" refers to a bivalent alkyl group. An
"alkylene chain" is a polymethylene group, i.e.,
--(CH.sub.2).sub.n--, wherein n is a positive integer, preferably
from 1 to 6, from 1 to 4, from 1 to 3, from 1 to 2, or from 2 to 3.
A substituted alkylene chain is a polymethylene group in which one
or more methylene hydrogen atoms are replaced with a substituent.
Suitable substituents include those described below for a
substituted aliphatic group.
[0063] The term "alkenylene" refers to a bivalent alkenyl group. A
substituted alkenylene chain is a polymethylene group containing at
least one double bond in which one or more hydrogen atoms are
replaced with a substituent. Suitable substituents include those
described below for a substituted aliphatic group.
[0064] As used herein, the term "cyclopropylenyl" refers to a
bivalent cyclopropyl group of the following structure:
##STR00005##
[0065] The term "halogen" means F, Cl, Br, or I.
[0066] The term "aryl" used alone or as part of a larger moiety as
in "aralkyl," "aralkoxy," or "aryloxyalkyl," refers to monocyclic
or bicyclic ring systems having a total of five to fourteen ring
members, wherein at least one ring in the system is aromatic and
wherein each ring in the system contains 3 to 7 ring members. The
term "aryl" may be used interchangeably with the term "aryl ring."
In certain embodiments of the present invention, "aryl" refers to
an aromatic ring system which includes, but not limited to, phenyl,
biphenyl, naphthyl, anthracyl and the like, which may bear one or
more substituents. Also included within the scope of the term
"aryl," as it is used herein, is a group in which an aromatic ring
is fused to one or more nonaromatic rings, such as indanyl,
phthalimidyl, naphthimidyl, phenanthridinyl, or tetrahydronaphthyl,
and the like.
[0067] The terms "heteroaryl" and "heteroar-," used alone or as
part of a larger moiety, e.g., "heteroaralkyl," or
"heteroaralkoxy," refer to groups having 5 to 10 ring atoms,
preferably 5, 6, or 9 ring atoms; having 6, 10, or 14 .pi.
electrons shared in a cyclic array; and having, in addition to
carbon atoms, from one to five heteroatoms. The term "heteroatom"
refers to nitrogen, oxygen, or sulfur, and includes any oxidized
form of nitrogen or sulfur, and any quaternized form of a basic
nitrogen. Heteroaryl groups include, without limitation, thienyl,
furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl,
oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl,
thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl,
indolizinyl, purinyl, naphthyridinyl, and pteridinyl. The terms
"heteroaryl" and "heteroar-", as used herein, also include groups
in which a heteroaromatic ring is fused to one or more aryl,
cycloaliphatic, or heterocyclyl rings, where the radical or point
of attachment is on the heteroaromatic ring. Nonlimiting examples
include indolyl, isoindolyl, benzothienyl, benzofuranyl,
dibenzofuranyl, indazolyl, benzimidazolyl, benzthiazolyl, quinolyl,
isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl,
4H-quinolizinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl,
phenoxazinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and
pyrido[2,3-b]-1,4-oxazin-3(4H)-one. A heteroaryl group may be mono-
or bicyclic. The term "heteroaryl" may be used interchangeably with
the terms "heteroaryl ring," "heteroaryl group," or
"heteroaromatic," any of which terms include rings that are
optionally substituted. The term "heteroaralkyl" refers to an alkyl
group substituted by a heteroaryl, wherein the alkyl and heteroaryl
portions independently are optionally substituted.
[0068] As used herein, the terms "heterocycle," "heterocyclyl,"
"heterocyclic radical," and "heterocyclic ring" are used
interchangeably and refer to a stable 5- to 7-membered monocyclic
or 7-10-membered bicyclic heterocyclic moiety that is either
saturated or partially unsaturated, and having, in addition to
carbon atoms, one or more, preferably one to four, heteroatoms, as
defined above. When used in reference to a ring atom of a
heterocycle, the term "nitrogen" includes a substituted nitrogen.
As an example, in a saturated or partially unsaturated ring having
0-3 heteroatoms selected from oxygen, sulfur or nitrogen, the
nitrogen may be N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in
pyrrolidinyl), or +NR (as in N-substituted pyrrolidinyl).
[0069] A heterocyclic ring can be attached to its pendant group at
any heteroatom or carbon atom that results in a stable structure
and any of the ring atoms can be optionally substituted. Examples
of such saturated or partially unsaturated heterocyclic radicals
include, without limitation, tetrahydrofuranyl,
tetrahydrothiophenyl pyrrolidinyl, piperidinyl, pyrrolinyl,
tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl,
oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepinyl,
oxazepinyl, thiazepinyl, morpholinyl, and quinuclidinyl. The terms
"heterocycle," "heterocyclyl," "heterocyclyl ring," "heterocyclic
group," "heterocyclic moiety," and "heterocyclic radical," are used
interchangeably herein, and also include groups in which a
heterocyclyl ring is fused to one or more aryl, heteroaryl, or
cycloaliphatic rings, such as indolinyl, 3H-indolyl, chromanyl,
phenanthridinyl, or tetrahydroquinolinyl. A heterocyclyl group may
be mono- or bicyclic. The term "heterocyclylalkyl" refers to an
alkyl group substituted by a heterocyclyl, wherein the alkyl and
heterocyclyl portions independently are optionally substituted.
[0070] As used herein, the term "partially unsaturated" refers to a
ring moiety that includes at least one double or triple bond. The
term "partially unsaturated" is intended to encompass rings having
multiple sites of unsaturation, but is not intended to include aryl
or heteroaryl moieties, as herein defined.
[0071] As described herein, compounds of the invention may contain
"optionally substituted" moieties. In general, the term
"substituted," whether preceded by the term "optionally" or not,
means that one or more hydrogens of the designated moiety are
replaced with a suitable substituent. Unless otherwise indicated,
an "optionally substituted" group may have a suitable substituent
at each substitutable position of the group, and when more than one
position in any given structure may be substituted with more than
one substituent selected from a specified group, the substituent
may be either the same or different at every position. Combinations
of substituents envisioned by this invention are preferably those
that result in the formation of stable or chemically feasible
compounds. The term "stable," as used herein, refers to compounds
that are not substantially altered when subjected to conditions to
allow for their production, detection, and, in certain embodiments,
their recovery, purification, and use for one or more of the
purposes disclosed herein.
[0072] Suitable monovalent substituents on a substitutable carbon
atom of an "optionally substituted" group are independently
halogen; --(CH.sub.2).sub.0-4R.sup..smallcircle.;
--(CH.sub.2).sub.0-4OR.sup..smallcircle.;
--O(CH.sub.2).sub.0-4R.sup..smallcircle.,
--O--(CH.sub.2).sub.0-4C(O)OR.sup..smallcircle.;
--(CH.sub.2).sub.0-4CH(OR.sup..smallcircle.).sub.2;
--(CH.sub.2).sub.0-4SR; --(CH.sub.2).sub.0-4Ph, which may be
substituted with R.sup..smallcircle.;
--(CH.sub.2).sub.0-4O(CH.sub.2).sub.0-1Ph which may be substituted
with R.sup..smallcircle.; --CH.dbd.CHPh, which may be substituted
with R.sup..smallcircle.;
--(CH.sub.2).sub.0-4O(CH.sub.2).sub.0-1-pyridyl which may be
substituted with R.sup..smallcircle.; --NO.sub.2; --CN; --N.sub.3;
--(CH.sub.2).sub.0-4N(R.sup..smallcircle.).sub.2;
--(CH.sub.2).sub.0-4N(R.sup..smallcircle.)C(O)R.sup..smallcircle.;
--N(R.sup..smallcircle.)C(S)R.sup..smallcircle.;
--(CH.sub.2).sub.0-4N(R)C(O)NR.sup..smallcircle..sub.2;
--N(R.sup..smallcircle.)C(S)NR.sup..smallcircle..sub.2;
--(CH.sub.2).sub.0-4N(R.sup..smallcircle.)C(O)OR.sup..smallcircle.;
--N(R.sup..smallcircle.)N(R.sup..smallcircle.)C(O)R.sup..smallcircle.;
--N(R.sup..smallcircle.)N(R.sup..smallcircle.)C(O)NR.sup..smallcircle..su-
b.2;
--N(R.sup..smallcircle.)N(R.sup..smallcircle.)C(O)OR.sup..smallcircle-
.; --(CH.sub.2).sub.0-4C(O)R.sup..smallcircle.;
--C(S)R.sup..smallcircle.;
--(CH.sub.2).sub.0-4C(O)OR.sup..smallcircle.;
--(CH.sub.2).sub.0-4C(O)SR.sup..smallcircle.;
--(CH.sub.2).sub.0-4C(O)OSiR.sup..smallcircle..sub.3;
--(CH.sub.2).sub.0-4OC(O)R.sup..smallcircle.;
--OC(O)(CH.sub.2).sub.0-4SR--, SC(S)SR.sup..smallcircle.;
--(CH.sub.2).sub.0-4SC(O)R.sup..smallcircle.;
--(CH.sub.2).sub.0-4C(O)NR.sup..smallcircle..sub.2;
--C(S)NR.sup..smallcircle..sub.2; --C(S)SR.sup..smallcircle.;
--SC(S)SR.sup..smallcircle.,
--(CH.sub.2).sub.0-4OC(O)NR.sup..smallcircle..sub.2;
--C(O)N(OR.sup..smallcircle.)R.sup..smallcircle.;
--C(O)C(O)R.sup..smallcircle.;
--C(O)CH.sub.2C(O)R.sup..smallcircle.;
--C(NOR.sup..smallcircle.)R.sup..smallcircle.;
--(CH.sub.2).sub.0-4SSR.sup..smallcircle.;
--(CH.sub.2).sub.0-4S(O).sub.2R.sup..smallcircle.;
--(CH.sub.2).sub.0-4 S(O).sub.2OR;
--(CH.sub.2).sub.0-4OS(O).sub.2R.sup..smallcircle.;
--S(O).sub.2NR.sup..smallcircle..sub.2;
--(CH.sub.2).sub.0-4S(O)R.sup..smallcircle.;
--N(R.sup..smallcircle.)S(O).sub.2NR.sup..smallcircle..sub.2;
--N(R.sup..smallcircle.)S(O).sub.2R.sup..smallcircle.;
--N(OR.sup..smallcircle.)R.sup..smallcircle.;
--C(NH)NR.sup..smallcircle..sub.2; --P(O).sub.2R.sup..smallcircle.;
--P(O)R.sup..smallcircle..sub.2; --OP(O)R.sup..smallcircle..sub.2;
--OP(O)(OR.sup..smallcircle.).sub.2; SiR.sup..smallcircle..sub.3;
--(C.sub.1-4 straight or branched
alkylene)O--N(R.sup..smallcircle.).sub.2; or --(C.sub.1-4 straight
or branched alkylene)C(O)O--N(R.sup..smallcircle.).sub.2, wherein
each R.sup..smallcircle. may be substituted as defined below and is
independently hydrogen, C.sub.1 aliphatic, --CH.sub.2Ph,
--O(CH.sub.2).sub.0-1-Ph, --CH.sub.2-(5-6 membered heteroaryl
ring), or a 5-6-membered saturated, partially unsaturated, or aryl
ring having 0-4 heteroatoms independently selected from nitrogen,
oxygen, or sulfur, or, notwithstanding the definition above, two
independent occurrences of R.sup..smallcircle., taken together with
their intervening atom(s), form a 3-12-membered saturated,
partially unsaturated, or aryl mono- or bicyclic ring having 0-4
heteroatoms independently selected from nitrogen, oxygen, or
sulfur, which may be substituted as defined below.
[0073] Suitable monovalent substituents on R.sup..smallcircle. (or
the ring formed by taking two independent occurrences of
R.sup..smallcircle. together with their intervening atoms), are
independently halogen, --(CH.sub.2).sub.0-2R.sup. , -(haloR.sup. ),
--(CH.sub.2).sub.0-2OH, --(CH.sub.2).sub.0-2OR',
--(CH.sub.2).sub.0-2CH(OR.sup. ).sub.2; --O(haloR.sup. ), --CN,
--N.sub.3, --(CH.sub.2).sub.0-2C(O)R.sup. ,
--(CH.sub.2).sub.0-2C(O)OH, --(CH.sub.2).sub.0-2C(O)OR.sup. ,
--(CH.sub.2).sub.0-2SR.sup. , --(CH.sub.2).sub.0-2SH,
--(CH.sub.2).sub.0-2NH.sub.2, --(CH.sub.2).sub.0-2NHR.sup. ,
--(CH.sub.2).sub.0-2NR.sup. .sub.2, --NO.sub.2, --SiR.sup. .sub.3,
--OSiR.sup. .sub.3, --C(O)SR.sup. , --(C.sub.1-4 straight or
branched alkylene)C(O)OR.sup. , or --SSR.sup. wherein each R.sup.
is unsubstituted or where preceded by "halo" is substituted only
with one or more halogens, and is independently selected from
C.sub.1-4 aliphatic, --CH.sub.2Ph, --O(CH.sub.2).sub.0-1Ph, or a
5-6-membered saturated, partially unsaturated, or aryl ring having
0-4 heteroatoms independently selected from nitrogen, oxygen, or
sulfur. Suitable divalent substituents on a saturated carbon atom
of R.sup..smallcircle. include .dbd.O and .dbd.S.
[0074] Suitable divalent substituents on a saturated carbon atom of
an "optionally substituted" group include the following: .dbd.O,
.dbd.S, .dbd.NNR*.sub.2, .dbd.NNHC(O)R*, .dbd.NNHC(O)OR*,
.dbd.NNHS(O).sub.2R*, .dbd.NR*, .dbd.NOR*,
--O(C(R*.sub.2)).sub.2-3O--, or --S(C(R*.sub.2)).sub.2-3S--,
wherein each independent occurrence of R* is selected from
hydrogen, C.sub.1-6 aliphatic which may be substituted as defined
below, or an unsubstituted 5-6-membered saturated, partially
unsaturated, or aryl ring having 0-4 heteroatoms independently
selected from nitrogen, oxygen, or sulfur. Suitable divalent
substituents that are bound to vicinal substitutable carbons of an
"optionally substituted" group include: --O(CR*.sub.2).sub.2-3O--,
wherein each independent occurrence of R* is selected from
hydrogen, C.sub.1-6 aliphatic which may be substituted as defined
below, or an unsubstituted 5-6-membered saturated, partially
unsaturated, or aryl ring having 0-4 heteroatoms independently
selected from nitrogen, oxygen, or sulfur.
[0075] Suitable substituents on the aliphatic group of R* include
halogen, --R.sup. , -(haloR.sup. ), --OH, --OR.sup. ,
--O(haloR.sup. ), --CN, --C(O)OH, --C(O)OR.sup. , --NH.sub.2,
--NHR.sup. , --NR.sup. .sub.2, or --NO.sub.2, wherein each R.sup.
is unsubstituted or where preceded by "halo" is substituted only
with one or more halogens, and is independently C.sub.1-4
aliphatic, --CH.sub.2Ph, --O(CH.sub.2).sub.0-1Ph, or a 5-6-membered
saturated, partially unsaturated, or aryl ring having 0-4
heteroatoms independently selected from nitrogen, oxygen, or
sulfur.
[0076] Suitable substituents on a substitutable nitrogen of an
"optionally substituted" group include --R.sup..dagger.,
--NR.sup..dagger..sub.2, --C(O)R.sup..dagger.,
--C(O)OR.sup..dagger., --C(O)C(O)R.sup..dagger.,
--C(O)CH.sub.2C(O)R.sup..dagger., --S(O).sub.2R.sup..dagger.,
--S(O).sub.2NR.sup..dagger..sub.2, --C(S)NR.sup..dagger..sub.2,
--C(NH)NR.sup..dagger..sub.2, or --N(R)S(O).sub.2R.sup..dagger.;
wherein each R.sup..dagger. is independently hydrogen, C.sub.1-6
aliphatic which may be substituted as defined below, unsubstituted
--OPh, or an unsubstituted 5-6-membered saturated, partially
unsaturated, or aryl ring having 0-4 heteroatoms independently
selected from nitrogen, oxygen, or sulfur, or, notwithstanding the
definition above, two independent occurrences of R.sup..dagger.,
taken together with their intervening atom(s) form an unsubstituted
3-12-membered saturated, partially unsaturated, or aryl mono- or
bicyclic ring having 0-4 heteroatoms independently selected from
nitrogen, oxygen, or sulfur.
[0077] Suitable substituents on the aliphatic group of
R.sup..dagger. are independently halogen, --R.sup. , -(haloR.sup.
), --OH, --OR*, --O(haloR.sup..dagger.), --CN, --C(O)OH,
--C(O)OR.sup. , --NH.sub.2, --NHR.sup. , --NR.sup..dagger..sub.2,
or --NO.sub.2, wherein each R.sup. is unsubstituted or where
preceded by "halo" is substituted only with one or more halogens,
and is independently C.sub.1-4 aliphatic, --CH.sub.2Ph,
--O(CH.sub.2).sub.0-1Ph, or a 5-6-membered saturated, partially
unsaturated, or aryl ring having 0-4 heteroatoms independently
selected from nitrogen, oxygen, or sulfur.
[0078] As used herein, the term "pharmaceutically acceptable salt"
refers to those salts which are, within the scope of sound medical
judgment, suitable for use in contact with the tissues of humans
and lower animals without undue toxicity, irritation, allergic
response and the like, and are commensurate with a reasonable
benefit/risk ratio. Pharmaceutically acceptable salts are well
known in the art. For example, S. M. Berge et al., describe
pharmaceutically acceptable salts in detail in J. Pharmaceutical
Sciences, 1977, 66, 1-19, incorporated herein by reference.
Pharmaceutically acceptable salts of the compounds of this
invention include those derived from suitable inorganic and organic
acids and bases. Examples of pharmaceutically acceptable, nontoxic
acid addition salts are salts of an amino group formed with
inorganic acids such as hydrochloric acid, hydrobromic acid,
phosphoric acid, sulfuric acid and perchloric acid or with organic
acids such as acetic acid, oxalic acid, maleic acid, tartaric acid,
citric acid, succinic acid or malonic acid or by using other
methods used in the art such as ion exchange. Other
pharmaceutically acceptable salts include adipate, alginate,
ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate,
borate, butyrate, camphorate, camphorsulfonate, citrate,
cyclopentanepropionate, digluconate, dodecylsulfate,
ethanesulfonate, formate, fumarate, glucoheptonate,
glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate,
hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate,
laurate, lauryl sulfate, malate, maleate, malonate,
methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate,
oleate, oxalate, palmitate, pamoate, pectinate, persulfate,
3-phenylpropionate, phosphate, pivalate, propionate, stearate,
succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate,
undecanoate, valerate salts, and the like.
[0079] Salts derived from appropriate bases include alkali metal,
alkaline earth metal, ammonium and N.sup.+(C.sub.1-alkyl).sub.4
salts. Representative alkali or alkaline earth metal salts include
sodium, lithium, potassium, calcium, magnesium, and the like.
Further pharmaceutically acceptable salts include, when
appropriate, nontoxic ammonium, quaternary ammonium, and amine
cations formed using counterions such as halide, hydroxide,
carboxylate, sulfate, phosphate, nitrate, loweralkyl sulfonate and
aryl sulfonate.
[0080] Unless otherwise stated, structures depicted herein are also
meant to include all isomeric (e.g., enantiomeric, diastereomeric,
and geometric (or conformational)) forms of the structure; for
example, the R and S configurations for each asymmetric center, Z
and E double bond isomers, and Z and E conformational isomers.
Therefore, single stereochemical isomers as well as enantiomeric,
diastereomeric, and geometric (or conformational) mixtures of the
present compounds are within the scope of the invention. Unless
otherwise stated, all tautomeric forms of the compounds of the
invention are within the scope of the invention. Additionally,
unless otherwise stated, structures depicted herein are also meant
to include compounds that differ only in the presence of one or
more isotopically enriched atoms. For example, compounds having the
present structures including the replacement of hydrogen by
deuterium or tritium, or the replacement of a carbon by a .sup.13C-
or .sup.14C-enriched carbon are within the scope of this invention.
Such compounds are useful, for example, as analytical tools, as
probes in biological assays, or as therapeutic agents in accordance
with the present invention. In certain embodiments, a warhead
moiety, R.sup.1, of a provided compound comprises one or more
deuterium atoms. In certain embodiments, Ring B of a provided
compound may be substituted with one or more deuterium atoms.
[0081] As used herein, the term "inhibitor" is defined as a
compound that binds to and/or inhibits IRAK-4 with measurable
affinity. In certain embodiments, an inhibitor has an IC.sub.50
and/or binding constant of less than about 50 .mu.M, less than
about 1 .mu.M, less than about 500 nM, less than about 100 nM, less
than about 10 nM, or less than about 1 nM.
[0082] A compound of the present invention may be tethered to a
detectable moiety. It will be appreciated that such compounds are
useful as imaging agents. One of ordinary skill in the art will
recognize that a detectable moiety may be attached to a provided
compound via a suitable substituent. As used herein, the term
"suitable substituent" refers to a moiety that is capable of
covalent attachment to a detectable moiety. Such moieties are well
known to one of ordinary skill in the art and include groups
containing, e.g., a carboxylate moiety, an amino moiety, a thiol
moiety, or a hydroxyl moiety, to name but a few. It will be
appreciated that such moieties may be directly attached to a
provided compound or via a tethering group, such as a bivalent
saturated or unsaturated hydrocarbon chain. In some embodiments,
such moieties may be attached via click chemistry. In some
embodiments, such moieties may be attached via a 1,3-cycloaddition
of an azide with an alkyne, optionally in the presence of a copper
catalyst. Methods of using click chemistry are known in the art and
include those described by Rostovtsev et al., Angew. Chem. Int. Ed.
2002, 41, 2596-99 and Sun et al., Bioconjugate Chem., 2006, 17,
52-57.
[0083] As used herein, the term "detectable moiety" is used
interchangeably with the term "label" and relates to any moiety
capable of being detected, e.g., primary labels and secondary
labels. Primary labels, such as radioisotopes (e.g., tritium,
.sup.32P, .sup.33P, .sup.35S, or .sup.14C), mass-tags, and
fluorescent labels are signal generating reporter groups which can
be detected without further modifications. Detectable moieties also
include luminescent and phosphorescent groups.
[0084] The term "secondary label" as used herein refers to moieties
such as biotin and various protein antigens that require the
presence of a second intermediate for production of a detectable
signal. For biotin, the secondary intermediate may include
streptavidin-enzyme conjugates. For antigen labels, secondary
intermediates may include antibody-enzyme conjugates. Some
fluorescent groups act as secondary labels because they transfer
energy to another group in the process of nonradiative fluorescent
resonance energy transfer (FRET), and the second group produces the
detected signal.
[0085] The terms "fluorescent label", "fluorescent dye", and
"fluorophore" as used herein refer to moieties that absorb light
energy at a defined excitation wavelength and emit light energy at
a different wavelength. Examples of fluorescent labels include, but
are not limited to: Alexa Fluor dyes (Alexa Fluor 350, Alexa Fluor
488, Alexa Fluor 532, Alexa Fluor 546, Alexa Fluor 568, Alexa Fluor
594, Alexa Fluor 633, Alexa Fluor 660 and Alexa Fluor 680), AMCA,
AMCA-S, BODIPY dyes (BODIPY FL, BODIPY R6G, BODIPY TMR, BODIPY TR,
BODIPY 530/550, BODIPY 558/568, BODIPY 564/570, BODIPY 576/589,
BODIPY 581/591, BODIPY 630/650, BODIPY 650/665), Carboxyrhodamine
6G, carboxy-X-rhodamine (ROX), Cascade Blue, Cascade Yellow,
Coumarin 343, Cyanine dyes (Cy3, Cy5, Cy3.5, Cy5.5), Dansyl,
Dapoxyl, Dialkylaminocoumarin,
4',5'-Dichloro-2',7'-dimethoxy-fluorescein, DM-NERF, Eosin,
Erythrosin, Fluorescein, FAM, Hydroxycoumarin, IRDyes (IRD40, IRD
700, IRD 800), JOE, Lissamine rhodamine B, Marina Blue,
Methoxycoumarin, Naphthofluorescein, Oregon Green 488, Oregon Green
500, Oregon Green 514, Pacific Blue, PyMPO, Pyrene, Rhodamine B,
Rhodamine 6G, Rhodamine Green, Rhodamine Red, Rhodol Green,
2',4',5',7'-Tetra-bromosulfone-fluorescein, Tetramethyl-rhodamine
(TMR), Carboxytetramethylrhodamine (TAMRA), Texas Red, Texas
Red-X.
[0086] The term "mass-tag" as used herein refers to any moiety that
is capable of being uniquely detected by virtue of its mass using
mass spectrometry (MS) detection techniques. Examples of mass-tags
include electrophore release tags such as
N-[3-[4'-[(p-Methoxytetrafluorobenzyl)oxy]phenyl]-3-methylglyceronyl]ison-
ipecotic Acid,
4'-[2,3,5,6-Tetrafluoro-4-(pentafluorophenoxyl)]methyl
acetophenone, and their derivatives. The synthesis and utility of
these mass-tags is described in U.S. Pat. Nos. 4,650,750,
4,709,016, 5,360,8191, 5,516,931, 5,602,273, 5,604,104, 5,610,020,
and 5,650,270. Other examples of mass-tags include, but are not
limited to, nucleotides, dideoxynucleotides, oligonucleotides of
varying length and base composition, oligopeptides,
oligosaccharides, and other synthetic polymers of varying length
and monomer composition. A large variety of organic molecules, both
neutral and charged (biomolecules or synthetic compounds) of an
appropriate mass range (100-2000 Daltons) may also be used as
mass-tags.
[0087] The terms "measurable affinity" and "measurably inhibit," as
used herein, means a measurable change in an IRAK protein kinase
activity between a sample comprising a compound of the present
invention, or composition thereof, and an IRAK protein kinase, and
an equivalent sample comprising an IRAK protein kinase, in the
absence of said compound, or composition thereof.
3. Description of Exemplary Embodiments
[0088] As described above, in certain embodiments, the present
invention provides a compound of formula I:
##STR00006##
or a pharmaceutically acceptable salt thereof, wherein: [0089] Ring
A is a 3-7 membered saturated or partially unsaturated carbocyclic
ring or a 4-7 membered saturated or partially unsaturated
heterocyclic ring having 1-3 heteroatoms independently selected
from nitrogen, oxygen, or sulfur; [0090] n is 0-4; [0091] each
R.sup.1 is independently --R, halogen, --CN, --NO.sub.2, --OR,
--CH.sub.2OR, --SR, --N(R).sub.2, --SO.sub.2R,
--SO.sub.2N(R).sub.2, --SOR, --C(O)R, --CO.sub.2R,
--C(O)N(R).sub.2, --C(O)N(R)--OR, --NRC(O)OR, --NRC(O)N(R).sub.2,
Cy, or --NRSO.sub.2R, or R.sup.1 is selected from one of the
following formulas:
[0091] ##STR00007## [0092] two R.sup.1 groups are taken together
with their intervening atoms to form an optionally substituted 4-7
membered fused, spiro-fused, or bridged bicyclic ring having 0-2
heteroatoms independently selected from nitrogen, oxygen, or
sulfur; [0093] each Cy is an optionally substituted ring selected
from a 3-7 membered saturated or partially unsaturated carbocyclic
ring or a 4-7 membered saturated or partially unsaturated
heterocyclic ring having 1-3 heteroatoms independently selected
from nitrogen, oxygen, or sulfur; [0094] each R is independently
hydrogen, or an optionally substituted group selected from
C.sub.1-6 aliphatic, phenyl, 4-7 membered saturated or partially
unsaturated heterocyclic having 1-2 heteroatoms independently
selected from nitrogen, oxygen, or sulfur, or 5-6 membered
heteroaryl ring having 1-4 heteroatoms independently selected from
nitrogen, oxygen, or sulfur, or: [0095] two R groups on the same
nitrogen are taken together with their intervening atoms to form a
4-7 membered saturated, partially unsaturated, or heteroaryl ring
having 0-3 heteroatoms, in addition to the nitrogen, independently
selected from nitrogen, oxygen, or sulfur; [0096] Ring B is a 4-8
membered partially unsaturated carbocyclic fused ring; or a 4-7
membered partially unsaturated heterocyclic fused ring having 1-2
heteroatoms selected from nitrogen, oxygen, or sulfur; wherein said
Ring B may be optionally substituted by one or more oxo, thiono, or
imino groups; [0097] m is 1-4; [0098] p is 0-2; [0099] W is N or
--C(R.sup.3)--; [0100] R.sup.z is R, CN, NO.sup.2, halogen,
--C(O)N(R).sub.2, --C(O)OR, --C(O)R, --N(R).sub.2, --NH--[Ar],
--N(R)C(O)OR, --NRC(O)N(R).sub.2, --OR, or --SO.sup.2N(R).sub.2;
[0101] [Ar] is an optionally substituted phenyl or heteroaromatic
ring; [0102] R.sup.3 is hydrogen, halogen, --CN, C.sub.1-4
aliphatic, C.sub.1-4 haloaliphatic, --OR, --C(O)R, or
--C(O)N(R).sub.2; [0103] L.sup.1 is a covalent bond or a C.sub.1-6
bivalent hydrocarbon chain wherein one or two methylene units of
the chain are optionally and independently replaced by --NR--,
--N(R)C(O)--, --C(O)N(R)--, --N(R)SO.sub.2--, --SO.sub.2N(R)--,
--O--, --C(O)--, --OC(O)--, --C(O)O--, --S--, --SO-- or
--SO.sub.2--; [0104] each L.sup.2 is independently a covalent bond
or a C.sub.1-6 bivalent hydrocarbon chain wherein one or two
methylene units of the chain are optionally and independently
replaced by --NR--, --N(R)C(O)--, --C(O)N(R)--, --N(R)SO.sub.2--,
--SO.sub.2N(R)--, --O--, --C(O)--, --OC(O)--, --C(O)O--, --S--,
--SO-- or --SO.sub.2--; [0105] each R.sup.4 is independently
halogen, --CN, --NO.sub.2, --OR, --SR, --N(R).sub.2, --SO.sub.2R,
--SO.sub.2N(R).sub.2, --SOR, --C(O)R, --CO.sub.2R,
--C(O)N(R).sub.2, --NRC(O)R, --NRC(O)N(R).sub.2, --C(O)N(R)OR,
--N(R)C(O)OR, --N(R)S(O).sub.2N(R).sub.2, --NRSO.sub.2R, or an
optionally substituted group selected from C.sub.1-6 aliphatic,
phenyl, 4-7 membered saturated or partially unsaturated
heterocyclic having 1-2 heteroatoms independently selected from
nitrogen, oxygen, or sulfur, or 5-6 membered heteroaryl ring having
1-4 heteroatoms independently selected from nitrogen, oxygen, or
sulfur, or: [0106] two -L.sup.2(R.sup.4).sub.p--R.sup.4 groups are
taken together with their intervening atoms to form an optionally
substituted 4-7 membered fused, spiro-fused, or bridged bicyclic
ring having 0-2 heteroatoms independently selected from nitrogen,
oxygen, or sulfur;
[0107] As defined generally above, the Ring A group of formula I is
a 3-7 membered saturated or partially unsaturated carbocyclic ring
or a 4-7 membered saturated or partially unsaturated heterocyclic
ring having 1-3 heteroatoms independently selected from nitrogen,
oxygen, or sulfur. In some embodiments, Ring A is a 3-7 membered
saturated or partially unsaturated carbocyclic ring. In certain
embodiments, Ring A is a 4-7 membered saturated or partially
unsaturated heterocyclic ring having 1-3 heteroatoms independently
selected from nitrogen, oxygen, or sulfur.
[0108] In some embodiments, Ring A is a 3-7 membered saturated
carbocyclic ring. In certain embodiments, Ring A is cyclopentyl or
cyclohexyl. In some embodiments, Ring A is cyclohexyl.
[0109] One of skill in the art will appreciate that a when Ring A
is a disubstituted cycloalkyl ring, said ring can have cis or trans
relative stereochemistry. In some embodiments, Ring A is a
trans-1,4-disubstituted cycloalkyl ring. In some embodiments, Ring
A a trans-1,4-disubstituted cyclohexyl ring.
[0110] In certain embodiments, Ring A is a 4-7 membered saturated
heterocyclic ring having 1-3 heteroatoms independently selected
from nitrogen, oxygen, or sulfur. In certain embodiments, Ring A is
a 5-6 membered saturated heterocyclic ring having 1-3 heteroatoms
independently selected from nitrogen, oxygen, or sulfur. In certain
embodiments, Ring A is piperidinyl, piperazinyl, morpholinyl,
thiomorpholinyl, tetrahydropyranyl, or tetrahydrofuranyl. In some
embodiments, when Ring A is a 4-7 membered saturated heterocyclic
ring, L.sup.1 is a covalent bond. In some embodiments, when Ring A
is a 4-7 membered saturated heterocyclic ring, L.sup.1 is not a
covalent bond.
[0111] As defined generally above, the n group of formula I is 0-4.
In some embodiments, n is 0. In other embodiments, n is 1-4. In
certain embodiments, n is 1 or 2.
[0112] As defined generally above, each R.sup.1 group of formula I
is independently --R, halogen, --CN, --NO.sub.2, --OR,
--CH.sub.2OR, --SR, --N(R).sub.2, --SO.sub.2R,
--SO.sub.2N(R).sub.2, --SOR, --C(O)R, --CO.sub.2R,
--C(O)N(R).sub.2, --C(O)N(R)--OR, --NRC(O)R, --NRC(O)N(R).sub.2,
Cy, or --NRSO.sub.2R; or R.sup.1 is selected from one of the
following formulas:
##STR00008##
two R.sup.1 groups are taken together with their intervening atoms
to form an optionally substituted 4-7 membered fused, spiro-fused,
or bridged bicyclic ring having 0-2 heteroatoms independently
selected from nitrogen, oxygen, or sulfur.
[0113] In certain embodiments, R.sup.1 is R, --OR, --N(R).sub.2,
--CO.sub.2R, --C(O)N(R).sub.2, --C(O)N(R)--OR,
--SO.sub.2N(R).sub.2, Cy, or --NRC(O)OR. In some embodiments,
R.sup.1 is --C(O)NH.sub.2, --C(O)NHCH.sub.3, --C(O)NH--OH,
--CH.sub.3, --CH.sub.2CH.sub.3, --SO.sub.2t-butyl, --OH, --C(O)OH,
--NH.sub.2, --NHCH.sub.3, --N(CH.sub.3).sub.2,
--N(CH.sub.2CH.sub.3).sub.2, --NHC(O)CH.sub.3, or --CH.sub.2phenyl.
In certain embodiments, R1 is selected from one of the following
formulas:
##STR00009##
In certain embodiments, R.sup.1 is Cy. In certain embodiments,
R.sup.1 is --N(R).sub.2. Exemplary R.sup.1 groups include those
depicted in Table 1.
[0114] In some embodiments, the present invention provides a
compound of formula I wherein two R.sup.1 groups are taken together
with their intervening atoms to form an optionally substituted 4-7
membered fused, spiro-fused, or bridged bicyclic ring having 0-2
heteroatoms independently selected from nitrogen, oxygen, or
sulfur. In certain embodiments, two R.sup.1 groups on adjacent
carbon atoms are taken together to form an optionally substituted
4-7 membered ring fused to Ring A. In other embodiments, two
R.sup.1 groups on the same carbon atom are taken together to form
an optionally substituted 4-7 membered spiro-fused ring. In other
embodiments, two R.sup.1 groups on non-adjacent carbon atoms are
taken together to form an optionally substituted bridged bicyclic
ring with Ring A.
[0115] As defined generally above, Cy is an optionally substituted
ring selected from a 3-7 membered saturated or partially
unsaturated carbocyclic ring or a 4-7 membered saturated or
partially unsaturated heterocyclic ring having 1-3 heteroatoms
independently selected from nitrogen, oxygen, or sulfur.
[0116] In some embodiments, Cy is a 3-7 membered saturated
carbocyclic ring. In certain embodiments, Cy is a 4-7 membered
saturated heterocyclic ring containing 1-2 heteroatoms
independently selected from nitrogen, oxygen or sulfur. In certain
embodiments Cy is a spirobicyclic 7-membered ring. In certain
embodiments, Cy is morpholinyl, pyrrolidinyl, azetidinyl,
piperidinyl or piperazinyl.
[0117] One of ordinary skill in the art will appreciate that an
R.sup.1 substituent on a saturated carbon of Ring A forms a chiral
center. In some embodiments, that chiral center is in the (R)
configuration. In other embodiments, that chiral center is in the
(S) configuration.
[0118] As defined generally above, the L.sup.1 group of formula I
is a covalent bond or a C.sub.1-6 bivalent hydrocarbon chain
wherein one or two methylene units of the chain are optionally and
independently replaced by --NR--, --N(R)C(O)--, --C(O)N(R)--,
--N(R)SO.sub.2--, --SO.sub.2N(R)--, --O--, --C(O)--, --OC(O)--,
--C(O)O--, --S--, --SO-- or --SO.sub.2--. In some embodiments,
L.sup.1 is a covalent bond. In other embodiments, L.sup.1 is a
C.sub.1-6 bivalent hydrocarbon chain wherein one or two methylene
units of the chain are optionally and independently replaced by
--NR--, --N(R)C(O)--, --C(O)N(R)--, --N(R)SO.sub.2--,
--SO.sub.2N(R)--, --O--, --C(O)--, --OC(O)--, --C(O)O--, --S--,
--SO-- or --SO.sub.2--.
[0119] In some embodiments, L.sup.1 is --NH-- (i.e., a C.sub.1
bivalent hydrocarbon chain wherein the methylene unit is replaced
by --NH--), --O--, --CH.sub.2O--, --OCH.sub.2--, --NHC(O)--,
--CH.sub.2NH--, or --NHCH.sub.2--. In some embodiments, L.sup.1 is
--O--. In some embodiments, L.sup.1 is --NR--. In some embodiments,
L.sup.1 is --OCH.sub.2--. In some embodiments, L.sup.1 is
--NRCH.sub.2--. Exemplary L.sup.1 groups include those depicted in
Table 1.
[0120] As defined generally above, the Ring B group of formula I is
a 4-8 membered partially unsaturated carbocyclic fused ring or a
4-7 membered partially unsaturated heterocyclic ring having 1-2
heteroatoms selected from nitrogen, oxygen or sulfur. In some
embodiments, Ring B is a 4-8 membered partially unsaturated
carbocyclic fused ring. In other embodiments, Ring B is a 4-7
membered partially unsaturated azacyclic fused ring having one or
two nitrogens. In some embodiments, Ring B is a cyclohexo- or
cyclopento-fused ring. In other embodiments, Ring B is a
piperidino-fused ring. In some embodiments, Ring B is a
tetrahydropyrano-fused ring. In some embodiments, Ring B is a
pyrrolidino-fused ring.
[0121] One of ordinary skill in the art will appreciate that a
substituent on a saturated carbon of Ring B forms a chiral center.
In some embodiments, that chiral center is in the (R)
configuration. In other embodiments, that chiral center is in the
(S) configuration.
[0122] As defined generally above, the m group of formula I is 1-4.
In other embodiments, m is 1-4. In certain embodiments, m is 1 or
2.
[0123] As defined generally above, each L.sup.2 is independently a
covalent bond or a C.sub.1-6 bivalent hydrocarbon chain wherein one
or two methylene units of the chain are optionally and
independently replaced by --NR--, --N(R)C(O)--, --C(O)N(R)--,
--N(R)SO.sub.2--, --SO.sub.2N(R)--, --O--, --C(O)--, --OC(O)--,
--C(O)O--, --S--, --SO-- or --SO.sub.2--.
[0124] In certain embodiments each L.sup.2 is independently a
covalent bond. In some embodiments each L.sup.2 is a C.sub.1-3
bivalent hydrocarbon chain wherein one or two methylene units of
the chain are optionally and independently replaced by
--C(O)N(R)--, --O--, --C(O)--, --S--, --SO-- or --SO.sub.2--. In
certain embodiments, L.sup.2 is methylene. In certain embodiments,
L.sup.2 is --CH.sub.2--C(O)--. In certain embodiments, L.sup.2 is a
C.sub.2 hydrocarbon chain substituted with a hydroxyl group
(--CH.sub.2CH(OH)--).
[0125] As defined generally above, each R.sup.4 is independently
halogen, --CN, --NO.sub.2, --OR, --SR, --N(R).sub.2, --SO.sub.2R,
--SO.sub.2N(R).sub.2, --SOR, --C(O)R, --CO.sub.2R,
--C(O)N(R).sub.2, --NRC(O)R, --NRC(O)N(R).sub.2, --C(O)N(R)OR,
--N(R)C(O)OR, --N(R)S(O).sub.2N(R).sub.2, --NRSO.sub.2R, or an
optionally substituted group selected from C.sub.1-6 aliphatic,
phenyl, 4-7 membered saturated or partially unsaturated
heterocyclic having 1-2 heteroatoms independently selected from
nitrogen, oxygen, or sulfur, or 5-6 membered heteroaryl ring having
1-4 heteroatoms independently selected from nitrogen, oxygen, or
sulfur, or: two -L.sup.2(R.sup.4).sub.p--R.sup.4 groups are taken
together with their intervening atoms to form an optionally
substituted 4-7 membered fused, spiro-fused, or bridged bicyclic
ring having 0-2 heteroatoms independently selected from nitrogen,
oxygen, or sulfur.
[0126] In some embodiments, each R.sup.4 is independently --CN,
--OR, --SR, --SOR, --SO.sub.2R, --C(O)N(R).sub.2, --NRC(O)R, or an
optionally substituted group selected from C.sub.1-6 aliphatic,
phenyl, 4-7 membered saturated or partially unsaturated
heterocyclic having 1-2 heteroatoms independently selected from
nitrogen, oxygen, or sulfur, or 5-6 membered heteroaryl ring having
1-4 heteroatoms independently selected from nitrogen, oxygen, or
sulfur. In certain embodiments, each R.sup.4 is independently --CN,
--OR, --SR, --SOR, --SO.sub.2R, --C(O)N(R).sub.2, or --NRC(O)R. In
certain embodiments R.sup.4 is an optionally substituted group
selected from C.sub.1-6 aliphatic, 4-7 membered saturated or
partially unsaturated heterocyclic having 1-2 heteroatoms
independently selected from nitrogen, oxygen, or sulfur, or 5-6
membered heteroaryl ring having 1-4 heteroatoms independently
selected from nitrogen, oxygen, or sulfur. In certain embodiments
R.sup.4 is hydroxyl. In certain embodiments R.sup.4 is
--C(O)N(R).sub.2.
[0127] In some embodiments, the present invention provides a
compound of formula I wherein two -L.sup.2(R.sup.4).sub.p--R.sup.4
groups are taken together with their intervening atoms to form an
optionally substituted 4-7 membered fused, spiro-fused, or bridged
bicyclic ring having 0-2 heteroatoms independently selected from
nitrogen, oxygen, or sulfur. In certain embodiments, two
-L.sup.2-R.sup.4 groups on adjacent carbon atoms are taken together
to form an optionally substituted 4-7 membered ring fused to Ring
B. In other embodiments, two -L.sup.2(R.sup.4).sub.p--R.sup.4
groups on the same carbon atom are taken together to form an
optionally substituted 4-7 membered spiro-fused ring. In other
embodiments, two -L.sup.2(R.sup.4).sub.p--R.sup.4 groups on
non-adjacent carbon atoms are taken together to form an optionally
substituted bridged bicyclic ring with Ring B.
[0128] In some embodiments, any one or more
-L.sup.2(R.sup.4).sub.p--R.sup.4 groups are independently selected
from deuterium, an unsubstituted alkyl group, a --CO.sub.2R group,
and an unsubstituted heterocyclyl group. In some embodiments, any
one or more -L.sup.2(R.sup.4).sub.p--R.sup.4 groups are not
independently selected from deuterium, an unsubstituted alkyl group
a --CO.sub.2R group, and an unsubstituted heterocyclyl group.
[0129] One of ordinary skill in the art will appreciate that an
-L.sup.2(R.sup.4).sub.p--R.sup.4 substituent on a saturated carbon
of Ring B forms a chiral center. In some embodiments, that chiral
center is in the (R) configuration. In other embodiments, that
chiral center is in the (S) configuration.
[0130] As defined generally above, the R.sup.z group of formula I
is --R, --CN, --NO.sub.2, halogen, --C(O)N(R).sub.2, --C(O)OR,
--C(O)R, --N(R).sub.2, --NH--[Ar], --N(R)C(O)OR,
--NRC(O)N(R).sub.2, --OR, or --SO.sup.2N(R).sub.2. In some
embodiments, R.sup.z is hydrogen. In other embodiments, R.sup.z is
CN, halogen, --N(R).sub.2 or --C(O)N(R).sub.2. Exemplary R.sup.z
groups include those depicted in Table 1.
[0131] As defined generally above, [Ar] is an optionally
substituted phenyl or heteroaromatic ring. In some embodiments,
[Ar] is an optionally substituted phenyl ring. In some embodiments,
[Ar] is an optionally substituted heteroaromatic ring. In some
embodiments, [Ar] is an optionally substituted 5-membered
heteroaromatic ring. In some embodiments, [Ar] is an optionally
substituted 6-membered heteroaromatic ring. In some embodiments,
[Ar] is an optionally substituted pyrazole ring.
[0132] As defined generally above, p is 0-2. In some embodiments p
is 0. In some embodiments p is 1. In certain embodiments, p is
2.
[0133] In some embodiments, the compound of formula I is not
selected from the following compounds:
##STR00010## ##STR00011## ##STR00012## ##STR00013## ##STR00014##
##STR00015## ##STR00016## ##STR00017## ##STR00018## ##STR00019##
##STR00020## ##STR00021## ##STR00022##
[0134] In certain embodiments, the present invention provides a
compound of formula I, wherein Ring B is a cyclopento fused ring,
and W is N, thereby forming a compound of formula II:
##STR00023##
or a pharmaceutically acceptable salt thereof, wherein each of Ring
A, L.sup.1, L.sup.2, R.sup.z, R.sup.1, R.sup.4, m, n, and p is as
defined above and described in embodiments herein, both singly and
in combination.
[0135] In certain embodiments, the present invention provides a
compound of formula II, wherein R.sup.1 is one of the following
formulas:
##STR00024##
thereby forming a compound of formula II-a or II-b:
##STR00025##
or a pharmaceutically acceptable salt thereof, wherein each of Ring
A, L.sup.1, L.sup.2, R, R.sup.z, R.sup.1, R.sup.4, m, n, and p is
as defined above and described in embodiments herein, both singly
and in combination.
[0136] In certain embodiments, the present invention provides a
compound of formula II, wherein m is 1, thereby forming a compound
of formula III:
##STR00026##
or a pharmaceutically acceptable salt thereof, wherein each of Ring
A, L.sup.1, L.sup.2, R.sup.z, R.sup.1, R.sup.4, n, and p is as
defined above and described in embodiments herein, both singly and
in combination.
[0137] In certain embodiments, the present invention provides a
compound of formula III, wherein Ring A is cyclohexyl, thereby
forming a compound of formula IV:
##STR00027##
or a pharmaceutically acceptable salt thereof, wherein each of,
L.sup.1, L.sup.2, R.sup.z, R.sup.1, R.sup.4, n, and p is as defined
above and described in embodiments herein, both singly and in
combination.
[0138] In certain embodiments, the present invention provides a
compound of formula III, wherein n is 1 and the cyclohexyl ring has
trans stereochemistry, thereby forming a compound of formula V:
##STR00028##
or a pharmaceutically acceptable salt thereof, wherein each of,
L.sup.1, L.sup.2, R.sup.z, R.sup.1, R.sup.4, and p is as defined
above and described in embodiments herein, both singly and in
combination.
[0139] In certain embodiments, the present invention provides a
compound of formula V, wherein R.sup.z is --N(R).sub.2, thereby
forming a compound of formula VI:
##STR00029##
or a pharmaceutically acceptable salt thereof, wherein each of,
L.sup.1, L.sup.2, R, R.sup.1, R.sup.4, and p is as defined above
and described in embodiments herein, both singly and in
combination.
[0140] In certain embodiments, the present invention provides a
compound of formula VII, wherein W.sup.1, W.sup.2, X.sup.1,
X.sup.2, Y.sup.1, Y.sup.2 and Z.sup.1 are each independently
hydrogen or deuterium:
##STR00030##
or a pharmaceutically acceptable salt thereof, wherein each of
L.sup.1, L.sup.2, R.sup.1, R.sup.z, and R.sup.4 is as defined above
for formula I and described in embodiments herein, both singly and
in combination.
[0141] In certain embodiments, the present invention provides a
compound of formula VIII, wherein W.sup.1, W.sup.2, X.sup.1,
X.sup.2, Y.sup.1, Y.sup.2, Z.sup.1 and Z.sup.2 are each
independently hydrogen or deuterium:
##STR00031##
or a pharmaceutically acceptable salt thereof, wherein each of
L.sup.1, L.sup.2, R.sup.1, R.sup.z, and R.sup.4 are defined above
for formula I and described in embodiments herein, both singly and
in combination.
[0142] In certain embodiments, the present invention provides a
compound of formula I, wherein Ring B is cyclohexo, W is N, and
R.sup.z is hydrogen, thereby forming a compound of formula IX:
##STR00032##
or a pharmaceutically acceptable salt thereof, wherein each of Ring
A, L.sup.1, L.sup.2, R.sup.1, R.sup.4, m, n, and p is as defined
above and described in embodiments herein, both singly and in
combination.
[0143] In certain embodiments, the present invention provides a
compound of formula IX, wherein m is 1, and L.sup.2 is attached
.alpha. to the thiophene ring, thereby forming a compound of
formula X:
##STR00033##
or a pharmaceutically acceptable salt thereof, wherein each of Ring
A, L.sup.1, L.sup.2, R.sup.1, R.sup.4, n, and p is as defined above
and described in embodiments herein, both singly and in
combination.
[0144] In certain embodiments, the present invention provides a
compound of formula IX, wherein m is 1, and L.sup.2 is attached
.beta. to the thiophene ring, thereby forming a compound of formula
XI:
##STR00034##
or a pharmaceutically acceptable salt thereof, wherein each of Ring
A, L.sup.1, L.sup.2, R.sup.1, R.sup.4, n, and p is as defined above
and described in embodiments herein, both singly and in
combination.
[0145] In certain embodiments, the present invention provides a
compound of formula III, wherein R.sup.z is hydrogen, and L.sup.2
is C.sub.2 alkylene, thereby forming a compound of formula XII:
##STR00035##
or a pharmaceutically acceptable salt thereof, wherein each of Ring
A, L.sup.1, R.sup.1, R.sup.4, n, and p is as defined above and
described in embodiments herein, both singly and in
combination.
[0146] In certain embodiments, the present invention provides a
compound of formula XII, wherein one instance of R4 is
--C(O)NR.sub.2, thereby forming a compound of formula XIII:
##STR00036##
or a pharmaceutically acceptable salt thereof, wherein each of Ring
A, L.sup.1, R, R.sup.1, R.sup.4, n, and p is as defined above and
described in embodiments herein, both singly and in
combination.
[0147] In certain embodiments, the present invention provides a
compound of formula XIII, wherein Ring A is 4-substituted
cyclohexyl, thereby forming a compound of formula XIV:
##STR00037##
or a pharmaceutically acceptable salt thereof, wherein each of
L.sup.1, R, R.sup.1, R.sup.4, n, and p is as defined above and
described in embodiments herein, both singly and in
combination.
[0148] In certain embodiments, the present invention provides a
compound of formula XIV, wherein n is 1, and R.sup.1 is --NR.sub.2,
thereby forming a compound of formula XV:
##STR00038##
or a pharmaceutically acceptable salt thereof, wherein each of
L.sup.1, R, R.sup.4, and p is as defined above and described in
embodiments herein, both singly and in combination.
[0149] In certain embodiments, the present invention provides a
compound of formula XV, wherein the stereochemistry of the
substituent on the cyclopento ring is (R), and the relative
stereochemistry on the cyclohexyl ring is trans thereby forming a
compound of formula XVI:
##STR00039##
or a pharmaceutically acceptable salt thereof, wherein each of
L.sup.1, R, R.sup.4, and p is as defined above and described in
embodiments herein, both singly and in combination.
[0150] In certain embodiments, the present invention provides a
compound of formula XVI wherein each R.sup.4 is independently
hydrogen, fluoro or --OR.
[0151] In certain embodiments the present invention provides a
compound of formula XVI wherein L.sup.1 is --O--. In certain
embodiments the present invention provides a compound of formula
XVI wherein L.sup.1 is --NH--.
[0152] In certain embodiments, the present invention provides a
compound of formula III, wherein R.sup.z is hydrogen, and L.sup.2
is C.sub.1 alkylene, thereby forming a compound of formula
XVII:
##STR00040##
or a pharmaceutically acceptable salt thereof, wherein each of Ring
A, L.sup.1, R.sup.1, R.sup.4, n, and p is as defined above and
described in embodiments herein, both singly and in
combination.
[0153] In certain embodiments, the present invention provides a
compound of formula XVII, wherein one instance of R4 is
--C(O)NR.sub.2, thereby forming a compound of formula XVIII:
##STR00041##
or a pharmaceutically acceptable salt thereof, wherein each of Ring
A, L.sup.1, R, R.sup.1, R.sup.4, n, and p is as defined above and
described in embodiments herein, both singly and in
combination.
[0154] In certain embodiments, the present invention provides a
compound of formula XVIII, wherein Ring A is 4-substituted
cyclohexyl, thereby forming a compound of formula XIX:
##STR00042##
or a pharmaceutically acceptable salt thereof, wherein each of
L.sup.1, R, R.sup.1, R.sup.4, n, and p is as defined above and
described in embodiments herein, both singly and in
combination.
[0155] In certain embodiments, the present invention provides a
compound of formula XIX, wherein n is 1, and R.sup.1 is --NR.sub.2,
thereby forming a compound of formula XX:
##STR00043##
or a pharmaceutically acceptable salt thereof, wherein each of
L.sup.1, R, R.sup.4, and p is as defined above and described in
embodiments herein, both singly and in combination.
[0156] In certain embodiments, the present invention provides a
compound of formula XX, wherein the stereochemistry of the
substituent on the cyclopento ring is (R), and the relative
stereochemistry on the cyclohexyl ring is trans thereby forming a
compound of formula XXI:
##STR00044##
or a pharmaceutically acceptable salt thereof, wherein each of
L.sup.1, R, R.sup.4, and p is as defined above and described in
embodiments herein, both singly and in combination.
[0157] In certain embodiments, the present invention provides a
compound of formula XXI wherein each R.sup.4 is independently
hydrogen, fluoro or --OR.
[0158] In certain embodiments the present invention provides a
compound of formula XXI wherein L.sup.1 is --O--. In certain
embodiments the present invention provides a compound of formula
XXI wherein L.sup.1 is --NH--.
[0159] In certain embodiments, the present invention provides a
compound of formula I, wherein Ring B is piperidino, m is 1, and
R.sup.z is hydrogen, thereby forming a compound of formula
XXII:
##STR00045##
or a pharmaceutically acceptable salt thereof, wherein each of Ring
A, L.sup.1, L.sup.2, R.sup.1, R.sup.4, n, and p is as defined above
and described in embodiments herein, both singly and in
combination.
[0160] In certain embodiments, the present invention provides a
compound of formula XXII, wherein L.sup.2 is a bond and p is 0,
thereby forming a compound of formula XXIII:
##STR00046##
or a pharmaceutically acceptable salt thereof, wherein each of Ring
A, L.sup.1, R.sup.1, R.sup.4, n, and p is as defined above and
described in embodiments herein, both singly and in
combination.
[0161] In certain embodiments the present invention provides a
compound of formula XXIII wherein R.sup.4 is --S(O).sub.2R,
--C(O)R, or --C(O)N(R).sub.2.
[0162] In certain embodiments, the present invention provides a
compound of formula II, wherein L.sup.1 is --O--, thereby forming a
compound of formula XXIV:
##STR00047##
or a pharmaceutically acceptable salt thereof, wherein each of Ring
A, L.sup.2, R.sup.z, R.sup.1, R.sup.4, m, n, and p is as defined
above and described in embodiments herein, both singly and in
combination.
[0163] In certain embodiments, the present invention provides a
compound of formula XXIV, wherein m is 1, thereby forming a
compound of formula XXV:
##STR00048##
or a pharmaceutically acceptable salt thereof, wherein each of Ring
A, L.sup.2, R.sup.z, R.sup.1, R.sup.4, n, and p is as defined above
and described in embodiments herein, both singly and in
combination.
[0164] In certain embodiments, the present invention provides a
compound of formula XXV, wherein Ring A is cyclohexyl, thereby
forming a compound of formula XXVI:
##STR00049##
or a pharmaceutically acceptable salt thereof, wherein each of,
L.sup.2, R.sup.z, R.sup.1, R.sup.4, n, and p is as defined above
and described in embodiments herein, both singly and in
combination.
[0165] In certain embodiments, the present invention provides a
compound of formula I, wherein R.sup.z is --NH--[Ar], thereby
forming a compound of formula XXVII:
##STR00050##
or a pharmaceutically acceptable salt thereof, wherein [Ar] is an
optionally substituted phenyl or heteroaromatic ring, and each of
Ring A, Ring B, L.sup.2, R.sup.z, R.sup.1, R.sup.4, m, n, and p is
as defined above and described in embodiments herein, both singly
and in combination.
[0166] In certain embodiments, the present invention provides a
compound of formula XXVII, wherein n is 1 and Ring A is
1,4-trans-substituted cyclohexyl, thereby forming a compound of
formula XXVIII:
##STR00051##
or a pharmaceutically acceptable salt thereof, wherein [Ar] is an
optionally substituted phenyl or heteroaromatic ring, and each of
Ring A, Ring B, L.sup.1, L.sup.2, R.sup.1, R.sup.4, m, and p is as
defined above and described in embodiments herein, both singly and
in combination.
[0167] As described generally above, [Ar] is an optionally
substituted phenyl or heteroaromatic ring. In some embodiments,
[Ar] is optionally substituted phenyl. In some embodiments, [Ar] is
an optionally substituted heteroaromatic ring. In some embodiments,
[Ar] is an optionally substituted 5-membered heteroaromatic ring.
In some embodiments, [Ar] is an optionally substituted 6-membered
heteroaromatic ring. In some embodiments, [Ar] is an optionally
substituted pyrazole ring.
[0168] In certain embodiments, the present invention provides a
compound of formula XXVIII, wherein Ring B is cyclopento, thereby
forming a compound of formula XXIX:
##STR00052##
or a pharmaceutically acceptable salt thereof, wherein each of
[Ar], L.sup.1, L.sup.2, R.sup.1, R.sup.4, m, and p is as defined
above and described in embodiments herein, both singly and in
combination.
[0169] In certain embodiments, the present invention provides a
compound of formula XXVIII, wherein Ring B is cyclohexo, thereby
forming a compound of formula XXIX:
##STR00053##
or a pharmaceutically acceptable salt thereof, wherein each of
[Ar], L.sup.1, L.sup.2, R.sup.1, R.sup.4, m, and p is as defined
above and described in embodiments herein, both singly and in
combination.
[0170] In certain embodiments, the present invention provides a
compound of formula XXVIII, wherein Ring B is a partially
unsaturated tetrahydropyrano-fused ring, thereby forming a compound
of one of formulae XXX-a, XXX-b, XXX-c, or XXX-d:
##STR00054##
or a pharmaceutically acceptable salt thereof, wherein each of
[Ar], L.sup.1, L.sup.2, R.sup.1, R.sup.4, m, and p is as defined
above and described in embodiments herein, both singly and in
combination.
[0171] In certain embodiments, the present invention provides a
compound of formula XXVIII, wherein Ring B is a partially
unsaturated piperidino-fused ring, thereby forming a compound of
one of formulae XXXI-a, XXXI-b, XXXI-c, or XXXI-d:
##STR00055##
or a pharmaceutically acceptable salt thereof, wherein each of
[Ar], L.sup.1, L.sup.2, R.sup.1, R.sup.4, m, and p is as defined
above and described in embodiments herein, both singly and in
combination.
[0172] In certain embodiments, the present invention provides a
compound of formula XXVIII, wherein Ring B is a partially
unsaturated pyrrolidino-fused ring, thereby forming a compound of
one of formulae XXXII-a, XXXII-b, or XXXII-c:
##STR00056##
or a pharmaceutically acceptable salt thereof, wherein each of
[Ar], L.sup.1, L.sup.2, R.sup.1, R.sup.4, m, and p is as defined
above and described in embodiments herein, both singly and in
combination.
[0173] In certain embodiments, the present invention provides a
compound of formula I, wherein n is 1, Ring A is trans-substituted
cyclohexyl, and Ring B is a partially unsaturated
tetrahydropyrano-fused ring, thereby forming a compound of one of
formulae XXXIII-a, XXXIII-b, XXXIII-c, or XXXIII-d:
##STR00057##
or a pharmaceutically acceptable salt thereof, wherein each of
L.sup.1, L.sup.2, R.sup.1, R.sup.4, R.sup.z, m, and p is as defined
above and described in embodiments herein, both singly and in
combination.
[0174] In certain embodiments, the present invention provides a
compound of formula I, wherein n is 1, Ring A is trans-substituted
cyclohexyl, and Ring B is a partially unsaturated piperidino-fused
ring, thereby forming a compound of one of formulae XXXIV-a,
XXXIV-b, XXXIV-c, or XXXIV-d:
##STR00058##
or a pharmaceutically acceptable salt thereof, wherein each of
L.sup.1, L.sup.2, R.sup.1, R.sup.4, R.sup.z, m, and p is as defined
above and described in embodiments herein, both singly and in
combination.
[0175] In certain embodiments, the present invention provides a
compound of formula I, wherein n is 1, Ring A is trans-substituted
cyclohexyl, and Ring B is a partially unsaturated pyrrolidino-fused
ring, thereby forming a compound of one of formulae XXXV-a, XXXV-b,
or XXXV-c:
##STR00059##
or a pharmaceutically acceptable salt thereof, wherein each of
L.sup.1, L.sup.2, R.sup.1, R.sup.4, R.sup.z, m, and p is as defined
above and described in embodiments herein, both singly and in
combination.
[0176] In certain embodiments, the present invention provides a
compound of formula XXXIII-a, XXXIII-b, XXXIII-c, or XXXIII-d,
wherein R.sup.z is hydrogen, thereby forming a compound of one of
formulae XXXVI-a, XXXVI-b, XXXVI-c, or XXXVI-d:
##STR00060##
or a pharmaceutically acceptable salt thereof, wherein each of
L.sup.1, L.sup.2, R.sup.1, R.sup.4, m, and p is as defined above
and described in embodiments herein, both singly and in
combination.
[0177] In certain embodiments, the present invention provides a
compound of formula XXXIV-a, XXXIV-b, XXXIV-c, or XXXIV-d, wherein
R.sup.z is hydrogen, thereby forming a compound of one of formulae
XXXVII-a, XXXVII-b, XXXVII-c, or XXXVII-d:
##STR00061##
or a pharmaceutically acceptable salt thereof, wherein each of
L.sup.1, L.sup.2, R.sup.1, R.sup.4, m, and p is as defined above
and described in embodiments herein, both singly and in
combination.
[0178] In certain embodiments, the present invention provides a
compound of formula XXXV-a, XXXV-b, or XXXV-c, wherein R.sup.z is
hydrogen, thereby forming a compound of one of formulae XXXVIII-a,
XXXVIII-b, or XXXVIII-c:
##STR00062##
or a pharmaceutically acceptable salt thereof, wherein each of
L.sup.1, L.sup.2, R.sup.1, R.sup.4, m, and p is as defined above
and described in embodiments herein, both singly and in
combination.
[0179] In certain embodiments, the present invention provides a
compound of formula I, wherein W is N, and R.sup.z is hydrogen,
thereby forming a compound of formula I-a:
##STR00063##
or a pharmaceutically acceptable salt thereof, wherein each of Ring
A, Ring B, L.sup.1, L.sup.2, W, R.sup.z, R.sup.1, R.sup.4, m, n,
and p is as defined above and described in embodiments herein, both
singly and in combination.
[0180] Exemplary compounds of the invention are set forth in Table
1, below.
TABLE-US-00001 TABLE 1 Exemplary Compounds Com- pound Structure I-1
##STR00064## I-2 ##STR00065## I-3 ##STR00066## I-4 ##STR00067## I-5
##STR00068## I-6 ##STR00069## I-7 ##STR00070## I-8 ##STR00071## I-9
##STR00072## I-10 ##STR00073## I-11 ##STR00074## I-12 ##STR00075##
I-13 ##STR00076## I-14 ##STR00077## I-15 ##STR00078## I-16
##STR00079## I-17 ##STR00080## I-18 ##STR00081## I-19 ##STR00082##
I-20 ##STR00083## I-21 ##STR00084## I-22 ##STR00085## I-23
##STR00086## I-24 ##STR00087## I-25 ##STR00088## I-26 ##STR00089##
I-27 ##STR00090## I-28 ##STR00091## I-29 ##STR00092## I-30
##STR00093## I-31 ##STR00094## I-32 ##STR00095## I-33 ##STR00096##
I-34 ##STR00097## I-35 ##STR00098## I-36 ##STR00099## I-37
##STR00100## I-38 ##STR00101## I-39 ##STR00102## I-40 ##STR00103##
I-41 ##STR00104## I-42 ##STR00105## I-43 ##STR00106## I-44
##STR00107## I-45 ##STR00108## I-46 ##STR00109## I-47 ##STR00110##
I-48 ##STR00111## I-49 ##STR00112## I-50 ##STR00113## I-51
##STR00114## I-52 ##STR00115## I-53 ##STR00116## I-54 ##STR00117##
I-55 ##STR00118## I-56 ##STR00119## I-57 ##STR00120## I-58
##STR00121## I-59 ##STR00122## I-60 ##STR00123## I-61 ##STR00124##
I-62 ##STR00125## I-63 ##STR00126## I-64 ##STR00127## I-65
##STR00128## I-66 ##STR00129## I-67 ##STR00130## I-68 ##STR00131##
I-69 ##STR00132## I-70 ##STR00133## I-71 ##STR00134## I-72
##STR00135## I-73 ##STR00136## I-74 ##STR00137## I-75 ##STR00138##
I-76 ##STR00139## I-77 ##STR00140## I-78 ##STR00141## I-79
##STR00142## I-80 ##STR00143## I-81 ##STR00144## I-82 ##STR00145##
I-83 ##STR00146## I-84 ##STR00147## I-85 ##STR00148## I-86
##STR00149## I-87 ##STR00150## I-88 ##STR00151## I-89 ##STR00152##
I-90 ##STR00153## I-91 ##STR00154## I-92 ##STR00155## I-93
##STR00156## I-94 ##STR00157## I-95 ##STR00158## I-96 ##STR00159##
I-97 ##STR00160## I-98 ##STR00161## I-99 ##STR00162## I-100
##STR00163## I-101 ##STR00164## I-102 ##STR00165## I-103
##STR00166## I-104 ##STR00167## I-105 ##STR00168## I-106
##STR00169## I-107 ##STR00170## I-108 ##STR00171## I-109
##STR00172## I-110 ##STR00173## I-111 ##STR00174## I-112
##STR00175## I-113 ##STR00176## I-116 ##STR00177## I-117
##STR00178## I-118 ##STR00179## I-119 ##STR00180## I-120
##STR00181## I-121 ##STR00182## I-122 ##STR00183## I-123
##STR00184## I-124 ##STR00185##
I-125 ##STR00186## I-126 ##STR00187## I-127 ##STR00188## I-128
##STR00189## I-129 ##STR00190## I-130 ##STR00191## I-131
##STR00192## I-132 ##STR00193## I-133 ##STR00194## I-134
##STR00195## I-135 ##STR00196## I-136 ##STR00197## I-137
##STR00198## I-138 ##STR00199## I-139 ##STR00200## I-140
##STR00201## I-141 ##STR00202## I-142 ##STR00203## I-143
##STR00204## I-144 ##STR00205## I-145 ##STR00206## I-146
##STR00207## I-147 ##STR00208## I-148 ##STR00209## I-149
##STR00210## I-150 ##STR00211## I-151 ##STR00212## I-152
##STR00213## I-153 ##STR00214## I-154 ##STR00215## I-155
##STR00216## I-156 ##STR00217## I-157 ##STR00218## I-158
##STR00219## I-159 ##STR00220## I-160 ##STR00221## I-161
##STR00222## I-162 ##STR00223## I-163 ##STR00224## I-167
##STR00225## I-168 ##STR00226## I-169 ##STR00227## I-170
##STR00228## I-171 ##STR00229## I-172 ##STR00230## I-173
##STR00231## I-174 ##STR00232## I-175 ##STR00233## I-176
##STR00234## I-177 ##STR00235## I-178 ##STR00236## I-179
##STR00237## I-181 ##STR00238## I-182 ##STR00239## I-183
##STR00240## I-184 ##STR00241## I-185 ##STR00242## I-186
##STR00243## I-187 ##STR00244## I-188 ##STR00245## I-190
##STR00246## I-192 ##STR00247## I-193 ##STR00248## I-194
##STR00249## I-195 ##STR00250## I-196 ##STR00251## I-197
##STR00252## I-198 ##STR00253## I-199 ##STR00254## I-200
##STR00255## I-201 ##STR00256## I-202 ##STR00257## I-203
##STR00258## I-204 ##STR00259## I-205 ##STR00260## I-206
##STR00261## I-207 ##STR00262## I-208 ##STR00263## I-209
##STR00264## I-210 ##STR00265## I-211 ##STR00266## I-212
##STR00267## I-213 ##STR00268## I-214 ##STR00269## I-215
##STR00270## I-216 ##STR00271## I-217 ##STR00272## I-218
##STR00273## I-219 ##STR00274## I-220 ##STR00275## I-221
##STR00276## I-222 ##STR00277## I-224 ##STR00278## I-226
##STR00279## I-227 ##STR00280## I-228 ##STR00281## I-229
##STR00282## I-230 ##STR00283## I-231 ##STR00284## I-232
##STR00285## I-233 ##STR00286## I-234 ##STR00287## I-235
##STR00288## I-236 ##STR00289## I-237 ##STR00290## I-238
##STR00291## I-240 ##STR00292## I-241 ##STR00293## I-242
##STR00294## I-242 ##STR00295## I-243 ##STR00296## I-244
##STR00297## I-245 ##STR00298## I-246 ##STR00299## I-247
##STR00300## I-248 ##STR00301## I-249 ##STR00302## I-250
##STR00303## I-251 ##STR00304## I-252 ##STR00305## I-253
##STR00306## I-254 ##STR00307## I-255 ##STR00308## I-256
##STR00309## I-257 ##STR00310## I-258 ##STR00311##
I-259 ##STR00312## I-260 ##STR00313## I-261 ##STR00314## I-262
##STR00315## I-263 ##STR00316## I-264 ##STR00317## I-265
##STR00318## I-266 ##STR00319## I-267 ##STR00320## I-268
##STR00321## I-269 ##STR00322## I-270 ##STR00323## I-271
##STR00324## I-272 ##STR00325## I-273 ##STR00326## I-274
##STR00327## I-275 ##STR00328## I-276 ##STR00329## I-277
##STR00330## I-278 ##STR00331## I-279 ##STR00332## I-280
##STR00333## I-281 ##STR00334## I-282 ##STR00335## I-283
##STR00336## I-284 ##STR00337## I-285 ##STR00338## I-286
##STR00339## I-287 ##STR00340## I-288 ##STR00341## I-289
##STR00342## I-290 ##STR00343## I-291 ##STR00344## I-292
##STR00345## I-293 ##STR00346## I-294 ##STR00347## I-295
##STR00348## I-296 ##STR00349## I-297 ##STR00350## I-298
##STR00351##
[0181] In some embodiments, the present invention provides a
compound set forth in Table 1, above, or a pharmaceutically
acceptable salt thereof.
[0182] Without wishing to be bound by any particular theory, it is
believed that proximity of an inhibitor compound, or pendant moiety
of an inhibitor compound, to the water of interest facilitates
displacement or disruption of that water by the inhibitor compound,
or pendant moiety of an inhibitor compound. In some embodiments, a
water molecule displaced or disrupted by an inhibitor compound, or
pendant moiety of an inhibitor compound, is an unstable water
molecule.
[0183] In certain embodiments, the present invention provides a
complex comprising IRAK-4 and an inhibitor, wherein at least one
unstable water of IRAK-4 is displaced or disrupted by the
inhibitor. In some embodiments, at least two unstable waters
selected are displaced or disrupted by the inhibitor.
4. General Methods of Providing the Present Compounds
[0184] The compounds of this invention may be prepared or isolated
in general by synthetic and/or semi-synthetic methods known to
those skilled in the art for analogous compounds and by methods
described in detail in the Examples, herein. Methods and
intermediates of the present invention are useful for preparing
compounds as described in, e.g. U.S. patent application Ser. No.
61/734,133, filed Dec. 6, 2012, in the name of Harriman et al., the
entirety of which is incorporated herein by reference.
[0185] In the Schemes below, where a particular protecting group,
leaving group, or transformation condition is depicted, one of
ordinary skill in the art will appreciate that other protecting
groups, leaving groups, and transformation conditions are also
suitable and are contemplated. Such groups and transformations are
described in detail in March's Advanced Organic Chemistry:
Reactions, Mechanisms, and Structure, M. B. Smith and J. March,
5.sup.th Edition, John Wiley & Sons, 2001, Comprehensive
Organic Transformations, R. C. Larock, 2.sup.nd Edition, John Wiley
& Sons, 1999, and Protecting Groups in Organic Synthesis, T. W.
Greene and P. G. M. Wuts, 3.sup.rd edition, John Wiley & Sons,
1999, the entirety of each of which is hereby incorporated herein
by reference.
[0186] As used herein, the phrase "oxygen protecting group"
includes, for example, carbonyl protecting groups, hydroxyl
protecting groups, etc. Hydroxyl protecting groups are well known
in the art and include those described in detail in Protecting
Groups in Organic Synthesis, T. W. Greene and P. G. M. Wuts,
3.sup.rd edition, John Wiley & Sons, 1999, the entirety of
which is incorporated herein by reference. Examples of suitable
hydroxyl protecting groups include, but are not limited to, esters,
allyl ethers, ethers, silyl ethers, alkyl ethers, arylalkyl ethers,
and alkoxyalkyl ethers. Examples of such esters include formates,
acetates, carbonates, and sulfonates. Specific examples include
formate, benzoyl formate, chloroacetate, trifluoroacetate,
methoxyacetate, triphenylmethoxyacetate, p-chlorophenoxyacetate,
3-phenylpropionate, 4-oxopentanoate,
4,4-(ethylenedithio)pentanoate, pivaloate (trimethylacetyl),
crotonate, 4-methoxy-crotonate, benzoate, p-benylbenzoate,
2,4,6-trimethylbenzoate, carbonates such as methyl,
9-fluorenylmethyl, ethyl, 2,2,2-trichloroethyl, 2-(trimethyl
silyl)ethyl, 2-(phenylsulfonyl)ethyl, vinyl, allyl, and
p-nitrobenzyl. Examples of such silyl ethers include
trimethylsilyl, triethylsilyl, t-butyldimethylsilyl,
t-butyldiphenylsilyl, triisopropylsilyl, and other trialkylsilyl
ethers. Alkyl ethers include methyl, benzyl, p-methoxybenzyl,
3,4-dimethoxybenzyl, trityl, t-butyl, allyl, and allyloxycarbonyl
ethers or derivatives. Alkoxyalkyl ethers include acetals such as
methoxymethyl, methylthiomethyl, (2-methoxyethoxy)methyl,
benzyloxymethyl, beta-(trimethylsilyl)ethoxymethyl, and
tetrahydropyranyl ethers. Examples of arylalkyl ethers include
benzyl, p-methoxybenzyl (MPM), 3,4-dimethoxybenzyl, O-nitrobenzyl,
p-nitrobenzyl, p-halobenzyl, 2,6-dichlorobenzyl, p-cyanobenzyl, and
2- and 4-picolyl.
[0187] Amino protecting groups are well known in the art and
include those described in detail in Protecting Groups in Organic
Synthesis, T. W. Greene and P. G. M. Wuts, 3.sup.rd edition, John
Wiley & Sons, 1999, the entirety of which is incorporated
herein by reference. Suitable amino protecting groups include, but
are not limited to, aralkylamines, carbamates, cyclic imides, allyl
amines, amides, and the like. Examples of such groups include
t-butyloxycarbonyl (BOC), ethyloxycarbonyl, methyloxycarbonyl,
trichloroethyloxycarbonyl, allyloxycarbonyl (Alloc),
benzyloxocarbonyl (CBZ), allyl, phthalimide, benzyl (Bn),
fluorenylmethylcarbonyl (Fmoc), formyl, acetyl, chloroacetyl,
dichloroacetyl, trichloroacetyl, phenylacetyl, trifluoroacetyl,
benzoyl, and the like. In certain embodiments, the amino protecting
group of the R.sup.10 moiety is phthalimido. In still other
embodiments, the amino protecting group of the R.sup.10 moiety is a
tert-butyloxycarbonyl (BOC) group. In certain embodiments, the
amino protecting group is a sulphone (SO.sub.2R).
[0188] In certain embodiments, compounds of the present invention
are generally prepared according to Scheme I set forth below:
##STR00352## ##STR00353##
[0189] In Scheme I above, each of n, LG, R.sup.1, R.sup.A1,
R.sup.A2, L.sup.1, Ring A, and Ring B is as defined above and below
and in classes and subclasses as described herein.
[0190] In one aspect, the present invention provides methods for
preparing chiral compounds of formula G-10 according to the steps
depicted in Scheme 1, above. In some embodiments, at step S-1, a
cyclic ketone of formula G-1 containing a Ring B is reacted with a
cyanoacetic acid ester, or an equivalent thereof, to effect a
condensation and dehydration reaction to form an olefin of formula
G-2. In certain embodiments, the condensation reaction is performed
in the presence of an amine and an acid. In some embodiments the
base is HMDS (hexamethyldisilazane). In some embodiments the acid
is acetic acid. In some embodiments, the S-1 reaction is performed
without additional solvent. In some embodiments the cyclic ketone
is cyclopentanone. In some embodiments the cyclic ketone is a
cyclohexanone. In some embodiments, the cyclic ketone is a
pyranone. In some embodiments R.sup.A1 is a C.sub.1-6 alkyl group.
In some embodiments R.sup.A1 is ethyl. In some embodiments R.sup.A2
is a C.sub.1-6 alkyl group. In some embodiments R.sup.A2 is
ethyl.
[0191] In some embodiments, step S-2 comprises contacting a
compound of formula G-2 with elemental sulfur in the presence of an
amine to form a compound of formula G-3. In some embodiments the
amine is dimethylamine. In some embodiments step S-2 is performed
with an alcohol as solvent. In some embodiments, the solvent is
ethanol. In some embodiments steps S-1 and S-2 are performed
without an intermediate purification of compound G-2.
[0192] In some embodiments, step S-3 comprises contacting the
intermediate of formula G-3 with formamide to form a
thienopyrimidine compound of formula G-4. In some embodiments the
reaction further comprises contacting the reaction mixture with
formamidine acetate.
[0193] In some embodiments, step S-4 comprises contacting the
compound of formula G-4 with a reagent to convert the hydroxyl
group into a leaving group LG. In some embodiments LG is a halogen.
In some embodiments LG is chlorine. In some embodiments LG is a
sulfonate. In some embodiments the reagent used to convert the
hydroxyl group into LG is phosphorus oxychloride. In some
embodiments step S-4 is performed in a solvent. In some embodiments
the solvent is acetonitrile. In some embodiments step S-4 is
performed without additional solvent.
[0194] In some embodiments step S-5 comprises contacting a compound
of formula G-5 with a reagent to convert the ester group into a
carboxylic acid, thereby forming a compound of formula G-6. In some
embodiments the deesterification reagent is a base. In some
embodiments the base is lithium hydroxide. In some embodiments the
reagent is an acid. In some embodiments the reaction is performed
in aqueous solvent. In some embodiments tetrahydrofuran is employed
as a cosolvent. In some embodiments the reaction mixture further
comprises TEAC (tetraethylammonium chloride) as a catalyst. In some
embodiments the TEAC is present in substoichiometric amounts. In
some embodiments step S-5 further comprises acidifying the crude
reaction to obtain the free acid.
[0195] One of skill in the art will appreciate that compounds of
formulae G-1, G-2, G-3, G-4, G-5, and G-6 contain a stereocenter,
and are present as an racemic mixture. One of skill in the art will
also appreciate that there are many methods known in the art for
the separation of enantiomers to obtain enantioenriched or
enantiopure isomers of those compounds, including but not limited
to chiral HPLC, fractional crystallization of diastereomeric salts,
kinetic enzymatic resolution (e.g. by fungal-, bacterial-, or
animal-derived lipases or esterases), and formation of covalent
diastereomeric derivatives using an enantioenriched reagent. In
some embodiments, the enantiomers of a compound of formula G-5 are
resolved by the action of lipase enzymes.
[0196] In some embodiments step S-6 comprises contacting a racemic
compound of formula G-6 with a chiral agent to form a mixture of
diastereomeric salts. The resulting diastereomeric mixture is then
separated by suitable means to obtain a compound of formula G-7.
Such suitable means for separating diastereomeric mixtures are well
known to one of ordinary skill in the art and include, but are not
limited to, those methods described herein. It will be appreciated
that, depending upon the chiral agent used, there may be one or
more basic moieties present. In certain embodiments, the chiral
base has two basic moieties as with, for example,
1,2-diphenylethane-1,2-diamine. In some embodiments the chiral
agent is an enantioenriched monoamine. In some embodiments the
chiral agent is selected from 1-phenethylamine, aminobutanol,
phenylglycinol, p-methoxybenzyl-1-phenethylamine, cinchonine,
p-dimethylaminobenzyl-1-phenethylamine, quinidine, cinchonidine,
quinine, ephedrine, and norephedrine. In some embodiments the
chiral agent is selected from cinchonine, cinchonidine, and
ephedrine. In some embodiments the chiral agent is cinchonine. In
some embodiments the chiral agent is cinchonidine. In some
embodiments the chiral agent is ephedrine. In some embodiments the
chiral agent is (-)-ephedrine.
[0197] Accordingly, one of ordinary skill in the art would
appreciate that a compound of formula G-6 may form a hemi salt with
said bi-functional chiral agent. As used herein, the term "hemi
salt" refers to an adduct having two molecules of a compound of
formula G-6 to each molecule of chiral acid. Alternatively, the
resulting salt may have a one-to-one mixture chiral acid to a
compound of formula G-6. In certain embodiments, the present
invention provides a compound comprises equal molar amounts of the
chiral agent to an acid of formula G-6. Furthermore, one of skill
in the art that following resolution of the diastereomeric mixture
of salts (e.g. by fractional crystallization), an enantioenriched
salt is obtained from both the crystalline fraction and from the
mother liquor. Accordingly, in some embodiments, the present
invention provides a compound of formula G-7 wherein said compound
comprises a molecule of a compound of formula G-8 in its salt form
together with one or more molecules of the chiral agent. In some
embodiments, the salt compound of formula G-7 comprises one
molecule of a compound of formula G-8 together with one molecule of
a chiral agent. In some embodiments, the salt compound of formula
G-7 is a hemi salt comprising two molecules of a compound of
formula G-8 together with one molecule of a dibasic chiral agent.
In some embodiments, the compound of formula G-7 is a cinchonine
salt, a cinchonidine salt, or an ephedrine salt.
[0198] In some embodiments the method of chiral resolution step S-6
comprises contacting a compound of formula G-6 with a chiral agent
in a solvent. In some embodiments the chiral agent is selected from
cinchonine, cinchonidine, and ephedrine. In some embodiments the
solvent is an alcohol. In some embodiments the solvent is
isopropanol. In some embodiments the mixture is heated. In some
embodiments the solution is supersaturated. In some embodiments the
reaction is seeded with a crystal. In some embodiments the
resulting crystal mass is recrystallized from isopropanol.
[0199] When the chiral agent is a chiral amine, the compound of
formula G-7, in step S-7, is treated with a suitable acid to form
the enantioenriched free acid compound G-8. Free acids according to
the invention are also prepared, for example, by contacting a
compound of formula G-7 with a suitable acid in the presence of a
solvent suitable for free acid formation. Such suitable acids
include strong inorganic acids, i.e., those that completely
dissociate in water. In certain embodiments, the acid is added in
an amount of at least about 1 mol. eq. and, in other embodiments,
in an amount of at least about 1 mol. eq. to about 2 mol. eq.
relative to the compound of formula G-7. Examples of such acids
include mineral acids, sulfonic acids, and combinations thereof. In
some embodiments, the suitable acid is hydrochloric acid. In some
embodiments, the solvent used to extract the free acid formed is an
organic solvent.
[0200] Examples of solvents suitable for use during free base
formation at step S-7 include polar solvents such as alkyl
alcohols, such as C.sub.1 to C.sub.4 alcohols (e.g. ethanol,
methanol, 2-propanol), water, dioxane, or THF (tetrahydrofuran) or
combinations thereof. In certain embodiments, the suitable solvent
is a C.sub.1 to C.sub.4 alcohol such as methanol, ethanol,
2-propanol, water, or combination thereof. According to one aspect
of the present invention, aqueous hydrochloric acid is used at step
S-7. According to another aspect of the present invention, the free
base formation at step S-7 is performed in a bi-phasic mixture of
solvents whereby the compound of formula G-8, as it is formed, is
extracted into an organic layer. Thus, a suitable bi-phasic mixture
of solvents includes an aqueous solvent and a non-miscible organic
solvent. Such non-miscible organic solvents are well known to one
of ordinary skill in the art and include halogenated hydrocarbon
solvents (e.g. dichloromethane and chloroform), benzene and
derivatives thereof (e.g. toluene), esters (e.g. ethyl acetate and
isopropyl acetate), and ethers (e.g. MTBE, THF and derivatives
thereof, glyme, and diglyme) and the like. In certain embodiments,
the free acid formation at step S-7 is performed in a bi-phasic
mixture comprising aqueous hydrochloric acid and dichloromethane.
In some embodiments, the suitable acid is water soluble such that
the reaction is performed in a mixture of dichloromethane and a
suitable aqueous acid, such as aqueous hydrochloric acid.
[0201] At step S-8, displacement of LG of the chiral compound G-8
affords a compound of formula G-9. In certain embodiments, step S-8
comprises contacting a compound of formula G-8 with a compound of
the formula
##STR00354##
wherein L.sup.1, R.sup.1, Ring A, and n are defined above and below
and in classes and subclasses as described herein.
[0202] In some embodiments L.sup.1 is selected from 0- and --NH--,
such that together with the hydrogen filling the open valence,
L.sup.1H denotes an --OH or --NH.sub.2 group. In some embodiments
L.sup.1H is --OH. In some embodiments L.sup.1H is --NH.sub.2.
[0203] In some embodiments n is 0-4. In some embodiments n is 1-4.
In some embodiments n is 1.
[0204] In some embodiments R.sup.1 is --NR.sub.2. In some
embodiments R.sup.1 is dimethylamino. In some embodiments R.sup.1
is morpholino. In some embodiments, Ring A is piperidine. In some
embodiments Ring A is cyclohexyl. In some embodiments step S-8
comprises contacting a compound of formula G-8 having the
structure:
##STR00355##
with a compound of the formula:
##STR00356##
thereby forming a compound of formula G-9 having the structure:
##STR00357##
[0205] In some embodiments step S-8 further comprises contacting
the reaction mixture with a base. In some embodiments the base is
sodium bis(trimethylsilyl)amide. In some embodiments the reaction
further comprises a solvent. In some embodiments the solvent is
THF.
[0206] In some embodiments step S-9 comprises contacting a compound
of formula G-9 with an amidating reagent system, thereby forming a
compound of formula G-10. In some embodiments the amidating reagent
system comprises thionyl chloride and ammonia. In some embodiments
step S-9 further comprises use of a solvent. In some embodiments
the solvent is methanol. In some embodiments step S-9 comprises
contacting a compound of formula G-9 first with an activating
reagent, and second with ammonia. In some embodiments the
activating reagent is thionyl chloride.
[0207] As used herein, the term "diastereomeric salt" refers to the
adduct of a chiral compound of formula G-6 with a chiral base.
[0208] As used herein, the term "enantiomeric salt" refers to the
salt of the resolved chiral compound of formula G-8, wherein said
compound of formula G-8 is enriched in one enantiomer. As used
herein, the term "enantiomerically enriched", as used herein
signifies that one enantiomer makes up at least 80% or 85% of the
preparation. In certain embodiments, the term enantiomerically
enriched signifies that at least 90% of the preparation is one of
the enantiomers. In other embodiments, the term signifies that at
least 95% of the preparation is one of the enantiomers. In other
embodiments, the term signifies that at least 98% of the
preparation is one of the enantiomers.
[0209] In certain embodiments, compounds of the present invention
wherein R.sup.z is [Ar]--NH-- are generally prepared according to
Scheme II set forth below:
##STR00358## ##STR00359##
[0210] In Scheme I above, each of n, [Ar], LG, R.sup.1, R.sup.A1,
R.sup.A2, L.sup.1, Ring A, and Ring B is as defined above and below
and in classes and subclasses as described herein.
[0211] In one aspect, the present invention provides methods for
preparing chiral compounds of formula H-10 according to the steps
depicted in Scheme 1, above. In some embodiments, at step S-1, a
cyclic ketone of formula H-1 containing a Ring B is reacted with a
cyanoacetic acid ester, or an equivalent thereof, to effect a
condensation and dehydration reaction to form an olefin of formula
H-2. In certain embodiments, the condensation reaction is performed
in the presence of an amine and an acid. In some embodiments the
base is HMDS (hexamethyldisilazane). In some embodiments the acid
is acetic acid. In some embodiments, the S-1 reaction is performed
without additional solvent. In some embodiments the cyclic ketone
is cyclopentanone. In some embodiments the cyclic ketone is a
cyclohexanone. In some embodiments, the cyclic ketone is a
pyranone. In some embodiments R.sup.A1 is a C.sub.1-6 alkyl group.
In some embodiments R.sup.A1 is ethyl. In some embodiments R.sup.A2
is a C.sub.1-6 alkyl group. In some embodiments R.sup.A2 is
ethyl.
[0212] In some embodiments, step S-2 comprises contacting a
compound of formula H-2 with elemental sulfur in the presence of an
amine to form a compound of formula H-3. In some embodiments the
amine is dimethylamine. In some embodiments step S-2 is performed
with an alcohol as solvent. In some embodiments, the solvent is
ethanol. In some embodiments steps S-1 and S-2 are performed
without an intermediate purification of compound H-2.
[0213] In some embodiments, step S-3 comprises contacting the
intermediate of formula H-3 with formamide to form a
thienopyrimidine compound of formula H-4. In some embodiments the
reaction further comprises contacting the reaction mixture with
formamidine acetate.
[0214] In some embodiments, step S-4 comprises contacting the
compound of formula H-4 with a reagent to convert the hydroxyl
group into a leaving group LG, thereby forming a compound of
formula H-5. In some embodiments LG is a halogen. In some
embodiments LG is chlorine. In some embodiments LG is a sulfonate.
In some embodiments the reagent used to convert the hydroxyl group
into LG is phosphorus oxychloride. In some embodiments step S-4 is
performed in a solvent. In some embodiments the solvent is
acetonitrile. In some embodiments step S-4 is performed without
additional solvent.
[0215] In some embodiments step S-5 comprises contacting a compound
of formula H-5 with a reagent to convert the ester group into a
carboxylic acid, thereby forming a compound of formula H-6. In some
embodiments the deesterification reagent is a base. In some
embodiments the base is lithium hydroxide. In some embodiments the
reagent is an acid. In some embodiments the reaction is performed
in aqueous solvent. In some embodiments tetrahydrofuran is employed
as a cosolvent. In some embodiments the reaction mixture further
comprises TEAC (tetraethylammonium chloride) as a catalyst. In some
embodiments the TEAC is present in substoichiometric amounts. In
some embodiments step S-5 further comprises acidifying the crude
reaction to obtain the free acid.
[0216] One of skill in the art will appreciate that compounds of
formulae H-1, H-2, H-3, H-4, H-5, and H-6 contain a stereocenter,
and are present as an racemic mixture. One of skill in the art will
also appreciate that there are many methods known in the art for
the separation of enantiomers to obtain enantioenriched or
enantiopure isomers of those compounds, including but not limited
to chiral HPLC, fractional crystallization of diastereomeric salts,
kinetic enzymatic resolution (e.g. by fungal-, bacterial-, or
animal-derived lipases or esterases), and formation of covalent
diastereomeric derivatives using an enantioenriched reagent. In
some embodiments, the enantiomers of a compound of formula H-5 are
resolved by the action of lipase enzymes.
[0217] In some embodiments step S-6 comprises contacting a racemic
compound of formula H-6 with a chiral agent to form a mixture of
diastereomeric salts. The resulting diastereomeric mixture is then
separated by suitable means to obtain a compound of formula H-7.
Such suitable means for separating diastereomeric mixtures are well
known to one of ordinary skill in the art and include, but are not
limited to, those methods described herein. It will be appreciated
that, depending upon the chiral agent used, there may be one or
more basic moieties present. In certain embodiments, the chiral
base has two basic moieties as with, for example,
1,2-diphenylethane-1,2-diamine. In some embodiments the chiral
agent is an enantioenriched monoamine. In some embodiments the
chiral agent is selected from 1-phenethylamine, aminobutanol,
phenylglycinol, p-methoxybenzyl-1-phenethylamine, cinchonine,
p-dimethylaminobenzyl-1-phenethylamine, quinidine, cinchonidine,
quinine, ephedrine, and norephedrine. In some embodiments the
chiral agent is selected from cinchonine, cinchonidine, and
ephedrine. In some embodiments the chiral agent is cinchonine. In
some embodiments the chiral agent is cinchonidine. In some
embodiments the chiral agent is ephedrine. In some embodiments the
chiral agent is (-)-ephedrine.
[0218] Accordingly, one of ordinary skill in the art would
appreciate that a compound of formula H-6 may form a hemi salt with
said bi-functional chiral agent. As used herein, the term "hemi
salt" refers to an adduct having two molecules of a compound of
formula H-6 to each molecule of chiral acid. Alternatively, the
resulting salt may have a one-to-one mixture chiral acid to a
compound of formula H-6. In certain embodiments, the present
invention provides a compound comprises equal molar amounts of the
chiral agent to an acid of formula H-6. Furthermore, one of skill
in the art that following resolution of the diastereomeric mixture
of salts (e.g. by fractional crystallization), an enantioenriched
salt is obtained from both the crystalline fraction and from the
mother liquor. Accordingly, in some embodiments, the present
invention provides a compound of formula H-7 wherein said compound
comprises a molecule of a compound of formula H-8 in its salt form
together with one or more molecules of the chiral agent. In some
embodiments, the salt compound of formula H-7 comprises one
molecule of a compound of formula H-8 together with one molecule of
a chiral agent. In some embodiments, the salt compound of formula
H-7 is a hemi salt comprising two molecules of a compound of
formula H-8 together with one molecule of a dibasic chiral agent.
In some embodiments, the compound of formula H-7 is a cinchonine
salt, a cinchonidine salt, or an ephedrine salt.
[0219] In some embodiments the method of chiral resolution step S-6
comprises contacting a compound of formula H-6 with a chiral agent
in a solvent. In some embodiments the chiral agent is selected from
cinchonine, cinchonidine, and ephedrine. In some embodiments the
solvent is an alcohol. In some embodiments the solvent is
isopropanol. In some embodiments the mixture is heated. In some
embodiments the solution is supersaturated. In some embodiments the
reaction is seeded with a crystal. In some embodiments the
resulting crystal mass is recrystallized from isopropanol.
[0220] When the chiral agent is a chiral amine, the compound of
formula H-7, in step S-7, is treated with a suitable acid to form
the enantioenriched free acid compound H-8. Free acids according to
the invention are also prepared, for example, by contacting a
compound of formula H-7 with a suitable acid in the presence of a
solvent suitable for free acid formation. Such suitable acids
include strong inorganic acids, i.e., those that completely
dissociate in water. In certain embodiments, the acid is added in
an amount of at least about 1 mol. eq. and, in other embodiments,
in an amount of at least about 1 mol. eq. to about 2 mol. eq.
relative to the compound of formula H-7. Examples of such acids
include mineral acids, sulfonic acids, and combinations thereof. In
some embodiments, the suitable acid is hydrochloric acid. In some
embodiments, the solvent used to extract the free acid formed is an
organic solvent.
[0221] Examples of solvents suitable for use during free base
formation at step S-7 include polar solvents such as alkyl
alcohols, such as C.sub.1 to C.sub.4 alcohols (e.g. ethanol,
methanol, 2-propanol), water, dioxane, or THF (tetrahydrofuran) or
combinations thereof. In certain embodiments, the suitable solvent
is a C.sub.1 to C.sub.4 alcohol such as methanol, ethanol,
2-propanol, water, or combination thereof. According to one aspect
of the present invention, aqueous hydrochloric acid is used at step
S-7. According to another aspect of the present invention, the free
base formation at step S-7 is performed in a bi-phasic mixture of
solvents whereby the compound of formula H-8, as it is formed, is
extracted into an organic layer. Thus, a suitable bi-phasic mixture
of solvents includes an aqueous solvent and a non-miscible organic
solvent. Such non-miscible organic solvents are well known to one
of ordinary skill in the art and include halogenated hydrocarbon
solvents (e.g. dichloromethane and chloroform), benzene and
derivatives thereof (e.g. toluene), esters (e.g. ethyl acetate and
isopropyl acetate), and ethers (e.g. MTBE, THF and derivatives
thereof, glyme, and diglyme) and the like. In certain embodiments,
the free acid formation at step S-7 is performed in a bi-phasic
mixture comprising aqueous hydrochloric acid and dichloromethane.
In some embodiments, the suitable acid is water soluble such that
the reaction is performed in a mixture of dichloromethane and a
suitable aqueous acid, such as aqueous hydrochloric acid.
[0222] At step S-8, displacement of LG of the chiral compound H-8
affords a compound of formula H-9. In certain embodiments, step S-8
comprises contacting a compound of formula H-8 with a compound of
the formula
##STR00360##
wherein L.sup.1, R.sup.1, Ring A, and n are defined above and below
and in classes and subclasses as described herein.
[0223] In some embodiments L.sup.1 is selected from 0- and --NH--,
such that together with the hydrogen filling the open valence,
L.sup.1H denotes an --OH or --NH.sub.2 group. In some embodiments
L.sup.1H is --OH. In some embodiments L.sup.1H is --NH.sub.2.
[0224] In some embodiments n is 0-4. In some embodiments n is 1-4.
In some embodiments n is 1.
[0225] In some embodiments R.sup.1 is --NR.sub.2. In some
embodiments R.sup.1 is dimethylamino. In some embodiments R.sup.1
is morpholino. In some embodiments, Ring A is piperidine. In some
embodiments Ring A is cyclohexyl.
[0226] In some embodiments step S-8 further comprises contacting
the reaction mixture with a base. In some embodiments the base is
sodium bis(trimethylsilyl)amide. In some embodiments the reaction
further comprises a solvent. In some embodiments the solvent is
THF.
[0227] In some embodiments step S-9 comprises contacting a compound
of formula H-9 with a compound of formula [Ar]--NH.sub.2, thereby
forming a compound of formula H-10. In some embodiments step S-9
further comprises contacting the reaction mixture with a base. In
some embodiments step S-9 further comprises contacting the reaction
mixture with a palladium catalyst. In some embodiments [Ar] is an
optionally substituted phenyl or heteroaromatic ring. In some
embodiments [Ar] is an optionally substituted phenyl ring. In some
embodiments [Ar] is an optionally substituted heteroaromatic ring.
In some embodiments [Ar] is an optionally substituted 5-6 membered
heteroaromatic ring containing 1-2 heteroatoms independently
selected from nitrogen, oxygen and sulfur.
[0228] In some embodiments step S-10 comprises contacting a
compound of formula H-10 with an amidating reagent system, thereby
forming a compound of formula H-11. In some embodiments the
amidating reagent system comprises thionyl chloride and ammonia. In
some embodiments step S-10 further comprises use of a solvent. In
some embodiments the solvent is methanol. In some embodiments step
S-10 comprises contacting a compound of formula H-10 first with an
activating reagent, and second with ammonia. In some embodiments
the activating reagent is thionyl chloride.
[0229] As used herein, the term "diastereomeric salt" refers to the
adduct of a chiral compound of formula H-6 with a chiral base.
[0230] As used herein, the term "enantiomeric salt" refers to the
salt of the resolved chiral compound of formula H-8, wherein said
compound of formula H-8 is enriched in one enantiomer. As used
herein, the term "enantiomerically enriched", as used herein
signifies that one enantiomer makes up at least 80% or 85% of the
preparation. In certain embodiments, the term enantiomerically
enriched signifies that at least 90% of the preparation is one of
the enantiomers. In other embodiments, the term signifies that at
least 95% of the preparation is one of the enantiomers. In other
embodiments, the term signifies that at least 98% of the
preparation is one of the enantiomers.
[0231] One of skill in the art will appreciate that various
functional groups present in compounds of the invention such as
aliphatic groups, alcohols, carboxylic acids, esters, amides,
aldehydes, halogens and nitriles can be interconverted by
techniques well known in the art including, but not limited to
reduction, oxidation, esterification, hydrolysis, partial
oxidation, partial reduction, halogenation, dehydration, partial
hydration, and hydration. "March's Advanced Organic Chemistry",
5.sup.th Ed., Ed.: Smith, M. B. and March, J., John Wiley &
Sons, New York: 2001, the entirety of which is incorporated herein
by reference. Such interconversions may require one or more of the
aforementioned techniques, and certain methods for synthesizing
compounds of the invention are described below in the
Exemplification.
5. Uses, Formulation and Administration
[0232] Pharmaceutically Acceptable Compositions
[0233] According to another embodiment, the invention provides a
composition comprising a compound of this invention or a
pharmaceutically acceptable derivative thereof and a
pharmaceutically acceptable carrier, adjuvant, or vehicle. The
amount of compound in compositions of this invention is such that
is effective to measurably inhibit an IRAK protein kinase, or a
mutant thereof, in a biological sample or in a patient. In certain
embodiments, the amount of compound in compositions of this
invention is such that is effective to measurably inhibit an IRAK
protein kinase, or a mutant thereof, in a biological sample or in a
patient. In certain embodiments, a composition of this invention is
formulated for administration to a patient in need of such
composition. In some embodiments, a composition of this invention
is formulated for oral administration to a patient.
[0234] The term "patient," as used herein, means an animal,
preferably a mammal, and most preferably a human.
[0235] The term "pharmaceutically acceptable carrier, adjuvant, or
vehicle" refers to a non-toxic carrier, adjuvant, or vehicle that
does not destroy the pharmacological activity of the compound with
which it is formulated. Pharmaceutically acceptable carriers,
adjuvants or vehicles that may be used in the compositions of this
invention include, but are not limited to, ion exchangers, alumina,
aluminum stearate, lecithin, serum proteins, such as human serum
albumin, buffer substances such as phosphates, glycine, sorbic
acid, potassium sorbate, partial glyceride mixtures of saturated
vegetable fatty acids, water, salts or electrolytes, such as
protamine sulfate, disodium hydrogen phosphate, potassium hydrogen
phosphate, sodium chloride, zinc salts, colloidal silica, magnesium
trisilicate, polyvinyl pyrrolidone, cellulose-based substances,
polyethylene glycol, sodium carboxymethylcellulose, polyacrylates,
waxes, polyethylene-polyoxypropylene-block polymers, polyethylene
glycol and wool fat.
[0236] A "pharmaceutically acceptable derivative" means any
non-toxic salt, ester, salt of an ester or other derivative of a
compound of this invention that, upon administration to a
recipient, is capable of providing, either directly or indirectly,
a compound of this invention or an inhibitorily active metabolite
or residue thereof.
[0237] As used herein, the term "inhibitorily active metabolite or
residue thereof" means that a metabolite or residue thereof is also
an inhibitor of an IRAK protein kinase, or a mutant thereof.
[0238] Compositions of the present invention may be administered
orally, parenterally, by inhalation spray, topically, rectally,
nasally, buccally, vaginally or via an implanted reservoir. The
term "parenteral" as used herein includes subcutaneous,
intravenous, intramuscular, intra-articular, intra-synovial,
intrasternal, intrathecal, intrahepatic, intralesional and
intracranial injection or infusion techniques. Preferably, the
compositions are administered orally, intraperitoneally or
intravenously. Sterile injectable forms of the compositions of this
invention may be aqueous or oleaginous suspension. These
suspensions may be formulated according to techniques known in the
art using suitable dispersing or wetting agents and suspending
agents. The sterile injectable preparation may also be a sterile
injectable solution or suspension in a non-toxic parenterally
acceptable diluent or solvent, for example as a solution in
1,3-butanediol. Among the acceptable vehicles and solvents that may
be employed are water, Ringer's solution and isotonic sodium
chloride solution. In addition, sterile, fixed oils are
conventionally employed as a solvent or suspending medium.
[0239] For this purpose, any bland fixed oil may be employed
including synthetic mono- or di-glycerides. Fatty acids, such as
oleic acid and its glyceride derivatives are useful in the
preparation of injectables, as are natural
pharmaceutically-acceptable oils, such as olive oil or castor oil,
especially in their polyoxyethylated versions. These oil solutions
or suspensions may also contain a long-chain alcohol diluent or
dispersant, such as carboxymethyl cellulose or similar dispersing
agents that are commonly used in the formulation of
pharmaceutically acceptable dosage forms including emulsions and
suspensions. Other commonly used surfactants, such as Tweens, Spans
and other emulsifying agents or bioavailability enhancers which are
commonly used in the manufacture of pharmaceutically acceptable
solid, liquid, or other dosage forms may also be used for the
purposes of formulation.
[0240] Pharmaceutically acceptable compositions of this invention
may be orally administered in any orally acceptable dosage form
including, but not limited to, capsules, tablets, aqueous
suspensions or solutions. In the case of tablets for oral use,
carriers commonly used include lactose and corn starch. Lubricating
agents, such as magnesium stearate, are also typically added. For
oral administration in a capsule form, useful diluents include
lactose and dried cornstarch. When aqueous suspensions are required
for oral use, the active ingredient is combined with emulsifying
and suspending agents. If desired, certain sweetening, flavoring or
coloring agents may also be added.
[0241] Alternatively, pharmaceutically acceptable compositions of
this invention may be administered in the form of suppositories for
rectal administration. These can be prepared by mixing the agent
with a suitable non-irritating excipient that is solid at room
temperature but liquid at rectal temperature and therefore will
melt in the rectum to release the drug. Such materials include
cocoa butter, beeswax and polyethylene glycols.
[0242] Pharmaceutically acceptable compositions of this invention
may also be administered topically, especially when the target of
treatment includes areas or organs readily accessible by topical
application, including diseases of the eye, the skin, or the lower
intestinal tract. Suitable topical formulations are readily
prepared for each of these areas or organs.
[0243] Topical application for the lower intestinal tract can be
effected in a rectal suppository formulation (see above) or in a
suitable enema formulation. Topically-transdermal patches may also
be used.
[0244] For topical applications, provided pharmaceutically
acceptable compositions may be formulated in a suitable ointment
containing the active component suspended or dissolved in one or
more carriers. Carriers for topical administration of compounds of
this invention include, but are not limited to, mineral oil, liquid
petrolatum, white petrolatum, propylene glycol, polyoxyethylene,
polyoxypropylene compound, emulsifying wax and water.
Alternatively, provided pharmaceutically acceptable compositions
can be formulated in a suitable lotion or cream containing the
active components suspended or dissolved in one or more
pharmaceutically acceptable carriers. Suitable carriers include,
but are not limited to, mineral oil, sorbitan monostearate,
polysorbate 60, cetyl esters wax, cetearyl alcohol,
2-octyldodecanol, benzyl alcohol and water.
[0245] For ophthalmic use, provided pharmaceutically acceptable
compositions may be formulated as micronized suspensions in
isotonic, pH adjusted sterile saline, or, preferably, as solutions
in isotonic, pH adjusted sterile saline, either with or without a
preservative such as benzylalkonium chloride. Alternatively, for
ophthalmic uses, the pharmaceutically acceptable compositions may
be formulated in an ointment such as petrolatum.
[0246] Pharmaceutically acceptable compositions of this invention
may also be administered by nasal aerosol or inhalation. Such
compositions are prepared according to techniques well-known in the
art of pharmaceutical formulation and may be prepared as solutions
in saline, employing benzyl alcohol or other suitable
preservatives, absorption promoters to enhance bioavailability,
fluorocarbons, and/or other conventional solubilizing or dispersing
agents.
[0247] Most preferably, pharmaceutically acceptable compositions of
this invention are formulated for oral administration. Such
formulations may be administered with or without food. In some
embodiments, pharmaceutically acceptable compositions of this
invention are administered without food. In other embodiments,
pharmaceutically acceptable compositions of this invention are
administered with food.
[0248] The amount of compounds of the present invention that may be
combined with the carrier materials to produce a composition in a
single dosage form will vary depending upon the host treated, the
particular mode of administration. Preferably, provided
compositions should be formulated so that a dosage of between
0.01-100 mg/kg body weight/day of the inhibitor can be administered
to a patient receiving these compositions.
[0249] It should also be understood that a specific dosage and
treatment regimen for any particular patient will depend upon a
variety of factors, including the activity of the specific compound
employed, the age, body weight, general health, sex, diet, time of
administration, rate of excretion, drug combination, and the
judgment of the treating physician and the severity of the
particular disease being treated. The amount of a compound of the
present invention in the composition will also depend upon the
particular compound in the composition.
[0250] Uses of Compounds and Pharmaceutically Acceptable
Compositions
[0251] Compounds and compositions described herein are generally
useful for the inhibition of kinase activity of one or more
enzymes.
[0252] Examples of kinases that are inhibited by the compounds and
compositions described herein and against which the methods
described herein are useful include those of the interleukin-1
receptor-associated kinase (IRAK) family of kinases, the members of
which include IRAK-1, IRAK-2, and IRAK-4, or a mutant thereof. Li
et al., "IRAK-4: A novel member of the IRAK family with the
properties of an IRAK-kinase," PNAS 2002, 99(8), 5567-5572,
Flannery et al., "The interleukin-1 receptor-associated kinases:
Critical regulators of innate immune signaling" Biochem Pharm 2010,
80(12), 1981-1991 incorporated by reference in its entirety.
[0253] The activity of a compound utilized in this invention as an
inhibitor of IRAK-1, IRAK-2, and/or IRAK-4, or a mutant thereof,
may be assayed in vitro, in vivo or in a cell line. In vitro assays
include assays that determine inhibition of either the
phosphorylation activity and/or the subsequent functional
consequences, or ATPase activity of activated IRAK-1, IRAK-2,
and/or IRAK-4, or a mutant thereof. Alternate in vitro assays
quantitate the ability of the inhibitor to bind to IRAK-1, IRAK-2
and/or IRAK-4. Inhibitor binding may be measured by radiolabeling
the inhibitor prior to binding, isolating the inhibitor/IRAK-1,
inhibitor/IRAK-2, or inhibitor/IRAK-4 complex and determining the
amount of radiolabel bound. Alternatively, inhibitor binding may be
determined by running a competition experiment where new inhibitors
are incubated with IRAK-1, IRAK-2, and/or IRAK-4 bound to known
radioligands. Representative in vitro and in vivo assays useful in
assaying an IRAK-4 inhibitor include those described and disclosed
in, e.g., Kim et al., "A critical role for IRAK4 kinase activity in
Toll-like receptor-mediated innate immunity," J. Exp. Med. 2007
204(5), 1025-1036; Lebakken et al., "A Fluorescence Lifetime Based
Binding Assay to Characterize Kinase Inhibitors," J. Biomol.
Screen. 2007, 12(6), 828-841; Maschera et al., "Overexpression of
an enzymatically inactive interleukin-1-receptor-associated kinase
activates nuclear factor-.kappa.B," Biochem. J. 1999, 339, 227-231;
Song et al., "The kinase activities of interleukin-e receptor
associated kinase (IRAK)-1 and 4 are redundant in the control of
inflammatory cytokine expression in human cells," Mol. Immunol.
2009, 46, 1458-1466, each of which is herein incorporated by
reference in its entirety. Detailed conditions for assaying a
compound utilized in this invention as an inhibitor of IRAK-1,
IRAK-2, and/or IRAK-4, or a mutant thereof, are set forth in the
Examples below.
[0254] The best characterized member of the IRAK family is the
serine/threonine kinase IRAK-4. IRAK-4 is implicated in signaling
innate immune responses from Toll-like receptors (TLRs) and
Toll/IL-1 receptors (TIRs).
[0255] Innate immunity detects pathogens through the recognition of
pathogen-associated molecular patterns by TLRs, when then links to
the adaptive immune response. TLRs recognize conserved structures
of both microbes and endogenous molecules. TLRs which recognize
bacterial and fungal components are located on the cell surface,
whereas TLRs which recognize viral or microbial nucleic acids are
localized to intracellular membranes such as endosomes and
phagosomes. Cell surface TLRs can be targeted by small molecules
and antibodies, whereas intracellular TLRs require targeting with
oligonucleotides.
[0256] TLRs mediate the innate immune response by upregulating the
expression of inflammatory genes in multiple target cells. See,
e.g., Sen et al., "Transcriptional signaling by double-stranded
RNA: role of TLR3," Cytokine & Growth Factor Rev. 2005, 16,
1-14, incorporated by reference in its entirety. While TLR-mediated
inflammatory response is critical for innate immunity and host
defense against infections, uncontrolled inflammation is
detrimental to the host leading to sepsis and chronic inflammatory
diseases, such as chronic arthritis, atherosclerosis, multiple
sclerosis, cancers, autoimmune disorders such as rheumatoid
arthritis, lupus, asthma, psoriasis, and inflammatory bowel
diseases.
[0257] Upon binding of a ligand, most TLRs recruit the adaptor
molecule MyD88 through the TIR domain, mediating the
MyD88-dependent pathway. MyD88 then recruits IRAK-4, which engages
with the nuclear factor-.kappa.B (NF-.kappa.B), mitogen-activated
protein (MAP) kinase and interferon-regulatory factor cascades and
leads to the induction of pro-inflammatory cytokines. The
activation of NF-.kappa.B results in the induction of inflammatory
cytokines and chemokines, such as TNF-.alpha., IL-1 .alpha., IL-6
and IL-8. The kinase activity of IRAK-4 has been shown to play a
critical role in the TLR-mediated immune and inflammatory
responses. IRAK4 is a key mediator of the innate immune response
orchestrated by interleukin-1 receptor (IL-1R), interleukin-18
receptor (IL-18R), IL-33 receptor (IL-33R), and Toll-like receptors
(TLRs). Inactivation of IRAK-1 and/or IRAK-4 activity has been
shown to result in diminished production of cytokines and
chemokines in response to stimulation of IL-1 and TLR ligands. See,
e.g., Picard et al., "Clinical features and outcome of patients
with IRAK-4 and MyD88 deficiency," Medicine (Baltimore), 2010,
89(6), 043-25; Li, "IRAK4 in TLR/IL-1R signaling: Possible clinical
applications," Eur. J. Immunology 2008, 38:614-618; Cohen et al.,
"Targeting protein kinases for the development of anti-inflammatory
drugs," Curr. Opin. Cell Bio. 2009, 21:317-324; Flannery et al.,
"The interleukin-1 receptor-associated kinases: Critical regulators
of innate immune signalling," Biochem. Pharm. 2010, 80(12),
1981-1991; Gottipati et al., "IRAK1: A critical signaling mediator
of innate immunity," Cellular Signaling 2008, 20, 269-276; Kim et
al., "A critical role for IRAK4 kinase activity in Toll-like
receptor-mediated innate immunity," J. Exp. Med. 2007 204(5),
1025-1036; Koziczak-Holbro et al., "IRAK-4 Kinase Activity Is
Required for Interleukin-1 (IL-1) Receptor- and Toll-like Receptor
7-mediated Signaling and Gene Expression," J. Biol. Chem. 2007,
282(18), 13552-13560; Kubo-Murai et al., "IRAK-4-dependent
Degradation of IRAK-1 is a Negative Feedback Signal for
TLR-mediated NF-.kappa.B Activation," J. Biochem. 2008, 143,
295-302; Maschera et al., "Overexpression of an enzymatically
inactive interleukin-1-receptor-associated kinase activates nuclear
factor-.kappa.B," Biochem. J. 1999, 339, 227-231; Lin et al.,
"Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1R
signalling," Nature 2010, 465(17), 885-891; Suzuki et al., "IRAK-4
as the central TIR signaling mediator in innate immunity," TRENDS
in Immunol. 2002, 23(10), 503-506; Suzuki et al., "Severe
impairment of interleukin-1 and Toll-like receptor signalling in
mice lacking IRAK-4," Nature 2002, 416, 750-754; Swantek et al.,
"IL-1 Receptor-Associated Kinase Modulates Host Responsiveness to
Endotoxin," J. Immunol. 2000, 164, 4301-4306; Hennessy, E., et al.,
"Targeting Toll-like receptors: emerging therapeutics?" Nature
Reviews, vol. 9, pp: 293-307 (2010); Dinarello, C. "Interleukin-18
and the Pathogenesis of Inflammatory Diseases," Seminars in
Nephrology, vol. 27, no. 1, pp: 98-114 (2007), each of which is
herein incorporated by reference in its entirety. In fact,
knockdown mice that express a catalytically inactive mutant IRAK-4
protein are completely resistant to septic shock and show impaired
IL-1 activity. Moreover, these mice are resistant to joint and bone
inflammation/destruction in an arthritis model, suggesting that
IRAK-4 may be targeted to treat chronic inflammation. Further,
while IRAK-4 appears to be vital for childhood immunity against
some pyogenic bacteria, it has been shown to play a redundant role
in protective immunity to most infections in adults, as
demonstrated by one study in which patients older than 14 lacking
IRAK-4 activity exhibited no invasive infections. Cohen et al.,
"Targeting protein kinases for the development of anti-inflammatory
drugs," Curr. Opin. Cell Bio. 2009, 21:317-324; Ku et al.,
"Selective predisposition to bacterial infections in
IRAK-4-deficient children: IRAK-4-dependent TLRs are otherwise
redundant in protective immunity," J. Exp. Med. 2007, 204(10),
2407-2422; Picard et al., "Inherited human IRAK-4 deficiency: an
update," Immunol. Res. 2007, 38, 347-352; Song et al., "The kinase
activities of interleukin-e receptor associated kinase (IRAK)-1 and
4 are redundant in the control of inflammatory cytokine expression
in human cells," Mol. Immunol. 2009, 46, 1458-1466; Rokosz, L. et
al., "Kinase inhibitors as drugs for chronic inflammatory and
immunological diseases: progress and challenges," Expert Opinions
on Therapeutic Targets, 12(7), pp: 883-903 (2008); Gearing, A.
"Targeting toll-like receptors for drug development: a summary of
commercial approaches," Immunology and Cell Biology, 85, pp:
490-494 (2007); Dinarello, C. "IL-1: Discoveries, controversies and
future directions," European Journal of Immunology, 40, pp: 595-653
(2010), each of which is herein incorporated by reference in its
entirety. Because TLR activation triggers IRAK-4 kinase activity,
IRAK-4 inhibition presents an attractive target for treating the
underlying causes of inflammation in countless diseases.
[0258] Representative IRAK-4 inhibitors include those described and
disclosed in e.g., Buckley et al., Bioorg. Med. Chem. Lett. 2008,
18, 3211-3214; Buckley et al., Bioorg. Med. Chem. Lett. 2008, 18,
3291-3295; Buckley et al., Bioorg. Med. Chem. Lett. 2008, 18,
3656-3660; Powers et al., "Discovery and initial SAR of inhibitors
of interleukin-1 receptor-associated kinase-4," Bioorg. Med. Chem.
Lett. 2006, 16, 2842-2845; Wng et al., "IRAK-4 Inhibitors for
Inflammation," Curr. Topics in Med. Chem. 2009, 9, 724-737, each of
which is herein incorporated by reference in its entirety.
[0259] As used herein, the terms "treatment," "treat," and
"treating" refer to reversing, alleviating, delaying the onset of,
or inhibiting the progress of a disease or disorder, or one or more
symptoms thereof, as described herein. In some embodiments,
treatment may be administered after one or more symptoms have
developed. In other embodiments, treatment may be administered in
the absence of symptoms. For example, treatment may be administered
to a susceptible individual prior to the onset of symptoms (e.g.,
in light of a history of symptoms and/or in light of genetic or
other susceptibility factors). Treatment may also be continued
after symptoms have resolved, for example to prevent or delay their
recurrence.
[0260] Provided compounds are inhibitors of one of more of IRAK-1,
IRAK-2, and/or IRAK-4 and are therefore useful for treating one or
more disorders associated with activity of one or more of IRAK-1,
IRAK-2, and/or IRAK-4. Thus, in certain embodiments, the present
invention provides a method for treating a IRAK-1-mediated, a
IRAK-2-mediated, and/or a IRAK-4-mediated disorder comprising the
step of administering to a patient in need thereof a compound of
the present invention, or pharmaceutically acceptable composition
thereof.
[0261] As used herein, the terms "IRAK-1-mediated",
"IRAK-2-mediated", and/or "IRAK-4-mediated" disorders, diseases,
and/or conditions as used herein means any disease or other
deleterious condition in which one or more of IRAK-1, IRAK-2,
and/or IRAK-4, or a mutant thereof, are known to play a role.
Accordingly, another embodiment of the present invention relates to
treating or lessening the severity of one or more diseases in which
one or more of IRAK-1, IRAK-2, and/or IRAK-4, or a mutant thereof,
are known to play a role.
[0262] In some embodiments, the present invention provides a method
for treating one or more disorders, diseases, and/or conditions
wherein the disorder, disease, or condition is a cancer, a
neurodegenative disorder, a viral disease, an autoimmune disease,
an inflammatory disorder, a hereditary disorder, a hormone-related
disease, a metabolic disorder, conditions associated with organ
transplantation, immunodeficiency disorders, a destructive bone
disorder, a proliferative disorder, an infectious disease, a
condition associated with cell death, thrombin-induced platelet
aggregation, liver disease, pathologic immune conditions involving
T cell activation, a cardiovascular disorder, or a CNS
disorder.
[0263] Diseases and conditions treatable according to the methods
of this invention include, but are not limited to, cancer (see,
e.g., Ngo, V. et al., "Oncogenically active MYD88 mutations in
human lymphoma," Nature, vol. 000, pp: 1-7 (2010); Lust, J. et al.,
"Induction of a Chronic Disease State in patients With Smoldering
of Indolent Multiple Myeloma by Targeting Interleukin
1.beta.-Induced Interleukin 6 Production and the Myeloma
Proliferative Component," Mayo Clinic Proceedings, 84(2), pp:
114-122 (2009)), diabetes, cardiovascular disease, viral disease,
autoimmune diseases such as lupus (see, e.g., Dinarello, C.
"Interleukin-18 and the Pathogenesis of Inflammatory Diseases,"
Seminars in Nephrology, vol. 27, no. 1, pp: 98-114 (2007); Cohen et
al., "Targeting protein kinases for the development of
anti-inflammatory drugs," Curr. Opin. Cell Bio. 2009, 21:317-324)
and rheumatoid arthritis (see, e.g., Geyer, M. et al., "Actual
status of antiinterleukin-1 therapies in rheumatic diseases,"
Current Opinion in Rheumatology, 22, pp: 246-251 (2010)),
autoinflammatory syndromes (see, e.g., Hoffman, H. et al.,
"Efficacy and Safety of Rilonacept (Interleukin-1 Trap) in Patients
with Cryopyrin-Associated Periodic Syndromes," Arthritis &
Rheumatism, vol. 58, no. 8, pp: 2443-2452 (2008)), atherosclerosis,
psoriasis, allergic disorders, inflammatory bowel disease (see,
e.g., Cario, E. "Therapeutic Impact of Toll-like Receptors on
Inflammatory Bowel Diseases: A Multiple-edged Sword," Inflamm.
Bowel Dis., 14, pp: 411-421 (2008)), inflammation (see, e.g.,
Dinarello, C. "Interleukin 1 and interleukin 18 as mediators of
inflammation and the aging process," The American Journal of
Clinical Nutrition, 83, pp: 447S-455S (2006)), acute and chronic
gout and gouty arthritis (see, e.g., Terkeltaub, R. "Update on
gout: new therapeutic strategies and options," Nature, vol. 6, pp:
30-38 (2010); Weaver, A. "Epidemiology of gout," Cleveland Clinic
Journal of Medicine, vol. 75, suppl. 5, pp: 59-512 (2008); Dalbeth,
N. et al., "Hyperuricaemia and gout: state of the art and future
perspectives," Annals of Rheumatic Diseases, 69, pp: 1738-1743
(2010); Martinon, F. et al., "Gout-associated uric acid crystals
activate the NALP3 inflammasome," Nature, vol. 440, pp: 237-241
(2006); So, A. et al., "A pilot study of IL-1 inhibition by
anakinra in acute gout," Arthritis Research & Therapy, vol. 9,
no. 2, pp: 1-6 (2007); Terkeltaub, R. et al., "The interleukin 1
inhibitor rilonacept in treatment of chronic gouty arthritis:
results of a placebo-controlled, monosequence crossover,
non-randomised, single-blind pilot study," Annals of Rheumatic
Diseases, 68, pp: 1613-1617 (2009); Torres, R. et al.,
"Hyperalgesia, synovitis and multiple biomarkers of inflammation
are suppressed by interleukin 1 inhibition in a novel animal model
of gouty arthritis," Annals of Rheumatic Diseases, 68, pp:
1602-1608 (2009)), neurological disorders, metabolic syndrome (see,
e.g., Troseid, M. "The role of interleukin-18 in the metabolic
syndrome," Cardiovascular Diabetology, 9:11, pp: 1-8 (2010)),
immunodeficiency disorders such as AIDS and HIV (see, e.g.,
Iannello, A. et al., "Role of Interleukin-18 in the Development and
Pathogenesis of AIDS," AIDS Reviews, 11, pp: 115-125 (2009)),
destructive bone disorders (see, e.g., Hennessy, E., et al.,
"Targeting Toll-like receptors: emerging therapeutics?" Nature
Reviews, vol. 9, pp: 293-307 (2010)), osteoarthritis, proliferative
disorders, Waldenstrom's Macroglobulinemia (see, e.g., Treon, et
al., "Whole genome sequencing reveals a widely expressed mutation
(MYD88 L265P) with oncogenic activity in Waldenstrom's
Macroglobulinemia" 53.sup.rd ASH Annual Meeting; Xu, et al., "A
somatic variant in MYD88 (L256P) revealed by whole genome
sequencing differentiates lymphoplasmacytic lymphoma from marginal
zone lymphomas" 53.sup.rd ASH Annual Meeting; Yang et al.,
"Disruption of MYD88 pathway signaling leads to loss of
constitutive IRAK1, NK-kB and JAK/STAT signaling and induces
apoptosis of cells expressing the MYD88 L265P mutation in
Waldenstrom's Macroglobulinemia" 53.sup.rd ASH Annual Meeting;
Iriyama et al., "Clinical significance of genetic mutations of
CD79B, CARD11, MYD88, and EZH2 genes in diffuse large B-cell
lymphoma patients" 53.sup.rd ASH Annual Meeting; infectious
diseases, conditions associated with cell death, pathologic immune
conditions involving T cell activation, and CNS disorders in a
patient. In one embodiment, a human patient is treated with a
compound of the current invention and a pharmaceutically acceptable
carrier, adjuvant, or vehicle, wherein said compound is present in
an amount to measurably inhibit IRAK-1 only, IRAK-2-only,
IRAK-4-only and/or IRAK1- and IRAK4 kinase activity.
[0264] Compounds of the current invention are useful in the
treatment of a proliferative disease selected from a benign or
malignant tumor, solid tumor, carcinoma of the brain, kidney,
liver, adrenal gland, bladder, breast, stomach, gastric tumors,
ovaries, colon, rectum, prostate, pancreas, lung, vagina, cervix,
testis, genitourinary tract, esophagus, larynx, skin, bone or
thyroid, sarcoma, glioblastomas, neuroblastomas, multiple myeloma,
gastrointestinal cancer, especially colon carcinoma or colorectal
adenoma, a tumor of the neck and head, an epidermal
hyperproliferation, psoriasis, prostate hyperplasia, a neoplasia, a
neoplasia of epithelial character, adenoma, adenocarcinoma,
keratoacanthoma, epidermoid carcinoma, large cell carcinoma,
non-small-cell lung carcinoma, lymphomas, Hodgkins and
Non-Hodgkins, a mammary carcinoma, follicular carcinoma,
undifferentiated carcinoma, papillary carcinoma, seminoma,
melanoma, an IL-1 driven disorder, an MyD88 driven disorder,
Smoldering of indolent multiple myeloma, or hematological
malignancies (including leukemia, diffuse large B-cell lymphoma
(DLBCL), ABC DLBCL, chronic lymphocytic leukemia (CLL), chronic
lymphocytic lymphoma, primary effusion lymphoma, Burkitt
lymphoma/leukemia, acute lymphocytic leukemia, B-cell
prolymphocytic leukemia, lymphoplasmacytic lymphoma, Waldenstrom's
macroglobulinemia (WM), splenic marginal zone lymphoma, multiple
myeloma, plasmacytoma, intravascular large B-cell lymphoma).
[0265] In some embodiments the proliferative disease which can be
treated according to the methods of this invention is an MyD88
driven disorder. In some embodiments, the MyD88 driven disorder
which can be treated according to the methods of this invention is
selected from ABC DLBCL, Waldenstrom's macroglobulinemia, Hodgkin's
lymphoma, primary cutaneous T-cell lymphoma and chronic lymphocytic
leukemia.
[0266] In some embodiments the proliferative disease which can be
treated according to the methods of this invention is an IL-1
driven disorder. In some embodiments the IL-1 driven disorder is
Smoldering of indolent multiple myeloma.
[0267] Compounds according to the invention are useful in the
treatment of inflammatory or obstructive airways diseases,
resulting, for example, in reduction of tissue damage, airways
inflammation, bronchial hyperreactivity, remodeling or disease
progression. Inflammatory or obstructive airways diseases to which
the present invention is applicable include asthma of whatever type
or genesis including both intrinsic (non-allergic) asthma and
extrinsic (allergic) asthma, mild asthma, moderate asthma, severe
asthma, bronchitic asthma, exercise-induced asthma, occupational
asthma and asthma induced following bacterial infection. Treatment
of asthma is also to be understood as embracing treatment of
subjects, e.g. of less than 4 or 5 years of age, exhibiting
wheezing symptoms and diagnosed or diagnosable as "wheezy infants",
an established patient category of major medical concern and now
often identified as incipient or early-phase asthmatics.
[0268] Compounds according to the invention are useful in the
treatment of heteroimmune diseases. Examples of such heteroimmune
diseases include, but are not limited to, graft versus host
disease, transplantation, transfusion, anaphylaxis, allergies
(e.g., allergies to plant pollens, latex, drugs, foods, insect
poisons, animal hair, animal dander, dust mites, or cockroach
calyx), type I hypersensitivity, allergic conjunctivitis, allergic
rhinitis, and atopic dermatitis.
[0269] Prophylactic efficacy in the treatment of asthma will be
evidenced by reduced frequency or severity of symptomatic attack,
e.g. of acute asthmatic or bronchoconstrictor attack, improvement
in lung function or improved airways hyperreactivity. It may
further be evidenced by reduced requirement for other, symptomatic
therapy, such as therapy for or intended to restrict or abort
symptomatic attack when it occurs, for example antiinflammatory or
bronchodilatory. Prophylactic benefit in asthma may in particular
be apparent in subjects prone to "morning dipping". "Morning
dipping" is a recognized asthmatic syndrome, common to a
substantial percentage of asthmatics and characterised by asthma
attack, e.g. between the hours of about 4 to 6 am, i.e. at a time
normally substantially distant form any previously administered
symptomatic asthma therapy.
[0270] Compounds of the current invention can be used for other
inflammatory or obstructive airways diseases and conditions to
which the present invention is applicable and include acute lung
injury (ALI), adult/acute respiratory distress syndrome (ARDS),
chronic obstructive pulmonary, airways or lung disease (COPD, COAD
or COLD), including chronic bronchitis or dyspnea associated
therewith, emphysema, as well as exacerbation of airways
hyperreactivity consequent to other drug therapy, in particular
other inhaled drug therapy. The invention is also applicable to the
treatment of bronchitis of whatever type or genesis including, but
not limited to, acute, arachidic, catarrhal, croupus, chronic or
phthinoid bronchitis. Further inflammatory or obstructive airways
diseases to which the present invention is applicable include
pneumoconiosis (an inflammatory, commonly occupational, disease of
the lungs, frequently accompanied by airways obstruction, whether
chronic or acute, and occasioned by repeated inhalation of dusts)
of whatever type or genesis, including, for example, aluminosis,
anthracosis, asbestosis, chalicosis, ptilosis, siderosis,
silicosis, tabacosis and byssinosis.
[0271] With regard to their anti-inflammatory activity, in
particular in relation to inhibition of eosinophil activation,
compounds of the invention are also useful in the treatment of
eosinophil related disorders, e.g. eosinophilia, in particular
eosinophil related disorders of the airways (e.g. involving morbid
eosinophilic infiltration of pulmonary tissues) including
hypereosinophilia as it effects the airways and/or lungs as well
as, for example, eosinophil-related disorders of the airways
consequential or concomitant to Loffler's syndrome, eosinophilic
pneumonia, parasitic (in particular metazoan) infestation
(including tropical eosinophilia), bronchopulmonary aspergillosis,
polyarteritis nodosa (including Churg-Strauss syndrome),
eosinophilic granuloma and eosinophil-related disorders affecting
the airways occasioned by drug-reaction.
[0272] Compounds of the invention are also useful in the treatment
of inflammatory or allergic conditions of the skin, for example
psoriasis, contact dermatitis, atopic dermatitis, alopecia areata,
erythema multiforma, dermatitis herpetiformis, scleroderma,
vitiligo, hypersensitivity angiitis, urticaria, bullous pemphigoid,
lupus erythematosus, systemic lupus erythematosus, pemphigus
vulgaris, pemphigus foliaceus, paraneoplastic pemphigus,
epidermolysis bullosa acquisita, acne vulgaris, and other
inflammatory or allergic conditions of the skin.
[0273] Compounds of the invention may also be used for the
treatment of other diseases or conditions, such as diseases or
conditions having an inflammatory component, for example, treatment
of diseases and conditions of the eye such as ocular allergy,
conjunctivitis, keratoconjunctivitis sicca, and vernal
conjunctivitis, diseases affecting the nose including allergic
rhinitis, and inflammatory disease in which autoimmune reactions
are implicated or having an autoimmune component or etiology,
including autoimmune hematological disorders (e.g. hemolytic
anemia, aplastic anemia, pure red cell anemia and idiopathic
thrombocytopenia), systemic lupus erythematosus, rheumatoid
arthritis, polychondritis, scleroderma, Wegener granulamatosis,
dermatomyositis, chronic active hepatitis, myasthenia gravis,
Steven-Johnson syndrome, idiopathic sprue, autoimmune inflammatory
bowel disease (e.g. ulcerative colitis and Crohn's disease),
irritable bowel syndrome, celiac disease, periodontitis, hyaline
membrane disease, kidney disease, glomerular disease, alcoholic
liver disease, multiple sclerosis, endocrine opthalmopathy, Grave's
disease, sarcoidosis, alveolitis, chronic hypersensitivity
pneumonitis, multiple sclerosis, primary biliary cirrhosis, uveitis
(anterior and posterior), Sjogren's syndrome, keratoconjunctivitis
sicca and vernal keratoconjunctivitis, interstitial lung fibrosis,
psoriatic arthritis, systemic juvenile idiopathic arthritis,
cryopyrin-associated periodic syndrome, nephritis, vasculitis,
diverticulitis, interstitial cystitis, glomerulonephritis (with and
without nephrotic syndrome, e.g. including idiopathic nephrotic
syndrome or minal change nephropathy), chronic granulomatous
disease, endometriosis, leptospiriosis renal disease, glaucoma,
retinal disease, ageing, headache, pain, complex regional pain
syndrome, cardiac hypertrophy, musclewasting, catabolic disorders,
obesity, fetal growth retardation, hyperchlolesterolemia, heart
disease, chronic heart failure, mesothelioma, anhidrotic ecodermal
dysplasia, Behcet's disease, incontinentia pigmenti, Paget's
disease, pancreatitis, hereditary periodic fever syndrome, asthma
(allergic and non-allergic, mild, moderate, severe, bronchitic, and
exercise-induced), acute lung injury, acute respiratory distress
syndrome, eosinophilia, hypersensitivities, anaphylaxis, nasal
sinusitis, ocular allergy, silica induced diseases, COPD (reduction
of damage, airways inflammation, bronchial hyperreactivity,
remodeling or disease progression), pulmonary disease, cystic
fibrosis, acid-induced lung injury, pulmonary hypertension,
polyneuropathy, cataracts, muscle inflammation in conjunction with
systemic sclerosis, inclusion body myositis, myasthenia gravis,
thyroiditis, Addison's disease, lichen planus, Type 1 diabetes, or
Type 2 diabetes, appendicitis, atopic dermatitis, asthma, allergy,
blepharitis, bronchiolitis, bronchitis, bursitis, cervicitis,
cholangitis, cholecystitis, chronic graft rejection, colitis,
conjunctivitis, Crohn's disease, cystitis, dacryoadenitis,
dermatitis, dermatomyositis, encephalitis, endocarditis,
endometritis, enteritis, enterocolitis, epicondylitis,
epididymitis, fasciitis, fibrositis, gastritis, gastroenteritis,
Henoch-Schonlein purpura, hepatitis, hidradenitis suppurativa,
immunoglobulin A nephropathy, interstitial lung disease,
laryngitis, mastitis, meningitis, myelitis myocarditis, myositis,
nephritis, oophoritis, orchitis, osteitis, otitis, pancreatitis,
parotitis, pericarditis, peritonitis, pharyngitis, pleuritis,
phlebitis, pneumonitis, pneumonia, polymyositis, proctitis,
prostatitis, pyelonephritis, rhinitis, salpingitis, sinusitis,
stomatitis, synovitis, tendonitis, tonsillitis, ulcerative colitis,
uveitis, vaginitis, vasculitis, or vulvitis.
[0274] In some embodiments the inflammatory disease which can be
treated according to the methods of this invention is an disease of
the skin. In some embodiments, the inflammatory disease of the skin
is selected from contact dermatitits, atompic dermatitis, alopecia
areata, erythema multiforma, dermatitis herpetiformis, scleroderma,
vitiligo, hypersensitivity angiitis, urticaria, bullous pemphigoid,
pemphigus vulgaris, pemphigus foliaceus, paraneoplastic pemphigus,
epidermolysis bullosa acquisita, and other inflammatory or allergic
conditions of the skin.
[0275] In some embodiments the inflammatory disease which can be
treated according to the methods of this invention is selected from
acute and chronic gout, chronic gouty arthritis, psoriasis,
psoriatic arthritis, rheumatoid arthritis, Juvenile rheumatoid
arthritis, Systemic jubenile idiopathic arthritis (SJIA), Cryopyrin
Associated Periodic Syndrome (CAPS), and osteoarthritis.
[0276] In some embodiments the inflammatory disease which can be
treated according to the methods of this invention is a TH17
mediated disease. In some embodiments the TH17 mediated disease is
selected from Systemic lupus erythematosus, Multiple sclerosis, and
inflammatory bowel disease (including Crohn's disease or ulcerative
colitis).
[0277] In some embodiments the inflammatory disease which can be
treated according to the methods of this invention is selected from
Sjogren's syndrome, allergic disorders, osteoarthritis, conditions
of the eye such as ocular allergy, conjunctivitis,
keratoconjunctivitis sicca and vernal conjunctivitis, and diseases
affecting the nose such as allergic rhinitis.
[0278] Cardiovascular diseases which can be treated according to
the methods of this invention include, but are not limited to,
restenosis, cardiomegaly, atherosclerosis, myocardial infarction,
ischemic stroke, congestive heart failure, angina pectoris,
reocclusion after angioplasty, restenosis after angioplasty,
reocclusion after aortocoronary bypass, restenosis after
aortocoronary bypass, stroke, transitory ischemia, a peripheral
arterial occlusive disorder, pulmonary embolism, and deep venous
thrombosis.
[0279] In some embodiments, the neurodegenerative disease which can
be treated according to the methods of this invention include, but
are not limited to, Alzheimer's disease, Parkinson's disease,
amyotrophic lateral sclerosis, Huntington's disease, cerebral
ischemia, and neurodegenerative disease caused by traumatic injury,
glutamate neurotoxicity, hypoxia, epilepsy, treatment of diabetes,
metabolic syndrome, obesity, organ transplantation and graft versus
host disease.
[0280] The loss of IRAK4 function results in decreased A.beta.
levels in an in vivo murine model of Alzheimer's disease and was
associated with diminished microgliosis and astrogliosis in aged
mice. Analysis of microglia isolated from the adult mouse brain
revealed an altered pattern of gene expression associated with
changes in microglial phenotype that were associated with
expression of IRF transcription factors that govern microglial
phenotype. Further, loss of IRAK4 function also promoted amyloid
clearance mechanisms, including elevated expression of
insulin-degrading enzyme. Finally, blocking IRAK function restored
olfactory behavior (Cameron et al. "Loss of Interleukin
Receptor-Associated Kinase 4 Signaling Suppresses Amyloid Pathology
and Alters Microglial Phenotype in a Mouse Model of Alzheimer's
Disease" Journal of Neuroscience (2012) 32(43), 15112-15123.
[0281] In some embodiments the invention provides a method of
treating, preventing or lessening the severity of Alzheimer's
disease comprising administering to a patient in need thereof a
compound of formula I or a pharmaceutically acceptable salt or
composition thereof.
[0282] In some embodiments the invention provides a method of
treating a disease or condition commonly occurring in connection
with transplantation. In some embodiments, the disease or condition
commonly occurring in connection with transplantation is selected
from organ transplantation, organ transplant rejection, and graft
versus host disease.
[0283] In some embodiments the invention provides a method of
treating a metabolic disease. In some embodiments the metabolic
disease is selected from Type 1 diabetes, Type 2 diabetes,
metabolic syndrome, and obesity.
[0284] In some embodiments the invention provides a method of
treating a viral disease. In some embodiments, the viral infection
is HIV infection.
[0285] Furthermore, the invention provides the use of a compound
according to the definitions herein, or a pharmaceutically
acceptable salt, or a hydrate or solvate thereof for the
preparation of a medicament for the treatment of a proliferative
disease, an inflammatory disease, an obstructive respiratory
disease, a cardiovascular disease, a metabolic disease, a
neurological disease, a neurodegenerative disease, a viral disease,
or a disorder commonly occurring in connection with
transplantation.
[0286] Combination Therapies
[0287] Depending upon the particular condition, or disease, to be
treated, additional therapeutic agents, which are normally
administered to treat that condition, may be administered in
combination with compounds and compositions of this invention. As
used herein, additional therapeutic agents that are normally
administered to treat a particular disease, or condition, are known
as "appropriate for the disease, or condition, being treated."
[0288] In certain embodiments, a provided combination, or
composition thereof, is administered in combination with another
therapeutic agent.
[0289] Examples of agents the combinations of this invention may
also be combined with include, without limitation: treatments for
Alzheimer's Disease such as Aricept.RTM. and Excelon.RTM.;
treatments for HIV such as ritonavir; treatments for Parkinson's
Disease such as L-DOPA/carbidopa, entacapone, ropinrole,
pramipexole, bromocriptine, pergolide, trihexephendyl, and
amantadine; agents for treating Multiple Sclerosis (MS) such as
beta interferon (e.g., Avonex.RTM. and Rebif.RTM.), Copaxone.RTM.,
and mitoxantrone; treatments for asthma such as albuterol and
Singulair.RTM.; agents for treating schizophrenia such as zyprexa,
risperdal, seroquel, and haloperidol; anti-inflammatory agents such
as corticosteroids, TNF blockers, IL-1 RA, azathioprine,
cyclophosphamide, and sulfasalazine; immunomodulatory and
immunosuppressive agents such as cyclosporin, tacrolimus,
rapamycin, mycophenolate mofetil, interferons, corticosteroids,
cyclophophamide, azathioprine, and sulfasalazine; neurotrophic
factors such as acetylcholinesterase inhibitors, MAO inhibitors,
interferons, anti-convulsants, ion channel blockers, riluzole, and
anti-Parkinsonian agents; agents for treating cardiovascular
disease such as beta-blockers, ACE inhibitors, diuretics, nitrates,
calcium channel blockers, and statins; agents for treating liver
disease such as corticosteroids, cholestyramine, interferons, and
anti-viral agents; agents for treating blood disorders such as
corticosteroids, anti-leukemic agents, and growth factors; agents
that prolong or improve pharmacokinetics such as cytochrome P450
inhibitors (i.e., inhibitors of metabolic breakdown) and CYP3A4
inhibitors (e.g., ketokenozole and ritonavir), and agents for
treating immunodeficiency disorders such as gamma globulin.
[0290] In certain embodiments, combination therapies of the present
invention, or a pharmaceutically acceptable composition thereof,
are administered in combination with a monoclonal antibody or an
siRNA therapeutic.
[0291] Those additional agents may be administered separately from
a provided combination therapy, as part of a multiple dosage
regimen. Alternatively, those agents may be part of a single dosage
form, mixed together with a compound of this invention in a single
composition. If administered as part of a multiple dosage regime,
the two active agents may be submitted simultaneously, sequentially
or within a period of time from one another normally within five
hours from one another.
[0292] As used herein, the term "combination," "combined," and
related terms refers to the simultaneous or sequential
administration of therapeutic agents in accordance with this
invention. For example, a combination of the present invention may
be administered with another therapeutic agent simultaneously or
sequentially in separate unit dosage forms or together in a single
unit dosage form.
[0293] The amount of additional therapeutic agent present in the
compositions of this invention will be no more than the amount that
would normally be administered in a composition comprising that
therapeutic agent as the only active agent. Preferably the amount
of additional therapeutic agent in the presently disclosed
compositions will range from about 50% to 100% of the amount
normally present in a composition comprising that agent as the only
therapeutically active agent.
[0294] In one embodiment, the present invention provides a
composition comprising a compound of formula I and one or more
additional therapeutic agents. The therapeutic agent may be
administered together with a compound of formula I, or may be
administered prior to or following administration of a compound of
formula I. Suitable therapeutic agents are described in further
detail below. In certain embodiments, a compound of formula I may
be administered up to 5 minutes, 10 minutes, 15 minutes, 30
minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5, hours, 6 hours, 7
hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14
hours, 15 hours, 16 hours, 17 hours, or 18 hours before the
therapeutic agent. In other embodiments, a compound of formula I
may be administered up to 5 minutes, 10 minutes, 15 minutes, 30
minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5, hours, 6 hours, 7
hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14
hours, 15 hours, 16 hours, 17 hours, or 18 hours following the
therapeutic agent.
[0295] In another embodiment, the present invention provides a
method of treating an inflammatory disease, disorder or condition
by administering to a patient in need thereof a compound of formula
I and one or more additional therapeutic agents. Such additional
therapeutic agents may be small molecules or recombinant biologic
agents and include, for example, acetaminophen, non-steroidal
anti-inflammatory drugs (NSAIDS) such as aspirin, ibuprofen,
naproxen, etodolac (Lodine.RTM.) and celecoxib, colchicine
(Colcrys.RTM.), corticosteroids such as prednisone, prednisolone,
methylprednisolone, hydrocortisone, and the like, probenecid,
allopurinol, febuxostat (Uloric.RTM.), sulfasalazine
(Azulfidine.RTM.), antimalarials such as hydroxychloroquine
(Plaquenil.RTM.) and chloroquine (Aralen.RTM.), methotrexate
(Rheumatrex.RTM.), gold salts such as gold thioglucose
(Solganal.RTM.), gold thiomalate (Myochrysine.RTM.) and auranofin
(Ridaura.RTM.), D-penicillamine (Depen.RTM. or Cuprimine.RTM.),
azathioprine (Imuran.RTM.), cyclophosphamide (Cytoxan.RTM.),
chlorambucil (Leukeran.RTM.), cyclosporine (Sandimmune.RTM.),
leflunomide (Arava.RTM.) and "anti-TNF" agents such as etanercept
(Enbrel.RTM.), infliximab (Remicade.RTM.), golimumab
(Simponi.RTM.), certolizumab pegol (Cimzia.RTM.) and adalimumab
(Humira.RTM.), "anti-IL-1" agents such as anakinra (Kineret.RTM.)
and rilonacept (Arcalyst.RTM.), canakinumab (Ilaris.RTM.), anti-Jak
inhibitors such as tofacitinib, antibodies such as rituximab
(Rituxan.RTM.), "anti-T-cell" agents such as abatacept
(Orencia.RTM.), "anti-IL-6" agents such as tocilizumab
(Actemra.RTM.), diclofenac, cortisone, hyaluronic acid
(Synvisc.RTM. or Hyalgan.RTM.), monoclonal antibodies such as
tanezumab, anticoagulants such as heparin (Calcinparine.RTM. or
Liquaemin.RTM.) and warfarin (Coumadin.RTM.), antidiarrheals such
as diphenoxylate (Lomotil.RTM.) and loperamide (Imodium.RTM.), bile
acid binding agents such as cholestyramine, alosetron
(Lotronex.RTM.), lubiprostone (Amitiza.RTM.), laxatives such as
Milk of Magnesia, polyethylene glycol (MiraLax.RTM.),
Dulcolax.RTM., Correctol.RTM. and Senokot.RTM., anticholinergics or
antispasmodics such as dicyclomine (Bentyl.RTM.), Singulair.RTM.,
beta-2 agonists such as albuterol (Ventolin.RTM. HFA,
Proventil.RTM. HFA), levalbuterol (Xopenex.RTM.), metaproterenol
(Alupent.RTM.), pirbuterol acetate (Maxair.RTM.), terbutaline
sulfate (Brethaire.RTM.), salmeterol xinafoate (Serevent.RTM.) and
formoterol (Foradil.RTM.), anticholinergic agents such as
ipratropium bromide (Atrovent.RTM.) and tiotropium (Spiriva.RTM.),
inhaled corticosteroids such as beclomethasone dipropionate
(Beclovent.RTM., Qvar.RTM., and Vanceril.RTM.), triamcinolone
acetonide (Azmacort.RTM.), mometasone (Asthmanex.RTM.), budesonide
(Pulmocort.RTM.), and flunisolide (Aerobid.RTM.), Afviar.RTM.,
Symbicort.RTM., Dulera.RTM., cromolyn sodium (Intal.RTM.),
methylxanthines such as theophylline (Theo-Dur.RTM., Theolair.RTM.,
Slo-bid.RTM., Uniphyl.RTM., Theo-24.RTM.) and aminophylline, IgE
antibodies such as omalizumab (Xolair.RTM.), nucleoside reverse
transcriptase inhibitors such as zidovudine (Retrovir.RTM.),
abacavir (Ziagen.RTM.), abacavir/lamivudine (Epzicom.RTM.),
abacavir/lamivudine/zidovudine (Trizivir.RTM.), didanosine
(Videx.RTM.), emtricitabine (Emtriva.RTM.), lamivudine
(Epivir.RTM.), lamivudine/zidovudine (Combivir.RTM.), stavudine
(Zerit.RTM.), and zalcitabine (Hivid.RTM.), non-nucleoside reverse
transcriptase inhibitors such as delavirdine (Rescriptor.RTM.),
efavirenz (Sustiva.RTM.), nevairapine (Viramune.RTM.) and
etravirine (Intelence.RTM.), nucleotide reverse transcriptase
inhibitors such as tenofovir (Viread.RTM.), protease inhibitors
such as amprenavir (Agenerase.RTM.), atazanavir (Reyataz.RTM.),
darunavir (Prezista.RTM.), fosamprenavir (Lexiva.RTM.), indinavir
(Crixivan.RTM.), lopinavir and ritonavir (Kaletra.RTM.), nelfinavir
(Viracept.RTM.), ritonavir (Norvir.RTM.), saquinavir
(Fortovase.RTM. or Invirase.RTM.), and tipranavir (Aptivus.RTM.),
entry inhibitors such as enfuvirtide (Fuzeon.RTM.) and maraviroc
(Selzentry.RTM.), integrase inhibitors such as raltegravir
(Isentress.RTM.), doxorubicin (Hydrodaunorubicin.RTM.), vincristine
(Oncovin.RTM.), bortezomib (Velcade.RTM.), and dexamethasone
(Decadron.RTM.) in combination with lenalidomide (Revlimid.RTM.),
or any combination(s) thereof.
[0296] In another embodiment, the present invention provides a
method of treating gout comprising administering to a patient in
need thereof a compound of formula I and one or more additional
therapeutic agents selected from non-steroidal anti-inflammatory
drugs (NSAIDS) such as aspirin, ibuprofen, naproxen, etodolac
(Lodine.RTM.) and celecoxib, colchicine (Colcrys.RTM.),
corticosteroids such as prednisone, prednisolone,
methylprednisolone, hydrocortisone, and the like, probenecid,
allopurinol and febuxostat (Uloric.RTM.).
[0297] In another embodiment, the present invention provides a
method of treating rheumatoid arthritis comprising administering to
a patient in need thereof a compound of formula I and one or more
additional therapeutic agents selected from non-steroidal
anti-inflammatory drugs (NSAIDS) such as aspirin, ibuprofen,
naproxen, etodolac (Lodine.RTM.) and celecoxib, corticosteroids
such as prednisone, prednisolone, methylprednisolone,
hydrocortisone, and the like, sulfasalazine (Azulfidine.RTM.),
antimalarials such as hydroxychloroquine (Plaquenil.RTM.) and
chloroquine (Aralen.RTM.), methotrexate (Rheumatrex.RTM.), gold
salts such as gold thioglucose (Solganal.RTM.), gold thiomalate
(Myochrysine.RTM.) and auranofin (Ridaura.RTM.), D-penicillamine
(Depen.RTM. or Cuprimine.RTM.), azathioprine (Imuran.RTM.),
cyclophosphamide (Cytoxan.RTM.), chlorambucil (Leukeran.RTM.),
cyclosporine (Sandimmune.RTM.), leflunomide (Arava.RTM.) and
"anti-TNF" agents such as etanercept (Enbrel.RTM.), infliximab
(Remicade.RTM.), golimumab (Simponi.RTM.), certolizumab pegol
(Cimzia.RTM.) and adalimumab (Humira.RTM.), "anti-IL-1" agents such
as anakinra (Kineret.RTM.) and rilonacept (Arcalyst.RTM.),
antibodies such as rituximab (Rituxan.RTM.), "anti-T-cell" agents
such as abatacept (Orencia.RTM.) and "anti-IL-6" agents such as
tocilizumab (Actemra.RTM.).
[0298] In some embodiments, the present invention provides a method
of treating osteoarthritis comprising administering to a patient in
need thereof a compound of formula I and one or more additional
therapeutic agents selected from acetaminophen, non-steroidal
anti-inflammatory drugs (NSAIDS) such as aspirin, ibuprofen,
naproxen, etodolac (Lodine.RTM.) and celecoxib, diclofenac,
cortisone, hyaluronic acid (Synvisc.RTM. or Hyalgan.RTM.) and
monoclonal antibodies such as tanezumab.
[0299] In some embodiments, the present invention provides a method
of treating lupus comprising administering to a patient in need
thereof a compound of formula I and one or more additional
therapeutic agents selected from acetaminophen, non-steroidal
anti-inflammatory drugs (NSAIDS) such as aspirin, ibuprofen,
naproxen, etodolac (Lodine.RTM.) and celecoxib, corticosteroids
such as prednisone, prednisolone, methylprednisolone,
hydrocortisone, and the like, antimalarials such as
hydroxychloroquine (Plaquenil.RTM.) and chloroquine (Aralen.RTM.),
cyclophosphamide (Cytoxan.RTM.), methotrexate (Rheumatrex.RTM.),
azathioprine (Imuran.RTM.) and anticoagulants such as heparin
(Calcinparine.RTM. or Liquaemin.RTM.) and warfarin
(Coumadin.RTM.).
[0300] In some embodiments, the present invention provides a method
of treating inflammatory bowel disease comprising administering to
a patient in need thereof a compound of formula I and one or more
additional therapeutic agents selected from mesalamine
(Asacol.RTM.) sulfasalazine (Azulfidine.RTM.), antidiarrheals such
as diphenoxylate (Lomotil.RTM.) and loperamide (Imodium.RTM.), bile
acid binding agents such as cholestyramine, alosetron
(Lotronex.RTM.), lubiprostone (Amitiza.RTM.), laxatives such as
Milk of Magnesia, polyethylene glycol (MiraLax.RTM.),
Dulcolax.RTM., Correctol.RTM. and Senokot.RTM. and anticholinergics
or antispasmodics such as dicyclomine (Bentyl.RTM.), anti-TNF
therapies, steroids, and antibiotics such as Flagyl or
ciprofloxacin.
[0301] In some embodiments, the present invention provides a method
of treating asthma comprising administering to a patient in need
thereof a compound of formula I and one or more additional
therapeutic agents selected from Singulair.RTM., beta-2 agonists
such as albuterol (Ventolin.RTM. HFA, Proventil.RTM. HFA),
levalbuterol (Xopenex.RTM.), metaproterenol (Alupent.RTM.),
pirbuterol acetate (Maxair.RTM.), terbutaline sulfate
(Brethaire.RTM.), salmeterol xinafoate (Serevent.RTM.) and
formoterol (Foradil.RTM.), anticholinergic agents such as
ipratropium bromide (Atrovent.RTM.) and tiotropium (Spiriva.RTM.),
inhaled corticosteroids such as prednisone, prednisolone,
beclomethasone dipropionate (Beclovent.RTM., Qvar.RTM., and
Vanceril.RTM.), triamcinolone acetonide (Azmacort.RTM.), mometasone
(Asthmanex.RTM.), budesonide (Pulmocort.RTM.), flunisolide
(Aerobid.RTM.), Afviar.RTM., Symbicort.RTM., and Dulera.RTM.,
cromolyn sodium (Intal.RTM.), methylxanthines such as theophylline
(Theo-Dur.RTM., Theolair.RTM., Slo-bid.RTM., Uniphyl.RTM.,
Theo-24.RTM.) and aminophylline, and IgE antibodies such as
omalizumab (Xolair.RTM.).
[0302] In some embodiments, the present invention provides a method
of treating COPD comprising administering to a patient in need
thereof a compound of formula I and one or more additional
therapeutic agents selected from beta-2 agonists such as albuterol
(Ventolin.RTM. HFA, Proventil.RTM. HFA), levalbuterol
(Xopenex.RTM.), metaproterenol (Alupent.RTM.), pirbuterol acetate
(Maxair.RTM.), terbutaline sulfate (Brethaire.RTM.), salmeterol
xinafoate (Serevent.RTM.) and formoterol (Foradil.RTM.),
anticholinergic agents such as ipratropium bromide (Atrovent.RTM.)
and tiotropium (Spiriva.RTM.), methylxanthines such as theophylline
(Theo-Dur.RTM., Theolair.RTM., Slo-bid.RTM., Uniphyl.RTM.,
Theo-24.RTM.) and aminophylline, inhaled corticosteroids such as
prednisone, prednisolone, beclomethasone dipropionate
(Beclovent.RTM., Qvar.RTM., and Vanceril.RTM.), triamcinolone
acetonide (Azmacort.RTM.), mometasone (Asthmanex.RTM.), budesonide
(Pulmocort.RTM.), flunisolide (Aerobid.RTM.), Afviar.RTM.,
Symbicort.RTM., and Dulera.RTM.,
[0303] In some embodiments, the present invention provides a method
of treating HIV comprising administering to a patient in need
thereof a compound of formula I and one or more additional
therapeutic agents selected from nucleoside reverse transcriptase
inhibitors such as zidovudine (Retrovir.RTM.), abacavir
(Ziagen.RTM.), abacavir/lamivudine (Epzicom.RTM.),
abacavir/lamivudine/zidovudine (Trizivir.RTM.), didanosine
(Videx.RTM.), emtricitabine (Emtriva.RTM.), lamivudine
(Epivir.RTM.), lamivudine/zidovudine (Combivir.RTM.), stavudine
(Zerit.RTM.), and zalcitabine (Hivid.RTM.), non-nucleoside reverse
transcriptase inhibitors such as delavirdine (Rescriptor.RTM.),
efavirenz (Sustiva.RTM.), nevairapine (Viramune.RTM.) and
etravirine (Intelence.RTM.), nucleotide reverse transcriptase
inhibitors such as tenofovir (Viread.RTM.), protease inhibitors
such as amprenavir (Agenerase.RTM.), atazanavir (Reyataz.RTM.),
darunavir (Prezista.RTM.), fosamprenavir (Lexiva.RTM.), indinavir
(Crixivan.RTM.), lopinavir and ritonavir (Kaletra.RTM.), nelfinavir
(Viracept.RTM.), ritonavir (Norvir.RTM.), saquinavir
(Fortovase.RTM. or Invirase.RTM.), and tipranavir (Aptivus.RTM.),
entry inhibitors such as enfuvirtide (Fuzeon.RTM.) and maraviroc
(Selzentry.RTM.), integrase inhibitors such as raltegravir
(Isentress.RTM.), and combinations thereof.
[0304] In another embodiment, the present invention provides a
method of treating a hematological malignancy comprising
administering to a patient in need thereof a compound of formula I
and one or more additional therapeutic agents selected from
rituximab (Rituxan.RTM.), cyclophosphamide (Cytoxan.RTM.),
doxorubicin (Hydrodaunorubicin.RTM.), vincristine (Oncovin.RTM.),
prednisone, a hedgehog signaling inhibitor, a BTK inhibitor, a
JAK/pan-JAK inhibitor, a TYK2 inhibitor, a PI3K inhibitor, a SYK
inhibitor, and combinations thereof.
[0305] In another embodiment, the present invention provides a
method of treating a solid tumor comprising administering to a
patient in need thereof a compound of formula I and one or more
additional therapeutic agents selected from rituximab
(Rituxan.RTM.), cyclophosphamide (Cytoxan.RTM.), doxorubicin
(Hydrodaunorubicin.RTM.), vincristine (Oncovin.RTM.), prednisone, a
hedgehog signaling inhibitor, a BTK inhibitor, a JAK/pan-JAK
inhibitor, a TYK2 inhibitor, a PI3K inhibitor, a SYK inhibitor, and
combinations thereof.
[0306] In another embodiment, the present invention provides a
method of treating a hematological malignancy comprising
administering to a patient in need thereof a compound of formula I
and a Hedgehog (Hh) signaling pathway inhibitor. In some
embodiments, the hematological malignancy is DLBCL (Ramirez et al
"Defining causative factors contributing in the activation of
hedgehog signaling in diffuse large B-cell lymphoma" Leuk. Res.
(2012), published online July 17, and incorporated herein by
reference in its entirety).
[0307] In another embodiment, the present invention provides a
method of treating diffuse large B-cell lymphoma (DLBCL) comprising
administering to a patient in need thereof a compound of formula I
and one or more additional therapeutic agents selected from
rituximab (Rituxan.RTM.), cyclophosphamide (Cytoxan.RTM.),
doxorubicin (Hydrodaunorubicin.RTM.), vincristine (Oncovin.RTM.),
prednisone, a hedgehog signaling inhibitor, and combinations
thereof.
[0308] In another embodiment, the present invention provides a
method of treating multiple myeloma comprising administering to a
patient in need thereof a compound of formula I and one or more
additional therapeutic agents selected from bortezomib
(Velcade.RTM.), and dexamethasone (Decadron.RTM.), a hedgehog
signaling inhibitor, a BTK inhibitor, a JAK/pan-JAK inhibitor, a
TYK2 inhibitor, a PI3K inhibitor, a SYK inhibitor in combination
with lenalidomide (Revlimid.RTM.).
[0309] In another embodiment, the present invention provides a
method of treating Waldenstrom's macroglobulinemia comprising
administering to a patient in need thereof a compound of formula I
and one or more additional therapeutic agents selected from
chlorambucil (Leukeran.RTM.), cyclophosphamide (Cytoxan.RTM.,
Neosar.RTM.), fludarabine (Fludara.RTM.), cladribine
(Leustatin.RTM.), rituximab (Rituxan.RTM.), a hedgehog signaling
inhibitor, a BTK inhibitor, a JAK/pan-JAK inhibitor, a TYK2
inhibitor, a PI3K inhibitor, and a SYK inhibitor.
[0310] In some embodiments, the present invention provides a method
of treating Alzheimer's disease comprising administering to a
patient in need thereof a compound of formula I and one or more
additional therapeutic agents selected from donepezil
(Aricept.RTM.), rivastigmine (Excelon.RTM.), galantamine
(Razadyne.RTM.), tacrine (Cognex.RTM.), and memantine
(Namenda.RTM.).
[0311] In another embodiment, the present invention provides a
method of treating organ transplant rejection or graft vs. host
disease comprising administering to a patient in need thereof a
compound of formula I and one or more additional therapeutic agents
selected from a steroid, cyclosporin, FK506, rapamycin, a hedgehog
signaling inhibitor, a BTK inhibitor, a JAK/pan-JAK inhibitor, a
TYK2 inhibitor, a PI3K inhibitor, and a SYK inhibitor.
[0312] In another embodiment, the present invention provides a
method of treating or lessening the severity of a disease
comprising administering to a patient in need thereof a compound of
formula I and a BTK inhibitor, wherein the disease is selected from
inflammatory bowel disease, arthritis, systemic lupus erythematosus
(SLE), vasculitis, idiopathic thrombocytopenic purpura (ITP),
rheumatoid arthritis, psoriatic arthritis, osteoarthritis, Still's
disease, juvenile arthritis, diabetes, myasthenia gravis,
Hashimoto's thyroiditis, Ord's thyroiditis, Graves' disease,
autoimmune thyroiditis, Sjogren's syndrome, multiple sclerosis,
systemic sclerosis, Lyme neuroborreliosis, Guillain-Barre syndrome,
acute disseminated encephalomyelitis, Addison's disease,
opsoclonus-myoclonus syndrome, ankylosing spondylosis,
antiphospholipid antibody syndrome, aplastic anemia, autoimmune
hepatitis, autoimmune gastritis, pernicious anemia, celiac disease,
Goodpasture's syndrome, idiopathic thrombocytopenic purpura, optic
neuritis, scleroderma, primary biliary cirrhosis, Reiter's
syndrome, Takayasu's arteritis, temporal arteritis, warm autoimmune
hemolytic anemia, Wegener's granulomatosis, psoriasis, alopecia
universalis, Behcet's disease, chronic fatigue, dysautonomia,
membranous glomerulonephropathy, endometriosis, interstitial
cystitis, pemphigus vulgaris, bullous pemphigoid, neuromyotonia,
scleroderma, vulvodynia, a hyperproliferative disease, rejection of
transplanted organs or tissues, Acquired Immunodeficiency Syndrome
(AIDS, also known as HIV), type 1 diabetes, graft versus host
disease, transplantation, transfusion, anaphylaxis, allergies
(e.g., allergies to plant pollens, latex, drugs, foods, insect
poisons, animal hair, animal dander, dust mites, or cockroach
calyx), type I hypersensitivity, allergic conjunctivitis, allergic
rhinitis, and atopic dermatitis, asthma, appendicitis, atopic
dermatitis, asthma, allergy, blepharitis, bronchiolitis,
bronchitis, bursitis, cervicitis, cholangitis, cholecystitis,
chronic graft rejection, colitis, conjunctivitis, Crohn's disease,
cystitis, dacryoadenitis, dermatitis, dermatomyositis,
encephalitis, endocarditis, endometritis, enteritis, enterocolitis,
epicondylitis, epididymitis, fasciitis, fibrositis, gastritis,
gastroenteritis, Henoch-Schonlein purpura, hepatitis, hidradenitis
suppurativa, immunoglobulin A nephropathy, interstitial lung
disease, laryngitis, mastitis, meningitis, myelitis myocarditis,
myositis, nephritis, oophoritis, orchitis, osteitis, otitis,
pancreatitis, parotitis, pericarditis, peritonitis, pharyngitis,
pleuritis, phlebitis, pneumonitis, pneumonia, polymyositis,
proctitis, prostatitis, pyelonephritis, rhinitis, salpingitis,
sinusitis, stomatitis, synovitis, tendonitis, tonsillitis,
ulcerative colitis, uveitis, vaginitis, vasculitis, or vulvitis,
B-cell proliferative disorder, e.g., diffuse large B cell lymphoma,
follicular lymphoma, chronic lymphocytic lymphoma, chronic
lymphocytic leukemia, acute lymphocytic leukemia, B-cell
prolymphocytic leukemia, lymphoplasmacytic lymphoma/Waldenstrom
macroglobulinemia, splenic marginal zone lymphoma, multiple myeloma
(also known as plasma cell myeloma), non-Hodgkin's lymphoma,
Hodgkin's lymphoma, plasmacytoma, extranodal marginal zone B cell
lymphoma, nodal marginal zone B cell lymphoma, mantle cell
lymphoma, mediastinal (thymic) large B cell lymphoma, intravascular
large B cell lymphoma, primary effusion lymphoma, Burkitt
lymphoma/leukemia, or lymphomatoid granulomatosis, breast cancer,
prostate cancer, or cancer of the mast cells (e.g., mastocytoma,
mast cell leukemia, mast cell sarcoma, systemic mastocytosis), bone
cancer, colorectal cancer, pancreatic cancer, diseases of the bone
and joints including, without limitation, rheumatoid arthritis,
seronegative spondyloarthropathies (including ankylosing
spondylitis, psoriatic arthritis and Reiter's disease), Behcet's
disease, Sjogren's syndrome, systemic sclerosis, osteoporosis, bone
cancer, bone metastasis, a thromboembolic disorder, (e.g.,
myocardial infarct, angina pectoris, reocclusion after angioplasty,
restenosis after angioplasty, reocclusion after aortocoronary
bypass, restenosis after aortocoronary bypass, stroke, transitory
ischemia, a peripheral arterial occlusive disorder, pulmonary
embolism, deep venous thrombosis), inflammatory pelvic disease,
urethritis, skin sunburn, sinusitis, pneumonitis, encephalitis,
meningitis, myocarditis, nephritis, osteomyelitis, myositis,
hepatitis, gastritis, enteritis, dermatitis, gingivitis,
appendicitis, pancreatitis, cholocystitus, agammaglobulinemia,
psoriasis, allergy, Crohn's disease, irritable bowel syndrome,
ulcerative colitis, Sjogren's disease, tissue graft rejection,
hyperacute rejection of transplanted organs, asthma, allergic
rhinitis, chronic obstructive pulmonary disease (COPD), autoimmune
polyglandular disease (also known as autoimmune polyglandular
syndrome), autoimmune alopecia, pernicious anemia,
glomerulonephritis, dermatomyositis, multiple sclerosis,
scleroderma, vasculitis, autoimmune hemolytic and thrombocytopenic
states, Goodpasture's syndrome, atherosclerosis, Addison's disease,
Parkinson's disease, Alzheimer's disease, diabetes, septic shock,
systemic lupus erythematosus (SLE), rheumatoid arthritis, psoriatic
arthritis, juvenile arthritis, osteoarthritis, chronic idiopathic
thrombocytopenic purpura, Waldenstrom macroglobulinemia, myasthenia
gravis, Hashimoto's thyroiditis, atopic dermatitis, degenerative
joint disease, vitiligo, autoimmune hypopituitarism, Guillain-Barre
syndrome, Behcet's disease, scleraderma, mycosis fungoides, acute
inflammatory responses (such as acute respiratory distress syndrome
and ischemia/reperfusion injury), and Graves' disease.
[0313] In another embodiment, the present invention provides a
method of treating or lessening the severity of a disease
comprising administering to a patient in need thereof a compound of
formula I and a PI3K inhibitor, wherein the disease is selected
from a cancer, a neurodegenative disorder, an angiogenic disorder,
a viral disease, an autoimmune disease, an inflammatory disorder, a
hormone-related disease, conditions associated with organ
transplantation, immunodeficiency disorders, a destructive bone
disorder, a proliferative disorder, an infectious disease, a
condition associated with cell death, thrombin-induced platelet
aggregation, chronic myelogenous leukemia (CML), chronic
lymphocytic leukemia (CLL), liver disease, pathologic immune
conditions involving T cell activation, a cardiovascular disorder,
and a CNS disorder.
[0314] In another embodiment, the present invention provides a
method of treating or lessening the severity of a disease
comprising administering to a patient in need thereof a compound of
formula I and a PI3K inhibitor, wherein the disease is selected
from benign or malignant tumor, carcinoma or solid tumor of the
brain, kidney (e.g., renal cell carcinoma (RCC)), liver, adrenal
gland, bladder, breast, stomach, gastric tumors, ovaries, colon,
rectum, prostate, pancreas, lung, vagina, endometrium, cervix,
testis, genitourinary tract, esophagus, larynx, skin, bone or
thyroid, sarcoma, glioblastomas, neuroblastomas, multiple myeloma
or gastrointestinal cancer, especially colon carcinoma or
colorectal adenoma or a tumor of the neck and head, an epidermal
hyperproliferation, psoriasis, prostate hyperplasia, a neoplasia, a
neoplasia of epithelial character, adenoma, adenocarcinoma,
keratoacanthoma, epidermoid carcinoma, large cell carcinoma,
non-small-cell lung carcinoma, lymphomas, (including, for example,
non-Hodgkin's Lymphoma (NHL) and Hodgkin's lymphoma (also termed
Hodgkin's or Hodgkin's disease)), a mammary carcinoma, follicular
carcinoma, undifferentiated carcinoma, papillary carcinoma,
seminoma, melanoma, or a leukemia, diseases include Cowden
syndrome, Lhermitte-Dudos disease and Bannayan-Zonana syndrome, or
diseases in which the PI3K/PKB pathway is aberrantly activated,
asthma of whatever type or genesis including both intrinsic
(non-allergic) asthma and extrinsic (allergic) asthma, mild asthma,
moderate asthma, severe asthma, bronchitic asthma, exercise-induced
asthma, occupational asthma and asthma induced following bacterial
infection, acute lung injury (ALI), adult/acute respiratory
distress syndrome (ARDS), chronic obstructive pulmonary, airways or
lung disease (COPD, COAD or COLD), including chronic bronchitis or
dyspnea associated therewith, emphysema, as well as exacerbation of
airways hyperreactivity consequent to other drug therapy, in
particular other inhaled drug therapy, bronchitis of whatever type
or genesis including, but not limited to, acute, arachidic,
catarrhal, croupus, chronic or phthinoid bronchitis, pneumoconiosis
(an inflammatory, commonly occupational, disease of the lungs,
frequently accompanied by airways obstruction, whether chronic or
acute, and occasioned by repeated inhalation of dusts) of whatever
type or genesis, including, for example, aluminosis, anthracosis,
asbestosis, chalicosis, ptilosis, siderosis, silicosis, tabacosis
and byssinosis, Loffler's syndrome, eosinophilic, pneumonia,
parasitic (in particular metazoan) infestation (including tropical
eosinophilia), bronchopulmonary aspergillosis, polyarteritis nodosa
(including Churg-Strauss syndrome), eosinophilic granuloma and
eosinophil-related disorders affecting the airways occasioned by
drug-reaction, psoriasis, contact dermatitis, atopic dermatitis,
alopecia areata, erythema multiforma, dermatitis herpetiformis,
scleroderma, vitiligo, hypersensitivity angiitis, urticaria,
bullous pemphigoid, lupus erythematosus, pemphisus, epidermolysis
bullosa acquisita, conjunctivitis, keratoconjunctivitis sicca, and
vernal conjunctivitis, diseases affecting the nose including
allergic rhinitis, and inflammatory disease in which autoimmune
reactions are implicated or having an autoimmune component or
etiology, including autoimmune hematological disorders (e.g.
hemolytic anemia, aplastic anemia, pure red cell anemia and
idiopathic thrombocytopenia), systemic lupus erythematosus,
rheumatoid arthritis, polychondritis, sclerodoma, Wegener
granulamatosis, dermatomyositis, chronic active hepatitis,
myasthenia gravis, Steven-Johnson syndrome, idiopathic sprue,
autoimmune inflammatory bowel disease (e.g. ulcerative colitis and
Crohn's disease), endocrine opthalmopathy, Grave's disease,
sarcoidosis, alveolitis, chronic hypersensitivity pneumonitis,
multiple sclerosis, primary biliary cirrhosis, uveitis (anterior
and posterior), keratoconjunctivitis sicca and vernal
keratoconjunctivitis, interstitial lung fibrosis, psoriatic
arthritis and glomerulonephritis (with and without nephrotic
syndrome, e.g. including idiopathic nephrotic syndrome or minal
change nephropathy, restenosis, cardiomegaly, atherosclerosis,
myocardial infarction, ischemic stroke and congestive heart
failure, Alzheimer's disease, Parkinson's disease, amyotrophic
lateral sclerosis, Huntington's disease, and cerebral ischemia, and
neurodegenerative disease caused by traumatic injury, glutamate
neurotoxicity and hypoxia.
[0315] The compounds and compositions, according to the method of
the present invention, may be administered using any amount and any
route of administration effective for treating or lessening the
severity of a cancer, an autoimmune disorder, a proliferative
disorder, an inflammatory disorder, a neurodegenerative or
neurological disorder, schizophrenia, a bone-related disorder,
liver disease, or a cardiac disorder. The exact amount required
will vary from subject to subject, depending on the species, age,
and general condition of the subject, the severity of the
infection, the particular agent, its mode of administration, and
the like. Compounds of the invention are preferably formulated in
dosage unit form for ease of administration and uniformity of
dosage. The expression "dosage unit form" as used herein refers to
a physically discrete unit of agent appropriate for the patient to
be treated. It will be understood, however, that the total daily
usage of the compounds and compositions of the present invention
will be decided by the attending physician within the scope of
sound medical judgment. The specific effective dose level for any
particular patient or organism will depend upon a variety of
factors including the disorder being treated and the severity of
the disorder; the activity of the specific compound employed; the
specific composition employed; the age, body weight, general
health, sex and diet of the patient; the time of administration,
route of administration, and rate of excretion of the specific
compound employed; the duration of the treatment; drugs used in
combination or coincidental with the specific compound employed,
and like factors well known in the medical arts. The term
"patient", as used herein, means an animal, preferably a mammal,
and most preferably a human.
[0316] Pharmaceutically acceptable compositions of this invention
can be administered to humans and other animals orally, rectally,
parenterally, intracisternally, intravaginally, intraperitoneally,
topically (as by powders, ointments, or drops), bucally, as an oral
or nasal spray, or the like, depending on the severity of the
infection being treated. In certain embodiments, the compounds of
the invention may be administered orally or parenterally at dosage
levels of about 0.01 mg/kg to about 50 mg/kg and preferably from
about 1 mg/kg to about 25 mg/kg, of subject body weight per day,
one or more times a day, to obtain the desired therapeutic
effect.
[0317] Liquid dosage forms for oral administration include, but are
not limited to, pharmaceutically acceptable emulsions,
microemulsions, solutions, suspensions, syrups and elixirs. In
addition to the active compounds, the liquid dosage forms may
contain inert diluents commonly used in the art such as, for
example, water or other solvents, solubilizing agents and
emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl
carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate,
propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in
particular, cottonseed, groundnut, corn, germ, olive, castor, and
sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene
glycols and fatty acid esters of sorbitan, and mixtures thereof.
Besides inert diluents, the oral compositions can also include
adjuvants such as wetting agents, emulsifying and suspending
agents, sweetening, flavoring, and perfuming agents.
[0318] Injectable preparations, for example, sterile injectable
aqueous or oleaginous suspensions may be formulated according to
the known art using suitable dispersing or wetting agents and
suspending agents. The sterile injectable preparation may also be a
sterile injectable solution, suspension or emulsion in a nontoxic
parenterally acceptable diluent or solvent, for example, as a
solution in 1,3-butanediol. Among the acceptable vehicles and
solvents that may be employed are water, Ringer's solution, U.S.P.
and isotonic sodium chloride solution. In addition, sterile, fixed
oils are conventionally employed as a solvent or suspending medium.
For this purpose any bland fixed oil can be employed including
synthetic mono- or diglycerides. In addition, fatty acids such as
oleic acid are used in the preparation of injectables.
[0319] Injectable formulations can be sterilized, for example, by
filtration through a bacterial-retaining filter, or by
incorporating sterilizing agents in the form of sterile solid
compositions which can be dissolved or dispersed in sterile water
or other sterile injectable medium prior to use.
[0320] In order to prolong the effect of a compound of the present
invention, it is often desirable to slow the absorption of the
compound from subcutaneous or intramuscular injection. This may be
accomplished by the use of a liquid suspension of crystalline or
amorphous material with poor water solubility. The rate of
absorption of the compound then depends upon its rate of
dissolution that, in turn, may depend upon crystal size and
crystalline form. Alternatively, delayed absorption of a
parenterally administered compound form is accomplished by
dissolving or suspending the compound in an oil vehicle. Injectable
depot forms are made by forming microencapsule matrices of the
compound in biodegradable polymers such as
polylactide-polyglycolide. Depending upon the ratio of compound to
polymer and the nature of the particular polymer employed, the rate
of compound release can be controlled. Examples of other
biodegradable polymers include poly(orthoesters) and
poly(anhydrides). Depot injectable formulations are also prepared
by entrapping the compound in liposomes or microemulsions that are
compatible with body tissues.
[0321] Compositions for rectal or vaginal administration are
preferably suppositories which can be prepared by mixing the
compounds of this invention with suitable non-irritating excipients
or carriers such as cocoa butter, polyethylene glycol or a
suppository wax which are solid at ambient temperature but liquid
at body temperature and therefore melt in the rectum or vaginal
cavity and release the active compound.
[0322] Solid dosage forms for oral administration include capsules,
tablets, pills, powders, and granules. In such solid dosage forms,
the active compound is mixed with at least one inert,
pharmaceutically acceptable excipient or carrier such as sodium
citrate or dicalcium phosphate and/or a) fillers or extenders such
as starches, lactose, sucrose, glucose, mannitol, and silicic acid,
b) binders such as, for example, carboxymethylcellulose, alginates,
gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants
such as glycerol, d) disintegrating agents such as agar-agar,
calcium carbonate, potato or tapioca starch, alginic acid, certain
silicates, and sodium carbonate, e) solution retarding agents such
as paraffin, f) absorption accelerators such as quaternary ammonium
compounds, g) wetting agents such as, for example, cetyl alcohol
and glycerol monostearate, h) absorbents such as kaolin and
bentonite clay, and i) lubricants such as talc, calcium stearate,
magnesium stearate, solid polyethylene glycols, sodium lauryl
sulfate, and mixtures thereof. In the case of capsules, tablets and
pills, the dosage form may also comprise buffering agents.
[0323] Solid compositions of a similar type may also be employed as
fillers in soft and hard-filled gelatin capsules using such
excipients as lactose or milk sugar as well as high molecular
weight polyethylene glycols and the like. The solid dosage forms of
tablets, dragees, capsules, pills, and granules can be prepared
with coatings and shells such as enteric coatings and other
coatings well known in the pharmaceutical formulating art. They may
optionally contain opacifying agents and can also be of a
composition that they release the active ingredient(s) only, or
preferentially, in a certain part of the intestinal tract,
optionally, in a delayed manner. Examples of embedding compositions
that can be used include polymeric substances and waxes. Solid
compositions of a similar type may also be employed as fillers in
soft and hard-filled gelatin capsules using such excipients as
lactose or milk sugar as well as high molecular weight polethylene
glycols and the like.
[0324] The active compounds can also be in micro-encapsulated form
with one or more excipients as noted above. The solid dosage forms
of tablets, dragees, capsules, pills, and granules can be prepared
with coatings and shells such as enteric coatings, release
controlling coatings and other coatings well known in the
pharmaceutical formulating art. In such solid dosage forms the
active compound may be admixed with at least one inert diluent such
as sucrose, lactose or starch. Such dosage forms may also comprise,
as is normal practice, additional substances other than inert
diluents, e.g., tableting lubricants and other tableting aids such
a magnesium stearate and microcrystalline cellulose. In the case of
capsules, tablets and pills, the dosage forms may also comprise
buffering agents. They may optionally contain opacifying agents and
can also be of a composition that they release the active
ingredient(s) only, or preferentially, in a certain part of the
intestinal tract, optionally, in a delayed manner. Examples of
embedding compositions that can be used include polymeric
substances and waxes.
[0325] Dosage forms for topical or transdermal administration of a
compound of this invention include ointments, pastes, creams,
lotions, gels, powders, solutions, sprays, inhalants or patches.
The active component is admixed under sterile conditions with a
pharmaceutically acceptable carrier and any needed preservatives or
buffers as may be required. Ophthalmic formulation, ear drops, and
eye drops are also contemplated as being within the scope of this
invention. Additionally, the present invention contemplates the use
of transdermal patches, which have the added advantage of providing
controlled delivery of a compound to the body. Such dosage forms
can be made by dissolving or dispensing the compound in the proper
medium. Absorption enhancers can also be used to increase the flux
of the compound across the skin. The rate can be controlled by
either providing a rate controlling membrane or by dispersing the
compound in a polymer matrix or gel.
[0326] According to one embodiment, the invention relates to a
method of inhibiting protein kinase activity in a biological sample
comprising the step of contacting said biological sample with a
compound of this invention, or a composition comprising said
compound.
[0327] According to another embodiment, the invention relates to a
method of inhibiting IRAK-1, IRAK-2, and/or IRAK-4, or a mutant
thereof, activity in a biological sample comprising the step of
contacting said biological sample with a compound of this
invention, or a composition comprising said compound. In certain
embodiments, the invention relates to a method of irreversibly
inhibiting IRAK-1, IRAK-2, and/or IRAK-4, or a mutant thereof,
activity in a biological sample comprising the step of contacting
said biological sample with a compound of this invention, or a
composition comprising said compound.
[0328] The term "biological sample", as used herein, includes,
without limitation, cell cultures or extracts thereof; biopsied
material obtained from a mammal or extracts thereof; and blood,
saliva, urine, feces, semen, tears, or other body fluids or
extracts thereof.
[0329] Inhibition of protein kinase, or a protein kinase selected
from IRAK-1, IRAK-2, and/or IRAK-4, or a mutant thereof, activity
in a biological sample is useful for a variety of purposes that are
known to one of skill in the art. Examples of such purposes
include, but are not limited to, blood transfusion,
organ-transplantation, biological specimen storage, and biological
assays.
[0330] Another embodiment of the present invention relates to a
method of inhibiting protein kinase activity in a patient
comprising the step of administering to said patient a compound of
the present invention, or a composition comprising said
compound.
[0331] According to another embodiment, the invention relates to a
method of inhibiting one or more of IRAK-1, IRAK-2, and/or IRAK-4,
or a mutant thereof, activity in a patient comprising the step of
administering to said patient a compound of the present invention,
or a composition comprising said compound. According to certain
embodiments, the invention relates to a method of irreversibly
inhibiting one or more of IRAK-1, IRAK-2, and/or IRAK-4, or a
mutant thereof, activity in a patient comprising the step of
administering to said patient a compound of the present invention,
or a composition comprising said compound. In other embodiments,
the present invention provides a method for treating a disorder
mediated by one or more of IRAK-1, IRAK-2, and/or IRAK-4, or a
mutant thereof, in a patient in need thereof, comprising the step
of administering to said patient a compound according to the
present invention or pharmaceutically acceptable composition
thereof. Such disorders are described in detail herein.
[0332] Depending upon the particular condition, or disease, to be
treated, additional therapeutic agents that are normally
administered to treat that condition, may also be present in the
compositions of this invention. As used herein, additional
therapeutic agents that are normally administered to treat a
particular disease, or condition, are known as "appropriate for the
disease, or condition, being treated."
[0333] A compound of the current invention may also be used to
advantage in combination with other antiproliferative compounds.
Such antiproliferative compounds include, but are not limited to
aromatase inhibitors; antiestrogens; topoisomerase I inhibitors;
topoisomerase II inhibitors; microtubule active compounds;
alkylating compounds; histone deacetylase inhibitors; compounds
which induce cell differentiation processes; cyclooxygenase
inhibitors; MMP inhibitors; mTOR inhibitors; antineoplastic
antimetabolites; platin compounds; compounds targeting/decreasing a
protein or lipid kinase activity and further anti-angiogenic
compounds; compounds which target, decrease or inhibit the activity
of a protein or lipid phosphatase; gonadorelin agonists;
anti-androgens; methionine aminopeptidase inhibitors; matrix
metalloproteinase inhibitors; bisphosphonates; biological response
modifiers; antiproliferative antibodies; heparanase inhibitors;
inhibitors of Ras oncogenic isoforms; telomerase inhibitors;
proteasome inhibitors; compounds used in the treatment of
hematologic malignancies; compounds which target, decrease or
inhibit the activity of Flt-3; Hsp90 inhibitors such as 17-AAG
(17-allylaminogeldanamycin, NSC330507), 17-DMAG
(17-dimethylaminoethylamino-17-demethoxy-geldanamycin, NSC707545),
IPI-504, CNF1010, CNF2024, CNF1010 from Conforma Therapeutics;
temozolomide (Temodal.RTM.); kinesin spindle protein inhibitors,
such as SB715992 or SB743921 from GlaxoSmithKline, or
pentamidine/chlorpromazine from CombinatoRx; MEK inhibitors such as
ARRY142886 from Array BioPharma, AZD6244 from AstraZeneca, PD181461
from Pfizer and leucovorin. The term "aromatase inhibitor" as used
herein relates to a compound which inhibits estrogen production,
for instance, the conversion of the substrates androstenedione and
testosterone to estrone and estradiol, respectively. The term
includes, but is not limited to steroids, especially atamestane,
exemestane and formestane and, in particular, non-steroids,
especially aminoglutethimide, roglethimide, pyridoglutethimide,
trilostane, testolactone, ketokonazole, vorozole, fadrozole,
anastrozole and letrozole. Exemestane is marketed under the trade
name Aromasin.TM.. Formestane is marketed under the trade name
Lentaron.TM.. Fadrozole is marketed under the trade name Afema.TM..
Anastrozole is marketed under the trade name Arimidex.TM..
Letrozole is marketed under the trade names Femara.TM. or
Femar.TM.. Aminoglutethimide is marketed under the trade name
Orimeten.TM.. A combination of the invention comprising a
chemotherapeutic agent which is an aromatase inhibitor is
particularly useful for the treatment of hormone receptor positive
tumors, such as breast tumors.
[0334] The term "antiestrogen" as used herein relates to a compound
which antagonizes the effect of estrogens at the estrogen receptor
level. The term includes, but is not limited to tamoxifen,
fulvestrant, raloxifene and raloxifene hydrochloride. Tamoxifen is
marketed under the trade name Nolvadex.TM.. Raloxifene
hydrochloride is marketed under the trade name Evista.TM..
Fulvestrant can be administered under the trade name Faslodex.TM..
A combination of the invention comprising a chemotherapeutic agent
which is an antiestrogen is particularly useful for the treatment
of estrogen receptor positive tumors, such as breast tumors.
[0335] The term "anti-androgen" as used herein relates to any
substance which is capable of inhibiting the biological effects of
androgenic hormones and includes, but is not limited to,
bicalutamide (Casodex.TM.). The term "gonadorelin agonist" as used
herein includes, but is not limited to abarelix, goserelin and
goserelin acetate. Goserelin can be administered under the trade
name Zoladex.TM..
[0336] The term "topoisomerase I inhibitor" as used herein
includes, but is not limited to topotecan, gimatecan, irinotecan,
camptothecian and its analogues, 9-nitrocamptothecin and the
macromolecular camptothecin conjugate PNU-166148. Irinotecan can be
administered, e.g. in the form as it is marketed, e.g. under the
trademark Camptosar.TM.. Topotecan is marketed under the trade name
Hycamptin.TM..
[0337] The term "topoisomerase II inhibitor" as used herein
includes, but is not limited to the anthracyclines such as
doxorubicin (including liposomal formulation, such as Caelyx.TM.),
daunorubicin, epirubicin, idarubicin and nemorubicin, the
anthraquinones mitoxantrone and losoxantrone, and the
podophillotoxines etoposide and teniposide. Etoposide is marketed
under the trade name Etopophos.TM.. Teniposide is marketed under
the trade name VM 26-Bristol Doxorubicin is marketed under the
trade name Acriblastin.TM. or Adriamycin.TM.. Epirubicin is
marketed under the trade name Farmorubicin.TM.. Idarubicin is
marketed. under the trade name Zavedos.TM.. Mitoxantrone is
marketed under the trade name Novantron.
[0338] The term "microtubule active agent" relates to microtubule
stabilizing, microtubule destabilizing compounds and microtublin
polymerization inhibitors including, but not limited to taxanes,
such as paclitaxel and docetaxel; vinca alkaloids, such as
vinblastine or vinblastine sulfate, vincristine or vincristine
sulfate, and vinorelbine; discodermolides; cochicine and
epothilones and derivatives thereof. Paclitaxel is marketed under
the trade name Taxol.TM.. Docetaxel is marketed under the trade
name Taxotere.TM.. Vinblastine sulfate is marketed under the trade
name Vinblastin R.P.TM.. Vincristine sulfate is marketed under the
trade name Farmistin.TM..
[0339] The term "alkylating agent" as used herein includes, but is
not limited to, cyclophosphamide, ifosfamide, melphalan or
nitrosourea (BCNU or Gliadel). Cyclophosphamide is marketed under
the trade name Cyclostin.TM.. Ifosfamide is marketed under the
trade name Holoxan.TM..
[0340] The term "histone deacetylase inhibitors" or "HDAC
inhibitors" relates to compounds which inhibit the histone
deacetylase and which possess antiproliferative activity. This
includes, but is not limited to, suberoylanilide hydroxamic acid
(SAHA).
[0341] The term "antineoplastic antimetabolite" includes, but is
not limited to, 5-fluorouracil or 5-FU, capecitabine, gemcitabine,
DNA demethylating compounds, such as 5-azacytidine and decitabine,
methotrexate and edatrexate, and folic acid antagonists such as
pemetrexed. Capecitabine is marketed under the trade name
Xeloda.TM.. Gemcitabine is marketed under the trade name
Gemzar.TM.
[0342] The term "platin compound" as used herein includes, but is
not limited to, carboplatin, cis-platin, cisplatinum and
oxaliplatin. Carboplatin can be administered, e.g., in the form as
it is marketed, e.g. under the trademark Carboplat.TM.. Oxaliplatin
can be administered, e.g., in the form as it is marketed, e.g.
under the trademark Eloxatin.TM..
[0343] The term "compounds targeting/decreasing a protein or lipid
kinase activity; or a protein or lipid phosphatase activity; or
further anti-angiogenic compounds" as used herein includes, but is
not limited to, protein tyrosine kinase and/or serine and/or
threonine kinase inhibitors or lipid kinase inhibitors, such as a)
compounds targeting, decreasing or inhibiting the activity of the
platelet-derived growth factor-receptors (PDGFR), such as compounds
which target, decrease or inhibit the activity of PDGFR, especially
compounds which inhibit the PDGF receptor, such as an
N-phenyl-2-pyrimidine-amine derivative, such as imatinib, SU101,
SU6668 and GFB-111; b) compounds targeting, decreasing or
inhibiting the activity of the fibroblast growth factor-receptors
(FGFR); c) compounds targeting, decreasing or inhibiting the
activity of the insulin-like growth factor receptor I (IGF-IR),
such as compounds which target, decrease or inhibit the activity of
IGF-IR, especially compounds which inhibit the kinase activity of
IGF-I receptor, or antibodies that target the extracellular domain
of IGF-I receptor or its growth factors; d) compounds targeting,
decreasing or inhibiting the activity of the Trk receptor tyrosine
kinase family, or ephrin B4 inhibitors; e) compounds targeting,
decreasing or inhibiting the activity of the AxI receptor tyrosine
kinase family; f) compounds targeting, decreasing or inhibiting the
activity of the Ret receptor tyrosine kinase; g) compounds
targeting, decreasing or inhibiting the activity of the Kit/SCFR
receptor tyrosine kinase, such as imatinib; h) compounds targeting,
decreasing or inhibiting the activity of the C-kit receptor
tyrosine kinases, which are part of the PDGFR family, such as
compounds which target, decrease or inhibit the activity of the
c-Kit receptor tyrosine kinase family, especially compounds which
inhibit the c-Kit receptor, such as imatinib; i) compounds
targeting, decreasing or inhibiting the activity of members of the
c-Abl family, their gene-fusion products (e.g. BCR-Abl kinase) and
mutants, such as compounds which target decrease or inhibit the
activity of c-Abl family members and their gene fusion products,
such as an N-phenyl-2-pyrimidine-amine derivative, such as imatinib
or nilotinib (AMN107); PD180970; AG957; NSC 680410; PD173955 from
ParkeDavis; or dasatinib (BMS-354825); j) compounds targeting,
decreasing or inhibiting the activity of members of the protein
kinase C (PKC) and Raf family of serine/threonine kinases, members
of the MEK, SRC, JAK/pan-JAK, FAK, PDK1, PKB/Akt, Ras/MAPK, PI3K,
SYK, TYK2, BTK and TEC family, and/or members of the
cyclin-dependent kinase family (CDK) including staurosporine
derivatives, such as midostaurin; examples of further compounds
include UCN-01, safingol, BAY 43-9006, Bryostatin 1, Perifosine;
llmofosine; RO 318220 and RO 320432; GO 6976; lsis 3521;
LY333531/LY379196; isochinoline compounds; FTIs; PD184352 or QAN697
(a P13K inhibitor) or AT7519 (CDK inhibitor); k) compounds
targeting, decreasing or inhibiting the activity of
protein-tyrosine kinase inhibitors, such as compounds which target,
decrease or inhibit the activity of protein-tyrosine kinase
inhibitors include imatinib mesylate (Gleevec.TM.) or tyrphostin
such as Tyrphostin A23/RG-50810; AG 99; Tyrphostin AG 213;
Tyrphostin AG 1748; Tyrphostin AG 490; Tyrphostin B44; Tyrphostin
B44 (+) enantiomer; Tyrphostin AG 555; AG 494; Tyrphostin AG 556,
AG957 and adaphostin
(4-{[(2,5-dihydroxyphenyl)methyl]amino}-benzoic acid adamantyl
ester; NSC 680410, adaphostin); 1) compounds targeting, decreasing
or inhibiting the activity of the epidermal growth factor family of
receptor tyrosine kinases (EGFR.sub.1 ErbB2, ErbB3, ErbB4 as homo-
or heterodimers) and their mutants, such as compounds which target,
decrease or inhibit the activity of the epidermal growth factor
receptor family are especially compounds, proteins or antibodies
which inhibit members of the EGF receptor tyrosine kinase family,
such as EGF receptor, ErbB2, ErbB3 and ErbB4 or bind to EGF or EGF
related ligands, CP 358774, ZD 1839, ZM 105180; trastuzumab
(Herceptin.TM.), cetuximab (Erbitux.TM.), Iressa, Tarceva, OSI-774,
Cl-1033, EKB-569, GW-2016, E1.1, E2.4, E2.5, E6.2, E6.4, E2.11,
E6.3 or E7.6.3, and 7H-pyrrolo-[2,3-d]pyrimidine derivatives; m)
compounds targeting, decreasing or inhibiting the activity of the
c-Met receptor, such as compounds which target, decrease or inhibit
the activity of c-Met, especially compounds which inhibit the
kinase activity of c-Met receptor, or antibodies that target the
extracellular domain of c-Met or bind to HGF, n) compounds
targeting, decreasing or inhibiting the kinase activity of one or
more JAK family members (JAK1/JAK2/JAK3/TYK2 and/or pan-JAK),
including but not limited to PRT-062070, SB-1578, baricitinib,
pacritinib, momelotinib, VX-509, AZD-1480, TG-101348, tofacitinib,
and ruxolitinib; o) compounds targeting, decreasing or inhibiting
the kinase activity of PI3 kinase (PI3K) including but not limited
to ATU-027, SF-1126, DS-7423, PBI-05204, GSK-2126458, ZSTK-474,
buparlisib, pictrelisib, PF-4691502, BYL-719, dactolisib, XL-147,
XL-765, and idelalisib; and; and q) compounds targeting, decreasing
or inhibiting the signaling effects of hedgehog protein (Hh) or
smoothened receptor (SMO) pathways, including but not limited to
cyclopamine, vismodegib, itraconazole, erismodegib, and IPI-926
(saridegib).
[0344] The term "PI3K inhibitor" as used herein includes, but is
not limited to compounds having inhibitory activity against one or
more enzymes in the phosphatidylinositol-3-kinase family,
including, but not limited to PI3K.alpha., PI3K.gamma.,
PI3K.delta., PI3Ki.beta., PI3K-C2.alpha., PI3K-C2.beta.,
PI3K-C2.gamma., Vps34, p110-.alpha., p110-.beta., p110-.gamma.,
p110-.delta., p85-.alpha., p85-.beta., p55-.gamma., p150, p101, and
p87. Examples of PI3K inhibitors useful in this invention include
but are not limited to ATU-027, SF-1126, DS-7423, PBI-05204,
GSK-2126458, ZSTK-474, buparlisib, pictrelisib, PF-4691502,
BYL-719, dactolisib, XL-147, XL-765, and idelalisib.
[0345] The term "BTK inhibitor" as used herein includes, but is not
limited to compounds having inhibitory activity against Bruton's
Tyrosine Kinase (BTK), including, but not limited to AVL-292 and
ibrutinib.
[0346] The term "SYK inhibitor" as used herein includes, but is not
limited to compounds having inhibitory activity against spleen
tyrosine kinase (SYK), including but not limited to PRT-062070,
R-343, R-333, Excellair, PRT-062607, and fostamatinib.
[0347] Further examples of BTK inhibitory compounds, and conditions
treatable by such compounds in combination with compounds of this
invention can be found in WO2008039218 and WO2011090760, the
entirety of which are incorporated herein by reference.
[0348] Further examples of SYK inhibitory compounds, and conditions
treatable by such compounds in combination with compounds of this
invention can be found in WO2003063794, WO2005007623, and
WO2006078846, the entirety of which are incorporated herein by
reference.
[0349] Further examples of PI3K inhibitory compounds, and
conditions treatable by such compounds in combination with
compounds of this invention can be found in WO2004019973,
WO2004089925, WO2007016176, U.S. Pat. No. 8,138,347, WO2002088112,
WO2007084786, WO2007129161, WO2006122806, WO2005113554, and
WO2007044729 the entirety of which are incorporated herein by
reference.
[0350] Further examples of JAK inhibitory compounds, and conditions
treatable by such compounds in combination with compounds of this
invention can be found in WO2009114512, WO2008109943, WO2007053452,
WO2000142246, and WO2007070514, the entirety of which are
incorporated herein by reference.
[0351] Further anti-angiogenic compounds include compounds having
another mechanism for their activity, e.g. unrelated to protein or
lipid kinase inhibition e.g. thalidomide (Thalomid.TM.) and
TNP-470.
[0352] Examples of proteasome inhibitors useful for use in
combination with compounds of the invention include, but are not
limited to bortezomib, disulfiram, epigallocatechin-3-gallate
(EGCG), salinosporamide A, carfilzomib, ONX-0912, CEP-18770, and
MLN9708.
[0353] Compounds which target, decrease or inhibit the activity of
a protein or lipid phosphatase are e.g. inhibitors of phosphatase
1, phosphatase 2A, or CDC25, such as okadaic acid or a derivative
thereof.
[0354] Compounds which induce cell differentiation processes
include, but are not limited to, retinoic acid, .alpha.- .gamma.-
or .delta.-tocopherol or .alpha.- .gamma.- or
.delta.-tocotrienol.
[0355] The term cyclooxygenase inhibitor as used herein includes,
but is not limited to, Cox-2 inhibitors, 5-alkyl substituted
2-arylaminophenylacetic acid and derivatives, such as celecoxib
(Celebrex.TM.), rofecoxib (Vioxx.TM.), etoricoxib, valdecoxib or a
5-alkyl-2-arylaminophenylacetic acid, such as
5-methyl-2-(2'-chloro-6'-fluoroanilino)phenyl acetic acid,
lumiracoxib.
[0356] The term "bisphosphonates" as used herein includes, but is
not limited to, etridonic, clodronic, tiludronic, pamidronic,
alendronic, ibandronic, risedronic and zoledronic acid. Etridonic
acid is marketed under the trade name Didronel.TM.. Clodronic acid
is marketed under the trade name Bonefos.TM.. Tiludronic acid is
marketed under the trade name Skelid.TM.. Pamidronic acid is
marketed under the trade name Aredia.TM.. Alendronic acid is
marketed under the trade name Fosamax.TM.. Ibandronic acid is
marketed under the trade name Bondranat.TM.. Risedronic acid is
marketed under the trade name Actonel.TM.. Zoledronic acid is
marketed under the trade name Zometa.TM.. The term "mTOR
inhibitors" relates to compounds which inhibit the mammalian target
of rapamycin (mTOR) and which possess antiproliferative activity
such as sirolimus (Rapamune.RTM.), everolimus (Certican.TM.),
CCI-779 and ABT578.
[0357] The term "heparanase inhibitor" as used herein refers to
compounds which target, decrease or inhibit heparin sulfate
degradation. The term includes, but is not limited to, PI-88. The
term "biological response modifier" as used herein refers to a
lymphokine or interferons.
[0358] The term "inhibitor of Ras oncogenic isoforms", such as
H-Ras, K-Ras, or N-Ras, as used herein refers to compounds which
target, decrease or inhibit the oncogenic activity of Ras; for
example, a "farnesyl transferase inhibitor" such as L-744832,
DK8G557 or R115777 (Zarnestra.TM.). The term "telomerase inhibitor"
as used herein refers to compounds which target, decrease or
inhibit the activity of telomerase. Compounds which target,
decrease or inhibit the activity of telomerase are especially
compounds which inhibit the telomerase receptor, such as
telomestatin.
[0359] The term "methionine aminopeptidase inhibitor" as used
herein refers to compounds which target, decrease or inhibit the
activity of methionine aminopeptidase. Compounds which target,
decrease or inhibit the activity of methionine aminopeptidase
include, but are not limited to, bengamide or a derivative
thereof.
[0360] The term "proteasome inhibitor" as used herein refers to
compounds which target, decrease or inhibit the activity of the
proteasome. Compounds which target, decrease or inhibit the
activity of the proteasome include, but are not limited to,
Bortezomib (Velcade.TM.) and MLN 341.
[0361] The term "matrix metalloproteinase inhibitor" or ("MMP"
inhibitor) as used herein includes, but is not limited to, collagen
peptidomimetic and nonpeptidomimetic inhibitors, tetracycline
derivatives, e.g. hydroxamate peptidomimetic inhibitor batimastat
and its orally bioavailable analogue marimastat (BB-2516),
prinomastat (AG3340), metastat (NSC 683551) BMS-279251, BAY
12-9566, TAA211, MMI270B or AAJ996.
[0362] The term "compounds used in the treatment of hematologic
malignancies" as used herein includes, but is not limited to,
FMS-like tyrosine kinase inhibitors, which are compounds targeting,
decreasing or inhibiting the activity of FMS-like tyrosine kinase
receptors (Flt-3R); interferon, 1-.beta.-D-arabinofuransylcytosine
(ara-c) and bisulfan; and ALK inhibitors, which are compounds which
target, decrease or inhibit anaplastic lymphoma kinase.
[0363] Compounds which target, decrease or inhibit the activity of
FMS-like tyrosine kinase receptors (Flt-3R) are especially
compounds, proteins or antibodies which inhibit members of the
Flt-3R receptor kinase family, such as PKC412, midostaurin, a
staurosporine derivative, SU11248 and MLN518.
[0364] The term "HSP90 inhibitors" as used herein includes, but is
not limited to, compounds targeting, decreasing or inhibiting the
intrinsic ATPase activity of HSP90; degrading, targeting,
decreasing or inhibiting the HSP90 client proteins via the
ubiquitin proteosome pathway. Compounds targeting, decreasing or
inhibiting the intrinsic ATPase activity of HSP90 are especially
compounds, proteins or antibodies which inhibit the ATPase activity
of HSP90, such as 17-allylamino, 17-demethoxygeldanamycin (17AAG),
a geldanamycin derivative; other geldanamycin related compounds;
radicicol and HDAC inhibitors.
[0365] The term "antiproliferative antibodies" as used herein
includes, but is not limited to, trastuzumab (Herceptin.TM.),
Trastuzumab-DM1, erbitux, bevacizumab (Avastin.TM.), rituximab
(Rituxan.RTM.), PRO64553 (anti-CD40) and 2C4 Antibody. By
antibodies is meant intact monoclonal antibodies, polyclonal
antibodies, multispecific antibodies formed from at least 2 intact
antibodies, and antibodies fragments so long as they exhibit the
desired biological activity.
[0366] For the treatment of acute myeloid leukemia (AML), compounds
of the current invention can be used in combination with standard
leukemia therapies, especially in combination with therapies used
for the treatment of AML. In particular, compounds of the current
invention can be administered in combination with, for example,
famesyl transferase inhibitors and/or other drugs useful for the
treatment of AML, such as Daunorubicin, Adriamycin, Ara-C, VP-16,
Teniposide, Mitoxantrone, Idarubicin, Carboplatinum and PKC412.
[0367] Other anti-leukemic compounds include, for example, Ara-C, a
pyrimidine analog, which is the 2'-alpha-hydroxy ribose
(arabinoside) derivative of deoxycytidine. Also included is the
purine analog of hypoxanthine, 6-mercaptopurine (6-MP) and
fludarabine phosphate. Compounds which target, decrease or inhibit
activity of histone deacetylase (HDAC) inhibitors such as sodium
butyrate and suberoylanilide hydroxamic acid (SAHA) inhibit the
activity of the enzymes known as histone deacetylases. Specific
HDAC inhibitors include MS275, SAHA, FK228 (formerly FR901228),
Trichostatin A and compounds disclosed in U.S. Pat. No. 6,552,065
including, but not limited to,
N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)-ethyl]-amino]methyl]phenyl]--
2E-2-propenamide, or a pharmaceutically acceptable salt thereof and
N-hydroxy-3-[4-[(2-hydroxyethyl){2-(1H-indol-3-yl)ethyl]-amino]methyl]phe-
nyl]-2E-2-propenamide, or a pharmaceutically acceptable salt
thereof, especially the lactate salt. Somatostatin receptor
antagonists as used herein refer to compounds which target, treat
or inhibit the somatostatin receptor such as octreotide, and
SOM230. Tumor cell damaging approaches refer to approaches such as
ionizing radiation. The term "ionizing radiation" referred to above
and hereinafter means ionizing radiation that occurs as either
electromagnetic rays (such as X-rays and gamma rays) or particles
(such as alpha and beta particles). Ionizing radiation is provided
in, but not limited to, radiation therapy and is known in the art.
See Hellman, Principles of Radiation Therapy, Cancer, in Principles
and Practice of Oncology, Devita et al., Eds., 4.sup.th Edition,
Vol. 1, pp. 248-275 (1993).
[0368] Also included are EDG binders and ribonucleotide reductase
inhibitors. The term "EDG binders" as used herein refers to a class
of immunosuppressants that modulates lymphocyte recirculation, such
as FTY720. The term "ribonucleotide reductase inhibitors" refers to
pyrimidine or purine nucleoside analogs including, but not limited
to, fludarabine and/or cytosine arabinoside (ara-C), 6-thioguanine,
5-fluorouracil, cladribine, 6-mercaptopurine (especially in
combination with ara-C against ALL) and/or pentostatin.
Ribonucleotide reductase inhibitors are especially hydroxyurea or
2-hydroxy-1H-isoindole-1,3-dione derivatives.
[0369] Also included are in particular those compounds, proteins or
monoclonal antibodies of VEGF such as
1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine or a
pharmaceutically acceptable salt thereof,
1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine succinate;
Angiostatin.TM.; Endostatin.TM.; anthranilic acid amides; ZD4190;
ZD6474; SU5416; SU6668; bevacizumab; or anti-VEGF antibodies or
anti-VEGF receptor antibodies, such as rhuMAb and RHUFab, VEGF
aptamer such as Macugon; FLT-4 inhibitors, FLT-3 inhibitors,
VEGFR-2 IgGI antibody, Angiozyme (RPI 4610) and Bevacizumab
(Avastin.TM.).
[0370] Photodynamic therapy as used herein refers to therapy which
uses certain chemicals known as photosensitizing compounds to treat
or prevent cancers. Examples of photodynamic therapy include
treatment with compounds, such as Visudyne.TM. and porfimer
sodium.
[0371] Angiostatic steroids as used herein refers to compounds
which block or inhibit angiogenesis, such as, e.g., anecortave,
triamcinolone, hydrocortisone, 11-.alpha.-epihydrocotisol,
cortexolone, 17.alpha.-hydroxyprogesterone, corticosterone,
desoxycorticosterone, testosterone, estrone and dexamethasone.
[0372] Implants containing corticosteroids refers to compounds,
such as fluocinolone and dexamethasone.
[0373] Other chemotherapeutic compounds include, but are not
limited to, plant alkaloids, hormonal compounds and antagonists;
biological response modifiers, preferably lymphokines or
interferons; antisense oligonucleotides or oligonucleotide
derivatives; shRNA or siRNA; or miscellaneous compounds or
compounds with other or unknown mechanism of action.
[0374] The compounds of the invention are also useful as
co-therapeutic compounds for use in combination with other drug
substances such as anti-inflammatory, bronchodilatory or
antihistamine drug substances, particularly in the treatment of
obstructive or inflammatory airways diseases such as those
mentioned hereinbefore, for example as potentiators of therapeutic
activity of such drugs or as a means of reducing required dosaging
or potential side effects of such drugs. A compound of the
invention may be mixed with the other drug substance in a fixed
pharmaceutical composition or it may be administered separately,
before, simultaneously with or after the other drug substance.
Accordingly the invention includes a combination of a compound of
the invention as hereinbefore described with an anti-inflammatory,
bronchodilatory, antihistamine or anti-tussive drug substance, said
compound of the invention and said drug substance being in the same
or different pharmaceutical composition.
[0375] Suitable anti-inflammatory drugs include steroids, in
particular glucocorticosteroids such as budesonide, beclamethasone
dipropionate, fluticasone propionate, ciclesonide or mometasone
furoate; non-steroidal glucocorticoid receptor agonists; LTB4
antagonists such LY293111, CGS025019C, CP-195543, SC-53228, BIIL
284, ONO 4057, SB 209247; LTD4 antagonists such as montelukast and
zafirlukast; PDE4 inhibitors such cilomilast (Ariflo.RTM.
GlaxoSmithKline), Roflumilast (Byk Gulden), V-11294A (Napp),
BAY19-8004 (Bayer), SCH-351591 (Schering-Plough), Arofylline
(Almirall Prodesfarma), PD189659/PD168787 (Parke-Davis), AWD-12-281
(Asta Medica), CDC-801 (Celgene), SeICID.TM. CC-10004 (Celgene),
VM554/UM565 (Vernalis), T-440 (Tanabe), KW-4490 (Kyowa Hakko
Kogyo); A2a agonists; A2b antagonists; and beta-2 adrenoceptor
agonists such as albuterol (salbutamol), metaproterenol,
terbutaline, salmeterol fenoterol, procaterol, and especially,
formoterol and pharmaceutically acceptable salts thereof. Suitable
bronchodilatory drugs include anticholinergic or antimuscarinic
compounds, in particular ipratropium bromide, oxitropium bromide,
tiotropium salts and CHF 4226 (Chiesi), and glycopyrrolate.
[0376] Suitable antihistamine drug substances include cetirizine
hydrochloride, acetaminophen, clemastine fumarate, promethazine,
loratidine, desloratidine, diphenhydramine and fexofenadine
hydrochloride, activastine, astemizole, azelastine, ebastine,
epinastine, mizolastine and tefenadine.
[0377] Other useful combinations of compounds of the invention with
anti-inflammatory drugs are those with antagonists of chemokine
receptors, e.g. CCR-1, CCR-2, CCR-3, CCR-4, CCR-5, CCR-6, CCR-7,
CCR-8, CCR-9 and CCR10, CXCR1, CXCR2, CXCR3, CXCR4, CXCR5,
particularly CCR-5 antagonists such as Schering-Plough antagonists
SC-351125, SCH-55700 and SCH-D, and Takeda antagonists such as
N-[[4-[[[6,7-dihydro-2-(4-methylphenyl)-5H-benzo-cyclohepten-8-yl]carbony-
l]amino]phenyl]-methyl]tetrahydro-N,N-dimethyl-2H-pyran-4-aminium
chloride (TAK-770).
[0378] The structure of the active compounds identified by code
numbers, generic or trade names may be taken from the actual
edition of the standard compendium "The Merck Index" or from
databases, e.g. Patents International (e.g. IMS World
Publications).
[0379] A compound of the current invention may also be used in
combination with known therapeutic processes, for example, the
administration of hormones or radiation. In certain embodiments, a
provided compound is used as a radiosensitizer, especially for the
treatment of tumors which exhibit poor sensitivity to
radiotherapy.
[0380] A compound of the current invention can be administered
alone or in combination with one or more other therapeutic
compounds, possible combination therapy taking the form of fixed
combinations or the administration of a compound of the invention
and one or more other therapeutic compounds being staggered or
given independently of one another, or the combined administration
of fixed combinations and one or more other therapeutic compounds.
A compound of the current invention can besides or in addition be
administered especially for tumor therapy in combination with
chemotherapy, radiotherapy, immunotherapy, phototherapy, surgical
intervention, or a combination of these. Long-term therapy is
equally possible as is adjuvant therapy in the context of other
treatment strategies, as described above. Other possible treatments
are therapy to maintain the patient's status after tumor
regression, or even chemopreventive therapy, for example in
patients at risk.
[0381] Those additional agents may be administered separately from
an inventive compound-containing composition, as part of a multiple
dosage regimen. Alternatively, those agents may be part of a single
dosage form, mixed together with a compound of this invention in a
single composition. If administered as part of a multiple dosage
regime, the two active agents may be submitted simultaneously,
sequentially or within a period of time from one another normally
within five hours from one another.
[0382] As used herein, the term "combination," "combined," and
related terms refers to the simultaneous or sequential
administration of therapeutic agents in accordance with this
invention. For example, a compound of the present invention may be
administered with another therapeutic agent simultaneously or
sequentially in separate unit dosage forms or together in a single
unit dosage form. Accordingly, the present invention provides a
single unit dosage form comprising a compound of the current
invention, an additional therapeutic agent, and a pharmaceutically
acceptable carrier, adjuvant, or vehicle.
[0383] The amount of both an inventive compound and additional
therapeutic agent (in those compositions which comprise an
additional therapeutic agent as described above) that may be
combined with the carrier materials to produce a single dosage form
will vary depending upon the host treated and the particular mode
of administration. Preferably, compositions of this invention
should be formulated so that a dosage of between 0.01-100 mg/kg
body weight/day of an inventive compound can be administered.
[0384] In those compositions which comprise an additional
therapeutic agent, that additional therapeutic agent and the
compound of this invention may act synergistically. Therefore, the
amount of additional therapeutic agent in such compositions will be
less than that required in a monotherapy utilizing only that
therapeutic agent. In such compositions a dosage of between
0.01-1,000 .mu.g/kg body weight/day of the additional therapeutic
agent can be administered.
[0385] The amount of additional therapeutic agent present in the
compositions of this invention will be no more than the amount that
would normally be administered in a composition comprising that
therapeutic agent as the only active agent. Preferably the amount
of additional therapeutic agent in the presently disclosed
compositions will range from about 50% to 100% of the amount
normally present in a composition comprising that agent as the only
therapeutically active agent.
[0386] The compounds of this invention, or pharmaceutical
compositions thereof, may also be incorporated into compositions
for coating an implantable medical device, such as prostheses,
artificial valves, vascular grafts, stents and catheters. Vascular
stents, for example, have been used to overcome restenosis
(re-narrowing of the vessel wall after injury). However, patients
using stents or other implantable devices risk clot formation or
platelet activation. These unwanted effects may be prevented or
mitigated by pre-coating the device with a pharmaceutically
acceptable composition comprising a kinase inhibitor. Implantable
devices coated with a compound of this invention are another
embodiment of the present invention.
EXEMPLIFICATION
[0387] As depicted in the Examples below, in certain exemplary
embodiments, compounds are prepared according to the following
general procedures. It will be appreciated that, although the
general methods depict the synthesis of certain compounds of the
present invention, the following general methods, and other methods
known to one of ordinary skill in the art, can be applied to all
compounds and subclasses and species of each of these compounds, as
described herein.
Example 1
Intermediate 1.4
##STR00361##
[0389] Synthesis of Compound 1.2.
[0390] Into a 10-L 4-necked round-bottom flask was placed ethyl
2-oxocyclopentane-1-carboxylate (1.1, 1000 g, 6.40 mol, 1.00
equiv), ethyl 2-cyanoacetate (861 g, 7.61 mol, 1.19 equiv), ethanol
(4000 mL), diethylamine (571 g, 7.81 mol, 1.22 equiv), and sulfur
(248 g, 7.75 mol, 1.21 equiv). The resulting solution was stirred
overnight at room temperature and then concentrated under vacuum.
The solution was diluted with 10 L of ethyl acetate and washed with
3.times.1 L of brine. The mixture was dried over anhydrous sodium
sulfate and concentrated under vacuum. The residue was loaded onto
a silica gel column and eluted with ethyl acetate/petroleum ether
(1:10) to afford 800 g (44%) of 1.2 as a yellow solid.
[0391] Synthesis of Compound 1.3.
[0392] A 10-L 4-necked round-bottom flask, purged and maintained
under an inert atmosphere of nitrogen, was charged with 1.2 (800 g,
2.82 mol, 1.00 equiv) and formamide (8 L). The resulting solution
was stirred for 5 h at 180.degree. C. The reaction mixture was
cooled to room temperature with a water bath. The resulting
solution was diluted with 10 L of water/ice. The solution was
extracted with 3.times.5 L of ethyl acetate and the organic layers
were combined. The mixture was washed with 2.times.5 L of brine,
dried over anhydrous sodium sulfate and concentrated under vacuum.
The residue was loaded onto a silica gel column and eluted with
ethyl acetate/petroleum ether (1:1) to afford 350 g (47%) of ethyl
12-hydroxy-7-thia-9,11-diazatricyclo[6.4.0.0
[2,6]]dodeca-1(8),2(6),9,11-tetraene-3-carboxylate 1.3 as a light
yellow solid.
[0393] Synthesis of Compound 1.4.
[0394] A 5-L 4-necked round-bottom flask, purged and maintained
under an inert atmosphere of nitrogen, was charged with 1.3 (350 g,
1.32 mol, 1.00 equiv) and POCl.sub.3 (1800 mL). The resulting
solution was stirred for 1 h at 110.degree. C. in an oil bath. The
reaction mixture was cooled to room temperature with a water bath.
The mixture was concentrated under vacuum. The reaction was then
quenched by the addition of 1 L of water/ice. The solution was
extracted with 2.times.500 mL of ethyl acetate and the organic
layers were combined. The mixture was washed with 1.times.500 mL of
brine and the residue loaded onto a silica gel column and eluted
with ethyl acetate/petroleum ether (1:5) to afford 260 g (69%) of
intermediate 1.4 as a white solid.
Example 2
Synthesis of Intermediate 2.5. (I-11); I-3 (2.2), (I-9) (2.4), I-1
(2.1)
##STR00362## ##STR00363##
[0396] Synthesis of Compound 2.1.
[0397] A 50-mL round-bottom flask was charged with intermediate 1.4
(1.79 g, 6.20 mmol, 1.00 equiv, 98%), N,N-dimethylformamide (15
mL), 1-N,1-N-dimethylcyclohexane-1,4-diamine dihydrochloride (1.63
g, 7.58 mmol, 1.81 equiv), and potassium carbonate (3.5 g, 24.82
mmol, 4.01 equiv, 98%). The resulting solution was stirred for 8 h
at 55.degree. C. in an oil bath. The reaction's progress was
monitored by TLC/LC-MS (ethyl acetate/petroleum ether=1/5). The
reaction was then quenched by the addition of 50 mL of water. The
resulting solution was extracted with 3.times.30 mL of ethyl
acetate and the organic layers combined. The resulting mixture was
washed with 2.times.20 mL of water. The mixture was dried over
anhydrous sodium sulfate and concentrated under vacuum to afford
2.1 g (87%) of 2.1 as a yellow oil.
[0398] Synthesis of Compound 2.2.
[0399] To a solution of compound 2.1 (0.66 g, 1.7 mmol) in THF (30
mL) was added LiAlH.sub.4 (258 mg, 6.8 mmol) in portions at
0.degree. C. The mixture was allowed to warm to r.t. with stirring
for 2 hours, and then Na.sub.2SO.sub.4.10H.sub.2O (2.2 g, 6.8 mmol)
was added. The suspension was stirred for 2 hours and filtered. The
filtrate was concentrated and the residue was purified by silica
gel column chromatography with MeOH/DCM (1:10) to give a white
solid product (450 mg, 76%). MS: m/z 347 (M+H).sup.+.
[0400] Synthesis of Compound 2.3.
[0401] Compound 2.2 (1.9 g, 5.5 mmol, 1 equiv) was dissolved in
SOCl.sub.2 (30 ml). The mixture was stirred at room temperature
overnight, whereupon the SOCl.sub.2 was removed under vacuum. The
residue was quenched by the addition of aqueous NaHCO.sub.3. The
mixture was extracted with CH.sub.2Cl.sub.2 (3.times.100 ml). The
combined CH.sub.2Cl.sub.2 layers were washed with brine, dried with
Na.sub.2SO.sub.4, filtered and concentrated. The residue was used
in the next step without further purification (1.8 g, 91%). MS: m/z
365 (M+H).sup.+.
[0402] Synthesis of Compound 2.4.
[0403] NaCN (450 mg, 9 mmol, 2 equiv) was dissolved in DMSO (10 ml)
at 60.degree. C. Then compound 2.3 (1.65 g, 4.5 mmol, 1 equiv) was
added. The mixture was heated to 70.degree. C. and stirred at this
temperature for 5 hours, whereupon the mixture was cooled to room
temperature and aqueous NaHCO.sub.3 (20 ml) was added. The mixture
was extracted with CH.sub.2Cl.sub.2 (3.times.30 ml). The
CH.sub.2Cl.sub.2 phase was washed with brine, dried with
Na.sub.2SO.sub.4, filtered and concentrated. The residue was
purified on silica gel to give the desired product (1.15 g, 74%).
MS: m/z 356 (M+H).sup.+.
[0404] Synthesis of Intermediate 2.5.
[0405] SOCl.sub.2 (10 ml) was added to MeOH (40 ml) under cooling
with an ice bath. After the addition was complete, the mixture was
stirred for 1 hour, whereupon compound 2.4 (1.1 g, 3 mmol) was
added to the solution. The mixture was heated to 70.degree. C. and
stirred at this temperature for 16 hours at which point the MeOH
was removed and water was added. NaHCO.sub.3 was added to the
mixture to adjust the pH to greater than 7. The mixture was
extracted by CH.sub.2Cl.sub.2 (50 ml). The CH.sub.2Cl.sub.2 phase
was washed with brine, dried with Na.sub.2SO.sub.4, filtered and
concentrated. The residue was purified on silica gel to give the
desired product (600 mg, 55%).
Example 3
Synthesis of Intermediate 3.1. (I-18 HCl)
##STR00364##
[0407] A 50-mL round-bottom flask was charged with a solution of
intermediate 2.5 (500 mg, 1.29 mmol, 1.00 equiv) and sodium
hydroxide (130 mg, 3.25 mmol, 2.53 equiv) in methanol (10 mL). The
reaction was stirred for 5 h at 50.degree. C. The resulting mixture
was concentrated under vacuum to afford a solution that was then
diluted with 20 mL of water. The resulting mixture was washed with
2.times.20 mL of dichloromethane in a separatory funnel. The pH
value of the aqueous layer was adjusted to 3 with 6N HCl.
Concentration of the solution under vacuum afforded 0.6 g (crude)
of intermediate 3.1 as a yellow solid that was used without further
purification.
Example 4
Intermediate 4.1. (I-18 Free Base)
##STR00365##
[0409] To a solution of 2.5 (1 g, 2.57 mmol) in THF (5 mL) and MeOH
(5 mL) was added a solution of NaOH (1 g, 25.7 mmol) in H.sub.2O (5
mL). The mixture was stirred for 15 hours at r.t. At this time the
pH was adjusted to 5 with HCl (1 M) and the desired product was
purified by reverse phase chromatography (Biotage) to give a white
solid (500 mg, 52%). .sup.1H NMR (500 MHz, D.sub.2O) 6 7.958 (s,
1H), 3.755 (m, 1H), 3.479-3.468 (m, 1H), 3.197 (t, 1H), 2.861 (m,
1H), 2.748 (s, 7H), 2.503 (m, 1H), 2.190-2.009 (m, 7H), 1.584-1.420
(m, 4H). MS: m/z 347 (M+H).sup.+.
Example 5
Synthesis of
(1r,4r)-N1,N1-dimethyl-N4-(5-(pyrrolidin-1-ylmethyl)-6,7-dihydro-5H-cyclo-
penta[4,5]thieno[2,3-d]pyrimidin-4-yl)cyclohexane-1,4-diamine
(I-10)
##STR00366##
[0411] Compound 2.3 (prepared as in Example 2; 150 mg, 0.4 mmol, 1
equiv) was dissolved in CH.sub.3CN. Then pyrrolidine (175 mg, 2.5
mmol, 6 equiv) and K.sub.2CO.sub.3 (110 mg, 0.8 mmol, 2 equiv) were
added. The mixture was heated to 80.degree. C. and stirred at this
temperature for 5 hours. The CH.sub.3CN was removed in vacuo. The
residue was purified by preparative HPLC to give Compound I-10 (40
mg, 20%). .sup.1H NMR (500 MHz, CDCl.sub.3) .delta. 8.35 (1H, s),
8.18-8.20 (1H, d), 4.10-4.13 (1H, m), 3.40-3.41 (1H, m), 2.94-3.01
(1H, m), 2.70-2.87 (2H, m), 2.56-2.68 (6H, m), 2.31 (6H, m),
2.23-2.30 (2H, m), 2.10-2.13 (2H, m), 1.95-1.93 (2H, m), 1.74-1.83
(4H, m), 1.45-1.51 (2H, m), 1.16-1.38 (2H, m). MS: m/z 400
(M+H).sup.+.
Example 6
Synthesis of
2-(12-[[4-(dimethylamino)cyclohexyl]amino]-7-thia-9,11-diazatricyclo[6.4.-
0.0 [2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl)-N-ethylacetamide
(I-23)
##STR00367##
[0413] A 100-mL round-bottom flask was charged with a solution of
intermediate 2.5 (220 mg, 0.57 mmol, 1.00 equiv) in tetrahydrofuran
(4 mL) and ethylamine (65-70% in H.sub.2O, 75 mL). This solution
was stirred overnight at room temperature. The resulting mixture
was concentrated under vacuum. The crude product (200 mg) was
purified by preparative HPLC (column: Waters-1 Xbridge RP 19*150;
mobile phase: 0.05% NH.sub.4HCO.sub.3 in H.sub.2O (A) and
CH.sub.3CN (B); detector: 220 nm and 254 nm) to afford 62.4 mg
(27%) of Compound I-23 as a white solid. .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 8.36 (s, 1H), 5.91-5.89 (d, 1H), 5.39 (m, 1H),
3.83-3.81 (m, 1H), 3.39-3.22 (m, 3H), 3.08-2.72 (m, 2H), 2.38-2.32
(m, 9H), 2.20-2.16 (m, 3H). 1.99-1.97 (m, 2H), 1.48-1.45 (m, 4H),
1.12-1.07 (t, 3H). MS: m/z 400 (M+H).sup.+.
Example 7
Synthesis of
2-(4-(((1r,4r)-4-(dimethylamino)cyclohexyl)amino)-6,7-dihydro-5H-cyclopen-
ta[4,5]thieno[2,3-d]pyrimidin-5-yl)ethanol (I-12)
##STR00368##
[0415] To a solution of 2.5 (0.66 g, 1.7 mmol) in THF (30 mL) was
added LiAlH.sub.4 (508 mg, 13.3 mmol) in portions at 0.degree. C.
The mixture was allowed to warm to r.t. with stirring for 2 hours.
Then, Na.sub.2SO.sub.4.10H.sub.2O (4.3 g, 13.3 mmol) was added and
the suspension was stirred for 2 hours. The solids were filtered
off and the filtrate was purified by silica gel column
chromatography with MeOH/CH.sub.2Cl.sub.2=1:10 to give Compound
I-12 as a white solid product (450 mg, 73%). .sup.1H NMR (500 MHz,
CDCl.sub.3) .delta. 8.365 (1H, s), 5.850-5.834 (1H, d), 4.169-4.138
(1H, m), 3.753-3.716 (2H, m), 3.570-3.563 (1H, t), 3.073-3.022 (1H,
m), 2.920-2.869 (1H, m), 2.705-2.663 (1H, m), 2.391 (1H, m), 2.341
(6H, s), 2.274-2.145 (4H, m), 1.971-1.948 (2H, m), 1.805-1.714 (2H,
m), 1.503-1.362 (4H, m). MS: m/z 347 (M+H).sup.+.
Example 8
Synthesis of
2-(12-[[4-(dimethylamino)cyclohexyl]amino]-7-thia-9,11-diazatricyclo[6.4.-
0.0
[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl)-N-(2-hydroxyethyl)acetamide
(I-26)
##STR00369##
[0417] Synthesis of Compound 8.1.
[0418] A 50-mL round-bottom flask was charged with intermediate 4.1
(80 mg, 0.21 mmol, 1.00 equiv) in DMF (10 mL), HOBT (35 mg, 0.26
mmol, 1.20 equiv), EDCI (81 mg, 2.00 equiv),
(2-aminoethoxy)(tert-butyl)dimethylsilane (93 mg, 0.53 mmol, 2.50
equiv) and triethylamine (65 mg, 0.64 mmol, 3.00 equiv). This
solution was stirred overnight at room temperature. The resulting
mixture was concentrated under vacuum to afford 80 mg (crude) of
compound 8.1 as a white solid that was used without further
purification.
[0419] Synthesis of Compound I-26.
[0420] A 50-mL round-bottom flask was charged with a solution of
8.1 (80 mg, 0.15 mmol, 1.00 equiv) in CH.sub.3CN (5 mL). HF (40 wt.
% in water, 0.25 mL) was added and the solution was stirred
overnight at room temperature. The resulting mixture was
concentrated under vacuum. The crude product was purified by
preparative HPLC (column: Waters-1 Xbridge RP 19*150; mobile phase:
0.05% NH.sub.4HCO.sub.3 in H.sub.2O (A), CH.sub.3CN (B); detector:
UV 220 nm and 254 nm) to afford 4.5 mg (7%) of Compound I-26 as a
white solid. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.38 (s,
1H), 5.97 (s, 1H), 5.86-5.87 (d, 1H), 4.12 (s, 1H), 3.95-3.81 (d,
1H), 3.80-3.60 (s, 2H), 3.60-3.30 (m, 2H), 3.20-3.00 (m, 1H),
3.00-2.87 (m, 1H), 2.86-2.70 (m, 1H), 2.50-2.30 (m, 1H) 2.27-2.10
(m, 3H), 1.90-2.70 (m, 1H) 1.60-1.20 (m, 4H). MS: m/z 400
(M+H).sup.+.
Example 9
Synthesis of
2-(12-[[4-(dimethylamino)cyclohexyl]amino]-7-thia-9,11-diazatricyclo[6.4.-
0.0
[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl)-N-(2-hydroxyethyl)acetamide
(I-27)
##STR00370##
[0422] Synthesis of Compound 9.1.
[0423] A 50-mL round-bottom flask was charged with a solution of
intermediate 4.1 (83 mg, 0.22 mmol, 1.00 equiv),
N,N-dimethylformamide (12 mL), EDCI (83 mg, 0.43 mmol, 2.00 equiv),
HOBT (35 mg, 0.26 mmol, 1.20 equiv),
(3-aminopropoxy)(tert-butyl)dimethylsilane (120 mg, 0.63 mmol, 2.90
equiv), and triethylamine (65 mg, 0.64 mmol, 3.00 equiv). This
solution was stirred overnight at room temperature. The resulting
mixture was concentrated under vacuum to afford 100 mg (crude) of
9.1 as a white solid that was used without further
purification.
[0424] Synthesis of Compound I-27.
[0425] A 50-mL round-bottom flask was charged with 9.1 (100 mg,
0.18 mmol, 1.00 equiv) in CH.sub.3CN (5 mL). This was followed by
the addition of HF (40 wt. % in water, 0.25 mL) dropwise with
stirring. This solution was stirred overnight at room temperature.
The resulting mixture was concentrated under vacuum to afford 11.8
mg (15%) of I-27 as a white solid. .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 8.40 (s, 1H), 6.10-5.90 (s, 1H), 5.90-5.80 (d,
1H), 4.20-4.00 (s, 1H), 3.95-3.81 (d, 1H), 3.70-3.55 (m, 2H),
3.55-3.45 (m, 1H), 3.45-3.30 (m, 1H), 3.30-3.00 (m, 1H), 3.00-2.85
(m, 1H), 2.85-2.70 (m, 1H) 2.50-2.30 (m, 9H), 2.39-2.15 (m, 3H)
2.16-1.90 (m, 2H), 1.90-1.60 (m, 2H), 1.58-1.40 (m, 4H). MS: m/z
434 (M+H).sup.+.
Example 10
Synthesis of
2-(4-(((1r,4r)-4-(dimethylamino)cyclohexyl)amino)-6,7-dihydro-5H-cyclopen-
ta[4,5]thieno[2,3-d]pyrimidin-5-yl)acetamide (I-13)
##STR00371##
[0427] A mixture of intermediate 4.1 (200 mg, 0.5 mmol, 1 equiv),
NH.sub.4Cl (200 mg, 4 mmol, 8 equiv), TEA (500 mg, 5 mmol, 10
equiv) and HATU (380 mg, 1 mmol, 2 equiv) in DMF (3 mL) was stirred
at 20.degree. C. for 24 h. The mixture was purified by preparative
HPLC to afford Compound I-13 (60 mg, 20%). .sup.1H NMR (500 MHz,
CDCl.sub.3) .delta. 8.37 (1H, s), 5.82 (1H, m), 5.37-5.45 (2H, m),
4.10-4.13 (1H, m), 3.85-3.87 (1H, m), 3.03-3.08 (1H, m), 2.90-2.95
(1H, m), 2.77-2.81 (1H, m), 2.45-2.47 (2H, m), 2.34 (6H, s),
2.17-2.24 (4H, m), 1.98-1.99 (2H, m), 1.38-1.47 (4H, m). MS: m/z
374 (M+H).sup.+.
Example 11
Synthesis of
2-(4-(((1r,4r)-4-(dimethylamino)cyclohexyl)amino)-6,7-dihydro-5H-cyclopen-
ta[4,5]thieno[2,3-d]pyrimidin-5-yl)-1-(pyrrolidin-1-yl)ethanone
(I-14)
##STR00372##
[0429] A mixture of 4.1 (200 mg, 0.5 mmol, 1 equiv), pyrrolidine
(70 mg, 1 mmol, 2 equiv), TEA (150 mg, 1.5 mmol, 3 equiv) and HATU
(200 mg, 0.5 mmol, 1 equiv) in DMF (3 mL) was stirred at 20.degree.
C. for 24 h. The mixture was purified by preparative HPLC to afford
Compound I-14 (70 mg, 30%). .sup.1H NMR (500 MHz, CDCl.sub.3)
.delta. 8.35 (1H, s), 6.26-6.28 (1H, d), 4.07-4.09 (1H, m),
3.93-3.95 (1H, m), 3.30-3.50 (3H, m), 3.04-3.09 (3H, m), 2.88-2.93
(1H, m), 2.75-2.80 (1H, m), 2.50-2.54 (1H, m), 2.31 (6H, s),
2.16-2.21 (4H, m), 1.75-1.96 (6H, m), 1.43-1.50 (4H, m). MS: m/z
428 (M+H).sup.+.
Example 12
Synthesis of
2-(4-(((1r,4S)-4-(dimethylamino)cyclohexyl)amino)-6,7-dihydro-5H-cyclopen-
ta[4,5]thieno[2,3-d]pyrimidin-5-yl)-1-((S)-3-hydroxypyrrolidin-1-yl)ethano-
ne (I-15)
##STR00373##
[0431] Compound I-15 was synthesized from intermediate 4.1 and
(S)-pyrrolidin-3-ol in a manner consistent with Example 9 to afford
Compound I-15 in 31% yield. .sup.1H NMR (500 MHz, CDCl.sub.3)
.delta. 8.34 (1H, s), 6.14-6.32 (1H, m), 4.38-4.44 (1H, m),
4.02-4.13 (1H, m), 3.88-3.98 (1H, m), 3.42-3.69 (3H, m), 3.14-3.38
(1H, m), 3.05-3.12 (1H, m), 2.72-2.96 (2H, m), 2.42-2.61 (2H, m),
2.30 (7H, m), 2.16-2.23 (2H, m), 1.78-2.04 (5H, m), 1.34-1.50 (4H,
m). MS: m/z 444 (M+H).sup.+.
Example 13
Synthesis of
2-(4-(((1r,4R)-4-(dimethylamino)cyclohexyl)amino)-6,7-dihydro-5H-cyclopen-
ta[4,5]thieno[2,3-d]pyrimidin-5-yl)-1-((R)-3-hydroxypyrrolidin-1-yl)ethano-
ne (I-16)
##STR00374##
[0433] Compound I-16 was synthesized from intermediate 4.1 and
(R)-pyrrolidin-3-ol in a manner consistent with Example 9 to afford
Compound I-16 in 46% yield. .sup.1H NMR (500 MHz, CDCl.sub.3)
.delta. 8.34 (1H, s), 6.14-6.18 (1H, m), 4.38-4.44 (1H, m),
4.02-4.13 (1H, m), 3.88-3.98 (1H, m), 2.71-3.72 (7H, m), 2.42-2.61
(2H, m), 2.29 (7H, s), 2.14-2.23 (2H, m), 1.75-2.04 (4H, m),
1.68-1.74 (1H, m), 1.34-1.50 (4H, m). MS: m/z 444 (M+H).sup.+.
Example 14
Synthesis of
2-(12-[[4-(dimethylamino)cyclohexyl]amino]-7-thia-9,11-diazatricyclo[6.4.-
0.0
[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl)-N-(2-hydroxyethyl)-N-methyla-
cetamide (I-30)
##STR00375##
[0435] Synthesis of Compound 14.1.
[0436] A 100-mL round-bottom flask was charged with a solution of
intermediate 3.1 (600 mg, 1.46 mmol, 1.00 equiv) in
N,N-dimethylformamide (20 mL),
2-[(tert-butyldimethylsilyl)oxy]ethyl(methyl)amine (360 mg, 1.90
mmol, 1.30 equiv), HOBT (320 mg, 2.37 mmol, 1.62 equiv), EDC (920
mg, 4.82 mmol, 3.30 equiv), and TEA (810 mg, 8.00 mmol, 5.48
equiv). The resulting solution was stirred overnight at room
temperature. The reaction was then quenched by the addition of 100
mL of water. The resulting solution was extracted with 3.times.50
mL of ethyl acetate and the organic layers combined. The combined
organic layers were washed with 3.times.50 mL of brine, dried over
anhydrous sodium sulfate and concentrated under vacuum. The residue
was loaded onto a silica gel column with dichloromethane/methanol
(elution gradient: 100:1-10:1 DCM:MeOH). Purification afforded 0.2
g (25%) of 14.1 as a yellow oil. MS: m/z 546 (M+H).sup.+.
[0437] Synthesis of Compound I-30.
[0438] A 50-mL round-bottom flask was charged with a solution of
14.1 (200 mg, 0.37 mmol, 1.00 equiv) in acetonitrile (5 mL) and
hydrogen fluoride (40 wt % in water, 0.2 mL). After stirring for 5
h at room temperature, the resulting mixture was concentrated under
vacuum. The crude product was purified by preparative HPLC [column:
Xbridge Shield RP 18, 5 um, 19*150 mm; mobile phase: water (50 mM
NH.sub.4HCO.sub.3) and CH.sub.3CN (5.0% CH.sub.3CN up to 45.0% in 8
min, hold for 2 min, ramp up to 100.0% in 1 min, then ramp down to
5.0% in 1 min); detector: UV 254 and 220 nm. 45.7 mg (29%) of 1-30
were obtained as a white solid. .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 8.33 (d, 1H), 6.06-6.09 (m, 1H), 4.08 (s, 1H), 3.92-3.94
(m, 1H), 3.79-3.81 (m, 1H), 3.67-3.77 (m, 1H), 3.48-3.65 (m, 1H),
3.34-3.38 (m, 1H), 3.02-3.08 (m, 1H), 2.99 (s, 3H), 2.62-2.92 (m,
3H), 2.52-2.58 (m, 1H), 2.30 (s, 7H), 2.16-2.26 (m, 2H), 1.94 (s,
2H), 1.36-1.46 (m, 4H). MS: m/z 432 (M+H).sup.+.
Example 15
Synthesis of Intermediate 15.4
##STR00376##
[0440] Synthesis of Compound 15.2.
[0441] Into a 10-L 4-necked round-bottom flask was placed a
solution of ethyl 2-(2-oxocyclopentyl)acetate (15.1, 550 g, 3.23
mol, 1.00 equiv) in ethanol (2200 mL) at room temperature. This was
followed by the addition of NCCH.sub.2COOEt (440 g, 1.21 equiv),
Et.sub.2NH (291.5 g, 1.23 equiv) and S (126.5 g, 1.22 equiv) in
portions at room temperature. The solution was stirred overnight at
room temperature and then concentrated under vacuum. The resulting
solution was diluted with 5000 mL of ethyl acetate and washed with
2.times.1000 mL of brine. The mixture was dried over anhydrous
sodium sulfate and concentrated under vacuum. The residue was
loaded onto a silica gel column with ethyl acetate/petroleum ether
(1:10) and purified to afford 430 g (45%) of ethyl
2-amino-4-(2-ethoxy-2-oxoethyl)-4H,5H,6H-cyclopenta[b]thiophene-3-carboxy-
late (15.2) as an orange oil.
[0442] Synthesis of Compound 15.3.
[0443] To a 10-L 4-necked round-bottom flask, purged and maintained
with an inert atmosphere of nitrogen, was added a solution of 15.2
(500 g, 1.68 mol, 1.00 equiv) in formamide (5 L) at room
temperature. The resulting solution was stirred for 5 h at
180.degree. C. in an oil bath. The reaction mixture was cooled to
room temperature and then quenched by the addition of 10 L of
water/ice. The resulting solution was extracted with 3.times.5 L of
ethyl acetate and the organic layers were combined. The mixture was
washed with 3.times.3000 mL of brine, dried over anhydrous sodium
sulfate and concentrated under vacuum. The solids were collected by
filtration to afford 200 g (43%) of ethyl
2-[12-hydroxy-7-thia-9,11-diazatricyclo[6.4.0.0
[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]acetate (15.3) as a yellow
solid.
[0444] Synthesis of Intermediate 15.4.
[0445] Two 2000-mL 4-necked round-bottom flasks were charged with a
solution of 15.3 (200 g, 718.58 mmol, 1.00 equiv) in POCl.sub.3
(2000 mL) at room temperature. The resulting solution was stirred
for 2 h at 110.degree. C. in an oil bath. The reaction mixture was
cooled to room temperature and concentrated under vacuum. The
reaction was then quenched by the addition of 1000 mL of ice-water.
The resulting solution was extracted with 3.times.500 mL of ethyl
acetate and the organic layers were combined. The combined organic
layers were washed with 2.times.500 mL of brine, dried over
anhydrous sodium sulfate and concentrated under vacuum to afford
200 g (94%) of ethyl 2-[12-chloro-7-thia-9,11-diazatricyclo[6.4.0.0
[2,6]]dodeca-1(12),2(6),8,10-tetraen-3-yl]acetate (15.4) as a light
yellow solid.
Example 16
Synthesis of
2-[(3S)-12-[[4-(dimethylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo[6-
.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-3-yl]ethan-1-ol
(I-33)
##STR00377## ##STR00378##
[0447] Synthesis of Compound 16.1.
[0448] The enantiomers of racemic 15.3 (4.7 g) were separated by
chiral HPLC under the following conditions: column: CHIRALPAK IC,
0.46*25 cm, 5 um; mobile phase: Hex:EtOH=50:50; flow rate: 1.0
ml/min; UV detection at 254 nm. The first enantiomer to elute
(16.2, t.sub.R=7.76 min, 1.5 g) was obtained in 100% ee as a light
yellow solid and the second enantiomer to elute (16.1,
t.sub.R=10.39 min, 1.4 g) was also obtained in 100% ee as a light
yellow solid.
[0449] Synthesis of Compound 16.3.
[0450] To a 50-mL round-bottom flask was added ethyl
2-[(3S)-12-hydroxy-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(12),2(-
6),8,10-tetraen-3-yl]acetate (16.2, 560 mg, 2.01 mmol, 1.00 equiv),
dioxane (10 mL) and phosphoroyl trichloride (3.5 mL). The reaction
was stirred for 4 h at 110.degree. C. under nitrogen. After
concentration under reduced pressure, the resulting solution was
poured dropwise into saturated aqueous NaHCO.sub.3 and extracted
with ethyl acetate (3.times.50 mL). The combined organic layers
were washed with brine and dried over sodium sulfate. After
evaporation in vacuo, the residue was purified by column
chromatography on silica gel with ethyl acetate/petroleum ether
(1:7) to afford ethyl
2-[(3S)-12-chloro-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(12),2(6-
),8,10-tetraen-3-yl]acetate (16.3, 550 mg, 92%) as a yellow
oil.
[0451] Synthesis of Compound 16.4.
[0452] A solution of tert-butyl N-(4-hydroxycyclohexyl)carbamate
(412 mg, 1.91 mmol, 1.10 equiv) in freshly distilled
tetrahydrofuran (10 mL) was treated with sodium hydride (60%
dispersion in mineral oil, 280 mg, 4.00 equiv) for 1 h at room
temperature under nitrogen. To this mixture was then added a
solution of 16.3 (510 mg, 1.72 mmol, 1.00 equiv) in dry
tetrahydrofuran (5 mL) via syringe. After stirring overnight at
room temperature, the reaction was then quenched with water and
extracted with ethyl acetate (3.times.50 mL). The combined organic
layers were washed with brine and dried over sodium sulfate. After
filtration and concentration under reduced pressure, the residue
was loaded onto a silica gel column with ethyl acetate/petroleum
ether (1:2) and purified to afford ethyl
2-[(3S)-12-[(4-[[(tert-butoxy)carbonyl]amino]cyclohexyl)oxy]-7-thia-9,11--
diazatricyclo[6.4.0.0
[2,6]]dodeca-1(12),2(6),8,10-tetraen-3-yl]acetate (16.4, 400 mg,
49%) as a yellow oil.
[0453] Synthesis of Compound 16.5.
[0454] To a 50-mL round-bottom flask containing 16.4 (180 mg, 0.38
mmol, 1.00 equiv) in distilled tetrahydrofuran (10 mL) was added
LiAlH.sub.4 (30 mg, 0.79 mmol, 2.00 equiv) at 0.degree. C. under
nitrogen. The resulting solution was stirred for 30 min at room
temperature. The reaction was then quenched with water and
extracted with ethyl acetate (3.times.20 mL). The combined organic
layers were washed with brine and dried over anhydrous sodium
sulfate and concentrated under vacuum to afford tert-butyl
N-(4-[[(3S)-3-(2-hydroxyethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dod-
eca-1(12),2(6),8,10-tetraen-12-yl]oxy]cyclohexyl)carbamate (16.5,
100 mg, 61%) as a yellow oil. MS: m/z 434 (M+H).sup.+.
[0455] Synthesis of Compound I-33.
[0456] To a 25-mL round-bottom flask containing a solution of 16.5
(100 mg, 0.23 mmol, 1.00 equiv) in methanol (5 mL) was added HCHO
(37%, 1 mL) and HCOOH (5 mL) at room temperature under nitrogen.
The resulting solution was stirred overnight at 100.degree. C. and
evaporated under reduced pressure. The crude product (80 mg) was
purified by preparative HPLC (SHIMADZU) under the following
conditions: column: SunFire Prep C18, 19*150 mm 5 um; mobile phase:
water (0.05% NH.sub.4HCO.sub.3) and CH.sub.3CN (start at 7.0%
CH.sub.3CN then ramp up to 63.0% in 13 min); UV detection at 254
and 220 nm. The product-containing fractions were collected and the
solvents evaporated to afford Compound I-33 (8 mg) as a colorless
oil. An ee of 100% was measured by chiral-SFC analysis. .sup.1H NMR
(300 MHz, CDCl.sub.3) .delta. 7.26 (s, 1H), 5.24 (m, 1H), 3.72 (t,
1H), 3.47 (m, 1H), 3.08 (m, 2H), 2.70 (m, 1H), 2.03-2.68 (m, 11H),
1.25-1.81 (m, 9H). MS: m/z 362 (M+H).sup.+.
Example 17
Synthesis of
2-[(3R)-12-[[4-(dimethylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo[6-
.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-3-yl]ethan-1-ol
(I-34)
##STR00379##
[0458] Compound I-34 was synthesized in a manner consistent with
Example 16, except that 16.1 was used rather than 16.2. .sup.1H NMR
(300 MHz, CDCl.sub.3) .delta. 7.26 (s, 1H), 5.24 (m, 1H), 3.75 (t,
1H), 3.47 (m, 1H), 3.08 (m, 2H), 2.70 (m, 1H), 2.03-2.68 (m, 13H),
1.25-1.80 (m, 6H). MS: m/z 362 (M+H).sup.+.
Example 18
Intermediate 18.3
##STR00380##
[0460] Synthesis of Compound 18.1.
[0461] To a solution of tert-butyl N-(4-hydroxycyclohexyl)carbamate
(710 mg, 3.30 mmol, 1.10 equiv) in 10 mL of distilled THF was added
sodium hydride (60% dispersion in mineral oil, 720 mg, 18.00 mmol,
6.00 equiv) at room temperature under nitrogen. After stirring for
30 min, intermediate 15.4 (891 mg, 3.00 mmol, 1.00 equiv) in THF
(10 mL) was added via syringe and the resulting solution was
stirred for 12 h at room temperature. The reaction was then
quenched by the addition of water and extracted with 3.times.50 mL
of ethyl acetate. The combined organic layers were washed with
brine, dried over anhydrous sodium sulfate and concentrated under
vacuum. The residue was loaded onto a silica gel column with ethyl
acetate/petroleum ether (1:4 to 1:2). Purification afforded 18.1
(260 mg, 18%) as a white solid.
[0462] Synthesis of Compound 18.2.
[0463] To a 50-mL round-bottom flask containing a solution of 18.1
(415 mg, 0.87 mmol, 1.00 equiv) in distilled DMF (10 mL) was added
sodium hydride (60% dispersion in mineral oil, 225 mg, 6.5 mmol) at
0.degree. C. and the reaction mixture was stirred for 30 min under
nitrogen. Then MeI (1.2 g) was added via syringe and the resulting
solution was stirred overnight at room temperature. The reaction
was then quenched with water and extracted with 3.times.50 mL of
ethyl acetate. The organic layers were combined, washed with brine
and dried over anhydrous sodium sulfate. After concentration under
reduced pressure, the residue was loaded onto a silica gel column
with ethyl acetate/petroleum ether (1:5) to afford 18.2 (278 mg,
65%) as a yellow oil.
[0464] Synthesis of Compound 18.3.
[0465] LiAlH.sub.4 (980 mg, 25.8 mmol) was treated with 18.2 (278
mg, 0.57 mmol, 1.00 equiv) in 20 mL of distilled THF in an ice/salt
bath under nitrogen. Then the resulting solution was stirred for 2
h at room temperature and the reaction was quenched by the addition
of methanol and diluted with water. The resulting solution was
extracted with 100 mL of ethyl acetate and the organic layer was
washed with brine and dried over anhydrous sodium sulfate. After
concentration in vacuo, the desired tert-butyl
N-(4-[[3-(2-hydroxyethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1-
(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)-N-methylcarbamate
(18.3, 251 mg, 99%) was obtained as a yellow oil.
Example 19
Synthesis of
4-[[3-(2-ethoxyethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),-
2(6),9,11-tetraen-12-yl]oxy]-N,N-dimethylcyclohexan-1-amine
(I-31)
##STR00381##
[0467] Synthesis of Compound 19.1.
[0468] To a 25-mL round-bottom flask was added a solution of
intermediate 18.3 (125 mg, 0.28 mmol, 1.00 equiv) in distilled DMF
(10 mL) followed by sodium hydride (60% dispersion in mineral oil,
96 mg, 2.80 mmol) at 0.degree. C. and the reaction mixture was
stirred for 30 min. Then bromoethane (305 mg, 2.80 mmol) was added
and the resulting solution was stirred overnight at room
temperature. The reaction was then quenched with water and
extracted with 100 mL of ethyl acetate. The organic layer was
washed with brine and dried over anhydrous sodium sulfate and
concentrated under vacuum. The residue was loaded onto a silica gel
column with EtOAc/petroleum ether (1:5). Purification afforded
tert-butyl
N-(4-[[3-(2-ethoxyethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(-
8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)-N-methylcarbamate (19.1,
19 mg, 14%) as a colorless oil.
[0469] Synthesis of Compound I-31.
[0470] A 25-mL round-bottom flask containing 19.1 (19 mg, 0.04
mmol, 1.00 equiv), formic acid (1 mL) and formaldehyde (37%, 5 mL)
was heated at 100.degree. C. for 12 h in an oil bath under
nitrogen. The mixture was concentrated under reduced pressure and
the residue (45 mg) purified by preparative HPLC (SHIMADZU) under
the following conditions: column: Xbridge Prep C18, 19*150 mm 5 um;
mobile phase: water (0.05% NH.sub.4HCO.sub.3) and CH.sub.3CN (5.0%
CH.sub.3CN up to 53.0% in 16 min); UV detection at 254 and 220 nm.
The product-containing fractions were collected and evaporated
under reduced pressure to afford compound I-31 (5.7 mg, 37%) as an
off-white oil. .sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 1.20 (m,
3H), 1.54 (m, 4H), 1.61 (m, 1H), 2.02-2.80 (m, 14H), 2.28-3.10 (m,
2H), 3.48 (m, 5H), 5.24 (m, 1H), 8.50 (s, 1H). MS: m/z 390
(M+H).sup.+.
Example 20
Synthesis of
4-[[3-(2-methoxyethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8)-
,2(6),9,11-tetraen-12-yl]oxy]-N,N-dimethylcyclohexan-1-amine
(I-32)
##STR00382##
[0472] Synthesis of Compound 20.1.
[0473] To a 25-mL round-bottom flask was added a solution of
intermediate 18.3 (80 mg, 0.18 mmol, 1.00 equiv) in distilled DMF
(8 mL) followed by sodium hydride (60% dispersion in mineral oil,
36 mg, 0.90 mmol) at 0.degree. C. and the reaction mixture was
stirred for 30 min. Then iodomethane (255 mg, 1.80 mmol) was added
and the resulting solution was stirred overnight at room
temperature. The reaction was then quenched with water and
extracted with 100 mL of ethyl acetate. The organic layer was
washed with brine and dried over anhydrous sodium sulfate and
concentrated under vacuum. The residue was loaded onto a silica gel
column with EtOAc/petroleum ether (1:5) and purified to afford 20.1
(50 mg, 61%) as a colorless oil.
[0474] Synthesis of Compound I-32.
[0475] A solution of 20.1 (50 mg, 0.11 mmol, 1.00 equiv) in
formaldehyde (37%, 5 mL) and formic acid (1 mL) was stirred for 12
h at 100.degree. C. in an oil bath under nitrogen. The mixture was
concentrated under vacuum and the crude product (50 mg) was
purified by preparative HPLC (SHIMADZU) under the following
conditions: column: Xbridge Prep C18, 19*150 mm 5 um; mobile phase:
water (0.05% NH.sub.4HCO.sub.3) and CH.sub.3CN (5.0% CH.sub.3CN up
to 55.0% in 15 min); UV detection at 254 and 220 nm. The
product-containing fractions were collected and evaporated under
reduced pressure to afford Compound I-32 (17.1 mg, 42%) as a
colorless oil. .sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 1.47 (m,
4H), 1.76 (m, 1H), 1.98 (m, 2H), 2.20-2.32 (m, 11H), 2.66 (m, 1H),
2.94 (m, 1H), 3.07 (m, 1H), 3.30 (s, 3H), 3.42 (m, 3H), 5.23 (m,
1H), 8.50 (s, 1H). MS: m/z 376 (M+H).sup.+.
Example 21
Synthesis of Intermediates 21.3 and 21.4
##STR00383##
[0477] Synthesis of Compound 21.1.
[0478] A solution of 15.3 (15 g, 53.89 mmol, 1.00 equiv) and
POCl.sub.3 (100 mL) in 100 mL of dioxane was heated at reflux for 3
h under nitrogen. After concentration under reduced pressure, the
resulting solution was poured dropwise into saturated aqueous
NaHCO.sub.3 and extracted with ethyl acetate (3.times.150 mL). The
combined organic layers were washed with brine and dried over
sodium sulfate. After evaporation in vacuo, the residue was
purified by column chromatography on silica gel with ethyl
acetate/petroleum ether (1:7) to afford 21.1 (15 g, 94%) as a light
yellow oil. MS: m/z 297, 299 (M+H).sup.+.
[0479] Synthesis of Compound 21.2.
[0480] To a 500-mL round-bottom flask under an atmosphere of
nitrogen was added 21.1 (6 g, 20.22 mmol, 1.00 equiv) in 100 mL of
distilled THF at -50.degree. C. DIBAL-H (25% w/w in hexane, 50 mL)
was added dropwise and the resulting solution was stirred for 2 h
at under -30.degree. C. under nitrogen. The reaction was quenched
with saturated aqueous ammonium chloride and extracted with ethyl
acetate (2.times.150 mL). The combined organic layers were washed
with brine, dried over anhydrous sodium sulfate and concentrated
under vacuum. The residue was purified by column chromatography on
silica gel with EtOAc/petroleum ether (1:5 to 1:1) to afford 21.2
(5.0 g, 97%) as a yellow solid. MS: m/z 255, 257 (M+H).sup.+.
[0481] Synthesis of Compounds 21.3 and 21.4.
[0482] The enantiomers of racemic 21.2 (5.0 g, 19.6 mmol) were
separated by chiral-SFC under the following conditions: column:
CHIRALPAK IA; 20% methanol with CO.sub.2; flow rate: 250 mL/min; UV
detection at 254 nm. The fractions corresponding to the peak with
t.sub.R=1.63 were collected and the methanol removed in vacuo to
give enantiomerically pure
(3R)-3-[2-[(tert-butyldimethylsilyl)oxy]ethyl]-12-chloro-7-thia-9,11-diaz-
atricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraene (21.3, 2.0 g)
in 100% ee. Similar treatment of the fractions corresponding to the
peak with t.sub.R=2.69 gave enantiomerically pure
(3S)-3-[2-[(tert-butyldimethylsilyl)oxy]ethyl]-12-chloro-7-thia-9,11-diaz-
atricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraene (21.4, 2.0 g)
in 100% ee.
Example 22
Synthesis of Intermediate 22.4
##STR00384##
[0484] Synthesis of Compound 22.1.
[0485] Intermediate 21.4 (3.3 g, 12.95 mmol, 1.00 equiv) was
treated with imidazole (1.24 g, 18.24 mmol, 1.41 equiv) and TBDMSCl
(2.34 g, 15.53 mmol, 1.20 equiv) in distilled DMF (10 mL) for 2 h
at room temperature under nitrogen. The reaction was then quenched
with water and extracted with ethyl acetate (3.times.50 mL). The
combined organic layers were washed with brine and dried over
anhydrous sodium sulfate. After filtration and concentration under
reduced pressure, the residue was loaded onto a silica gel column
with ethyl acetate/petroleum ether (1:5) and purified to afford
(3S)-3-[2-[(tert-butyldimethylsilyl)oxy]ethyl]-12-chloro-7-thia-9,11-diaz-
atricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraene (22.1, 4.5 g,
94%) as a yellow oil.
[0486] Synthesis of Compound 22.2.
[0487] Sodium hydride (60% dispersion in mineral oil, 1.96 g, 49.00
mmol, 4.02 equiv) was treated with tert-butyl
N-(4-hydroxycyclohexyl)-N-methylcarbamate (3.92 g, 17.09 mmol, 1.40
equiv) in distilled THF (50 mL) at 0.degree. C. for 1 h under
nitrogen. Then a solution of 22.1 (4.5 g, 12.20 mmol, 1.00 equiv)
in 15 mL of THF was added to the reaction mixture, which was
stirred for a further 2 h at 60.degree. C. The reaction was then
quenched by the addition of 20 mL of water at 0.degree. C. and
extracted with ethyl acetate (3.times.100 mL). The combined organic
layers were washed with brine and dried over anhydrous sodium
sulfate. After filtration and concentration under reduced pressure,
the residue was loaded onto a silica gel column with ethyl
acetate/petroleum ether (1:5) and purified to afford tert-butyl
N-(4-[[(3S)-3-[2-[(tert-butyldimethylsilyl)oxy]ethyl]-7-thia-9,11-diazatr-
icyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)-N--
methylcarbamate (22.2, 6.5 g, 95%) as yellow oil. MS: m/z 562
(M+H).sup.+.
[0488] Synthesis of Compound 22.3.
[0489] A solution of 22.2 (6.5 g, 11.57 mmol, 1.00 equiv) and
Bu.sub.4NF (4.5 g, 17.24 mmol, 1.49 equiv) in tetrahydrofuran (100
mL) was stirred for 2 h at room temperature. The reaction was then
quenched by the addition of water and extracted with ethyl acetate
(2.times.100 mL). The combined organic layers were washed with
brine and dried over anhydrous sodium sulfate. After filtration and
concentration under reduced pressure, the residue was loaded onto a
silica gel column with ethyl acetate/petroleum ether (1:1) and
purified to give tert-butyl N-(4-[[(3
S)-3-(2-hydroxyethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),-
2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)-N-methylcarbamate (22.3, 5
g, 97%) as a yellow oil. MS: m/z 448 (M+H).sup.+.
[0490] Synthesis of Intermediate 22.4.
[0491] A solution of 22.3 (1.25 g, 2.79 mmol, 1.00 equiv) and
dipyridinium dichromate (4 g, 10.64 mmol, 4.00 equiv) in 10 mL of
DMF was stirred for 15 h at room temperature. The reaction was then
quenched with water and extracted with ethyl acetate (3.times.50
mL). The combined organic layers were washed with brine, dried over
anhydrous sodium sulfate and concentrated under vacuum. The residue
was loaded onto a silica gel column with ethyl acetate/petroleum
ether (1:2 to 3:5) and purified to afford
2-[(3S)-12-[(4-[[(tert-butoxy)carbonyl](methyl)amino]cyclohexyl)ox-
y]-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3--
yl]acetic acid (22.4, 900 mg, 70%) as a colourless oil.
Example 23
Synthesis of
2-[(3S)-12-[[4-(dimethylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo[6-
.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]-N-(5-fluoropyridin-2-yl)ac-
etamide (I-38)
##STR00385##
[0493] Synthesis of Compound 23.1.
[0494] To a solution of intermediate 22.4 (200 mg, 0.43 mmol, 1.00
equiv) in distilled DMF (8 mL) at room temperature under nitrogen
was added 5-fluoropyridin-2-amine (55 mg, 0.49 mmol, 1.13 equiv),
HATU (200 mg) and DIPEA (170 mg). The resulting solution was
stirred for 2 h at room temperature and quenched with water and
extracted with ethyl acetate (3.times.30 mL). The combined organic
layers were washed with brine, dried over anhydrous sodium sulfate
and concentrated under vacuum. The residue was loaded onto a silica
gel column with ethyl acetate/petroleum ether (1:2 to 3:5) and
purified to give tert-butyl N-(4-[[(3
S)-3-[[(5-fluoropyridin-2-yl)carbamoyl]methyl]-7-thia-9,11-diazatricyclo[-
6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)-N-methylc-
arbamate (23.1, 195 mg, 81%) as a yellow oil. MS: m/z 556
(M+H).sup.+.
[0495] Synthesis of Compound I-38.
[0496] To a 25-mL round-bottom flask containing a solution of 23.1
(195 mg, 0.35 mmol, 1.00 equiv) in dichloromethane (15 mL) was
added hydrochloric acid (12 M, 2 mL) at 0.degree. C. under
nitrogen. The resulting solution was stirred for 2 h at room
temperature and concentrated under vacuum. The resulting
N-(5-fluoropyridin-2-yl)-2-[(3S)-12-[[4-(methylamino)cyclohexyl]oxy]-7-th-
ia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]acet-
amide hydrochloride (130 mg, crude) was used in the next step
directly without further purification. A solution of this material
(130 mg, crude) and HCHO (37%, 1 mL) in methanol (10 mL) was
stirred at room temperature for 30 min, whereupon NaBH.sub.3CN (55
mg, 0.78 mmol, 3.06 equiv) was added and the mixture stirred for an
additional 2 h at room temperature. The reaction was then quenched
by the addition of 20 mL of water and extracted with 3.times.30 mL
of ethyl acetate. The combined organic layers were concentrated
under vacuum. The crude product (70 mg) was purified by preparative
HPLC (SHIMADZU) under the following conditions: column: Xbridge
Prep C18 5 um, 19*150 mm; mobile phase: water (0.05%
NH.sub.4HCO.sub.3) and CH.sub.3CN (6.0% CH.sub.3CN up to 50.0% in
25 min); UV detection at 254 and 220 nm. The fractions were
collected and evaporated under reduced pressure to give the
2-[(3S)-12-[[4-(dimethylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo[6-
.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]-N-(5-fluoropyridin-2-yl)ac-
etamide (I-38, 21.4 mg) as a white solid. .sup.1H NMR (300 MHz,
CDCl.sub.3) .delta. 8.49 (s, 1H), 8.20 (m, 2H), 7.63 (m, 1H), 5.28
(m, 1H), 3.93 (t, 1H), 3.33 (m, 2H), 3.03 (m, 1H), 2.82 (m, 1H),
2.77 (m, 1H), 2.55 (m, 10H), 2.03 (m, 2H), 1.55 (m, 4H). MS: m/z
470 (M+H).sup.+.
Example 24
Synthesis of
2-[(3S)-12-[[4-(dimethylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo[6-
.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-3-yl]-N-ethylacetamide
(I-36)
##STR00386##
[0498] Synthesis of Compound 24.1.
[0499] A 25-mL round-bottom flask was charged with intermediate
22.4 (200 mg, 0.43 mmol, 1.00 equiv), HOBt (90 mg, 0.67 mmol, 1.54
equiv), EDCI (191 mg, 1.00 mmol, 2.31 equiv), ethanamine
hydrochloride (45 mg, 0.55 mmol, 1.27 equiv), triethylamine (135
mg, 1.34 mmol, 3.08 equiv) and 10 mL of distilled DMF. The
resulting solution was stirred for 4 h at room temperature under
nitrogen. The reaction was then quenched with water and extracted
with 3.times.25 mL of ethyl acetate. The combined organic layers
were washed with brine and dried over anhydrous sodium sulfate.
After filtration and concentration under reduced pressure, the
residue was loaded onto a silica gel column with ethyl
acetate/petroleum ether (1:2 to 3:5) and purified to provide the
desired tert-butyl
N-(4-[[(3S)-3-[(ethylcarbamoyl)methyl]-7-thia-9,11-diazatricyclo[6.4.0.0[-
2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)-N-methylcarbamate
(24.1, 165 mg, 78%) as a white solid. MS: m/z 470 (M+H).sup.+.
[0500] Synthesis of Compound I-36.
[0501] To a 25-mL round-bottom flask was added 24.1 (165 mg, 0.34
mmol, 1.00 equiv) and hydrochloric acid (12 M, 2 mL) in
dichloromethane (12 mL). The reaction was stirred for 2 h at room
temperature. The resulting mixture was concentrated under vacuum to
afford 1-(ethylamino)-2-[(3
S)-12-[[4-(methylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo[6.4.0.0[-
2,6]]dodeca-1(12),2(6),8,10-tetraen-3-yl]ethan-1-ol hydrochloride
(105 mg, crude) as a yellow oil that was used in the next step
without further purification. To a solution of this compound (105
mg, crude) in methanol (10 mL) was added HCHO (37%, 2 mL) and the
reaction was stirred for 1 h at room temperature. Then NaBH.sub.3CN
(50 mg, 63%) was added and the reaction stirred for another 2 h at
ambient temperature. The resulting mixture was concentrated under
reduced pressure and the crude product (85 mg) purified by
preparative HPLC (SHIMADZU) under the following conditions: column:
Xbridge Prep C18 5 um, 19*150 mm; mobile phase: water (0.05%
NH.sub.4HCO.sub.3) and CH.sub.3OH NMR (6.0% CH.sub.3OH up to 50.0%
in 25 min); UV detection at 254 nm. The fractions were collected
and evaporated under reduced pressure to give the desired Compound
I-36 (43 mg) as a white solid. An enantiomeric excess of 100% was
measured by chiral HPLC analysis. .sup.1H NMR (400 MHz,
CD.sub.3OD): .delta. 8.48 (s, 1H), 5.30 (m, 1H), 3.84 (m, 1H),
2.94-3.32 (m, 5H), 2.73 (m, 1H), 2.20-2.68 (m, 11H), 1.50-1.72 (m,
4H), 1.15 (t, 3H). MS: m/z 403 (M+H).sup.+.
Example 25
Synthesis of Intermediate 25.1
##STR00387##
[0503] Intermediate 21.3 (1.3 g, 5.10 mmol, 1.00 equiv) was treated
with imidazole (500 mg, 7.44 mmol, 1.40 equiv) and TBDMSCl (920 mg,
6.10 mmol, 1.20 equiv) in distilled DMF (10 mL) for 2 h at room
temperature under nitrogen. The reaction was then quenched with
water and extracted with ethyl acetate (3.times.50 mL). The
combined organic layers were washed with brine and dried over
anhydrous sodium sulfate. After filtration and concentration under
reduced pressure, the residue was loaded onto a silica gel column
with ethyl acetate/petroleum ether (1:5) and purified to give
(3R)-3-[2-[(tert-butyldimethylsilyl)oxy]ethyl]-12-chloro-7-thia-9-
,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraene
(25.1, 1.8 g, 96%) as a yellow oil.
Example 26
Synthesis of Intermediate 26.3
##STR00388##
[0505] Synthesis of Compound 26.1.
[0506] To a 50-mL round-bottom flask was added a solution of 25.1
(560 mg, 1.52 mmol, 1.00 equiv) and TEA (461 mg, 3.0 equiv) in
distilled DMF (10 mL) at room temperature under nitrogen. Then
tert-butyl trans-N-(4-aminocyclohexyl)carbamate (1628 mg, 7.60
mmol, 4.98 equiv) was added and the resulting solution was stirred
for 14 h at 50.degree. C. The reaction was then quenched with water
and extracted with 2.times.100 mL of ethyl acetate. The combined
organic layers were dried over sodium sulfate and concentrated
under vacuum to afford 26.1 (721 mg, 87%) as a colorless oil.
[0507] Synthesis of Compound 26.2.
[0508] To a solution of 26.1 (721 mg, 1.32 mmol, 1.00 equiv) in 10
mL of THF was added TBAF (476 mg, 1.82 mmol, 1.38 equiv) at room
temperature. The resulting solution was stirred for 2 h at ambient
temperature and then quenched by the addition of water and
extracted with 2.times.80 mL of ethyl acetate. The combined organic
layers were dried over sodium sulfate and concentrated under
reduced pressure. The residue was purified by column chromatography
on silica gel with ethyl acetate/petroleum ether (1:2) to give the
desired tert-butyl
N-(4-[[(3R)-3-(2-hydroxyethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dod-
eca-1(8),2(6),9,11-tetraen-12-yl]amino]cyclohexyl)carbamate (26.2,
542 mg, 95%) as a white solid.
[0509] Synthesis of Compound 26.3.
[0510] Compound 26.2 (542 mg, 1.25 mmol, 1.00 equiv) was treated
with Dess-Martin periodinane (637 mg, 1.50 mmol, 1.20 equiv) in 20
mL of DCM at 0.degree. C. The resulting solution was stirred for 4
h at room temperature then quenched with water and extracted with
2.times.50 mL of ethyl acetate. The combined organic layers were
washed with brine, dried over sodium sulfate and concentrated under
reduced pressure. The residue was loaded onto a silica gel column
with ethyl acetate/petroleum ether (1:2) to provide the desired
tert-butyl
N-(4-[[(3R)-3-(2-oxoethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca--
1(8),2(6),9,11-tetraen-12-yl]amino]cyclohexyl)carbamate 26.3 (494
mg, 92%) as a white solid.
Example 27 and Example 28
Synthesis of
(R)-3-((R)-4-(((1r,4R)-4-(dimethylamino)cyclohexyl)oxy)-6,7-dihydro-5H-cy-
clopenta[4,5]thieno[2,3-d]pyrimidin-5-yl)-1,1,1-trifluoropropan-2-ol
(I-68) and
(S)-3-((R)-4-(((1r,4R)-4-(dimethylamino)cyclohexyl)oxy)-6,7-dihydro-5H-cy-
clopenta[4,5]thieno[2,3-d]pyrimidin-5-yl)-1,1,1-trifluoropropan-2-ol
(I-70)
##STR00389##
[0512] Synthesis of Compound 27.1.
[0513] A 25-mL round-bottom flask, purged and maintained with an
inert atmosphere of nitrogen, was charged with a solution of 21.3
(300 mg, 1.18 mmol, 1.00 equiv) in 10 mL) in anhydrous
dichloromethane (15 mL). Dess-Martin periodinane (757 mg, 1.79
mmol, 1.52 equiv) was added and the resulting solution was stirred
for 2 h at 0.degree. C. in a water/ice bath. After completion of
the reaction, the reaction was then quenched by the addition of
saturated aqueous sodium bicarbonate and extracted with 3.times.20
mL of DCM. The combined organic layers were washed with brine,
dried (Na.sub.2SO.sub.4) and concentrated under vacuum. The residue
was applied onto a silica gel column with ethyl acetate/petroleum
ether (1:8) and purified to afford the compound 27.1 (267 mg, 90%)
as a white solid.
[0514] Synthesis of Compound 27.2.
[0515] To a solution of 27.1 (267 mg, 1.06 mmol, 1.00 equiv) in 10
mL of distilled THF was added trimethyl(trifluoromethyl)silane (280
mg, 1.97 mmol, 1.86 equiv) and TEA (0.1 mL). The reaction was
stirred at 0.degree. C. for 30 min under nitrogen. Then TBAF (0.01
mL) was added via syringe at 0.degree. C. and the resulting
solution was stirred for 5 min. The resulting solution was diluted
with 15 mL of water and extracted with of ethyl acetate (100 mL).
The organic layer was washed with brine, dried over sodium sulfate
and concentrated under vacuum. The residue was applied onto a
silica gel column with ethyl acetate/petroleum ether (1:1) to
afford 27.2 (320 mg, 77%) as a red oil.
[0516] Synthesis of Compound 27.3.
[0517] To a 100-mL 3-necked round-bottom flask containing a
solution of trans-4-(dimethylamino)cyclohexan-1-ol (232 mg, 1.62
mmol, 2.00 equiv) in 10 mL of anhydrous THF was added NaH (60%
dispersion in mineral oil, 128 mg, 5.33 mmol, 6.58 equiv) at
0.degree. C. and the resulting mixture was stirred for 30 min in a
water/ice bath. Then compound 27.2 (320 mg, 0.81 mmol, 1.00 equiv)
was added and the resulting solution was allowed to react, with
stirring, for an additional 3 h while the temperature was
maintained at 55 OC in an oil bath. After completion, the reaction
was quenched by the addition of 10 mL of saturated aqueous
NH.sub.4Cl and extracted with 3.times.30 mL of DCM. The organic
layers were combined, dried (Na.sub.2SO.sub.4) and concentrated
under vacuum. The residue was applied onto a silica gel column with
dichloromethane/methanol/NH.sub.4OH (10:1:0.1) and purified to give
the product as a mixture of diastereomers (180 mg).
[0518] Synthesis of Compounds I-68 and I-70.
[0519] The diastereomers of 27.3 (180 mg) were separated by
preparative HPLC (SHIMADZU) under the following conditions: column:
Xbridge Prep C18 5 um, 19*150 mm; mobile phase: water (0.1% HCOOH)
and MeOH (6.0% MeOH up to 53.0% in 19 min); UV detection at 254/220
nm. The product-containing fractions were collected and evaporated
(to remove the water and CH.sub.3OH) to give Compounds I-70 (28 mg)
and I-68 (74.1 mg) as white solids.
[0520] Analytical data for I-70: .sup.1H NMR (300 MHz, CD.sub.3OD)
.delta. 8.45 (s, 2H), 5.32-5.30 (m, 1H), 3.93-3.99 (m, 1H),
3.78-3.66 (m, 1H), 3.32-2.94 (m, 3H), 2.84-2.65 (m, 7H), 2.40-2.19
(m, 7H), 1.90-1.56 (m, 5H). MS: m/z 430 (M+H).sup.+.
[0521] Analytical data for I-68: .sup.1H NMR (300 MHz, CD.sub.3OD)
.delta. 8.44 (s, 2H), 5.33-5.31 (m, 1H), 4.10-4.05 (m, 1H),
3.47-3.32 (m, 1H), 3.29-2.90 (m, 3H), 2.84-2.68 (m, 7H), 2.55-2.17
(m, 7H), 1.77-1.62 (m, 5H). MS: m/z 430 (M+H).sup.+.
Example 29
Synthesis of
2-((R)-4-(((1r,4R)-4-morpholinocyclohexyl)oxy)-6,7-dihydro-5H-cyclopenta[-
4,5]thieno[2,3-d]pyrimidin-5-yl)acetamide (I-67)
##STR00390##
[0523] Synthesis of Compound 29.1.
[0524] 4-(Morpholin-4-yl)cyclohexan-1-ol (commercially available;
218 mg, 1.2 mmol, 1.50 equiv) was treated with NaH (60% dispersion
in mineral oil, 128 mg, 3.2 mmol, 4 equiv) in freshly distilled
tetrahydrofuran (15 mL) for 30 min at 0.degree. C. in a water/ice
bath under nitrogen. Then a solution of intermediate 25.1 (289 mg,
0.8 mmol, 1.00 equiv) in 5 mL of THF was added via syringe and the
resulting solution was allowed to stir for an additional 3 h at
60.degree. C. in an oil bath. The reaction was then quenched with
saturated aqueous NH.sub.4Cl and extracted with 3.times.50 mL of
ethyl acetate. The combined organic layers were washed with brine,
dried (Na.sub.2SO.sub.4) and concentrated under vacuum. The residue
was applied onto a silica gel column with ethyl acetate/petroleum
ether (1:5-1:2) and purified to afford compound 29.1 (260 mg, 63%)
as a colorless oil.
[0525] Synthesis of Compound 29.2.
[0526] To a solution of 29.1 (260 mg, 0.5 mmol, 1.0 equiv) in 10 mL
of DCM was added 0.5 mL of concentrated hydrochloric acid in an
ice/water bath. The resulting solution was stirred for 2 h and
concentrated in vacuo. The residue was neutralized with saturated
aqueous Na.sub.2CO.sub.3 and extracted with 3.times.50 mL of ethyl
acetate. The organic layers were combined, washed with brine, dried
(Na.sub.2SO.sub.4) and concentrated under reduced pressure. The
residue was purified by column chromatography on silica gel with
DCM/MeOH (15:1) to afford the desired alcohol 29.2 (185 mg, 91%) as
a colorless oil.
[0527] Synthesis of Compound 29.3.
[0528] Alcohol 29.2 (185 mg, 0.46 mmol, 1.00 equiv) was oxidized
with dipyridinium dichromate (752 mg, 2.00 mmol, 4.36 equiv) in 50
mL of DMF for 24 h at room temperature. The resulting solution was
diluted with water and extracted with 3.times.50 mL of mixed
solutions of CHCl.sub.3/iso-PrOH. The organic layers were combined,
dried (Na.sub.2SO.sub.4) and concentrated under vacuum. The residue
was applied onto a silica gel column with dichloromethane/methanol
(5:1 to 1:1) and purified to afford 105 mg (55%) of acid 29.3 as a
yellow oil.
[0529] Synthesis of Compound I-67.
[0530] A 50 mL round-bottom flask containing a solution of acid
29.3 (105 mg, 0.25 mmol, 1.00 equiv), NH.sub.4Cl (80 mg, 1.50 mmol,
6.00 equiv), EDCI (57 mg, 0.3 mmol, 1.2 equiv),
4-dimethylaminopyridine (37 mg, 0.3 mmol, 1.2 equiv) and HOBt (40
mg, 0.3 mmol, 1.2 equiv) in 5 mL of anhydrous DMF was stirred for
24 h at room temperature. The resulting solution was diluted with
water and extracted with 4.times.50 mL of mixed solution of
CHCl.sub.3:iso-PrOH. The combined organic layers were concentrated
under vacuum. The crude product was purified by preparative HPLC
(SHIMADZU) under the following conditions: column: SunFire Prep
C18, 19*150 mm 5 um; mobile phase: water (0.05% NH.sub.4CO.sub.3)
and CH.sub.3CN (6.0% CH.sub.3CN up to 50.0% in 25 min); UV
detection at 254/220 nm. The product-containing fractions were
collected and concentrated to give Compound I-67 (22.5 mg) as a
white solid. .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 8.43 (s,
1H), 5.27-5.20 (m, 1H), 3.80-3.70 (m, 5H), 3.29-3.27 (m, 1H),
3.12-2.90 (m, 2H), 2.73-2.67 (m, 5H), 2.49-2.42 (m, 1H), 2.32-2.19
(m, 4H), 2.10-2.06 (d, 2H), 1.67-1.46 (m, 4H). MS: m/z 417
(M+H).sup.+.
Example 30 and Example 31
Synthesis of
(2R)-1-[(3R)-12-[[4-(dimethylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricy-
clo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]butan-2-ol
formate (I-52) and
(2S)-1-[(3R)-12-[[4-(dimethylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricy-
clo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]butan-2-ol
formate (I-54)
##STR00391##
[0532] Synthesis of Compound 30.1.
[0533] To a 50-mL round-bottom flask, purged and maintained under
an inert atmosphere of nitrogen, was added a solution of 26.3 (244
mg, 0.57 mmol, 1.00 equiv) in distilled THF (10 mL) at 0.degree. C.
under nitrogen. Then C.sub.2H.sub.5MgBr (1 M in THF, 2.85 mL, 5.0
equiv) was added dropwise at 0.degree. C. via syringe. The
resulting solution was stirred for an additional 2 h at 0.degree.
C., quenched with saturated aqueous NH.sub.4Cl and extracted with
3.times.20 mL of ethyl acetate. The combined organic layers were
washed with brine, dried over sodium sulfate and concentrated under
reduced pressure. The residue was loaded onto a silica gel column
with ethyl acetate/petroleum ether (1:5) and purified to give
racemic tert-butyl
N-(4-[[(3R)-3-(2-hydroxybutyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dod-
eca-1(8),2(6),9,11-tetraen-12-yl]amino]cyclohexyl)carbamate (30.1,
130 mg, 50%) as a colorless oil.
[0534] Synthesis of Compounds I-52 and I-54.
[0535] A 50-mL round-bottom flask was charged with 30.1 (130 mg,
0.28 mmol, 1.00 equiv) and dichloromethane (10 mL) and cooled to
0.degree. C. Then hydrochloric acid (12 M, 2.0 mL) was added and
the resulting solution was stirred for 3 h at room temperature.
After 3 h, the mixture was concentrated under vacuum. The pH value
of the solution was adjusted to 8 with saturated aqueous sodium
carbonate and then the solution was extracted with 2.times.40 mL of
ethyl acetate. The organic layers were combined and dried over
sodium sulfate and concentrated under vacuum to give
1-[(3R)-12-[(4-aminocyclohexyl)amino]-7-thia-9,11-diazatricyclo[6.4.-
0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]butan-2-ol (80 mg,
crude) as a colorless oil. To a solution of this material (80 mg,
crude) in methanol (5 mL) was added HCHO (37%, 0.8 mL). The
reaction was stirred for 1 h at room temperature. Then NaBH.sub.3CN
(33.9 mg, 0.54 mmol, 2.44 equiv) was added and the resulting
solution was stirred for an additional 2 h at ambient temperature
and concentrated under vacuum. The crude product (80 mg) was
purified by preparative HPLC (SHIMADZU) under the following
conditions: column: SunFire Prep C18, 19*150 mm 5 um; mobile phase:
water with 0.1% HCOOH and CH.sub.3CN; UV detection at 254 nm. The
product-containing fractions were collected and evaporated to
remove the water and CH.sub.3CN to give
(2R)-1-[(3R)-12-[[4-(dimethylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricy-
clo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]butan-2-ol
formate (I-52, 8.6 mg) as a white solid and
(2S)-1-[(3R)-12-[[4-(dimethylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricy-
clo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]butan-2-ol
formate (I-54, 5.9 mg) as a grey solid, respectively.
[0536] Analytical data for I-52: .sup.1H NMR (300 MHz, CD.sub.3OD)
.delta. 8.55 (br s, 1H), 8.23 (s, 1H) 4.19 (m, 1H), 3.57-3.59 (m,
1H), 3.31-3.38 (m, 1H), 3.23 (m, 1H), 3.11-3.14 (m, 1H), 2.83-2.91
(m, 7H), 2.68-2.75 (m, 1H), 2.33-2.37 (m, 1H), 2.18-2.27 (m, 4H),
1.61-1.79 (m, 6H), 1.48-1.57 (m, 2H), 0.95 (t, 3H). MS: m/z 389
(M+H).sup.+.
[0537] Analytical data for I-54: .sup.1H NMR (300 MHz, CD.sub.3OD)
.delta. 8.45 (br s, 1H), 8.12 (s, 1H), 4.08-4.12 (m, 1H), 3.51-3.54
(m, 2H), 3.20-3.22 (m, 1H), 2.82-2.98 (m, 1H), 2.74-2.79 (m, 6H),
2.57-2.64 (m, 1H), 2.05-2.18 (m, 5H), 1.32-1.83 (m, 8H), 0.84 (t,
3H). MS: m/z 389 (M+H).sup.+.
Example 32 and Example 33
Synthesis of
(2R)-1-[(3R)-12-[[4-(dimethylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricy-
clo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]propan-2-ol
formate (I-53) and
(2S)-1-[(3R)-12-[[4-(dimethylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricy-
clo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]propan-2-ol
formate (I-55)
##STR00392##
[0539] Synthesis of Compound 32.1.
[0540] To a 50-mL 3-neck round-bottom flask, purged and maintained
under an atmosphere of nitrogen, was added a solution of 26.3 (250
mg, 0.58 mmol, 1.00 equiv) in freshly distilled tetrahydrofuran (10
mL) at 0.degree. C. under nitrogen. CH.sub.3MgBr (1.0 M in THF, 2.9
mL, 5.0 equiv) was added at 0.degree. C. via syringe. The resulting
solution was stirred for 2 h at 0.degree. C. and quenched with
saturated aqueous NH.sub.4Cl and extracted with 3.times.30 mL of
ethyl acetate. The combined organic layers were washed with brine,
dried over sodium sulfate and concentrated under reduced pressure.
The residue was loaded onto a silica gel column with ethyl
acetate/petroleum ether (1:5) to give a mixture of the 2-hydroxy
diastereomers of tert-butyl
N-(4-[[(3R)-3-(2-hydroxypropyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]do-
deca-1(8),2(6),9,11-tetraen-12-yl]amino]cyclohexyl)carbamate (32.1,
109 mg, 42%) as a colorless oil.
[0541] Synthesis of Compounds I-53 and I-55.
[0542] To a 50-mL round-bottom flask was added 32.1 (109 mg, 0.24
mmol, 1.00 equiv) and dichloromethane (10 mL) and the solution was
cooled to 0.degree. C. Then hydrochloric acid (12 M, 2.0 mL) was
added and the solution was stirred for 3 h at room temperature. The
resulting mixture was concentrated under vacuum. The pH value of
the solution was adjusted to 8 with saturated aqueous sodium
carbonate and extracted with 2.times.40 mL of ethyl acetate. The
organic layers were combined, dried over sodium sulfate and
concentrated under vacuum to give the desired
1-[(3R)-12-[(4-aminocyclohexyl)amino]-7-thia-9,11-diazatricyclo[6.4.0.0[2-
,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]propan-2-ol (70 mg, crude)
as a colorless oil. To a solution of this oil (70 mg, crude) in
methanol (5 mL) was added HCHO (37%, 0.8 mL) and then the reaction
was stirred for 1 h at room temperature. Then NaBH.sub.3CN (29.7
mg, 0.47 mmol, 2.35 equiv) was added and stirring was continued for
an additional 2 h at ambient temperature, whereupon it was
concentrated under vacuum. The crude product (80 mg) was purified
by preparative HPLC (SHIMADZU) under the following conditions:
column: SunFire Prep C18, 19*150 mm 5 um; mobile phase: water
(0.05% HCOOH solution) and CH.sub.3CN (start at 6.0% CH.sub.3CN
then ramp up to 50.0% over 25 min); UV detection at 254 and 220 nm.
The product-containing fractions were collected and evaporated to
afford Compound I-53 (12.9 mg) as a white solid and Compound I-55
(5.6 mg) as a grey solid. Analytical data for I-53: .sup.1H NMR
(300 MHz, CD.sub.3OD) .delta. 8.54 (br s, 1H), 8.23 (s, 1H),
4.18-4.19 (m, 1H), 3.70-3.76 (m, 1H), 3.55-3.58 (m, 1H), 3.05-3.33
(m, 2H), 2.84-2.92 (m, 7H), 2.68-2.75 (m, 1H), 2.16-2.37 (m, 5H),
1.55-1.78 (m, 6H), 1.23 (t, 3H). MS: m/z 375 (M+H).sup.+.
Analytical data for I-55: .sup.1H NMR (300 MHz, CD.sub.3OD) .delta.
8.55 (br s, 1H), 8.23 (s, 1H), 4.18-4.19 (m, 1H), 3.70-3.76 (m,
1H), 3.55-3.58 (m, 1H), 3.05-3.33 (m, 2H), 2.84-2.92 (m, 7H),
2.68-2.75 (m, 1H), 2.16-2.37 (m, 5H), 1.55-1.78 (m, 6H), 1.23 (t,
3H). MS: m/z 375(M+H).sup.+.
Example 34
Synthesis of Intermediate 34.2
##STR00393##
[0544] Synthesis of Compound 34.1.
[0545] Sodium hydride (60% dispersion in mineral oil, 0.9 g, 22.5
mmol, 4.60 equiv) was treated with tert-butyl
N-(4-hydroxycyclohexyl)-N-methylcarbamate (1.8 g, 7.85 mmol, 1.6
equiv) in distilled THF (50 mL) at 0.degree. C. for 1 h under
nitrogen. Then a solution of 25.1 (1.8 g, 4.88 mmol, 1.00 equiv) in
15 mL of THF was added to the reaction mixture and the latter was
stirred for 2 h at 60.degree. C. The reaction was then quenched by
the addition of 20 mL of water at 0.degree. C. and extracted with
ethyl acetate (3.times.100 mL). The combined organic layers were
washed with brine and dried over anhydrous sodium sulfate. After
filtration and concentration under reduced pressure, the residue
was loaded onto a silica gel column with ethyl acetate/petroleum
ether (1:5) and purified to afford tert-butyl
N-(4-[[(3R)-3-[2-[(tert-butyldimethylsilyl)oxy]ethyl]-7-thia-9,11-diazatr-
icyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)-N--
methylcarbamate (34.1, 1.6 g, 58%) as a yellow oil.
[0546] Synthesis of Compound 34.2.
[0547] A solution of 34.1 (1.6 g, 2.85 mmol, 1.00 equiv) and
Bu.sub.4NF (1.1 g, 1.5 equiv) in tetrahydrofuran (50 mL) was
stirred for 2 h at room temperature. The reaction was then quenched
by the addition of water and extracted with ethyl acetate
(3.times.50 mL). The combined organic layers were washed with brine
and dried over anhydrous sodium sulfate. After filtration and
concentration under reduced pressure, the residue was loaded onto a
silica gel column with ethyl acetate/petroleum ether (1:1) and
purified to afford intermediate 34.2 (1.2 g, 81%) as a yellow oil.
MS: m/z 448 (M+H).sup.+.
Example 35
Synthesis of Intermediate 35.1
##STR00394##
[0549] Synthesis of Intermediate 35.1.
[0550] A solution of 34.2 (1.15 g, 2.57 mmol, 1.00 equiv) and
dipyridinium dichromate (4 g, 10.64 mmol, 4.14 equiv) in 10 mL of
DMF was stirred for 15 h at room temperature. The reaction was then
quenched with water and extracted with ethyl acetate (3.times.50
mL). The combined organic layers were washed with brine, dried over
anhydrous sodium sulfate and concentrated under vacuum. The residue
was loaded onto a silica gel column with ethyl acetate/petroleum
ether (1:2 to 3:5) to afford
2-[(3R)-12-[(4-[[(tert-butoxy)carbonyl](methyl)amino]cyclohexyl)oxy]-7-th-
ia-9,11-diazatricyclo[6.4.0.0[2,6]]-dodeca-1(8),2(6),9,11-tetraen-3-yl]ace-
tic acid (35.1, 0.9 g, 76%) as a colourless oil.
Example 36
Synthesis of
2-[(3R)-12-[[4-(dimethylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo[6-
.4.0.0[2,6]]-dodeca-1(8),2(6),9,11-tetraen-3-yl]-N-(5-fluoropyridin-2-yl)a-
cetamide (I-37)
##STR00395##
[0552] Synthesis of Compound 36.1.
[0553] A solution of 35.1 (200 mg, 0.43 mmol, 1.00 equiv),
5-fluoropyridin-2-amine (55 mg, 0.49 mmol, 1.13 equiv), HATU (200
mg) and DIPEA (170 mg) in distilled DMF (8 mL) was stirred at room
temperature under nitrogen for 2 h. The reaction was then quenched
with water and extracted with ethyl acetate (3.times.30 mL). The
combined organic layers were washed with brine, dried over
anhydrous sodium sulfate and concentrated under vacuum. The residue
was loaded onto a silica gel column with ethyl acetate/petroleum
ether (1:2 to 3:5) to give tert-butyl
N-(4-[[(3R)-3-[[(5-fluoropyridin-2-yl)carbamoyl]methyl]-7-thia-9,11-diaza-
tricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)--
N-methylcarbamate (36.1, 200 mg, 83%) as a yellow oil. MS: m/z 556
(M+H).sup.+.
[0554] Synthesis of Compound I-37.
[0555] To a 25-mL round-bottom flask containing a solution of 36.1
(200 mg, 0.36 mmol, 1.00 equiv) in dichloromethane (15 mL) was
added hydrochloric acid (12 M, 2 mL) at 0.degree. C. under
nitrogen. The resulting solution was stirred for 2 h at room
temperature and concentrated under vacuum to afford
N-(5-fluoropyridin-2-yl)-2-[(3R)-12-[[4-(methylamino)cyclohexyl]oxy]-7-th-
ia-9,11-diazatricyclo[6.4.0.0 [2,6]]dodeca-1(8),2(6),9,
11-tetraen-3-yl]acetamide hydrochloride (130 mg, crude), which was
used in the next step without further purification.
[0556] A solution of this compound (130 mg, crude) and HCHO (37%, 1
mL) in methanol (10 mL) was stirred at room temperature for 30
min., whereupon NaBH.sub.3CN (55 mg, 0.78 mmol, 3.06 equiv) was
added to the mixture and stirring was continued for an additional 2
h at room temperature. The reaction was then quenched by the
addition of 20 mL of water and extracted with 3.times.30 mL of
ethyl acetate. The combined organic layers were concentrated under
vacuum. The crude product (70 mg) was purified by preparative HPLC
(SHIMADZU) under the following conditions: column: Xbridge Prep C18
5 um, 19*150 mm; mobile phase: water (0.05% NH.sub.4HCO.sub.3
solution) and CH.sub.3CN (start at 6.0% CH.sub.3CN then ramp up to
50.0% over 25 min); UV detection at 254 and 220 nm. The fractions
were collected and evaporated under reduced pressure to give
Compound I-37 (33.4 mg) as a white solid. .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta. 8.49 (s, 1H), 8.20 (m, 2H), 7.63 (m, 1H), 5.29
(m, 1H), 3.91 (t, 1H), 3.32 (m, 2H), 3.03 (m, 1H), 2.82 (m, 1H),
2.77 (m, 1H), 2.55 (m, 10H), 2.03 (m, 2H), 1.55 (m, 4H). MS: m/z
470 (M+H).sup.+.
Example 37
Synthesis of
2-[(3S)-12-[[4-(dimethylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo[6-
.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-3-yl]-N-ethylacetamide
(I-35)
##STR00396##
[0558] Synthesis of Compound 37.1.
[0559] To a 25-mL round-bottom flask was added intermediate 35.1
(200 mg, 0.43 mmol, 1.00 equiv), HOBt (90 mg, 0.67 mmol, 1.54
equiv), EDCI (191 mg, 1.00 mmol, 2.31 equiv), ethanamine
hydrochloride (45 mg, 0.55 mmol, 1.27 equiv) and triethylamine (135
mg, 1.34 mmol, 3.08 equiv) in 10 mL of distilled DMF. The reaction
was stirred for 4 h at room temperature under nitrogen. It was then
quenched with water and extracted with 3.times.25 mL of ethyl
acetate. The combined organic layers were washed with brine and
dried over anhydrous sodium sulfate. After filtration and
concentration under reduced pressure, the residue was loaded onto a
silica gel column with ethyl acetate/petroleum ether (1:2 to 3:5)
and purified to provide the desired compound 37.1 (160 mg, 76%) as
a white solid. MS: m/z 489 (M+H).sup.+.
[0560] Synthesis of Compound I-35.
[0561] To a 25-mL round-bottom flask was added 37.1 (160 mg, 0.33
mmol, 1.00 equiv) and hydrochloric acid (12 M, 2 mL) in
dichloromethane (12 mL). The reaction was stirred for 2 h at room
temperature. The resulting mixture was concentrated under vacuum to
give
1-(ethylamino)-2-[(3S)-12-[[4-(methylamino)cyclohexyl]oxy]-7-thia-9,11-di-
azatricyclo[6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-3-yl]ethan-1-ol
hydrochloride (100 mg, crude) as yellow oil which was used in the
next step without further purification. To a solution of this
compound (100 mg, crude) in methanol (10 mL) was added HCHO (37%, 2
mL) and the reaction was stirred for 1 h at room temperature. Then
NaBH.sub.3CN (50 mg, 63%) was added and stirring continued for
another 2 h at ambient temperature. The resulting mixture was
concentrated under reduced pressure and the crude product (80 mg)
purified by preparative HPLC (SHIMADZU) under the following
conditions: column: Xbridge Prep C18 5 um, 19*150 mm; mobile phase:
water (0.05% NH.sub.4HCO.sub.3 solution) and CH.sub.3OH NMR (start
at 6.0% CH.sub.3OH and ramp up to 50.0% over 25 min); UV detection
at 254 nm. The product-containing fractions were collected and
evaporated under reduced pressure to afford Compound I-35 (12.5 mg)
as a white solid. An ee of 100% was measured by chiral HPLC
analysis. .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.48 (s, 1H),
5.30 (m, 1H), 3.82 (m, 1H), 2.98-3.33 (m, 5H), 2.73 (m, 1H),
2.20-2.68 (m, 11H), 1.50-1.72 (m, 4H), 1.15 (t, 3H). MS: m/z 403
(M+H).sup.+.
Example 38
Synthesis of Intermediate 38.2
##STR00397##
[0563] Synthesis of Compound 38.1.
[0564] To a 25-mL, round-bottom, dry flask containing a solution of
35.1 (200 mg, 0.43 mmol, 1.00 equiv) in distilled DMF (6 mL) was
added EDCI (99 mg, 0.52 mmol, 1.19 equiv), HOBt (70 mg, 0.52 mmol,
1.20 equiv), 4-dimethylaminopyridine (63 mg, 0.52 mmol, 1.19 equiv)
and NH.sub.4Cl (68 mg, 1.28 mmol, 2.96 equiv) successively at room
temperature under nitrogen. The resulting solution was stirred for
14 h at ambient temperature and quenched with 20 mL of water and
extracted with 3.times.30 mL of ethyl acetate. The combined organic
layers were washed with brine (three times) and dried over
anhydrous sodium sulfate. After filtration and concentration under
reduced pressure, the residue was loaded onto a silica gel column
with ethyl acetate/petroleum ether (1:1) and purified to afford
38.1 (150 mg, 75%) as a white solid.
[0565] Synthesis of Intermediate 38.2.
[0566] To a solution of 38.1 (150 mg, 0.33 mmol, 1.00 equiv) in
dichloromethane (10 mL) was added hydrochloric acid (12 M, 2 mL) at
0.degree. C. and the resulting solution was stirred for 2 h at room
temperature. The reaction was then quenched with saturated aqueous
sodium bicarbonate and extracted with ethyl acetate (3.times.20
mL). The combined organic layers were washed with brine and
concentrated under reduced pressure to give
2-[(3R)-12-[[4-(methylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo[6.4-
.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]acetamide (100 mg,
crude) as a yellow oil.
Example 39
Synthesis of
2-[(3R)-12-[[4-(dimethylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo[6-
.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]acetamide (I-43)
##STR00398##
[0568] Synthesis of Compound I-43.
[0569] Intermediate 38.2 (100 mg, crude) was treated with HCHO
(37%, 1 mL) in methanol (8 mL) and the reaction stirred at room
temperature for 30 min. Then NaBH.sub.3CN (52.5 mg, 0.83 mmol, 3.00
equiv) was added and the reaction stirred for a further 2 h at
ambient temperature. The solvent was removed under reduced pressure
to give the product (100 mg, crude), which was purified by
preparative HPLC (SHIMADZU) under the following conditions: column:
Xbridge Prep C18 5 um, 19*150 mm; mobile phase: water (0.05%
NH.sub.4HCO.sub.3 solution) and CH.sub.3CN (start at 6.0%
CH.sub.3CN then ramp up to 50.0% over 25 min); UV detection at 254
nm. The product-containing fractions were collected and evaporated
under reduced pressure to provide Compound I-43 (76.8 mg) as a
white solid. .sup.1H NMR (300 MHz, CDCl.sub.3): .delta. 8.51 (s,
1H), 5.34 (m, 3H), 3.81 (m, 1H), 3.04 (m, 3H), 2.98 (m, 2H), 2.35
(m, 11H), 2.01 (m, 2H), 1.74 (m, 1H), 1.44-1.66 (m, 4H). MS: m/z
374 (M+H).sup.+.
Example 40
Synthesis of Intermediate 40.2
##STR00399##
[0571] Synthesis of Compound 40.1.
[0572] A 50-mL round-bottom flask containing a solution of
intermediate 34.2 (1.0 g, 2.23 mmol, 1.00 equiv) and TEA (339 mg,
3.35 mmol, 1.50 equiv) in dichloromethane (25 mL) was added
methanesulfonyl chloride (306 mg, 2.67 mmol, 1.20 equiv) at
0.degree. C. under nitrogen. The resulting solution was stirred for
2 h at room temperature and quenched by the addition of water. The
reaction mixture was extracted with dichloromethane (2.times.40
mL). The combined organic layers were washed with brine and dried
over anhydrous sodium sulfate. After filtration and concentration
under reduced pressure, the residue was loaded onto a silica gel
column with ethyl acetate/petroleum ether (1:2) and purified to
afford compound 40.1 (1.1 g, 94%) as a yellow oil. MS: m/z 526
(M+H).sup.+.
[0573] Synthesis of Compound 40.2.
[0574] 40.1 (1.1 g, 2.09 mmol, 1.00 equiv) was placed in a 50 mL
round-bottom flask and treated with NaCN (308 mg, 6.29 mmol, 3.00
equiv) in DMSO (15 mL) for 4 h at 80.degree. C. under nitrogen. The
reaction was then quenched with water and extracted with ethyl
acetate (3.times.40 mL). The organic layers were combined, washed
with brine and dried over anhydrous sodium sulfate. After
filtration and concentration under reduced pressure, the residue
was purified by column chromatography on silica gel with ethyl
acetate/petroleum ether (1:3) to give the desired intermediate 40.2
(920 mg, 96%) as a yellow solid. MS: m/z 457 (M+H).sup.+.
Example 41
Synthesis of
3-[(3S)-12-[[4-(dimethylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo
1[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]propanenitrile
(I-42)
##STR00400##
[0576] Synthesis of Compound I-42.
[0577] To a solution of intermediate 40.2 (200 mg, 0.44 mmol, 1.00
equiv) in dichloromethane (10 mL) was added hydrochloric acid (12
M, 2 mL) at 0.degree. C. and the resulting solution was stirred for
2 h at room temperature. The reaction was then quenched with
saturated aqueous sodium bicarbonate and extracted with ethyl
acetate (3.times.20 mL). The combined organic layers were washed
with brine and concentrated under reduced pressure to afford
3-[(3S)-12-[[4-(methylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo[6.4-
.0.0[2,6]]dodeca-1(8),2(6),9, 11-tetraen-3-yl]propanenitrile (120
mg, crude) as a yellow oil.
[0578] A solution of this material and HCHO (37%, 1 mL) in methanol
(8 mL) was stirred at room temperature for 30 min. Then
NaBH.sub.3CN (64 mg, 1.02 mmol, 3.02 equiv) was added and stirred
for 2 h at ambient temperature. The solvent was removed under
reduced pressure to give the product (100 mg, crude), which was
purified by preparative HPLC (SHIMADZU) under the following
conditions: column: Xbridge Prep C18 5 um, 19*150 mm; mobile phase:
water (0.05% NH.sub.4HCO.sub.3 solution) and CH.sub.3CN (start at
6.0% CH.sub.3CN then ramp up to 50.0% over 25 min); UV detection at
254 nm. The product-containing fractions were collected and
evaporated under reduced pressure to provide Compound I-42 (86.4
mg) as a white solid. .sup.1H NMR (300 MHz, CD.sub.3OD): .delta.
8.49 (s, 1H), 5.32 (m, 1H), 3.33 (m, 1H), 3.07 (m, 2H), 2.74 (m,
1H), 2.35-2.54 (m, 12H), 2.11 (m, 2H), 1.74 (m, 1H), 1.44-1.66 (m,
4H). MS: m/z 371 (M+H).sup.+.
Example 42
Synthesis of
3-[(3S)-12-[[4-(dimethylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo[6-
.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]propanamide
(I-44)
##STR00401##
[0580] Synthesis of Compound 42.1.
[0581] To a solution of intermediate 40.2 (200 mg, 0.44 mmol, 1.00
equiv) and potassium carbonate (166 mg, 1.20 mmol, 2.75 equiv) in
DMSO (10 mL) was added H.sub.2O.sub.2(30%, 3 mL) at 0.degree. C.
The resulting solution was stirred for 18 h at room temperature,
quenched with saturated aqueous Na.sub.2SO.sub.3 and extracted with
ethyl acetate (3.times.60 mL). The combined organic layers were
washed with brine, dried over anhydrous sodium sulfate and
concentrated under vacuum. Compound 42.1 (110 mg, 53%) was obtained
as a white solid. MS: m/z 475 (M+H).sup.+.
[0582] Synthesis of Compound I-44.
[0583] To a solution of 42.1 (110 mg, 0.23 mmol, 1.00 equiv) in
dichloromethane (10 mL) was added hydrochloric acid (12 M, 2 mL) at
0.degree. C. and the resulting solution was stirred for 2 h at room
temperature. The reaction was then quenched with saturated aqueous
sodium bicarbonate and extracted with ethyl acetate (3.times.20
mL). The combined organic layers were washed with brine and
concentrated under reduced pressure to give
3-[(3S)-12-[[4-(methylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo[6.4-
.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]propanamide (70 mg,
81%) as a yellow oil. A solution of this material (70 mg, 0.19
mmol, 1.00 equiv) and HCHO (37%, 1 mL) in methanol (8 mL) was
stirred at room temperature for 30 min. Then NaBH.sub.3CN (35 mg,
0.56 mmol, 2.97 equiv) was added and stirring continued for 2 h at
ambient temperature. The solvent was removed under reduced pressure
to give the product (70 mg, crude), which was purified by
preparative HPLC (SHIMADZU) under the following conditions: column:
Xbridge Prep C18 5 um, 19*150 mm; mobile phase: water (0.05%
NH.sub.4HCO.sub.3 solution) and CH.sub.3CN (start at 6.0%
CH.sub.3CN then ramp up to 50.0% over 25 min); UV detection at 254
nm. The product-containing fractions were collected and evaporated
under reduced pressure to afford Compound I-44 (67.5 mg) as a white
solid. .sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 8.46 (s, 1H), 5.78
(d, 2H), 5.22 (m, 1H), 3.44 (m, 1H), 3.02 (m, 2H), 2.67 (m, 1H),
2.33 (m, 13H), 1.90 (m, 3H), 1.44 (m, 4H). MS: m/z 389
(M+H).sup.+.
Example 43
Synthesis of Intermediate 43.1
##STR00402##
[0585] Synthesis of Compound 43.1.
[0586] To a solution of 34.2 (1.1 g, 2.46 mmol, 1.00 equiv) in
dichloromethane (60 mL) was added Dess-Martin periodinane (1.1 g,
2.69 mmol, 1.10 equiv) in portions at 0.degree. C. under nitrogen.
After the addition was complete, the resulting solution was stirred
for 2 h at room temperature and then diluted with ethyl acetate.
The organic layer was washed with NaHCO.sub.3 (aq.), brine, dried
over anhydrous Na.sub.2SO.sub.4, and concentrated under reduced
pressure. The residue was loaded onto a silica gel column with
ethyl acetate/petroleum ether (1:10-1:5) and purified to afford
intermediate 43.1 (0.93 g, 85%) as a light yellow oil.
Example 44
Synthesis of
(2S)-1-[(3R)-12-[[4-(dimethylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricy-
clo[6.4.0.0[2,61]]dodeca-1(8),2(6),9,11-tetraen-3-yl]propan-2-ol
(I-40)
##STR00403##
[0588] Synthesis of Compounds 44.1 and 44.2.
[0589] To a solution of 43.1 (450 mg, 1.01 mmol, 1.00 equiv) in
distilled tetrahydrofuran (20 mL) was added dropwise
bromo(methyl)magnesium (0.5 mL, 1.50 equiv) at 0.degree. C. under
nitrogen. The resulting solution was stirred for 2 h at room
temperature, quenched with water and extracted with ethyl acetate.
After drying over Na.sub.2SO.sub.4 and evaporation of the solvents
under reduced pressure, the residue was loaded onto a silica gel
column with ethyl acetate/petroleum ether (1:10-1:5) and the
diastereomers separated to give both 44.1 (0.11 g) and 44.2 (0.16
g) as light yellow oils.
[0590] Synthesis of Compound 44.3.
[0591] To a solution of 44.1 (100 mg, 0.22 mmol, 1.00 equiv) in
dichloromethane (8 mL) was added hydrochloric acid (12 M, 0.5 mL)
at 0.degree. C. under nitrogen. The resulting solution was stirred
for 2 h at room temperature. After the reaction was complete, the
solvent was removed by evaporation under reduced pressure to give
44.3 (70 mg, crude) as a light yellow oil which was used directly
without further purification.
[0592] Synthesis of Compound I-40.
[0593] To a solution of 44.3 (70 mg, 0.18 mmol, 1.00 equiv) in
methanol (8 mL) was added HCHO (37%, 1.5 mL) at room temperature.
The resulting solution was stirred for 1 h at ambient temperature,
and then NaBH.sub.3CN (33.0 mg, 0.53 mmol, 3.00 equiv) was added.
The resulting mixture was stirred overnight at room temperature.
After evaporation, the crude product (80 mg) was purified by
preparative HPLC (SHIMADZU) under the following conditions: column:
SunFire Prep C18, 19*150 mm 5 um; mobile phase: water (0.05%
NH.sub.4HCO.sub.3 solution) and CH.sub.3CN (7.0% CH.sub.3CN then
ramp up to 63.0% over 14 min); UV detection at 254 and 220 nm. The
product fractions were collected and evaporated under reduced
pressure to afford Compound I-40 (40 mg, 61%) as a white solid.
.sup.1H NMR (400 MHz, CD.sub.3OD): .delta. 8.48 (s, 1H), 5.30-5.32
(m, 1H), 3.90-3.98 (m, 1H), 3.30-3.40 (m, 1H), 3.09-3.15 (m, 1H),
2.95-3.02 (m, 1H), 2.60-2.70 (m, 1H), 2.45-2.53 (m, 1H), 2.30-2.40
(m, 9H), 2.02-2.12 (m, 3H), 1.50-1.70 (m, 5H), 1.31 (d, 3H). MS:
m/z 376 (M+H).sup.+.
Example 45
Synthesis of
(2R)-1-[(3R)-12-[[4-(dimethylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricy-
clo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]propan-2-ol
(I-41)
##STR00404##
[0595] Synthesis of Compound 45.2.
[0596] To a solution of 44.2 (prepared as in Example 44; 150 mg,
0.32 mmol, 1.00 equiv) in dichloromethane (10 mL) was added
hydrochloric acid (12 M, 0.8 mL) at 0.degree. C. under nitrogen.
The resulting solution was stirred for 2 h at room temperature. The
solvent was removed under reduced pressure to afford compound 45.2
(110 mg, crude) as a light yellow oil which was used in the next
step without further purification.
[0597] Synthesis of Compound I-41.
[0598] To a solution of 45.2 (110 mg, crude) in methanol (10 mL)
was added HCHO (37%, 2.0 mL) and the reaction was stirred for 1 h
at room temperature. Then NaBH.sub.3CN (52.2 mg, 0.83 mmol, 3.00
equiv) was added and the resulting solution was stirred overnight
at room temperature. After evaporation under reduced pressure, the
crude product (100 mg) was purified by preparative HPLC (SHIMADZU)
under the following conditions: column: SunFire Prep C18, 19*150 mm
5 um; mobile phase: water (0.05% NH.sub.4HCO.sub.3) and CH.sub.3CN
(7.0% CH.sub.3CN then ramp up to 63.0% in 13 min); UV detection at
254 and 220 nm. The product-containing fractions were collected and
evaporated to remove the solvents to afford Compound I-41 (46.3 mg,
58%) as a white solid. .sup.1H NMR (300 MHz, CD.sub.3OD): .delta.
8.48 (s, 1H), 5.20-5.30 (m, 1H), 3.85-3.95 (m, 1H), 3.50-3.60 (m,
1H), 3.05-3.15 (m, 1H), 2.90-3.00 (m, 1H), 2.60-2.70 (m, 1H),
2.25-2.40 (m, 10H), 2.15-2.25 (m, 1H), 2.00-2.14 (m, 2H), 1.63-1.68
(m, 2H), 1.40-1.52 (m, 3H), 1.21 (d, 3H). MS: m/z 376
(M+H).sup.+.
Example 46
Synthesis of
2-(((1R,4r)-4-(((R)-5-((S)-2-hydroxypropyl)-6,7-dihydro-5H-cyclopenta[4,5-
]thieno[2,3-d]pyrimidin-4-yl)oxy)cyclohexyl)(methyl)amino)-1-(pyrrolidin-1-
-yl)ethanone (I-69)
##STR00405##
[0600] To a 50-mL round-bottom flask was added a solution of 44.1
(130 mg, 0.28 mmol, 1.0 equiv) in 5.5 mL of dichloromethane. After
cooling to 0.degree. C., hydrochloric acid (12 M, 0.5 mL) was added
and the resulting solution was stirred for 3 h at room temperature.
The reaction mixture was concentrated under reduced pressure to
give the
(2S)-1-[(3R)-12-[[4-(methylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricycl-
o[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]propan-2-ol
hydrochloride (80 mg, crude) as a light yellow oil. This material
(80 mg, crude) was dissolved in DMF (5 mL) and potassium carbonate
(240 mg) and 2-chloro-1-(pyrrolidin-1-yl)ethan-1-one (120 mg) were
added at room temperature and the resulting mixture was stirred for
14 h at 25.degree. C. After completion of the reaction, the product
was extracted with DCM, washed with brine, and concentrated in
vacuo. The crude product (120 mg) was purified by preparative HPLC
(SHIMADZU) under the following conditions: column: SunFire Prep
C18, 19*150 mm 5 um; mobile phase: water (0.1% HCOOH) and
CH.sub.3CN (6.0% CH.sub.3CN up to 50.0% in 25 min); UV detection at
254/220 nm. The product containing fractions were collected and
concentrated to afford Compound I-69 (32.8 mg) as a white solid.
.sup.1H NMR (400 MHz, CD.sub.3OD): .delta. 8.45 (1H, s), 5.35-5.15
(1H, m), 3.99-3.80 (1H, m), 3.59-3.56 (3H, m), 3.43 (2H, t),
3.31-3.36 (2H, s), 3.16-3.05 (1H, m), 3.04-2.89 (1H, m), 2.62-2.67
(2H, m), 2.39-2.21 (6H, m), 2.20-2.10 (1H, m), 2.03-1.97 (4H, m),
1.92-1.85 (2H, m), 1.73-1.60 (2H, m), 1.59-1.41 (3H, m), 1.20 (3H,
d). MS: m/z 473 (M+H).sup.+.
Example 47
Synthesis of racemic
2-[(3R)-12-[[4-(dimethylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo[6-
.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]-1-(1,3-oxazol-2-yl)ethan-1-
-ol (I-60)
##STR00406##
[0602] Synthesis of Compound 47.1.
[0603] To a 50-mL round-bottom flask containing 1,3-oxazole (90 mg,
1.30 mmol, 1.00 equiv) in freshly distilled THF (10 mL) was added
BH.sub.3-THF (1 M, 1.43 mL) dropwise at 0.degree. C. under
nitrogen. After stirring at room temperature for 1 h, the solution
was cooled to -78.degree. C. and then n-BuLi (2.5 M in hexane, 0.68
mL) was added dropwise via a syringe. Stirring was continued for an
additional 1 h. A solution of intermediate 43.1 (580 mg, 1.30 mmol,
1.00 equiv) in THF (50 mL) was added at -78.degree. C. and stirred
for 2 h at -40.degree. C. After the reaction was complete, it was
quenched with 5% AcOH-EtOH and stirred for an additional 14 h at
room temperature. The resulting solution was concentrated under
vacuum and the residue was loaded onto a silica gel column with
ethyl acetate/petroleum ether (1:1) to afford 47.1 (250 mg, 37%) as
a yellow oil. MS: m/z 515 (M+H).sup.+.
[0604] Synthesis of Compound I-60.
[0605] Hydrochloric acid (12 M, 2 mL) was added to a solution of
47.1 (250 mg, 0.49 mmol, 1.00 equiv) in dichloromethane (10 mL) at
0.degree. C. The reaction was stirred for 2 h at room temperature
then quenched by the addition of 20 mL of saturated aqueous sodium
bicarbonate and extracted with 2.times.30 mL of dichloromethane.
The combined organic layers were washed with brine, dried over
anhydrous sodium sulfate and concentrated under vacuum to afford
2-[(3R)-12-[[4-(methylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo[6.4-
.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]-1-(1,3-oxazol-2-yl)ethan-1-o-
l (180 mg, crude) as a yellow oil which was used in the next
reaction without further purification. To a solution of this
material (180 mg, 0.43 mmol, 1.00 equiv) in 4 mL of methanol was
added HCHO (30%, 1 mL) and the reaction mixture was stirred at room
temperature for 30 min. NaBH.sub.3CN (109 mg, 1.73 mmol, 3.98
equiv) was added to the mixture and stirring was continued for
another 2 h at ambient temperature. The reaction was then quenched
by the addition of H.sub.2O and extracted with dichloromethane (15
mL), dried over anhydrous sodium sulfate and concentrated under
vacuum. The crude product (80 mg) was purified by preparative HPLC
(SHIMADZU) under the following conditions: column: SunFire Prep
C18, 19*150 mm 5 um; mobile phase: water (0.05% NH.sub.4HCO.sub.3)
and CH.sub.3CN (start at 6.0% CH.sub.3CN then ramp up to 55.0% over
19 min); UV detection at 254 and 220 nm. The product-containing
fractions were collected and evaporated to remove the solvents
under reduced pressure to afford the racemic Compound I-60 (48.2
mg, 26%) as a white solid. .sup.1H NMR (400 MHz, CDCl.sub.3):
.delta. 8.511 (s, 1H), 7.58 (d, 1H), 7.07 (d, 1H), 5.24-5.28 (m,
1H), 4.90-5.00 (m, 1H), 3.7-3.8 (m, 0.5H), 3.4-3.6 (m, 0.5H),
2.95-3.12 (m, 3H), 2.59-2.74 (m, 2H), 2.23-2.37 (m, 10H), 2.00-2.09
(m, 3H), 1.47-1.61 (m, 4H). MS: m/z 429 (M+H).sup.+.
Example 48
Synthesis of
3-[(3R)-12-[[4-(dimethylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo[6-
.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]-2-hydroxypropanamide
(I-57)
##STR00407##
[0607] Synthesis of Compound 48.1.
[0608] A 25-mL round-bottom flask was charged with 43.1 (250 mg,
0.56 mmol, 1.00 equiv) and TEA (57 mg, 0.56 mmol, 1.00 equiv) in
distilled dichloromethane (15 mL). Trimethylsilanecarbonitrile (111
mg, 1.12 mmol, 2.0 equiv) was added and the reaction was stirred
for 2 h at room temperature under nitrogen. The reaction was then
quenched by the addition of water and extracted with 3.times.20 mL
of dichloromethane. The combined organic layers were washed with
brine and dried over sodium sulfate. After concentration in vacuo,
the residue was loaded onto a silica gel column with ethyl
acetate/petroleum ether (1:3) and purified to afford compound 48.1
(200 mg, 75%) as a colorless oil. MS: m/z 473 (M+H).sup.+.
[0609] Synthesis of Compound 48.2.
[0610] A solution of 48.1 (170 mg, 0.36 mmol, 1.00 equiv), LiOH (13
mg) and H.sub.2O.sub.2(30%, 0.5 mL) in methanol (4 mL) was stirred
for 3 h at 0.degree. C. The reaction was then quenched by the
addition of water and extracted with 3.times.20 mL of ethyl
acetate. The combined organic layers were washed with brine and
dried over sodium sulfate. Concentration in vacuo afforded compound
48.2 (70 mg, 40%) as a white solid. MS: m/z 491 (M+H).sup.+.
[0611] Synthesis of Compound I-57.
[0612] To a 25-mL round-bottom flask was added a solution of 48.2
(70 mg, 0.14 mmol, 1.00 equiv) in dichloromethane (5 mL) at
0.degree. C. Then hydrochloric acid (12 M, 1 mL) was added and the
resulting solution was stirred for 2 h at room temperature. The
reaction was then quenched by the addition of saturated aqueous
sodium bicarbonate and extracted with 2.times.20 mL of
dichloromethane. The combined organic layers was concentrated in
vacuo to give the
2-hydroxy-3-[(3R)-12-[[4-(methylamino)cyclohexyl]oxy]-7-thia-9,11-diazatr-
icyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3yl]propanamide
(50 mg, crude) as a yellow oil. This material (50 mg, crude) was
dissolved in methanol (5 mL). HCHO (37%, 0.5 mL) was added and the
resulting solution was stirred for 30 min at room temperature. Then
NaBH.sub.3CN (32 mg, 0.51 mmol, 4.0 equiv) was added and stirring
was continued overnight at ambient temperature. The reaction was
then quenched by the addition of H.sub.2O and extracted with
dichloromethane (15 mL), dried over anhydrous sodium sulfate and
concentrated under vacuum. The crude product (80 mg) was purified
by preparative HPLC (SHIMADZU) under the following conditions:
column: SunFire Prep C18, 19*150 mm 5 um; mobile phase: water
(0.05% NH.sub.4HCO.sub.3) and CH.sub.3CN (start at 6.0% CH.sub.3CN
then ramp up to 55.0% over 19 min); UV detection at 254 and 220 nm.
The product-containing fractions were collected and evaporated
under reduced pressure to afford Compound I-57 (26.4 mg) as a white
solid. .sup.1H NMR (400 MHz, CDCl.sub.3): .delta. 8.52 (s, 1H),
6.49 (d, 1H), 5.72 (d, 1H), 5.23 (m, 1H), 4.16 (m, 1H), 3.68 (m,
2H), 3.14 (m, 1H), 3.01 (m, 1H), 2.74 (m, 1H), 2.23-2.39 (m, 10H),
2.01 (m, 3H), 1.27-1.47 (m, 4H). MS: m/z 405 (M+H).sup.+.
Example 49
Synthesis of
(2S)-3-[(3R)-12-[[4-(dimethylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricy-
clo[6.4.0.0
[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]-2-hydroxypropanamide
(I-74)
##STR00408##
[0614] Synthesis of Compound 49.1.
[0615] Reference: For the preparation of the starting material
compound 48.1, please refer to the experimental procedure for the
synthesis of compound I-57. Into a 50-mL round-bottom flask, a
solution of tert-butyl
N-(4-[[(3R)-3-(2-cyano-2-hydroxyethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[-
2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)-N-methylcarbamate
(1.9 g, 4.02 mmol, 1.00 equiv) in 10 mL of distilled DMF was added
imidazole (544 mg, 8.00 mmol, 2.0 equiv) and
tert-butyl(chloro)dimethylsilane (905 mg, 6.00 mmol, 1.49 equiv) at
0.degree. C. under nitrogen. The resulting solution was stirred for
2 h at 20.degree. C. After completion, the reaction was then
quenched by the addition of 20 mL of water and extracted with
3.times.80 mL of ethyl acetate. The combined organic layers were
washed with brine (three times), dried over anhydrous sodium
sulfate and concentrated under vacuum. The residue was purified by
column chromatography on silica gel with EtOAc/petroleum ether
(1:20 to 1:5) to give 2.2 g (93%) of the desired tert-butyl
N-(4-[[(3R)-3-[2-[(tert-butyldimethylsilyl)oxy]-2-cyanoethyl]-7-thia-9,11-
-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cycloh-
exyl)-N-methylcarbamate as a yellow oil. MS: m/z 587
(M+H).sup.+.
[0616] Synthesis of Compound 49.2.
[0617] A 50-mL round-bottom flask containing a solution of
tert-butyl
N-(4-[[(3R)-3-[2-[(tert-butyldimethylsilyl)oxy]-2-cyanoethyl]-7-thia-9,11-
-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cycloh-
exyl)-N-methylcarbamate (2.2 g, 3.75 mmol, 1.00 equiv) in 20 mL of
methanol was added LiOH (315 mg) followed by addition of
H.sub.2O.sub.2(30%, 3 mL) via syringe at 0.degree. C. with vigorous
stirring. The resulting solution was stirred for 3 h at 20.degree.
C. The reaction was then quenched by the addition of 50 mL of
saturated aqueous Na.sub.2SO.sub.3 and extracted with 3.times.100
mL of ethyl acetate. The organic layers were combined, washed with
2.times.30 mL of brine, and concentrated under reduced pressure.
The residue was applied onto a silica gel column with ethyl
acetate/petroleum ether (1:1-2:1) to afford the desired tert-butyl
N-(4-[[(3R)-3-[(2S)-2-[(tert-butyldimethylsilyl)oxy]-2-carbamoylethyl]-7--
thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]o-
xy]cyclohexyl)-N-methylcarbamate (0.9 g) as a white solid. MS: m/z
605 (M+H).sup.+, 627 (M+Na).sup.+.
[0618] Synthesis of Compound 49.3.
[0619] Into a 10-mL round-bottom flask was placed a solution of
tert-butyl
N-(4-[[(3R)-3-[(2S)-2-carbamoyl-2-hydroxyethyl]-7-thia-9,11-diazatricyclo-
[6.4.0.0
[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)-N-methy-
lcarbamate (0.9 g, 1.49 mmol, 1.00 equiv) in dichloromethane (10
mL) at 0.degree. C. under nitrogen. Then hydrochloric acid (12 M,
2.0 mL) was added and the resulting solution was stirred for 5 h at
0.degree. C. After completion of the reaction, the solvents were
evaporated under reduced pressure. The residue was neutralized with
2 M aqueous sodium bicarbonate and extracted with 3.times.60 mL of
dichloromethane. The organic layers were combined and washed with
brine, dried over anhydrous sodium sulfate and concentrated under
vacuum to give 520 mg (crude) of
(2S)-2-hydroxy-3-[(3R)-12-[[4-(methylamino)cyclohexyl]oxy]-7-thia-9,11-di-
azatricyclo[6.4.0.0 [2,6]]dodeca-1(8),2(6),9,
11-tetraen-3-yl]propanamide as a yellow oil.
[0620] Synthesis of Compound I-74.
[0621] Compound 49.3 (520 mg, crude) and HCHO (37%, 608 uL, 7.5
mmol, 5.0 equiv) in methanol (8 mL) was stirred at room temperature
for 30 min. and then NaBH.sub.3CN (283 mg, 4.5 mmol, 3.0 equiv) was
added and the resulting solution was stirred for 12 h at room
temperature. The crude product (500 mg) was purified by preparative
HPLC under the following conditions (SHIMADZU): column: SunFire
Prep C18, 19*150 mm 5 um; mobile phase: water with 0.05% HCOOH and
CH.sub.3CN (6.0% CH.sub.3CN up to 55.0% in 19 min); UV detection at
254/220 nm. The product-containing fractions were collected and
partially evaporated to remove CH.sub.3CN and water (bath
temperature 25.degree. C.) under reduced pressure. The residue was
lyophilized overnight to afford the desired
(2S)-3-[(3R)-12-[[4-(dimethylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricy-
clo[6.4.0.0
[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]-2-hydroxypropanamide
formate (182 mg) as a white solid. MS: m/z 405 (M+H).sup.+. .sup.1H
NMR (400 MHz, CD.sub.3OD): .delta. 8.60 (1H, brs), 8.47 (1H, s),
5.36-5.30 (1H, m), 4.15 (1H, t), 3.55 (1H, t), 3.36 (1H, m),
3.18-3.09 (1H, m), 3.08-2.94 (1H, m), 2.87 (6H, s), 2.76-2.69 (1H,
m), 2.59-2.41 (3H, m), 2.40-2.32 (1H, m), 2.25-2.15 (2H, m),
1.95-1.55 (5H, m).
Example 50
Synthesis of
(2R)-2-hydroxy-3-[(3R)-12-[[4-(methylamino)cyclohexyl]oxy]-7-thia-9,11-di-
azatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]propanamide
(I-140)
##STR00409##
[0623] Synthesis of Compound 50.1.
[0624] A solution of tert-butyl
N-(4-[[(3R)-3-(2-cyano-2-hydroxyethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[-
2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)-N-methylcarbamate
(301 mg, 0.64 mmol, 1.00 equiv), imidazole (73 mg, 1.07 mmol, 1.69
equiv) and TBSCl (150 mg, 1.00 mmol, 1.57 equiv) in
N,N-dimethylformamide (7 mL) was stirred overnight at room
temperature. The resulting solution was diluted with 30 mL of
water, extracted with 3.times.40 mL of ethyl acetate, washed with
50 mL of brine, concentrated under vacuum and purified onto a
silica gel column with ethyl acetate/petroleum ether (1:3). This
resulted in tert-butyl
N-(4-[[(3R)-3-[2-[(tert-butyldimethylsilyl)oxy]-2-cyanoethyl]-7-thia-9,11-
-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cycloh-
exyl)-N-methylcarbamate (350 mg, 94%) as colorless oil.
[0625] Synthesis of Compound 50.2.
[0626] A 50-mL round-bottom flask containing a solution of
tert-butyl
N-(4-[[(3R)-3-[2-[(tert-butyldimethylsilyl)oxy]-2-cyanoethyl]-7-thia-9,11-
-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cycloh-
exyl)-N-methylcarbamate (2.2 g, 3.75 mmol, 1.00 equiv) in 20 mL of
methanol was added LiOH (315 mg), followed by addition of
H.sub.2O.sub.2(30%, 3 mL) via syringe at 0.degree. C. with vigorous
stirring. The resulting solution was stirred for 3 h at 20.degree.
C. The reaction was then quenched by the addition of 50 mL of
saturated aqueous Na.sub.2SO.sub.3, extracted with 3.times.100 mL
of ethyl acetate. The organic layers were combined, washed with
2.times.30 mL of brine, and concentrated under reduced pressure.
The residue was applied onto a silica gel column with ethyl
acetate/petroleum ether (1:1-2:1) to afford the desired tert-butyl
N-(4-[[(3R)-3-[(2R)-2-[(tert-butyldimethylsilyl)oxy]-2-carbamoylethyl]-7--
thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]o-
xy]cyclohexyl)-N-methylcarbamate (0.7 g) as a white solid. MS: m/z
605 (M+H).sup.+, 627 (M+Na).sup.+.
[0627] Synthesis of Compound I-140.
[0628] Into a 10-mL round-bottom flask was placed a solution of
tert-butyl
N-(4-[[(3R)-3-[(2R)-2-carbamoyl-2-hydroxyethyl]-7-thia-9,11-diazatricyclo-
[6.4.0.0
[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)-N-methy-
lcarbamate (0.7 g, 1.16 mmol, 1.00 equiv) in dichloromethane (10
mL) at 0.degree. C. under nitrogen. Then hydrochloric acid (12 M,
2.0 mL) was added and the resulting solution was stirred for 5 h at
0.degree. C. After completion of the reaction, the solvents were
evaporated under reduced pressure. The residue was neutralized with
2 M aqueous sodium bicarbonate and extracted with 3.times.60 mL of
dichloromethane. The organic layers were combined and washed with
brine, dried over anhydrous sodium sulfate and concentrated under
vacuum to give 400 mg (crude) of
(2R)-2-hydroxy-3-[(3R)-12-[[4-(methylamino)cyclohexyl]oxy]-7-thia-9,11-di-
azatricyclo[6.4.0.0
[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]propanamide as a yellow
oil. .sup.1H NMR (300 MHz, CD.sub.3OD): .delta. 8.46 (s, 1H), 5.30
(m, 1H), 4.08 (m, 1H), 3.66 (m, 1H), 3.19-3.12 (m, 1H), 3.02-2.96
(m, 1H), 2.74-2.25 (m, 9H), 2.13-2.10 (m, 2H), 1.82-1.68 (m, 3H),
1.45-1.25 (m, 2H). MS: m/z 391 (M+H).sup.+.
Example 51
Synthesis of
(2R)-3-[(3R)-12-[[4-(dimethylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricy-
clo[6.4.0.0
[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]-2-hydroxypropanamide
(I-75)
##STR00410##
[0630] Synthesis of Compound I-75.
[0631] Compound I-140 (400 mg, crude) and HCHO (37%, 486 uL, 6.0
mmol, 5.0 equiv) in methanol (8 mL) were stirred at room
temperature for 30 min. then NaBH.sub.3CN (221 mg, 3.5 mmol, 3.0
equiv) was added and the resulting solution was stirred for 12 h at
room temperature. The crude product (400 mg) was purified by
preparative HPLC under the following conditions (SHIMADZU): column:
SunFire Prep C18, 19*150 mm 5 um; mobile phase: water with 0.05%
HCOOH and CH.sub.3CN (6.0% CH.sub.3CN up to 55.0% in 19 min); UV
detection at 254/220 nm. The product-containing fractions were
collected and partially evaporated to remove CH.sub.3CN and water
(bath temperature 25.degree. C.) under reduced pressure to afford
the desired
(2R)-3-[(3R)-12-[[4-(dimethylamino)cyclohexyl]oxy]-7-thia-9,11-di-
azatricyclo[6.4.0.0
[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]-2-hydroxypropanamide
formate (200 mg) as a white solid. MS m/z 405 (M+H).sup.+. .sup.1H
NMR (300 MHz, CD.sub.3OD): .delta. 8.60 (1H, brs), 8.45 (1H, s),
5.28-5.25 (1H, m), 4.08 (1H, dd), 3.66 (1H, t), 3.30-3.20 (1H, m),
3.19-3.09 (1H, m), 3.08-2.95 (1H, m), 2.86 (6H, s), 2.78-2.62 (1H,
m), 2.52-2.38 (3H, m), 2.32-2.15 (3H, m), 1.87-1.72 (5H, m).
Example 52
Synthesis of
2-[(4-[[(3R)-3-[(2R)-2-hydroxybutyl]-7-thia-9,11-diazatricyclo[6.4.0.0[2,-
6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)(methyl)amino]-1-(py-
rrolidin-1-yl)ethan-1-one (I-71)
##STR00411##
[0633] Synthesis of Compounds 52.1 and 52.2.
[0634] A 50-mL round-bottom flask containing a solution of 43.1
(460 mg, 1.03 mmol, 1.00 equiv) in 20 mL of freshly distilled THF
was cooled down to 0.degree. C. under nitrogen. Then
bromo(ethyl)magnesium (1 M in THF, 3.10 mL) was added dropwise via
syringe and the resulting solution was stirred for 2 h at 0.degree.
C. The reaction was then quenched with saturated aqueous NH.sub.4Cl
and extracted with 3.times.50 mL of ethyl acetate. The combined
organic layers were washed with brine, dried (Na.sub.2SO.sub.4) and
concentrated under reduced pressure. The residue was applied onto a
silica gel column with ethyl acetate/petroleum ether (1:2) and
purified to give the alcohols 52.1 (180 mg) and 52.2 (160 mg) as
colorless oils.
[0635] Synthesis of Compound I-71.
[0636] A 50-mL round-bottom flask was charged with 52.1 (180 mg,
0.38 mmol, 1.00 equiv) in 5.5 mL of dichloromethane and cooled to
0.degree. C. Then hydrochloric acid (12 M, 0.5 mL) was added and
the resulting solution was stirred for 3 h at room temperature. The
reaction mixture was concentrated under reduced pressure to give
(2R)-1-[(3R)-12-[[4-(methylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricycl-
o[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]butan-2-ol
hydrochloride (100 mg, crude) as a light yellow oil. This material
(100 mg, crude) was dissolved in DMF (4 mL) and potassium carbonate
(220 mg) and 2-chloro-1-(pyrrolidin-1-yl)ethan-1-one (100 mg) were
added at room temperature and the resulting mixture was stirred for
14 h at 25.degree. C. After completion of the reaction, the product
was extracted with DCM, washed with brine, and concentrated in
vacuo. The crude product (160 mg) was purified by preparative HPLC
(SHIMADZU) under the following conditions: column: SunFire Prep
C18, 19*150 mm 5 um; mobile phase: water (0.1% HCOOH) and
CH.sub.3CN (6.0% CH.sub.3CN up to 50.0% in 25 min); UV detection at
254/220 nm. The product-containing fractions were collected and
concentrated to give the Compound I-71 (85.8 mg) as a white solid.
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.47 (1H, s), 5.29 (1H,
m), 3.67-3.68 (1H, m), 3.56-3.59 (2H, t), 3.43-3.47 (2H, t),
3.38-3.32 (2H, m), 3.09 (1H, m), 2.97-2.98 (1H, m), 2.64-2.68 (2H,
m), 2.25-2.46 (5H, m), 1.88-1.08 (7H, m), 1.44-1.59 (6H, m), 1.04
(3H, t). MS: m/z 487 (M+H).sup.+.
Example 53
Synthesis of
2-(((1R,4r)-4-(((R)-5-((S)-2-hydroxybutyl)-6,7-dihydro-5H-cyclopenta[4,5]-
thieno[2,3-d]pyrimidin-4-yl)oxy)cyclohexyl)(methyl)amino)-1-(pyrrolidin-1--
yl)ethanone (I-72)
##STR00412##
[0638] Compound I-72 was synthesized in a manner consistent with
Example 46 from alcohol 52.2 (prepared as described in Example 52)
and 2-chloro-1-(pyrrolidin-1-yl)ethan-1-one. Isolated a white solid
in 31% yield. .sup.1H NMR (400 MHz, CD.sub.3OD): .delta. 8.46 (1H,
s), 5.40-5020 (1H, m), 3.63-3.56 (4H, m), 3.47-3.43 (2H, t), 3.35
(2H, m), 3.03 (1H, m), 2.99-2.97 (1H, m), 2.70-2.64 (2H, m),
2.37-2.30 (6H, m), 2.28-2.16 (1H, m), 2.03-1.88 (6H, m), 1.73-1.67
(2H, m), 1.53-1.45 (5H, m), 0.96 (3H, t). MS: m/z 487
(M+H).sup.+.
Example 54
Synthesis of
2-(12-[[4-(dimethylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo[6.4.0.-
0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl)acetonitrile (I-22)
##STR00413## ##STR00414##
[0640] Synthesis of Compound 54.1.
[0641] To a solution of commercially-available trans-tert-butyl
4-hydroxycyclohexylcarbamate (1.83 g, 8.5 mmol) in anhydrous THF
(30 mL) was added NaH (340 mg, 8.5 mmol) at 0.degree. C. The
mixture was allowed to warm to r.t. with stirring for 2 hours. Then
intermediate 1.4 (2 g, 7.1 mmol) was added. The mixture was stirred
for 18 hours then poured into ice water (100 mL) and extracted with
EtOAc (3.times.80 mL). The combined organic layers were washed
(brine), dried (Na.sub.2SO.sub.4), filtered and concentrated. The
residue was purified by silica gel column chromatography with
petroleum ether/ethyl acetate (1:1) to give a white solid product
(1.72 g, 56%). MS: m/z 462 (M+H).sup.+.
[0642] Synthesis of Compound 54.2.
[0643] Compound 54.1 (1.72 g, 3.73 mmol) was added to a solution of
HCl in 1,4-dioxane (18.6 mL, 18.6 mmol) at r.t. The mixture was
stirred for 2 h and then concentrated under reduced pressure.
Washing with petroleum ether gave a white solid product (2.2 g,
100%). MS: m/z 362 (M+H).sup.+.
[0644] Synthesis of Compound 54.3.
[0645] To a solution of 54.2 (1.3 g, 3.6 mmol) in MeOH (60 mL) was
added (CHO).sub.n(2.16 g, 72 mmol) and AcOH (1.51 g, 25.2 mmol).
The suspension was heated at 40.degree. C. with stirring for 15
hours and then concentrated. The residue was purified by silica gel
column chromatography with MeOH/CH.sub.2Cl.sub.2 (1:20) to give a
white solid product (1.3 g, 89%). .sup.1H NMR (500 MHz, CDCl.sub.3)
.delta. 8.50 (s, 1H), 5.19-5.17 (m, 1H), 4.17-4.13 (m, 3H),
3.22-3.16 (m, 1H), 3.06-3.01 (m, 1H), 2.92-2.85 (m, 1H), 2.62-2.55
(m, 1H), 2.52-2.36 (m, 6H), 2.27 (m, 2H), 2.07-2.04 (m, 2H),
1.57-1.48 (m, 4H), 1.38-1.35 (t, 1H), 1.25-1.22 (t, 3H). MS: m/z
390 (M+H).sup.+.
[0646] Synthesis of Compound 54.4.
[0647] To a solution of 54.3 (1.3 g, 3.3 mmol) in THF (30 mL) was
added LiAlH.sub.4 (508 mg, 13.3 mmol) in portions at 0.degree. C.
The mixture was allowed to warm to r.t. with stirring for 2 hours,
and then Na.sub.2SO.sub.4.10H.sub.2O (4.3 g, 13.3 mmol) was added.
The suspension was stirred for 2 hours and filtered. The filtrate
was purified by silica gel column chromatography with MeOH/DCM
(1:10) to give a white solid product (810 mg, 70%). .sup.1H NMR
(500 MHz, CDCl.sub.3) .delta. 8.51 (s, 1H), 5.30-5.24 (m, 1H),
3.86-3.85 (d, 2H), 3.56-3.53 (m, 1H), 3.15-3.08 (m, 1H), 3.00-2.94
(m, 1H), 2.70-2.65 (m, 1H), 2.43-2.29 (m, 10H), 2.04-2.02 (d, 2H),
1.60-1.50 (m, 5H). MS: m/z 348 (M+H).sup.+.
[0648] Synthesis of Compound 54.5.
[0649] To a 100-mL 3-necked round-bottom flask was added a solution
of 54.4 (1.3 g, 3.74 mmol, 1.00 equiv) in dichloromethane (20 mL)
and TEA (570 mg, 5.63 mmol, 1.51 equiv). This was followed by the
addition of methanesulfonyl chloride (520 mg, 4.54 mmol, 1.21
equiv) dropwise with stirring at 0.degree. C. The resulting
solution was stirred for 2 h at room temperature. The reaction was
then quenched by the addition of 20 mL of water. The resulting
solution was diluted with 100 mL of dichloromethane and washed with
3.times.50 mL of brine. The mixture was dried over anhydrous sodium
sulfate and concentrated under vacuum to afford 1.5 g (crude) of
mesylate 54.5 as a yellow oil.
[0650] Synthesis of Compound I-22.
[0651] To a 50-mL 3-necked round-bottom flask was added compound
54.5 (500 mg, 1.17 mmol, 1.00 equiv), DMSO (20 mL) and sodium
carbonitrile (100 mg, 2.04 mmol, 1.74 equiv). The reaction was
stirred for 3 h at 70.degree. C., whereupon it was diluted with 100
mL of DCM. The resulting mixture was washed with 3.times.10 mL of
saturated aqueous sodium bicarbonate and 3.times.20 mL of brine.
The mixture was dried over anhydrous sodium sulfate and
concentrated under vacuum. The residue was purified by preparative
HPLC (2#-Waters 2767-2(HPLC-08)) under the following conditions:
column: Xbridge Shield RP 18; mobile phase: water (50 mM ammonium
bicarbonate) and acetonitrile (start at 5.0% acetonitrile then ramp
up to 30.0% in 7 min, up to 100.0% in 1 min, then down to 5.0% in 1
min); detector: UV 254 and 220 nm. This procedure afforded 50 mg
(11%) of Compound I-22 as a white solid. .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 8.53 (s, 1H), 5.24-5.27 (d, 1H), 3.69 (s, 1H),
3.18-3.28 (m, 1H), 3.00-3.09 (m, 1H), 2.81-2.98 (m, 2H), 2.69-2.77
(m, 1H), 2.55 (br 1H), 2.45 (s, 6H), 2.37-2.41 (m, 3H), 2.02-2.24
(m, 2H), 1.50-1.79 (q, 4H). MS: m/z 357 (M+H).sup.+.
Example 55
Synthesis of
2-(4-(((1r,4r)-4-(dimethylamino)cyclohexyl)oxy)-6,7-dihydro-5H-cyclopenta-
[4,5]thieno[2,3-d]pyrimidin-5-yl)ethanol (I-21)
##STR00415##
[0653] Synthesis of 55.1.
[0654] A 100-mL 3-necked round-bottom flask purged and maintained
with an inert atmosphere of nitrogen was charged with a solution of
I-22 (600 mg, 1.68 mmol, 1.00 equiv) in dichloromethane (60 mL).
This was followed by the addition of diisobutylaluminium hydride
(0.3 mL) dropwise with stirring at -78.degree. C. The resulting
solution was stirred for 30 min at -30.degree. C. Then to this
mixture was added diisobutylaluminium hydride (0.3 mL) dropwise
with stirring at -78.degree. C. The resulting solution was stirred
for 30 min at -30.degree. C. The reaction was quenched by the
addition of 3 mL of water and diluted with 200 mL of
dichloromethane. The resulting mixture was washed with 4.times.50
mL of brine. The organic layer was dried over anhydrous sodium
sulfate and concentrated under vacuum to afford 0.4 g (66%) of
aldehyde 55.1 as a yellow solid.
[0655] Synthesis of Compound I-21.
[0656] A 100-mL 3-necked round-bottom flask, purged and maintained
with an inert atmosphere of nitrogen, was charged with aldehyde
55.1 (400 mg, 1.11 mmol, 1.00 equiv), methanol (10 mL) and sodium
borohydride (100 mg, 2.72 mmol, 2.44 equiv). The resulting solution
was stirred for 1 h at room temperature. The reaction was then
quenched by the addition of 50 mL of water. The resulting solution
was extracted with 3.times.50 mL of ethyl acetate and the organic
layers combined. The resulting mixture was washed with 3.times.50
mL of brine. The mixture was dried over anhydrous sodium sulfate
and concentrated under vacuum to afford 0.35 g (87%) of Compound
I-21 as a yellow oil. MS: m/z 362 (M+H).sup.+.
Example 56
Synthesis of
4-(((1r,4r)-4-(dimethylamino)cyclohexyl)oxy)-6,7-dihydro-5H-cyclopenta[4,-
5]thieno[2,3-d]pyrimidine-5-carboxylic acid (I-8)
##STR00416##
[0658] To a solution of 56.1 (1 g, 2.57 mmol) in THF (5 mL) and
MeOH (5 mL) was added a solution of NaOH (1 g, 25.7 mmol) in
H.sub.2O (5 mL). The mixture was stirred for 15 hours at r.t. and
then the pH was adjusted to 5 with HCl (1 M). Purification by
reverse phase chromatography (Biotage) gave a white solid product
(350 mg, 38%). .sup.1H NMR (500 MHz, CDCl.sub.3) .delta. 8.46 (1H,
s), 5.20-5.16 (1H, m), 4.10-4.07 (1H, m), 3.23-3.17 (1H, m),
3.02-2.96 (1H, m), 2.91-2.84 (1H, m), 2.68-2.62 (1H, m), 2.55-2.29
(7H, s), 2.40-2.37 (1H, d), 2.29 (1H, s), 2.17 (1H, s), 2.09-2.07
(1H, m), 1.67-1.52 (4H, m) MS: m/z 362 (M+H).sup.+.
Example 57
Synthesis of Intermediate 57.4
##STR00417##
[0660] Synthesis of Compound 57.1.
[0661] Sodium hydride (60% dispersion in mineral oil, 3.4 g, 84.16
mmol, 4.00 equiv) was added slowly to a solution of tert-butyl
((1r,4r)-4-hydroxycyclohexyl)(methyl)carbamate
(commercially-available; 6.27 g, 27.34 mmol, 1.40 equiv) in
distilled THF (50 ml) at 0.degree. C. under nitrogen. The resulting
mixture was stirred for 30 min at room temperature. Intermediate
1.4 (5.95 g, 21.04 mmol, 1.00 equiv) in THF (20 ml) was added
dropwise to the above mixture and stirred for 4 hours at ambient
temperature. The reaction was then quenched with water and
extracted with ethyl acetate (3.times.100 mL). The organic layers
were combined, dried over anhydrous sodium sulfate, and
concentrated under vacuum. The residue was purified by a silica gel
column with ethyl acetate/petroleum ether (1:10 to 1:3) to provide
57.1 (8.3 g, 83%) as a colorless oil.
[0662] Synthesis of Compound 57.2.
[0663] To a 500-mL round-bottom flask, purged and maintained under
an inert atmosphere of nitrogen, was added a solution of 57.1 (8.3
g, 17.45 mmol, 1.00 equiv) in 200 mL of distilled THF at 0.degree.
C. under nitrogen. LAH (663 mg, 17.45 mmol, 1.00 equiv) was slowly
added and then the reaction was stirred for 4 h at room
temperature. The reaction was then quenched by the addition of
saturated aqueous NH.sub.4Cl and extracted with ethyl acetate
(2.times.150 mL). The combined organic layers were washed with
brine and dried over anhydrous sodium sulfate. After concentration
under reduced pressure, the residue was purified with a silica gel
column (eluting with ethyl acetate/petroleum ether (1:2 to 2:1)) to
provide compound 57.2 (7.2 g, 95%) as a white solid.
[0664] Synthesis of Compound 57.3.
[0665] To a solution of 57.2 (3.6 g, 8.30 mmol, 1.00 equiv) and
triethylamine (2.53 g, 25.00 mmol, 3.00 equiv) in dry
dichloromethane (100 ml) was added methanesulfonyl chloride (1.9 g,
16.59 mmol, 1.50 equiv) dropwise at 0.degree. C. under nitrogen.
The resulting solution was stirred for an additional 2 h at room
temperature. The reaction solution was diluted with dichloromethane
and washed with brine (twice). The organic layer was dried and
concentrated under vacuum to give the desired compound 57.3 (4.7 g,
crude) as a light yellow syrup which was used in the next step
without further purification.
[0666] Synthesis of Compound 57.4.
[0667] To a 100-mL 3-necked round-bottom flask purged and
maintained with an inert atmosphere of nitrogen was added a
solution of ethanethiol (485 mg, 7.81 mmol, 1.00 equiv) in
distilled DMF (10 mL). After cooling to 0.degree. C. under
nitrogen, sodium hydride (605 dispersion in mineral oil, 312 mg,
2.00 equiv) was added and stirring continued for 30 min at room
temperature. A solution of 57.3 (2.0 g, crude) in DMF (10 ml) was
added via syringe and the resulting solution was stirred for 3 h at
ambient temperature. The reaction was quenched with water and
extracted with ethyl acetate (2.times.100 mL). The combined organic
layers were dried over anhydrous sodium sulfate and concentrated
under reduced pressure. The residue was purified by column
chromatography on silica gel (using ethyl acetate/petroleum ether
(1:3 to 1:1) as the eluent) to provide compound 57.4 (1.2 g) as a
yellow oil.
Example 58
Synthesis of
4-([3-[(ethylsulfanyl)methyl]-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dode-
ca-1(12),2(6),8,10-tetraen-12-yl]oxy)-N,N-dimethylcyclohexan-1-amine
(I-39)
##STR00418##
[0669] To a solution of intermediate 57.4 (400 mg, 0.84 mmol, 1.00
equiv) in 10 mL of dichloromethane was added hydrochloric acid (12
M, 2 ml) at 0.degree. C. and the resulting solution was stirred for
2 h at room temperature. The reaction mixture was concentrated
under reduced pressure. The crude product was dissolved in methanol
(10 ml) and formaldehyde (37%, 2 ml) was added. After stirring for
1 h at room temperature NaBH.sub.3CN (158 mg, 2.51 mmol, 3.00
equiv) was slowly added at 0.degree. C. and the resulting solution
was stirred overnight at room temperature. The next day, the
reaction mixture was quenched with water and extracted with ethyl
acetate (2.times.50 mL). The organic layers were combined, dried
over anhydrous sodium sulfate, and concentrated under vacuum. The
crude product (140 mg) was purified by preparative HPLC (Waters)
under the following conditions: column: SunFire Prep C18, 19*150 mm
5 um; mobile phase: water (0.05% NH.sub.4HCO.sub.3 solution) and
CH.sub.3CN (30% CH.sub.3CN then ramp up to 100.0% over 20 min); UV
detection at 254 nm. The product-containing fractions were
collected and concentrated under reduced pressure. The residue was
lyophilized overnight to give 1-39 (31.4 mg) as a white solid.
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.24 (s, 1H), 8.14 (s,
1H), 8.03 (s, 1H), 7.75 (s, 1H), 7.41 (s, 1H), 7.20-7.30 (m, 2H),
7.10 (d, 2H), 7.00 (d, 2H), 4.50-4.60 (m, 1H), 3.81 (s, 2H), 3.71
(s, 2H), 3.55-3.60 (m, 2H), 3.16-3.22 (m, 2H), 2.30-2.40 (m, 2H),
2.10-2.20 (m, 2H). MS: m/z 392 (M+H).sup.+.
Example 59
Synthesis of
4-[[(3S)-3-[[(S)-ethanesulfinyl]methyl]-7-thia-9,11-diazatricyclo[6.4.0.0-
[2,6]]dodeca-1(12),2(6),8,10-tetraen-12-yl]oxy]-N,N-dimethylcyclohexan-1-a-
mine (I-45) and Example 60: Synthesis of
4-[[(3S)-3-[[(R)-ethanesulfinyl]methyl]-7-thia-9,11-diazatricyclo[6.4.0.0-
[2,6]]dodeca-1(12),2(6),8,10-tetraen-12-yl]oxy]-N,N-dimethylcyclohexan-1-a-
mine (I-46)
##STR00419##
[0671] A solution of Compound I-39 (140 mg, 0.36 mmol, 1.00 equiv)
in chloroform (8 ml) was cooled to -30.degree. C. A solution of
m-CPBA (62 mg, 0.36 mmol, 1.00 equiv) in chloroform (2 ml) was
added dropwise under nitrogen. The resulting solution was stirred
for 3 hours below -10.degree. C. The pH value of the reaction
solution was adjusted to 10 with saturated aqueous sodium
bicarbonate and extracted with dichloromethane. The combined
organic layers were washed with brine, dried over anhydrous sodium
sulfate and concentrated under vacuum. The crude product (100 mg)
was purified by preparative HPLC (SHIMADZU) under the following
conditions: column: SunFire Prep C18, 19*150 mm 5 um; mobile phase:
water (0.05% NH.sub.4HCO.sub.3) and CH.sub.3CN (35% CH.sub.3CN then
ramp up to 100.0% over 20 min); UV detection at 254 nm. The
fractions containing the first peak were collected and concentrated
under reduced pressure. The residue was lyophilized overnight to
give Compound I-45 (26.2 mg) as a white solid. .sup.1H NMR (300
MHz, CD.sub.3OD): .delta. 8.24 (s, 1H), 8.14 (s, 1H), 8.03 (s, 1H),
7.75 (s, 1H), 7.41 (s, 1H), 7.20-7.30 (m, 2H), 7.10 (d, 2H), 7.00
(d, 2H), 4.50-4.60 (m, 1H), 3.81 (s, 2H), 3.71 (s, 2H), 3.55-3.60
(m, 2H), 3.16-3.22 (m, 2H), 2.30-2.40 (m, 2H), 2.10-2.20 (m, 2H).
MS: m/z 408 (M+H).sup.+.
[0672] Compound I-47 was obtained under the same conditions as in
Example 59 by collecting the fractions that contained the second
peak to elute in the purification. Evaporation of the solvent
followed by lyophilization of the residue afforded 1-47 (12.8 mg)
as a white solid. .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 8.24
(s, 1H), 8.14 (s, 1H), 8.03 (s, 1H), 7.75 (s, 1H), 7.41 (s, 1H),
7.20-7.30 (m, 2H), 7.10 (d, 2H), 7.00 (d, 2H), 4.50-4.60 (m, 1H),
3.81 (s, 2H), 3.71 (s, 2H), 3.55-3.60 (m, 2H), 3.16-3.22 (m, 2H),
2.30-2.40 (m, 2H), 2.10-2.20 (m, 2H). MS: m/z 408 (M+H).sup.+.
Example 61
Synthesis of
4-([3-[(ethanesulfonyl)methyl]-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dod-
eca-1(12),2(6),8,10-tetraen-12-yl]oxy)-N,N-dimethylcyclohexan-1-amine
(I-47)
##STR00420##
[0674] Synthesis of Compound 61.1.
[0675] To a solution of intermediate 57.4 (200 mg, 0.42 mmol, 1.00
equiv) in chloroform (10 ml) was added m-CPBA (145 mg, 0.84 mmol,
2.00 equiv) at 0.degree. C. under nitrogen. The resulting solution
was stirred for 3 hours at room temperature. The pH value of the
solution was adjusted to 10 with saturated aqueous sodium
bicarbonate and extracted with dichloromethane (2.times.30 mL). The
combined organic layers were washed with brine, dried over
anhydrous sodium sulfate and concentrated under vacuum. The residue
was loaded onto a silica gel column and eluted with ethyl
acetate/petroleum ether (1:10) to afford the sulfone 61.1 (140 mg,
66%) as a white solid.
[0676] Synthesis of Compound I-47.
[0677] To a 50-mL round-bottom flask containing a solution of 61.1
(140 mg, 0.27 mmol, 1.00 equiv) in 10 mL of dichloromethane was
added hydrochloric acid (12 M, 2 ml) at 0.degree. C. and the
resulting solution was stirred for 2 h at room temperature. The
reaction mixture was concentrated under reduced pressure. The crude
product was dissolved in methanol (10 ml) and formaldehyde (37%, 2
ml) was added. The reaction was stirred for 1 h at room
temperature, then NaBH.sub.3CN (158 mg, 2.51 mmol) was slowly added
at 0.degree. C. The resulting solution was stirred overnight at
room temperature. The reaction mixture was quenched with water and
extracted with ethyl acetate (2.times.50 mL). The organic layers
were combined, dried over anhydrous sodium sulfate, and
concentrated under vacuum. The crude product (140 mg) was purified
by preparative HPLC (SHIMADZU) under the following conditions:
column: SunFire Prep C18, 19*150 mm 5 um; mobile phase: water
(0.05% NH.sub.4HCO.sub.3) and CH.sub.3CN (6.0% CH.sub.3CN then ramp
up to 50.0% over 12 min); UV detection at 254 and 220 nm. The
product-containing fractions were collected and concentrated under
reduced pressure. The residue was lyophilized overnight to give
Compound I-47 (41.9 mg, 36%) as a white solid. .sup.1H NMR (400
MHz, CD.sub.3OD): .delta. 8.24 (s, 1H), 8.14 (s, 1H), 8.03 (s, 1H),
7.75 (s, 1H), 7.41 (s, 1H), 7.20-7.30 (m, 2H), 7.10 (d, 2H), 7.00
(d, 2H), 4.50-4.60 (m, 1H), 3.81 (s, 2H), 3.71 (s, 2H), 3.55-3.60
(m, 2H), 3.16-3.22 (m, 2H), 2.30-2.40 (m, 2H), 2.10-2.20 (m, 2H).
MS: m/z 424 (M+H).sup.+.
Example 62
Intermediate 62.1
##STR00421##
[0679] To a 5-L 4-necked round-bottom flask was added intermediate
1.4 (200 g, 707.35 mmol, 1.00 equiv) and tetrahydrofuran (2 L).
This was followed by the addition of DIBAL-H (2 L) dropwise with
stirring at -78.degree. C. in 30 min. The resulting solution was
stirred for 1 h at -78.degree. C. and an additional 1 h with
warming to -10.degree. C. The reaction was then quenched by the
addition of 2 L of water. The pH value of the solution was adjusted
to 7 with hydrogen chloride (3 mol/L). The resulting solution was
diluted with 1 L of ethyl acetate and the solids were filtered off.
The resulting solution was extracted with 2.times.500 mL of ethyl
acetate and the organic layers were combined. The combined organic
layers were washed with 2.times.1 L of brine, dried over anhydrous
sodium sulfate and concentrated under vacuum. The residue was
loaded onto a silica gel column with ethyl acetate/petroleum ether
(1:1) and purified to afford 120 g (70%) of intermediate 62.1 as a
light yellow solid. .sup.1H NMR (300 MHz, CDCl.sub.3): .delta.
2.57-2.79 (m, 2H), 2.99-3.28 (m, 2H), 3.68-3.85 (m, 2H), 4.01-4.05
(m, 1H), 8.75 (s, 1H). MS: m/z 241 (M+H).sup.+.
Example 63
Intermediates 63.1 and 63.2
##STR00422##
[0681] The enantiomers of racemic 62.1 (6.0 g) were separated by
chiral HPLC (SHIMADZU) under the following conditions: column:
Chiralpak IC, 0.46*25 cm, 5 um; mobile phase: hexane (0.1%
TEA):IPA=90:10; UV detection at 254 nm. The desired
[(3S)-12-chloro-7-thia-9,11-diazatricyclo[6.4.0.0
[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]methanol (63.1,
t.sub.R=15.15 min, 2.0 g) was obtained as a pale-yellow solid in
100% ee. [(3R)-12-chloro-7-thia-9,11-diazatricyclo[6.4.0.0
[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]methanol (63.2,
t.sub.R=12.22 min, 2.0 g) was also obtained in 100% ee.
Example 64
Synthesis of
N,N-dimethyl-4-[[(3R)-3-[(prop-2-yn-1-yloxy)methyl]-7-thia-9,11-diazatric-
yclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexan-1-ami-
ne (I-48)
##STR00423##
[0683] Synthesis of Compound 64.1.
[0684] A solution of intermediate 63.2 (prepared as in Example 63;
1.2 g, 4.99 mmol, 1.00 equiv), 1H-imidazole (680 mg, 9.99 mmol,
2.00 equiv) and TBDMSCl (0.87 g) in distilled DMF (20 mL) was
stirred for 2 h at room temperature. The reaction was then quenched
with water and extracted with ethyl acetate (3.times.50 mL). The
combined organic layers were washed with brine, dried over sodium
sulfate and concentrated under vacuum. The residue was purified by
column chromatography on silica gel with EtOAc/petroleum ether
(1:10 to 1:5) to afford compound 64.1 (2.0 g) as a yellow oil. MS:
m/z 355 (M+H).sup.+.
[0685] Synthesis of Compound 64.2.
[0686] Sodium hydride (60% dispersion in mineral oil, 650 mg, 16.25
mmol, 3.00 equiv) was treated with tert-butyl
trans-4-hydroxycyclohexyl(methyl)carbamate (1.73 g, 7.54 mmol, 1.40
equiv) in 20 mL of distilled THF at 0.degree. C. for 1 h under
nitrogen. Then a solution of 64.1 (1.908 g, 5.38 mmol, 1.00 equiv)
in dry THF (10 mL) was added and the resulting solution was stirred
for 2 h at 60.degree. C. in an oil bath. After cooling to room
temperature, the reaction was quenched with water and extracted
with ethyl acetate (3.times.50 mL). The combined organic layers
were washed with brine, dried over anhydrous sodium sulfate and
concentrated under vacuum. The residue was loaded onto a silica gel
column with ethyl acetate/petroleum ether (1:5) and purified to
give compound 64.2 (1.94 g, 66%) as a yellow oil.
[0687] Synthesis of Compound 64.3.
[0688] To a 100-mL round-bottom flask was added a solution of 64.2
(1.94 g, 3.54 mmol, 1.00 equiv) in 50 mL of THF followed by TBAF
(1.85 g, 7.08 mmol, 2.00 equiv) and the resulting solution was
stirred for 3 h at room temperature. The solvent was evaporated
under reduced pressure and the residue diluted with 100 mL of ethyl
acetate and washed with brine. The organic phase was dried over
anhydrous sodium sulfate and concentrated in vacuo, whereupon the
residue was loaded onto a silica gel column with ethyl
acetate/petroleum ether (1:4) and purified to afford the alcohol
64.3 (1.5 g, 98%) as a white solid.
[0689] Synthesis of Compound 64.4.
[0690] To a 100-mL 3-necked round-bottom flask containing a
solution of 64.3 (200 mg, 0.46 mmol, 1.00 equiv) in distilled THF
(20 mL) was added sodium hydride (60% dispersion in mineral oil,
73.6 mg, 1.84 mmol, 4.00 equiv) at 0.degree. C. under nitrogen.
After stirring for 30 min, 3-bromoprop-1-yne (164 mg, 1.38 mmol,
3.00 equiv) was added via syringe and the resulting solution was
heated to reflux overnight in an oil bath. The reaction was then
quenched with water and extracted with 3.times.20 mL of ethyl
acetate. The combined organic layers were dried over sodium sulfate
and concentrated under reduced pressure, and then the residue was
loaded onto a silica gel column with ethyl acetate/petroleum ether
(1:5). Purification afforded alkyne 64.4 (150 mg, 69%) as a yellow
solid.
[0691] Synthesis of Compound I-48.
[0692] To a 100-mL round-bottom flask was added a solution of 64.4
(200 mg, 0.42 mmol, 1.00 equiv) in dichloromethane (10 mL). HCl (12
M, 2 mL) was added at 0.degree. C. and the resulting mixture was
stirred for 1 hour at room temperature. The solvent was removed
under vacuum. The resulting residue was dissolved in MeOH (10 mL)
and HCHO (37%, 1 mL) was added followed by stirring at ambient
temperature for 1 h. Then NaBH.sub.3CN (79 mg, 1.26 mmol, 3.00
equiv) was added and the resulting solution was stirred overnight
at room temperature. The reaction's progress was monitored by LCMS.
Upon completion, the mixture was concentrated in vacuo and the
crude product (100 mg) was purified by preparative HPLC (Waters)
under the following conditions: column: Xbridge RP18, 19*150 mm 5
um; mobile phase: water (with 20 mM NH.sub.4HCO.sub.3) and
CH.sub.3CN (10.0% CH.sub.3CN then ramp up to 40.0% over 20 min, up
to 95.0% over 2 min, then down to 10.0% over 2 min); UV detection
at 254 and 220 nm. The product-containing fractions were collected
and evaporated under reduced pressure to give Compound I-48 (12.8
mg) as a colorless oil. .sup.1H NMR (300 MHz, CD.sub.3OD): .delta.
8.49 (s, 1H), 5.26-5.29 (m, 1H), 4.12-4.16 (m, 2H), 3.95-3.98 (m,
1H), 3.58-3.64 (m, 2H), 2.82-3.4 (m, 2H), 2.81 (m, 1H), 2.42-2.65
(m, 2H), 2.31 (s, 9H), 2.06-2.09 (m, 2H), 1.47-1.70 (m, 4H). MS:
m/z 386 (M+H).sup.+.
Example 65
Synthesis of Intermediate 65.1
##STR00424##
[0694] A solution of 63.1 (1.2 g, 4.99 mmol, 1.00 equiv),
1H-imidazole (680 mg, 9.99 mmol, 2.00 equiv) and TBDMSCl (0.87 g)
in distilled DMF (20 mL) was stirred for 2 h at room temperature.
The reaction was then quenched with water and extracted with ethyl
acetate (3.times.50 mL). The combined organic layers were washed
with brine, dried over sodium sulfate and concentrated under
vacuum. The residue was purified by column chromatography on silica
gel with EtOAc/petroleum ether (1:10 to 1:5) to afford 65.1 (2.0 g)
as a yellow oil. MS: m/z 355 (M+H).sup.+.
Example 66
Synthesis of Intermediate 66.2
##STR00425##
[0696] Synthesis of Compound 66.1.
[0697] Sodium hydride (60% dispersion in mineral oil, 1.33 g, 33.24
mmol, 4.0 equiv) was treated with tert-butyl
N-(4-hydroxycyclohexyl)-N-methylcarbamate (2.66 g, 11.6 mmol, 1.40
equiv) in 50 mL of distilled THF at 0.degree. C. under nitrogen.
After stirring for 30 min, a solution of 65.1 (2.0 g, 8.31 mmol,
1.00 equiv) in dry THF (10 mL) was added dropwise and the resulting
solution was stirred for 5 h at 60.degree. C. The reaction was then
quenched with saturated aqueous ammonium chloride and extracted
with ethyl acetate (3.times.100 mL). The combined organic layers
were washed with brine, dried over Na.sub.2SO.sub.4 and
concentrated in vacuo. The residue was loaded onto a silica gel
column with ethyl acetate/petroleum ether (1:10 to 1:2) and
purified to afford carbamate 66.1 (2.3 g, 64%) as a yellow oil. MS:
m/z 548 (M+H).sup.+.
[0698] Synthesis of Compound 66.2.
[0699] To a solution of 66.1 (1.0 g, 1.83 mmol, 1.00 equiv) in 10
mL of tetrahydrofuran was added TBAF (600 mg, 2.29 mmol, 1.26
equiv) at room temperature. The resulting solution was stirred for
4 h at ambient temperature and quenched by the addition of water.
The resulting solution was extracted with ethyl acetate (3.times.50
mL). The organic layers were washed with brine and dried over
anhydrous sodium sulfate. After concentration in vacuo, the residue
was loaded onto a silica gel column with ethyl acetate/petroleum
ether (1:15 to 1:1) and purified to afford intermediate 66.2 (0.7
g, 88%) as a yellow oil. MS: m/z 435 (M+H).sup.+.
Example 67
Synthesis of
N,N-dimethyl-4-[[(3S)-3-[(prop-2-yn-1-yloxy)methyl]-7-thia-9,11-diazatric-
yclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexan-1-ami-
ne (I-49)
##STR00426##
[0701] Synthesis of Compound 67.1.
[0702] To a solution of intermediate 66.2 (200 mg, 0.46 mmol, 1.00
equiv) in distilled THF (10 mL) was added sodium hydride (60%
dispersion in mineral oil, 400 mg, 10.00 mmol, 21.7 equiv) at
0.degree. C. under nitrogen. After stirring for 30 min,
3-bromoprop-1-yne (118 mg, 0.99 mmol, 2.15 equiv) was added via
syringe and the reaction solution was stirred for 3 h at 60.degree.
C. in an oil bath. The reaction was then quenched with water and
extracted with 3.times.25 mL of ethyl acetate. The combined organic
layers were washed with brine and dried over anhydrous sodium
sulfate. After concentration in vacuo, the residue was loaded onto
a silica gel column with EtOAc/petroleum ether (1:3) and purified
to afford alkyne 67.1 (210 mg, 97%) as a yellow oil. MS: m/z 472
(M+H).sup.+.
[0703] Synthesis of Compound I-49.
[0704] To a 25-mL round-bottom flask, purged and maintained with an
inert atmosphere of nitrogen, was added alkyne 67.1 (200 mg, 0.42
mmol, 1.00 equiv) and 10 mL of dichloromethane. Then hydrochloric
acid (12 M, 2.0 mL) was added at 0.degree. C. and the resulting
solution was stirred for 3 h at room temperature. The reaction
mixture was concentrated under vacuum to give
N-methyl-4-[[(3S)-3-[(prop-2-yn-1-yloxy)methyl]-7-thia-9,11-diazatricyclo-
[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexan-1-amine
hydrochloride (150 mg, crude) as a yellow oil. To a solution of
this material (150 mg, crude) in 10 mL of methanol was added HCHO
(37%, 1.5 mL) at room temperature and the reaction mixture was
stirred for about 30 min. Then NaBH.sub.3CN (80 mg, 1.26 mmol, 3
equiv) was added and the resulting solution was stirred overnight.
After concentration under reduced pressure, the crude product (150
mg) was purified by preparative HPLC (Waters) under the following
conditions: column: Xbridge RP18, 19*150 mm 5 um; mobile phase:
water (with 20 mM NH.sub.4HCO.sub.3) and CH.sub.3CN (10.0%
CH.sub.3CN then ramp up to 40.0% in 20 min, up to 95.0% in 2 min,
then down to 10.0% in 2 min); UV detection at 254 and 220 nm. The
product-containing fractions were collected and evaporated under
reduced pressure to give Compound I-49 (50 mg) as a white solid.
.sup.1H NMR (300 MHz, CD.sub.3OD): .delta. 1.48 (m, 4H), 1.95 (m,
2H), 2.25 (m, 8H), 2.42 (m, 1H), 2.50 (m, 1H), 2.72 (t, J=2.4 Hz,
1H), 3.22 (m, 1H), 3.85 (m, 1H), 4.05 (m, 2H), 5.15 (m, 1H), 8.35
(s, 1H). MS: m/z 386 (M+H).sup.+.
Example 68
Synthesis of
4-[[(3S)-3-[(but-2-yn-1-yloxy)methyl]-7-thia-9,11-diazatricyclo[6.4.0.0[2-
,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]-N,N-dimethylcyclohexan-1-amin-
e (I-56)
##STR00427##
[0706] Synthesis of Compound 68.1.
[0707] To a solution of intermediate 66.2 (200 mg, 0.46 mmol, 1.00
equiv) in 10 mL of distilled THF was added sodium hydride (60%
dispersion in mineral oil, 100 mg, 2.5 mmol) at 0.degree. C. under
nitrogen. After stirring for 30 min, 1-bromobut-2-yne (132 mg, 0.99
mmol, 2.15 equiv) was added via syringe and the reaction mixture
was stirred at 60.degree. C. for 3 h. The cooled reaction mixture
was then quenched with water and extracted with 3.times.30 mL of
ethyl acetate. The organic layers were combined, washed with brine
and dried over sodium sulfate. After concentration in vacuo, the
residue was loaded onto a silica gel column with ethyl
acetate/petroleum ether (1:5) to give the desired alkyne 67.1 (180
mg, 80%) as a yellow oil. MS: m/z 486 (M+H).sup.+.
[0708] Synthesis of Compound I-56.
[0709] Compound I-56 was prepared in a manner consistent with
Example 67. 97 mg of a colorless oil were obtained. .sup.1H NMR
(300 MHz, CD.sub.3OD): .delta. 1.49 (m, 4H), 1.69 (t, 3H), 1.95 (m,
2H), 2.23 (m, 9H), 2.53 (m, 2H), 2.97 (m, 2H), 3.75 (m, 1H), 3.98
(m, 1H), 5.18 (m, 2H), 8.36 (s, 1H). MS: m/z 400 (M+H).sup.+.
Example 69
Synthesis of
4-[[(3S)-3-[[(2E)-but-2-en-1-yloxy]methyl]-7-thia-9,11-diazatricyclo[6.4.-
0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]-N,N-dimethylcyclohexan-1-
-amine (I-59)
##STR00428##
[0711] Synthesis of Compound 69.1.
[0712] To a solution of intermediate 66.2 (400 mg, 0.92 mmol, 1.00
equiv) in 10 mL of distilled THF was added sodium hydride (60%
dispersion in mineral oil, 200 mg, 2.5 mmol) was added at 0.degree.
C. under nitrogen. After stirring for 30 min, (2E)-1-bromobut-2-ene
(150 mg, 1.12 mmol, 1.20 equiv) was added via syringe and the
reaction mixture was stirred at 60.degree. C. for 3 h. The cooled
reaction mixture was then quenched with water and extracted with
3.times.60 mL of ethyl acetate. The organic layers were combined,
washed with brine and dried over sodium sulfate. After
concentration in vacuo, the residue was loaded onto a silica gel
column with ethyl acetate/petroleum ether (1:5 to 1:2) and purified
to give alkene 69.1 (200 mg, 40%) as a yellow oil. MS: m/z 488
(M+H).sup.+.
[0713] Synthesis of Compound I-59.
[0714] Compound I-59 was prepared in a manner consistent with
Example 67. 50 mg of a colorless oil were obtained. .sup.1H NMR
(300 MHz, CD.sub.3OD): .delta. 1.52 (m, 6H), 2.08 (t, J=2.7 Hz,
2H), 2.38 (m, 3H), 2.39 (m, 1H), 2.52 (s, 6H), 2.86 (m, 1H), 3.02
(m, 2H), 3.43 (m, 2H), 3.72 (m, 2H), 3.93 (m, 1H), 5.40 (m, 1H),
5.49 (m, 1H), 5.51 (m, 1H), 8.35 (s, 1H), 8.44 (br s, 1H). MS: m/z
402 (M+H).sup.+.
Example 70
Synthesis of
(S)-1-((S)-4-(((1r,4S)-4-(dimethylamino)cyclohexyl)oxy)-6,7-dihydro-5H-cy-
clopenta[4,5]thieno[2,3-d]pyrimidin-5-yl)propan-1-ol (I-50)
##STR00429##
[0716] Synthesis of Compound 70.1.
[0717] To a solution of intermediate 66.2 (260.4 mg, 0.60 mmol,
1.00 equiv) in dichloromethane (10 mL) was added Dess-Martin
periodinane (279.8 mg, 0.66 mmol, 1.10 equiv) at room temperature
under nitrogen. The reaction mixture was stirred for 5 h at ambient
temperature and diluted with DCM (30 mL), washed with brine and
dried over anhydrous sodium sulfate. After concentration under
reduced pressure, the aldehyde 70.1 (210 mg, 82%) was obtained as a
yellow oil. MS: m/z 432 (M+H).sup.+.
[0718] Synthesis of Compound 70.2.
[0719] To a solution of 70.1 (210 mg, 0.49 mmol, 1.00 equiv) in
distilled THF (10 mL) was added bromo(ethyl)magnesium (129 mg, 0.97
mmol, 1.99 equiv) at 0.degree. C. under nitrogen. The resulting
solution was stirred for 2 h at room temperature. The reaction was
then quenched by the addition of H.sub.2O and extracted with ethyl
acetate (50 mL), dried over anhydrous sodium sulfate and
concentrated under vacuum. The residue was loaded onto a silica gel
column with EtOAc/petroleum ether (1:1) and purified to give
alcohol 70.2 (100 mg, 45%) as a yellow oil. MS: m/z 462
(M+H).sup.+.
[0720] Synthesis of Compound I-50.
[0721] A solution of 70.2 (100 mg, 0.22 mmol, 1.00 equiv) in 5 mL
of DCM was added to a solution of saturated HCl(g)/1,4-dioxane (10
mL) at room temperature. The reaction mixture was stirred at
ambient temperature for 2 h. The pH value of the solution was
adjusted to 10 with 2 M aqueous sodium hydroxide and extracted with
dichloromethane (50 mL). The organic layer was concentrated under
reduced pressure to give the desired
1-[(3S)-12-[[4-(methylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo[6.4-
.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]propan-1-ol (78 mg,
crude) as a yellow oil. To a solution of this material (78 mg,
crude) in methanol (3 mL) was added HCHO (37%, 1 mL) and the
reaction was stirred for 30 min at room temperature. Then
NaBH.sub.3CN (42 mg, 0.67 mmol, 3.10 equiv) was added and the
resulting solution was stirred overnight at ambient temperature.
The reaction was then quenched by the addition of H.sub.2O and
extracted with dichloromethane (15 mL), dried over anhydrous sodium
sulfate and concentrated under vacuum. The crude product (80 mg)
was purified by preparative HPLC (SHIMADZU) under the following
conditions: column: SunFire Prep C18, 19*150 mm 5 um; mobile phase:
water (0.05% NH.sub.4HCO.sub.3) and CH.sub.3CN (6.0% CH.sub.3CN
then ramp up to 55.0% in 19 min); UV detection at 254 and 220 nm.
The product-containing fractions were collected and evaporated
under reduced pressure to afford Compound I-50 (10.4 mg) as a white
solid. .sup.1H NMR (400 MHz, CD.sub.3OD): .delta. 8.47 (s, 1H),
5.28-5.30 (m, 1H), 4.16-4.19 (m, 1H), 3.43-3.45 (m, 1H), 3.08-3.10
(m, 1H), 2.92-2.99 (m, 1H), 2.45-2.62 (m, 2H), 2.29-2.40 (m, 9H),
2.01-2.13 (m, 2H), 1.50-1.79 (m, 6H), 1.07 (t, 3H). MS: m/z 376
(M+H).sup.+.
Example 71
Synthesis of racemic
2-cyano-3-(12-[[4-(dimethylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricycl-
o[6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-3-yl)propanamide
(I-51)
##STR00430##
[0723] Synthesis of Compound 71.1.
[0724] To a solution of 66.2 (270 mg, 0.62 mmol, 1.00 equiv) in
dichloromethane (25 mL) cooled to 0.degree. C. was added PPh.sub.3
(244 mg, 0.93 mmol, 1.50 equiv) and imidazole (63 mg, 0.93 mmol,
1.50 equiv) under nitrogen, followed by iodine (236 mg, 0.93 mmol,
1.50 equiv). The resulting solution was stirred overnight at room
temperature and diluted with dichloromethane (100 mL), then washed
with saturated aqueous sodium sulfite and brine. The
dichloromethane layer was dried over anhydrous sodium sulfate.
After filtration and concentration, the residue was purified using
a silica gel column (eluting with EtOAc/petroleum ether (1:6-1:3))
to provide the desired iodide 71.1 (270 mg, 80%) as a light yellow
foam. MS: m/z 544 (M+H).sup.+.
[0725] Synthesis of Compound 71.2.
[0726] A mixture of 71.1 (270 mg, 0.50 mmol, 1.00 equiv),
18-crown-6 (159 mg, 0.60 mmol, 1.20 equiv), potassium carbonate
(117 mg, 0.85 mmol, 1.70 equiv) and ethyl 2-cyanoacetate (565 mg,
5.00 mmol, 10.00 equiv) in benzene (25 mL) was stirred overnight at
80.degree. C. under nitrogen. After concentration under reduced
pressure, the residue was purified using a silica gel column
(eluting with EtOAc/petroleum ether (1:4 to 1:1)) to provide 71.2
(230 mg, 88%) as a yellow oil. MS: m/z 529 (M+H).sup.+.
[0727] Synthesis of Compound 71.3.
[0728] NH.sub.3 (gas) was bubbled through 10 mL of ethanol at
0.degree. C. for 30 min. Then a solution of 71.2 (230 mg, 0.44
mmol, 1.00 equiv) in ethanol was added and the reaction was stirred
overnight at room temperature. Upon completion of the reaction, the
solvents were evaporated under reduced pressure to give 71.3 (210
mg, 97%) as a yellow solid which was used directly without further
purification. MS: m/z 500 (M+H).sup.+.
[0729] Synthesis of Compound I-51.
[0730] A solution of 71.3 (210 mg, 0.42 mmol, 1.00 equiv) in
dichloromethane (10 mL) was cooled to 0.degree. C., hydrochloric
acid (12 M, 0.3 mL) was added and the resulting solution was
stirred for 1 h at room temperature. The solvent was removed under
vacuum to provide 180 mg (crude) of
2-cyano-3-[(3R)-12-[[4-(methylamino)cyclohexyl]oxy]-7-thia-9,11-diazatric-
yclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]propanamide
hydrochloride. This solid was dissolved in methanol (20 mL) and
formaldehyde (37%, 0.5 mL) was added. After stirring for 20 min.
NaBH.sub.3CN (100 mg, 1.59 mmol) was added and stirring was
continued for 1 h at room temperature. The reaction mixture was
diluted with EtOAc (150 mL) and washed with saturated aqueous
Na.sub.2CO.sub.3 and brine (100 mL). The organic layer was dried
over anhydrous Na.sub.2SO.sub.4. After filtration and
concentration, the residue was purified by preparative HPLC
(Waters) under the following conditions: column: Xbridge RP18,
19*150 mm 5 um; mobile phase: water (with 20 mM NH.sub.4HCO.sub.3)
and CH.sub.3CN (10.0% CH.sub.3CN and ramp up to 40.0% in 20 min, up
to 95.0% in 2 min, then down to 10.0% in 2 min); UV detection at
254 and 220 nm. After concentration and lyophilization in vacuo,
the desired racemic Compound I-51 (35 mg) was obtained as a white
solid. .sup.1H NMR (300 MHz, CD.sub.3OD): .delta. 7.48 (s, 1H);
5.36-5.28 (m, 1H); 3.62-3.54 (m, 1H); 3.18-3.06 (m, 2H); 2.79-2.72
(m, 2H); 2.68-2.28 (m, 11H); 2.17-2.06 (m, 2H); 1.90-1.72 (m, 3H);
1.56-1.47 (m, 2H). MS: m/z 414 (M+H).sup.+.
Example 72
Synthesis of
4-(((1s,4s)-4-(dimethylamino)cyclohexyl)amino)-6,7-dihydro-5H-cyclopenta[-
4,5]thieno[2,3-d]pyrimidine-5-carboxylic acid (I-5)
##STR00431##
[0732] A 50-mL round-bottom flask was charged with 2.1 (2 g, 5.04
mmol, 1.00 equiv, 98%) in methanol (15 mL) and sodium hydroxide
(310 mg, 7.59 mmol, 1.51 equiv). The resulting solution was stirred
for 5 hours at 50.degree. C. in an oil bath. The resulting mixture
was concentrated under vacuum. The residue was dissolved in 20 mL
of sodium hydroxide (aq., 10%). The resulting solution was
extracted with 3.times.20 mL of ethyl acetate and the aqueous
layers combined. The pH value of the aqueous layer was adjusted to
3 with hydrogen chloride (aq., 10%). The resulting mixture was
concentrated under vacuum to afford 4.5 g (74%) Compound I-5 as a
yellow solid.
Example 73
Synthesis of
12-[[4-(dimethylamino)cyclohexyl]amino]-N-(2-hydroxyethyl)-N-methyl-7-thi-
a-9,11-diazatricyclo[6.4.0.0
[2,6]]dodeca-1(12),2(6),8,10-tetraene-3-carboxamide (I-29)
##STR00432##
[0734] Synthesis of Compound 73.2.
[0735] A 100-mL 3-necked round-bottom flask was charged with
2-(methylamino)ethan-1-ol (5 g, 65.24 mmol, 1.00 equiv, 98%) in
dichloromethane (80 mL) and TEA (21 g, 203.76 mmol, 3.12 equiv,
98%). This was followed by the addition of
tert-butyl(chloro)dimethylsilane (15 g, 97.53 mmol, 1.49 equiv) at
0.degree. C. The resulting solution was stirred for 3 h at room
temperature. The reaction was then quenched by the addition of 200
mL of water and ice mixture. The resulting solution was extracted
with 3.times.100 mL of dichloromethane and the organic layers
combined. The resulting mixture was washed with 2.times.50 mL of
water. The mixture was dried over anhydrous sodium sulfate and
concentrated under vacuum to afford 3 g (24%) of amine 73.2 as a
green liquid.
[0736] Synthesis of Compound 73.3.
[0737] A 20-mL round-bottom flask was charged with a solution of
I-5 (600 mg, 0.50 mmol, 1.00 equiv, 30%) in N,N-dimethylformamide
(5 mL), 2-[(tert-butyldimethylsilyl)oxy]ethyl(methyl)amine (100 mg,
0.53 mmol, 1.06 equiv), EDCI (260 mg, 1.33 mmol, 2.66 equiv, 98%),
HOBt (90 mg, 0.65 mmol, 1.31 equiv, 98%), and triethylamine (130
mg, 1.26 mmol, 2.52 equiv, 98%). The resulting solution was stirred
for 2 h at room temperature. The reaction was then quenched by the
addition of 20 mL of water. The resulting solution was extracted
with 4.times.20 mL of ethyl acetate and the organic layers
combined. The combined organic layers were washed with 2.times.20
mL of water. The mixture was dried over anhydrous sodium sulfate
and concentrated under vacuum. The residue was loaded onto a silica
gel column with dichloromethane/methanol (5:1) and purified to
afford 180 mg (68%) of amide 73.3 as a yellow oil.
[0738] Synthesis of Compound I-29.
[0739] A 10-mL round-bottom flask was charged with a solution of
73.3 (600 mg, 1.11 mmol, 1.00 equiv, 98%) in acetonitrile (5 mL)
and HF (40 wt % in water, 0.25 mL). The resulting solution was
stirred for 2 h at room temperature. The reaction was then quenched
by the addition of 2 mL of saturated aqueous sodium carbonate. The
resulting mixture was concentrated under vacuum and purified by
flash preparative HPLC to afford 63.4 mg (13%) of Compound I-29 as
a white solid. .sup.1H NMR (300 MHz, CDCl.sub.3): .delta. 8.33 (s,
1H), 5.58-5.70 (m, 1H), 3.98-3.80 (m, 1H), 4.00-4.01 (d, J=3 Hz,
1H), 3.72-3.89 (m, 2H), 3.08-3.58 (m, 2H), 2.87-3.31 (m, 3H),
2.44-2.56 (m, 1H), 2.24-2.31 (d, J=21 Hz, 6H), 2.16-2.19 (d, J=9
Hz, 2H), 1.91 (s, 2H), 1.74 (s, 4H), 1.36-1.44 (m, 2H), 1.15-1.25
(m, 2H). MS: m/z 418 (M+H).sup.+.
Example 74
Synthesis of
12-[[4-(dimethylamino)cyclohexyl]amino]-N-(2-hydroxyethyl)-7-thia-9,11-di-
azatricyclo[6.4.0.0
[2,6]]dodeca-1(12),2(6),8,10-tetraene-3-carboxamide (I-17)
##STR00433##
[0741] Synthesis of Compound 74.1.
[0742] A 10-mL round-bottom flask was charged with a solution of
I-5 (600 mg, 0.50 mmol, 1.00 equiv, 30%) in N,N-dimethylformamide
(7 mL), (2-aminoethoxy)(tert-butyl)dimethylsilane (100 mg, 0.57
mmol, 1.14 equiv), EDCI (260 mg, 1.33 mmol, 2.67 equiv, 98%), HOBt
(90 mg, 0.65 mmol, 1.31 equiv, 98%), and triethylamine (130 mg,
1.26 mmol, 2.53 equiv, 98%). The resulting solution was stirred for
9 h at room temperature. The reaction was then quenched by the
addition of 30 mL of water. The resulting solution was extracted
with 3.times.30 mL of ethyl acetate and the organic layers
combined. The resulting mixture was washed with 2.times.20 mL of
water. The mixture was dried over anhydrous sodium sulfate and
concentrated under vacuum to afford 105 mg (41%) of 74.1 as a
yellow oil.
[0743] Synthesis of Compound I-17.
[0744] A 10-mL round-bottom flask was charged with compound 74.1
(105 mg, 0.20 mmol, 1.00 equiv, 98%), acetonitrile (5 mL), and
hydrogen fluoride (40 wt % in water, 0.25 mL). The resulting
solution was stirred for 2 h at room temperature. The reaction was
then quenched by the addition of 0.5 mL of saturated sodium
carbonate aqueous. The resulting mixture was concentrated under
vacuum. The residue was dissolved in 5 mL of DMF and purified by
flash preparative HPLC to give 52.6 mg (65%) of Compound I-17 as a
white solid. .sup.1H NMR (400 MHz, CDCl.sub.3): .delta. 8.38 (s,
1H), 7.02 (s, 1H), 6.34 (s, 1H), 4.17-4.20 (d, 1H), 4.07-4.09 (m,
1H), 3.72-3.74 (d, 2H), 3.50-3.53 (t, 1H), 3.38-3.42 (m, 1H),
3.22-3.28 (m, 1H), 3.06-3.12 (m, 1H), 2.91-2.94 (t, 1H), 2.64-2.70
(t, 1H), 2.51 (s, 4H), 2.24-2.29 (t, 2H), 2.02-2.15 (m, 2H),
1.37-1.66 (m, 6H), 1.28-1.34 (t, 2H). MS: m/z 404 (M+H).sup.+.
Example 75
Synthesis of
12-[[4-(dimethylamino)cyclohexyl]amino]-N-(pyridin-3-ylmethyl)-7-thia-9,1-
1-diazatricyclo[6.4.0.0
[2,6]]dodeca-1(12),2(6),8,10-tetraene-3-carboxamide (I-25)
##STR00434##
[0746] A 10-mL round-bottom flask was charged with I-5 (700 mg,
0.58 mmol, 1.00 equiv, 30%), N,N-dimethylformamide (5 mL),
pyridin-3-ylmethanamine (75.6 mg, 0.69 mmol, 1.18 equiv), EDCI (335
mg, 1.72 mmol, 2.95 equiv, 98%), HOBt (119 mg, 0.86 mmol, 1.48
equiv, 98%), and TEA (177 mg, 1.72 mmol, 2.95 equiv, 98%). The
resulting solution was stirred overnight at room temperature. The
reaction was then quenched by the addition of 20 mL of water. The
resulting solution was extracted with 3.times.20 mL of ethyl
acetate and the organic layers combined. The resulting mixture was
washed with 2.times.20 mL of water. The mixture was dried over
anhydrous sodium sulfate and concentrated under vacuum. The residue
was purified by flash preparative HPLC to give 5.2 mg (2%) of
Compound I-25 as an off-white solid. .sup.1H NMR (300 MHz,
CDCl.sub.3): .delta. 8.52 (s, 1H), 8.48 (s, 1H), 8.36 (s, 1H),
7.46-7.48 (d, J=6, 1H), 7.21-7.26 (t, J=3, 1H), 6.97 (s, 1H), 6.11
(s, 1H), 4.50-4.57 (m, 1H), 4.33-4.39 (m, 1H), 4.20-4.23 (d, J=9,
1H), 4.04-4.07 (t, J=3, 1H), 2.98-3.17 (m, 2H), 2.88-2.95 (m, 2H),
2.57-2.64 (t, J=6, 6H), 2.33 (s, 1H), 2.17-2.21 (d, J=12, 3H),
1.45-1.57 (m, 1H), 1.25-1.40 (m, 4H). MS: m/z 451 (M+H).sup.+.
Example 76
12-[[4-(dimethylamino)cyclohexyl]amino]-N-(3-hydroxypropyl)-7-thia-9,11-di-
azatricyclo[6.4.0.0
[2,6]]dodeca-1(12),2(6),8,10-tetraene-3-carboxamide (I-28)
##STR00435##
[0748] Synthesis of Compound 76.1.
[0749] A 10-mL round-bottom flask was charged with a solution of
intermediate I-5 (1 g, 0.83 mmol, 1.00 equiv, 30%) in
N,N-dimethylformamide (7 mL),
(3-aminopropoxy)(tert-butyl)dimethylsilane (190 mg, 0.98 mmol, 1.18
equiv), EDCI (478 mg, 2.45 mmol, 2.95 equiv, 98%), HOBt (169 mg,
1.23 mmol, 1.47 equiv, 98%), and TEA (253 mg, 2.45 mmol, 2.95
equiv, 98%). The resulting solution was stirred overnight at room
temperature. The reaction was then quenched by the addition of 30
mL of water. The resulting solution was extracted with 3.times.30
mL of ethyl acetate and the organic layers combined. The resulting
mixture was washed with 2.times.20 mL of water. The mixture was
dried over anhydrous sodium sulfate and concentrated under vacuum
to afford 200 mg (45%) of amide 76.1 as a yellow green oil.
[0750] Synthesis of Compound I-28.
[0751] A 10-mL round-bottom flask was charged with a solution of
amide 76.1 (200 mg, 0.30 mmol, 1.00 equiv, 80%) in acetonitrile (5
mL) and HF (40 wt % in water, 0.25 mL). The resulting solution was
stirred for 3 h at room temperature. The reaction was then quenched
by the addition of 2 mL of saturated aqueous sodium carbonate. The
resulting mixture was concentrated under vacuum. The residue was
purified by flash preparative HPLC to give 12.8 mg (10%) of
Compound I-28 as a light yellow solid. .sup.1H NMR (400 MHz,
CDCl.sub.3): .delta. 8.37 (s, 1H), 7.17 (s, 1H), 6.53 (s, 1H),
4.14-4.16 (d, 1H), 4.06-4.10 (m, 1H), 3.67-3.70 (t, 2H), 3.67-3.68
(d, 1H), 3.41-3.46 (m, 1H), 3.15-3.22 (m, 1H), 3.04-3.10 (m, 1H),
2.85-2.91 (m, 1H), 2.61-2.66 (m, 1H), 2.44-2.53 (d, 6H), 2.29-2.44
(d, 2H), 2.04-2.26 (d, 2H), 1.72 (s, 2H), 1.42-1.58 (m, 4H), 1.26
(s, 2H). MS: m/z 418 (M+H).sup.+.
Example 77
Synthesis of
N-benzyl-12-[[4-(dimethylamino)cyclohexyl]amino]-7-thia-9,11-diazatricycl-
o[6.4.0.0 [2,6]]dodeca-1(12),2(6),8,10-tetraene-3-carboxamide
(I-24)
##STR00436##
[0753] A 10-mL round-bottom flask was charged with I-5 (700 mg,
0.58 mmol, 1.00 equiv, 30%) in N,N-dimethylformamide (5 mL),
phenylmethanamine (75.1 mg, 0.69 mmol, 1.18 equiv), EDCI (335 mg,
1.72 mmol, 2.95 equiv, 98%), HOBt (119 mg, 0.86 mmol, 1.48 equiv,
98%), TEA (177 mg, 1.72 mmol, 2.95 equiv, 98%). The resulting
solution was stirred overnight at room temperature. The reaction
was then quenched by the addition of 20 mL of water. The resulting
solution was extracted with 3.times.15 mL of ethyl acetate and the
organic layers combined. The resulting mixture was washed with
2.times.15 mL of water. The resulting mixture was dried and
concentrated under vacuum. The residue was purified by flash
preparative HPLC to give 40 mg (15%) of Compound I-24 as a white
solid. .sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 8.38 (1H, s),
7.11-7.13 (1H, d, J=6 Hz), 5.85 (1H, s), 4.45-4.50 (1H, m),
4.34-4.39 (1H, t, J=6 Hz), 4.18-4.22 (1H, d, J=12 Hz), 4.01-4.04
(1H, d, J=9 Hz), 3.08-3.16 (2H, m), 2.88-2.96 (1H, m), 2.60-2.65
(1H, m), 2.37-2.58 (6H, m), 2.24-2.37 (1H, m), 2.14-2.22 (1H, m),
2.06-2.14 (2H, t, J=12 Hz), 1.36-1.48 (1H, m), 1.22-1.29 (5H, m).
MS: m/z 450 (M+H).sup.+.
Example 78
Synthesis of ethyl
4-(((1r,4r)-4-aminocyclohexyl)amino)-6,7-dihydro-5H-cyclopenta[4,5]thieno-
[2,3-d]pyrimidine-5-carboxylate (I-2)
##STR00437##
[0755] A mixture of intermediate 1.4 (2.8 g, 10 mmol, 1 equiv), TEA
(5 g, 50 mmol, 5 equiv) and (1r,4r)-cyclohexane-1,4-diamine (5.7 g,
50 mmol, 5 equiv) in CH.sub.3CN (30 mL) was heated at 45.degree. C.
for 24 h. The solvent was removed under vacuum and the residue was
purified by column chromatography to afford 3 g (83%) of I-2.
.sup.1H NMR (500 MHz, CDCl.sub.3) .delta. 8.36 (1H, s), 6.59 (1H,
d), 4.23-4.09 (4H, m), 3.25-3.22 (1H, m), 3.00-2.87 (2H, m),
2.80-2.78 (1H, m), 2.65-2.61 (1H, m), 2.22-1.87 (6H, m), 1.44 (4H,
m), 1.34 (3H, t). MS: m/z 361 (M+H).sup.+.
Example 79
Synthesis of Intermediate 79.4
##STR00438##
[0757] Synthesis of Compound 79.1.
[0758] 2,2-dimethylcyclopentanone (5 g, 44.6 mmol, 1 equiv) was
dissolved in toluene (100 mL). Then ethyl 2-cyanoacetate (5.04 g,
44.6 mmol, 1 equiv), ammonium acetate (2.4 g, 31.2 mmol, 0.7 equiv)
and acetic acid (2.8 mL) were added in the mixture at room
temperature. The mixture was refluxed for 20 hours. 10% NaCl
solution (100 mL) was added. The organic layer was washed with
water (50 mL) and brine (50 mL), dried with sodium sulfate and
filtered. The organic layer was concentrated and the residue was
purified by column chromatography to give 79.1 (2.47 g, 32%) as a
colorless oil. MS: m/z 208 (M+H).sup.+.
[0759] Synthesis of Compound 79.2.
[0760] Diethylamine (433 mg, 5.93 mmol, 0.5 equiv) was slowly added
to a solution of 79.1 (2.47 g, 11.87 mmol, 1 equiv) and sulfur (418
mg, 13.06 mmol, 1.1 equiv) in ethanol (120 mL) at 50.degree. C. The
reaction was stirred for 2 hours at 50.degree. C. The mixture was
filtered and the filtrate concentrated. The residue was purified by
column chromatography (hexane:ethyl acetate=20:1) to give 79.2
(2.34 g, 83%) as a yellow solid. MS: m/z 240 (M+H).sup.+.
[0761] Synthesis of Compound 79.3.
[0762] 79.2 (2.3 g, 9.9 mmol, 1 equiv) was dissolved in formamide
(12 mL). The reaction was stirred for 1 hour at 180.degree. C. Then
water (50 mL) was added and the product extracted with ethyl
acetate (50 mL.times.3). The combined organic layers were washed
with water (100 mL.times.2) and brine (100 mL), dried with sodium
sulfate and filtered. The organic layer was concentrated and the
residue purified by column chromatography (hexane:ethyl
acetate=6:5) to give the desired product (1.57 g, 75%) as a yellow
solid. MS: m/z 221 (M+H).sup.+.
[0763] Synthesis of Compound 79.4.
[0764] 79.3 (1.5 g, 6.8 mmol, 1 equiv) was dissolved in phosphoryl
trichloride (40 mL). The reaction was stirred for 2 hours at
120.degree. C., whereupon it was slowly added to water (150 mL) and
extracted with ethyl acetate (60 mL.times.3). The combined organic
layers were washed with brine (100 mL) and dried with sodium
sulfate. The organic layer was concentrated and the residue
purified by column chromatography (hexane:ethyl acetate=20:1). The
desired product (1.3 g, 83%) was obtained as a yellow solid. MS:
m/z 239 (M+H).sup.+.
Example 80
Synthesis of
(1r,4r)-N1-(5,5-dimethyl-6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrim-
idin-4-yl)-N4,N4-dimethylcyclohexane-1,4-diamine (I-6)
##STR00439##
[0766] Synthesis of Compound 80.1.
[0767] Intermediate 79.4 (238 mg, 1 mmol, 1 equiv) and
trans-1,4-diaminocyclohexane (1.1 g, 10 mmol, 10 equiv) were
dissolved in acetonitrile (15 mL). Then triethylamine (1 g, 10
mmol, 10 equiv) was added to the mixture. The reaction was stirred
for 20 hours at 50.degree. C. It was then concentrated and the
residue was purified by reverse phase chromatography on a Biotage
instrument. The desired product (154 mg, 48%) was obtained as a
yellow solid. MS: m/z 317 (M+H).sup.+.
[0768] Synthesis of Compound I-6.
[0769] 80.1 (140 mg, 0.44 mmol, 1 equiv) was dissolved in methanol
(5 mL). 36% aq. formaldehyde (92 mg, 1.1 mmol, 2.5 equiv) and
acetic acid (133 mg, 2.2 mmol, 5 equiv) were added to the solution.
The mixture was stirred for 10 minutes at room temperature, and
then sodium cyanoborohydride (377 mg, 1.77 mmol, 4 equiv) was added
to the mixture. The reaction was stirred for 20 hours at room
temperature. It was then added to water (50 mL) slowly, and
extracted with ethyl acetate (50 mL.times.3). The organic layer was
washed with brine (100 mL), and dried with sodium sulfate. The
organic layer was concentrated and purified by preparative HPLC.
The desired product I-6 (31 mg, 20%) was obtained as a white solid.
.sup.1H NMR: (400 MHz, CDCl.sub.3) .delta. 8.36 (s, 1H), 5.04 (d,
1H), 4.17-2.24 (m, 1H), 3.22 (t, 1H), 2.97 (t, 2H), 2.78 (m, 6H),
2.40 (d, 2H), 2.33-2.37 (m, 4H), 1.73 (dd, 2H), 1.44 (s, 6H),
1.25-1.42 (m, 2H). MS: m/z 345 (M+H).sup.+.
Example 81
Synthesis of
(1r,4r)-4-((5,5-dimethyl-6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrim-
idin-4-yl)oxy)-N,N-dimethylcyclohexanamine (I-7)
##STR00440##
[0771] To a suspension of (1r,4r)-4-(dimethylamino)cyclohexanol
(600 mg, 4.2 mmol, 1 equiv) in THF (10 mL) was added compound 79.4
(250 mg, 1.05 mmol) and t-BuOK (235 mg, 2.1 mmol). The suspension
was heated to 80.degree. C. in a sealed tube for 1 h in a
microwave. The suspension was poured into water (10 mL) and then
extracted by EtOAc (10 mL.times.3). The residue was purified by
preparative HPLC to give a white solid product (30 mg, 10%).
.sup.1H NMR: (500 MHz, CDCl.sub.3) .delta. 8.52 (1H, s), 8.47 (1H,
2), 5.31-5.29 (1H, m), 3.04-2.99 (3H, m), 2.63 (6H, s), 2.44 (2H,
s), 2.33-2.30 (2H, t), 2.22 (2H, s), 1.68-1.64 (4H, m), 1.38 (6H,
s). MS: m/z 346 (M+H).sup.+.
Example 82
N-(2-amino-2-oxoethyl)-2-((R)-4-(((1r,4R)-4-(dimethylamino)cyclohexyl)oxy)-
-6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-5-yl)acetamide
(I-58)
##STR00441##
[0773] Synthesis of Compound 82.1.
[0774] Into a 50-mL round-bottom flask, a solution of
2-[(3R)-12-[(4-[[(tert-butoxy)carbonyl](methyl)amino]cyclohexyl)oxy]-7-th-
ia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]acet-
ic acid (270 mg, 0.58 mmol, 1.00 equiv) in 30 mL of distilled DMF
was added HATU (331 mg, 0.87 mmol, 1.50 equiv), DIEA (375 mg, 2.90
mmol, 5.00 equiv) and 2-aminoacetamide hydrochloride (128 mg, 1.16
mmol, 2.00 equiv) subsequently at room temperature under nitrogen.
The resulting solution was stirred for 1 h at room temperature.
After completion, the reaction was diluted with EtOAc, washed with
brine, dried over anhydrous sodium sulfate. After filtration and
concentration in vacuo, the residue was purified by a silica gel
column with DCM/MeOH (30:1-10:1) to provide 280 mg (92%) of
tert-butyl
N-(4-[[(3R)-3-[[(carbamoylmethyl)carbamoyl]methyl]-7-thia-9,11-diazatricy-
clo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)-N-met-
hylcarbamate as a yellow solid. MS: m/z 518 (M+H).sup.+.
[0775] Synthesis of Compound I-58.
[0776] HCl (gas) was introduced into DCM (50 mL) at 0.degree. C.
for 30 min with stirring. Then a solution of tert-butyl
N-(4-[[(3R)-3-[[(carbamoylmethyl)carbamoyl]methyl]-7-thia-9,11-diazatricy-
clo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)-N-met-
hylcarbamate (140 mg, 0.27 mmol, 1.00 equiv) in 5 mL of DCM was
added and the resulting solution was stirred overnight at room
temperature. The solvent was removed under vacuum to provide 120 mg
of
N-(carbamoylmethyl)-2-[(3R)-12-[[4-(methylamino)cyclohexyl]oxy]-7-thia-9,-
11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]acetamide
hydrochloride as a yellow solid. The solid was dissolved in
methanol (10 mL) and HCHO (37%, 0.5 mL) and acetic acid (0.5 mL)
were added at room temperature. After stirring for 20 min at room
temperature, NaBH.sub.3CN (100 mg) was added and the resulting
mixture was stirred for 1 h at ambient temperature. After
concentration in vacuo, the residue was purified by preparative
HPLC under the following conditions (Waters): column: X-briage C18,
19*150 mm 5 um; mobile phase: CH.sub.3CN and water with 20 mM
NH.sub.4HCO.sub.3 (10.0% CH.sub.3CN up to 50.0% in 10 min, up to
95% in 2 min, down to 10.0% in 2 min); flow rate: 20 mL/min; UV
detection at 254/220 nm. The product-containing fractions were
collected and partially evaporated to remove water and CH.sub.3CN
under reduced pressure. The residue was lyophilized overnight to
give the desired
N-(2-amino-2-oxoethyl)-2-((R)-4-(((1r,4R)-4-(dimethylamino)cyclohexyl)oxy-
)-6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-5-yl)acetamide
(154.3 mg, 71%) as a white solid. MS: m/z 432 [M+H].sup.+, 454
[M+Na].sup.+; .sup.1H NMR (400 MHz, CD.sub.3OD): .delta. 8.47 (1H,
s), 5.28-5.23 (1H, m), 3.89 (2H, s), 3.86-3.77 (1H, m), 3.15-2.99
(3H, m), 2.74-2.68 (1H, m), 2.44-2.34 (11H, m), 2.06-2.04 (2H, m),
1.73-1.58 (2H, m), 1.57-1.43 (2H, m).
Example 83
Synthesis of Intermediate 83.5 (2-amino-N-methylacetamide
hydrochloride)
##STR00442##
[0778] Synthesis of Compound 83.2.
[0779] Into a 250-mL round-bottom flask, a solution of methyl
2-aminoacetate hydrochloride (2.0 g, 15.93 mmol, 1.00 equiv) in 100
mL of anhydrous methanol was added CH.sub.3NH.sub.2 (2 M in THF,
35.7 mL) and the resulting solution was stirred for 48 h at room
temperature under nitrogen. After completion of the reaction, the
resulting mixture was concentrated under reduced pressure to afford
2-amino-N-methylacetamide hydrochloride (2.5 g, crude) as a
colorless oil containing large amounts of methylamine.
[0780] Synthesis of Compound 83.3.
[0781] Into a 50-mL round-bottom flask, a solution of
2-amino-N-methylacetamide hydrochloride (1.2 g, crude) and 4 M
aqueous sodium hydroxide (3 mL) in 10 mL of THF was added
Boc.sub.2O (900 mg) at 0.degree. C. and the resulting solution was
stirred for 2 h at room temperature. The resulting solution was
diluted with 20 mL of water and extracted with 3.times.50 mL of
ethyl acetate. The combined organic layers were washed with brine,
dried over anhydrous sodium sulfate and concentrated under vacuum.
The residue was applied onto a silica gel column with ethyl
acetate/petroleum ether (1:20 to 1:10) to afford the desired
tert-butyl N-[(methylcarbamoyl)methyl]carbamate (0.3 g, 31%) as a
colorless oil. .sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 6.51 (br
s, 1H), 5.43 (br s, 1H), 3.78 (d, 2H), 2.87-2.81 (d, 3H), 1.44 (s,
9H).
[0782] Synthesis of Intermediate 83.5.
[0783] A solution of tert-butyl
N-[(methylcarbamoyl)methyl]carbamate (300 mg, 1.59 mmol, 1.00
equiv) in DCM (5 mL) was added hydrochloric acid (1.2 mL) and
stirred for 4 h at room temperature. The resulting mixture was
concentrated under vacuum to afford the corresponding
2-amino-N-methylacetamide hydrochloride (185 mg) as a colorless
oil. MS: m/z 89 (M+H).sup.+. .sup.1H NMR (300 MHz, CDCl.sub.3):
.delta. 8.45 (br s, 1H), 8.19 (s, 3H), 3.50 (d, 2H), 2.65 (d,
3H).
Example 84
2-[2-[(3R)-12-[[4-(dimethylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo-
[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]acetamido]-N-methylacetam-
ide (I-61)
##STR00443##
[0785] Synthesis of Compound 84.1.
[0786] Note: For the preparation of the starting material compound
35.1, please see Example 35. A solution of
2-[(3R)-12-[(4-[[(tert-butoxy)carbonyl](methyl)amino]cyclohexyl)oxy]-7-th-
ia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]acet-
ic acid (150 mg, 0.32 mmol, 1.00 equiv), HATU (183 mg, 0.48 mmol,
1.48 equiv), DIPEA (165 mg) and 2-amino-N-methylacetamide
hydrochloride (intermediate 83.5, 120 mg, 0.96 mmol, 3.0 equiv) in
10 mL of anhydrous DMF was stirred for 24 h at room temperature
under nitrogen. After completion of the reaction, the resulting
solution was diluted with water and extracted with 3.times.40 mL of
ethyl acetate. The organic layers were combined, washed with brine,
dried (Na.sub.2SO.sub.4) and concentrated under vacuum. The residue
was applied onto a silica gel column with dichloromethane/methanol
(30:1) to afford tert-butyl
N-methyl-N-(4-[[(3R)-3-([[(methylcarbamoyl)methyl]carbamoyl]methyl)-7-thi-
a-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]-
cyclohexyl)carbamate (130 mg, 75%) as a yellow oil. MS: m/z 532
[M+H].sup.+.
[0787] Synthesis of Compound I-61.
[0788] A solution of tert-butyl
N-methyl-N-(4-[[(3R)-3-([[(methylcarbamoyl)methyl]carbamoyl]methyl)-7-thi-
a-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]-
cyclohexyl)carbamate (130 mg, 0.24 mmol, 1.00 equiv) in 5.5 mL of
dichloromethane was added concentrated hydrochloric acid (0.5 mL)
at 0.degree. C. under nitrogen. The resulting solution was stirred
for 2 h at 0.degree. C. in a water/ice bath and concentrated under
reduced pressure to afford N-methyl-2-[2-[(3R)-12-[[4-(methyl
amino)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),-
2(6),9,11-tetraen-3-yl]acetamido]acetamide hydrochloride (105 mg,
crude) as a yellow oil. MS: m/z 432 [M+H].sup.+.
[0789] A solution of
N-methyl-2-[2-[(3R)-12-[[4-(methylamino)cyclohexyl]oxy]-7-thia-9,11-diaza-
tricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]acetamido]acetami-
de hydrochloride (105 mg, 0.22 mmol, 1.00 equiv) in 5 mL of
methanol was added formaldehyde (37%, 1.0 mL) at room temperature
under nitrogen for 1 h. Then sodium cyanoborohydride (59 mg, 0.97
mmol, 4.32 equiv) was added and stirred overnight at ambient
temperature. The solvent was removed under reduced pressure and the
crude product (100 mg, crude) was purified by preparative HPLC
under the following conditions (SHIMADZU): column: SunFire Prep
C18, 19*150 mm 5 um; mobile phase: water with 0.05%
NH.sub.4CO.sub.3 and CH.sub.3CN (6.0% CH.sub.3CN up to 50.0% in 25
min); UV detection at 254/220 nm. The product containing fractions
were collected and evaporated to remove the water and CH.sub.3CN to
give
2-[2-[(3R)-12-[[4-(dimethylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricycl-
o[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]acetamido]-N-methylaceta-
mide (40 mg) as a white solid. MS: m/z 446 [M+H].sup.+. .sup.1H NMR
(300 MHz, CD.sub.3OD) .delta. 8.37 (s, 1H), 5.20-5.12 (m, 1H),
3.74-3.68 (m, 3H), 3.20-2.84 (m, 3H), 2.65-2.47 (m, 4H), 2.36-2.17
(m, 11H), 1.95 (d, 2H), 1.59-1.51 (m, 4H).
Example 85
(2R)-1-[(3R)-12-[[4-(dimethylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricyc-
lo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]propan-2-ol
(I-53) and Example 86
(2S)-1-[(3R)-12-[[4-(dimethylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricy-
clo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]propan-2-ol
(I-55)
##STR00444##
[0791] Synthesis of Compound 85.1.
[0792] Note: For the preparation of the starting material compound
26.3, see Example 26. Into a 50-mL 3-necked round-bottom flask,
purged and maintained with an inert atmosphere of nitrogen, was
placed a solution of tert-butyl
N-(4-[[(3R)-3-(2-oxoethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca--
1(8),2(6),9,11-tetraen-12-yl]amino]cyclohexyl)carbamate (250 mg,
0.58 mmol, 1.00 equiv) in freshly distilled tetrahydrofuran (10 mL)
at 0.degree. C. under nitrogen. The CH.sub.3MgBr (1.0 M in THF, 2.9
mL, 5.0 equiv) was added at 0.degree. C. via syringe. The resulting
solution was stirred for 2 h at 0.degree. C. and quenched with
saturated aqueous NH.sub.4Cl and extracted with 3.times.30 mL of
ethyl acetate. The combined organic layers were washed with brine
and dried over sodium sulfate and concentrated under reduced
pressure. The residue was applied onto a silica gel column with
ethyl acetate/petroleum ether (1:5) to give the desired racemic
tert-butyl
N-(4-[[(3R)-3-(2-hydroxypropyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]do-
deca-1(8),2(6),9,11-tetraen-12-yl]amino]cyclohexyl)carbamate (109
mg, 42%) as a colorless oil.
[0793] Synthesis of Compound I-53 and Compound I-55.
[0794] Into a 50-mL round-bottom flask containing tert-butyl
N-(4-[[(3R)-3-(2-hydroxypropyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]do-
deca-1(8),2(6),9,11-tetraen-12-yl]amino]cyclohexyl)carbamate (109
mg, 0.24 mmol, 1.00 equiv) in dichloromethane (10 mL) at 0.degree.
C. Then hydrochloric acid (12 M, 2.0 mL) was added and the
resulting solution was stirred for 3 h at room temperature. The
resulting mixture was concentrated under vacuum. The pH value of
the solution was adjusted to 8 with saturated aqueous sodium
carbonate and extracted with 2.times.40 mL of ethyl acetate. The
organic layers were combined and dried over sodium sulfate and
concentrated under vacuum to give the desired
1-[(3R)-12-[(4-aminocyclohexyl)amino]-7-thia-9,11-diazatricyclo[6.4.0.0[2-
,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]propan-2-ol (70 mg, crude)
as a colorless oil.
[0795] To a solution of
1-[(3R)-12-[(4-aminocyclohexyl)oxy]-7-thia-9,11-diazatricyclo[6.4.0.0[2,6-
]]dodeca-1(8),2(6),9,11-tetraen-3-yl]propan-2-ol (70 mg, crude) in
methanol (5 mL) was added HCHO (37%, 0.8 mL) and stirred for 1 h at
room temperature. Then NaBH.sub.3CN (29.7 mg, 0.47 mmol, 2.35
equiv) was added and the resulting solution was stirred for
additional 2 h at ambient temperature and concentrated under
vacuum. The crude product (80 mg) was purified by preparative HPLC
under the following conditions (SHIMADZU): column: SunFire Prep
C18, 19*150 mm 5 um; mobile phase: water with 0.05% HCOOH and
CH.sub.3CN (6.0% CH.sub.3CN up to 50.0% in 25 min); UV detection at
254/220 nm. The product containing fractions were collected and
evaporated to remove the water and CH.sub.3CN to give
(2R)-1-[(3R)-12-[[4-(dimethylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricy-
clo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]propan-2-ol
formate (12.9 mg) as a white solid and
(2S)-1-[(3R)-12-[[4-(dimethylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricy-
clo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]propan-2-ol
formate (5.6 mg) as a grey solid, respectively.
Example 85 (I-53)
[0796] MS: (ES, m/z): 375 (M+H).sup.+. .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta. 8.54 (1H, br s), 8.23 (1H, s), 4.18-4.19 (1H,
m), 3.70-3.76 (1H, m), 3.55-3.58 (1H, m), 3.05-3.33 (2H, m),
2.84-2.92 (7H, m), 2.68-2.75 (1H, m), 2.16-2.37 (5H, m), 1.55-1.78
(6H, m), 1.23 (3H, t).
Example 86 (I-55)
[0797] MS (ES): m/z 375 (M+H).sup.+. .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta. 8.55 (1H, br s), 8.23 (1H, s), 4.18-4.19 (1H,
m), 3.70-3.76 (1H, m), 3.55-3.58 (1H, m), 3.05-3.33 (2H, m),
2.84-2.92 (7H, m), 2.68-2.75 (1H, m), 2.16-2.37 (5H, m), 1.55-1.78
(6H, m), 1.23 (3H, t).
Example 87
N,N-dimethyl-4-[[(3S)-3-[2-(1,3-oxazol-2-yl)ethyl]-7-thia-9,11-diazatricyc-
lo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexan-1-amine-
. (I-63)
##STR00445##
[0799] Synthesis of Compound 87.1.
[0800] Note: For the preparation of the starting material compound
47.1, see Example 47. A solution of iodine (244 mg), Ph.sub.3P (252
mg) and imidazole (143 mg, 2.10 mmol, 3.49 equiv) in dry
dichloromethane (20 mL) was stirred at 0.degree. C. for 30 min
under nitrogen. Then a solution of tert-butyl
N-(4-[[(3R)-3-[2-hydroxy-2-(1,3-oxazol-2-yl)ethyl]-7-thia-9,11-diazatricy-
clo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)-N-met-
hylcarbamate (310 mg, 0.60 mmol, 1.00 equiv) was added dropwise to
the reaction mixture and the resulting solution was stirred for 2.5
h at room temperature. The reaction was then quenched with
saturated aqueous NaHSO.sub.3 and extracted with 2.times.30 mL of
dichloromethane. The organic layers were combined and washed with
brine, dried over anhydrous sodium sulfate. After concentrated in
vacuo, the residue was applied onto a silica gel column with ethyl
acetate/petroleum ether (1:1) to give tert-butyl
N-(4-[[(3R)-3-[2-iodo-2-(1,3-oxazol-2-yl)ethyl]-7-thia-9,11-diazatricyclo-
[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)-N-methyl-
carbamate (230 mg, 61%) as a yellow solid. MS (ES): m/z 625
(M+H).sup.+.
[0801] Synthesis of Compound 87.2.
[0802] A 25-mL round-bottom flask containing a solution of
tert-butyl
N-(4-[[(3R)-3-[2-iodo-2-(1,3-oxazol-2-yl)ethyl]-7-thia-9,11-diazatricyclo-
[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)-N-methyl-
carbamate (150 mg, 0.24 mmol, 1.00 equiv) in a mixed methanol (5
mL) and tetrahydrofuran (5 mL) was added NaBH.sub.4 (40 mg, 1.08
mmol, 4.50 equiv) at 0.degree. C. The resulting solution was
stirred for 4 h at 0.degree. C. and concentrated under reduced
pressure. The residue was diluted with EtOAc and washed with brine,
dried over sodium sulfate and concentrated under vacuum. The
residue was applied onto a silica gel column with ethyl
acetate/petroleum ether (1:10 to 1:22) to afford the desired
tert-butyl
N-methyl-N-(4-[[(3S)-3-[2-(1,3-oxazol-2-yl)ethyl]-7-thia-9,11-diazatricyc-
lo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)carbama-
te (110 mg, 92%) as a yellow solid. MS (ES, m/z): 499
(M+H).sup.+
[0803] Synthesis of Compound I-63.
[0804] To a solution of tert-butyl
N-methyl-N-(4-[[(3S)-3-[2-(1,3-oxazol-2-yl)ethyl]-7-thia-9,11-diazatricyc-
lo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)carbama-
te (110 mg, 0.22 mmol, 1.00 equiv) in dichloromethane (5 mL) was
added hydrogen chloride (12 M, 1 mL) at 0.degree. C. and the
resulting mixture was stirred at room temperature for 2 h. The
reaction mixture was concentrated under reduced pressure and the
residue was neutralized with sodium hydroxide and extracted with
2.times.30 mL of dichloromethane. The combine organic layers were
concentrated in vacuo to give
N-methyl-4-[[(3S)-3-[2-(1,3-oxazol-2-yl)ethyl]-7-thia-9,11-diazatricyclo[-
6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexan-1-amine
(80 mg, crude) as a yellow oil.
[0805] To the crude product (80 mg) in methanol (5 mL) was added
HCHO (37%, 0.8 mL) and the reaction solution was stirred at room
temperature for 30 min. NaBH.sub.3CN (50 mg) was added and the
resulting solution was stirred for 12 h at ambient temperature. The
crude product (70 mg) was purified by preparative HPLC under the
following conditions (SHIMADZU): column: SunFire Prep C18, 19*150
mm 5 um; mobile phase: water with 0.05% NH.sub.4HCO.sub.3 and
CH.sub.3CN (7.0% CH.sub.3CN up to 63.0% in 14 min); UV detection at
254/220 nm. The product fractions was collected and evaporated
under reduced pressure to remove the solvents to give
N,N-dimethyl-4-[[(3S)-3-[2-(1,3-oxazol-2-yl)ethyl]-7-thia-9,11-diazatricy-
clo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexan-1-amin-
e (39 mg) as an off-white semi-solid. MS (ES, m/z): 413
(M+H).sup.+. .sup.1H NMR (300 MHz, CD.sub.3OD): .delta. 8.41 (1H,
s), 7.70 (1H, s), 6.96 (1H, s), 5.22 (1H, m), 3.42 (1H, m), 3.05
(2H, m), 2.77 (3H, m), 2.37 (11H, m), 2.05 (3H, m), 1.55 (4H,
m).
Example 88
(S)-1-((R)-4-(((1r,4R)-4-morpholinocyclohexyl)oxy)-6,7-dihydro-5H-cyclopen-
ta[4,5]thieno[2,3-d]pyrimidin-5-yl)butan-2-ol (I-64) and Example
89:
(R)-1-((R)-4-(((1r,4R)-4-morpholinocyclohexyl)oxy)-6,7-dihydro-5H-cyclope-
nt[4,5]thieno[2,3-d]pyrimidin-5-yl)butan-2-ol. (I-65)
##STR00446##
[0807] Synthesis of Compound 88.1.
[0808] Note: For the preparation of the starting material compound
29.2, please see Example 29. A solution of
2-[(3R)-12-[[4-(morpholin-4-yl)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo[-
6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]ethan-1-ol (190 mg,
0.47 mmol, 1.00 equiv) in 10 mL of dichloromethane was added
Dess-Martin periodinane at 0.degree. C. in a water/ice bath under
nitrogen. The resulting mixture was stirred for 2 h at room
temperature. After completion of the reaction, the mixture was then
diluted with saturated aqueous sodium bicarbonate and extracted
with 3.times.30 mL of ethyl acetate. The combined organic layers
were dried over sodium sulfate and concentrated under vacuum. The
residue was applied onto a silica gel column with ethyl
acetate/petroleum ether (1:5 to 1:1) to afford
2-[(3R)-12-[[4-(morpholin-4-yl)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo[-
6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]acetaldehyde (130
mg, 69%) as a colorless oil. MS (ES): m/z 402 [M+H].sup.+.
[0809] Synthesis of Compound I-64 and Compound I-65.
[0810] A solution of
[(3R)-12-[[4-(morpholin-4-yl)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo[6.-
4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]acetaldehyde (130 mg,
0.32 mmol, 1.00 equiv) in 5 mL of anhydrous THF was added
bromo(ethyl)magnesium (1 M in THF, 0.62 mL, 2.0 equiv) dropwise at
0.degree. C. under nitrogen. The resulting solution was stirred for
4 h at room temperature and then quenched by the addition of
saturated aqueous NH.sub.4Cl and extracted with 3.times.50 mL of
DCM/i-PrOH (3:1). The combined organic layers was dried over
anhydrous sodium sulfate and concentrated under vacuum. The crude
product (150 mg) was purified by preparative HPLC under the
following conditions (SHIMADZU): column: SunFire Prep C18, 19*150
mm 5 um; mobile phase: water with 0.05% NH.sub.4CO.sub.3 and
CH.sub.3CN (6.0% CH.sub.3CN up to 54.0% in 25 min); UV detection at
254/220 nm to afford
(S)-1-((R)-4-(((1r,4R)-4-morpholinocyclohexyl)oxy)-6,7-dihydro-5H-cyclope-
nta[4,5]thieno[2,3-d]pyrimidin-5-yl)butan-2-ol (11.8 mg) and
(R)-1-((R)-4-(((1
r,4R)-4-morpholinocyclohexyl)oxy)-6,7-dihydro-5H-cyclopenta[4,5]thieno[2,-
3-d]pyrimidin-5-yl)butan-2-ol (23.9 mg) as white solids.
Example 88 (I-64)
[0811] MS: 432 (M+H).sup.+. .sup.1H NMR (300 MHz, CDCl.sub.3)
.delta. 8.47 (s, 2H), 5.24-5.20 (m, 1H), 3.75-3.58 (m, 5H),
3.06-2.93 (m, 2H), 2.70-2.61 (m, 4H), 2.28-1.98 (m, 3H), 1.59-1.41
(m, 10H), 1.28-1.23 (m, 2H), 0.95-0.85 (m, 3H).
Example 89 (I-65)
[0812] MS: 432 (M+H).sup.+. .sup.1H NMR (300 MHz, CDCl.sub.3)
.delta. 8.47 (s, 2H), 5.25 (m, 1H), 3.71-3.39 (m, 6H), 3.04-2.90
(m, 2H), 2.67-2.55 (m, 5H), 2.34-2.22 (m, 4H), 2.01-1.81 (m, 3H),
1.64-1.39 (m, 7H), 0.94-0.92 (m, 3H).
Example 90
2-[(3R)-12-[[4-(morpholin-4-yl)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo[6-
.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-3-yl]ethan-1-ol.
(I-66)
##STR00447##
[0814] Synthesis of Compound 90.1.
[0815] Note: For the preparation of the starting material compound
25.1, see Example 25. Sodium hydride (60% dispersion in mineral
oil, 130 mg, 3.25 mmol, 4.00 equiv) was treated with
trans-4-(morpholin-4-yl)cyclohexan-1-ol (192 mg, 1.04 mmol, 1.27
equiv) in freshly distilled THF (15 mL) at 0.degree. C. under
nitrogen. After stirring for 30 min at room temperature, then
(3R)-3-[2-[(tert-butyldimethylsilyl)oxy]ethyl]-12-chloro-7-thia-9,11-diaz-
atricyclo[6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraene (300 mg,
0.81 mmol, 1.00 equiv) was added and the resulting solution was
allowed to react, with stirring, for an additional 2 hr at room
temperature. The reaction was then quenched with saturated aqueous
NH.sub.4Cl, extracted with 3.times.20 mL of ethyl acetate. The
combined organic layers were washed with brine, dried over sodium
sulfate and concentrated under vacuum. The residue was applied onto
a silica gel column with ethyl acetate/petroleum ether (1:8) to
provide
(3R)-3-[2-[(tert-butyldimethylsilyl)oxy]ethyl]-12-[[4-(morpholin-4-yl)cyc-
lohexyl]oxy]-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-
-tetraene (378 mg, 90%) as a yellow oil. MS (ES): m/z 518
[M+H].sup.+.
[0816] Synthesis of Compound I-66.
[0817] To
(3R)-3-[2-[(tert-butyldimethylsilyl)oxy]ethyl]-12-[[4-(morpholin-
-4-yl)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(12),-
2(6),8,10-tetraene (230 mg, 0.44 mmol, 1.00 equiv) dissolved in
methanol (10 mL) was added hydrochloric acid (12 M, 0.5 mL) slowly
at 0.degree. C. The resulting solution was stirred for 2 hr at room
temperature and then quenched with saturated aqueous sodium
bicarbonate, extracted with 3.times.50 mL of ethyl acetate. The
combined organic layers were concentrated under vacuum. The crude
product (200 mg) was purified by preparative HPLC under the
following conditions (SHIMADZU): column: SunFire Prep C18, 19*150
mm 5 um; mobile phase: water with 0.05% NH.sub.4HCO.sub.3 and
CH.sub.3CN (25% CH.sub.3CN up to 100% in 15 min); flow rate: 20
mL/min; UV detection at 254/220 nm. The product-containing
fractions were collected and partially evaporated to remove water
and CH.sub.3CN under reduced pressure. The residue was lyophilized
overnight to give
2-[(3R)-12-[[4-(morpholin-4-yl)cyclohexyl]oxy]-7-thia-9,11-diazat-
ricyclo[6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-3-yl]ethan-1-ol
(94 mg) as a white solid. MS (ES): m/z 404 [M+H].sup. +. .sup.1H
NMR (400 MHz, CD.sub.3OD): .delta. 8.48 (1H, s), 5.29 (1H, m) 3.76
(4H, m), 3.66 (3H, m), 3.10-2.95 (2H, m), 2.72 (5H, m), 2.69 (1H,
s), 2.41 (3H, m), 2.36 (1H, m), 2.15 (2H, m), 1.73-1.54 (5H,
m).
Example 91
2-[(3R)-12-[[4-(methylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo[6.4.-
0.0 [2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]acetamide (I-79)
[0818] Synthesis of Compound 91.1.
##STR00448##
[0819] Note: For the preparation of the starting material 35.1,
please see Example 35. Into a 50-mL round-bottom flask containing a
solution of
2-[(3R)-12-[(4-[[(tert-butoxy)carbonyl](methyl)amino]cyclohexyl)oxy]-7-th-
ia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]acet-
ic acid (220 mg, 0.48 mmol, 1.00 equiv) in 4 mL of distilled DMF
was added HOBT (96.6 mg), 4-dimethylaminopyridine (86.6 mg), EDCI
(136.7 mg) and NH.sub.4Cl (153.18 mg, 2.86 mmol, 6.01 equiv)
successively at room temperature under nitrogen. The resulting
solution was stirred for 14 hr at 25.degree. C. and diluted with
water, extracted with 3.times.50 mL of ethyl acetate. The combined
organic layers was washed with brine, dried over sodium sulfate and
concentrated under vacuum. The residue was applied onto a silica
gel column with ethyl acetate/petroleum ether (2:1) to give
tert-butyl
N-(4-[[(3R)-3-(carbamoylmethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]do-
deca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)-N-methylcarbamate
(176 mg, 80%) as a colorless oil. MS (ES): m/z 461 [M+H].sup.+.
[0820] Synthesis of Compound I-79.
[0821] Into a 50-mL round-bottom flask placed a solution of
tert-butyl
N-(4-[[(3R)-3-(carbamoylmethyl)-7-thia-9,11-diazatricyclo[6.4.0.0
[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)-N-methylcarbama-
te (170 mg, 0.37 mmol, 1.00 equiv) in dichloromethane (4 mL) was
added hydrochloric acid (12 M, 0.5 mL) at 0.degree. C. and the
resulting solution was stirred for 4 hr at 25.degree. C. The
reaction was then quenched with saturated aqueous sodium
bicarbonate, extracted with 3.times.50 mL of DCM. The organic
layers were combined and concentrated under vacuum. The crude
product (150 mg) was purified by preparative HPLC under the
following conditions (SHIMADZU): column: SunFire Prep C18, 19*150
mm 5 um; mobile phase: water with 100 mM NH.sub.4HCO.sub.3 and
CH.sub.3CN (6.0% CH.sub.3CN up to 60% in 20 min); flow rate: 20
mL/min; UV detection at 254/220 nm. The product-containing
fractions were collected and partially evaporated to remove water
and CH.sub.3CN under reduced pressure. The residue was lyophilized
overnight to give the desired
2-[(3R)-12-[[4-(methylamino)cyclohexyl]oxy]-7-thia-9,11-diazatric-
yclo[6.4.0.0 [2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]acetamide (83
mg, 62%) as a white solid. MS (ES): m/z 361 [M+H].sup.+. .sup.1H
NMR (300 MHz, CD.sub.3OD): .delta. 8.43 (1H, s), 5.28 (1H, m), 3.76
(1H, m), 3.00-3.28 (1H, m), 2.97-2.99 (2H, m), 2.66-2.73 (1H, m),
2.42-2.49 (1H, m), 2.36 (3H, s), 2.29-2.18 (4H, m), 2.00-2.03 (2H,
m), 1.65-1.57 (2H-m), 1.26-1.35 (2H, m).
Example 92
2-[(3R)-12-[(4-[methyl[2-oxo-2-(pyrrolidin-1-yl)ethyl]amino]cyclohexyl)oxy-
]-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-y-
l]acetamide (I-73)
##STR00449##
[0823] Synthesis of Compound I-73:
[0824] A solution of
2-[(3R)-12-[[4-(methylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo[6.4-
.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]acetamide (90 mg, 0.25
mmol, 1.00 equiv) in 8 mL of DMF was added
2-chloro-1-(pyrrolidin-1-yl)ethan-1-one (55 mg, 0.37 mmol, 1.50
equiv) and potassium carbonate (69 mg, 0.50 mmol, 2.00 equiv) and
the resulting solution was stirred overnight at room temperature.
The reaction was quenched with water and extracted with DCM. The
organic phase was washed with brine, dried over anhydrous sodium
sulfate and concentrated under vacuum. The crude product (80 mg)
was purified by preparative HPLC under the following conditions
(SHIMADZU): column: SunFire Prep C18, 19*150 mm 5 um; mobile phase:
water with 0.05% NH.sub.4HCO.sub.3 and CH.sub.3CN (6.0% CH.sub.3CN
up to 50.0% in 16 min); flow rate: 20 mL/min; UV detection at
254/220 nm. The product-containing fractions were collected and
partially evaporated to remove water and CH.sub.3CN under reduced
pressure. The residue was lyophilized overnight to give the desired
2-[(3R)-12-[(4-[methyl[2-oxo-2-(pyrrolidin-1-yl)ethyl]amino]cyclohexyl)ox-
y]-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3--
yl]acetamide (50 mg) as a white solid. LCMS (ES): m/z 472
[M+H].sup.+. .sup.1H NMR (300 MHz, CD.sub.3OD): .delta. 8.43 (1H,
s), 5.25-5.20 (1H, m), 3.85-3.69 (1H, m), 3.52 (2H, t), 3.42 (2H,
t), 3.37 (2H, s), 3.15-2.85 (2H, m), 2.73-2.58 (2H, m), 2.29-2.18
(7H, m), 1.96-1.79 (6H, m), 1.67-1.47 (4H, m).
Example 93
2-[[(3S)-12-[[4-(dimethylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo[6-
.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]methoxy]acetamide
(I-76)
##STR00450## ##STR00451##
[0826] Synthesis of Compound 93.1.
[0827] To a 50-mL round-bottom flask containing a solution of
tert-butyl N-(4-[[(3
S)-3-(hydroxymethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dod-
eca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)-N-methylcarbamate
(940 mg, 2.17 mmol, 1.00 equiv) in freshly distilled DMF (6 mL) was
added sodium hydride (60% dispersion in mineral oil, 347.3 mg)
slowly at 0.degree. C. under nitrogen. After the addition, the
reaction mixture was stirred at room temperature for 30 min. Then
1-[(2-iodoethoxy)methyl]-4-methoxybenzene (2.535 g, 8.68 mmol, 4.00
equiv) was added to the mixture and stirred for 14 hrs at ambient
temperature. The reaction was quenched slowly with saturated
aqueous NH.sub.4Cl and extracted with 3.times.100 mL of ethyl
acetate. The combined organic layers were washed with brine, dried
over sodium sulfate and concentrated in vacuo. The residue was
applied onto a silica gel column with ethyl acetate/petroleum ether
(1:5) to give tert-butyl
N-(4-[[(3S)-3-([2-[(4-methoxyphenyl)methoxy]ethoxy]methyl)-7-thia-9,11-di-
azatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexy-
l)-N-methylcarbamate (700 mg, 54%) as a colorless oil. MS: m/z 598
(M+H).sup.+.
[0828] Synthesis of Compound 93.2.
[0829] A solution of tert-butyl
N-(4-[[(3S)-3-([2-[(4-methoxyphenyl)methoxy]ethoxy]methyl)-7-thia-9,11-di-
azatricyclo[6.4.0.0
[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)-N-methylcarbama-
te (700 mg, 1.17 mmol, 1.00 equiv) in dichloromethane (10 mL)/water
(0.5 mL) was added DDQ (399 mg, 1.76 mmol, 1.50 equiv) and the
resulting solution was stirred for 14 hrs at 25.degree. C. under
nitrogen. The resulting solution was diluted with water and
extracted with 3.times.100 mL of ethyl acetate. The organic layers
were combined, washed with brine, dried over sodium sulfate and
concentrated in vacuo. The residue was applied onto a silica gel
column with ethyl acetate/petroleum ether (1:1) to give tert-butyl
N-(4-[[(3
S)-3-[(3-hydroxypropoxy)methyl]-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]do-
deca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)-N-methylcarbamate
(370 mg, 64%) as a colorless oil. MS: m/z 478 (M+H).sup.+.
[0830] Synthesis of Compound 93.3.
[0831] A 50-mL round-bottom flask was charged with a solution of
tert-butyl N-(4-[[(3
S)-3-[(3-hydroxypropoxy)methyl]-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]do-
deca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)-N-methylcarbamate
(370 mg, 0.75 mmol, 1.00 equiv) in 5 mL of DMF and PDC (1.656 g,
4.40 mmol, 5.85 equiv) was added at room temperature. The resulting
solution was stirred for 14 hrs at 25.degree. C. After completion,
the resulting solution was extracted with 3.times.50 mL of ethyl
acetate. The combined organic layers were washed with brine, dried
over sodium sulfate and concentrated in vacuo. The residue was
applied onto a silica gel column with ethyl acetate/petroleum ether
(1:2) to give
3-[[(3S)-12-[(4-[[(tert-butoxy)carbonyl](methyl)amino]cyclohexyl)oxy]-7-t-
hia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]met-
hoxy]propanoic acid (190 mg, 50%) as a colorless oil. MS: m/z 492
(M+H).sup.+.
[0832] Synthesis of Compound 93.4.
[0833] To a 50-mL round-bottom flask purged and maintained with an
inert atmosphere of nitrogen was added a solution of
2-[[(3S)-12-[(4-[[(tert-butoxy)carbonyl](methyl)amino]cyclohexyl)oxy]-7-t-
hia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-3-yl]me-
thoxy]acetic acid (120 mg, 0.24 mmol, 1.00 equiv), HOBT (49 mg,
0.36 mmol, 1.49 equiv), EDCI (70 mg, 0.37 mmol, 1.50 equiv),
4-dimethylaminopyridine (44 mg, 0.36 mmol, 1.48 equiv) and
NH.sub.4Cl (76 mg, 1.42 mmol, 5.82 equiv) in distilled DMF (5 mL)
at room temperature under nitrogen. The resulting solution was
stirred for 14 hrs at ambient temperature, quenched with water and
extracted with 3.times.50 mL of ethyl acetate. The combined organic
layers were washed with brine, dried over sodium sulfate and
concentrated under vacuum. The residue was applied onto a silica
gel column with ethyl acetate/petroleum ether (2:1) to afford the
desired tert-butyl
N-(4-[[(3S)-3-[(carbamoylmethoxy)methyl]-7-thia-9,11-diazatricyclo[6.4.0.-
0[2,6]]dodeca-1(12),2(6),8,10-tetraen-12-yl]oxy]cyclohexyl)-N-methylcarbam-
ate (75 mg, 63%) as a colorless oil. MS: m/z 491 (M+H).sup.+.
[0834] Synthesis of Compound I-76.
[0835] A solution of tert-butyl
N-(4-[[(3S)-3-[(carbamoylmethoxy)methyl]-7-thia-9,11-diazatricyclo[6.4.0.-
0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)-N-methylcarbama-
te (115 mg, 0.23 mmol, 1.00 equiv) in dichloromethane (4 mL) cooled
down to 0.degree. C. was added hydrochloric acid (12 M, 0.5 mL).
The resulting solution was stirred for 1 h at 0.degree. C. and
concentrated in vacuo to give
2-[[(3S)-12-[[4-(methylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricyc-
lo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]methoxy]acetamide
hydrochloride (100 mg, crude) as a light yellow solid. The crude
hydrochloride (100 mg) dissolved in methanol (3 mL) was added HCHO
(37%, 0.5 mL) and stirred for 1 h at 0.degree. C. Then NaBH.sub.3CN
(44.35 mg, 0.71 mmol) was added and the resulting solution was
stirred for 2 h at room temperature. The reaction mixture was
diluted with water, extracted with 3.times.20 mL of
chloroform/i-PrOH. The combined organic layers were concentrated
under vacuum. The crude product (80 mg) was purified by preparative
HPLC under the following conditions (SHIMADZU): column: SunFire
Prep C18, 19*150 mm 5 um; mobile phase: water with 0.05%
NH.sub.4HCO.sub.3 and CH.sub.3CN (6.0% CH.sub.3CN up to 53.0% in 13
min); flow rate: 20 mL/min; UV detection at 254/220 nm. The
product-containing fractions were collected and partially
evaporated to remove water and CH.sub.3CN under reduced pressure.
The residue was lyophilized overnight to give the desired
2-[[(3S)-12-[[4-(dimethylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo[-
6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]methoxy]acetamide
(35 mg) as a white solid. MS (ES): m/z 405 [M+H].sup.+. .sup.1H NMR
(300 MHz, CD.sub.3OD): .delta. 8.44 (1H, s), 5.28-5.21 (1H, m),
3.94-3.88 (3H, m), 3.61-3.56 (2H, m), 3.14-2.97 (2H, m), 2.67-2.54
(2H, m), 2.42-2.31 (10H, m), 2.02 (2H, d), 1.62-1.43 (4H, m).
Example 94
(2R)-3-[(3R)-12-[[4-(dimethylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricyc-
lo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]-2-methoxypropanamide
(I-77)
##STR00452## ##STR00453##
[0837] Synthesis of Compound 94.1.
[0838] Note: For the preparation of the starting material compound
43.1, see Example 43. Into a 50-mL round-bottom flask containing a
solution of tert-butyl
N-methyl-N-(4-[[(3R)-3-(2-oxoethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6-
]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)carbamate (460
mg, 1.03 mmol, 1.00 equiv) in methanol (15 mL) was added
trimethoxymethane (548 mg, 5.16 mmol, 5.00 equiv) and
4-methylbenzene-1-sulfonic acid (18 mg, 0.10 mmol, 0.10 equiv) at
room temperature under nitrogen. The reaction mixture was stirred
for 4 hr at ambient temperature. After completion, the reaction was
quenched with saturated aqueous NaHCO.sub.3 and extracted with
3.times.50 mL of ethyl acetate. The combined organic layers were
washed with brine, dried over anhydrous sodium sulfate and
concentrated under vacuum. The residue was purified on a silica gel
column with ethyl acetate/petroleum ether (1:8) to afford the
desired tert-butyl
N-(4-[[(3R)-3-(2,2-dimethoxyethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]-
]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)-N-methylcarbamate
(470 mg, 93%) as a colorless oil. LC-MS (ES): m/z 562
[M+H].sup.+.
[0839] Synthesis of Compound 94.2.
[0840] Into a 100-mL 3-necked round-bottom flask was placed a
solution of tert-butyl
N-(4-[[(3R)-3-(2,2-dimethoxyethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]-
]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)-N-methylcarbamate
(470 mg, 0.96 mmol, 1.00 equiv) in distilled DCM (15 mL). TMSCN
(474 mg) and BF.sub.3.Et.sub.2O (15 mg) were added via syringe
under nitrogen at 0.degree. C. The resulting solution was stirred
for 3 hr in a water/ice bath. After completion, the reaction was
quenched with saturated aqueous NaHCO.sub.3 and extracted with
3.times.50 mL of ethyl acetate. The combined organic layers were
washed with brine, dried over anhydrous sodium sulfate and
concentrated under vacuum to afford the desired
2-methoxy-3-[(3R)-12-[[4-(methylamino)cyclohexyl]oxy]-7-thia-9,11-diazatr-
icyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]propanenitrile
(400 mg, crude) as a yellow oil. MS (ES): m/z 387 [M+H].sup.+.
[0841] Synthesis of Compound 94.3.
[0842] Into a 50-mL round-bottom flask, a solution of
2-methoxy-3-[(3R)-12-[[4-(methylamino)cyclohexyl]oxy]-7-thia-9,11-diazatr-
icyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]propanenitrile
(400 mg, 1.03 mmol, 1.00 equiv) in dichloromethane (20 mL) was
added di-tert-butyl dicarbonate (500 mg, 2.29 mmol, 2.21 equiv) and
TEA (1.0 mL) and the resulting mixture was stirred for 3 hr at room
temperature. After completion, the resulting solution was diluted
with 20 mL of water and extracted with 3.times.50 mL of
dichloromethane. The combined organic layers were washed with
brine, dried over anhydrous sodium sulfate and concentrated under
vacuum. The residue was purified on a silica gel column with ethyl
acetate/petroleum ether (1:5) to afford the corresponding
tert-butyl
N-(4-[[(3R)-3-(2-cyano-2-methoxyethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[-
2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)-N-methylcarbamate
(360 mg, 71%) as a colorless oil. MS (ES): m/z 487 [M+H].sup.+
[0843] Synthesis of Compound 94.4.
[0844] A solution of tert-butyl
N-(4-[[(3R)-3-(2-cyano-2-methoxyethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[-
2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)-N-methylcarbamate
(360 mg, 0.74 mmol, 1.00 equiv) in methanol (10 mL) was added
H.sub.2O.sub.2(30%, 1 mL) and LiOH (36 mg, 1.50 mmol, 2.03 equiv)
in a water/ice bath and the resulting mixture was stirred for 2 h.
After completion, the reaction was quenched with saturated aqueous
NaHSO.sub.3 and extracted with 3.times.50 mL of ethyl acetate. The
combined organic layers were washed with brine, dried over
anhydrous sodium sulfate and concentrated under vacuum. The residue
was purified by preparative TLC (eluent with EtOAc/petroleum ether
1:1) to afford tert-butyl
N-(4-[[(3R)-3-[(2S)-2-carbamoyl-2-methoxyethyl]-7-thia-9,11-diazatricyclo-
[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)-N-methyl-
carbamate (100 mg) as a colorless oil and tert-butyl
N-(4-[[(3R)-3-[(2R)-2-carbamoyl-2-methoxyethyl]-7-thia-9,11-diazatricyclo-
[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)-N-methyl-
carbamate (140 mg) as a colorless oil, respectively. MS (ES): m/z
505 [M+H].sup.+
[0845] Synthesis of Compound I-77.
##STR00454##
[0846] Into a 25-mL round-bottom flask, a solution of tert-butyl
N-(4-[[(3R)-3-[(2R)-2-carbamoyl-2-methoxyethyl]-7-thia-9,11-diazatricyclo-
[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)-N-methyl-
carbamate (140 mg, 0.28 mmol, 1.00 equiv) in dichloromethane (10
mL) was added hydrochloric acid (2 M, 1.0 mL) at 0.degree. C. and
the resulting mixture was stirred at room temperature for 5 h.
After completion, the resulting mixture was concentrated under
vacuum to afford
(2R)-2-methoxy-3-[(3R)-12-[[4-(methylamino)cyclohexyl]oxy]-7-thia-9,11-di-
azatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]propanamide
hydrochloride (110 mg) as a light yellow solid. The residue
hydrochloride (110 mg) was dissolved in 5 mL of methanol, HCHO
(37%, 0.5 mL) was added and the solution stirred for 30 min at room
temperature. Then NaBH.sub.3CN (65 mg) was added and the resulting
solution was allowed to react, with stirring, for an additional 2
hr at ambient temperature. After completion, the resulting solution
was diluted with 20 mL of water, extracted with 3.times.50 mL of
DCM and concentrated under vacuum. The crude product (100 mg) was
purified by preparative HPLC under the following conditions
(SHIMADZU): column: SunFire Prep C18, 19*150 mm 5 um; mobile phase:
water with 0.1% HCOOH and CH.sub.3CN (6.0% CH.sub.3CN up to 75% in
20 min); flow rate: 20 mL/min; UV detection at 254/220 nm. The
product-containing fractions were collected and partially
evaporated to remove water and CH.sub.3CN under reduced pressure.
The residue was lyophilized overnight to give the desired
(2R)-3-[(3R)-12-[[4-(dimethylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricy-
clo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]-2-methoxypropanamide
formate (47.5 mg, 45%) as an off-white solid. MS (ES): m/z 419
[M-HCOOH+H].sup.+. .sup.1H NMR (300 MHz, CD.sub.3OD): .delta. 8.44
(m, 2H), 5.28 (s, 1H), 3.59-3.52 (m, 2H), 3.34-3.27 (m, 4H),
3.08-2.82 (m, 8H), 2.65-2.62 (m, 1H), 2.45-2.18 (m, 6H), 1.85-1.82
(m, 5H).
Example 95
(2S)-3-[(3R)-12-[[4-(dimethylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricyc-
lo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]-2-methoxypropanamide
(I-78)
##STR00455##
[0848] Synthesis of Compound I-78.
[0849] Note: For the preparation of the starting material compound
94.5, please see Example 94. A 25-mL round-bottom flask was charged
with a solution of tert-butyl
N-(4-[[(3R)-3-[(2S)-2-carbamoyl-2-methoxyethyl]-7-thia-9,11-diazatricyclo-
[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)-N-methyl-
carbamate (100 mg, 0.20 mmol, 1.00 equiv) in dichloromethane (10
mL). Hydrochloric acid (2 M, 0.8 mL) was added at 0.degree. C. and
the resulting mixture was stirred at room temperature for 5 h.
After completion, the resulting mixture was concentrated under
vacuum to afford
(2S)-2-methoxy-3-[(3R)-12-[[4-(methylamino)cyclohexyl]oxy]-7-thia-9,11-di-
azatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]propanamide
hydrochloride (90 mg) as a light yellow solid. The residue
hydrochloride (90 mg) dissolved in 5 mL of methanol was added HCHO
(37%, 0.5 mL) and stirred for 30 min at room temperature. Then
NaBH.sub.3CN (50 mg) was added and the resulting solution was
allowed to react, with stirring, for an additional 2 hr at ambient
temperature. After completion, the resulting solution was diluted
with 20 mL of water, extracted with 3.times.50 mL of DCM and
concentrated under vacuum. The crude product (90 mg) was purified
by preparative HPLC under the following conditions (SHIMADZU):
column: SunFire Prep C18, 19*150 mm 5 um; mobile phase: water with
0.1% HCOOH and CH.sub.3CN (6.0% CH.sub.3CN up to 75% in 20 min);
flow rate: 20 mL/min; UV detection at 254/220 nm. The
product-containing fractions were collected and partially
evaporated to remove water and CH.sub.3CN under reduced pressure.
The residue was lyophilized overnight to give the desired
(2S)-3-[(3R)-12-[[4-(dimethylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricy-
clo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]-2-methoxypropanamide
(31.3 mg, 40%) as an off-white semi-solid. MS (ES): m/z 419
[M-1.2HCOOH+H].sup.+. .sup.1H NMR (300 MHz, CD.sub.3OD): .delta.
8.44 (m, 2H), 5.30-5.27 (s, 1H), 3.67-3.63 (m, 1H), 3.46-3.27 (m,
5H), 3.08-2.84 (m, 8H), 2.72-2.66 (m, 1H), 2.48-2.17 (m, 6H),
1.83-1.28 (m, 5H).
Example 96
(2S)-2-methoxy-3-[(3R)-12-[[4-(methylamino)cyclohexyl]oxy]-7-thia-9,11-dia-
zatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]propanenitrile
(I-80) and
Example 97
(2R)-2-methoxy-3-[(3R)-12-[[4-(methylamino)cyclohexyl]oxy]-7-thia-9,11-dia-
zatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]propanenitrile
(I-81)
##STR00456##
[0851] Into a 50-mL round-bottom flask, a solution of tert-butyl
N-(4-[[(3R)-3-(2-cyano-2-methoxyethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[-
2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)-N-methylcarbamate
(100 mg, 0.21 mmol, 1.00 equiv) in dichloromethane (10 mL) was
added hydrochloric acid (12 M, 0.5 mL) in a water/ice bath and
stirred for 4 h. After completion and concentration in vacuo, the
residue was neutralised with saturated aqueous sodium bicarbonate,
extracted with 3.times.50 mL of DCM. The combined organic layers
were concentrated under vacuum and the crude product (80 mg) was
purified by preparative HPLC under the following conditions:
(SHIMADZU): column: Xbridge Prep C18 5 um, 19*150 mm; mobile phase:
water with 0.05% NH.sub.4HCO.sub.3 and CH.sub.3CN (6.0% CH.sub.3CN
up to 56.0% in 15 min); flow rate: 20 mL/min; UV detection at
254/220 nm. The product-containing fractions were collected and
partially evaporated to remove water and CH.sub.3CN under reduced
pressure. The residue was lyophilized overnight to give the
corresponding
(2S)-2-methoxy-3-[(3R)-12-[[4-(methylamino)cyclohexyl]oxy]-7-thia-9,11-di-
azatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]propanenitrile
(12.5 mg) as a off-white semi-solid and
(2R)-2-methoxy-3-[(3R)-12-[[4-(methylamino)cyclohexyl]oxy]-7-thia-9,11-di-
azatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]propanenitrile
(3.5 mg) as a light yellow semi-solid, respectively.
Example 96 (I-80)
[0852] MS (ES): m/z 387 [M+H].sup.+. .sup.1H NMR (300 MHz,
CD.sub.3OD): .delta. 8.44 (m, 1H), 5.32 (m, 1H), 3.44-3.09 (m, 6H),
2.57-2.23 (m, 11H), 2.12-1.90 (m, 1H), 1.72-1.63 (m, 3H), 1.33-1.25
(m, 5H), 0.95 (m, 1H).
Example 97 (I-81)
[0853] MS (ES): m/z 387 [M+H].sup.+. .sup.1H NMR (300 MHz,
CD.sub.3OD): .delta. 8.44 (m, 1H), 5.30 (m, 1H), 4.83-4.25 (m, 1H),
3.63-3.27 (m, 5H), 3.06-2.95 (m, 2H), 2.65-2.26 (m, 11H), 2.13-1.90
(m, 4H), 1.69-1.25 (m, 4H).
Example 98
Synthesis of
(R)-1-((R)-4-(((1r,4R)-4-morpholinocyclohexyl)oxy)-6,7-dihydro-5H-cyclope-
nta[4,5]thieno[2,3-d]pyrimidin-5-yl)propan-2-ol (I-82) and Example
99: Synthesis of (S)-1-((R)-4-(((1
r,4R)-4-morpholinocyclohexyl)oxy)-6,7-dihydro-5H-cyclopenta[4,5]thieno[2,-
3-d]pyrimidin-5-yl)propan-2-ol (I-83)
##STR00457## ##STR00458##
[0855] Synthesis of Compound 98.1.
[0856] Note: For the preparation of the starting material 25.1, see
Example 25. Into a 100-mL round-bottom flask purged and maintained
with an inert atmosphere of nitrogen, a solution of
trans-4-(morpholin-4-yl)cyclohexan-1-ol (528 mg, 2.85 mmol, 1.50
equiv) in freshly distilled THF (30 mL) was added sodium hydride
(304 mg, 7.60 mmol, 4.01 equiv, 60% dispersion in mineral oil)
portionwise at 0.degree. C. under nitrogen. The resulting mixture
was stirred for 30 min in a water/ice bath. Then a solution of
(3R)-3-[2-[(tert-butyldimethylsilyl)oxy]ethyl]-12-chloro-7-thia-9,11-diaz-
atricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraene (700 mg, 1.90
mmol, 1.00 equiv) in 5 mL of THF was added via syringe and the
resulting solution was allowed to react, with stirring, for an
additional 4 hr at 55.degree. C. in an oil bath. After completion,
the reaction was quenched by the addition of 20 mL of saturated
aqueous NH.sub.4Cl and extracted with 3.times.80 mL of ethyl
acetate. The combined organic layers were washed with brine, dried
over sodium sulfate and concentrated under vacuum. The residue was
purified on a silica gel column with ethyl acetate/petroleum ether
(1:5 to 1:0) to afford the desired
(3R)-3-[2-[(tert-butyldimethylsilyl)oxy]ethyl]-12-[[4-(morpholin-4-yl)cyc-
lohexyl]oxy]-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11--
tetraene (850 mg, 87%) as a colorless oil. MS (ES): m/z 518
[M+H].sup.+.
[0857] Synthesis of Compound 98.2.
[0858] To a solution of
(3R)-3-[2-[(tert-butyldimethylsilyl)oxy]ethyl]-12-[[4-(morpholin-4-yl)cyc-
lohexyl]oxy]-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11--
tetraene (850 mg, 1.64 mmol, 1.00 equiv) in methanol (20 mL) was
added hydrochloric acid (2 M, 1.0 mL) and the resulting mixture was
stirred for 1 hr at 0.degree. C. in a water/ice bath. After
completion, the reaction was quenched with sodium bicarbonate
(sat.) and extracted with 3.times.80 mL of ethyl acetate. The
combined organic layers were washed with brine, dried over sodium
sulfate and concentrated under vacuum. The residue was purified on
a silica gel column with chloroform/methanol (15:1) to afford
2-[(3R)-12-[[4-(morpholin-4-yl)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo[-
6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]ethan-1-ol (600 mg,
91%) as a colorless oil. MS (ES): m/z 404 [M+H].sup.+.
[0859] Synthesis of Compound 98.3.
[0860] A 50-mL round-bottom flask, purged and maintained with an
inert atmosphere of nitrogen, was charged with a dichloromethane
(15 mL) solution of
2-[(3R)-12-[[4-(morpholin-4-yl)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo[-
6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]ethan-1-ol (200 mg,
0.50 mmol, 1.00 equiv). Dess-Martin periodinane (318 mg, 0.75 mmol,
1.51 equiv) was added and the resulting mixture was stirred for 2
hr at 0.degree. C. in a water/ice bath. After completion, the
reaction was quenched with sodium bicarbonate (sat.) and extracted
with 3.times.60 mL of EtOAc. The combined organic layers were
washed with brine, dried over sodium sulfate and concentrated under
vacuum. The residue was purified on a silica gel column with ethyl
acetate/petroleum ether (1:1) to afford the corresponding
2-[(3R)-12-[[4-(morpholin-4-yl)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo[-
6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]acetaldehyde (150
mg, 75%) as a colorless oil. MS (ES): m/z 402 [M+H].sup.+.
[0861] Synthesis of I-82 and I-83.
[0862] A solution of
2-[(3R)-12-[[4-(morpholin-4-yl)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo[-
6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]acetaldehyde (150
mg, 0.37 mmol, 1.00 equiv) in 20 mL of distilled THF was cooled
down to 0.degree. C. under nitrogen. A solution of
bromo(methyl)magnesium (1 M in hexane, 0.74 mL, 2.00 equiv) was
added slowly via syringe and stirred for 3 hr in a water/ice bath.
After completion, the reaction was quenched with NH.sub.4Cl (sat.),
extracted with 3.times.80 mL of ethyl acetate. The combined organic
layers were concentrated under vacuum, the residue (200 mg) was
purified by preparative HPLC under the following conditions
(SHIMADZU): column: SunFire Prep C18, 19*150 mm 5 um; mobile phase:
water with 100 mM NH.sub.4HCO.sub.3 and CH.sub.3CN (6.0% CH.sub.3CN
up to 60% in 20 min); flow rate: 20 mL/min; UV detection at 254/220
nm. The product-containing fractions were collected and partially
evaporated to remove water and CH.sub.3CN under reduced pressure.
The residue was lyophilized overnight to give the desired product
(R)-1-((R)-4-(((1
r,4R)-4-morpholinocyclohexyl)oxy)-6,7-dihydro-5H-cyclopenta[4,5]thieno[2,-
3-d]pyrimidin-5-yl)propan-2-ol (32 mg) as a white solid and
(S)-1-((R)-4-(((1r,4R)-4-morpholinocyclohexyl)oxy)-6,7-dihydro-5H-cyclope-
nta[4,5]thieno[2,3-d]pyrimidin-5-yl)propan-2-ol (55.5 mg) as a
white solid.
Example 98 (I-82)
[0863] MS (ES): m/z 418 [M-0.88HCOOH+H].sup.+. .sup.1H NMR (300
MHz, CD.sub.3OD): .delta. 8.44 (s, 2H), 5.29-5.27 (m, 1H),
3.91-3.79 (m, 5H), 3.29-3.27 (m, 1H), 3.09-2.85 (m, 7H), 2.66-2.58
(m, 1H), 2.3.9-1.90 (m, 6H), 1.64-1.50 (m, 5H), 1.27-1.25 (m,
3H).
Example 99 (I-83)
[0864] MS (ES): m/z 418 [M-1.56HCOOH+H].sup.+. .sup.1H NMR (300
MHz, CD.sub.3OD): .delta. 8.42 (s, 2H), 5.29-5.26 (m, 1H),
3.90-3.83 (m, 5H), 3.56-3.51 (m, 1H), 3.32-3.27 (m, 1H), 3.04-2.88
(m, 7H), 2.68-2.61 (m, 1H), 2.40-2.90 (m, 6H), 1.75-1.15 (m,
8H).
Example 100
Synthesis of
3-((S)-4-(((1r,4S)-4-morpholinocyclohexyl)oxy)-6,7-dihydro-5H-cyclopenta[-
4,5]thieno[2,3-d]pyrimidin-5-yl)propanamide (I-84)
##STR00459##
[0866] Synthesis of Compound 100.1.
[0867] To a solution of
2-[(3R)-12-[[4-(morpholin-4-yl)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo[-
6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]ethan-1-ol (202 mg,
0.50 mmol, 1.00 equiv) in N,N-dimethylformamide (5 mL) was added
MsCl (86 mg, 0.75 mmol, 1.50 equiv) and triethylamine (153 mg, 1.51
mmol, 3.00 equiv) at 0.degree. C. under nitrogen. The resulting
solution was stirred for 2 h at room temperature and diluted with
DCM (80 mL), washed with brine, dried over anhydrous sodium sulfate
and concentrated under vacuum to give the desired
2-[(3R)-12-[[4-(morpholin-4-yl)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo[-
6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]ethyl
methanesulfonate (230 mg, 95%) as a white solid. MS (ES): m/z 482
[M+H].sup.+.
[0868] Synthesis of Compound 100.2.
[0869] Into a 50-mL round-bottom flask, purged and maintained with
an inert atmosphere of nitrogen, was placed a solution of
2-[(3R)-12-[[4-(morpholin-4-yl)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo[-
6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]ethyl
methanesulfonate (230 mg, 0.48 mmol, 1.00 equiv) in DMSO (5 mL) at
room temperature. Then NaCN (141 mg, 2.88 mmol, 6.00 equiv) and
4-dimethylaminopyridine (5.86 mg, 0.05 mmol, 0.10 equiv) were added
and the resulting solution was stirred for 2 h at 80.degree. C.
After cooling down to room temperature, the reaction was quenched
with brine, extracted with DCM. The organic phase was dried over
anhydrous sodium sulfate and concentrated under vacuum. The residue
was purified by column chromatography on silica gel with
EtOAc/petroleum ether (1:10 to 1:2) to afford the desired
3-[(3S)-12-[[4-(morpholin-4-yl)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo[-
6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]propanenitrile (170
mg, 86%) as a white solid. LCMS (ES): m/z 413 [M+H].sup.+.
[0870] Synthesis of I-84.
[0871] A solution of
3-[(3S)-12-[[4-(morpholin-4-yl)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo[-
6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]propanenitrile (170
mg, 0.41 mmol, 1.00 equiv) in methanol (5 mL) was added
LiOH.H.sub.2O (53 mg, 1.26 mmol, 3.00 equiv) at 0.degree. C. Then
H.sub.2O.sub.2(30%, 0.5 mL) was added via syringe at 0.degree. C.
The resulting solution was stirred for 2 h and quenched with
saturated aqueous Na.sub.2SO.sub.3, extracted with 3.times.30 mL of
dichloromethane. The combined organic layers were washed with
brine, dried over anhydrous sodium sulfate and concentrated under
vacuum. The residue was purified by preparative HPLC under the
following conditions (SHIMADZU): column: SunFire Prep C18, 19*150
mm 5 um; mobile phase: water with 0.05% NH.sub.4HCO.sub.3 and
CH.sub.3CN (25% CH.sub.3CN up to 100% in 25 min); flow rate: 20
mL/min; UV detection at 254/220 nm. The product-containing
fractions were collected and partially evaporated to remove water
and CH.sub.3CN under reduced pressure. The residue was lyophilized
overnight to give product
3-((S)-4-(((1r,4S)-4-morpholinocyclohexyl)oxy)-6,7-dihydro-5H-cyclopenta[-
4,5]thieno[2,3-d]pyrimidin-5-yl)propanamide formate (92.6 mg, 47%)
as a white solid. MS (ES): m/z 431 [M-0.83HCOOH+H].sup.+. .sup.1H
NMR (400 MHz, CD.sub.3OD) .delta. 8.48 (1H, s), 8.38 (1H, s),
5.33-5.25 (1H, m), 3.85 (4H, t), 3.50-3.41 (1H, m), 3.15-3.09 (1H,
m), 3.08-2.95 (5H, m), 2.93-2.85 (1H, m), 2.75-2.65 (1H, m),
2.50-2.35 (2H, m), 2.30-2.15 (6H, m), 1.95-1.82 (1H, m), 1.80-1.55
(4H, m).
Example 101
The Preparation of the Intermediate 101.5
##STR00460##
[0872] Example 102
Synthesis of
2-((R)-4-(((1r,4R)-4-(ethylamino)cyclohexyl)oxy)-6,7-dihydro-5H-cyclopent-
a[4,5]thieno[2,3-d]pyrimidin-5-yl)acetamide. (I-85)
##STR00461## ##STR00462##
[0874] Synthesis of Compound 102.1.
[0875] Note: For the preparation of the starting material compound
25.1, please refer to the experimental procedure for the synthesis
of compound Example 25. To a solution of tert-butyl
N-ethyl-N-(4-hydroxycyclohexyl)carbamate (intermediate 101.5,
322.68 mg, 1.33 mmol, 1.22 equiv) in distilled tetrahydrofuran (10
mL) was added sodium hydride (151.76 mg) slowly at 0.degree. C. and
the reaction mixture was stirred at room temperature for 30 min.
Then
(3R)-3-[2-[(tert-butyldimethylsilyl)oxy]ethyl]-12-chloro-7-thia-9,11-diaz-
atricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraene (400 mg, 1.08
mmol, 1.00 equiv) in THF (5 mL) was added to the mixture via
syringe and the resulting solution was stirred for 3 hr at ambient
temperature. The reaction was then quenched by the addition of 40
mL of saturated aqueous NH.sub.4Cl and extracted with 3.times.80 mL
of ethyl acetate. The combined organic layers were combined, washed
with brine, dried over sodium sulfate and concentrated under
vacuum. The residue was applied onto a silica gel column with ethyl
acetate/petroleum ether (1:5) to afford tert-butyl
N-(4-[[(3R)-3-[2-[(tert-butyldimethylsilyl)oxy]ethyl]-7-thia-9,11-diazatr-
icyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)-N--
ethylcarbamate (570 mg, 91%) as a colorless oil. MS (ES): m/z 576
[M+H].sup.+.
[0876] Synthesis of Compound 102.2.
[0877] Into a 50-mL round-bottom flask containing a solution of
tert-butyl
N-(4-[[(3R)-3-[2-[(tert-butyldimethylsilyl)oxy]ethyl]-7-thia-9,11-diazatr-
icyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)-N--
ethylcarbamate (570 mg, 0.99 mmol, 1.00 equiv) in THF (6 mL) was
added TBAF (522 mg, 2.00 mmol, 2.02 equiv) and the resulting
solution was stirred for 2 hrs at 25.degree. C. The reaction
mixture was concentrated under vacuum. The residue was applied onto
a silica gel column with ethyl acetate/petroleum ether (1:2) to
provide the desired tert-butyl
N-ethyl-N-(4-[[(3R)-3-(2-hydroxyethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[-
2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)carbamate
(450 mg, 98%) as a colorless oil. MS (ES): m/z 462 [M+H].sup.+.
[0878] Synthesis of Compound 102.3.
[0879] A solution of tert-butyl
N-ethyl-N-(4-[[(3R)-3-(2-hydroxyethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[-
2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)carbamate
(450 mg, 0.97 mmol, 1.00 equiv) and PDC (1791 mg, 4.76 mmol, 4.88
equiv) in 5 mL of DMF was stirred for 14 hrs at 25.degree. C. After
completion, the resulting solution was diluted with water and
extracted with 3.times.50 mL of ethyl acetate. The combined organic
layers were washed with 3.times.20 mL of brine, dried over sodium
sulfate and concentrated under vacuum. The residue was applied onto
a silica gel column with ethyl acetate/petroleum ether (2:1) to
give 310 mg (67%) of
2-[(3R)-12-[(4-[[(tert-butoxy)carbonyl](ethyl)amino]cyclohexyl)oxy]-7-thi-
a-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]aceti-
c acid as a colorless oil. MS (ES): m/z 476 [M+H].sup.+.
[0880] Synthesis of Compound 102.4.
[0881] A 50-mL round-bottom flask was charged with a solution of
2-[(3R)-12-[(4-[[(tert-butoxy)carbonyl](ethyl)amino]cyclohexyl)oxy]-7-thi-
a-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]aceti-
c acid (310 mg, 0.65 mmol, 1.00 equiv), HOBt (132 mg), EDCI (186.9
mg), 4-dimethylaminopyridine (118 mg) and NH.sub.4Cl (209 mg, 3.91
mmol, 5.99 equiv) in distilled DMF (6 mL). The solution was stirred
for 14 hrs at 25.degree. C. under nitrogen. The resulting solution
was diluted with water and extracted with 3.times.50 mL of ethyl
acetate. The combined organic layers were washed with 3.times.20 mL
of brine, dried over sodium and concentrated under vacuum. The
residue was applied onto a silica gel column with ethyl
acetate/petroleum ether (2:1) to afford tert-butyl
N-(4-[[(3R)-3-(carbamoylmethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]do-
deca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)-N-ethylcarbamate
(230 mg, 74%) as a colorless oil. MS (ES): m/z 475 [M+H]+.
[0882] Synthesis of Compound I-85.
[0883] To a solution of tert-butyl
N-(4-[[(3R)-3-(carbamoylmethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]do-
deca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)-N-ethylcarbamate
(230 mg, 0.48 mmol, 1.00 equiv) in dichloromethane (4 mL) was added
hydrochloric acid (12 M, 0.5 mL) at 0.degree. C. and the resulting
solution was stirred for 3 hr at 0.degree. C. The resulting mixture
was concentrated under vacuum. The crude product (180 mg) was
purified by preparative HPLC under the following conditions
(SHIMADZU): column: SunFire Prep C18, 19*150 mm 5 um; mobile phase:
water with 100 mM NH.sub.4HCO.sub.3 and CH.sub.3CN (6.0% CH.sub.3CN
up to 60% in 20 min); flow rate: 20 mL/min; UV detection at 254/220
nm. The product-containing fractions were collected and partially
evaporated to remove water and CH.sub.3CN under reduced pressure.
The residue was lyophilized overnight to give the desired
2-[(3R)-12-[[4-(ethylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo[6.4.-
0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]acetamide (114.4 mg,
63%) as a white solid. MS (ES): m/z 375 [M+H].sup.+. .sup.1H-NMR
(300 MHz, CD.sub.3OD): .delta. 8.47 (1H, s), 5.29 (1H, m), 4.82
(1H, m), 3.07-3.10 (1H, m), 2.93-2.99 (2H, m), 2.58-2.73 (4H, m),
2.23-2.23 (4H, m), 2.03-2.18 (2H, m), 1.66 (2H, m), 1.40-1.30 (2H,
m), 1.03-1.18 (3H, t).
Example 103
Synthesis of
2-cyano-3-((R)-4-(((1r,4R)-4-morpholinocyclohexyl)oxy)-6,7-dihydro-5H-cyc-
lopenta[4,5]thieno[2,3-d]pyrimidin-5-yl)propanamide (I-86)
##STR00463## ##STR00464##
[0885] Synthesis of Compound 103.1.
[0886] Note: For the preparation of the starting material compound
65.1, please refer to the experimental procedure for Example 65. To
a solution of trans-4-(morpholin-4-yl)cyclohexan-1-ol (277 mg, 1.50
mmol, 1.50 equiv) in distilled THF (20 mL) was added sodium hydride
(605 dispersion in mineral oil, 200 mg, 5.00 mmol, 5.00 equiv)
slowly at 0.degree. C. under nitrogen. After stirring for 30 min at
room temperature, a solution of
3-[[(tert-butyldimethylsilyl)oxy]methyl]-12-chloro-7-thia-9,11-diazatr-
icyclo[6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraene (355 mg, 1.00
mmol, 1.00 equiv) in 5 mL of THF was added dropwise and the
resulting solution was stirred for 6 h at ambient temperature. The
reaction was quenched with NH.sub.4Cl (sat.), extracted with EtOAc
(3.times.80 mL). The combined organic layers were washed with
brine, dried over anhydrous sodium sulfate. After filtration and
concentration in vacuo, the residue was purified by a silica gel
column with EtOAc/petroleum ether (1:1-3:1) to provide 350 mg (69%)
of the title
3-[[(tert-butyldimethylsilyl)oxy]methyl]-12-[[4-(morpholin-4-yl)cyclohexy-
l]oxy]-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetra-
ene as a light yellow oil. MS: (ES, m/z): 504 [M+H].sup.+.
[0887] Synthesis of compound 103.2.
[0888] To a solution of
3-[[(tert-butyldimethylsilyl)oxy]methyl]-12-[[4-(morpholin-4-yl)cyclohexy-
l]oxy]-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetra-
ene (350 mg, 0.69 mmol, 1.00 equiv) in methanol (30 mL) was added
hydrochloric acid (3 M in water, 1 mL) was added at 0.degree. C.
and the resulting solution was stirred for 1 h at room temperature.
The reaction was quenched with NaHCO.sub.3/brine and extracted with
EtOAc ((3.times.80 mL). The organic layers were combined and dried
over anhydrous sodium sulfate. After filtration and concentration
in vacuo, the residue was purified by a silica gel column with
DCM/MeOH(30:1-10:1) to provide 260 mg (96%) of
(12-[[4-(morpholin-4-yl)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo[6.4.0.0-
[2,6]]dodeca-1(12),2(6),8,10-tetraen-3-yl)methanol as a light
yellow semi-solid. MS (ES): m/z 390 [M+H].sup.+.
[0889] Synthesis of Compound 103.3.
[0890] A 20-mL round-bottom flask purged and maintained with an
inert atmosphere of nitrogen was charged with a solution of
(12-[[4-(morpholin-4-yl)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo[6.4.0.0-
[2,6]]dodeca-1(12),2(6),8,10-tetraen-3-yl)methanol (260 mg, 0.67
mmol, 1.00 equiv) in DCM (20 mL). Imidazole (91 mg, 1.34 mmol, 2.00
equiv) and PPh.sub.3 (264 mg, 1.01 mmol, 1.50 equiv) were added
successively, followed by the addition of I.sub.2 (255 mg, 1.00
mmol, 1.50 equiv) at room temperature. The resulting solution was
stirred overnight at ambient temperature and diluted with DCM and
washed with Na.sub.2SO.sub.3 (sat.) and brine. The organic layer
was dried over anhydrous sodium sulfate. After filtration and
concentration under reduced pressure, the residue was purified by a
silica gel column with EtOAc/petroleum ether (1:1-3:1) to provide
the desired
3-(iodomethyl)-12-[[4-(morpholin-4-yl)cyclohexyl]oxy]-7-thia-9,11-diazatr-
icyclo[6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraene (287 mg, 86%)
as a light yellow solid. MS (ES): m/z 500 [M+H].sup.+.
[0891] Synthesis of Compound 103.4.
[0892] A mixture of
(3S)-3-(iodomethyl)-12-[[4-(morpholin-4-yl)cyclohexyl]oxy]-7-thia-9,11-di-
azatricyclo[6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraene (287 mg,
0.57 mmol, 1.00 equiv), 18-Crown-6 (190 mg, 0.72 mmol, 1.25 equiv),
potassium carbonate (141 mg, 1.02 mmol, 1.78 equiv) and ethyl
2-cyanoacetate (678 mg, 5.99 mmol, 10.43 equiv) in benzene (20 mL)
was stirred overnight at 80.degree. C. under nitrogen. After
cooling to room temperature, the solvent was removed under vacuum
and the residue was purified by a silica gel column with
DCM/MeOH(30:1-10:1) to provide 230 mg (83%) of ethyl
2-cyano-3-[(3R)-12-[[4-(morpholin-4-yl)cyclohexyl]oxy]-7-thia-9,11-diazat-
ricyclo[6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-3-yl]propanoate
as a light yellow solid. MS (ES): m/z 485 [M+H].sup.+.
[0893] Synthesis of Compound I-86.
[0894] NH.sub.3 (gas) was introduced into ethanol (60 mL) at
0.degree. C. with stirring for 1 h. Ethyl
2-cyano-3-[(3R)-12-[[4-(morpholin-4-yl)cyclohexyl]oxy]-7-thia-9,11-diazat-
ricyclo[6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-3-yl]propanoate
(230 mg, 0.47 mmol, 1.00 equiv) was added and the resulting
solution was stirred overnight at room temperature. After
concentration in vacuo, the residue was purified by preparative
HPLC under the following conditions (Waters): column: Xbridge Prep
C18, 19*150 mm 5 um; mobile phase: water with 100 mM
NH.sub.4HCO.sub.3 and CH.sub.3CN (20.0% CH.sub.3CN up to 63.0% in
12 min); flow rate: 20 mL/min; UV detection at 254/220 nm. The
product-containing fractions were collected and partially
evaporated to remove water and CH.sub.3CN under reduced pressure.
The residue was lyophilized overnight to give the desired
2-cyano-3-((R)-4-(((1r,4R)-4-morpholinocyclohexyl)oxy)-6,7-dihydro-5H-cyc-
lopenta[4,5]thieno[2,3-d]pyrimidin-5-yl)propanamide (154.3 mg, 71%)
as a white solid. MS (ES): m/z 456 [M+H].sup.+. .sup.1H NMR (400
MHz, CD.sub.3OD): .delta. 8.48 (1H, s), 5.36-5.29 (1H, m), 3.73
(4H, t), 3.62-3.59 (1H, m), 3.39-3.33 (1H, m), 3.25-3.02 (2H, m),
2.82-2.59 (6H, m), 2.48-2.23 (4H, m), 2.18-2.06 (2H, m), 1.91-1.72
(3H, m), 1.55-1.43 (2H, m).
Example 104
Synthesis of
2-hydroxy-3-((R)-4-(((1r,4R)-4-morpholinocyclohexyl)oxy)-6,7-dihydro-5H-c-
yclopenta[4,5]thieno[2,3-d]pyrimidin-5-yl)propanamide (I-87)
##STR00465## ##STR00466##
[0896] Synthesis of Compound 104.1.
[0897] Note: The starting material compound 98.3, please see
Example 98. A solution of
2-[(3R)-12-[[4-(morpholin-4-yl)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo[-
6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]acetaldehyde (450
mg, 1.12 mmol, 1.00 equiv) in 10 mL of DCM was added
trimethylsilanecarbonitrile (333 mg, 3.36 mmol, 3.00 equiv) and TEA
(61 mg, 0.60 mmol, 0.54 equiv) at 0.degree. C. under nitrogen. The
resulting solution was stirred for 2 h in a water/ice bath. After
completion, the resulting solution was diluted with water and
extracted with 3.times.50 mL of DCM. The combined organic layers
were concentrated under reduced pressure. The desired
3-[(3R)-12-[[4-(morpholin-4-yl)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo[-
6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]-2-[(trimethylsilyl)oxy]pr-
opanenitrile (500 mg, with major removal of TMS compound) was
obtained as a yellow oil which was used directly in the next step.
The mixture (500 mg, crude) was dissolved in 10 mL of methanol and
hydrochloric acid (2 M, 0.5 mL) was added with cooling by a
water/ice bath. The solution was stirred for 2 h. After completion,
the reaction was quenched by the addition of 20 mL of saturated
sodium bicarbonate (aq.), extracted with 3.times.50 mL of ethyl
acetate. The combined organic layers were dried over anhydrous
sodium sulfate. After filtration and concentration under reduced
pressure, the residue was purified on a silica gel column with
dichloromethane/methanol (30:1) to afford the resulting
2-[(3R)-12-[[4-(morpholin-4-yl)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo[-
6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]ethan-1-ol (370 mg)
as a colorless oil. MS (ES): m/z 429 [M+H].sup.+.
[0898] Synthesis of Compound 104.2.
[0899] A 100-mL round-bottom flask was charged with a solution of
2-hydroxy-3-[(3R)-12-[[4-(morpholin-4-yl)cyclohexyl]oxy]-7-thia-9,11-diaz-
atricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]propanenitrile
(290 mg, 0.68 mmol, 1.00 equiv) in dichloromethane (10 mL). TBSCl
(153 mg, 1.02 mmol, 1.51 equiv), imidazole (92 mg, 1.35 mmol, 2.00
equiv) and 4-dimethylaminopyridine (17 mg, 0.14 mmol, 0.21 equiv)
were added successively at 0.degree. C. under nitrogen. The
resulting mixture was stirred overnight at room temperature. After
completion, the resulting solution was diluted with water,
extracted with 3.times.30 mL of dichloromethane, dried over sodium
sulfate and concentrated under vacuum. The residue was purified by
column chromatography on silica gel with ethyl acetate/petroleum
ether (1:1) to afford the desired
2-[(tert-butyldimethylsilyl)oxy]-3-[(3R)-12-[[4-(morpholin-4-yl)cyclohexy-
l]oxy]-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetrae-
n-3-yl]propanenitrile (350 mg, 95%) as a yellow oil. MS (ES): m/z
543 [M+H].sup.+.
[0900] Synthesis of Compound 104.3.
[0901] To a solution of
2-[(tert-butyldimethylsilyl)oxy]-3-[(3R)-12-[[4-(morpholin-4-yl)cyclohexy-
l]oxy]-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetrae-
n-3-yl]propanenitrile (300 mg, 0.55 mmol, 1.00 equiv) in methanol
(20 mL) was added LiOH.H.sub.2O (47 mg, 1.12 mmol, 3.55 equiv) and
H.sub.2O.sub.2(30%, 0.8 mL). The solution was stirred for 2 hr in a
water/ice bath. After completion, the reaction was quenched by the
addition of 30 mL of saturated aqueous Na.sub.2SO.sub.3 and
extracted with 3.times.50 mL of ethyl acetate. The combined organic
layers were dried over anhydrous sodium sulfate. After filtration
and concentration under reduced pressure, purification by column
chromatography on silica gel with dichloromethane/methanol (20:1)
afforded the
2-[(tert-butyldimethylsilyl)oxy]-3-[(3R)-12-[[4-(morpholin-4-yl)cyclohexy-
l]oxy]-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetrae-
n-3-yl]propanamide (197 mg, 64%) as a colorless oil. MS (ES): m/z
561 [M+H].sup.+.
[0902] Synthesis of Example I-87.
[0903] A 100-mL round-bottom flask was charged with a solution of
2-[(tert-butyldimethylsilyl)oxy]-3-[(3R)-12-[[4-(morpholin-4-yl)cyclohexy-
l]oxy]-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetrae-
n-3-yl]propanamide (197 mg, 0.35 mmol, 1.00 equiv) in methanol (10
mL). Hydrochloric acid (2 M, 0.8 mL) was added and stirring
continued for 2 hr in a water/ice bath. After completion, the
reaction was quenched with saturated aqueous sodium bicarbonate and
extracted with 3.times.30 mL of DCM. The organic phase was dried
over sodium sulfate and concentrated under vacuum. The residue was
purified by preparative TLC (DCM/MeOH:10/1) to afford the
2-hydroxy-3-[(3R)-12-[[4-(morpholin-4-yl)cyclohexyl]oxy]-7-thia-9,11-diaz-
atricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]propanamide
(124 mg, 79%) as a white solid. MS (ES): m/z 447 [M+H].sup.+.
.sup.1H NMR (400 MHz, CDCl.sub.3): .delta. 8.46 (s, 1H), 5.28-5.25
(m, 1H), 4.17-4.06 (m, 51H), 3.74-3.72 (m, 5H), 3.37-2.98 (m, 2H),
2.72-2.28 (m, 10H), 2.11-2.08 (m, 2H), 1.79-1.46 (m, 5H).
Example 105 and Example 106
Syntheses of
(1R)-2-((R)-4-(((1r,4R)-4-(dimethylamino)cyclohexyl)oxy)-6,7-dihydro-5H-c-
yclopenta[4,5]thieno[2,3-d]pyrimidin-5-yl)-1-(tetrahydrofuran-2-yl)ethanol
(I-88) and
(1S)-2-((R)-4-(((1r,4R)-4-(dimethylamino)cyclohexyl)oxy)-6,7-dihydro-5H-c-
yclopenta[4,5]thieno[2,3-d]pyrimidin-5-yl)-1-(tetrahydrofuran-2-yl)ethanol
(I-89)
##STR00467##
[0905] Synthesis of Compound 105.1.
[0906] For the preparation of the starting material compound 43.1,
please refer to Example 43. A 50-mL three necked round-bottom
flask, purged and maintained with an inert atmosphere of nitrogen,
was charged with a solution of tert-butyl
N-methyl-N-(4-[[(3R)-3-(2-oxoethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6-
]]dodeca-1(12),2(6),8,10-tetraen-12-yl]oxy]cyclohexyl)carbamate
(500 mg, 1.12 mmol, 1.00 equiv) in 10 mL of distilled THF.
Et.sub.3B (11.2 mL, 1N) was added slowly at 0.degree. C. over 20
min. Then t-BuOOH (1.225 mL) was added dropwise to the mixture at
the same temperature. After being stirred for 10 min, the mixture
was allowed to warmed to room temperature and stirring was
continued for an additional period during which the reaction
proceeded to completion (Caution: Triethylborane, a liquid
pyrophoric toward oxygen, should be handled so as to avoid exposure
to air. The addition of tert-butyl hydroperoxide to trialkylboranes
may lead to highly exothermic reactions and gas evolution. We
encountered no violent reaction with the present procedures, but
special care is advised.) The reaction mixture was treated with 28%
NH.sub.4OH and extracted with CH.sub.2Cl.sub.2. (A 28% NH.sub.4OH
solution allows the removal of unidentified polar materials
possibly derived from Et.sub.3B. Removal of polar byproducts in the
crude mixture, detectable on an iodine/silica gel TLC plate, may
otherwise be difficult. The crude mixture must thus be washed with
28% NH.sub.4OH for adequate purification.) The extracts were washed
with saturated aqueous NaHSO.sub.3 and dried over anhydrous sodium
sulfate and concentrated under vacuum. The residue was applied onto
a silica gel column with ethyl acetate/petroleum ether (1:5) to
provide tert-butyl
N-(4-[[(3R)-3-[(2S)-2-hydroxy-2-[(2S)-oxolan-2-yl]ethyl]-7-thia-9,11-diaz-
atricyclo[6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-12-yl]oxy]cyclohexyl-
)-N-methylcarbamate (230 mg, 40%) as a colorless oil. MS (ES): m/z
518 [M+H].sup.+.
[0907] Syntheses of Compound I-88 and Compound I-89.
[0908] Into a 50-mL round-bottom flask containing tert-butyl
N-(4-[[(3R)-3-[(2S)-2-hydroxy-2-[(2S)-oxolan-2-yl]ethyl]-7-thia-9,11-diaz-
atricyclo[6.4.0.0
[2,6]]dodeca-1(12),2(6),8,10-tetraen-12-yl]oxy]cyclohexyl)-N-methylcarbam-
ate (230 mg, 0.44 mmol, 1.00 equiv) in dichloromethane (10 mL) at
0.degree. C. was added hydrochloric acid (12 M, 2.0 mL) and the
resulting solution was stirred for 3 h at room temperature. The
resulting mixture was concentrated under vacuum to give the
corresponding hydrochloride (220 mg, crude) which was used directly
in the next step. A solution of hydrochloride (220 mg, crude) in
methanol (8 mL) was added HCHO (37%, 1.0 mL) and stirred for 1 h at
room temperature. Then NaBH.sub.3CN (68 mg, 1.08 mmol, 3.0 equiv)
was added and the resulting solution was stirred for additional 2 h
at ambient temperature and concentrated under vacuum. The crude
product (200 mg) was purified by preparative HPLC under the
following conditions (SHIMADZU): column: SunFire Prep C18, 19*150
mm 5 um; mobile phase: water with 0.1% HCOOH and CH.sub.3CN (30%
CH.sub.3CN up to 60% in 20 min); flow rate: 20 mL/min; UV detection
at 254 nm. The product-containing fractions were collected and
partially evaporated to remove the water and CH.sub.3CN under
reduced pressure and the residue was lyophilized overnight to give
(1R)-2-((R)-4-(((1r,4R)-4-(dimethylamino)cyclohexyl)oxy)-6,7-dihydro-5H-c-
yclopenta[4,5]thieno[2,3-d]pyrimidin-5-yl)-1-(tetrahydrofuran-2-yl)ethanol
(17.6 mg) as an off-white semi-solid and (1
S)-2-((R)-4-(((1r,4R)-4-(dimethylamino)cyclohexyl)oxy)-6,7-dihydro-5H-cyc-
lopenta[4,5]thieno[2,3-d]pyrimidin-5-yl)-1-(tetrahydrofuran-2-yl)ethanol
(10.5 mg) as an off-white semi-solid, respectively.
Example 105 (I-88)
[0909] MS (ES): m/z 432 [M-HCOOH+H].sup.+. .sup.1H NMR (400 MHz,
CD.sub.3OD): .delta. 8.48 (2H, br s), 5.35 (1H, s) 3.88 (4H, m),
3.13 (3H, m), 2.99 (6H, m), 2.84 (1H, m), 2.71-2.66 (3H, m), 2.45
(3H, m), 1.95-1.90 (9H, m), 1.61 (1H, m).
Example 106 (I-89)
[0910] MS (ES): m/z 432 [M-1.5HCOOH+H].sup.+. .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.48 (2.5H, br s), 5.35 (1H, s) 3.88-3.75 (5H,
m), 3.13 (2H, m), 2.99 (6H, m), 2.84 (1H, m), 2.21-2.40 (6H, m),
1.78-1.95 (8H, m), 1.46 (1H, t).
Example 107
Synthesis of
2-(((1R,4r)-4-(((R)-5-(2-hydroxyethyl)-6,7-dihydro-5H-cyclopenta[4,5]thie-
no[2,3-d]pyrimidin-4-yl)oxy)cyclohexyl)(methyl)amino)-1-(pyrrolidin-1-yl)e-
thanone. (I-90)
##STR00468##
[0912] Synthesis of Compound 107.1.
[0913] Note: For the preparation of the starting material compound
34.2, please refer to the experimental procedure for the synthesis
of compound Example 34. A 50-mL round-bottom flask, purged and
maintained with an inert atmosphere of nitrogen, was charged with a
solution of tert-butyl
N-(4-[[(3R)-3-(2-hydroxyethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dod-
eca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)-N-methylcarbamate
(197 mg, 0.44 mmol, 1.00 equiv) in dichloromethane (15 mL).
Hydrochloric acid (conc., 0.5 mL) was added at 0.degree. C. and the
resulting solution was stirred for 2 h at room temperature. The pH
value of the solution was adjusted to 10 with aqueous sodium
bicarbonate (sat.) and extracted with dichloromethane. The organic
layer was washed with brine, dried over anhydrous sodium sulfate
and concentrated under vacuum to give
2-[(3R)-12-[[4-(methylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo[6.4-
.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]ethan-1-ol (118 mg,
77%) as a yellow solid. MS (ES): m/z 348[M+H].sup.+.
[0914] Synthesis of Compound I-90.
[0915] To a solution of
2-[(3R)-12-[[4-(methylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo[6.4-
.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]ethan-1-ol (120 mg,
0.35 mmol, 1.00 equiv) in distilled DMF (5 mL) was added
2-chloro-1-(pyrrolidin-1-yl)ethan-1-one (75 mg, 0.51 mmol, 1.50
equiv) and potassium carbonate (26 mg, 0.19 mmol, 2.00 equiv) at
room temperature. The resulting solution was stirred overnight at
room temperature. The reaction mixture was diluted with DCM (100
mL), washed with brine, dried over anhydrous sodium sulfate and
concentrated under vacuum. The residue was applied onto a silica
gel column with methanol/DCM (1:10) to afford the desired
2-[(4-[[(3R)-3-(2-hydroxyethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]do-
deca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)(methyl)amino]-1-(pyrroli-
din-1-yl)ethan-1-one (130 mg, 82%) as a white solid. MS (ES): m/z
459 [M+H].sup.+. .sup.1H NMR (400 MHz, CD.sub.3OD): .delta. 8.47
(1H, s), 5.32-5.20 (1H, m), 3.66 (2H, t), 3.58 (2H, t), 3.50-3.41
(3H, m), 3.37 (2H, s), 3.15-3.05 (1H, m), 3.00-2.92 (1H, m),
2.75-2.60 (2H, m), 2.37 (3H, s), 2.33-2.15 (4H, m), 2.03-1.88 (6H,
m), 1.71-1.54 (4H, m).
Example 108
Intermediate 108.12
##STR00469## ##STR00470##
[0917] Synthesis of Compound 108.2.
[0918] A 250-mL round-bottom flask, purged and maintained with an
inert atmosphere of nitrogen, was charged with
4-hydroxycyclohexane-1-carboxylic acid (15.7 g, 108.90 mmol, 1.00
equiv) in methanol (90 mL). Sulfuric acid (0.8 mL) was added to the
mixture slowly. The resulting solution was stirred for 10 hr at
60.degree. C. The reaction was then quenched by the addition of 200
mL of sodium bicarbonate (sat.). The resulting solution was
extracted with 3.times.200 mL of ethyl acetate and the organic
layers combined and dried over anhydrous sodium sulfate and
concentrated under reduced pressure. The resulting trans-methyl
4-hydroxycyclohexane-1-carboxylate (16.6 g, 96%) was obtained as a
light yellow oil.
[0919] Synthesis of Compound 108.3.
[0920] A 500-mL round-bottom flask, purged and maintained with an
inert atmosphere of nitrogen, was charged with a solution of methyl
trans-4-hydroxycyclohexane-1-carboxylate (16.6 g, 104.93 mmol, 1.00
equiv) and imidazole (14.28 g, 180.53 mmol, 1.72 equiv) in
distilled DMF (25 mL). Tert-butyl(chloro)dimethylsilane (28.3 g,
187.76 mmol, 1.79 equiv) was added slowly and the resulting
solution was stirred for 14 hrs at room temperature. After
completion, the reaction was then quenched with water and extracted
with 3.times.200 mL of ethyl acetate. The combined organic layers
were washed with water, brine and dried over sodium sulfate. After
concentration under reduced pressure, the residue was applied onto
a silica gel column with ethyl acetate/petroleum ether (10:1) to
give the desired methyl trans-4-[(tert-butyldimethyl
silyl)oxy]cyclohexane-1-carboxylate (27.4 g, 96%) as a colorless
oil.
[0921] Synthesis of Compound 108.4.
[0922] A 500-mL round-bottom flask containing a solution of
diisopropylamine (10 g, 99.01 mmol, 3.00 equiv) in freshly
distilled THF (100 mL) was cooled down to -78.degree. C. under
nitrogen. Then n-BuLi (2.5 M in hexane, 39.6 mL) was added dropwise
and the resulting solution was stirred at -78.degree. C. for 1 h. A
solution of methyl
trans-4-[(tert-butyldimethylsilyl)oxy]cyclohexane-1-carboxylate (9
g, 33.03 mmol, 1.00 equiv) in THF (20 mL) was added via syringe and
the reaction mixture was held at -78.degree. C. for another 1 h.
Iodoethane (25.74 g, 165.04 mmol, 5.00 equiv) was added to the
mixture and stirred for additional 2 h at -78.degree. C. Then the
reaction temperature was raised to room temperature in 1 h with
stirring. The reaction was then quenched with saturated aqueous
NH.sub.4Cl and extracted with 3.times.100 mL of ethyl acetate. The
combined organic layers were washed with brine, dried over sodium
sulfate and concentrated under vacuum. The residue was applied onto
a silica gel column with ethyl acetate/petroleum ether (1:15) to
give the major methyl
cis-4-[(tert-butyldimethylsilyl)oxy]-1-ethylcyclohexane-1-carboxylate
(8.2 g, 83%) as a yellow oil. The desired cis-compound was
confirmed by .sup.1H NMR spectroscopy.
[0923] Synthesis of Compound 108.5.
[0924] To a 500-mL round-bottom flask containing a solution of
methyl
cis-4-[(tert-butyldimethylsilyl)oxy]-1-ethylcyclohexane-1-carboxylate
(8.2 g, 27.29 mmol, 1.00 equiv) in 150 mL of THF was added
TBAF-3H.sub.2O (12.9 g, 40.95 mmol, 1.50 equiv) and the resulting
solution was stirred for 4 hrs at 30.degree. C. The resulting
mixture was concentrated under vacuum and the residue was applied
onto a silica gel column with ethyl acetate/petroleum ether (1:2)
to give methyl cis-1-ethyl-4-hydroxycyclohexane-1-carboxylate (4.5
g, 89%) as a yellow oil.
[0925] Synthesis of Compound 108.6.
[0926] A solution of methyl
cis-1-ethyl-4-hydroxycyclohexane-1-carboxylate (3.5 g, 18.79 mmol,
1.00 equiv) in 100 mL of THF was added 4-nitrobenzoic acid (6.3 g,
37.70 mmol, 2.01 equiv), PPh.sub.3 (9.85 g, 37.55 mmol, 2.00 equiv)
and DIAD (7.6 g, 37.58 mmol, 2.00 equiv) successively at room
temperature under N.sub.2. The resulting solution was stirred for
48 hrs at ambient temperature. After completion, the reaction was
quenched with water and extracted with EtOAc (3.times.100 mL). The
combined organic layers were dried over sodium sulfate and
concentrated under vacuum. The residue was applied onto a silica
gel column with ethyl acetate/petroleum ether (1:15) to give the
desired trans-4-ethyl-4-(methoxycarbonyl)cyclohexyl 4-nitrobenzoate
(2.3 g, 36%) as a white solid. .sup.1H NMR (300 MHz, CDCl.sub.3):
.delta. 8.32 (2H, d), 8.21 (2H, d), 5.28-5.20 (1H, M), 3.72 (3H,
s), 2.10-2.04 (2H, m), 1.98-1.90 (2H, m), 1.84-1.73 (2H, m),
1.68-1.56 (5H, m), 0.88 (3H, t).
[0927] Synthesis of Compound 108.7.
[0928] To a 50-mL round-bottom flask containing a solution of
4-ethyl-4-(methoxycarbonyl)cyclohexyl 4-nitrobenzoate (2.3 g, 6.86
mmol, 1.00 equiv) in a mixture of methanol (15 mL) and water (3 mL)
was added potassium carbonate (2.84 g, 20.55 mmol, 3.00 equiv) and
the resulting solution was stirred for 2 hr at 40.degree. C. The
resulting solution was quenched with water and extracted with
3.times.50 mL of ethyl acetate. The combined organic layers were
washed with brine and dried over anhydrous sodium sulfate and
concentrated under vacuum. The residue was purified by column
chromatography on silica gel with ethyl acetate/petroleum ether
(1:18) to afford the corresponding trans-methyl
1-ethyl-4-hydroxycyclohexane-1-carboxylate (1.2 g, 94%) as a white
solid. .sup.1H NMR (300 MHz, CDCl.sub.3): .delta. 3.89-3.85 (1H,
m), 3.69 (3H, s), 1.95-1.79 (2H, m), 1.72-1.54 (8H, m), 0.80 (3H,
t).
[0929] Synthesis of Compound 108.8.
[0930] To a solution of trans-methyl
1-ethyl-4-hydroxycyclohexane-1-carboxylate (1.0 g, 5.37 mmol, 1.00
equiv) and DIEA (2.08 g, 16.09 mmol, 3.00 equiv) in dichloromethane
(20 mL) was added SEMCl (1.79 g) slowly at room temperature. The
resulting solution was stirred for 14 hr at ambient temperature.
The reaction was then quenched with water and extracted with
3.times.40 mL of ethyl acetate. The combined organic layers were
washed with brine, dried over sodium sulfate and concentrated under
vacuum. The residue was applied onto a silica gel column with ethyl
acetate/petroleum ether (1:10) to provide trans-methyl
1-ethyl-4-[[2-(trimethylsilyl)ethoxy]methoxy]cyclohexane-1-carboxylate
(1.5 g, 88%) as a colorless oil. .sup.1H NMR (300 MHz, CD.sub.3OD):
.delta. 4.65 (2H, s), 3.71-3.58 (6, H, m), 1.86-1.82 (2H, m),
1.68-1.49 (8H, m), 0.90 (2H, t), 0.78 (3H, t).
[0931] Synthesis of Compound 108.9.
[0932] A solution of trans-methyl
1-ethyl-4-[[2-(trimethylsilyl)ethoxy]methoxy]cyclohexane-1-carboxylate
(1.5 g, 4.74 mmol, 1.00 equiv) in a mixed methanol (20 mL)/water (5
mL) was added sodium hydroxide (948 mg, 23.70 mmol, 5.00 equiv) and
the resulting solution was stirred for 14 hr at 75.degree. C. After
cooling down to r.t, the pH value of the mixture was adjusted to 4
with 2 M aqueous hydrochloric acid and extracted with 3.times.50 mL
of ethyl acetate. The combined organic layers were washed with
brine, dried over anhydrous sodium sulfate and concentrated under
vacuum. The desired
trans-1-ethyl-4-[[2-(trimethylsilyl)ethoxy]methoxy]cyclohexane-1-carboxyl-
ic acid (1.3 g, 91%) was obtained as a yellow oil. .sup.1H NMR (300
MHz, CD.sub.3OD): .delta. 4.69 (2H, s), 3.80-3.70 (1H, m), 3.67
(2H, t), 1.87-1.82 (2H, m), 1.75-1.54 (8H, m), 0.95 (2H, t), 0.92
(3H, t).
[0933] Synthesis of Compound 108.10.
[0934] A solution of
1-ethyl-4-[[2-(trimethylsilyl)ethoxy]methoxy]cyclohexane-1-carboxylic
acid (1.24 g, 4.10 mmol, 1.00 equiv), DPPA (2.03 g, 7.38 mmol, 1.80
equiv) and TEA (1.24 g, 12.25 mmol, 2.99 equiv) in
2-methylpropan-2-ol (30 mL) was stirred for 14 hr at reflux under
nitrogen. The reaction mixture was quenched with water, extracted
with 3.times.50 mL of EtOAc. The organic layers were combined,
washed with brine, dried over sodium sulfate and concentrated under
vacuum. The residue was applied onto a silica gel column with ethyl
acetate/petroleum ether (1:6) to give
(2-[[(4-ethyl-4-isocyanatocyclohexyl)oxy]methoxy]ethyl)trimethylsilane
(0.9 g, 73%) as colorless oil. .sup.1H NMR (400 MHz, CD.sub.3OD):
.delta. 4.70 (2H, s), 3.89-3.80 (1H, m), 3.67 (2H, t), 1.80-1.73
(6H, m), 1.65-1.58 (4H, m), 1.00 (3H, t), 0.94 (2H, t).
[0935] Synthesis of Compound 108.11.
[0936] Into a 25-mL round-bottom flask contained a solution of
(2-[[(4-ethyl-4-isocyanatocyclohexyl)oxy]methoxy]ethyl),
trimethylsilane (840 mg, 2.80 mmol, 1.00 equiv) in tetrahydrofuran
(10 mL) was added hydrochloric acid (5 M, 2 mL) slowly and the
resulting solution was stirred for 14 hrs at 30.degree. C. The
resulting mixture was concentrated under vacuum to provide the
desired 4-amino-4-ethylcyclohexan-1-ol hydrochloride (410 mg,
crude) as a white solid.
[0937] Synthesis of Intermediate 108.12.
[0938] A solution of 4-amino-4-ethylcyclohexan-1-ol hydrochloride
(380 mg, 2.11 mmol, 1.00 equiv) and sodium hydroxide (127 mg, 1.13
mmol, 0.54 equiv) in a mixture of THF (30 mL)/water (5 mL) was
added (Boc).sub.2O (462 mg, 2.12 mmol, 1.00 equiv) at 0.degree. C.
The resulting solution was stirred for 3 hr at room temperature and
diluted with water, extracted with 3.times.50 mL of ethyl acetate.
The organic layers were combined, washed with brine, dried over
anhydrous sodium sulfate and concentrated under vacuum. The residue
was purified by column chromatography on silica gel with ethyl
acetate/petroleum ether (1:6) to give the desired trans-tert-butyl
N-(1-ethyl-4-hydroxycyclohexyl)carbamate (450 mg, 87%) as a
colorless oil. .sup.1H NMR (300 MHz, CD.sub.3OD): .delta. 3.80-3.72
(1H, m), 1.69-1.61 (8H, m), 1.50-1.32 (11H, m), 0.78 (3H, t).
Example 109
Synthesis of
2-((R)-4-(((1r,4R)-4-(dimethylamino)-4-ethylcyclohexyl)oxy)-6,7-dihydro-5-
H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-5-yl)ethanol (I-91)
##STR00471##
[0940] Synthesis of Compound 109.1.
[0941] Sodium hydride (605 dispersion in mineral oil, 283 mg, 7.08
mmol, 3.65 equiv) was treated with tert-butyl
N-(1-ethyl-4-hydroxycyclohexyl)carbamate (430 mg, 1.77 mmol, 0.91
equiv) in 50 mL of distilled THF at room temperature for 30 mins.
Then a solution of
(3R)-3-[2-[(tert-butyldimethylsilyl)oxy]ethyl]-12-chloro-7-thia-9,11-diaz-
atricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraene (25.1, 716
mg, 1.94 mmol, 1.00 equiv) in THF (5 mL) was added dropwise and the
resulting solution was stirred for 14 hr at 18.degree. C. The
reaction was then quenched with saturated aqueous NH.sub.4Cl and
extracted with 3.times.50 mL of ethyl acetate. The combined organic
layers were washed with brine, dried over sodium sulfate and
concentrated in vacuo. The residue was applied onto a silica gel
column with ethyl acetate/petroleum ether (1:5) to afford the
corresponding tert-butyl
N-(4-[[(3R)-3-[2-[(tert-butyldimethylsilyl)oxy]ethyl]-7-thia-9,11-diazatr-
icyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]-1-ethylcycloh-
exyl)carbamate (480 mg, 43%) as a colorless oil. MS: 576
[M+H].sup.+.
[0942] Synthesis of Compound 109.2.
[0943] Into a 25-mL round-bottom flask contained a solution of
tert-butyl
N-(4-[[(3R)-3-[2-[(tert-butyldimethylsilyl)oxy]ethyl]-7-thia-9,11-diazatr-
icyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]-1-ethylcycloh-
exyl)carbamate (240 mg, 0.42 mmol, 1.00 equiv) in dichloromethane
(10 mL) was added hydrochloric acid (5 M, 1 mL) and the resulting
solution was stirred for 5 hr at RT. The reaction was then quenched
saturated aqueous sodium bicarbonate, extracted with 3.times.40 mL
of dichloromethane. The combined organic layers were washed with
brine, dried over anhydrous sodium sulfate and concentrated under
vacuum to give 120 mg (80%) of
2-[(3R)-12-[(4-amino-4-ethylcyclohexyl)oxy]-7-thia-9,11-diazatricyclo[6.4-
.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]ethan-1-ol as a yellow
oil. MS: 362 [M+H].sup.+.
[0944] Synthesis of Compound I-91.
[0945] Into a 10-mL round-bottom flask placed a solution of
2-[(3R)-12-[(4-amino-4-ethylcyclohexyl)oxy]-7-thia-9,11-diazatricyclo[6.4-
.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]ethan-1-ol (120 mg,
0.33 mmol, 1.00 equiv) in 5 mL of methanol was added HCHO (37%, 1
mL) and the reaction was stirred at room temperature for 30 min.
Then NaBH.sub.3CN (83 mg, 1.32 mmol, 3.97 equiv) was added to the
reaction mixture and stirred for 8 hr at room temperature. After
completion, the reaction mixture was diluted with water and
extracted with DCM. After concentration in vacuo, The crude product
(120 mg) was purified by preparative HPLC under the following
conditions (SHIMADZU): column: SunFire Prep C18, 19*150 mm 5 um;
mobile phase: water with 50 mM NH.sub.4HCO.sub.3 and CH.sub.3CN
(6.0% CH.sub.3CN up to 52.0% in 14 min); flow rate: 20 mL/min; UV
detection at 254/220 nm. The product-containing fractions were
collected and partially evaporated to remove water and CH.sub.3CN
under reduced pressure. The residue was lyophilized overnight to
give the desired
2-[(3R)-12-[[4-(dimethylamino)-4-ethylcyclohexyl]oxy]-7-thia-9,11-diazatr-
icyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]ethan-1-ol
(41.4 mg) as a white semi-solid. MS (ES): m/z 390 [M+H].sup.+.
.sup.1H NMR (400 MHz, CD.sub.3OD): .delta. 8.47 (s, 1H), 5.44-5.46
(m, 1H), 3.64-3.69 (m, 2H), 3.32-3.33 (m, 1H), 3.10-3.12 (m, 1H),
2.99-3.02 (m, 1H), 2.68 (m, 1H), 2.09-2.39 (m, 10H), 1.61-1.86 (m,
9H), 0.93-0.96 (t, 3H).
Example 110
(S)-2-hydroxy-3-((R)-4-(((1r,4R)-4-morpholinocyclohexyl)oxy)-6,7-dihydro-5-
H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-5-yl)propanamide (I-92)
and
Example 111
(R)-2-hydroxy-3-((R)-4-(((1r,4R)-4-morpholinocyclohexyl)oxy)-6,7-dihydro-5-
H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-5-yl)propanamide (I-93)
##STR00472##
[0947] Note: The starting material Compound I-87, please see
Example 104. The racemic I-87 (1.6 g, 96.5% purity) was separated
by chiral HPLC under the following conditions (Gilson G.times.281):
column: Chiralpak AD-H, 2*25 cm Chiral-P(AD-H); Mobile Phase: phase
A: hexanes (0.1% DEA) (HPLC grade), phase B: IPA (HPLC grade),
gradient: 30% B in 9 min; flow rate: 20 mL/min; UV detection at
220/254 nm; The former fractions (tR=4.75 min) were collected and
evaporated under reduced pressure and lyophilized overnight to
afford the
(R)-2-hydroxy-3-((R)-4-(((1r,4R)-4-morpholinocyclohexyl)oxy)-6,7-dihydro--
5H-cyclopenta[4, 5]thieno[2,3-d]pyrimidin-5-yl)propanamide I-93
(520 mg) with 100% ee as a white solid. And the latter fractions
(tR=5.82 min) were handled as former fractions to give the desired
(S)-2-hydroxy-3-((R)-4-(((1r,4R)-4-morpholinocyclohexyl)oxy)-6,7-dihydro--
5H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-5-yl)propanamide I-92 (510
mg) with 99.6% ee as a white solid. The ee values of the two
isomers were determined by chiral HPLC under the following
conditions (SHIMADZU-SPD-20A): column: Chiralpak AD-H, 0.46*25 cm,
5 um (DAICEL); Mobile phase: Hex (0.1% TEA): IPA=85:15; UV
detection at 254 nm. Flow rate: 1.0 mL/min. tR (I-93)=7.939 min and
tR (I-92)=11.918 min.
Example 110 (I-92)
[0948] MS (ES): m/z 447 [M+H].sup.+. .sup.1H NMR (400 MHz,
CDCl.sub.3): .delta. 8.46 (s, 1H), 5.32-5.22 (m, 1H), 4.15 (t, 1H),
3.73 (t, 4H), 3.59 (td, 1H), 3.19-3.08 (m, 1H), 3.02-2.92 (m, 1H),
2.78-2.70 (m, 1H), 2.69-2.60 (m, 4H), 2.58-2.20 (m, 5H), 2.10 (d,
2H), 1.75-1.63 (m, 3H), 1.53-1.40 (m, 2H).
Example 111 (I-93)
[0949] MS (ES, m/z) 447 [M+H].sup.+. .sup.1H NMR (400 MHz,
CD.sub.3CD+CDCl.sub.3): .delta. 8.47 (s, 1H), 5.32-5.22 (m, 1H),
4.08 (dd, 1H), 4.89-4.62 (m, 5H), 3.20-3.10 (m, 1H), 3.05-2.95 (m,
1H), 2.75-2.55 (m, 5H), 2.44-2.38 (m, 2H), 2.34-2.28 (m, 3H), 2.10
(d, 2H), 1.82-1.62 (m, 3H), 1.58-1.40 (m, 2H).
Example 112
Synthesis of
3-((S)-4-(((1r,4S)-4-(methyl(2-oxo-2-(pyrrolidin-1-yl)ethyl)amino)cyclohe-
xyl)oxy)-6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-5-yl)propana-
mide (I-94)
##STR00473##
[0951] Synthesis of Compound 112.1.
[0952] Note: For the preparation of the starting material Compound
I-90, please refer to Example 107. A 25-mL round-bottom flask,
purged and maintained with an inert atmosphere of nitrogen, was
charged with a solution of
2-[(4-[[(3R)-3-(2-hydroxyethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]do-
deca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)(methyl)amino]-1-(pyrroli-
din-1-yl)ethan-1-one (100 mg, 0.22 mmol, 1.00 equiv) in 5 mL of
distilled DMF. MsCl (38 mg, 0.33 mmol, 1.50 equiv) and
triethylamine (66.7 mg, 0.66 mmol, 3.00 equiv) were added at
0.degree. C. The resulting solution was stirred overnight at room
temperature. The reaction was then quenched with water, extracted
with DCM. The organic phase was washed with brine, dried over
anhydrous sodium sulfate and concentrated under vacuum. The residue
was purified by column chromatography on silica gel with DCM/MeOH
(20:1 to 10:1) to give
2-[(3R)-12-[(4-[methyl[2-oxo-2-(pyrrolidin-1-yl)ethyl]amino]cyclohexyl)ox-
y]-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,
11-tetraen-3-yl]ethyl methanesulfonate (107 mg) as a white solid.
MS (ES): m/z 537 [M+H].sup.+.
[0953] Synthesis of Compound 112.2.
[0954] To a solution of
2-[(3R)-12-[(4-[methyl[2-oxo-2-(pyrrolidin-1-yl)ethyl]amino]cyclohexyl)ox-
y]-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3--
yl]ethyl methanesulfonate (107 mg, 0.20 mmol, 1.00 equiv) in DMSO
(5 mL) were added NaCN (58.8 mg, 1.20 mmol, 6.00 equiv) and
4-dimethylaminopyridine (2.4 mg, 0.02 mmol, 0.10 equiv) at room
temperature. The resulting solution was stirred for 2 h at
80.degree. C. After cooling to room temperature, the reaction was
then quenched by the addition of aqueous FeSO.sub.4 solution and
extracted with DCM. The organic phase was washed with brine, dried
over anhydrous sodium sulfate and concentrated under vacuum. The
residue was applied onto a silica gel column with DCM/MeOH (10:1)
to give the desired
3-[(3S)-12-[(4-[methyl[2-oxo-2-(pyrrolidin-1-yl)ethyl]amino]cyclohexyl)ox-
y]-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3--
yl]propanenitrile (80 mg, 86%) as a yellow solid. MS (ES): m/z 468
[M+H].sup.+.
[0955] Synthesis of Compound I-94.
[0956] A 25-mL round-bottom flask, purged and maintained with an
inert atmosphere of nitrogen, was charged with a solution of
3-[(3S)-12-[(4-[methyl[2-oxo-2-(pyrrolidin-1-yl)ethyl]amino]cyclohexyl)ox-
y]-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3--
yl]propanenitrile (80 mg, 0.17 mmol, 1.00 equiv) in methanol (5 mL)
and cooled to 0.degree. C. Then LiOH.H.sub.2O (22 mg, 0.52 mmol,
3.00 equiv) and H.sub.2O.sub.2(30%, 0.3 mL) were added at 0.degree.
C. and the resulting solution was stirred for 2 h at the same
temperature. The reaction was quenched by the addition of saturated
aqueous Na.sub.2SO.sub.3 and extracted DCM. The organic phase was
washed with brine, dried over anhydrous sodium sulfate and
concentrated under vacuum. The residue was purified by preparative
HPLC under the following conditions (SHIMADZU): column: SunFire
Prep C18, 19*150 mm 5 um; mobile phase: water with 0.05%
NH.sub.4HCO.sub.3 and CH.sub.3CN (6.0% CH.sub.3CN up to 50.0% in 16
min); flow rate: 20 mL/min; UV detection at 254/220 nm. The
product-containing fractions were collected and partially
evaporated to remove water and CH.sub.3CN under reduced pressure.
The residue was lyophilized overnight to give the desired
3-[(3S)-12-[(4-[methyl[2-oxo-2-(pyrrolidin-1-yl)ethyl]amino]cyclohexyl)ox-
y]-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3--
yl]propanamide (82.5 mg) as a white solid. MS (ES): m/z 486
[M+H].sup.+; .sup.1H NMR (400 MHz, CD.sub.3OD): .delta. 8.47 (1H,
s), 5.32-5.22 (1H, m), 3.58 (2H, t), 3.45 (2H, t), 3.35 (2H, s),
3.20-3.09 (1H, m), 3.03-2.95 (1H, m), 2.73-2.65 (2H, m), 2.37 (3H,
s), 2.33-2.19 (5H, m), 2.03-1.88 (6H, m), 1.66 (2H, m), 1.69-1.52
(4H, m).
Example 113
Synthesis of
2-[(3R)-12-[[4-(dimethylamino)-4-ethylcyclohexyl]oxy]-7-thia-9,11-diazatr-
icyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]acetamide
(I-95)
##STR00474##
[0958] Synthesis of Compound 113.1.
[0959] To a 25-mL round-bottom flask containing a solution of
tert-butyl
N-(4-[[(3R)-3-[2-[(tert-butyldimethylsilyl)oxy]ethyl]-7-thia-9,11-diazatr-
icyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]-1-ethylcycloh-
exyl)carbamate (240 mg, 0.42 mmol, 1.00 equiv) in 10 mL of THF was
added TBAF.3H.sub.2O (264 mg, 0.84 mmol, 2.01 equiv) at room
temperature. The resulting solution was stirred for 3 h at this
temperature and concentrated under reduced pressure. The residue
was applied onto a silica gel column with ethyl acetate/petroleum
ether (1:1) to give 180 mg (94%) of the desired tert-butyl
N-(1-ethyl-4-[[(3R)-3-(2-hydroxyethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[-
2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)carbamate
as a colorless oil. MS: m/z 462 (M+H).sup.+.
[0960] Synthesis of Compound 113.2.
[0961] To a 50-mL round-bottom flask containing a solution of
tert-butyl
N-(1-ethyl-4-[[(3R)-3-(2-hydroxyethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[-
2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)carbamate
(180 mg, 0.39 mmol, 1.00 equiv) in N,N-dimethylformamide (5 mL) was
added PDC (716 mg, 1.90 mmol, 4.88 equiv) and the resulting
solution was stirred for 14 hrs at 25.degree. C. The reaction was
then quenched by the addition of 20 mL of water and extracted with
3.times.50 mL of ethyl acetate. The combined organic layers were
washed with brine, dried over sodium sulfate and concentrated under
vacuum. The residue was applied onto a silica gel column with ethyl
acetate/petroleum ether (1:1) to give the desired
2-[(3R)-12-[(4-[[(tert-butoxy)carbonyl]amino]-4-ethylcyclohexyl)oxy]-7-th-
ia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]acet-
ic acid (100 mg, 54%) as a colorless oil. MS (ES): m/z 476
[M+H].sup.+.
[0962] Synthesis of Compound 113.3.
[0963] To a solution of
2-[(3R)-12-[(4-[[(tert-butoxy)carbonyl]amino]-4-ethylcyclohexyl)oxy]-7-th-
ia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]acet-
ic acid (100 mg, 0.21 mmol, 1.00 equiv) in 5 mL of distilled DMF
was added HOBt (42.6 mg), EDCI (60 mg), 4-dimethylaminopyridine
(38.2 mg) and NH.sub.4Cl (56 mg, 1.05 mmol, 4.98 equiv)
suuccessively and the resulting solution was stirred for 14 hr at
25.degree. C. under nitrogen. The reaction was then quenched with
water and extracted with 3.times.50 mL of ethyl acetate. The
organic layers were combined, washed with brine, dried over sodium
sulfate and concentrated under vacuum. The residue was applied onto
a silica gel column with ethyl acetate/petroleum ether (2:1) to
give tert-butyl
N-(4-[[(3R)-3-(carbamoylmethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]do-
deca-1(8),2(6),9,11-tetraen-12-yl]oxy]-1-ethylcyclohexyl)carbamate
(60 mg, 60%) as colorless oil. MS (ES): m/z 476 [M+H].sup.+.
[0964] Synthesis of compound Compound I-95.
[0965] To a 50-mL round-bottom flask containing a solution of
tert-butyl
N-(4-[[(3R)-3-(carbamoylmethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]do-
deca-1(8),2(6),9,11-tetraen-12-yl]oxy]-1-ethylcyclohexyl)carbamate
(60 mg, 0.13 mmol, 1.00 equiv) in dichloromethane (4 mL) was added
hydrochloric acid (8 M, 0.5 mL) at 0.degree. C. The resulting
solution was stirred for 1 hr at the same temperature. The reaction
mixture was concentrated in vacuo to give the
2-[(3R)-12-[(4-amino-4-ethylcyclohexyl)oxy]-7-thia-9,11-diazatricyclo[6.4-
.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]acetamide
hydrochloride (50 mg, crude) as a white solid. The solid (50 mg,
crude) was dissolved in 5 mL of methanol, HCHO (37%, 0.5 mL) was
added and the solution was stirred at room temperature for 30 min.
NaBH.sub.3CN (22 mg) was added to the mixture and stirred
overnight. The reaction was then quenched by the addition of 30 mL
of water, extracted with 3.times.40 mL of chloroform/isopropanol.
The combined organic layers were concentrated under vacuum. The
crude product (50 mg) was purified by preparative HPLC under the
following conditions (SHIMADZU): column: SunFire Prep C18, 19*150
mm 5 um; mobile phase: water with 50 mM NH.sub.4HCO.sub.3 and
CH.sub.3CN (6.0% CH.sub.3CN up to 52.0% in 14 min); flow rate: 20
mL/min; UV detection at 254/220 nm. The product-containing
fractions were collected and partially evaporated to remove water
and CH.sub.3CN under reduced pressure. The residue was lyophilized
overnight to give the desired
2-[(3R)-12-[[4-(dimethylamino)-4-ethylcyclohexyl]oxy]-7-thia-9,11-
-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]acetamide
(25.1 mg) as a white solid. MS (ES): m/z 403 [M+H].sup.+. .sup.1H
NMR (300 MHz, CD.sub.3OD): .delta. 8.47 (1H, s), 5.29 (1H, m),
3.85-3.89 (1H, m), 2.9-3.20 (3H, m), 2.70-2.88 (1H, m), 2.22-2.46
(8H, m), 2.06-2.17 (2H, m), 1.65-1.93 (8H, m), 0.98-1.07 (3H,
m).
Example 114
Synthesis of
(R)-2-((R)-4-(((1r,4R)-4-(dimethylamino)cyclohexyl)oxy)-6,7-dihydro-5H-cy-
clopenta[4,5]thieno[2,3-d]pyrimidin-5-yl)-1-(1H-pyrazol-3-yl)ethanol
(I-98) and
Example 115
Synthesis of
(S)-2-((R)-4-(((1r,4R)-4-(dimethylamino)cyclohexyl)oxy)-6,7-dihydro-5H-cy-
clopenta[4,5]thieno[2,3-d]pyrimidin-5-yl)-1-(1H-pyrazol-3-yl)ethanol
(I-96)
##STR00475##
[0967] Synthesis of Compound 114.1.
[0968] Note: For the preparation of the starting material compound
43.1, please refer to Example 43. Into a 50-mL round-bottom flask
purged and maintained with an inert atmosphere of nitrogen,
1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-pyrazole (245 mg, 1.24
mmol, 1.20 equiv) in 20 mL of distilled THF was cooled down to
-78.degree. C. in liquid N.sub.2/ethanol bath. n-BuLi (2.5 M in
hexane, 0.536 mL) was added dropwise with stirring, which was
continued for 1 h. Then a solution of tert-butyl
N-methyl-N-(4-[[(3R)-3-(2-oxoethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6-
]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)carbamate (460
mg, 1.03 mmol, 1.00 equiv) in tetrahydrofuran (10 mL) was added
dropwise -78.degree. C. via syringe and the resulting mixture was
stirred for 3 h at the same temperature. The reaction was quenched
with saturated aqueous NH.sub.4Cl and extracted with 3.times.50 mL
of ethyl acetate. The combined organic layers were washed with
brine, dried over sodium sulfate and concentrated in vacuo. The
residue was applied onto a silica gel column with ethyl
acetate/petroleum ether (1:1) to give the desired product 114.1
(500 mg, 75%) as a white solid. The ratio of the isomers (27:73)
was determined by chiral HPLC under the following conditions:
CHIRALPAK AD-H, 0.46*25 cm, 5 um; mobile phase: hex:EtOH=90:10;
flow rate: 1 mL/min; UV detection at 220/254 nm. MS (ES): m/z 644
[M+H].sup.+.
[0969] Synthesis of Compound 114.2 and 114.3.
##STR00476##
[0970] The racemate 114.1 (500 mg) was separated by chiral HPLC
under the following conditions (Gilson G.times.281): column:
Chiralpak AD-H, 2*25 cm; mobile phase, hexane (HPLC grade):EtOH
(HPLC grade)=90:10; flow rate: 20 mL/min; UV detection at 220/254
nm. The former fractions were collected and evaporated under
reduced pressure to give tert-butyl
N-(4-[[(3R)-3-[(2R)-2-hydroxy-2-(1-[[2-(trimethylsilyl)ethoxy]methyl]-1H--
pyrazol-3-yl)ethyl]-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6-
),9,11-tetraen-12-yl]oxy]cyclohexyl)-N-methylcarbamate (70 mg) as a
white solid with 99% ee and the latter fractions were concentrated
to provide the desired tert-butyl
N-(4-[[(3R)-3-[(2S)-2-hydroxy-2-(1-[[2-(trimethylsilyl)ethoxy]methyl]-1H--
pyrazol-3-yl)ethyl]-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6-
),9,11-tetraen-12-yl]oxy]cyclohexyl)-N-methylcarbamate (180 mg) as
a white solid with 99.7% ee. The ee values of the isomers were
determined by chiral HPLC under the following conditions: CHIRALPAK
IA, 0.46*25 cm, 5 um; mobile phase: Hex:IPA=90:10; flow rate: 1
mL/min; UV detection at 220/254 nm.
[0971] Synthesis of Compound I-98.
[0972] A solution of tert-butyl
N-(4-[[(3R)-3-[(2R)-2-hydroxy-2-(1-[[2-(trimethylsilyl)ethoxy]methyl]-1H--
pyrazol-3-yl)ethyl]-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6-
),9,11-tetraen-12-yl]oxy]cyclohexyl)-N-methylcarbamate (70 mg, 0.11
mmol, 1.00 equiv) in dichloromethane (10 mL) was added hydrochloric
acid (2 M, 1 mL) with stirring at 0.degree. C. The resulting
solution was stirred for 24 h at room temperature and concentrated
under vacuum to give 60 mg of the crude
(1R)-2-[(3R)-12-[[4-(methylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricycl-
o[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]-1-(1H-pyrazol-3-yl)etha-
n-1-ol hydrochloride as a yellow solid. The crude hydrochloride in
5 mL of methanol was added HCHO (37%, 0.5 mL) and the reaction
solution was stirred at room temperature for 30 min. The
NaBH.sub.3CN (18 mg, 0.30 mmol, 3.10 equiv) was added to the
mixture and the resulting solution was stirred for 4 h at ambient
temperature. After concentration in vacuo, the crude product was
purified by preparative HPLC under the following conditions
(Waters): column: X-briage C18, 19*150 mm 5 um; mobile phase,
CH.sub.3CN and water with 20 mM NH.sub.4HCO.sub.3 (10.0% CH.sub.3CN
up to 50.0% in 10 min, up to 95% in 2 min, down to 10.0% in 2 min);
flow rate: 20 mL/min; UV detection at 254/220 nm. The
product-containing fractions were collected and partially
evaporated to remove water and CH.sub.3CN under reduced pressure.
The residue was lyophilized overnight to give the desired
(1R)-2-[(3R)-12-[[4-(dimethylamino)cyclohexyl]oxy]-7-thia-9,11-di-
azatricyclo[6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-3-yl]-1-(1H-pyrazo-
l-3-yl)ethan-1-ol (26 mg) as a white solid. MS (ES): m/z 428
[M+H].sup.+. .sup.1H NMR (400 MHz, CD.sub.3OD): .delta. 8.46 (s,
1H), 7.50 (s, 1H), 6.27 (s, 1H), 5.25-5.29 (m, 1H), 3.67-3.71 (m,
1H), 3.01-3.15 (m, 1H), 2.97-3.00 (m, 1H), 2.57-2.65 (m, 3H), 2.46
(s, 6H), 2.30-2.34 (m, 3H), 2.08-2.10 (m, 2H), 1.90-1.92 (m, 1H),
1.85-1.89 (m, 2H), 1.53-1.59 (m, 2H), 1.30-1.37 (m, 1H).
[0973] Synthesis of Compound I-96.
[0974] To a solution of tert-butyl
N-(4-[[(3R)-3-[(2S)-2-hydroxy-2-(1-[[2-(trimethylsilyl)ethoxy]methyl]-1H--
pyrazol-3-yl)ethyl]-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6-
),9,11-tetraen-12-yl]oxy]cyclohexyl)-N-methylcarbamate (180 mg,
0.28 mmol, 1.00 equiv) in dichloromethane (10 mL) was added
hydrochloric acid (12 M, 1 mL) with stirring at 0.degree. C. The
resulting solution was stirred for 24 h at room temperature and
concentrated under vacuum to give 160 mg of the crude
(1S)-2-[(3R)-12-[[4-(methylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricycl-
o[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]-1-(1H-pyrazol-3-yl)etha-
n-1-ol hydrochloride as a yellow solid. The crude hydrochloride in
5 mL of methanol was added HCHO (37%, 0.5 mL) and the reaction
solution was stirred at room temperature for 30 min. The
NaBH.sub.3CN (46 mg, 0.73 mmol, 3.0 equiv) was added to the mixture
and the resulting solution was stirred for 4 h at ambient
temperature. After concentration in vacuo, the crude product was
purified by preparative HPLC under the following conditions
(Waters): column: X-briage C18, 19*150 mm 5 um; mobile phase,
CH.sub.3CN and water with 20 mM NH.sub.4HCO.sub.3 (10.0% CH.sub.3CN
up to 50.0% in 10 min, up to 95% in 2 min, down to 10.0% in 2 min);
flow rate: 20 mL/min; UV detection at 254/220 nm. The
product-containing fractions were collected and partially
evaporated to remove water and CH.sub.3CN under reduced pressure.
The residue was lyophilized overnight to give the desired
(1S)-2-[(3R)-12-[[4-(dimethylamino)cyclohexyl]oxy]-7-thia-9,11-di-
azatricyclo[6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-3-yl]-1-(1H-pyrazo-
l-3-yl)ethan-1-ol (65.9 mg) as a white solid. MS (ES): m/z 428
[M+H].sup.+. .sup.1H NMR (400 MHz, CD.sub.3OD): .delta. 8.45 (s,
1H), 7.65 (s, 1H), 6.35 (s, 1H), 5.23-5.25 (m, 1H), 4.92-4.95 (m,
1H), 3.36-3.38 (m, 1H), 3.10-3.15 (m, 1H), 2.93-2.98 (m, 1H),
2.71-2.74 (m, 1H), 2.51-2.52 (m, 2H), 2.48 (s, 6H), 2.15-2.17 (m,
2H), 1.89-2.03 (m, 3H), 1.44-1.49 (m, 4H).
Example 116
Synthesis of
2-hydroxy-3-((R)-4-(((1r,4R)-4-morpholinocyclohexyl)amino)-6,7-dihydro-5H-
-cyclopenta[4,5]thieno[2,3-d]pyrimidin-5-yl)propanamide (I-118)
##STR00477## ##STR00478##
[0976] Synthesis of Compound 116.1.
[0977] To a solution of compound 27.1 (140 mg, 0.55 mmol, 1.00
equiv) in dichloromethane (5 mL) was added
trimethylsilanecarbonitrile (168 mg, 1.69 mmol, 3.00 equiv) and
triethylamine (28 mg, 0.28 mmol, 0.50 equiv) at 0.degree. C. under
nitrogen. The resulting solution was stirred for 1 h at 0.degree.
C. until the starting aldehyde disappeared. The resulting mixture
was diluted with DCM, washed with saturated aqueous sodium
bicarbonate, dried over anhydrous sodium sulfate and concentrated
under vacuum. The residue was applied onto a silica gel column with
ethyl acetate/petroleum ether (1:10) to provide 155 mg of
3-[(3R)-12-chloro-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(12),2(6-
),8,10-tetraen-3-yl]-2-[(trimethylsilyl)oxy]propanenitrile
(contains de-TMS alcohol 116.2) as a white solid. MS: m/z 352
(M+H).sup.+.
[0978] Synthesis of Compound 116.2.
[0979] To a solution of
3-[(3R)-12-chloro-7-thia-9,11-diazatricyclo[6.4.0.0
[2,6]]dodeca-1(12),2(6),8,10-tetraen-3-yl]-2-[(trimethylsilyl)oxy]propane-
nitrile (240 mg, 0.68 mmol, 1.00 equiv) in methanol (5 mL) was
added 1 mL of concentrated hydrochloric acid at 0.degree. C. After
stirring for 1 h at room temperature, the pH value of the solution
was adjusted to 10 with saturated aqueous sodium bicarbonate,
diluted with DCM, washed with brine, dried over anhydrous sodium
sulfate and concentrated under vacuum to give 170 mg (89%) of
3-[(3R)-12-chloro-7-thia-9,11-diazatricyclo[6.4.0.0
[2,6]]dodeca-1(12),2(6),8,10-tetraen-3-yl]-2-hydroxypropanenitrile
as a white solid. MS: m/z 280 (M+H).sup.+.
[0980] Synthesis of Compound 116.3.
[0981] To a solution of
3-[(3R)-12-chloro-7-thia-9,11-diazatricyclo[6.4.0.0
[2,6]]dodeca-1(12),2(6),8, 10-tetraen-3-yl]-2-hydroxypropanenitrile
(170 mg, 0.61 mmol, 1.00 equiv) in 5 mL of distilled DMF was added
tert-butyl(chloro)dimethylsilane (138 mg, 0.92 mmol, 1.50 equiv)
and imidazole (124 mg, 1.82 mmol, 3.00 equiv) at room temperature
under nitrogen. The resulting solution was stirred for 2 h at
ambient temperature and diluted with DCM (30 mL), washed with
brine, dried over anhydrous sodium sulfate and concentrated under
vacuum to give 236 mg (99%) of
2-[(tert-butyldimethylsilyl)oxy]-3-[(3R)-12-chloro-7-thia-9,11-d-
iazatricyclo[6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-3-yl]propanenitri-
le as a white solid. MS: m/z 395 (M+H).sup.+.
[0982] Synthesis of Compound 116.4.
[0983] To a solution of
2-[(tert-butyldimethylsilyl)oxy]-3-[(3R)-12-chloro-7-thia-9,11-diazatricy-
clo[6.4.0.0
[2,6]]dodeca-1(12),2(6),8,10-tetraen-3-yl]propanenitrile (150 mg,
0.38 mmol, 1.00 equiv) in NMP (1 mL) was added triethylamine (310
mg, 3.06 mmol, 8.00 equiv) and 4-(morpholin-4-yl)cyclohexan-1-amine
(560 mg, 3.04 mmol, 8.00 equiv) at room temperature. The resulting
solution was stirred overnight at 75.degree. C. under nitrogen.
After cooling to room temperature, the resulting solution was
diluted with DCM (30 mL), washed with brine, dried over anhydrous
sodium sulfate and concentrated under vacuum. The residue was
applied onto a silica gel column with dichloromethane/methanol
(20:1) to give 185 mg (90%) of
2-[(tert-butyldimethylsilyl)oxy]-3-[(3R)-12-[[4-(morpholin-4-yl)cyclohexy-
l]amino]-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tet-
raen-3-yl]propanenitrile as a white solid. MS: m/z 542
(M+H).sup.+.
[0984] Synthesis of Compound 116.5.
[0985] To a solution of
2-[(tert-butyldimethylsilyl)oxy]-3-[(3R)-12-[[4-(morpholin-4-yl)cyclohexy-
l]amino]-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tet-
raen-3-yl]propanenitrile (180 mg, 0.33 mmol, 1.00 equiv) in
methanol (5 mL) was added LiOH.H.sub.2O (40 mg, 0.95 mmol, 3.00
equiv) and 0.5 mL of H.sub.2O.sub.2(30%) at 0.degree. C. The
resulting solution was stirred for 1 h at 0.degree. C. and then
quenched with saturated aqueous Na.sub.2SO.sub.3, diluted with DCM
(30 mL), washed with brine, dried over anhydrous sodium sulfate and
concentrated under vacuum. The residue was applied onto a silica
gel column with dichloromethane/methanol (20:1) to give 130 mg
(70%) of
2-[(tert-butyldimethylsilyl)oxy]-3-[(3R)-12-[[4-(morpholin-4-yl)cyclohexy-
l]amino]-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tet-
raen-3-yl]propanamide as a white solid. MS: m/z 560
(M+H).sup.+.
[0986] Synthesis of Compound I-118.
[0987] To a solution of
2-[(tert-butyldimethylsilyl)oxy]-3-[(3R)-12-[[4-(morpholin-4-yl)cyclohexy-
l]amino]-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tet-
raen-3-yl]propanamide (200 mg, 0.36 mmol, 1.00 equiv) in methanol
(5 mL) was added hydrochloric acid (0.5 mL) and stirred for 2 h at
room temperature. After completion of the reaction, the pH value of
the mixture was adjusted to 10 with saturated aqueous sodium
bicarbonate, diluted with DCM (30 mL), washed with brine, dried
over anhydrous sodium sulfate and concentrated under vacuum. The
residue was applied onto a silica gel column with
dichloromethane/methanol (20:1) to give 140 mg (88%) of Compound
I-118 as a white solid. MS: m/z 446 (M+H).sup.+.
Example 117
Synthesis of
(S)-2-hydroxy-3-((R)-4-(((1r,4R)-4-morpholinocyclohexyl)amino)-6,7-dihydr-
o-5H-cycyclopenta[4,5]thieno[2,3-d]pyrimidin-5-yl)propanamide
(I-120) and
(R)-2-hydroxy-3-((R)-4-(((1r,4R)-4-morpholinocyclohexyl)amino)-6,7-dihydr-
o-5H-cycyclopenta[4,5]thieno[2,3-d]pyrimidin-5-yl)propanamide
(I-121)
##STR00479##
[0989] Synthesis of compounds I-120 and I-121.
[0990] The enantiomers of racemic Compound I-118 (250 mg) were
separated by preparative chiral HPLC under the following conditions
(Gilson G.times.281): column: Chiralpak IC, 2*25 cm, 5 um; mobile
phase: phase A: hexanes (0.2% TEA, HPLC grade), phase B: EtOH (0.2%
TEA, HPLC grade), gradient: 20% B in 30 min; flow rate: 17 mL/min;
UV detection at 220/254 nm. The fractions containing Compound I-120
were collected and evaporated under reduced pressure and
lyophilized overnight to afford Compound I-120 (113 mg) with 100%
ee as a white solid. The ee value (t.sub.R=26.363 min) was
determined under the following conditions (SHIMADZU): column:
Chiralpak IC, 0.46*25 cm, 5 um; mobile phase: hexanes (0.1% TEA):
EtOH=75:25; UV detection at 254 nm. Flow rate: 1.0 mL/min. MS: m/z
446 (M+H).sup.+. .sup.1H NMR (400 MHz, CD.sub.3OD): .delta. 8.23
(s, 1H), 4.21-4.11 (M, 1H), 4.10 (t, 1H), 3.80-3.60 (m, 5H),
3.20-3.05 (m, 1H), 3.01-2.85 (m, 1H), 2.74-2.65 (m, 5H), 2.45-2.23
(m, 2H), 2.25-1.95 (m, 6H), 1.78-1.43 (m, 4H). The fractions
containing Compound I-121 were collected and evaporated under
reduced pressure and lyophilized overnight to afford the compound
I-121 (83 mg) with 99.6% ee as a white solid. The ee value
(tR=31.755 min) was determined by the same conditions. MS: m/z 445
(M+H).sup.+. .sup.1H NMR (400 MHz, CD.sub.3OD): .delta. 8.24 (s,
1H), 4.19-4.14 (M, 1H), 4.12 (dd, 1H), 3.75-3.73 (m, 4H), 3.65-3.57
(m, 1H), 3.17-3.09 (m, 1H), 2.99-2.92 (m, 1H), 2.76-2.66 (m, 5H),
2.51-2.37 (m, 2H), 2.22-2.07 (m, 4H), 2.00-1.92 (m, 1H), 1.80-1.72
(m, 1H), 1.68-1.43 (m, 4H).
Example 118
Synthesis of Intermediate 118.7
##STR00480## ##STR00481##
[0992] Synthesis of Compound 118.1.
[0993] A solution of
2-[(3R)-12-chloro-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6)-
,9,11-tetraen-3-yl]acetaldehyde (450 mg, 1.78 mmol, 1.00 equiv) in
tetrahydrofuran (10 mL) was stirred at 0.degree. C. Then EtMgBr
(3.4 mL, 1 N in THF) was added at -10.degree. C. The resulting
solution was stirred for 3 h at -10.degree. C. The reaction was
then quenched by the addition of 10 mL of water. The resulting
solution was extracted with 3.times.60 mL of ethyl acetate and the
organic layers combined and concentrated under vacuum. The residue
was applied onto a silica gel column with ethyl acetate/petroleum
ether (1:5). This resulted in 450 mg (89%) of
1-[(3R)-12-chloro-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca--
1(8),2(6),9,11-tetraen-3-yl]butan-2-ol as a colorless oil.
[0994] Synthesis of Compound 118.2.
[0995] A solution of
1-[(3R)-12-chloro-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6)-
,9,11-tetraen-3-yl]butan-2-ol (450 mg, 1.59 mmol, 1.00 equiv),
imidazole (195 mg, 2.86 mmol, 1.80 equiv) and TBSCl (357 mg, 2.38
mmol, 1.50 equiv) in N,N-dimethylformamide (7 mL) was stirred at
room temperature for 4 h. The reaction was then quenched by the
addition of 10 mL of water. The resulting solution was extracted
with 3.times.60 mL of ethyl acetate and the organic layers
combined. The resulting mixture was washed with 3.times.40 mL of
water. The solvent was removed. The residue was applied onto a
silica gel column and eluted with PE/EA (10:1). This resulted in
480 mg (76%) of
(3R)-3-[2-[(tert-butyldimethylsilyl)oxy]butyl]-12-chloro-7-thia-9,11-diaz-
atricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraene as a
colorless oil.
[0996] Synthesis of Compound 118.3.
[0997] A solution of
(3R)-3-[2-[(tert-butyldimethylsilyl)oxy]butyl]-12-chloro-7-thia-9,11-diaz-
atricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraene (480 mg, 1.21
mmol, 1.00 equiv), triethylamine (350 mg, 3.46 mmol, 2.86 equiv)
and tert-butyl N-(4-aminocyclohexyl)carbamate (760 mg, 3.55 mmol,
2.93 equiv) in DMSO (5 mL) was stirred overnight at 60.degree. C.
The reaction was then quenched by the addition of 15 mL of water.
The resulting solution was extracted with 3.times.70 mL of ethyl
acetate and the organic layers combined. The resulting mixture was
washed with 3.times.40 mL of water. The resulting mixture was
concentrated under vacuum. The residue was applied onto a silica
gel column with ethyl acetate/petroleum ether (1:5). This resulted
in 800 mg (crude) of tert-butyl
N-(4-[[(3R)-3-[2-[(tert-butyldimethylsilyl)oxy]butyl]-7-thia-9,11-diazatr-
icyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]amino]cyclohexyl)c-
arbamate as a white solid. MS: m/z 575 (M+H).sup.+.
[0998] Synthesis of Compound 118.4.
[0999] A solution of
tert-butyl-N-(4-[[(3R)-3-[2-[(tert-butyldimethylsilyl)oxy]butyl]-7-thia-9-
,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]amino]c-
yclohexyl)carbamate (800 mg, 1.39 mmol, 1.00 equiv) in
tetrahydrofuran (20 mL) was stirred at 0.degree. C. This was
followed by the addition of sodium hydride (134 mg, 3.35 mmol, 2.41
equiv) at 0.degree. C. The resulting solution was stirred for 30
min at 0.degree. C. To this was added PMBBr (1.397 g, 6.95 mmol,
4.99 equiv). The resulting solution was allowed to react, with
stirring, overnight at 50.degree. C. The reaction was then quenched
by the addition of 20 mL of water. The resulting solution was
extracted with 3.times.80 mL of ethyl acetate and the organic
layers combined and concentrated under vacuum. The residue was
applied onto a silica gel column with dichloromethane/methanol
(20:1). This resulted in 650 mg (67%) of tert-butyl
N-(4-[[(3R)-3-[2-[(tert-butyldimethylsilyl)oxy]butyl]-7-thia-9,11-diazatr-
icyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl][(4-methoxyphenyl)-
methyl]amino]cyclohexyl)carbamate as a yellow solid. MS: m/z 695
(M+H).sup.+.
[1000] Synthesis of Compound 118.5.
[1001] A solution of tert-butyl
N-(4-[[(3R)-3-[2-[(tert-butyldimethylsilyl)oxy]butyl]-7-thia-9,11-diazatr-
icyclo[6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-12-yl][(4-methoxyphenyl-
)methyl]amino]cyclohexyl)carbamate (480 mg, 0.69 mmol, 1.00 equiv)
in methanol (8 mL) was stirred at room temperature and hydrogen
chloride (5 N) (3 mL) was added to the mixture. The resulting
solution was stirred for 5 h at room temperature. The reaction was
then quenched by the addition of 20 mL of sodium bicarbonate
(sat.). The resulting solution was extracted with 3.times.50 mL of
ethyl acetate and the organic layers combined and concentrated
under vacuum. This resulted in 300 mg (90%) of
1-[(3R)-12-[(4-aminocyclohexyl)[(4-methoxyphenyl)methyl]amino]-7-thia-9,1-
1-diazatricyclo[6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-3-yl]butan-2-o-
l as a white solid.
[1002] Synthesis of Compound 118.6.
[1003] A solution of
1-[(3R)-12-[(4-aminocyclohexyl)amino]-7-thia-9,11-diazatricyclo[6.4.0.0[2-
,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]butan-2-ol (250 mg, 0.69
mmol, 1.00 equiv) and Boc.sub.2O (215 mg, 0.99 mmol, 1.42 equiv) in
tetrahydrofuran (15 mL) was stirred at room temperature and then a
solution of sodium hydroxide (39 mg, 0.97 mmol, 1.41 equiv) in
water (3.5 mL) was added to the mixture. The resulting solution was
stirred for 3 h at room temperature. The reaction was then quenched
by the addition of 10 mL of NH.sub.4Cl (aq.). The resulting
solution was extracted with 4.times.30 mL of ethyl acetate and the
organic layers combined and concentrated under vacuum. The residue
was applied onto a silica gel column with DCM/MeOH (10/1). This
resulted in 110 mg (34%) of tert-butyl
N-(4-[[(3R)-3-(2-hydroxybutyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dod-
eca-1(8),2(6),9,11-tetraen-12-yl]amino]cyclohexyl)carbamate as a
yellow solid.
[1004] Synthesis of Compound 118.7.
[1005] A solution of tert-butyl
N-(4-[[(3R)-3-(2-hydroxybutyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dod-
eca-1(12),2(6),8,10-tetraen-12-yl][(4-methoxyphenyl)methyl]amino]cyclohexy-
l)carbamate (200 mg, 0.34 mmol, 1.00 equiv) in tetrahydrofuran (26
mg, 0.36 mmol, 1.05 equiv) was stirred at 0.degree. C., sodium
hydride (69 mg, 2.88 mmol, 8.35 equiv) was added to the mixture,
the reaction was stirred for 30 min. Then iodomethane (122 mg) was
added too. The resulting solution was stirred for 3 h at 0.degree.
C. The reaction was then quenched by the addition of 50 mL of
water. The resulting solution was extracted with 3.times.50 mL of
ethyl acetate and the organic layers combined and concentrated
under vacuum. The residue was applied onto a silica gel column with
dichloromethane/methanol (10/1). This resulted in 200 mg (98%) of
tert-butyl
N-(4-[[(3R)-3-(2-methoxybutyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dod-
eca-1(12),2(6),8,10-tetraen-12-yl][(4-methoxyphenyl)methyl]amino]cyclohexy-
l)carbamate as a yellow solid.
Example 119
Synthesis of
(1r,4R)-N1-((R)-5-((R)-2-methoxybutyl)-6,7-dihydro-5H-cyclopenta[4,5]thie-
no[2,3-d]pyrimidin-4-yl)-N4,N4-dimethylcyclohexane-1,4-diamine
(I-147) and
(1r,4R)-N1-((R)-5-((S)-2-methoxybutyl)-6,7-dihydro-5H-cyclopenta[4,5]thie-
no[2,3-d]pyrimidin-4-yl)-N4,N4-dimethylcyclohexane-1,4-diamine
(I-148)
##STR00482##
[1007] Synthesis of Compound I-147 and I-148. A solution of
tert-butyl
N-(4-[[(3R)-3-(2-methoxybutyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dod-
eca-1(8),2(6),9,11-tetraen-12-yl][(4-methoxyphenyl)methyl]amino]cyclohexyl-
)carbamate (200 mg, 0.34 mmol, 1.00 equiv) in trifluoroacetic acid
(5 mL) was heated to reflux for 2 hr. The resulting mixture was
concentrated under vacuum. This resulted in 120 mg (crude) of
1-N-[(3R)-3-(2-methoxybutyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodec-
a-1(8),2(6),9,11-tetraen-12-yl]cyclohexane-1,4-diamine as a
colorless oil. It was not purified for the next reaction.
[1008] A solution of
1-N-[(3R)-3-(2-methoxybutyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodec-
a-1(12),2(6),8,10-tetraen-12-yl]cyclohexane-1,4-diamine (120 mg,
0.33 mmol, 1.00 equiv) and HCHO (37%) (1.0 mL) in MeOH (6 mL). The
resulting solution was stirred for 0.5 h at room temperature. Then
NaBH.sub.3CN (66.0 mg, 1.05 mmol, 3.17 equiv) was added. The
resulting solution was allowed to react, with stirring, for an
additional 3 h at room temperature. The crude product (70 mg) was
purified by preparative HPLC under the following conditions
(1#-Pre-HPLC-001(SHIMADZU)): column: Xbridge Prep C18 5 um, 19*150
mm; mobile phase: water with 0.05% NH.sub.4HCO.sub.3 and CH.sub.3CN
(6.0% CH.sub.3CN up to 50.0% in 25 min); Detector, 254/220 nm. This
resulted in 11.2 mg of Compound I-147 as a yellow solid and 17.7 mg
of Compound I-148.
[1009] Analytical data for I-147: MS: m/z 403 (M-1.2HCOOH+H).sup.+.
.sup.1H NMR (400 Hz, CD.sub.3OD): .delta. 8.48 (2H, br s), 4.19
(1H, m), 3.50 (1H, m), 3.33 (3H, m), 3.11 (1H, m), 2.91 (7H, m),
2.72 (1H, m), 2.35 (2H, m), 2.28 (2H, m), 1.95 (1H, m), 1.70-1.89
(7H, m), 0.94 (3H, t).
[1010] Analytical data for I-148: MS: m/z 403
(M-1.29HCOOH+H).sup.+. .sup.1H NMR (400 Hz, CD.sub.3OD): .delta.
8.48 (2.28H, br s), 4.19 (1H, m) 3.50 (1H, m), 3.33 (3H, m), 3.11
(1H, m), 2.91 (7H, m), 2.72 (1H, m), 2.27 (5H, m), 1.62-1.96 (8H,
m), 0.94 (3H, t).
Example 120
Synthesis of Intermediate 120.5
##STR00483##
[1012] Synthesis of Compound 120.2.
[1013] Into a 500-mL round-bottom flask (1 atm) purged and
maintained with an inert atmosphere of nitrogen, was placed a
suspension of LiAlH.sub.4 (3.8 g) in tetrahydrofuran (150 mL). This
was followed by the addition of a solution of tert-butyl
N-(4-aminocyclohexyl)carbamate (4.28 g, 19.97 mmol, 1.00 equiv) in
tetrahydrofuran (50 mL) dropwise with stirring. The resulting
solution was stirred for 4 hr at 80.degree. C. The reaction was
then quenched by the addition of Na.sub.2SO.sub.4.10H.sub.2O. The
solids were filtered out. The filtrate was concentrated under
vacuum. This resulted in 2.3 g (90%) of
1-N-methylcyclohexane-1,4-diamine as a yellow solid.
[1014] Synthesis of Compound 120.3.
[1015] Into a 50-mL round-bottom flask was placed a solution of
ethyl 1,3-dioxo-2,3-dihydro-1H-isoindole-2-carboxylate (1.55 g,
7.07 mmol, 0.91 equiv), 1-N-methylcyclohexane-1,4-diamine (1 g,
7.80 mmol, 1.00 equiv) and TEA (1.58 g, 15.61 mmol, 2.00 equiv) in
dichloromethane (25 mL). The resulting solution was stirred for 14
hr at room temperature. The reaction was then quenched by the
addition of 20 mL of water. The resulting solution was extracted
with 3.times.30 mL of dichloromethane and the organic layers
combined. The resulting mixture was washed with 2.times.20 mL of
sodium chloride (sat.). The mixture was dried over anhydrous sodium
sulfate and concentrated under vacuum. This resulted in 1.6 g (79%)
of 2-[4-(methylamino)cyclohexyl]-2,3-dihydro-1H-isoindole-1,3-dione
as a yellow oil.
[1016] Synthesis of Compound 120.4.
[1017] Into a 50-mL round-bottom flask was placed a solution of
2-[4-(methylamino)cyclohexyl]-2,3-dihydro-1H-isoindole-1,3-dione
(1.6 g, 6.19 mmol, 1.00 equiv) and TEA (1.25 g, 12.35 mmol, 1.99
equiv) in dichloromethane (20 mL). This was followed by the
addition of di-tert-butyl dicarbonate (1.62 g, 7.42 mmol, 1.20
equiv) in portions. The resulting solution was stirred for 4 hr at
room temperature. The reaction was then quenched by the addition of
30 mL of water. The resulting solution was extracted with
3.times.30 mL of dichloromethane and the organic layers combined.
The resulting mixture was washed with 2.times.20 mL of sodium
chloride (sat.). The residue was applied onto a silica gel column
with ethyl acetate/petroleum ether (1:5). The collected fractions
were combined and concentrated under vacuum. This resulted in 1.8 g
(81%) of tert-butyl
N-[4-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)cyclohexyl]-N-methylcarbamat-
e as a white solid.
[1018] Synthesis of Compound 120.5.
[1019] Into a 100-mL round-bottom flask was placed a solution of
tert-butyl
N-[4-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)cyclohexyl]-N-methylcarbamat-
e (1.8 g, 5.02 mmol, 1.00 equiv) and hydrazine hydrate (2 mL) in
ethanol (40 mL). The resulting solution was stirred for 4 hr at
50.degree. C. The solids were filtered out. The resulting mixture
was concentrated under vacuum. This resulted in 600 mg (52%) of
tert-butyl N-(4-aminocyclohexyl)-N-methylcarbamate as a yellow
solid.
Example 121
Synthesis of
2-(((1R,4r)-4-(((R)-5-(2-hydroxyethyl)-6,7-dihydro-5H-cyclopenta[4,5]thie-
no[2,3-d]pyrimidin-4-yl)amino)cyclohexyl)(methyl)amino)-1-(pyrrolidin-1-yl-
)ethanone (I-116)
##STR00484##
[1021] Synthesis of Compound 121.1.
[1022] Into a 25-mL round-bottom flask was placed a solution of
tert-butyl N-(4-aminocyclohexyl)-N-methylcarbamate (430 mg, 1.88
mmol, 4.00 equiv),
2-[(3R)-12-chloro-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(12),2(6-
),8,10-tetraen-3-yl]ethan-1-ol (120 mg, 0.47 mmol, 1.00 equiv) and
TEA (143 mg, 1.41 mmol, 3.00 equiv) in N,N-dimethylformamide (8
mL). The resulting solution was stirred for 60 hr at 45.degree. C.
The reaction was then quenched by the addition of 20 mL of water.
The resulting solution was extracted with 3.times.20 mL of ethyl
acetate and the organic layers combined. The resulting mixture was
washed with 2.times.20 mL of sodium chloride (sat.). The residue
was applied onto a silica gel column with ethyl acetate (100%). The
collected fractions were combined and concentrated under vacuum.
This resulted in 120 mg (57%) of tert-butyl
N-(4-[[(3R)-3-(2-hydroxyethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dod-
eca-1(12),2(6),8,10-tetraen-12-yl]amino]cyclohexyl)-N-methylcarbamate
as a yellow oil.
[1023] Synthesis of Compound 121.2.
[1024] Into a 50-mL round-bottom flask was placed a solution of
tert-butyl
N-(4-[[(3R)-3-(2-hydroxyethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dod-
eca-1(12),2(6),8,10-tetraen-12-yl]amino]cyclohexyl)-N-methylcarbamate
(120 mg, 0.27 mmol, 1.00 equiv) in dichloromethane (10 mL). This
was followed by the addition of hydrogen chloride (conc.) (1 mL)
dropwise with stirring. The resulting solution was stirred for 4 h
at room temperature. The reaction was then quenched by the addition
of 30 mL of sodium bicarbonate (sat.). The resulting solution was
extracted with 3.times.20 mL of dichloromethane and the organic
layers combined. The resulting mixture was washed with 2.times.20
mL of sodium chloride (sat.). The mixture was dried over anhydrous
sodium sulfate and concentrated under vacuum. This resulted in 85
mg (91%) of
2-[(3R)-12-[[4-(methylamino)cyclohexyl]amino]-7-thia-9,11-diazatricyclo[6-
.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-3-yl]ethan-1-ol as a
yellow oil.
[1025] Synthesis of Compound I-116.
[1026] Into a 50-mL round-bottom flask (1 atm) purged and
maintained with an inert atmosphere of nitrogen was placed a
solution of 2-chloro-1-(pyrrolidin-1-yl)ethan-1-one (144 mg, 0.98
mmol, 3.98 equiv),
2-[(3R)-12-[[4-(methylamino)cyclohexyl]amino]-7-thia-9,11-diazatricyclo[6-
.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-3-yl]ethan-1-ol (85 mg,
0.25 mmol, 1.00 equiv) and potassium carbonate (101 mg, 0.73 mmol,
3.00 equiv) in N,N-dimethylformamide (10 mL). The resulting
solution was stirred for 14 hr at room temperature. The reaction
was then quenched by the addition of 20 mL of water. The resulting
solution was extracted with 3.times.20 mL of dichloromethane and
the organic layers combined. The mixture was concentrated. The
crude product (150 mg) was purified by flash preparative HPLC under
the following conditions (IntelFlash-2): column: C18 silica gel;
mobile phase: methanol:H.sub.2O:NH.sub.4HCO.sub.3=1:1:0.05
increasing to methanol:H.sub.2O:NH.sub.4HCO.sub.3=3:1:0.05 within
15 min; detector: 254 nm. 110 mg product was obtained. The product
(110 mg) was repurified by preparative HPLC under the following
conditions (1#-Pre-HPLC-016(Waters)): column: SunFire Prep C18,
19*150 mm 5 um; mobile phase: water with 50 mL NH.sub.4CO.sub.3 and
CH.sub.3CN (5.0% CH.sub.3CN up to 43.0% in 11 min, up to 95.0% in 2
min, down to 5.0% in 2 min); detector: 254/220 nm. This resulted in
80.5 mg (72%) of
2-[(4-[[(3R)-3-(2-hydroxyethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]do-
deca-1(12),2(6),8,10-tetraen-12-yl]amino]cyclohexyl)(methyl)amino]-1-(pyrr-
olidin-1-yl)ethan-1-one as a white solid. .sup.1H NMR (300 MHz,
CD.sub.3OD): .delta. 8.25 (s, 1H), 4.11 (m, 1H), 3.62-3.69 (m, 5H),
3.55-3.59 (m, 2H), 3.42-3.47 (m, 2H), 3.09-3.12 (m, 1H), 2.93 (m,
1H), 2.69-2.749 (m, 2H), 2.37 (s, 3H), 2.11-2.32 (m, 3H), 1.87-2.01
(m, 6H), 1.72 (m, 2H), 1.50 (t, 3H).
Example 122
Synthesis of
3-((S)-4-(((1r,4S)-4-(methyl(2-oxo-2-(pyrrolidin-1-yl)ethyl)amino)cyclohe-
xyl)amino)-6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-5-yl)propa-
namide (I-127)
##STR00485##
[1028] Synthesis of Compound 122.1.
[1029] Into a 50-mL round-bottom flask was placed a solution of
2-[(4-[[(3R)-3-(2-hydroxyethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]do-
deca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)(methyl)amino]-1-(pyrroli-
din-1-yl)ethan-1-one (80 mg, 0.17 mmol, 1.00 equiv), TEA (53 mg,
0.52 mmol, 3.00 equiv) and MsCl (40 mg) in dichloromethane (10 mL).
The reaction was stirred overnight at room temperature. The
resulting solution was diluted with 20 mL of water. The resulting
solution was extracted with 3.times.30 mL of ethyl acetate and the
organic layers combined and dried over anhydrous sodium sulfate and
concentrated under vacuum. This resulted in
2-[(3R)-12-[(4-[methyl[2-oxo-2-(pyrrolidin-1-yl)ethyl]amino]cyclohexyl)ox-
y]-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3--
yl]ethyl methanesulfonate (91 mg, 97%) as a yellow oil.
[1030] Synthesis of Compound 122.2.
[1031] Into a 50-mL round-bottom flask was placed a solution of
2-[(3R)-12-[(4-[methyl[2-oxo-2-(pyrrolidin-1-yl)ethyl]amino]cyclohexyl)ox-
y]-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3--
yl]ethyl methanesulfonate (91 mg, 0.17 mmol, 1.00 equiv),
4-dimethylaminopyridine (11 mg, 0.09 mmol, 0.53 equiv) and NaCN (50
mg, 1.02 mmol, 6.02 equiv) in DMSO (10 mL). The solution was
stirred for 5 h at 60 OC. The resulting solution was diluted with
30 mL of saturated sodium bicarbonate. The resulting solution was
extracted with 3.times.30 mL of ethyl acetate and the organic
layers combined and dried over anhydrous sodium sulfate and
concentrated under vacuum. The residue was purified by preparative
TLC (DCM/MeOH=10:1). This resulted in
3-[(3S)-12-[(4-[methyl[2-oxo-2-(pyrrolidin-1-yl)ethyl]amino]cyclohexyl)ox-
y]-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3--
yl]propanenitrile (75 mg, 95%) as a colorless oil.
[1032] Synthesis of Compound I-127.
[1033] Into a 50-mL round-bottom flask was placed a solution of
3-[(3
S)-12-[(4-[methyl[2-oxo-2-(pyrrolidin-1-yl)ethyl]amino]cyclohexyl)amino]--
7-thia-9, 11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,
11-tetraen-3-yl]propanenitrile (75 mg, 0.16 mmol, 1.00 equiv),
LiOH.H.sub.2O (5 mg, 0.12 mmol, 0.74 equiv) and H.sub.2O.sub.2
(30%) (0.3 mL) in methanol (10 mL). The reaction was stirred for 2
h at 0.degree. C. in a water/ice bath. The reaction was then
quenched by the addition of 20 mL of saturated Na.sub.2SO.sub.3.
The resulting solution was extracted with 3.times.30 mL of ethyl
acetate and the organic layers combined and concentrated under
vacuum. The crude product (70 mg) was purified by preparative HPLC
under the following conditions (1#-Pre-HPLC-016(Waters)): column:
SunFire Prep C18, 19*150 mm 5 um; mobile phase: water with 50 mL
NH.sub.4CO.sub.3 and CH.sub.3CN (5.0% CH.sub.3CN up to 46.0% in 10
min, up to 95.0% in 2 min, down to 5.0% in 2 min); detector:
254/220 nm. The product was freeze-dried. This resulted in 3-[(3
S)-12-[(4-[methyl[2-oxo-2-(pyrrolidin-1-yl)ethyl]amino]cyclohexy-
l)amino]-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetr-
aen-3-yl]propanamide (10.6 mg, 14%) as a white solid. MS: m/z 485
(M+H).sup.+. .sup.1H NMR (400 MHz, CD.sub.3OD): .delta. 8.23 (s,
1H), 4.89-4.27 (m, 1H), 3.59-3.33 (m, 7H), 3.08-2.94 (m, 2H),
2.69-2.61 (m, 2H), 2.75-2.17 (m, 6H), 2.10-1.47 (m, 14H).
Example 123
Synthesis of Intermediate 123.2
##STR00486##
[1035] Synthesis of Compound 123.1.
[1036] Sodium hydride (60% dispersion in mineral oil, 240 mg, 6.00
mmol, 3.00 equiv) was treated with tert-butyl
N-(4-hydroxycyclohexyl)-N-methylcarbamate (642 mg, 2.80 mmol, 1.40
equiv) in freshly distilled tetrahydrofuran (14 mL) at 0.degree. C.
under nitrogen for 30 min. To this mixture was added a solution of
(3S)-3-[[(tert-butyldimethylsilyl)oxy]methyl]-12-chloro-7-thia-9,11-diaza-
tricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraene (710 mg, 2.00
mmol, 1.00 equiv) in 5 mL of THF via syringe and the resulting
solution was stirred overnight at room temperature. After
completion, the reaction was quenched with saturated aqueous
NH.sub.4Cl and extracted with ethyl acetate. The combined organic
layers were washed with brine, dried over anhydrous sodium sulfate
and concentrated under vacuum. The residue was applied onto a
silica gel column with dichloromethane/methanol (8:1) to give the
desired tert-butyl
N-(4-[[(3S)-3-[[(tert-butyldimethylsilyl)oxy]methyl]-7-thia-9,11-diazatri-
cyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)-N-m-
ethylcarbamate (963 mg, 88%) as light yellow oil. MS: m/z 548
(M+H).sup.+.
[1037] Synthesis of Compound 123.2.
[1038] A solution of tert-butyl
N-(4-[[(3S)-3-[[(tert-butyldimethylsilyl)oxy]methyl]-7-thia-9,11-diazatri-
cyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)-N-m-
ethylcarbamate (963 mg, 1.76 mmol, 1.00 equiv) in 5 mL of THF was
added TBAF (919 mg, 3.51 mmol, 2.00 equiv) at room temperature. The
resulting solution was stirred overnight at 25.degree. C. and
diluted with water, extracted with 3.times.50 mL of ethyl acetate.
The combined organic layers were washed with brine, dried over
anhydrous sodium sulfate and concentrated under vacuum. The residue
was applied onto a silica gel column with ethyl acetate/petroleum
ether (1:1) to afford the tert-butyl
N-(4-[[(3S)-3-(hydroxymethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dode-
ca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)-N-methylcarbamate
(691 mg, 91%) as a white solid. MS: m/z 434 (M+H).sup.+.
Example 124
Synthesis of Intermediate 124.3
##STR00487##
[1040] Synthesis of Compound 124.1.
[1041] A solution of tert-butyl
N-(4-[[(3S)-3-(hydroxymethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dode-
ca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)-N-methylcarbamate
(691 mg, 1.59 mmol, 1.00 equiv) in 4 mL of DCM was added MsCl (366
mg, 3.18 mmol, 2.00 equiv) and triethylamine (643 mg, 6.35 mmol,
4.00 equiv) at 0.degree. C. under nitrogen. The resulting solution
was stirred for 2 h at room temperature and quenched with water.
The resulting solution was extracted with 3.times.30 mL of DCM. The
combined organic layers were washed with brine, dried over
anhydrous sodium sulfate and concentrated under vacuum afford
tert-butyl N-(4-[[(3
S)-3-[(methanesulfonyloxy)methyl]-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]-
dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)-N-methylcarbamate
(900 mg, crude) as a red oil. MS: m/z 512 (M+H).sup.+.
[1042] Synthesis of Compound 124.2.
[1043] Into a 50-mL round-bottom flask purged and maintained with
an inert atmosphere of nitrogen, was placed tert-butyl
N-(4-[[(3S)-3-[(methanesulfonyloxy)methyl]-7-thia-9,11-diazatricyclo[6.4.-
0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)-N-methylcarba-
mate (900 mg, 1.76 mmol, 1.00 equiv) in 6 mL of DMSO at room
temperature. NaCN (600 mg, 12.24 mmol, 6.96 equiv) and
4-dimethylaminopyridine (100 mg, 0.82 mmol, 0.47 equiv) were added
and the resulting solution was stirred for 2 h at 80.degree. C.
After cooling to room temperature, the reaction was quenched with
water and extracted with 3.times.50 mL of ethyl acetate. The
combined organic layers were washed with brine, dried over
anhydrous sodium sulfate and concentrated under vacuum. The residue
was applied onto a silica gel column with ethyl acetate/petroleum
ether (1:4) to provide tert-butyl
N-(4-[[(3R)-3-(cyanomethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-
-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)-N-methylcarbamate
(709 mg, 91%) as a white solid. MS: m/z 443 (M+H).sup.+.
[1044] Synthesis of Compound 124.3.
[1045] A solution of tert-butyl
N-(4-[[(3R)-3-(cyanomethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-
-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)-N-methylcarbamate
(709 mg, 1.60 mmol, 1.00 equiv) in 6 mL of MeOH was added LiOH.H2O
(135 mg, 3.21 mmol, 2.01 equiv) and H.sub.2O.sub.2(30%, 1 mL) at
0.degree. C. The resulting solution was stirred for 2 h at room
temperature and quenched with saturated aqueous NaHSO.sub.3
solution and extracted with 3.times.50 mL of ethyl acetate. The
combined extracts were washed with brine, dried over anhydrous
sodium sulfate and concentrated under vacuum. The residue was
applied onto a silica gel column with ethyl acetate/petroleum ether
(1:4) to give tert-butyl
N-(4-[[(3R)-3-(carbamoylmethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]do-
deca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)-N-methylcarbamate
(524 mg, 71%) as a white solid. MS: m/z 461 [M+H]+.
Example 125
2-((R)-4-(((1
r,4R)-4-(methyl(2-(pyridin-2-yl)ethyl)amino)cyclohexyl)oxy)-6,7-dihydro-5-
H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-5-yl)acetamide (I-128)
##STR00488##
[1047] Synthesis of Compound 125.1. A solution of tert-butyl
N-(4-[[(3R)-3-(carbamoylmethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]do-
deca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)-N-methylcarbamate
(524 mg, 1.14 mmol, 1.00 equiv) in DCM (6 mL) was added 6 M aqueous
hydrochloric acid (1 mL) at 0.degree. C. and the resulting solution
was stirred for 2 h at room temperature. After concentrated under
reduced pressure, the desired
2-[(3R)-12-[[4-(methylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo[6.4-
.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]acetamide
hydrochloride (451 mg, crude) was obtained as a light yellow
solid.
[1048] Synthesis of Compound I-128.
[1049] The hydrochloride (111 mg, 0.29 mmol, 1.00 equiv) in 4 mL of
distilled DMF was added DIEA (119 mg, 0.92 mmol, 3.13 equiv) and
2-(2-bromoethyl)pyridine (57 mg, 0.31 mmol, 1.04 equiv) at room
temperature. The resulting solution was stirred overnight at
100.degree. C. in an oil bath. The resulting mixture was diluted
with water and extracted with DCM and concentrated under vacuum.
The crude product (110 mg) was purified by preparative HPLC under
the following conditions (Waters): column: Xbridge Prep C18, 5 um,
19*50 mm; mobile phase: water with 0.05% NH4HCO3 and CH3CN (10%
CH3CN up to 25% in 10 min, up to 95% in 1.5 min, down to 10% in 1.5
min); UV detection at 254/220 nm. The product-containing fractions
were collected and partially evaporated under reduced pressure to
remove CH.sub.3CN and water. The residue was lyophilized overnight
to give the desired
2-[(1R)-8-[(4-[methyl[2-(pyridin-2-yl)ethyl]amino]cyclohexyl)oxy]-1H,2H,3-
H,4H-cyclopenta[a]inden-1-yl]acetamide (16.3 mg) as a light yellow
solid. MS: m/z 466 (M+H).sup.+. .sup.1H NMR (400 MHz, CD.sub.3OD):
.delta. 8.48 (d, 2H), 7.80 (t, 1H), 7.79 (d, 1H), 7.77-7.27 (m,
1H), 5.29-5.23 (m, 1H), 3.81-3.79 (m, 1H), 3.16-3.10 (m, 1H),
3.03-2.93 (m, 6H), 2.78-2.73 (m, 2H), 2.44 (s, 3H), 2.33-2.26 (m,
4H), 2.02 (d, 3H), 1.68-1.59 (m, 4H), 1.57-1.54 (m, 1H).
Example 126
Synthesis of
2-((R)-4-(((1r,4R)-4-((2-fluoroethyl)(methyl)amino)cyclohexyl)oxy)-6,7-di-
hydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-5-yl)acetamide
(I-125)
##STR00489##
[1051] Synthesis of Compound I-125.
[1052] To a solution of
2-[(3R)-12-[[4-(methylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo[6.4-
.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]acetamide (90 mg, 0.25
mmol, 1.00 equiv) in DMF (4 mL) was added 1-bromo-2-fluoroethane
(317.5 mg, 2.50 mmol, 10.00 equiv) and DIEA (195 mg, 1.51 mmol,
6.00 equiv). The resulting solution was stirred overnight at
70.degree. C. The mixture was diluted with DCM (40 mL), washed with
brine (40 mL), dried over sodium sulfate and concentrated under
vacuum. The crude product (70 mg) was purified by preparative HPLC
under the following conditions (Waters): column: SunFire Prep C18,
19*150 mm 5 um; mobile phase: water with NH.sub.4CO.sub.3 and
CH.sub.3CN (6.0% CH.sub.3CN up to 46.0% in 10 min, up to 95.0% in 2
min down to 6.0% in 2 min); flow rate: 20 mL/min; UV detection at
254/220 nm. The product-containing fractions were collected and
evaporated partially to remove water and CH.sub.3CN under reduced
pressure. The residue was lyophilized overnight to give (60 mg) of
the corresponding product
2-[(3R)-12-([4-[(2-fluoroethyl)(methyl)amino]cyclohexyl]oxy)-7-thia-9,11--
diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]acetamide
as a white solid. MS: m/z 407 (M+H).sup.+. .sup.1H NMR (400 MHz,
CD.sub.3OD): .delta. 8.48 (s, 1H), 5.25-5.30 (m, 1H), 4.62 (t, 1H,
J=4.8 Hz), 4.50 (t, 1H, J=4.8 Hz), 3.78-3.83 (m, 1H), 3.11-3.18 (m,
1H), 2.97-3.01 (m, 2H), 2.91 (t, 1H, J=4.8 Hz), 2.85 (t, 1H, J=4.8
Hz), 2.59-2.83 (m, 2H), 2.41 (s, 3H), 2.21-2.40 (m, 4H), 1.98-2.01
(m, 2H), 1.53-1.68 (m, 4H).
Example 127
Synthesis of
2,2-difluoro-3-((R)-4-(((1r,4R)-4-morpholinocyclohexyl)oxy)-6,7-dihydro-5-
H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-5-yl)propanamide
(I-142)
##STR00490## ##STR00491##
[1054] Synthesis of Compound 127.1.
[1055]
2-[(3R)-12-[[4-(morpholin-4-yl)cyclohexyl]oxy]-7-thia-9,11-diazatri-
cyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]ethan-1-ol
(500 mg, 1.24 mmol, 1.00 equiv) was dissolved in dichloromethane
(10 mL). Then Dess-Martin periodinane (820 mg) was added at
0.degree. C. The resulting solution was stirred overnight at
25.degree. C. The reaction was then quenched by the addition of 20
mL of sodium bicarbonate (sat.). The resulting solution was
extracted with 3.times.50 mL of dichloromethane and the organic
layers combined and concentrated under vacuum. The residue was
applied onto a silica gel column with dichloromethane/methanol
(20:1). This resulted in 480 mg (96%) of
2-[(3R)-12-[[4-(morpholin-4-yl)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo[-
6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]acetaldehyde as a
colorless oil.
[1056] Synthesis of Compound 127.2.
[1057] A solution of
2-[(3R)-12-[[4-(morpholin-4-yl)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo[-
6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]acetaldehyde (480
mg, 1.20 mmol, 1.00 equiv), TEA (60 mg, 0.59 mmol, 0.50 equiv) and
TMSCN (355 mg, 3.59 mmol, 3.00 equiv) in dichloromethane (10 mL)
was prepared and stirred for 2 h at 25.degree. C. The reaction was
then quenched by the addition of 20 mL of water. The resulting
solution was extracted with 3.times.50 mL of ethyl acetate and the
organic layers combined. The resulting mixture was washed with
3.times.20 mL of brine. The mixture was dried over anhydrous sodium
sulfate and concentrated under vacuum. This resulted in 450 mg
(crude) of
2-hydroxy-3-[(3R)-12-[[4-(morpholin-4-yl)cyclohexyl]oxy]-7-thia-9,11-diaz-
atricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]propanenitrile
as a colorless oil.
[1058] Synthesis of Compound 127.3.
[1059] A solution of
2-hydroxy-3-[(3R)-12-[[4-(morpholin-4-yl)cyclohexyl]oxy]-7-thia-9,11-diaz-
atricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]propanenitrile
(400 mg, 0.93 mmol, 1.00 equiv) and hydrogen chloride (12 N) (0.6
mL) in methanol (10 mL) was prepared and stirred overnight at room
temperature. The reaction was then quenched by the addition of 20
mL of sodium bicarbonate (sat.). The resulting solution was
extracted with 3.times.50 mL of ethyl acetate and the organic
layers combined and concentrated under vacuum. The residue was
applied onto a silica gel column with dichloromethane/methanol
(20:1). This resulted in 230 mg (53%) of methyl
2-hydroxy-3-[(3R)-12-[[4-(morpholin-4-yl)cyclohexyl]oxy]-7-thia-9,11-diaz-
atricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]propanoate
as a colorless oil.
[1060] Synthesis of Compound 127.4.
[1061] A solution of ethyl
2-hydroxy-3-[(3R)-12-[[4-(morpholin-4-yl)cyclohexyl]oxy]-7-thia-9,11-diaz-
atricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]propanoate
(230 mg, 0.50 mmol, 1.00 equiv) and Dess-Martin periodinane (317
mg) in dichloromethane (10 mL) was prepared. The resulting solution
was stirred for 3 h at 25.degree. C. The reaction was then quenched
by the addition of 20 mL of sodium bicarbonate (sat.). The
resulting solution was extracted with 3.times.50 mL of
dichloromethane and the organic layers combined and concentrated
under vacuum. The residue was applied onto a silica gel column with
dichloromethane/methanol (30:1). This resulted in 180 mg (79%) of
methyl
3-[(3R)-12-[[4-(morpholin-4-yl)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo[-
6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]-2-oxopropanoate as
a colorless oil.
[1062] Synthesis of Compound 127.5.
[1063] A solution of methyl
3-[(3R)-12-[[4-(morpholin-4-yl)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo[-
6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]-2-oxopropanoate
(150 mg, 0.33 mmol, 1.00 equiv), DAST (150 mg, 0.93 mmol, 2.85
equiv) in dichloromethane (10 mL) was prepared and stirred
overnight at 25.degree. C. The reaction was then quenched by the
addition of 20 mL of sodium bicarbonate (sat.). The resulting
solution was extracted with 3.times.50 mL of ethyl acetate and the
organic layers combined and concentrated under vacuum. The residue
was applied onto a silica gel column with dichloromethane/methanol
(40:1). This resulted in 120 mg (76%) of methyl
2,2-difluoro-3-[(3R)-12-[[4-(morpholin-4-yl)cyclohexyl]oxy]-7-thia-9,11-d-
iazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]propanoate
as a colorless oil.
[1064] Synthesis of Compound I-142.
[1065] A 50-mL sealed tube was charged with ethanol (20 mL) and
NH.sub.3(g) (30 mL) was introduced at 0.degree. C. This was
followed by the addition of methyl
2,2-difluoro-3-[(3R)-12-[[4-(morpholin-4-yl)cyclohexyl]oxy]-7-thia-9,11-d-
iazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]propanoate
(120 mg, 0.25 mmol, 1.00 equiv). The resulting solution was stirred
overnight at 25.degree. C. The resulting mixture was concentrated
under vacuum. The crude product (100 mg) was purified by
preparative HPLC under the following conditions
(1#-Pre-HPLC-016(Waters)): column: SunFire Prep C18, 19*150 mm 5
um; mobile phase: water with 50 mL NH.sub.4CO.sub.3 and CH.sub.3CN
(5.0% CH.sub.3CN up to 45.0% in 11 min, up to 95.0% in 2 min, down
to 5.0% in 2 min); detector: 254/220 nm. This resulted in 31.9 mg
(27%) of
2,2-difluoro-3-[(3R)-12-[[4-(morpholin-4-yl)cyclohexyl]oxy]-7-th-
ia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]prop-
anamide as a white solid. MS: m/z 467 (M+H).sup.+. .sup.1H NMR (300
MHz, CD.sub.3OD: 6 8.474 (1H, s), 5.226-5.333 (1H, m), 3.70-3.73
(5H, m), 2.728-3.172 (4H, m), 2.62-2.65 (4H, m), 2.07-2.49 (7H, m),
1.63-1.75 (2H, m), 1.41-1.53 (2H, m).
Example 128
Synthesis of
(S)-3-((R)-4-(((1r,4R)-4-aminocyclohexyl)oxy)-6,7-dihydro-5H-cyclopenta[4-
,5]thieno[2,3-d]pyrimidin-5-yl)-2-hydroxypropanamide (I-135) and
(R)-3-((R)-4-(((1
r,4R)-4-aminocyclohexyl)oxy)-6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]p-
yrimidin-5-yl)-2-hydroxypropanamide (I-138)
##STR00492## ##STR00493## ##STR00494##
[1067] Synthesis of Compound 128.1.
[1068] To a solution of tert-butyl N-(4-hydroxycyclohexyl)carbamate
(262 mg, 1.22 mmol, 1.50 equiv) in tetrahydrofuran (10 mL) was
added sodium hydride (114 mg) at 0.degree. C. The reaction was
stirred at 0.degree. C. for 30 min, then
(3R)-3-[2-[(tert-butyldimethylsilyl)oxy]ethyl]-12-chloro-7-thia-9,11-diaz-
atricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraene (300 mg, 0.81
mmol, 1.00 equiv) was added to the mixture. The resulting solution
was stirred for 3 h at 50.degree. C. The reaction was then quenched
by the addition of 10 mL of NH.sub.4Cl (sat.). The resulting
solution was extracted with 3.times.60 mL of ethyl acetate and the
organic layers combined and concentrated under vacuum. The residue
was applied onto a silica gel column with ethyl acetate/petroleum
ether (1:8). This resulted in 500 mg (98%) of tert-butyl
N-(4-[[(3R)-3-[2-[(tert-butyldimethyl
silyl)oxy]ethyl]-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),-
9,11-tetraen-12-yl]oxy]cyclohexyl)carbamate as a colorless oil.
[1069] Synthesis of Compound 128.2.
[1070] Tert-butyl
N-(4-[[(3R)-3-[2-[(tert-butyldimethylsilyl)oxy]ethyl]-7-thia-9,11-diazatr-
icyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)car-
bamate (500 mg, 0.91 mmol, 1.00 equiv) and TBAF (576 mg, 2.20 mmol,
2.41 equiv) were combined in tetrahydrofuran (8 mL). The resulting
solution was stirred overnight at room temperature. The reaction
was then quenched by the addition of 10 mL of water. The resulting
solution was extracted with 3.times.80 mL of ethyl acetate and the
organic layers combined and concentrated under vacuum. The residue
was applied onto a silica gel column with ethyl acetate/petroleum
ether (1:2). This resulted in 390 mg (99%) of tert-butyl
N-(4-[[(3R)-3-(2-hydroxyethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dod-
eca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)carbamate as a
white solid.
[1071] Synthesis of Compound 128.3.
[1072] Tert-butyl
N-(4-[[(3R)-3-(2-hydroxyethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dod-
eca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)carbamate (390 mg,
0.90 mmol, 1.00 equiv) and Dess-Martin periodinane (571 mg, 1.35
mmol, 1.50 equiv) were combined in dichloromethane (8 mL). The
resulting solution was stirred for 3 h at 0.degree. C. The reaction
was then quenched by the addition of 15 mL of sodium bicarbonate
(sat.). The resulting solution was extracted with 3.times.80 mL of
ethyl acetate and the organic layers combined and concentrated
under vacuum. The residue was applied onto a silica gel column with
ethyl acetate/petroleum ether (1:3). This resulted in 300 mg (77%)
of tert-butyl
N-(4-[[(3R)-3-(2-oxoethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca--
1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)carbamate as a white
solid.
[1073] Synthesis of Compound 128.4.
[1074] Tert-butyl
N-(4-[[(3R)-3-(2-oxoethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca--
1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)carbamate (300 mg, 0.70
mmol, 1.00 equiv), triethylamine (35 mg, 0.35 mmol, 0.50 equiv) and
TMSCN (206 mg) were combined in dichloromethane (8 mL). The
resulting solution was stirred for 3 h at 0 OC. The reaction was
then quenched by the addition of 10 mL of NH.sub.4Cl (sat.). The
resulting solution was extracted with 3.times.80 mL of ethyl
acetate and the organic layers combined and concentrated under
vacuum. The residue was applied onto a silica gel column with ethyl
acetate/petroleum ether (1/5). This resulted in 330 mg (89%) of
tert-butyl
N-(4-[[(3R)-3-[2-cyano-2-[(trimethylsilyl)oxy]ethyl]-7-thia-9,11-diazatri-
cyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)carb-
amate as a white solid.
[1075] Synthesis of Compound 128.5.
[1076] Tert-butyl
N-(4-[[(3R)-3-[2-cyano-2-[(trimethylsilyl)oxy]ethyl]-7-thia-9,11-diazatri-
cyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)carb-
amate (320 mg, 0.60 mmol, 1.00 equiv) and TBAF (286 mg, 1.09 mmol,
1.81 equiv) were combined in tetrahydrofuran (8 mL). The resulting
solution was stirred for 3 h at room temperature. The reaction was
then quenched by the addition of 10 mL of water. The resulting
solution was extracted with 3.times.50 mL of ethyl acetate and the
organic layers combined and concentrated under vacuum. The residue
was applied onto a silica gel column with ethyl acetate/petroleum
ether (1/2). This resulted in 215 mg (78%) of tert-butyl
N-(4-[[(3R)-3-(2-cyano-2-hydroxyethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[-
2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)carbamate
as a white solid.
[1077] Synthesis of Compound 128.6.
[1078] Tert-butyl
N-(4-[[(3R)-3-(2-cyano-2-hydroxyethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[-
2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)carbamate
(210 mg, 0.46 mmol, 1.00 equiv), imidazole (62 mg, 0.91 mmol, 1.99
equiv) and TBSCl (103 mg) were combined in N,N-dimethylformamide (5
mL). The resulting solution was stirred for 3 h at room
temperature. The reaction was then quenched by the addition of 20
mL of water. The resulting solution was extracted with 3.times.60
mL of ethyl acetate and the organic layers combined. The resulting
mixture was washed with 3.times.40 mL of water. The resulting
mixture was concentrated under vacuum. The residue was applied onto
a silica gel column with ethyl acetate/petroleum ether (1/5). This
resulted in 280 mg (98%) of tert-butyl
N-(4-[[(3R)-3-[2-[(tert-butyldimethylsilyl)oxy]-2-cyanoethyl]-7-thia-9,11-
-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cycloh-
exyl)carbamate as colorless oil.
[1079] Synthesis of Compounds 128.7 and 128.8.
[1080] Tert-butyl
N-(4-[[(3R)-3-[2-[(tert-butyldimethylsilyl)oxy]-2-cyanoethyl]-7-thia-9,11-
-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cycloh-
exyl)carbamate (250 mg, 0.44 mmol, 1.00 equiv), LiOH (54 mg, 2.25
mmol, 5.17 equiv) and H.sub.2O.sub.2(0.5 mL) were combined in
methanol (8 mL). The resulting solution was stirred for 4 h at
0.degree. C. The reaction was then quenched by the addition of 20
mL of Na.sub.2SO.sub.3 (sat.). The resulting solution was extracted
with 3.times.40 mL of ethyl acetate and the organic layers combined
and concentrated under vacuum. The residue was applied onto a
silica gel column with ethyl acetate/petroleum ether (1.2/1). This
resulted in 80 mg (31%) of tert-butyl
N-(4-[[(3R)-3-[(2S)-2-[(tert-butyldimethylsilyl)oxy]-2-carbamoylethyl]-7--
thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,
11-tetraen-12-yl]oxy]cyclohexyl)carbamate as a white solid and 70
mg (27%) of tert-butyl
N-(4-[[(3R)-3-[(2R)-2-[(tert-butyldimethylsilyl)oxy]-2-carbamoylethyl]-7--
thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]o-
xy]cyclohexyl)carbamate as a white solid.
[1081] Synthesis of Compound I-135.
[1082] A solution of tert-butyl
N-(4-[[(3R)-3-[(2S)-2-[(tert-butyldimethylsilyl)oxy]-2-carbamoylethyl]-7--
thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]o-
xy]cyclohexyl)carbamate (80 mg, 0.14 mmol, 1.00 equiv),
dichloromethane (5 mL) and hydrogen chloride (conc.) (0.3 mL) was
prepared. After stirring for 3 h at room temperature, the reaction
was then quenched by the addition of 10 mL of sodium bicarbonate
(aq.). The resulting mixture was concentrated under vacuum. The
crude product (80 mg) was purified by preparative HPLC under the
following conditions (1#-Pre-HPLC-015(Waters)): column: Xbridge
Prep C18, 5 um, 19*50 mm; mobile phase: water with 50 mmol NH4HCO3
and CH3CN (10% CH3CN up to 27% in 10 min, up to 95% in 1.5 min,
down to 10% in 1.5 min); detector: 254/220 nm. 30.9 mg product was
obtained. This resulted in 30.9 mg (61%) of
(2S)-3-[(3R)-12-[(4-aminocyclohexyl)oxy]-7-thia-9,11-diazatricyclo[6.4-
.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]-2-hydroxypropanamide
as a white solid. MS: m/z 377 (M+H).sup.+. .sup.1H NMR (400 Hz,
CD.sub.3OD): .delta. 8.47 (1H, br s), 5.33 (1H, m) 4.15 (1H, m),
3.50 (1H, m), 3.12 (2H, m), 3.00 (1H, m), 2.98 (1H, m), 2.88-2.53
(3H, m), 2.47-2.20 (4H, m), 1.87-1.66 (5H, m), 1.42 (2H, m).
[1083] Synthesis of Compound I-138.
[1084] A solution of tert-butyl
N-(4-[[(3R)-3-[(2R)-2-[(tert-butyldimethylsilyl)oxy]-2-carbamoylethyl]-7--
thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]o-
xy]cyclohexyl)carbamate (70 mg, 0.12 mmol, 1.00 equiv), hydrogen
chloride (conc.) (0.3 mL) in dichloromethane (5 mL). The resulting
solution was stirred for 3 h at room temperature. The reaction was
then quenched by the addition of 10 mL of sodium bicarbonate (aq.).
The resulting mixture was concentrated under vacuum. The crude
product (100 mg) was purified by preparative HPLC under the
following conditions (1#-Pre-HPLC-015(Waters)): column: Xbridge
Prep C18, 5 um, 19*50 mm; mobile phase: water with 50 mmol
NH.sub.4HCO.sub.3 and CH.sub.3CN (5% CH.sub.3CN up to 28% in 10
min, up to 95% in 1.5 min, down to 5% in 1.5 min); detector:
254/220 nm. 32 mg product was obtained. This resulted in 32 mg
(72%) of
(2R)-3-[(3R)-12-[(4-aminocyclohexyl)oxy]-7-thia-9,11-diazatricyclo[6.4.0.-
0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]-2-hydroxypropanamide as
a white solid. MS: m/z 377 (M+H).sup.+. .sup.1H NMR (300 MHz,
CD.sub.3OD): .delta. 8.46 (1H, br s), 5.33 (1H, m), 4.15 (1H, m),
3.60 (1H, m), 3.16 (1H, m), 3.00-2.90 (2H, m), 2.87 (1H, m),
2.88-2.53 (3H, m), 2.45-2.24 (4H, m), 1.87-1.66 (5H, m), 1.42 (2H,
m).
Example 129
Synthesis of
(2S)-3-[(3R)-12-[[4-(ethylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo-
[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]-2-hydroxypropanamide
(I-136)
##STR00495## ##STR00496##
[1086] Synthesis of Compound 129.1.
[1087] Into a 100-mL round-bottom flask was placed a solution of
tert-butyl N-ethyl-N-(4-hydroxycyclohexyl)carbamate (811 mg, 3.33
mmol, 2.05 equiv) in tetrahydrofuran (6 mL). Then sodium hydride
(472 mg, 11.80 mmol, 7.26 equiv, 60%) was added to the mixture. The
resulting solution was stirred for 0.5 h at 0.degree. C. Then
(3R)-3-[2-[(tert-butyldimethylsilyl)oxy]ethyl]-12-chloro-7-thia-9,11-diaz-
atricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11tetraene (600 mg, 1.63
mmol, 1.00 equiv) was added. The resulting solution was allowed to
react, with stirring, for an additional 2.5 h at room temperature.
The reaction was then quenched by the addition of 29 mL of
NH.sub.4Cl (sat.). The resulting solution was extracted with
3.times.50 mL of ethyl acetate and the organic layers combined and
concentrated under vacuum. The residue was applied onto a silica
gel column with ethyl acetate/petroleum ether (1:8). This resulted
in 680 mg (73%) of tert-butyl
N-(4-[[(3R)-3-[2-[(tert-butyldimethylsilyl)oxy]ethyl]-7-thia-9,11-diazatr-
icyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)-N--
ethylcarbamate as colorless oil.
[1088] Synthesis of Compound 129.2.
[1089] Into a 100-mL round-bottom flask was placed a solution of
tert-butyl
N-(4-[[(3R)-3-[2-[(tert-butyldimethylsilyl)oxy]ethyl]-7-thia-9,11-diazatr-
icyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)-N--
ethylcarbamate (680 mg, 1.18 mmol, 1.00 equiv) and TBAF.3H2O (747
mg, 2.36 mmol, 2.00 equiv) in tetrahydrofuran (10 mL). The
resulting solution was stirred for 2 h at 25.degree. C. The
resulting mixture was concentrated under vacuum. The residue was
applied onto a silica gel column with ethyl acetate/petroleum ether
(1:1). This resulted in 500 mg (92%) of tert-butyl
N-ethyl-N-(4-[[(3R)-3-(2-hydroxyethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[-
2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)carbamate
as a colorless oil.
[1090] Synthesis of Compound 129.3.
[1091] Into a 100-mL round-bottom flask was placed a solution of
tert-butyl
N-ethyl-N-(4-[[(3R)-3-(2-hydroxyethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[-
2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)carbamate
(500 mg, 1.08 mmol, 1.00 equiv) and Dess-Martin periodinane (689
mg, 1.62 mmol, 1.50 equiv) in dichloromethane (10 mL). The
resulting solution was stirred for 2 h at 25.degree. C. The
reaction was then quenched by the addition of 30 mL of water. The
resulting solution was extracted with 3.times.50 mL of
dichloromethane and the organic layers combined and concentrated
under vacuum. The residue was applied onto a silica gel column with
ethyl acetate/petroleum ether (1:3). This resulted in 480 mg (96%)
of tert-butyl
N-ethyl-N-(4-[[(3R)-3-(2-oxoethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]-
]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl) carbamate as
colorless oil.
[1092] Synthesis of Compound 129.4.
[1093] Into a 100-mL round-bottom flask was placed a solution of
tert-butyl
N-ethyl-N-(4-[[(3R)-3-(2-oxoethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]-
]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)carbamate (480
mg, 1.04 mmol, 1.00 equiv), TEA (50.6 mg, 0.50 mmol, 0.48 equiv)
and TMSCN (297 mg, 3.00 mmol, 2.87 equiv) in dichloromethane (6
mL). The resulting solution was stirred for 1 h at 0.degree. C. The
resulting mixture was concentrated under vacuum. This resulted in
580 mg (crude) of tert-butyl
N-(4-[[(3R)-3-[2-cyano-2-[(trimethylsilyl)oxy]ethyl]-7-thia-9,11-diazatri-
cyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)-N-e-
thylcarbamate as a colorless oil.
[1094] Synthesis of Compound 129.5.
[1095] Into a 50-mL round-bottom flask was placed a solution of
tert-butyl
N-(4-[[(3R)-3-[2-cyano-2-[(trimethylsilyl)oxy]ethyl]-7-thia-9,11-diazatri-
cyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)-N-e-
thylcarbamate (580 mg, 1.04 mmol, 1.00 equiv) and TBAF.3H.sub.2O
(656 mg, 2.08 mmol, 2.00 equiv) in tetrahydrofuran (6 mL). The
resulting solution was stirred for 1 h at room temperature. The
resulting mixture was concentrated under vacuum. The residue was
applied onto a silica gel column with ethyl acetate/petroleum ether
(1:1). This resulted in 500 mg (99%) of tert-butyl
N-(4-[[(3R)-3-(2-cyano-2-hydroxyethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[-
2,6]]dodeca-1
(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)-N-ethylcarbamate as
colorless oil.
[1096] Synthesis of Compound 129.6.
[1097] Into a 50-mL round-bottom flask, was placed a solution of
tert-butyl
N-(4-[[(3R)-3-(2-cyano-2-hydroxyethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[-
2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)-N-ethylcarbamate
(500 mg, 1.03 mmol, 1.00 equiv), imidazole (139 mg, 2.04 mmol, 1.99
equiv) and TBSCl (231 mg, 1.54 mmol, 1.50 equiv) in
N,N-dimethylformamide (3 mL). The resulting solution was stirred
for 1 h at room temperature. The reaction was then quenched by the
addition of 20 mL of water. The resulting solution was extracted
with 3.times.50 mL of ethyl acetate and the organic layers
combined. The resulting mixture was washed with 3.times.30 mL of
brine. The resulting mixture was concentrated under vacuum. The
residue was applied onto a silica gel column with ethyl
acetate/petroleum ether (1:10). This resulted in 590 mg (96%) of
tert-butyl
N-(4-[[(3R)-3-[2-[(tert-butyldimethylsilyl)oxy]-2-cyanoethyl]-7-thia-9,11-
-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cycloh-
exyl)-N-ethylcarbamate as colorless oil.
[1098] Synthesis of Compounds 129.7 and 129.8.
[1099] Into a 50-mL round-bottom flask was placed a solution of
tert-butyl
N-(4-[[(3R)-3-[2-[(tert-butyldimethylsilyl)oxy]-2-cyanoethyl]-7-thia-9,11-
-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cycloh-
exyl)-N-ethylcarbamate (490 mg, 0.82 mmol, 1.00 equiv),
LiOH.H.sub.2O (66.9 mg, 1.59 mmol, 1.96 equiv) and
H.sub.2O.sub.2(30%) (0.5 mL) in methanol (4 mL). The resulting
solution was stirred for 1 h at 0.degree. C. The reaction was then
quenched by the addition of 20 mL of Na.sub.2SO.sub.3 (sat.). The
resulting solution was extracted with 3.times.50 mL of ethyl
acetate and the organic layers combined and concentrated under
vacuum. The residue was applied onto a silica gel column with ethyl
acetate/petroleum ether (1:2.5). This resulted in 200 mg (79%) of
tert-butyl,N-(4-[[(3R)-3-[(2R)-2-[(tert-butyldimethylsilyl)oxy]-2-carbamo-
ylethyl]-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetr-
aen-12-yl]oxy]cyclohexyl)-N-ethylcarbamate as a colorless oil and
160 mg (63%) of tert-butyl
((1R,4r)-4-(((R)-5-((S)-3-amino-2-((tert-butyldimethylsilyl)oxy)-3-oxopro-
pyl)-6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-yl)oxy)cyclohe-
xyl)(ethyl)carbamate as a colorless oil.
[1100] Synthesis of Compound I-136.
[1101] Into a 50-mL round-bottom flask was placed a solution of
tert-butyl
N-(4-[[(3R)-3-[(2S)-2-[(tert-butyldimethylsilyl)oxy]-2-carbamoylethyl]-7--
thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]o-
xy]cyclohexyl)-N-ethylcarbamate (160 mg, 0.26 mmol, 1.00 equiv) and
hydrogen chloride (conc.) (0.3 mL) in dichloromethane (3 mL). The
resulting solution was stirred for 1 h at 0.degree. C. The
resulting mixture was concentrated under vacuum. The crude product
(200 mg) was purified by preparative HPLC under the following
conditions (1#-Pre-HPLC-015(Waters)): column: Xbridge Prep C18, 5
um, 19*50 mm; mobile phase: water with 50 mmol NH.sub.4HCO.sub.3
and CH.sub.3CN (10% CH.sub.3CN up to 25% in 10 min, up to 95% in
1.5 min, down to 10% in 1.5 min); detector: 254/220 nm. 47.3 mg
product was obtained. This resulted in 47.3 mg (45%) of
(2S)-3-[(3R)-12-[[4-(ethylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo-
[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]-2-hydroxypropanamide
as a white solid. MS: m/z 405 (M+H).sup.+. .sup.1H NMR (300 MHz,
CD.sub.3OD): .delta. 8.474 (1H, s), 5.24-5.26 (1H, m), 4.08-4.12
(1H, d), 3.53 (1H, m), 3.04-3.28 (1H, m), 2.92-2.95 (1H, m),
2.50-2.71 (4H, m), 2.40-2.47 (2H, m), 2.15-2.23 (2H, m), 1.98-2.07
(2H, m), 1.61-1.96 (3H, m), 1.26-1.34 (2H, m).
Example 130
Synthesis of
(2R)-3-[(3R)-12-[[4-(ethylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo-
[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]-2-hydroxypropanamide
(I-139)
##STR00497##
[1103] Synthesis of Compound I-139.
[1104] A solution of tert-butyl
N-(4-[[(3R)-3-[(2R)-2-[(tert-butyldimethylsilyl)oxy]-2-carbamoylethyl]-7--
thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]o-
xy]cyclohexyl)-N-ethylcarbamate (200 mg, 0.32 mmol, 1.00 equiv),
hydrogen chloride (conc.) (0.3 mL) in dichloromethane (3 mL). The
resulting solution was stirred for 1 h at 0.degree. C. The
resulting mixture was concentrated under vacuum. The crude product
(200 mg) was purified by preparative HPLC under the following
conditions (1#-Pre-HPLC-016(Waters)): column: SunFire Prep C18,
19*150 mm 5 um; mobile phase: water WITH 50 mL NH.sub.4CO.sub.3 and
CH.sub.3CN (5.0% CH.sub.3CN up to 44.5.0% in 10 min, up to 95.0% in
2 min, down to 5.0% in 2 min); detector: 254/220 nm. 57.4 mg
product was obtained. This resulted in 57.4 mg (44%) of
(2R)-3-[(3R)-12-[[4-(ethylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo-
[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]-2-hydroxypropanamide
as a white solid. MS: m/z 405 (M+H).sup.+. .sup.1H-NMR (300 MHz,
CD.sub.3OD): .delta. 8.474 (1H, s), 5.25-5.22 (1H, m), 4.00-4.03
(1H, t), 3.61 (1H, m), 3.07-3.10 (1H, m), 2.94-2.98 (1H, m),
2.52-2.68 (4H, m), 2.18-2.39 (2H, m), 1.64-1.71 (3H, m), 1.26-1.34
(2H, m), 1.08-1.13 (3H, d).
Example 131
Synthesis of Intermediate 131.1
##STR00498##
[1106] Synthesis of Intermediate 131.1.
[1107] A solution of tert-butyl
N-(1-ethyl-4-[[(3R)-3-(2-hydroxyethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[-
2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)carbamate
(1.1 g, 2.38 mmol, 1.00 equiv) in dichloromethane (10 mL) was
stirred at 0.degree. C., then Dess-Martin (1.5 g) was added at
0.degree. C. The resulting solution was stirred for 2 h at
25.degree. C. The reaction was then quenched by the addition of 10
mL of sodium bicarbonate (aq.), extracted with 3.times.80 mL of
dichloromethane and the organic layers combined and concentrated
under vacuum. The residue was applied onto a silica gel column with
ethyl acetate/petroleum ether (1:3). This resulted in 1.0 g (91%)
of tert-butyl
N-(1-ethyl-4-[[(3R)-3-(2-oxoethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]-
]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)carbamate as a
colorless oil.
Example 132
Synthesis of
(2R)-1-[(3R)-12-[[4-(dimethylamino)-4-ethylcyclohexyl]oxy]-7-thia-9,11-di-
azatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]butan-2-ol
(I-101)
##STR00499##
[1109] Synthesis of Compounds 132.1 and 132.2.
[1110] A solution of tert-butyl
N-(1-ethyl-4-[[(3R)-3-(2-oxopropyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6-
]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)carbamate (330
mg, 0.70 mmol, 1.00 equiv) in tetrahydrofuran (10 mL) was stirred
at 0.degree. C. This was followed by the addition of
C.sub.2H.sub.5MgBr (0.479 mL) dropwise with stirring at 0.degree.
C. The resulting solution was stirred for 2 h at 0.degree. C. The
reaction was then quenched by the addition of 20 mL of NH.sub.4Cl
(aq.) and then extracted with 3.times.40 mL of ethyl acetate and
the organic layers combined and concentrated under vacuum. The
residue was applied onto a silica gel column with ethyl
acetate/petroleum ether (1:4.5). This resulted in 120 mg (35%) of
tert-butyl
N-(1-ethyl-4-[[(3R)-3-[(2R)-2-hydroxybutyl]-7-thia-9,11-diazatricyclo[6.4-
.0.0[2,6]]dodeca-1(8),2(6),9,
11-tetraen-12-yl]oxy]cyclohexyl)carbamate as a colorless oil and 70
mg (21%) of tert-butyl
N-(1-ethyl-4-[[(3R)-3-[(2S)-2-hydroxybutyl]-7-thia-9,11-diazatricyclo[6.4-
.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)carbamate
as a colorless oil.
[1111] Synthesis of Compound 132.3.
[1112] A solution of tert-butyl
N-(1-ethyl-4-[[(3R)-3-[(2R)-2-hydroxybutyl]-7-thia-9,11-diazatricyclo[6.4-
.0.0[2,6]]dodeca-1(8),2(6),9,
11-tetraen-12-yl]oxy]cyclohexyl)carbamate (120 mg, 0.25 mmol, 1.00
equiv) in dichloromethane (10 mL) was stirred at 0.degree. C. And
then hydrogen chloride (0.5 mL) was added. The resulting solution
was stirred for 1 h at 0.degree. C. The resulting mixture was
concentrated under vacuum. This resulted in 90 mg (crude) of
(2R)-1-[(3R)-12-[(4-amino-4-ethylcyclohexyl)oxy]-7-thia-9,11-diazatricycl-
o[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]butan-2-ol
hydrochloride as colorless oil.
[1113] Synthesis of Compound I-101.
[1114] A solution of
(2R)-1-[(3R)-12-[(4-amino-4-ethylcyclohexyl)oxy]-7-thia-9,11-diazatricycl-
o[6.4.0.0[2,6]]dodeca-1(8),2(6),9, 11-tetraen-3-yl]butan-2-ol
hydrochloride (90 mg, 0.21 mmol, 1.00 equiv) and HCHO (0.8 mL)(37%)
in methanol (6 mL) was stirred at room temperature for 0.5 h. Then
NaBH.sub.3CN (72.88 mg, 1.16 mmol, 5.49 equiv) was added. The
resulting solution was allowed to react, with stirring, for an
additional 2 h at room temperature. The reaction was then quenched
by the addition of 20 mL of water and then extracted with
3.times.50 mL of chloroform/iso-propanol (3/1) and the organic
layers combined and concentrated under vacuum. The crude product
(98 mg) was purified by preparative HPLC under the following
conditions (Waters): column: column: SunFire Prep C18, 19*150 mm 5
um; mobile phase: water with 50 mL NH4CO3 and CH3CN (5.0% CH3CN up
to 44.0% in 12 min, up to 95.0% in 2 min, down to 5.0% in 2 min);
Detector, 254/220 nm. This resulted in 34.6 mg (39%) of
(2R)-1-[(3R)-12-[[4-(dimethylamino)-4-ethylcyclohexyl]oxy]-7-thia-9,11-di-
azatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]butan-2-ol
as an off-white solid. MS: 418 (M+H).sup.+. .sup.1H NMR (300 MHz,
CD.sub.3OD): .delta. 8.47 (1H, s), 5.33-5.42 (1H, m), 3.68 (1H, m),
3.42-3.45 (1H, m), 3.00-3.14 (1H, m), 2.92-2.98 (1H, m), 2.70-2.73
(1H, m), 2.50-2.67 (1H, m), 2.31-2.45 (1H, m), 2.06-2.11 (3H, m),
1.41-1.82 (11H, m), 0.91-1.05 (6H, m).
Example 133
Synthesis of
(2S)-1-[(3R)-12-[(4-amino-4-ethylcyclohexyl)oxy]-7-thia-9,11-diazatricycl-
o[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]but-3-en-2-ol
(I-126)
##STR00500##
[1116] A 50-mL round-bottom flask was charged with a solution of
tert-butyl
N-(1-ethyl-4-[[(3R)-3-[(2S)-2-hydroxybut-3-en-1-yl]-7-thia-9,11-diazatric-
yclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)carba-
mate (35 mg, 0.07 mmol, 1.00 equiv; prepared in a manner analogous
to compounds 132.1 and 132.2 in Example 132) and hydrogen chloride
(conc.) (0.2 mL) in dichloromethane (10 mL). After stirring for 1 h
at 0.degree. C. in an water/ice bath, the reaction was then
quenched by the addition of 20 mL of saturated sodium bicarbonate.
The resulting solution was extracted with 4.times.30 mL of ethyl
acetate and the organic layers combined and concentrated under
vacuum. The crude product (30 mg) was purified by preparative HPLC
under the following conditions (1#-Pre-HPLC-016(Waters)): column:
SunFire Prep C18, 19*150 mm 5 um; mobile phase: water with 50 mL
NH.sub.4CO.sub.3 and CH.sub.3CN (5.0% CH.sub.3CN up to 44.0% in 10
min, up to 95.0% in 2 min, down to 5.0% in 2 min); detector:
254/220 nm. The product was freeze-dried. This resulted in
(2S)-1-[(3R)-12-[(4-amino-4-ethylcyclohexyl)oxy]-7-thia-9,11-diazatric-
yclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]but-3-en-2-ol
(14.6 mg, 52%) as a white solid. .sup.1H NMR (400 MHz, CD.sub.3OD):
.delta.: 8.48 (s, 1H), 5.97-5.93 (m, 1H), 5.45-5.43 (m, 1H), 5.29
(d, J=8, 1H), 5.17 (d, J=8, 1H), 4.24-4.26 (m, 1H), 3.39-3.32 (m,
1H), 3.13-2.99 (m 2H), 2.66-2.47 (m, 2H), 2.20-2.16 (m, 3H),
1.93-1.55 (m, 9H), 0.99 (s, 3H). MS: m/z 388 (M+H).sup.+.
Example 134
Synthesis of
(R)-1-((R)-4-(((1r,4R)-4-(dimethylamino)-4-ethylcyclohexyl)oxy)-6,7-dihyd-
ro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-5-yl)but-3-en-2-ol
(I-124)
##STR00501##
[1118] Synthesis of Compound 134.2.
[1119] A 100-mL round-bottom flask was charged with a solution of
tert-butyl
N-(1-ethyl-4-[[(3R)-3-[(2R)-2-hydroxybut-3-en-1-yl]-7-thia-9,11-diazatric-
yclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)carba-
mate (60 mg, 0.12 mmol, 1.00 equiv; prepared in a manner analogous
to compounds 132.1 and 132.2 in Example 132) and hydrogen chloride
(conc.) (0.3 mL) in methanol (10 mL). After stirring for 2 h at
0.degree. C. in a water/ice bath. The resulting mixture was
concentrated under vacuum. This resulted in
(2R)-1-[(3R)-12-[(4-amino-4-ethylcyclohexyl)oxy]-7-thia-9,11-diazatricycl-
o[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]but-3-en-2-ol
hydrochloride (30 mg, crude) as colorless oil.
[1120] Synthesis of Compound I-124.
[1121] A 50-mL round-bottom flask was charged with a solution of
(2R)-1-[(3R)-12-[(4-amino-4-ethylcyclohexyl)oxy]-7-thia-9,11-diazatricycl-
o[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]but-3-en-2-ol
hydrochloride (30 mg, 0.07 mmol, 1.00 equiv) and HCHO (0.5 mL) in
methanol (10 mL). After stirring for 0.5 h at room temperature,
NaBH.sub.3CN (10 mg, 0.16 mmol, 2.25 equiv) was added. The
resulting solution was allowed to react, with stirring, for an
additional 4 h at room temperature. The resulting solution was
diluted with 20 mL of water. The resulting solution was extracted
with 3.times.30 mL of ethyl acetate and the organic layers combined
and concentrated under vacuum. The crude product (30 mg) was
purified by preparative HPLC under the following conditions
(1#-Pre-HPLC-016(Waters)): column: SunFire Prep C18, 19*150 mm 5
um; mobile phase: water with 50 mL HCOOH and CH.sub.3CN (5.0%
CH.sub.3CN up to 43.0% in 11 min, up to 95.0% in 2 min, down to
5.0% in 2 min); detector: 254/220 nm. Compound I-124 (5.3 mg, 16%)
was obtained as a yellow solid. .sup.1H NMR (400 MHz, CD.sub.3OD):
.delta. 8.50 (br, 1H), 8.45 (s, 1H), 5.90-5.86 (m, 1H), 5.45-5.44
(m, 1H), 5.24 (d, J=13 Hz, 1H), 5.02 (d, J=8 Hz, 1H), 4.24-4.21 (m,
1H), 3.68 (m, 1H), 3.33-3.00 (m, 2H), 2.84-2.71 (m, 1H), 2.34-1.92
(m, 13H), 1.05 (m, 3H). LCMS: m/z 416 (M-0.83HCOOH+H).sup.+.
Example 135
2-((R)-4-(((1r,4R)-4-(dimethylamino)cyclohexyl)oxy)-6,7-dihydro-5H-cyclope-
nta[4,5]thieno[2,3-d]pyrimidin-5-yl)-N--((R)-2-hydroxypropyl)acetamide
(I-141)
##STR00502##
[1123] Synthesis of Compound 135.1.
[1124] To a solution of
2-[(3R)-12-[(4-[[(tert-butoxy)carbonyl](methyl)amino]cyclohexyl)oxy]-7-th-
ia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-3-yl]ace-
tic acid (500 mg, 1.08 mmol, 1.00 equiv) and
[(2S)-1-aminopropan-2-yl]oxy(tert-butyl)dimethylsilane (250 mg,
1.32 mmol, 1.22 equiv) in N,N-dimethylformamide (30 mL) were added
DIEA (500 mg, 3.87 mmol, 3.57 equiv) and HBTU (2.1 g, 5.54 mmol,
5.11 equiv). The resulting solution was stirred for 5 h at room
temperature. The residue was dissolved in 50 mL of H.sub.2O. The
resulting solution was extracted with 5.times.40 mL of
dichloromethane and the organic layers combined and dried over
anhydrous sodium sulfate. The solids were filtered off. The
resulting mixture was concentrated under vacuum. The residue was
applied onto a silica gel column and eluted with EtOAc/PE (1/1).
This resulted in 480 mg (70%) of tert-butyl
N-(4-[[(3R)-3-([[(2R)-2-[(tert-butyldimethylsilyl)oxy]propyl]carbamoyl]me-
thyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetrae-
n-12-yl]oxy]cyclohexyl)-N-methylcarbamate.
[1125] Synthesis of Compound 135.2.
[1126] To a solution of tert-butyl
N-(4-[[(3R)-3-([[(2R)-2-[(tert-butyldimethylsilyl)oxy]propyl]carbamoyl]me-
thyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetrae-
n-12-yl]oxy]cyclohexyl)-N-methylcarbamate (300 mg, 0.47 mmol, 1.00
equiv) in dichloromethane (3 mL) was added hydrogen chloride
(conc.) (2 mL). The resulting solution was stirred for 2 h at room
temperature. The pH value of the solution was adjusted to 7-8 with
sodium carbonate (sat.). The resulting solution was extracted with
5.times.30 mL of ethyl acetate and the organic layers combined and
dried over sodium sulfate and concentrated under vacuum. This
resulted in 150 mg (76%) of
N-[(2R)-2-hydroxypropyl]-2-[(3R)-12-[[4-(methylamino)cyclohexyl]oxy]-7-th-
ia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-3-yl]ace-
tamide as a yellow oil.
[1127] Synthesis of Compound I-141.
[1128] To a solution of
N-[(2R)-2-hydroxypropyl]-2-[(3R)-12-[[4-(methylamino)cyclohexyl]oxy]-7-th-
ia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-3-yl]ace-
tamide (130 mg, 0.31 mmol, 1.00 equiv) in methanol (5 mL) was added
HCHO (37%) (1 mL). The resulting solution was stirred for 20 min at
room temperature. Then NaBH3CN (100 mg, 1.59 mmol, 5.12 equiv) was
added. The resulting solution was allowed to react, with stirring,
for an additional 3 h at room temperature. The reaction was then
quenched by the addition of 1 mL of water. The resulting mixture
was concentrated under vacuum. The crude product (120 mg) was
purified by preparative HPLC under the following conditions:
column: SunFire Prep C18, 19*150 mm 5 um; mobile phase: water with
50 mL NH.sub.4CO.sub.3 and CH.sub.3CN (5.0% CH.sub.3CN up to 43.0%
in 12 min, up to 95.0% in 2 min, down to 5.0% in 2 min); detector:
254/220 nm. This resulted in 21 mg (16%) of
2-[(3R)-12-[[4-(dimethylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo[6-
.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-3-yl]-N-[(2R)-2-hydroxypropyl]a-
cetamide as a white solid. MS: m/z 433 (M+H).sup.+. .sup.1H NMR
(300 MHz, CD.sub.3OD): .delta. 1.20 (3H, d), 1.41-1.75 (4H, m),
2.14 (2H, d), 2.21-2.41 (10H, m), 2.40 (1H, m), 2.67 (1H, m),
2.90-3.10 (2H, m), 3.2 (2H, m), 3.3 (1H, m), 3.82 (2H, m), 5.27
(1H, m), 8.47 (1H, s).
Example 136
Synthesis of
2-((R)-4-(((1r,4R)-4-((2-methoxyethyl)(methyl)amino)cyclohexyl)oxy)-6,7-d-
ihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-5-yl)acetamide
(I-130)
##STR00503##
[1130] Synthesis of Compound I-130.
[1131] To a solution of 125.1 (100 mg, 0.25 mmol, 1.00 equiv) in
N,N-dimethylformamide (4 mL) was added 1-bromo-2-methoxyethane (1
mL) and DIEA (97 mg, 0.75 mmol, 3.00 equiv) at room temperature
under nitrogen. The resulting solution was stirred overnight at
100.degree. C. in an oil bath. After completion, the reaction was
cooled down to room temperature and diluted with 50 mL of ethyl
acetate. The organic layer was washed with water and brine, dried
over sodium sulfate and concentrated under vacuum. The crude
product (100 mg) was purified by preparative HPLC under the
following conditions (Waters): column: Xbridge Prep C18, 5 um,
19*50 mm; mobile phase: water with 50 mmol NH.sub.4HCO.sub.3 and
CH.sub.3CN (10% CH.sub.3CN up to 36% in 10 min, up to 95% in 2.5
min, down to 10% in 2.5 min); flow rate: 20 mL/min; UV detection at
254/220 nm. The product-containing fractions were collected and
partially evaporated to remove water and CH.sub.3CN under reduced
pressure. The residue was lyophilized overnight to give the desired
product (30 mg) as a white solid. MS: m/z 419 (M+H).sup.+. .sup.1H
NMR (400 MHz, CD.sub.3OD): .delta. 8.45 (s, 1H), 5.25-4.85 (m, 1H),
3.79-3.73 (m, 1H), 3.51-3.47 (t, 2H), 3.32 (s, 3H), 3.12-3.05 (m,
1H), 2.99-2.91 (m, 2H), 2.77-2.60 (m, 4H), 2.33-2.18 (m, 7H),
1.98-1.94 (d, 2H), 1.64-1.44 (m, 4H).
Example 137
Synthesis of
2-((R)-4-(((1r,4R)-4-(methyl(oxetan-3-yl)amino)cyclohexyl)oxy)-6,7-dihydr-
o-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-5-yl)acetamide
(I-129)
##STR00504##
[1133] To a solution of
2-[(3R)-12-[[4-(methylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo[6.4-
.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]acetamide
hydrochloride (100 mg, 0.25 mmol, 1.00 equiv) in methanol (5 mL)
was added oxetan-3-one (1 mL), NaCNBH.sub.3 (44 mg, 0.75 mmol, 3.00
equiv) and AcOH (0.2 mL) in water/ice bath. The resulting solution
was stirred for 2 h at room temperature. After completion, the
resulting mixture was concentrated under vacuum. The crude product
(100 mg) was purified by preparative HPLC under the following
conditions (Waters): column: Xbridge Prep C18, 5 um, 19*50 mm;
mobile phase: water with 0.05% NH.sub.4HCO.sub.3 and CH.sub.3CN
(10% CH.sub.3CN up to 35% in 11 min, up to 95% in 2.5 min, down to
10% in 2.5 min); flow rate: 20 mL/min; UV detection at 254/220 nm.
The product-containing fractions were collected and partially
evaporated to remove water and CH.sub.3CN under reduced pressure.
The residue was lyophilized overnight to give the desired product
(74 mg) as a white solid. MS: m/z 417 (M+H).sup.+. .sup.1H NMR (400
MHz, CD.sub.3OD): .delta. 8.48 (s, 1H), 5.28-5.21 (m, 1H),
4.69-4.67 (d, 4H), 4.08-4.01 (m, 1H), 3.82-3.80 (m, 1H), 3.18-3.10
(m, 1H), 3.04-2.97 (m, 2H), 2.77-2.70 (m, 1H), 2.53-2.47 (m, 1H),
2.32-2.30 (m, 3H), 2.29-2.25 (m, 4H), 1.88-1.84 (d, 2H), 1.66-1.31
(m, 4H).
Example 138
Synthesis of
4-[[(3R)-3-[(2R)-2-methoxybutyl]-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]d-
odeca-1(8),2(6),9,11-tetraen-12-yl]oxy]-N,N-dimethylcyclohexan-1-amine
(I-117)
##STR00505##
[1135] Synthesis of Compound 138.1.
[1136] A solution of compound 52.1 (250 mg, 0.53 mmol, 1.00 equiv)
in tetrahydrofuran (10 mL) was stirred at 0.degree. C. Then sodium
hydride (105 mg) was added at 0.degree. C. After stirring for 30
min, CH.sub.3I (112 mg, 0.79 mmol, 1.50 equiv) was added. The
resulting solution was stirred for 2 h at 25.degree. C. The
reaction was then quenched by the addition of 20 mL of NH.sub.4Cl
(aq.). The resulting solution was extracted with 3.times.50 mL of
ethyl acetate and the organic layers combined and concentrated
under vacuum. The residue was applied onto a silica gel column with
ethyl acetate/petroleum ether (1:5). This resulted in 200 mg (78%)
of tert-butyl
N-(4-[[(3R)-3-[(2R)-2-methoxybutyl]-7-thia-9,11-diazatricyclo[6.4.0.0[2,6-
]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)-N-methylcarbamate
as a colorless oil.
[1137] Synthesis of Compound 138.2.
[1138] A solution of tert-butyl
N-(4-[[(3R)-3-[(2R)-2-methoxybutyl]-7-thia-9,11-diazatricyclo[6.4.0.0[2,6-
]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)-N-methylcarbamate
(200 mg, 0.41 mmol, 1.00 equiv) in dichloromethane (10 mL) was
stirred at room temperature. This was followed by the addition of
hydrogen chloride (0.8 mL) dropwise with stirring at 0.degree. C.
The resulting solution was stirred for 1 h at 0.degree. C. The
resulting mixture was concentrated under vacuum. This resulted in
120 mg (crude) of
4-[[(3R)-3-[(2R)-2-methoxybutyl]-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]d-
odeca-1(8),2(6),9,11-tetraen-12-yl]oxy]-N-methylcyclohexan-1-amine
hydrochloride as a colorless oil.
[1139] Synthesis of Compound I-117.
[1140] A solution of
4-[[(3R)-3-[(2R)-2-methoxybutyl]-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]d-
odeca-1(8),2(6),9,11-tetraen-12-yl]oxy]-N-methylcyclohexan-1-amine
hydrochloride (120 mg, 0.28 mmol, 1.00 equiv) and HCHO (0.8 mL in
methanol (6 mL) was stirred at room temperature. The resulting
solution was stirred for 0.5 h at room temperature. Then
NaBH.sub.3CN (97.02 mg, 1.54 mmol, 5.48 equiv) was added. The
resulting solution was allowed to react, with stirring, for an
additional 2 h at room temperature. The reaction was then quenched
by the addition of 10 mL of water. The resulting solution was
extracted with 3.times.50 mL of chloroform/iso-propanol (3/1) and
the organic layers combined and concentrated under vacuum. The
crude product (100 mg) was purified by preparative HPLC under the
following conditions (1#-Pre-HPLC-016(Waters)): column: SunFire
Prep C18, 19*150 mm 5 um; mobile phase: water with 50 mL HCOOH and
CH.sub.3CN (5.0% CH.sub.3CN up to 45.0% in 11 min, up to 95.0% in 2
min, down to 5.0% in 2 min); Detector, UV 254/220 nm. This resulted
in 34.2 mg (30%) of Compound I-117 as a colorless oil. .sup.1H NMR
(CD.sub.3OD, 300 MHz): .delta. 8.47 (1H, s), 5.26-5.27 (1H, m),
3.31-3.35 (1H, m), 3.26-3.30 (4H, m), 3.08-3.11 (1H, m), 2.95-3.00
(1H, m), 2.64 (1H, m), 2.20-2.42 (10H, m), 1.97-2.08 (3H, m),
1.47-1.75 (7H, m), 0.96-1.01 (3H, t). MS: m/z 404 (M+H).sup.+.
Example 139
Synthesis of
(1R,4r)-4-(((R)-5-((S)-2-methoxybutyl)-6,7-dihydro-5H-cyclopenta[4,5]thie-
no[2,3-d]pyrimidin-4-yl)oxy)-N,N-dimethylcyclohexanamine
(I-119)
##STR00506##
[1142] Compound I-119 was prepared in a manner consistent with
I-117 except that starting material 52.2 was used rather than 52.1.
Isolated a light yellow oil. MS: m/z 404 (M-0.48HCOOH+H).sup.+.
.sup.1H NMR (CD.sub.3OD, 300MH): .delta. 8.47 (1H, s), 5.26-5.27
(1H, m), 3.58 (1H, m), 3.31-3.37 (3H, d), 3.22-3.25 (1H, m),
3.05-3.09 (1H, m), 2.91-3.01 (2H, m), 2.63-2.72 (7H, m), 2.31-2.38
(3H, m), 2.11-2.19 (3H, m), 1.60-1.74 (4H, m), 1.42-1.57 (3H, m),
0.87-0.92 (3H, t).
Example 140
Synthesis of
(S)-3-((R)-4-(((1r,4R)-4-(dimethylamino)cyclohexyl)oxy)-6,7-dihydro-5H-cy-
clopenta[4,5]thieno[2,3-d]pyrimidin-5-yl)-2-hydroxy-N-(hydroxymethyl)propa-
namide (I-100)
##STR00507##
[1144] A solution of
(2S)-2-hydroxy-3-[(3R)-12-[[4-(methylamino)cyclohexyl]oxy]-7-thia-9,11-di-
azatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]propanamide
(400 mg, 1.02 mmol, 1.00 equiv) and HCOH (37%) (0.8 mL) in methanol
(5 mL) was stirred at room temperature for 30 min, then
NaBH.sub.3CN (323 mg, 5.14 mmol, 5.02 equiv) was added. The
resulting solution was stirred for 2 h at 25.degree. C. The
reaction was then quenched by the addition of water. The resulting
solution was extracted with 3.times.20 mL of
chloroform/iso-propanol (3/1) and the organic layers combined and
concentrated under vacuum. The crude product (80 mg) was purified
by preparative HPLC under the following conditions
(1#-Pre-HPLC-001(SHIMADZU)): column: SunFire Prep C18, 19*150 mm 5
um; mobile phase: water with 0.05% HCOOH and CH.sub.3CN (6.0% CH3CN
up to 56.0% in 13 min); Detector, 254/220 nm. This resulted in 67.5
mg (16%) of 1-74 as an off-white solid and 55.4 mg (12%) of I-100.
MS: m/z 435 (M+H).sup.+. .sup.1H NMR (400 MHz, CD.sub.3OD): .delta.
8.474 (1H, s), 5.226-5.333 (1H, m), 4.10-4.20 (1H, d), 3.70-3.77
(1H, m), 3.10-3.20 (1H, m), 2.90-3.05 (1H, m), 2.69-2.88 (1H, m),
2.45-2.60 (3H, m), 2.20-2.40 (8H, m), 2.00-2.15 (2H, m), 1.66-1.91
(3H, m), 1.45-1.55 (2H, m).
Example 141
Synthesis of
(2S)-2-hydroxy-3-[(3R)-12-[(4-[methyl[2-oxo-2-(pyrrolidin-1-yl)ethyl]amin-
o]cyclohexyl)oxy]-7-thia-9,11-diazatricyclo[6.4.0.0
[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]propanamide (I-149)
##STR00508##
[1146] Into a 50-mL round-bottom flask, a solution of
(2S)-2-hydroxy-3-[(3R)-12-[[4-(methylamino)cyclohexyl]oxy]-7-thia-9,11-di-
azatricyclo[6.4.0.0
[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]propanamide hydrochloride
(110 mg, 0.26 mmol, 1.00 equiv), potassium carbonate (179 mg, 1.30
mmol, 5.03 equiv) and 2-chloro-1-(pyrrolidin-1-yl)ethan-1-one (152
mg, 1.03 mmol, 4.00 equiv) in N,N-dimethylformamide (6 mL) was
stirred overnight at room temperature. The resulting solution was
diluted with 20 mL of water. The resulting solution was extracted
with 4.times.20 mL of ethyl acetate and the organic layers combined
and concentrated under vacuum. The crude product was purified by
flash preparative HPLC under the following conditions
(IntelFlash-1): column: silica gel; mobile phase; Detector, UV 254
nm. This resulted in
(2S)-2-hydroxy-3-[(3R)-12-[(4-[methyl[2-oxo-2-(pyrrolidin-1-yl)ethyl]amin-
o]cyclohexyl)oxy]-7-thia-9,11-diazatricyclo[6.4.0.0
[2,6]]dodeca-1(8),2(6),9, 11-tetraen-3-yl]propanamide (63.8 mg,
49%) as a white solid. .sup.1H NMR (400 MHz, CD.sub.3OD): .delta.
8.47 (s, 1H), 5.28 (m, 1H), 4.17-4.14 (m, 1H), 3.59-3.32 (m, 7H),
3.15-2.98 (m, 2H), 2.76-2.70 (m, 2H), 2.52-2.33 (m, 7H), 2.04-1.89
(m, 6H), 1.74-1.53 (m, 5H). MS: m/z 502 (M+H)..sup.+
Example 142
Synthesis of
3-[(3R)-12-[[4-(dimethylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo[6-
.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]-2,2-difluoropropanamide
(I-144)
##STR00509## ##STR00510##
[1148] Synthesis of Compound 142.1.
[1149] A solution of tert-butyl
N-(4-[[(3R)-3-(2-cyano-2-hydroxyethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[-
2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)-N-methylcarbamate
(445 mg, 0.94 mmol, 1.00 equiv) and hydrogen chloride (conc.) (2.9
mL) in methanol (7 mL) was stirred for 8 h at 50.degree. C. The
reaction was diluted with 50 mL water, and then quenched by the
addition of 10 mL of sodium carbonate (sat.). The resulting
solution was extracted with 3.times.30 mL of ethyl acetate, dried
over anhydrous sodium sulfate and concentrated under vacuum. This
resulted in methyl
2-hydroxy-3-[(3R)-12-[[4-(methylamino)cyclohexyl]oxy]-7-thia-9,11-diazatr-
icyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]propanoate
(375 mg, crude) as a yellow oil.
[1150] Synthesis of Compound 142.2.
[1151] A solution of methyl
2-hydroxy-3-[(3R)-12-[[4-(methylamino)cyclohexyl]oxy]-7-thia-9,11-diazatr-
icyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]propanoate
(375 mg, 0.92 mmol, 1.00 equiv), TEA (0.5 mL) and di-tert-butyl
dicarbonate (303 mg, 1.39 mmol, 1.50 equiv) in dichloromethane (20
mL) was stirred overnight at room temperature. The resulting
solution was diluted with 30 mL of water. The resulting solution
was extracted with 3.times.30 mL of ethyl acetate and the organic
layers combined and concentrated under vacuum. The residue was
purified onto a silica gel column with ethyl acetate/petroleum
ether (1:3). This resulted in methyl
3-[(3R)-12-[(4-[[(tert-butoxy)carbonyl](methyl)amino]cyclohexyl)oxy]-7-th-
ia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]-2-h-
ydroxypropanoate (275 mg, 59%) as a colorless oil.
[1152] Synthesis of Compound 142.3.
[1153] A solution of methyl
3-[(3R)-12-[(4-[[(tert-butoxy)carbonyl](methyl)amino]cyclohexyl)oxy]-7-th-
ia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]-2-h-
ydroxypropanoate (275 mg, 0.54 mmol, 1.00 equiv) and Dess-Martin
oxidant (230 mg, 0.54 mmol, 1.00 equiv) in dichloromethane (15 mL)
was stirred for 2 h at room temperature. The reaction was then
quenched by the addition of 20 mL of saturated sodium bicarbonate,
extracted with 3.times.30 mL of ethyl and concentrated under
vacuum. The residue was applied onto a silica gel column with ethyl
acetate/petroleum ether (1:4). This resulted in methyl
3-[(3R)-12-[(4-[[(tert-butoxy)carbonyl](methyl)amino]cyclohexyl)oxy]-7-th-
ia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]-2-o-
xopropanoate (205 mg, 75%) as a colorless oil.
[1154] Synthesis of Compound 142.4.
[1155] A solution of methyl
3-[(3R)-12-[(4-[[(tert-butoxy)carbonyl](methyl)amino]cyclohexyl)oxy]-7-th-
ia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]-2-o-
xopropanoate (170 mg, 0.34 mmol, 1.00 equiv) and
diethyl(trifluoro-4-sulfanyl)amine (163 mg, 1.01 mmol, 3.00 equiv)
in dichloromethane (8 mL) was stirred for 2 days at 25.degree. C.
The reaction was then quenched by the addition of 20 mL of
saturated sodium bicarbonate, extracted with 3.times.30 mL of ethyl
acetate, concentrated under vacuum and applied onto a silica gel
column with ethyl acetate/petroleum ether (1:4). This resulted in
methyl
3-[(3R)-12-[(4-[[(tert-butoxy)carbonyl](methyl)amino]cyclohexyl)oxy]-7-th-
ia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]-2,2-
-difluoropropanoate (180 mg) as a colorless oil.
[1156] Synthesis of Compound 142.5.
[1157] A solution of methyl
3-[(3R)-12-[(4-[[(tert-butoxy)carbonyl](methyl)amino]cyclohexyl)oxy]-7-th-
ia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]-2,2-
-difluoropropanoate (170 mg, 0.32 mmol, 1.00 equiv) and hydrogen
chloride (conc.) (10 mL) in dichloromethane (0.3 mL) was stirred
for 2 h at 0.degree. C. in a water/ice bath. The resulting mixture
was concentrated under vacuum. This resulted in
2,2-difluoro-3-[(3R)-12-[[4-(methylamino)cyclohexyl]oxy]-7-thia-9,11-diaz-
atricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]propanoic
acid hydrochloride (130 mg, crude) as a yellow oil.
[1158] Synthesis of Compound 142.6.
[1159] A solution of
2,2-difluoro-3-[(3R)-12-[[4-(methylamino)cyclohexyl]oxy]-7-thia-9,11-diaz-
atricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]propanoic
acid hydrochloride (130 mg, 0.29 mmol, 1.00 equiv) and HCHO (37%)
(0.15 mL) in methanol (10 mL) was stirred for 30 min at room
temperature. NaBH.sub.3CN (80 mg, 1.27 mmol, 4.38 equiv) was added.
The resulting solution was allowed to react, with stirring, for an
additional 4 h at room temperature. The resulting solution was
diluted with 20 mL of water, extracted with 3.times.30 mL of ethyl
acetate, dried over anhydrous sodium sulfate and concentrated under
vacuum. This resulted in
3-[(3R)-12-[[4-(dimethylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo[6-
.4.0.0[2,6]]dodeca-1(8),2(6),9,
11-tetraen-3-yl]-2,2-difluoropropanoic acid (105 mg, 85%) as a
yellow oil.
[1160] Synthesis of Compound 142.7.
[1161] A solution of
3-[(3R)-12-[[4-(dimethylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo[6-
.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]-2,2-difluoropropanoic
acid (130 mg, 0.31 mmol, 1.00 equiv) was dissolved in methanol (15
mL). Sulfuroyl dichloride (72 mg, 0.61 mmol, 1.98 equiv) was added
dropwise. The resulting solution was stirred overnight at
30.degree. C. The reaction was then quenched by the addition of 20
mL of saturated sodium bicarbonate, extracted with chloroform,
dried over anhydrous sodium sulfate and concentrated under vacuum.
This resulted in methyl
3-[(3R)-12-[[4-(dimethylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo[6-
.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]-2,2-difluoropropanoate
(103 mg, crude) as a yellow oil.
[1162] Synthesis of Compound I-144.
[1163] A solution of NH.sub.3 (g) was transferred into ethanol (20
mL) over 30 min. This was followed by the addition of methyl
3-[(3R)-12-[[4-(dimethylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo[6-
.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]-2,2-difluoropropanoate
(103 mg, 0.23 mmol, 1.00 equiv). The resulting solution was stirred
overnight at room temperature. The resulting mixture was
concentrated under vacuum. The crude product (100 mg) was purified
by preparative HPLC under the following conditions
(1#-Pre-HPLC-016(Waters)): column: XBridge Prep C18 OBD column: 5
um, 19 150 mm; mobile phase: water (50 mM NH.sub.4HCO.sub.3) and
CH.sub.3CN (14.0% CH.sub.3CN up to 33.0% in 12 min, up to 95.0% in
1 min, down to 14.0% in 2 min); Detector, UV 254/220 nm. The
product was freeze-dried. This resulted in
3-[(3R)-12-[[4-(dimethylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo[6-
.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]-2,2-difluoropropanamide
(41.3 mg, 42%) as a white solid. .sup.1H NMR (300 MHz, CD.sub.3OD):
.delta. 8.51 (s, 1H), 5.30-5.23 (m, 1H), 3.66-3.51 (m, 1H),
3.32-2.70 (m, 4H), 2.51-2.01 (m, 13H), 1.74-1.44 (m, 4H). MS: m/z
425 (M+H).sup.+.
Example 143
Synthesis of
2-[(3R)-12-[(4-[methyl[2-oxo-2-(pyrrolidin-1-yl)ethyl]amino]cyclohexyl)am-
ino]-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen--
3-yl]acetamide (I-123)
##STR00511## ##STR00512##
[1165] Synthesis of Compound 143.1.
[1166]
[(3S)-12-chloro-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),-
2(6),9,11-tetraen-3-yl]methanol (315 mg, 1.31 mmol, 1.00 equiv),
TEA (530 mg) and tert-butyl N-(4-aminocyclohexyl)-N-methylcarbamate
(450 mg, 1.97 mmol, 1.51 equiv) were combined in
N,N-dimethylformamide (5 mL). The resulting solution was stirred
for 48 h at 25.degree. C. The reaction was then quenched by the
addition of 20 mL of water. The resulting solution was extracted
with 3.times.100 mL of ethyl acetate and the organic layers
combined and concentrated under vacuum. The residue was applied
onto a silica gel column with ethyl acetate/petroleum ether (1:2).
This resulted in 400 mg (70%) of tert-butyl
N-(4-[[(3S)-3-(hydroxymethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dode-
ca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)-N-methylcarbamate
as a colorless oil.
[1167] Synthesis of Compound 143.2.
[1168] Tert-butyl
N-(4-[[(3S)-3-(hydroxymethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dode-
ca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)-N-methylcarbamate
(400 mg, 0.92 mmol, 1.00 equiv), TEA (374 mg) and MsCl (212.8 mg)
were combined in dichloromethane (10 mL). The resulting solution
was stirred for 1 h at 25.degree. C. The reaction was then quenched
by the addition of 30 mL of water. The resulting solution was
extracted with 3.times.80 mL of ethyl acetate and the organic
layers combined. The resulting mixture was washed with 3.times.30
mL of brine. The mixture was dried over anhydrous sodium sulfate
and concentrated under vacuum. This resulted in 500 mg (crude) of
tert-butyl
N-(4-[[(3S)-3-[(methanesulfonyloxy)methyl]-7-thia-9,11-diazatricyclo[6.4.-
0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)-N-methylcarba-
mate as a yellow oil.
[1169] Synthesis of Compound 143.3.
[1170] Tert-butyl
N-(4-[[(3S)-3-[(methanesulfonyloxy)methyl]-7-thia-9,11-diazatricyclo[6.4.-
0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]amino]cyclohexyl)-N-methylcar-
bamate (500 mg, 0.98 mmol, 1.00 equiv), 4-dimethylaminopyridine
(11.9 mg, 0.15 mmol, 0.16 equiv) and NaCN (400 mg, 8.16 mmol, 8.34
equiv) were combined in DMSO (6 mL). The resulting solution was
stirred for 3 h at 80.degree. C. The reaction was then quenched by
the addition of 20 mL of sodium bicarbonate (aq.). The resulting
solution was extracted with 3.times.60 mL of ethyl acetate and the
organic layers combined and concentrated under vacuum. The residue
was applied onto a silica gel column with ethyl acetate/petroleum
ether (1:1). This resulted in 300 mg (69%) of tert-butyl
N-(4-[[(3R)-3-(cyanomethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-
-1(8),2(6),9,11-tetraen-12-yl]amino]cyclohexyl)-N-methylcarbamate
as a colorless oil.
[1171] Synthesis of Compound 143.4.
[1172] A solution of tert-butyl
N-(4-[[(3R)-3-(cyanomethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-
-1(8),2(6),9,11-tetraen-12-yl]amino]cyclohexyl)-N-methylcarbamate
(300 mg, 0.68 mmol, 1.00 equiv), LiOH.H.sub.2O (35.67 mg, 0.87
mmol, 1.28 equiv) in methanol (5 mL) was stirred at room
temperature. This was followed by the addition of
H.sub.2O.sub.2(0.8 mL) dropwise with stirring at 0.degree. C. The
resulting solution was stirred for 2 h at 0.degree. C. The reaction
was then quenched by the addition of 20 mL of Na.sub.2SO.sub.3
(aq.). The resulting solution was extracted with 3.times.50 mL of
ethyl acetate and the organic layers combined and concentrated
under vacuum. The residue was applied onto a silica gel column with
ethyl acetate/petroleum ether (1:1). This resulted in 130 mg (42%)
of tert-butyl
N-(4-[[(3R)-3-(carbamoylmethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]do-
deca-1(8),2(6),9,11-tetraen-12-yl]amino]cyclohexyl)-N-methylcarbamate
as a white solid.
[1173] Synthesis of Compound 143.5.
[1174] A solution of tert-butyl
N-(4-[[(3R)-3-(carbamoylmethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]do-
deca-1(8),2(6),9,11-tetraen-12-yl]amino]cyclohexyl)-N-methylcarbamate
(130 mg, 0.28 mmol, 1.00 equiv) in dichloromethane (10 mL) was
stirred at room temperature. This was followed by the addition of
hydrogen chloride (0.8 mL) dropwise with stirring at 0.degree. C.
The resulting solution was stirred for 1 h at 0.degree. C. The
resulting mixture was concentrated under vacuum. This resulted in
100 mg (crude) of
2-[(3R)-12-[[4-(methylamino)cyclohexyl]amino]-7-thia-9,11-diazatricyclo[6-
.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]acetamide
hydrochloride as a colorless oil.
[1175] Synthesis of compound I-123.
[1176] A solution of
2-[(3R)-12-[[4-(methylamino)cyclohexyl]amino]-7-thia-9,11-diazatricyclo[6-
.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]acetamide
hydrochloride (100 mg, 0.25 mmol, 1.00 equiv), potassium carbonate
(62.4 mg, 0.45 mmol, 1.79 equiv) and
2-chloro-1-(pyrrolidin-1-yl)ethan-1-one (234.5 mg, 1.59 mmol, 6.29
equiv) in N,N-dimethylformamide (3 mL). The resulting solution was
stirred for 14 h at 25.degree. C. The reaction was then quenched by
the addition of 10 mL of water. The resulting solution was
extracted with 3.times.50 mL of chloroform/iso-propanol (3:1) and
the organic layers combined and concentrated under vacuum. The
crude product (70 mg) was purified by preparative HPLC under the
following conditions (1#-Pre-HPLC-016(Waters)): column: SunFire
Prep C18, 19*150 mm 5 um; mobile phase: water WITH 50 mL
NH.sub.4CO.sub.3 and CH.sub.3CN (6.0% CH.sub.3CN up to 46.0% in 10
min, up to 95.0% in 2 min, down to 6.0% in 2 min); detector:
254/220 nm. 24.2 mg product was obtained. This resulted in 24.2 mg
(20%) of
2-[(3R)-12-[(4-[methyl[2-oxo-2-(pyrrolidin-1-yl)ethyl]amino]cyclohexyl)am-
ino]-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen--
3-yl]acetamide as a white solid. MS: m/z 471 (M+H).sup.+. .sup.1H
NMR (CD.sub.3OD, 300 MHz): .delta. 8.47 (1H, s), 40.9-4.14 (1H, m),
3.81-3.88 (1H, m), 3.55-3.59 (2H, t), 3.42-3.47 (2H, t), 3.31-3.37
(2H, d), 3.06-3.14 (1H, m), 2.89-2.97 (1H, m), 2.64-2.79 (2H, m),
2.43-2.45 (5H, m), 2.31-2.38 (1H, m), 2.26-2.29 (2H, m), 1.87-2.16
(6H, m), 1.47-1.59 (4H, m).
Example 145
Synthesis of
2-[(3R)-12-(piperidin-4-ylmethoxy)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]-
]dodeca-1(12),2(6),8,10-tetraen-3-yl]acetamide (I-143)
##STR00513## ##STR00514##
[1178] Synthesis of Compound 145.1.
[1179] To a solution of tert-butyl
4-(hydroxymethyl)piperidine-1-carboxylate (319 mg, 1.48 mmol, 1.50
equiv) in tetrahydrofuran (10 mL) was added sodium hydride (79 mg,
1.98 mmol, 2.00 equiv, 60%). The resulting solution was stirred for
0.5 h at 60.degree. C. in an oil bath. Then
(3S)-3-[[(tert-butyldimethylsilyl)oxy]methyl]-12-chloro-7-thia-9,11-diaza-
tricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraene (350 mg, 0.99
mmol, 1.00 equiv) was added. The resulting solution was allowed to
react, with stirring, for an additional 1 h while the temperature
was maintained at reflux in an oil bath. The reaction was then
quenched by the addition of 10 mL of ethanol. The resulting mixture
was concentrated under vacuum. The residue was applied onto a
silica gel column with ethyl acetate/petroleum ether (1:10). This
resulted in 450 mg (85%) of tert-butyl
4-([[(3S)-3-[[(tert-butyldimethylsilyl)oxy]methyl]-7-thia-9,11-diazatricy-
clo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]methyl)piperidine-
-1-carboxylate as a colorless oil.
[1180] Synthesis of Compound 145.2.
[1181] To a solution of tert-butyl
4-([[(3S)-3-[[(tert-butyldimethylsilyl)oxy]methyl]-7-thia-9,11-diazatricy-
clo[6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-12-yl]oxy]methyl)piperidin-
e-1-carboxylate (437 mg, 0.82 mmol, 1.00 equiv) in tetrahydrofuran
(20 mL) was added TBAF (427 mg, 1.64 mmol, 2.00 equiv). The
resulting solution was stirred for 2 h at room temperature. The
resulting solution was diluted with 100 mL of ethyl acetate. The
resulting mixture was washed with 3.times.30 mL of brine. The
mixture was dried over anhydrous sodium sulfate and concentrated
under vacuum. This resulted in 320 mg (93%) of tert-butyl
4-([[(3S)-3-(hydroxymethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-
-1(12),2(6),8,10-tetraen-12-yl]oxy]methyl)piperidine-1-carboxylate
as a colorless oil.
[1182] Synthesis of Compound 145.3.
[1183] To a solution of tert-butyl
4-([[(3S)-3-(hydroxymethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-
-1(8),2(6),9,11-tetraen-12-yl]oxy]methyl)piperidine-1-carboxylate
(300 mg, 0.72 mmol, 1.00 equiv) and triethylamine (287 mg, 2.84
mmol, 4.00 equiv) in dichloromethane (20 mL) was added dropwise
methanesulfonyl chloride (163 mg, 1.42 mmol, 2.00 equiv). The
resulting solution was stirred for 1 h at room temperature. The
reaction was then quenched by the addition of 20 mL of water. The
resulting solution was extracted with 3.times.30 mL of
dichloromethane and the organic layers combined and dried over
anhydrous sodium sulfate and concentrated under vacuum. This
resulted in 360 mg (crude) of tert-butyl 4-([[(3
S)-3-[(methanesulfonyloxy)methyl]-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]-
dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]methyl)piperidine-1-carboxylate
as a yellow oil.
[1184] Synthesis of Compound 145.4.
[1185] To a solution of tert-butyl
4-([[(3S)-3-[(methanesulfonyloxy)methyl]-7-thia-9,11-diazatricyclo[6.4.0.-
0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]methyl)piperidine-1-carboxy-
late (390 mg, 0.78 mmol, 1.00 equiv) and 4-dimethylaminopyridine
(10 mg, 0.08 mmol, 0.10 equiv) in DMSO (10 mL) was added sodium
carbonitrile (390 mg, 7.96 mmol, 10.00 equiv). The resulting
solution was stirred for 1 h at 65.degree. C. in an oil bath. The
reaction was then quenched by the addition of 20 ml of sodium
bicarbonate solution. The resulting solution was extracted with
3.times.50 mL of ethyl acetate and the organic layers combined. The
resulting mixture was washed with 3.times.20 mL of brine. The solid
was dried in an oven under reduced pressure. The residue was
applied onto a silica gel column with ethyl acetate:PE (1:5). This
resulted in 300 mg (89%) of tert-butyl
4-([[(3R)-3-(cyanomethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1-
(8),2(6),9,11-tetraen-12-yl]oxy]methyl)piperidine-1-carboxylate as
a white solid.
[1186] Synthesis of Compound 145.5.
[1187] To a solution of tert-butyl
4-([[(3R)-3-(cyanomethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1-
(8),2(6),9,11-tetraen-12-yl]oxy]methyl)piperidine-1-carboxylate
(290 mg, 0.68 mmol, 1.00 equiv) in methanol (20 mL) were added
LiOH.H.sub.2O (114 mg, 2.71 mmol, 4.01 equiv). This was followed by
the addition of H.sub.2O.sub.2(30%) (114 mg, 4.00 equiv) dropwise
with stirring at 0.degree. C. The resulting solution was stirred
for 4 h at room temperature. The resulting solution was diluted
with 50 mL of ethyl acetate. The resulting mixture was washed with
3.times.20 mL of brine. The mixture was dried over sodium sulfate
and concentrated under vacuum. This resulted in 220 mg (73%) of
tert-butyl
4-([[(3R)-3-(carbamoylmethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dode-
ca-1(8),2(6),9,11-tetraen-12-yl]oxy]methyl)piperidine-1-carboxylate
as a white solid.
[1188] Synthesis of compound I-143.
[1189] To a solution of tert-butyl
4-([[(3R)-3-(carbamoylmethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dode-
ca-1(12),2(6),8,10-tetraen-12-yl]oxy]methyl)piperidine-1-carboxylate
(200 mg, 0.45 mmol, 1.00 equiv) in dichloromethane (15 mL) was
added hydrogen chloride (12 N) (0.5 mL). The resulting solution was
stirred for 1 h at room temperature. The resulting mixture was
concentrated under vacuum. The crude product (200 mg) was purified
by preparative HPLC under the following conditions
(1#-Pre-HPLC-016(Waters)): column: SunFire Prep C18, 19*150 mm 5
um; mobile phase: water with 50 mL NH.sub.4CO.sub.3 and CH.sub.3CN
(5.0% CH.sub.3CN up to 42.0% in 10 min, up to 95.0% in 2 min, down
to 5.0% in 2 min); detector: 254/220 nm. This resulted in 33.6 mg
(22%) of
2-[(3R)-12-(piperidin-4-ylmethoxy)-7-thia-9,11-diazatricyclo[6.4-
.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-3-yl]acetamide as a white
solid. .sup.1H NMR (400 MHz, CD.sub.3OD): .delta. 1.44-1.59 (m,
2H), 1.86-1.97 (m, 2H), 2.11 (s, 1H), 2.21-2.36 (m, 2H), 2.69-2.78
(m, 3H), 2.91-3.09 (m, 2H), 3.12-3.33 (m, 3H), 3.47-3.90 (m, 1H),
4.37-4.90 (m, 2H), 8.49 (s, 1H).
Example 146
Synthesis of Intermediate 146.5
##STR00515##
[1191] Synthesis of Compound 146.1.
[1192] To a solution of tert-butyl N-(4-hydroxycyclohexyl)carbamate
(860 mg, 3.99 mmol, 2.00 equiv) in tetrahydrofuran (25 mL) was
added sodium hydride (240 mg, 6.00 mmol, 3.00 equiv, 60%). The
resulting mixture was stirred for 30 minutes at 60.degree. C.
(3S)-3-[[(tert-butyldimethylsilyl)oxy]methyl]-12-chloro-7-thia-9,11-diaza-
tricyclo[6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraene (700 mg, 1.97
mmol, 1.00 equiv) was added to this solution. Stirring was
continued for 4 h at 60.degree. C. The reaction was then quenched
by the addition of 10 mL of water. The resulting solution was
extracted with 3.times.50 mL of ethyl acetate and the organic
layers combined and dried over anhydrous sodium sulfate and
concentrated under vacuum. The residue was applied onto a silica
gel column with ethyl acetate/petroleum ether (1:4). This resulted
in 0.35 g (33%) of tert-butyl
N-(4-[[(3S)-3-[[(tert-butyldimethylsilyl)oxy]methyl]-7-thia-9,11-diazatri-
cyclo[6.4.0.0
[2,6]]dodeca-1(12),2(6),8,10-tetraen-12-yl]oxy]cyclohexyl)carbamate
as a light yellow solid.
[1193] Synthesis of Compound 146.2.
[1194] To a solution of tert-butyl
N-(4-[[(3S)-3-[[(tert-butyldimethylsilyl)oxy]methyl]-7-thia-9,11-diazatri-
cyclo[6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-12-yl]oxy]cyclohexyl)car-
bamate (400 mg, 0.75 mmol, 1.00 equiv) in tetrahydrofuran (20 mL)
was added TBAF (392 mg, 1.50 mmol, 2.00 equiv). The resulting
solution was stirred for 2 h at room temperature and concentrated
under vacuum. The residue was applied onto a silica gel column with
ethyl acetate/petroleum ether (1:3). This resulted in 230 mg (73%)
of tert-butyl N-(4-[[(3
S)-3-(hydroxymethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(12),-
2(6),8,10-tetraen-12-yl]oxy]cyclohexyl)carbamate as a white
solid.
[1195] Synthesis of Compound 146.3.
[1196] To a solution of tert-butyl
N-(4-[[(3S)-3-(hydroxymethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dode-
ca-1(12),2(6),8,10-tetraen-12-yl]oxy]cyclohexyl) carbamate (230 mg,
0.55 mmol, 1.00 equiv) and triethylamine (167 mg, 1.65 mmol, 3.00
equiv) in dichloromethane (20 mL) was added methanesulfonyl
chloride (126 mg, 1.10 mmol, 2.00 equiv). The resulting solution
was stirred for 2 h at room temperature. The resulting mixture was
washed with 2.times.20 mL of brine. The mixture was dried over
anhydrous sodium sulfate and concentrated under vacuum. This
resulted in 240 mg (88%) of tert-butyl N-(4-[[(3
S)-3-[(methanesulfonyloxy)methyl]-7-thia-9,11-diazatricyclo[6.4-
.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-12-yl]oxy]cyclohexyl)carbamate
as a yellow oil.
[1197] Synthesis of Compound 146.4.
[1198] To a solution of tert-butyl
N-(4-[[(3S)-3-[(methanesulfonyloxy)methyl]-7-thia-9,11-diazatricyclo[6.4.-
0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)carbamate
(220 mg, 0.44 mmol, 1.00 equiv) and 4-dimethylaminopyridine (10 mg,
0.08 mmol, 0.19 equiv) in DMSO (10 mL) was added sodium
carbonitrile (220 mg, 4.49 mmol, 10.00 equiv). The resulting
solution was stirred for 2 h at 60.degree. C. The resulting
solution was diluted with 50 mL of ethyl acetate. The resulting
mixture was washed with 20 mL of sodium bicarbonate solution. The
resulting mixture was washed with 3.times.20 mL of brine. The
mixture was dried over anhydrous sodium sulfate and concentrated
under vacuum. This resulted in 180 mg (crude) of tert-butyl
N-(4-[[(3R)-3-(cyanomethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-
-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)carbamate as a yellow
solid.
[1199] Synthesis of Intermediate 146.5.
[1200] To a solution of tert-butyl
N-(4-[[(3R)-3-(cyanomethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-
-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)carbamate (160 mg,
0.37 mmol, 1.00 equiv) and LiOH.H.sub.2O (80 mg, 1.90 mmol, 5.00
equiv) in methanol (15 mL) was added H.sub.2O.sub.2/H.sub.2O (1.0
mL). The resulting solution was stirred for 2 h at room
temperature. The resulting solution was extracted with 3.times.50
mL of chloroform and the organic layers combined and dried over
anhydrous sodium sulfate and concentrated under vacuum. This
resulted in 132 mg (79%) of tert-butyl
N-(4-[[(3R)-3-(carbamoylmethyl)-7-thia-9,11-diazatricyclo[6.4.0.0
[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)carbamate
as a white solid.
Example 147
Synthesis of
2-[(3R)-12-[(4-aminocyclohexyl)oxy]-7-thia-9,11-diazatricyclo[6.4.0.0[2,6-
]]dodeca-1(12),2(6),8,10-tetraen-3-yl]acetamide (I-150)
##STR00516##
[1202] To a solution of tert-butyl
N-(4-[[(3R)-3-(carbamoylmethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]do-
deca-1(12),2(6),8,10-tetraen-12-yl]oxy]cyclohexyl)carbamate (120
mg, 0.27 mmol, 1.00 equiv) in dichloromethane (15 mL) was added
hydrochloric acid (conc.) (0.2 mL). The resulting solution was
stirred for 1 h at room temperature. The pH value of the solution
was adjusted to pH>8 with saturated sodium bicarbonate solution.
The solids were collected by filtration and then washed with water
and methanol. This afforded 33.2 mg (36%) of
2-[(3R)-12-[(4-aminocyclohexyl)oxy]-7-thia-9,11-diazatricyclo[6.-
4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-3-yl]acetamide as a white
solid. .sup.1H NMR (300 MHz, CD.sub.3OD, ppm): 6 1.32-1.46 (m, 2H),
1.61-1.70 (m, 2H), 1.98-2.03 (m, 2H), 2.17-2.30 (m, 4H), 2.62-2.74
(m, 1H), 2.82-3.20 (m, 4H), 2.72-3.80 (m, 1H), 5.23-5.31 (m, 1H),
8.42 (s, 1H).
Example 148
Synthesis of
2-[(3R)-12-([4-[(oxetan-3-yl)amino]cyclohexyl]oxy)-7-thia-9,11-diazatricy-
clo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]acetamide
(I-132)
##STR00517##
[1204] A solution of tert-butyl
N-(4-[[(3R)-3-(carbamoylmethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]do-
deca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)carbamate (400 mg,
0.90 mmol, 1.00 equiv) in DCM (10 mL) was added concentrated
hydrochloric acid (0.5 mL) at 0.degree. C. The resulting solution
was stirred for 2 h at room temperature. The pH value of the
solution was adjusted to 10 with saturated aqueous sodium
bicarbonate, extracted with dichloromethane (50 mL), dried over
anhydrous sodium sulfate and concentrated under vacuum. The residue
was dissolved in 5 mL of MeOH (5 mL), oxetan-3-one (288 mg, 4.00
mmol, 10.00 equiv) was added and the reaction was stirred for
around 30 min. Then NaBH.sub.3CN (76 mg, 1.21 mmol, 3.00 equiv) was
added and the resulting solution was stirred overnight at
35.degree. C. The reaction was then quenched by the addition of
cooled brine, extracted with DCM (50 mL), dried over anhydrous
sodium sulfate and concentrated under vacuum. The crude product
(110 mg) was purified by preparative HPLC under the following
conditions (Waters): column: SunFire Prep C18, 19*150 mm 5 um;
mobile phase: water with NH.sub.4HCO.sub.3 and CH.sub.3CN (5.0%
CH.sub.3CN up to 45.0% in 12 min, up to 95.0% in 2 min, down to
5.0% in 2 min); UV detection at 254/220 nm. Flow rate: 20 mL/min.
The desired
2-[(3R)-12-([4-[(oxetan-3-yl)amino]cyclohexyl]oxy)-7-thia-9,11-diazatricy-
clo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]acetamide (90
mg) was obtained as a white solid. MS: m/z 403 (M+H).sup.+. .sup.1H
NMR (300 MHz, CDCl.sub.3): .delta. 8.51 (s, 1H), 5.24-5.35 (m, 3H),
4.85 (t, 2H, J=6.9 Hz), 4.46 (t, 2H, J=6.9 Hz), 4.06-4.11 (m, 1H),
3.80-3.85 (m, 1H), 2.95-3.21 (m, 3H), 2.78-2.86 (m, 1H), 2.55-2.71
(m, 1H), 2.21-2.33 (m, 4H), 1.91-1.99 (m, 2H), 1.57-1.74 (m, 4H),
1.29-1.43 (m, 4H).
Example 149
Synthesis of
2-[(3R)-12-([4-[bis(2-methoxyethyl)amino]cyclohexyl]oxy)-7-thia-9,11-diaz-
atricyclo[6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-3-yl]acetamide
(I-134)
##STR00518##
[1206] To a solution of intermediate 146.5 (200 mg, 0.45 mmol, 1.00
equiv) in DCM (10 mL) was added hydrogen chloride (conc., 0.5 mL)
at 0.degree. C. The resulting solution was stirred for 2 h at room
temperature. The pH value of the solution was adjusted to 10 with
saturated aqueous sodium bicarbonate, extracted with DCM (40 mL),
dried over anhydrous sodium sulfate and evaporated to give the
crude product. The product was dissolved in DMF (5 mL) and DIEA
(333 mg, 2.58 mmol, 6.00 equiv) and 1-bromo-2-methoxyethane (598
mg, 4.30 mmol, 10.00 equiv) were added. The resulting solution was
stirred overnight at 65.degree. C. The mixture was diluted with DCM
(50 mL), washed with brine (50 mL), dried over anhydrous sodium
sulfate and concentrated under vacuum. The crude product (100 mg)
was purified by preparative HPLC under the following conditions
(Waters): column: SunFire Prep C18, 19*150 mm 5 um; mobile phase:
water with NH.sub.4HCO.sub.3 and CH.sub.3CN (5.0% CH3CN up to 43.0%
in 10 min, up to 95.0% in 2 min, down to 5.0% in 2 min); flow rate:
20 mL/min; UV detection at 254/220 nm. The desired
2-[(3R)-12-([4-[bis(2-methoxyethyl)amino]cyclohexyl]oxy)-7-thia-9,11-diaz-
atricyclo[6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-3-yl]acetamide
(65.7 mg) was obtained at a white solid. MS: m/z 463 (M+H).sup.+.
.sup.1H NMR (300 MHz, CDCl.sub.3): .delta. 8.51 (s, 1H), 5.32-5.21
(m, 3H), 3.91-3.83 (m, 1H), 3.52-3.45 (m, 7H), 3.38 (s, 3H),
3.19-2.98 (m, 3H), 2.89-2.61 (m, 5H), 2.39-2.25 (m, 4H), 1.98-1.89
(m, 2H), 1.69-1.45 (m, 5H).
Example 150
Synthesis of
2-[(3R)-12-([4-[(2-methoxyethyl)amino]cyclohexyl]oxy)-7-thia-9,11-diazatr-
icyclo[6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-3-yl]acetamide
(I-133)
##STR00519##
[1208] To a solution of tert-butyl
N-(4-[[(3R)-3-(carbamoylmethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]do-
deca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)carbamate (200 mg,
0.45 mmol, 1.00 equiv) in DCM (10 mL) was added hydrogen chloride
(conc., 0.5 mL) at 0.degree. C. The resulting solution was stirred
for 2 h at room temperature. The pH value of the solution was
adjusted to 10 with saturated aqueous sodium bicarbonate, extracted
with DCM (40 mL), dried over anhydrous sodium sulfate and
evaporated under reduced pressure. The crude product was dissolved
in DMF (5 mL) and DIEA (333 mg, 2.58 mmol, 6.00 equiv) and
1-bromo-2-methoxyethane (598 mg, 4.30 mmol, 10.00 equiv) were
added. Stirring was continued for 2 h at 65.degree. C. The mixture
was diluted with DCM (50 mL), washed with brine (50 mL), dried over
anhydrous sodium sulfate and concentrated under vacuum. The crude
product (100 mg) was purified by preparative HPLC under the
following conditions (Waters): column: SunFire Prep C18, 19*150 mm
5 um; mobile phase: water with NH.sub.4HCO.sub.3 and CH.sub.3CN
(5.0% CH.sub.3CN up to 43.0% in 10 min, up to 95.0% in 2 min, down
to 5.0% in 2 min); flow rate: 20 mL/min; UV detection at 254/220
nm. The product-containing fractions were collected and partially
evaporated under reduced pressure to give the desired
2-[(3R)-12-([4-[(2-methoxyethyl)amino]cyclohexyl]oxy)-7-thia-9,11-
-diazatricyclo[6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-3-yl]acetamide
(50 mg) as a white solid. MS: m/z 405 (M+H).sup.+. .sup.1H NMR (300
MHz, CDCl.sub.3): .delta. 8.52 (s, 1H), 5.32-5.23 (m, 2H),
3.91-3.83 (m, 1H), 3.52 (t, 2H, J=5.1 Hz), 3.38 (s, 3H), 3.19-2.98
(m, 3H), 2.91-2.71 (m, 3H), 2.69-2.55 (m, 1H), 2.39-2.21 (m, 4H),
2.11-2.01 (m, 2H), 1.72-1.23 (m, 4H).
Example 151
Synthesis of Intermediate 151.7
##STR00520##
[1210] Synthesis of Compound 151.2.
[1211] To a solution of bis(2-chloroethyl)amine (20 g, 112.05 mmol,
1.00 equiv) and triethylamine (17 mL) in dichloromethane (250 mL)
was added di-tert-butyl dicarbonate (26.9 g, 123.25 mmol, 1.10
equiv). The resulting solution was stirred for 30 min at 0.degree.
C. in a water/ice bath. The resulting mixture was washed with
2.times.200 mL of H.sub.2O. The mixture was dried over anhydrous
magnesium sulfate. The solids were filtered out. The resulting
mixture was concentrated under vacuum. This resulted in 34.6 g
(crude) of tert-butyl N,N-bis(2-chloroethyl)carbamate as an
off-white oil.
[1212] Synthesis of Compound 151.3.
[1213] Into a 500-mL round-bottom flask was placed tert-butyl
2-chloroethyl N-(2-chloroethyl)carbamate (24 g, 98.70 mmol, 1.00
equiv), 4-aminocyclohexan-1-ol (12 g, 104.19 mmol, 1.06 equiv), KI
(20 g), potassium carbonate (41 g, 296.65 mmol, 3.01 equiv) and
CH.sub.3CN (200 mL). The resulting solution was heated to reflux
for 3 hr. The solids were filtered out. The resulting mixture was
concentrated under vacuum. The residue was applied onto a silica
gel column with dichloromethane/methanol (7:1). This resulted in
5.5 g (20%) of
1-tert-butyl-6-(4-hydroxycyclohexyl)-1[3],3,6-oxadiazocan-2-one as
a yellow oil.
[1214] Synthesis of Compound 151.4.
[1215] To a solution of tert-butyl
4-(4-hydroxycyclohexyl)piperazine-1-carboxylate (700 mg, 2.46 mmol,
1.94 equiv) in tetrahydrofuran (15 mL) was added sodium hydride
(600 mg, 15.00 mmol, 11.83 equiv). The resulting solution was
stirred for 0.5 h at 0.degree. C. Then 65.1 (450 mg, 1.27 mmol,
1.00 equiv) was added. The resulting solution was allowed to react
with stirring for an additional 3 h while the temperature was
maintained at reflux. The reaction was then quenched by the
addition of 30 mL of water. The resulting solution was extracted
with 3.times.30 mL of dichloromethane and the organic layers
combined and dried over anhydrous sodium sulfate. The solids were
filtered out. The resulting mixture was concentrated under vacuum.
This resulted in 400 mg (52%) of tert-butyl 4-(4-[[(3
S)-3-[[(tert-butyldimethylsilyl)oxy]methyl]-7-thia-9,11-diazatricyclo[6.4-
.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-12-yl]oxy]cyclohexyl)piperazine-1-
-carboxylate as a yellow oil.
[1216] Synthesis of Compound 151.5.
[1217] To a solution of tert-butyl
4-(4-[[(3S)-3-[[(tert-butyldimethylsilyl)oxy]methyl]-7-thia-9,11-diazatri-
cyclo[6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-12-yl]oxy]cyclohexyl)pip-
erazine-1-carboxylate (400 mg, 0.66 mmol, 1.00 equiv) in methanol
(10 mL) was added TBAF (1 g, 3.82 mmol, 5.76 equiv). The resulting
solution was stirred for 2 h at 0.degree. C. The reaction was then
quenched by the addition of 30 mL of water. The resulting solution
was extracted with 3.times.30 mL of dichloromethane and the organic
layers combined and dried over anhydrous sodium sulfate. The solids
were filtered out. The resulting mixture was concentrated under
vacuum. This resulted in 300 mg (93%) of tert-butyl
4-(4-[[(3S)-3-(hydroxymethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dode-
ca-1(12),2(6),8,10-tetraen-12-yl]oxy]cyclohexyl)piperazine-1-carboxylate
as a yellow oil.
[1218] Synthesis of Compound 151.6.
[1219] To a solution of tert-butyl
4-(4-[[(3S)-3-(hydroxymethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dode-
ca-1(12),2(6),8,10-tetraen-12-yl]oxy]cyclohexyl)piperazine-1-carboxylate
(300 mg, 0.61 mmol, 1.00 equiv) and triethylamine (190 mg, 1.88
mmol, 3.06 equiv) in dichloromethane (10 mL) was added MsCl (140
mg, 1.22 mmol, 1.98 equiv). The resulting solution was stirred for
1 h at room temperature. The resulting mixture was washed with 30
mL of H.sub.2O. The mixture was dried over anhydrous sodium
sulfate. The solids were filtered out. The resulting mixture was
concentrated under vacuum. This resulted in 300 mg (86%) of
tert-butyl
4-(4-[[(3S)-3-[(methanesulfonyloxy)methyl]-7-thia-9,11-diazatricyclo[6.4.-
0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-12-yl]oxy]cyclohexyl)piperazine-1--
carboxylate as a yellow oil.
[1220] Synthesis of Intermediate 151.7.
[1221] To a solution of tert-butyl
4-(4-[[(3S)-3-[(methanesulfonyloxy)methyl]-7-thia-9,11-diazatricyclo[6.4.-
0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-12-yl]oxy]cyclohexyl)piperazine-1--
carboxylate (300 mg, 0.53 mmol, 1.00 equiv) in DMSO (10 mL) was
added NaCN (160 mg, 3.20 mmol, 6.05 equiv) and
4-dimethylaminopyridine (3 mg, 0.02 mmol, 0.05 equiv). The
resulting solution was stirred for 2 h at 80.degree. C. The
reaction was then quenched by the addition of 30 mL of sodium
bicarbonate (sat.). The resulting solution was extracted with
3.times.30 mL of dichloromethane and the organic layers combined
and dried over anhydrous sodium sulfate. The solids were filtered
out. The resulting mixture was concentrated under vacuum. This
resulted in 260 mg (crude) of tert-butyl
4-(4-[[(3R)-3-(cyanomethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-
-1(12),2(6),8,10-tetraen-12-yl]oxy]cyclohexyl)piperazine-1-carboxylate
as a yellow oil.
Example 152
Synthesis of
2-[(3R)-12-[[4-(piperazin-1-yl)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo[-
6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-3-yl]acetamide
(I-131)
##STR00521##
[1223] Synthesis of Compound 152.1.
[1224] To a solution of
tert-butyl-4-(4-[[(3R)-3-(cyanomethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[-
2,6]]dodeca-1(12),2(6),8,10-tetraen-12-yl]oxy]cyclohexyl)piperazine-1-carb-
oxylate (260 mg, 0.52 mmol, 1.00 equiv) in methanol (15 mL) were
added LiOH.H.sub.2O (150 mg, 3.57 mmol, 6.84 equiv),
H.sub.2O.sub.2(30%) (0.8 mL). The resulting solution was stirred
for 4 h at 0.degree. C. The reaction was then quenched by the
addition of 10 mL of Na.sub.2SO.sub.3 (aq.). The resulting solution
was extracted with 3.times.30 mL of dichloromethane and the organic
layers combined and concentrated under vacuum. This resulted in 120
mg (45%) of tert-butyl
4-(4-[[(3R)-3-(carbamoylmethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]do-
deca-1(12),2(6),8,10-tetraen-12-yl]oxy]cyclohexyl)piperazine-1-carboxylate
as a yellow oil.
[1225] Synthesis of Compound I-131.
[1226] To a solution of tert-butyl
4-(4-[[(3R)-3-(carbamoylmethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]do-
deca-1(12),2(6),8,10-tetraen-12-yl]oxy]cyclohexyl)piperazine-1-carboxylate
(120 mg, 0.23 mmol, 1.00 equiv) in dichloromethane (4 mL) was added
trifluoroacetic acid (2 mL). The resulting solution was stirred for
2 h at room temperature. The resulting mixture was concentrated
under vacuum. The crude product (110 mg) was purified by
preparative HPLC under the following conditions: column: SunFire
Prep C18, 19*150 mm 5 um; mobile phase: water with 50 mL
NH.sub.4CO.sub.3 and CH.sub.3CN (15.0% CH.sub.3CN up to 36.0% in 13
min, up to 95.0% in 2 min, down to 15.0% in 2 min); detector:
254/220 nm. This resulted in 64.7 mg (67%) of
2-[(3R)-12-[[4-(piperazin-1-yl)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo[-
6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-3-yl]acetamide as a
white solid. MS: m/z 416 (M+H).sup.+. .sup.1H NMR (300 MHz,
CD.sub.3OD): .delta. 1.46-1.86 (4H, m), 2.03-2.24 (2H, m) 2.29-2.44
(5H, m), 2.69-2.77 (5H, m), 2.96-3.01 (6H, m), 3.01-3.10 (1H, m),
3.59-3.79 (1H, m), 5.00-5.26 (1H, m), 8.47 (1H, s).
Example 153
Synthesis of Intermediate 153.7
##STR00522##
[1228] Synthesis of Compound 153.2.
[1229] Into a 1 L round-bottom flask was placed a solution of
cyclohex-2-en-1-one (15.00 g, 156.04 mmol, 1.00 equiv) in anhydrous
THF (300 mL). 1,3-diethyl 2-bromopropanedioate (56.00 g, 234.25
mmol, 1.50 equiv), In powder (18.00 g, 1.00 equiv) and TMSCl (87.00
g, 800.81 mmol, 5.00 equiv) were added under nitrogen. The
resulting solution was stirred for 30 min at room temperature and
quenched by the addition of 200 mL of saturated aqueous sodium
carbonate, extracted with 3.times.300 mL of ethyl acetate. The
combined organic layers were washed with brine, dried over
anhydrous sodium sulfate and concentrated under vacuum. The residue
was applied onto a silica gel column with ethyl acetate/petroleum
ether (1:5) to give 1,3-diethyl 2-(3-oxocyclohexyl)propanedioate
(28.50 g, 71%) as a yellow oil.
[1230] Synthesis of Compound 153.3.
[1231] A solution of 1,3-diethyl 2-(3-oxocyclohexyl)propanedioate
(28.50 g, 111.20 mmol, 1.00 equiv) and sodium chloride (7.02 g,
1.10 equiv) in a mixture of water (4 mL) and DMSO (80 mL) was
heated for 24 h at 180.degree. C. in an oil bath. After cooling to
r.t, the reaction was diluted with water and extracted with
3.times.300 mL of ethyl acetate. The organic layers were combined,
washed with water and brine, dried over anhydrous sodium sulfate
and concentrated under vacuum to give the desired ethyl
2-(3-oxocyclohexyl)acetate (22.7 g, crude) as a yellow oil.
[1232] Synthesis of Compound 153.4.
[1233] A 500-mL round-bottom flask was charged with a solution of
ethyl 2-(3-oxocyclohexyl)acetate (22.70 g, crude), ethyl
2-cyanoacetate (16.30 g, 144.10 mmol, 1.20 equiv), S (4.70 g, 1.20
equiv) and Et.sub.2NH (10.50 g, 1.20 equiv) in 200 mL of ethanol.
The reaction was stirred overnight at room temperature. The solvent
was removed under reduced pressure. The residue was applied onto a
silica gel column with ethyl acetate/petroleum ether (1:5) to give
ethyl
2-amino-5-(2-ethoxy-2-oxoethyl)-4,5,6,7-tetrahydro-1-benzothiophene-3-car-
boxylate (20.68 g) as yellow oil. MS: m/z 312 (M+H).sup.+.
[1234] Synthesis of Compound 153.5.
[1235] A solution of ethyl
2-amino-5-(2-ethoxy-2-oxoethyl)-4,5,6,7-tetrahydro-1-benzothiophene-3-car-
boxylate (20.68 g, 66.41 mmol, 1.00 equiv) in 100 mL of formamide
was stirred overnight at 180.degree. C. in an oil bath. After the
starting material disappeared, the reaction was cooled to room
temperature, quenched with water and extracted with 3.times.200 mL
of ethyl acetate. The combined organic layers were washed with
brine, dried over anhydrous sodium sulfate and concentrated under
vacuum. The residue was applied onto a silica gel column with ethyl
acetate/petroleum ether (1:2) to afford the corresponding ethyl
2-[3-hydroxy-8-thia-4,6-diazatricyclo[7.4.0.0[2,7]]trideca-1(9),2(7),3,5--
tetraen-12-yl]acetate (10.10 g, 52%) as yellow oil. MS: m/z 293
(M+H).sup.+.
[1236] Synthesis of Compound 153.6.
[1237] A 250-mL round-bottom flask was charged with a solution of
ethyl
2-[3-hydroxy-8-thia-4,6-diazatricyclo[7.4.0.0[2,7]]trideca-1(9),2(7),3,5--
tetraen-12-yl]acetate (10.10 g, 34.55 mmol, 1.00 equiv) in
POCl.sub.3 (80 g, 521.75 mmol, 15.00 equiv) was stirred for 1 h at
90.degree. C. in an oil bath under nitrogen. The resulting mixture
was concentrated under vacuum. The residue was added dropwise to a
cooled saturated aqueous sodium bicarbonate and extracted with
3.times.200 mL of ethyl acetate. The combined organic layers were
washed with brine, dried over anhydrous sodium sulfate and
concentrated under vacuum. The residue was applied onto a silica
gel column with ethyl acetate/petroleum ether (1:5) to give the
ethyl 2-[3-chloro-8-thia-4,6-diazatricyclo[7.4.0.0[2,7]]trideca-1
(9),2(7),3,5-tetraen-12-yl]acetate (6.67 g, 62%) as a yellow solid.
MS: m/z 311, 313 (M+H).sup.+.
[1238] Synthesis of Intermediate 153.7.
[1239] A solution of ethyl
2-[3-chloro-8-thia-4,6-diazatricyclo[7.4.0.0[2,7]]trideca-1
(9),2(7),3,5-tetraen-12-yl]acetate (2.88 g, 9.27 mmol, 1.00 equiv)
in 25 mL of distilled THF was added DIBAL-H (25% in hexane, 10.56
g, 2.00 equiv) dropwise at -30.degree. C. under nitrogen. The
resulting solution was stirred for 2 h at this temperature and
quenched with saturated aqueous NH.sub.4Cl, extracted with
3.times.100 mL of ethyl acetate. The organic layers were combined,
washed with brine, dried over anhydrous sodium sulfate and
concentrated under vacuum. The residue was applied onto a silica
gel column with ethyl acetate/petroleum ether (1:1) to afford 2.20
g (88%) of the desired
2-[3-chloro-8-thia-4,6-diazatricyclo[7.4.0.0[2,7]]trideca-1(9),2(7),3,5-t-
etraen-12-yl]ethan-1-ol as a light yellow solid. MS: m/z 269, 270
[M+H].sup.+.
Example 154
Synthesis of
2-[(12S)-3-[[4-(dimethylamino)cyclohexyl]oxy]-8-thia-4,6-diazatricyclo[7.-
4.0.0[2,7]]trideca-1(9),2(7),3,5-tetraen-12-yl]acetamide
(I-112)
##STR00523## ##STR00524##
[1241] Purification of Compound 154.1.
[1242] The racemic
2-[3-chloro-8-thia-4,6-diazatricyclo[7.4.0.0[2,7]]trideca-1(9),2(7),3,5-t-
etraen-12-yl]ethan-1-ol (2.20 g, 8.19 mmol, 1.00 equiv) was
resolute by chiral preparative SFC under the following conditions:
column: Chiralpak IA, 2*25 cm, 5 um; mobile phase, CO.sub.2 (80%),
methanol (domestic, 20%); flow rate: 40 g/min; UV detection at 254
nm. The fractions of the first peak to elute (t.sub.R=9.28 min)
were collected and evaporated under reduced pressure to give the
desired
2-[(12S)-3-chloro-8-thia-4,6-diazatricyclo[7.4.0.0[2,7]]trideca-1(9),2(7)-
,3,5-tetraen-12-yl]ethan-1-ol (compound 154.1, stereochemistry
unconfirmed, 660 mg) as an off-white solid with 100% ee. The
fractions of the second peak to elute (t.sub.R=10.53 min) were
concentrated to give
2-[(12R)-3-chloro-8-thia-4,6-diazatricyclo[7.4.0.0[2,7]]trideca-1
(9),2(7),3,5-tetraen-12-yl]ethan-1-ol (compound 154.2,
stereochemistry unconfirmed, 790 mg) as an off-white solid with
98.5% ee.
[1243] Synthesis of Compound 154.3.
[1244] To a solution of
2-[(12S)-3-chloro-8-thia-4,6-diazatricyclo[7.4.0.0[2,7]]trideca-1(9),2(7)-
,3,5-tetraen-12-yl]ethan-1-ol (300 mg, 1.12 mmol, 1.00 equiv) in 5
mL of distilled DMF was added TBSCl (252 mg, 1.50 equiv) and
imidazole (137 mg, 2.01 mmol, 1.80 equiv) at room temperature under
nitrogen. The resulting solution was stirred for 1 h at ambient
temperature and then quenched with water, extracted with 3.times.50
mL of ethyl acetate. The combined organic layers were washed with
brine, dried over anhydrous sodium sulfate and concentrated under
reduced pressure. The residue was applied onto a silica gel column
with ethyl acetate/petroleum ether (1:5) to provide
(12S)-12-[2-[(tert-butyldimethylsilyl)oxy]ethyl]-3-chloro-8-thia--
4,6-diazatricyclo[7.4.0.0[2,7]]trideca-1(9),2(7),3,5-tetraene (420
mg, 98%) as a light yellow solid. MS: m/z 384, 386 (M+H).sup.+.
[1245] Synthesis of Compound 154.4.
[1246] A solution of tert-butyl N-(4-hydroxycyclohexyl)carbamate
(181 mg, 0.84 mmol, 1.40 equiv) in 8 mL of distilled THF was added
sodium hydride (60% dispersion in mineral oil, 72 mg, 1.80 mmol,
3.00 equiv) at 0.degree. C. and stirred for another 30 min under
nitrogen. Then
(12S)-12-[2-[(tert-butyldimethylsilyl)oxy]ethyl]-3-chloro-8-thia-4,6-diaz-
atricyclo[7.4.0.0[2,7]]trideca-1(9),2(7),3,5-tetraene (230 mg, 0.60
mmol, 1.00 equiv) was added and stirred overnight at room
temperature. The reaction was then quenched with saturated aqueous
NH.sub.4Cl, extracted with 3.times.50 mL of ethyl acetate. The
combined organic layers were washed with brine, dried over
anhydrous sodium sulfate and concentrated under vacuum. The residue
was applied onto a silica gel column with ethyl acetate/petroleum
ether (1:4) to give 240 mg (71%) of tert-butyl
N-(4-[[(12S)-12-[2-[(tert-butyldimethylsilyl)oxy]ethyl]-8-thia-4,6-diazat-
ricyclo[7.4.0.0[2,7]]tri
deca-1(9),2(7),3,5-tetraen-3-yl]oxy]cyclohexyl)carbamate as a
yellow oil. MS: m/z 562 [M+H].sup.+.
[1247] Synthesis of Compound 154.5.
[1248] To a solution of tert-butyl
N-(4-[[(12S)-12-[2-[(tert-butyldimethylsilyl)oxy]ethyl]-8-thia-4,6-diazat-
ricyclo[7.4.0.0[2,7]]tri deca-1
(9),2(7),3,5-tetraen-3-yl]oxy]cyclohexyl)carbamate (240 mg, 0.43
mmol, 1.00 equiv) in 4 mL of THF was added TBAF (223 mg, 0.85 mmol,
2.00 equiv) and the resulting solution was stirred overnight at
25.degree. C. in an oil bath. The reaction was then quenched with
water and extracted with 3.times.50 mL of ethyl acetate. The
combined organic layers were washed with brine, dried over
anhydrous sodium sulfate and concentrated under vacuum. The residue
was applied onto a silica gel column with ethyl acetate/petroleum
ether (1:2) to provide tert-butyl
N-(4-[[(12S)-12-(2-hydroxyethyl)-8-thia-4,6-diazatricyclo[7.4.0.0[2,7]]tr-
ideca-1 (9),2(7),3,5-tetraen-3-yl]oxy]cyclohexyl)carbamate (172 mg,
90%) as yellow oil. MS: m/z 448 (M+H).sup.+.
[1249] Synthesis of Compound 154.6.
[1250] To a solution of tert-butyl
N-(4-[[(12S)-12-(2-hydroxyethyl)-8-thia-4,6-diazatricyclo[7.4.0.0[2,7]]tr-
ideca-1(9),2(7),3,5-tetraen-3-yl]oxy]cyclohexyl)carbamate (172 mg,
0.38 mmol, 1.00 equiv) in 4 mL of DMF was added PDC (847 mg, 2.25
mmol, 6.00 equiv) and the resulting solution was stirred overnight
at room temperature. The reaction was then quenched by the addition
of water and extracted with 4.times.50 mL of chloroform/isopropanol
(3:1). The combined organic layers were washed with brine, dried
over anhydrous sodium sulfate and concentrated under vacuum. The
residue was applied onto a silica gel column with ethyl
acetate/petroleum ether (1:1) to provide
2-[(12S)-3-[(4-[[(tert-butoxy)carbonyl]amino]cyclohexyl)oxy]-8-th-
ia-4,6-diazatricyclo[7.4.0.0[2,7]]trideca-1(9),2(7),3,5-tetraen-12-yl]acet-
ic acid (148 mg, 83%) as an off-white solid. MS: m/z 462
(M+H).sup.+.
[1251] Synthesis of Compound 154.7.
[1252] To a solution of
2-[(12S)-3-[(4-[[(tert-butoxy)carbonyl]amino]cyclohexyl)oxy]-8-thia-4,
6-diazatricyclo[7.4.0.0[2,7]]trideca-1(9),2(7),3,5-tetraen-12-yl]acetic
acid (148 mg, 0.32 mmol, 1.00 equiv) in 6 mL of distilled DMF was
added NH.sub.4Cl (103 mg, 1.93 mmol, 6.00 equiv), EDCI (92 mg, 0.48
mmol, 1.50 equiv), 4-dimethylaminopyridine (58 mg, 0.47 mmol, 1.50
equiv) and HOBt (65 mg, 0.48 mmol, 1.50 equiv) successively and the
resulting solution was stirred overnight at room temperature. The
reaction was then quenched with water and extracted with 3.times.50
mL of ethyl acetate. The organic layers were combined, washed with
brine, dried over anhydrous sodium sulfate and concentrated under
vacuum. The residue was applied onto a silica gel column with ethyl
acetate/petroleum ether (2:1) to give 80 mg (54%) of the desired
tert-butyl
N-(4-[[(12S)-12-(carbamoylmethyl)-8-thia-4,6-diazatricyclo[7.4.0.0[2,7]]t-
rideca-1(9),2(7),3,5-tetraen-3-yl]oxy]cyclohexyl)carbamate as a
white solid. MS: m/z 460 (M+H).sup.+.
[1253] Synthesis of Compound I-112.
[1254] Into a 50-mL round-bottom flask purged and maintained with
an inert atmosphere of nitrogen, was placed tert-butyl
N-(4-[[(12S)-12-(carbamoylmethyl)-8-thia-4,6-diazatricyclo[7.4.0.0[2,7]]t-
rideca-1(9),2(7),3,5-tetraen-3-yl]oxy]cyclohexyl)carbamate (80 mg,
0.17 mmol, 1.00 equiv) in dichloromethane (5 mL) at 0.degree. C.
Then hydrochloric acid (6 M, 0.5 mL) was added and the resulting
solution was stirred overnight at room temperature. The resulting
mixture was concentrated under vacuum to give 86 mg (crude) of
2-[(12S)-3-[(4-aminocyclohexyl)oxy]-8-thia-4,6-diazatricyclo[7.4.0.0[2,7]-
]trideca-1(9),2(7),3,5-tetraen-12-yl]acetamide hydrochloride as a
yellow solid. The crude hydrochloride dissolved in 5 mL of methanol
was added HCHO (37%, 1 mL) and AcOH (0.5 mL). After stirring for 30
min, NaCNBH3 (34 mg, 0.54 mmol, 2.50 equiv) was added and the
resulting mixture was stirred overnight at room temperature. The
resulting mixture was concentrated under vacuum. The crude product
(80 mg) was purified by preparative HPLC under the following
conditions (Waters): column: X bridge Prep C18 5 um, 19*150 mm;
mobile phase: water with 0.05% NH4HCO3 and CH3CN (5.0% CH3CN up to
41.0% in 9 min, up to 95.0% in 2 min, down to 5.0% in 2 min); flow
rate: 20 mL/min; UV detection at 220/254 nm. This resulted in 21.5
mg (26%) of
2-[(12S)-3-[[4-(dimethylamino)cyclohexyl]oxy]-8-thia-4,6-diazatricyclo[7.-
4.0.0[2,7]]trideca-1(9),2(7),3,5-tetraen-12-yl]acetamide as a white
solid. MS: m/z 389 (M+H).sup.+. .sup.1H NMR (400 MHz, CDCl.sub.3):
.delta. 8.51 (s, 1H), 5.47-5.40 (d, 2H), 5.25-5.19 (m, 1H),
3.31-3.25 (m, 1H), 2.92-2.90 (m, 2H), 2.61-2.55 (m, 1H), 2.41-2.29
(m, 11H), 2.20-2.15 (m, 1H), 2.13-2.00 (m, 2H), 1.69-1.56 (m,
6H).
Example 155
Synthesis of
2-((R)-4-(((1r,4R)-4-morpholinocyclohexyl)oxy)-5,6,7,8-tetrahydrobenzo[4,-
5]thieno[2,3-d]pyrimidin-6-yl)ethanol (I-145)
##STR00525##
[1256] Synthesis of Compound 155.1.
[1257] A solution of
2-[(12R)-3-chloro-8-thia-4,6-diazatricyclo[7.4.0.0[2,7]]trideca-1(9),2(7)-
,3,5-tetraen-12-yl]ethan-1-ol (300 mg, 1.12 mmol, 1.00 equiv) in 5
mL of distilled DMF was added TBSCl (252 mg, 1.50 equiv) and
imidazole (137 mg, 2.01 mmol, 1.80 equiv) at room temperature under
nitrogen. The resulting solution was stirred for 1 h at ambient
temperature and then quenched water, extracted with 3.times.50 mL
of ethyl acetate. The combined organic layers were washed with
brine, dried over anhydrous sodium sulfate and concentrated under
reduced pressure. The residue was applied onto a silica gel column
with ethyl acetate/petroleum ether (1:5) to provide
(12R)-12-[2-[(tert-butyldimethylsilyl)oxy]ethyl]-3-chloro-8-thia--
4,6-diazatricyclo[7.4.0.0[2,7]]trideca-1(9),2(7),3,5-tetraene (420
mg, 98%) as a light yellow solid. LC-MS (ES, m/z): 384, 386
[M+H].sup.+.
[1258] Synthesis of Compound 155.2.
[1259] A solution of trans-4-(morpholin-4-yl)cyclohexan-1-ol (135
mg, 0.73 mmol, 1.40 equiv) in 6 mL of distilled THF was added
sodium hydride (60% dispersion in mineral oil, 83 mg, 2.08 mmol,
4.00 equiv) at 0.degree. C. under nitrogen. Then
(12R)-12-[2-[(tert-butyldimethyl
silyl)oxy]ethyl]-3-chloro-8-thia-4,6-diazatricyclo[7.4.0.0[2,7]]trideca-1-
(9),2(7),3,5-tetraene (200 mg, 0.52 mmol, 1.00 equiv) was added and
the resulting solution was stirred for 1 h at 70.degree. C. in an
oil bath. After cooling to r.t, the reaction was quenched with
water and extracted with 3.times.50 mL of ethyl acetate. The
organic layers were combined, washed with brine, dried over
anhydrous sodium sulfate and concentrated under vacuum. The residue
was applied onto a silica gel column with dichloromethane/methanol
(10:1). This resulted in 200 mg (72%) of
(12R)-12-[2-[(tert-butyldimethylsilyl)oxy]ethyl]-3-[[4-(morpholin-4-yl)cy-
clohexyl]oxy]-8-thia-4,6-diazatricyclo[7.4.0.0[2,7]]trideca-1(9),2(7),3,5--
tetraene as a white solid. MS: m/z 532 (M+H).sup.+.
[1260] Synthesis of Compound I-145.
[1261] To a 50-mL round-bottom flask containing
(12R)-12-[2-[(tert-butyldimethylsilyl)oxy]ethyl]-3-[[4-(morpholin-4-yl)cy-
clohexyl]oxy]-8-thia-4,6-diazatricyclo[7.4.0.0[2,7]]trideca-1(9),2(7),3,5--
tetraene (157 mg, 0.30 mmol, 1.00 equiv) in methanol (4 mL) was
added 6 M aqueous hydrochloric acid (0.9 mL) at 0.degree. C. and
the resulting solution was stirred for 2 h at room temperature. The
resulting mixture was concentrated under vacuum. After
basification, the crude product (160 mg) was purified by
preparative HPLC under the following conditions (Waters): column:
SunFire Prep C18, 19*150 mm 5 um; mobile phase: water with 0.05%
HCOOH and CH.sub.3CN (5.0% CH.sub.3CN up to 40.0% in 11 min, up to
95.0% in 2 min, down to 5.0% in 2 min); flow rate: 20 mL/min; UV
detection at 254/220 nm. This resulted in 53.4 mg (40%) of Compound
I-145 as a white solid. MS: m/z 418 (M-0.8HCOOH+H).sup.+. .sup.1H
NMR: (300 MHz, CDCl.sub.3) .delta. 8.50 (s, 1H), 8.36 (s, 1H),
6.18-5.61 (m, 1H), 5.23-5.19 (m, 1H), 3.89-3.80 (m, 6H), 3.23-3.13
(m, 1H), 2.88 (s, 1H), 2.77-2.66 (m, 1H), 2.52-2.43 (m, 1H),
2.48-2.35 (m, 2H), 2.12-1.81 (m, 4H), 1.78-1.42 (m, 7H).
Example 156
Synthesis of
2-[(12R)-3-[[4-(dimethylamino)cyclohexyl]oxy]-8-thia-4,6-diazatricyclo[7.-
4.0.0[2,7]]trideca-1(9),2(7),3,5-tetraen-12-yl]acetamide
(I-113)
##STR00526##
[1263] Synthesis of Compound 156.1.
[1264] Sodium hydride (60% dispersion in mineral oil, 62 mg, 1.55
mmol, 30.00 equiv) was treated with tert-butyl
trans-N-(4-hydroxycyclohexyl)carbamate (157 mg, 0.73 mmol, 1.40
equiv) in 8 mL of freshly distilled THF for 30 min in a water/ice
bath under nitrogen. Then a solution of
(12R)-12-[2-[(tert-butyldimethylsilyl)oxy]ethyl]-3-chloro-8-thia-4,6-diaz-
atricyclo[7.4.0.0[2,7]]trideca-1(9),2(7),3,5-tetraene (200 mg, 0.52
mmol, 1.00 equiv) in 5 mL of THF was added via syringe and the
mixture was stirred at room temperature overnight. The reaction was
quenched with saturated aqueous NH.sub.4Cl and extracted with
3.times.50 mL of ethyl acetate. The combined organic layers were
washed with brine, dried over anhydrous sodium sulfate and
concentrated under reduced pressure. The residue was applied onto a
silica gel column with ethyl acetate/petroleum ether (1:4) to give
tert-butyl
N-(4-[[(12R)-12-[2-[(tert-butyldimethylsilyl)oxy]ethyl]-8-thia-4,6-diazat-
ricyclo[7.4.0.0[2,7]]trideca-1(9),2(7),3,5-tetraen-3-yl]oxy]cyclohexyl)car-
bamate (200 mg, 68%) as a yellow oil.
[1265] Synthesis of Compound 156.2.
[1266] To a solution of tert-butyl
N-(4-[[(12R)-12-[2-[(tert-butyldimethylsilyl)oxy]ethyl]-8-thia-4,6-diazat-
ricyclo[7.4.0.0[2,7]]tri
deca-1(9),2(7),3,5-tetraen-3-yl]oxy]cyclohexyl)carbamate (200 mg,
0.36 mmol, 1.00 equiv) in 6 mL of THF was added TBAF (186 mg, 0.71
mmol, 2.00 equiv) at room temperature and the resulting solution
was stirred overnight at ambient temperature. The reaction was then
quenched with water, extracted with 3.times.30 mL of ethyl acetate.
The combined organic layers were washed with brine, dried over
anhydrous sodium sulfate and concentrated under vacuum.
Purification by column chromatography on silica gel with ethyl
acetate/petroleum ether (1:2) afford 129 mg (81%) of the desired
tert-butyl
N-(4-[[(12R)-12-(2-hydroxyethyl)-8-thia-4,6-diazatricyclo[7.4.0.0[2,7]]tr-
ideca-1(9),2(7),3,5-tetraen-3-yl]oxy]cyclohexyl)carbamate as a
yellow oil.
[1267] Synthesis of Compound 156.3.
[1268] To a 50-mL round-bottom flask purged and maintained with an
inert atmosphere of nitrogen was added tert-butyl
N-(4-[[(12R)-12-(2-hydroxyethyl)-8-thia-4,6-diazatricyclo[7.4.0.0[2,7]]tr-
ideca-1(9),2(7),3,5-tetraen-3-yl]oxy]cyclohexyl)carbamate (129 mg,
0.29 mmol, 1.00 equiv) in 4 mL of DMF. Then PDC (639 mg, 1.70 mmol,
6.00 equiv) was added and the resulting solution was stirred
overnight at room temperature. The reaction was then quenched with
water and extracted with 4.times.40 mL of CHCl.sub.3/isopropanol
(3:1). The combined organic layers were washed with brine, dried
over anhydrous sodium sulfate and concentrated under vacuum. The
residue was applied onto a silica gel column with ethyl
acetate/petroleum ether (1:1) to provide
2-[(12R)-3-[(4-[[(tert-butoxy)carbonyl]amino]cyclohexyl)oxy]-8-thia-4,
6-diazatricyclo[7.4.0.0[2,7]]trideca-1(9),2(7),3,5-tetraen-12-yl]acetic
acid (98 mg, 74%) as an off-white solid.
[1269] Synthesis of Compound 156.4.
[1270] To a 50-mL round-bottom flask purged and maintained with an
inert atmosphere of nitrogen and containing a solution of
2-[(12R)-3-[(4-[[(tert-butoxy)carbonyl]amino]cyclohexyl)oxy]-8-thia-4,6-d-
iazatricyclo[7.4.0.0[2,7]]trideca-1(9),2(7),3,5-tetraen-12-yl]acetic
acid (98 mg, 0.21 mmol, 1.00 equiv) in 4 mL of DMF was added
NH.sub.4Cl (68 mg, 1.27 mmol, 6.00 equiv), EDCI (61 mg, 0.32 mmol,
1.50 equiv), 4-dimethylaminopyridine (39 mg, 0.32 mmol, 1.50 equiv)
and HOBt (43 mg, 0.32 mmol, 1.50 equiv) successively. The resulting
solution was stirred overnight at room temperature and quenched
with water and extracted with 3.times.50 mL of ethyl acetate. The
combined organic layers were washed with brine, dried over
anhydrous sodium sulfate and concentrated under vacuum. The residue
was applied onto a silica gel column with ethyl acetate/petroleum
ether (2:1) to give tert-butyl
N-(4-[[(12R)-12-(carbamoylmethyl)-8-thia-4,6-diazatricyclo[7.4.0.0[2,7]]t-
rideca-1(9),2(7),3,5-tetraen-3-yl]oxy]cyclohexyl)carbamate (72 mg,
74%) as a white solid.
[1271] Synthesis of Compound I-113.
[1272] A solution of tert-butyl
N-(4-[[(12R)-12-(carbamoylmethyl)-8-thia-4,6-diazatricyclo[7.4.0.0[2,7]]t-
rideca-1(9),2(7),3,5-tetraen-3-yl]oxy]cyclohexyl)carbamate (72 mg,
0.16 mmol, 1.00 equiv) in 5 mL of dichloromethane (5 mL) was added
6 M aqueous hydrochloric acid (0.5 mL) at 0.degree. C. and the
resulting solution was stirred overnight at room temperature. The
resulting mixture was concentrated under vacuum to give 62 mg
(crude) of
2-[(12R)-3-[(4-aminocyclohexyl)oxy]-8-thia-4,6-diazatricyclo[7.4.0.0[2,7]-
]trideca-1(9),2(7),3,5-tetraen-12-yl]acetamide hydrochloride as a
yellow solid. The crude hydrochloride in 4 mL of MeOH was added
HCHO (37%, 1 mL) and 0.5 mL of HOAc at room temperature. Then
NaCNBH.sub.3 (31 mg, 0.49 mmol, 2.54 equiv) was added and the
resulting solution was stirred for 4 h at ambient temperature. The
resulting mixture was filtered through a thin silica column and
further purified by preparative HPLC under the following conditions
(Waters): column: Xbridge Prep C18 5 um, 19*150 mm; mobile phase:
water with 0.05% NH.sub.4HCO.sub.3 and CH.sub.3CN (5.0% CH.sub.3CN
up to 41.0% in 9 min, up to 95.0% in 2 min, down to 5.0% in 2 min);
flow rate: 20 mL/min; UV detection at 220/254 nm. The
product-containing fractions were collected and evaporated under
reduced pressure to give the desired
2-[(12R)-3-[[4-(dimethylamino)cyclohexyl]oxy]-8-thia-4,6-diazatricyclo[7.-
4.0.0[2,7]]trideca-1(9),2(7),3,5-tetraen-12-yl]acetamide (13.8 mg)
as a white solid. MS: 389 (M+H).sup.+. .sup.1H NMR (300 MHz,
CDCl.sub.3): .delta. 8.51 (s, 1H), 5.46-5.40 (m, 1H), 5.24-5.21 (m,
1H), 3.30-3.24 (m, 1H), 2.91 (m, 2H), 2.62-2.59 (m, 1H), 2.56-2.32
(m, 11H), 2.15-2.11 (m, 1H), 2.02-2.00 (m, 3H), 1.74-1.49 (m,
6H).
Example 157
Synthesis of
N-[(2R)-2-hydroxypropyl]-2-[(3R)-12-[[4-(methylamino)cyclohexyl]oxy]-7-th-
ia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-3-yl]ace-
tamide (I-151)
##STR00527##
[1274] Synthesis of Compound 157.1.
[1275] To a solution of
2-[(3R)-12-[(4-[[(tert-butoxy)carbonyl](methyl)amino]cyclohexyl)oxy]-7-th-
ia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-3-yl]ace-
tic acid (500 mg, 1.08 mmol, 1.00 equiv) and
[(2S)-1-aminopropan-2-yl]oxy(tert-butyl)dimethylsilane (250 mg,
1.32 mmol, 1.22 equiv) in N,N-dimethylformamide (30 mL) were added
DIEA (500 mg, 3.87 mmol, 3.57 equiv) and HBTU (2.1 g, 5.54 mmol,
5.11 equiv). The resulting solution was stirred for 5 h at room
temperature. The residue was dissolved in 50 mL of H.sub.2O. The
resulting solution was extracted with 5.times.40 mL of
dichloromethane and the organic layers combined and dried over
anhydrous sodium sulfate. After evaporation, the residue was
applied onto a silica gel column and eluted with EA/PE (1/1). This
resulted in 480 mg (70%) of tert-butyl
N-(4-[[(3R)-3-([[(2R)-2-[(tert-butyldimethylsilyl)oxy]propyl]carbamoyl]me-
thyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetrae-
n-12-yl]oxy]cyclohexyl)-N-methylcarbamate as a yellow solid.
[1276] Synthesis of Compound I-151.
[1277] To a solution of tert-butyl
N-(4-[[(3R)-3-([[(2R)-2-[(tert-butyldimethylsilyl)oxy]propyl]carbamoyl]me-
thyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetrae-
n-12-yl]oxy]cyclohexyl)-N-methylcarbamate (60 mg, 0.09 mmol, 1.00
equiv) in dichloromethane (2 mL) was added hydrogen chloride (6 N)
(1 mL). The resulting solution was stirred for 1 h at room
temperature. The resulting mixture was concentrated under vacuum.
The crude product (50 mg) was purified by preparative HPLC under
the following conditions: column: SunFire Prep C18, 19*150 mm 5 um;
mobile phase: water with 50 mL NH.sub.4CO.sub.3 and CH.sub.3CN
(5.0% CH.sub.3CN up to 43.0% in 12 min, up to 95.0% in 2 min, down
to 5.0% in 2 min); detector: 254/220 nm. This resulted in 22 mg
(55%) of
N-[(2R)-2-hydroxypropyl]-2-[(3R)-12-[[4-(methylamino)cyclohexyl]oxy]-7-th-
ia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-3-yl]ace-
tamide as a white solid. MS: m/z 419 (M+H).sup.+. .sup.1H NMR (300
MHz, CD.sub.3OD): .delta. 1.20 (3H, d), 1.41-1.61 (2H, m),
1.61-1.75 (2H, m), 2.15 (2H, d), 2.21-2.40 (4H, m), 2.61 (3H, s),
2.67-2.81 (2H, m), 2.90-3.10 (2H, m), 3.10-3.21 (2H, m), 3.3 (1H,
m), 3.82 (2H, m), 5.27 (1H, m), 8.48 (1H, s).
Example 158
Synthesis of
2-[(3R)-12-[[4-(4-benzylpiperazin-1-yl)cyclohexyl]oxy]-7-thia-9,11-diazat-
ricyclo[6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-3-yl]acetamide
(I-122)
##STR00528## ##STR00529##
[1279] Synthesis of Compound 158.2.
[1280] To a solution of 1,4-dioxaspiro[4.5]decan-8-one (11 g, 70.43
mmol, 1.24 equiv) and acetic acid (3 mL) in DCE (100 mL) was added
1-benzylpiperazine (10 g, 56.73 mmol, 1.00 equiv). The resulting
solution was stirred for 30 min at 0.degree. C., and then to the
above solution was added NaBH(OAc).sub.3 (20 g). The resulting
solution was stirred overnight at room temperature. The reaction
was then quenched by the addition of 60 mL of NaOH (10%). The
resulting solution was extracted with 5.times.50 mL of
dichloromethane and the organic layers combined. The mixture was
dried over anhydrous sodium sulfate. The solids were filtered out.
The resulting mixture was concentrated under vacuum. This resulted
in 16 g (89%) of
1-benzyl-4-[1,4-dioxaspiro[4.5]decan-8-yl]piperazine as a white
solid.
[1281] Synthesis of Compound 158.3.
[1282] To a solution of
1-benzyl-4-[1,4-dioxaspiro[4.5]decan-8-yl]piperazine (8.9 g, 28.13
mmol, 1.00 equiv) in acetone (150 mL) was added (3 mol/L) hydrogen
chloride (350 mL). The resulting solution was stirred overnight at
70.degree. C. in an oil bath. Acetone was removed under vacuum. The
pH was adjust to the value of 9-10 with K.sub.2CO.sub.3 (aq.). The
resulting solution was extracted with 3.times.200 mL of
dichloromethane and the organic layers combined. The resulting
mixture was washed with 200 mL of saturated sodium chloride
solution. The mixture was dried over anhydrous sodium sulfate and
concentrated under vacuum. This resulted in 7.6 g (crude) of
4-(4-benzylpiperazin-1-yl)cyclohexan-1-one as an off-white
solid.
[1283] Synthesis of Compound 158.4.
[1284] To a solution of 4-(4-benzylpiperazin-1-yl)cyclohexan-1-one
(10 g, 36.71 mmol, 1.00 equiv) in tetrahydrofuran (150 mL) was
added LAH (3 g, 79.05 mmol, 2.15 equiv). The resulting solution was
stirred for 2 h at 70.degree. C. The reaction was then quenched by
the addition of 5 mL of water. The resulting mixture was
concentrated under vacuum. The residue was applied onto a silica
gel column with dichloromethane/methanol (10:1). This resulted in 6
g (60%) of 4-(4-benzylpiperazin-1-yl)cyclohexan-1-ol as a white
solid.
[1285] Synthesis of Compound 158.5.
[1286] To a solution of 4-(4-benzylpiperazin-1-yl)cyclohexan-1-ol
(1160 mg, 4.23 mmol, 3.00 equiv) in tetrahydrofuran (50 mL) was
added sodium hydride (170 mg, 4.25 mmol, 3.02 equiv, 60%). The
reaction mixture was stirred for 30 min, and then to the above
solution was added
(3S)-3-[[(tert-butyldimethylsilyl)oxy]methyl]-12-chloro-7-thia-9,11-diaza-
tricyclo[6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraene (500 mg, 1.41
mmol, 1.00 equiv). Stirring was continued at 55.degree. C.
overnight. The reaction was then quenched by the addition of 50 mL
of water. The resulting solution was extracted with 5.times.50 mL
of dichloromethane and the organic layers combined and dried over
anhydrous magnesium sulfate. After evaporation, the residue was
applied onto a silica gel column with ethyl acetate/petroleum ether
(1:1). This resulted in 420 mg (50%) of
(3S)-12-[[4-(4-benzylpiperazin-1-yl)cyclohexyl]oxy]-3-[[(tert-bu-
tyldimethylsilyl)oxy]methyl]-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-
-1(12),2(6),8,10-tetraene as a yellow oil.
[1287] Synthesis of Compound 158.6.
[1288] To a solution of
(3S)-12-[[4-(4-benzylpiperazin-1-yl)cyclohexyl]oxy]-3-[[(tert-butyldimeth-
ylsilyl)oxy]methyl]-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(12),2(-
6),8,10-tetraene (420 mg, 0.71 mmol, 1.00 equiv) in tetrahydrofuran
(15 mL) was added TBAF (570 mg, 2.18 mmol, 3.08 equiv). The
resulting solution was stirred for 3 h at 25.degree. C. After
concentration under vacuum, dichloromethane (15 mL), triethylamine
(0.1 mL) and MsCl (0.1 mL) were added to the residue. The resulting
solution was stirred for 2 h at 25.degree. C. The reaction was then
quenched by the addition of 50 mL of water. The resulting solution
was extracted with 4.times.50 mL of dichloromethane and the organic
layers combined and dried over anhydrous magnesium sulfate. The
solids were filtered out. The resulting mixture was concentrated
under vacuum. This resulted in 350 mg (89%) of
[(3S)-12-[[4-(4-benzylpiperazin-1-yl)cyclohexyl]oxy]-7-thia-9,11-diazatri-
cyclo[6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-3-yl]methyl
methanesulfonate as a yellow oil.
[1289] Synthesis of Compound 158.7.
[1290] To a solution of
[(3S)-12-[[4-(4-benzylpiperazin-1-yl)cyclohexyl]oxy]-7-thia-9,11-diazatri-
cyclo[6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-3-yl]methyl
methanesulfonate (360 mg, 0.65 mmol, 1.00 equiv) in DMSO (10 mL)
was added NaCN (160 mg). The resulting solution was stirred for 2 h
at 80.degree. C. in an oil bath. The reaction was then quenched by
the addition of 100 mL of sodium bicarbonate (sat.). The resulting
solution was extracted with 6.times.50 mL of dichloromethane and
the organic layers combined. The mixture was dried over anhydrous
magnesium sulfate. The resulting mixture was concentrated under
vacuum. This resulted in 270 mg (86%) of
2-[(3R)-12-[[4-(4-benzylpiperazin-1-yl)cyclohexyl]oxy]-7-thia-9,11-diazat-
ricyclo[6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-3-yl]acetonitrile
as a yellow solid.
[1291] Synthesis of Compound I-122.
[1292] To a solution of
2-[(3R)-12-[[4-(4-benzylpiperazin-1-yl)cyclohexyl]oxy]-7-thia-9,11-diazat-
ricyclo[6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-3-yl]acetonitrile
(270 mg, 0.55 mmol, 1.00 equiv) in methanol (25 mL) were added
LiOH.H.sub.2O (70 mg) and H.sub.2O.sub.2(30%) (1.2 mL). The
resulting solution was stirred for 4 h at 0.degree. C. in a
water/ice bath. The reaction was then quenched by the addition of
100 mL of Na.sub.2SO.sub.3 (sat.). The resulting solution was
extracted with 6.times.50 mL of dichloromethane and the organic
layers combined. After evaporation, the residue was purified by
silica gel column with dichloromethane/methanol (4:1). This
resulted in 90 mg (32%) of Compound I-122 as a white solid.
[1293] .sup.1H NMR (300 MHz, CD.sub.3OD): .delta. 1.40-1.70 (m,
4H), 2.00-2.10 (m, 2H), 2.20-2.40 (m, 6H), 2.55-2.80 (m, 8H),
2.95-3.05 (m, 2H), 3.10-3.20 (m, 1H), 3.56 (s, 2H), 3.70-3.85 (m,
1H), 5.20-5.35 (m, 1H), 7.20-7.50 (m, 5H), 8.48 (s, 1H).
Example 159
Synthesis of
2-((R)-4-(((1r,4R)-4-(3-oxopiperazin-1-yl)cyclohexyl)oxy)-6,7-dihydro-5H--
cyclopenta[4,5]thieno[2,3-d]pyrimidin-5-yl)acetamide (I-158) and
Example 160: Synthesis of
2-((R)-4-(((1s,4S)-4-(3-oxopiperazin-1-yl)cyclohexyl)oxy)-6,7-dihydro-5H--
cyclopenta[4,5]thieno[2,3-d]pyrimidin-5-yl)acetamide (I-157)
##STR00530## ##STR00531##
[1295] Synthesis of Compound 159.1.
[1296] To a solution of 1,4-dioxaspiro[4.5]decan-8-ol (379 mg, 2.40
mmol, 1.20 equiv) in freshly distilled THF (10 mL) was added sodium
hydride (60% dispersion in mineral oil, 320 mg, 8.00 mmol, 4.00
equiv) in ice/water bath and stirred for 30 min under nitrogen. A
solution of
(3S)-3-[[(tert-butyldimethylsilyl)oxy]methyl]-12-chloro-7-thia-9,11-diaza-
tricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraene (710 mg, 2.00
mmol, 1.00 equiv) in 10 mL of anhydrous THF was added dropwise and
the resulting solution was stirred for 3 h at 60.degree. C. After
cooling, the mixture was then quenched with water, extracted with
EtOAc (100 mL), dried over anhydrous sodium sulfate. The solvents
were evaporated under reduced pressure to obtain
(3S)-3-[[(tert-butyldimethylsilyl)oxy]methyl]-12-[1,4-dioxaspiro[4.5]deca-
n-8-yloxy]-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-te-
traene (840 mg, 88%) as a yellow oil.
[1297] Synthesis of Compound 159.2.
[1298] To a solution of
(3S)-3-[[(tert-butyldimethylsilyl)oxy]methyl]-12-[1,4-dioxaspiro[4.5]deca-
n-8-yloxy]-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-te-
traene (840 mg, 1.76 mmol, 1.00 equiv) in THF (20 mL) was added
hydrochloric acid (3 M, 10 mL) at 0.degree. C. and stirred
overnight at room temperature. The pH value of the solution was
adjusted to 10 with sodium bicarbonate (sat.), extracted with
dichloromethane (100 mL), dried over anhydrous sodium sulfate and
concentrated under vacuum. The residue was applied on a silica gel
column and eluted with EtOAc/petroleum ether (1:1) to give 450 mg
(80%) of
4-[[(3S)-3-(hydroxymethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca--
1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexan-1-one as a yellow
oil.
[1299] Synthesis of Compound 159.3.
[1300] To a solution of
4-[[(3S)-3-(hydroxymethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca--
1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexan-1-one (450 mg, 1.41
mmol, 1.00 equiv) in DCM (10 mL) was added methanesulfonyl chloride
(242 mg, 2.11 mmol, 1.50 equiv) and triethylamine (430 mg, 4.25
mmol, 3.00 equiv) via syringe under nitrogen. The resulting
solution was stirred for 2 h at room temperature. The resulting
mixture was diluted with 50 mL of DCM, washed with brine, dried
over anhydrous sodium sulfate and evaporated to give 500 mg (89%)
of
[(3S)-12-[(4-oxocyclohexyl)oxy]-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]do-
deca-1(8),2(6),9,11-tetraen-3-yl]methyl methanesulfonate as a
yellow oil.
[1301] Synthesis of Compound 159.4.
[1302] To a solution of
[(3S)-12-[(4-oxocyclohexyl)oxy]-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]do-
deca-1(8),2(6),9,11-tetraen-3-yl]methyl methanesulfonate (500 mg,
1.26 mmol, 1.00 equiv) in methanol (10 mL) was added
piperazin-2-one (126 mg, 1.26 mmol, 1.00 equiv) and acetic acid (1
mL). The solution was stirred for 1 h and then acetyl
ethaneperoxoate sodioboranyl acetate (534 mg, 2.52 mmol, 2.00
equiv) was added. Stirring was continued for 2 h at 0.degree. C.
The mixture was then quenched with saturated aqueous sodium
bicarbonate, extracted with DCM (60 mL), dried over anhydrous
sodium sulfate and concentrated under vacuum. The desired
[(3S)-12-[[4-(3-oxopiperazin-1-yl)cyclohexyl]oxy]-7-thia-9,11-diazatricyc-
lo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]methyl
methanesulfonate (450 mg, 74%) was obtained as a yellow solid.
[1303] Synthesis of Compound 159.5.
[1304] To a solution of
[(3S)-12-[[4-(3-oxopiperazin-1-yl)cyclohexyl]oxy]-7-thia-9,11-diazatricyc-
lo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]methyl
methanesulfonate (450 mg, 0.94 mmol, 1.00 equiv) in DMSO (10 mL)
was added NaCN (276 mg, 5.63 mmol, 6.00 equiv) and DMAP (11 mg,
0.094 mmol, 0.10 equiv) at room temperature. The resulting solution
was stirred for 2 h at 80.degree. C. After cooling to r.t, the
resulting solution was diluted with DCM (100 mL), washed with
brine, dried over anhydrous sodium sulfate and concentrated under
vacuum. The residue was purified by column chromatography on silica
gel with DCM/MeOH (10:1) to afford 330 mg (86%) of
2-[(3R)-12-[[4-(3-oxopiperazin-1-yl)cyclohexyl]oxy]-7-thia-9,11-diazat-
ricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]acetonitrile
as a yellow solid.
[1305] Synthesis of Compound 159.6.
[1306] To a solution of
2-[(3R)-12-[[4-(3-oxopiperazin-1-yl)cyclohexyl]oxy]-7-thia-9,11-diazatric-
yclo[6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-3-yl]acetonitrile
(330 mg, 0.80 mmol, 1.00 equiv) in methanol (10 mL) was added
LiOH.H.sub.2O (101 mg, 2.40 mmol, 3.00 equiv) and
H.sub.2O.sub.2(30%, 0.5 mL) at 0.degree. C. The resulting solution
was stirred for 2 h at room temperature and quenched with
Na.sub.2SO.sub.3 (aq.), extracted with DCM (80 mL), dried over
anhydrous sodium sulfate and concentrated under vacuum. The residue
was applied onto a silica gel column with dichloromethane/methanol
(10:1) to give 50 mg (15%) of
2-[(3R)-12-[[4-(3-oxopiperazin-1-yl)cyclohexyl]oxy]-7-thia-9,11-diazatric-
yclo[6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-3-yl]acetamide as
a white solid. [Note: The product was found to decompose during
column purification].
[1307] Synthesis of Compounds I-158 and I-157.
[1308] The racemic
2-[(3R)-12-[[4-(3-oxopiperazin-1-yl)cyclohexyl]oxy]-7-thia-9,11-diazatric-
yclo[6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-3-yl]acetamide (50
mg) was resolved by preparative chiral HPLC under the following
conditions (Gilson): column: Venusil Chiral OD-H21.1*25 cm, 5 um
Chiral-P(OD); mobile phase: Hex (0.2% TEA):EtOH (0.2% TEA); flow
rate: 20 mL/min; UV detection at 254/220 nm. The product-containing
fractions were collected and partially evaporated to remove hexane
and EtOH under reduced pressure. The residues were lyophilized
overnight to give the desired products I-158 (28 mg) and I-157 (18
mg) as white solids.
Example 159
[1309] MS: m/z 430 (M+H).sup.+. .sup.1H NMR (300 MHz, CD.sub.3OD):
.delta. 8.48 (s, 1H), 5.61-5.57 (m, 1H), 3.91-3.79 (m, 1H), 3.31
(s, 2H), 3.21-2.71 (m, 7H), 2.66-2.52 (m, 1H), 2.39-2.18 (m, 4H),
1.89-1.61 (m, 7H).
Example 160
[1310] MS: m/z 430 (M+H). .sup.1H NMR (300 MHz, CD.sub.3OD):
.delta. 8.47 (s, 1H), 6.33-5.26 (m, 1H), 3.89-3.75 (m, 1H),
3.31-2.98 (m, 6H), 2.95-2.71 (m, 3H), 2.61-2.45 (m, 1H), 2.39-2.21
(m, 4H), 2.10-2.01 (m, 2H), 1.78-1.41 (m, 5H).
Example 161
Synthesis of Intermediate 161.12
##STR00532## ##STR00533##
[1312] Synthesis of Compound 161.2.
[1313] To a solution of 4-hydroxycyclohexane-1-carboxylic acid (13
g, 90.17 mmol, 1.00 equiv) in methanol (100 mL) was added sulfuric
acid (0.8 mL) and the resulting solution was stirred for 5 h at
60.degree. C. After cooling, the reaction mixture was concentrated
under reduced pressure and the residue was diluted with saturated
aqueous sodium bicarbonate and extracted with 3.times.200 mL of
ethyl acetate. The combined organic layers were washed with brine,
dried over anhydrous sodium sulfate and concentrated under vacuum.
This resulted in 14 g (crude) of methyl
4-hydroxycyclohexane-1-carboxylate as a colorless oil.
[1314] Synthesis of Compound 161.3.
[1315] A 500-mL round-bottom flask purged and maintained with an
inert atmosphere of nitrogen was charged with a solution of methyl
4-hydroxycyclohexane-1-carboxylate (14.0 g, 88.50 mmol, 1.00 equiv)
in anhydrous N,N-dimethylformamide (20 mL) at 0.degree. C. Then
tert-butyl(chloro)dimethylsilane (23.9 g, 158.57 mmol, 1.79 equiv)
and imidazole (12.05 g) were added and the resulting solution was
stirred overnight at room temperature. The reaction was then
quenched by the addition of 100 mL of water and extracted with
3.times.150 mL of ethyl acetate. The combined organic layers were
washed with brine, dried over anhydrous sodium sulfate and
concentrated under vacuum. The residue was applied onto a silica
gel column with ethyl acetate/petroleum ether (1/10) to give
4-[(tert-butyldimethylsilyl)oxy]cyclohexane-1-carboxylate (24.0 g,
95%) as a colorless oil.
[1316] Synthesis of Compound 161.4.
[1317] To a solution of anhydrous DIPA (26.7 g, 263.86 mmol, 3.00
equiv) in freshly distilled THF (500 mL) was added n-BuLi (2.5 M in
hexane, 110 mL) dropwise with stirring at -78.degree. C. under
nitrogen. After the addition, the resulting solution was stirred
for 0.5 h at -78.degree. C. To this was added dropwise a solution
of methyl 4-[(tert-butyldimethylsilyl)oxy]cyclohexane-1-carboxylate
(24 g, 88.09 mmol, 1.00 equiv) in 50 mL of THF and the resulting
solution was allowed to react for an additional 1 h at -78.degree.
C. To the mixture was added CH.sub.3I (62.64 g, 441.31 mmol, 5.01
equiv) dropwise with stirring at this low temperature. Stirring was
continued for 1 h. The reaction was quenched with water and
extracted with 3.times.150 mL of ethyl acetate. The combined
organic layers were washed with brine, dried over anhydrous sodium
sulfate and concentrated under vacuum. The residue was applied onto
a silica gel column with ethyl acetate/petroleum ether (1/10) to
provide the desired methyl
4-[(tert-butyldimethylsilyl)oxy]-1-methylcyclohexane-1-carboxylate
(22.0 g, 87%) as a colorless oil.
[1318] Synthesis of Compound 161.5.
[1319] To a solution of methyl
4-[(tert-butyldimethylsilyl)oxy]-1-methylcyclohexane-1-carboxylate
(10.0 g, 34.91 mmol, 1.00 equiv) in 100 mL of tetrahydrofuran was
added TBAF.3H.sub.2O (16.5 g, 52.30 mmol, 1.50 equiv) at room
temperature and stirred for 5 h. Then the reaction was quenched
with water, extracted with 3.times.100 mL of ethyl acetate. The
organic layers were combined, washed with brine, dried over sodium
sulfate and concentrated under vacuum. The residue was applied onto
a silica gel column with ethyl acetate/petroleum ether (1/2) to
give 5.8 g (96%) of methyl
4-hydroxy-1-methylcyclohexane-1-carboxylate as a light yellow
oil.
[1320] Synthesis of Compound 161.6.
[1321] To a solution of methyl
4-hydroxy-1-methylcyclohexane-1-carboxylate (5.8 g, 33.68 mmol,
1.00 equiv) and 4-nitrobenzoic acid (11.26 g, 67.38 mmol, 2.00
equiv) in 80 mL of anhydrous THF was added PPh.sub.3 (17.67 g,
67.37 mmol, 2.00 equiv) at room temperature. Then DIAD (13.62 g,
67.36 mmol, 2.00 equiv) was added dropwise and the resulting
solution was stirred for 2 h at room temperature. The reaction was
quenched water, extracted with 3.times.150 mL of ethyl acetate. The
combined organic layers were dried over sodium sulfate and
concentrated under vacuum. The residue was applied onto a silica
gel column with ethyl acetate/petroleum ether (1/50) to give
4-(methoxycarbonyl)-4-methylcyclohexyl 4-nitrobenzoate (5.5 g, 51%)
as a white solid.
[1322] Synthesis of Compound 161.7.
[1323] Into a 250-mL round-bottom flask containing a solution of
4-(methoxycarbonyl)-4-methylcyclohexyl 4-nitrobenzoate (4.5 g,
14.00 mmol, 1.00 equiv) in methanol/water (30 mL/6 mL) was added
potassium carbonate (5.8 g, 41.97 mmol, 3.00 equiv) and the
resulting solution was stirred overnight at 50.degree. C. The
reaction was quenched by the addition of NH.sub.4Cl (aq.) and
extracted with 3.times.100 mL of ethyl acetate. The organic phase
was washed with brine, dried over sodium sulfate and concentrated
under vacuum. The residue was applied onto a silica gel column with
ethyl acetate/petroleum ether (1/2) to afford the desired methyl
4-hydroxy-1-methylcyclohexane-1-carboxylate (2.2 g, 91%) as a
colorless oil.
[1324] Synthesis of Compound 161.8.
[1325] To a solution of methyl
4-hydroxy-1-methylcyclohexane-1-carboxylate (2.1 g, 12.19 mmol,
1.00 equiv) in 20 mL of dichloromethane was added DIEA (4.74 g,
36.68 mmol, 3.01 equiv) and SEMCl (4.08 g, 24.47 mmol, 2.00 equiv)
at 0.degree. C. under nitrogen. The resulting solution was stirred
for 2 h at room temperature and quenched with water. The resulting
solution was extracted with 3.times.100 mL of ethyl acetate. The
organic layers were washed with brine, dried over sodium sulfate
and concentrated under reduced pressure. The residue was applied
onto a silica gel column with ethyl acetate/petroleum ether (1/20)
to give the desired methyl
1-methyl-4-[[2-(trimethylsilyl)ethoxy]methoxy]cyclohexane-1-carboxylate
(3.6 g, 98%) as a colorless oil.
[1326] Synthesis of Compound 161.9.
[1327] To a 250-mL round-bottom flask containing a solution of
methyl 1-methyl-4-[[2-(trimethyl
silyl)ethoxy]methoxy]cyclohexane-1-carboxylate (3.6 g, 11.90 mmol,
1.00 equiv) in a mixed methanol/water (25 mL/4 mL) was added sodium
hydroxide (2.38 g, 59.50 mmol, 5.00 equiv) and the resulting
solution was heated to reflux overnight. After cooling, the pH
value of the solution was adjusted to 4 with hydrochloric acid (2.0
M), extracted with 3.times.100 mL of ethyl acetate. The combined
organic layers were washed with brine, dried over sodium sulfate
and concentrated under reduced pressure. The desired
1-methyl-4-[[2-(trimethylsilyl)ethoxy]methoxy]cyclohexane-1-carboxylic
acid (3.12 g, 91%) was obtained as a light yellow oil which was
used in the next step without further purification.
[1328] Synthesis of Compound 161.10.
[1329] To a solution of
1-methyl-4-[[2-(trimethylsilyl)ethoxy]methoxy]cyclohexane-1-carboxylic
acid (3.1 g, 10.75 mmol, 1.00 equiv) in tert-butanol (40 mL) was
added DPPA (5.33 g, 19.37 mmol, 1.80 equiv) and TEA (3.28 g, 32.41
mmol, 3.02 equiv) at room temperature. The resulting solution was
heated to reflux overnight and cooled down to room temperature. The
reaction was quenched with water and extracted with 3.times.100 mL
of ethyl acetate. The combined organic layers were washed with
brine, dried over sodium sulfate and concentrated under reduced
pressure. The residue was applied onto a silica gel column with
ethyl acetate/petroleum ether (1/100) to give
(2-[[(4-isocyanato-4-methylcyclohexyl)oxy]methoxy]ethyl)trimethylsilane
(1.5 g, 49%) as a colorless oil.
[1330] Synthesis of Compound 161.11.
[1331] To a solution of
(2-[[(4-isocyanato-4-methylcyclohexyl)oxy]methoxy]ethyl)trimethylsilane
(1.5 g, 5.25 mmol, 1.00 equiv) in THF (30 mL) was added
hydrochloric acid (6 N, 3.0 mL) and the resulting solution was
stirred for 2 h at room temperature. Upon completion, the resulting
mixture was concentrated under vacuum to give
trans-4-amino-4-methylcyclohexanol hydrochloride (1.0 g, crude) as
a white solid.
[1332] Synthesis of Intermediate 161.12.
[1333] To a solution of 4-amino-4-methylcyclohexan-1-ol
hydrochloride (1.0 g, 6.04 mmol, 1.00 equiv) in THF/water (20 mL/5
mL) was added 2M aqueous sodium hydroxide until the pH was 9-10 at
0.degree. C. Then Boc.sub.2O (1.57 g, 7.19 mmol, 1.19 equiv) was
added and the resulting solution was stirred for 4 h at room
temperature. The reaction was diluted with water and extracted with
3.times.80 mL of ethyl acetate. The combined organic layers were
washed with brine, dried over sodium sulfate and concentrated under
reduced pressure. The residue was applied onto a silica gel column
with ethyl acetate/petroleum ether (1/1) to give the desired
tert-butyl N-(4-hydroxy-1-methylcyclohexyl)carbamate (720 mg, 52%)
as a white solid.
Example 162
Synthesis of Intermediate 162.4
##STR00534##
[1335] Synthesis of Compound 162.1.
[1336] To a solution of tert-butyl
N-(4-hydroxy-1-methylcyclohexyl)carbamate (700 mg, 3.05 mmol, 1.00
equiv) in anhydrous THF (10 mL) was added sodium hydride (60%
dispersion in mineral oil, 600 mg, 15.00 mmol, 4.91 equiv) at
0.degree. C. under nitrogen. The resulting solution was stirred for
0.5 h at room temperature. To this was added (3
S)-3-[[(tert-butyldimethylsilyl)oxy]methyl]-12-chloro-7-thia-9,11-diazatr-
icyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraene (1.18 g, 3.32
mmol, 1.09 equiv) and stirring was continued for 5 h at 30.degree.
C. The reaction was then quenched by the addition of 30 mL of
NH.sub.4Cl (aq.) and extracted with 3.times.80 mL of ethyl acetate.
The organic phase was dried over sodium sulfate and concentrated
under vacuum. The residue was applied onto a silica gel column with
ethyl acetate/petroleum ether (1/15) to yield 1.20 g (72%) of
tert-butyl N-(4-[[(3
S)-3-[[(tert-butyldimethylsilyl)oxy]methyl]-7-thia-9,11-diazatricyclo[6.4-
.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]-1-methylcyclohexyl)carb-
amate as a light yellow solid.
[1337] Synthesis of Compound 162.2.
[1338] To a solution of tert-butyl
N-(4-[[(3S)-3-[[(tert-butyldimethylsilyl)oxy]methyl]-7-thia-9,11-diazatri-
cyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]-1-methylcycloh-
exyl)carbamate (1.20 g, 2.19 mmol, 1.00 equiv) in tetrahydrofuran
(15 mL) was added TBAF.3H.sub.2O (1.09 g, 3.45 mmol, 1.58 equiv) at
0.degree. C. and the resulting solution was stirred for 3 h at room
temperature. The reaction was quenched with water and extracted
with 3.times.100 mL of ethyl acetate. The organic layers were
washed with brine, dried over sodium sulfate and concentrated under
vacuum. Purification by column chromatography on silica gel with
ethyl acetate/petroleum ether (1:20 to 1:5) afforded tert-butyl
N-(4-[[(3S)-3-(hydroxymethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dode-
ca-1(8),2(6),9,11-tetraen-12-yl]oxy]-1-methylcyclohexyl)carbamate
(900 mg, 95%) as a colorless oil.
[1339] Synthesis of Compound 162.3.
[1340] To a solution of tert-butyl
N-(4-[[(3S)-3-(hydroxymethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dode-
ca-1(8),2(6),9,11-tetraen-12-yl]oxy]-1-methylcyclohexyl)carbamate
(1.0 g, 2.31 mmol, 1.00 equiv) in dichloromethane (20 mL) was added
MsCl (632 mg, 5.54 mmol, 2.40 equiv) and triethylamine (839 mg,
8.29 mmol, 3.59 equiv) at 0.degree. C. The resulting solution was
stirred for 1 h at room temperature and quenched with water. The
resulting solution was extracted with 3.times.50 mL of DCM and the
organic layers were combined, dried over sodium sulfate and
concentrated under vacuum. The residue was applied onto a silica
gel column with ethyl acetate/petroleum ether (1/3) to yield 1.07 g
(91%) of tert-butyl N-(4-[[(3
S)-3-[(methanesulfonyloxy)methyl]-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]-
dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]-1-methylcyclohexyl)carbamate
as a light yellow oil.
[1341] Synthesis of Intermediate 162.4.
[1342] To a 50-mL round-bottom flask containing a solution of
tert-butyl N-(4-[[(3
S)-3-[(methanesulfonyloxy)methyl]-7-thia-9,11-diazatricyclo[6.4-
.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]-1-methylcyclohexyl)carb-
amate (1.0 g, 1.95 mmol, 1.00 equiv) in DMSO (12 mL) was added NaCN
(479 mg, 9.78 mmol, 5.00 equiv) and 4-dimethylaminopyridine (30 mg,
0.25 mmol, 0.13 equiv) and the solution was stirred for 2.5 h at
80.degree. C. After cooling, the reaction was then quenched by the
addition of water, extracted with 3.times.100 mL of ethyl acetate.
The organic layers were combined, washed with brine, dried over
sodium sulfate and concentrated under vacuum. The residue was
applied onto a silica gel column with ethyl acetate/petroleum ether
(1/2) to give the desired tert-butyl
N-(4-[[(3R)-3-(cyanomethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-
-1(8),2(6),9,11-tetraen-12-yl]oxy]-1-methylcyclohexyl)carbamate
(830 mg, 96%) as a white solid.
Example 163
Synthesis of
2-[(3R)-12-[(4-amino-4-methylcyclohexyl)oxy]-7-thia-9,11-diazatricyclo[6.-
4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]acetamide (I-161)
##STR00535##
[1344] Synthesis of Compound 163.1.
[1345] A 50-mL round-bottom flask purged and maintained with an
inert atmosphere of nitrogen was charged with tert-butyl
N-(4-[[(3R)-3-(cyanomethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-
-1(8),2(6),9,11-tetraen-12-yl]oxy]-1-methylcyclohexyl)carbamate
(600 mg, 1.36 mmol, 1.00 equiv) in methanol (8.0 mL). Then
LiOH.H.sub.2O (171 mg, 4.08 mmol, 3.00 equiv) and
H.sub.2O.sub.2(30%, 1.0 mL) were added at 0.degree. C. and the
resulting solution was stirred overnight at this temperature. The
reaction was then quenched by the addition of 40 mL of NaHSO.sub.3
(aq.) and extracted with 3.times.60 mL of ethyl acetate. The
combined organic layers were washed with brine, dried over sodium
sulfate and concentrated under vacuum. The residue was applied onto
a silica gel column with ethyl acetate/petroleum ether (1/1) to
afford tert-butyl
N-(4-[[(3R)-3-(carbamoylmethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]do-
deca-1(8),2(6),9,11-tetraen-12-yl]oxy]-1-methylcyclohexyl)carbamate
(450 mg, 72%) as a white solid.
[1346] Synthesis of Compound I-161.
[1347] A solution of tert-butyl
N-(4-[[(3R)-3-(carbamoylmethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]do-
deca-1(8),2(6),9,11-tetraen-12-yl]oxy]-1-methylcyclohexyl)carbamate
(100 mg, 0.22 mmol, 1.00 equiv) in dichloromethane (5.0 mL) was
added hydrochloric acid (6 N, 0.3 mL) at 0.degree. C. The resulting
solution was stirred for 2 h at room temperature and concentrated
under vacuum. The crude product (90 mg) was purified by preparative
HPLC under the following conditions (Waters): column: XBridge Prep
C18 OBD column: 5 um, 19*150 mm, mobile phase: water with 0.05%
NH4HCO3 and CH3CN (5% CH3CN up to 16% in 2 min, hold 16% in 11 min,
up to 95% in 2 min, down to 5% in 2 min); flow rate: 20 mL/min; UV
detection at 254 & 220 nm. This resulted in 28.4 mg (36%) of
2-[(3R)-12-[(4-amino-4-methylcyclohexyl)oxy]-7-thia-9,11-diazatricyclo[6.-
4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]acetamide as a white
solid. MS: m/z 361 (M+H).sup.+. .sup.1H NMR (300 MHz, CD.sub.3OD):
.delta. 8.48 (1H, s), 5.44 (1H, m), 3.80 (1H, m), 3.28 (1H, m),
2.96 (2H, m), 2.71 (1H, m), 2.26 (2H, m), 2.09 (2H, m), 1.79-1.91
(4H, m), 1.55 (2H, m), 1.22 (3H, s).
Example 164
Synthesis of
2-[(3R)-12-[[4-(dimethylamino)-4-methylcyclohexyl]oxy]-7-thia-9,11-diazat-
ricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]acetamide
(I-155)
##STR00536##
[1349] To a solution of
2-[(3R)-12-[(4-amino-4-methylcyclohexyl)oxy]-7-thia-9,11-diazatricyclo[6.-
4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]acetamide (200 mg,
0.55 mmol, 1.00 equiv) in 8 mL of methanol was added HCHO (37%, 1.2
mL). The solution was stirred for 0.5 h at room temperature. Then
NaBH.sub.3CN (105 mg, 1.67 mmol, 3.01 equiv) was added and the
resulting solution was allowed to react, with stirring, for an
additional 1 h at room temperature. The reaction was quenched with
NH.sub.4Cl (aq.) and extracted with 3.times.60 mL of DCM. The
combined organic layers were concentrated under vacuum. The crude
product (150 mg) was purified by preparative HPLC under the
following conditions (Waters): column: XBridge Prep C18 OBD column:
5 um, 19*150 mm; mobile phase: water with 0.05% NH.sub.4HCO.sub.3
and CH.sub.3CN (5% CH.sub.3CN up to 47% in 13 min, up to 95% in 2
min, down to 5% in 2 min); flow rate: 20 mL/min; UV detection at
254 & 220 nm. This resulted in 39.8 mg of
2-[(3R)-12-[[4-(dimethylamino)-4-methylcyclohexyl]oxy]-7-thia-9,11-diazat-
ricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]acetamide
as a white solid. MS: m/z 389 (M+H).sup.+. .sup.1H NMR (300 MHz,
CD.sub.3OD): .delta. 8.49 (1H, s), 5.41 (1H, m), 3.80 (1H, m), 3.19
(1H, m), 3.04 (1H, m), 2.98 (1H, m), 2.85 (6H, s), 2.76 (1H, m),
2.31 (4H, m), 2.14 (2H, m), 1.96 (4H, m), 1.47 (3H, s).
Example 165
Synthesis of
2-[(3R)-12-[[4-methyl-4-(methylamino)cyclohexyl]oxy]-7-thia-9,11-diazatri-
cyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]acetamide
(I-156)
##STR00537##
[1351] Synthesis of 165.1.
[1352] To a 50-mL round-bottom flask containing a solution of
tert-butyl
N-(4-[[(3R)-3-(cyanomethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-
-1(8),2(6),9,11-tetraen-12-yl]oxy]-1-methylcyclohexyl)carbamate
(100 mg, 0.23 mmol, 1.00 equiv) in distilled DMF (3 mL) was added
sodium hydride (60% dispersion in mineral oil 37 mg, 0.93 mmol,
4.09 equiv) at 0.degree. C. The resulting solution was stirred for
0.5 h at this temperature. Then CH.sub.3I (321 mg, 2.26 mmol, 1.00
equiv) was added and the resulting solution was allowed to react,
with stirring, for an additional 2 h at 30.degree. C. The reaction
was then quenched with saturated aqueous NH.sub.4Cl and extracted
with 3.times.30 mL of ethyl acetate. The combined organic layers
were washed with brine, dried over sodium sulfate and concentrated
under vacuum. The residue was applied onto a silica gel column with
ethyl acetate/petroleum ether (1:2) to give tert-butyl
N-(4-[[(3R)-3-(cyanomethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-
-1(8),2(6),9,11-tetraen-12-yl]oxy]-1-methylcyclohexyl)-N-methylcarbamate
(80 mg, 78%) as a white solid.
[1353] Synthesis of 165.2
[1354] To a solution of tert-butyl
N-(4-[[(3R)-3-(cyanomethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-
-1(8),2(6),9,11-tetraen-12-yl]oxy]-1-methylcyclohexyl)-N-methylcarbamate
(100 mg, 0.2 mmol, 1.00 equiv) in 10 mL of methanol was added
LiOH.H.sub.2O (30 mg, 0.7 mmol, 3.26 equiv) and H.sub.2O.sub.2(30%,
0.8 mL) and stirred for 4 h at 0.degree. C. The reaction was then
quenched with saturated aqueous NaHSO.sub.3, extracted with
3.times.50 mL of ethyl acetate. The combined organic layers were
washed with brine, dried over sodium sulfate and concentrated under
vacuum. The residue was purified by column chromatography on silica
gel with EtOAc/PE (1:2) to give the desired tert-butyl
N-(4-[[(3R)-3-(carbamoylmethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]do-
deca-1(8),2(6),9,11-tetraen-12-yl]oxy]-1-methylcyclohexyl)-N-methylcarbama-
te (85 mg) as a light yellow oil.
[1355] Synthesis of Compound I-156.
[1356] To a 50-mL round-bottom flask containing a solution of
tert-butyl
N-(4-[[(3R)-3-(carbamoylmethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]do-
deca-1(8),2(6),9,11-tetraen-12-yl]oxy]-1-methylcyclohexyl)-N-methylcarbama-
te (85 mg, 0.18 mmol, 1.00 equiv) in dichloromethane (5 mL) was
added hydrochloric acid (6 M, 0.1 mL) at 0.degree. C. The resulting
solution was stirred for 2 h at room temperature and concentrated
under vacuum. The crude product (70 mg) was purified by preparative
HPLC under the following conditions (Waters): column: XBridge Prep
C18 OBD column: 5 um, 19*150 mm; mobile phase: water with 0.05%
NH.sub.4HCO.sub.3 and CH.sub.3CN (10% CH.sub.3CN up to 30% in 10
min, up to 95% in 2 min, down to 10% in 2 min); flow rate: 20
mL/min; UV detection at 254 & 220 nm. This resulted in 46.9 mg
(70%) of
2-[(3R)-12-[[4-methyl-4-(methylamino)cyclohexyl]oxy]-7-thia-9,11-diazatri-
cyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]acetamide as
a white solid. MS: m/z 375 (M+H).sup.+. .sup.1H NMR (300 MHz,
CD.sub.3OD): .delta. 8.47 (1H, s), 5.44 (1H, m), 3.84 (1H, m), 3.14
(1H, m), 3.02 (1H, m), 2.79 (1H, m), 2.25-2.35 (5H, m), 2.10 (2H,
m), 1.75-1.90 (4H, m), 1.63 (2H, m), 1.19 (3H, s).
Example 166
Synthesis of
2-[(3R)-12-[(4-[2-oxa-6-azaspiro[3.3]heptan-6-yl]cyclohexyl)oxy]-7-thia-9-
,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]acetamid-
e (I-152)
##STR00538## ##STR00539##
[1358] Synthesis of Compound 166.2.
[1359] To a solution of 4-aminocyclohexan-1-ol (690 mg, 5.99 mmol,
1.00 equiv), 3,3-bis(chloromethyl)oxetane (1.395 g, 9.00 mmol, 1.50
equiv) in acetonitrile (25 mL) was added potassium carbonate (3.0
g, 21.71 mmol, 3.62 equiv), KI (250 mg, 1.49 mmol, 0.25 equiv) and
potassium hydroxide (672 mg, 11.98 mmol, 2.00 equiv) at room
temperature and the resulting mixture was stirred overnight at
90.degree. C. in an oil bath. The solids were filtered out and the
filtrate was concentrated under vacuum. The residue was applied
onto a silica gel column with dichloromethane/methanol (30:1 to
10:1) to give the desired
4-[2-oxa-6-azaspiro[3.3]heptan-6-yl]cyclohexan-1-ol (370 mg, 31%)
as an off-white solid.
[1360] Synthesis of Compound 166.3.
[1361] To a solution of
4-[2-oxa-6-azaspiro[3.3]heptan-6-yl]cyclohexan-1-ol (250 mg, 1.27
mmol, 1.19 equiv) in 15 mL of freshly distilled THF was added
sodium hydride (60% dispersion in mineral oil, 169.9 mg, 4.25 mmol,
4.00 equiv) in portions at 0.degree. C. under nitrogen. The
resulting solution was stirred for 0.5 h at this temperature. Then
(3 S)-3-[[(tert-butyldimethyl
silyl)oxy]methyl]-12-chloro-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-
-1(12),2(6),8,10-tetraene (377 mg, 1.06 mmol, 1.00 equiv) was added
and the resulting solution was allowed to react, with stirring, for
an additional 2 h at ambient temperature. After completion of the
reaction, the reaction mixture was quenched by the addition of 20
mL of saturated aqueous NH.sub.4Cl and extracted with 3.times.50 mL
of ethyl acetate. The combined organic layers were washed with
brine, dried over sodium sulfate and concentrated under vacuum. The
residue was applied onto a silica gel column with ethyl acetate to
give the desired (3
S)-3-[[(tert-butyldimethylsilyl)oxy]methyl]-12-[(4-[2-oxa-6-azaspiro[3.3]-
heptan-6-yl]cyclohexyl)oxy]-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca--
1(12),2(6),8,10-tetraene (0.5 g, 91%) as a colorless oil.
[1362] Synthesis of Compound 166.4.
[1363] To a solution of
(3S)-3-[[(tert-butyldimethylsilyl)oxy]methyl]-12-[(4-[2-oxa-6-azaspiro[3.-
3]heptan-6-yl]cyclohexyl)oxy]-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodec-
a-1(12),2(6),8,10-tetraene (360 mg, 0.70 mmol, 1.00 equiv) in
methanol (65 mL) was added 0.04 M aqueous hydrochloric acid (13 mL)
at 0.degree. C. The resulting solution was stirred for 4 h at
0.degree. C. and then quenched with saturated aqueous sodium
bicarbonate. The resulting solution was extracted with 3.times.50
mL of ethyl acetate. The combined organic layers were washed with
brine, dried over anhydrous sodium sulfate and concentrated under
vacuum. The solvents were evaporated under reduced pressure to
yield 250 mg (crude) of the desired
[(3S)-12-[(4-[2-oxa-6-azaspiro[3.3]heptan-6-yl]cyclohexyl)oxy]-7-thia-9,1-
1-diazatricyclo[6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-3-yl]methanol
as a colorless oil.
[1364] Synthesis of Compound 166.5.
[1365] To a solution of
[(3S)-12-[(4-[2-oxa-6-azaspiro[3.3]heptan-6-yl]cyclohexyl)oxy]-7-thia-9,1-
1-diazatricyclo[6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-3-yl]methanol
(250 mg, 0.62 mmol, 1.00 equiv) and TEA (188 mg, 1.86 mmol, 2.99
equiv) in dichloromethane (10 mL) was added MsCl (142 mg, 1.25
mmol, 2.00 equiv) and the resulting mixture was stirred for 1 h at
25.degree. C. under nitrogen. After completion, the reaction was
quenched with water and extracted with 3.times.50 mL of ethyl
acetate. The organic layers were combined, washed with brine and
dried over anhydrous sodium sulfate. The solvents were concentrated
under reduced pressure vacuum to afford
[(3S)-12-[(4-[2-oxa-6-azaspiro[3.3]heptan-6-yl]cyclohexyl)oxy]-7-thia-9,1-
1-diazatricyclo[6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-3-yl]methyl
methanesulfonate (250 mg, crude) as a yellow oil.
[1366] Synthesis of Compound 166.6.
[1367] A solution of
[(3S)-12-[(4-[2-oxa-6-azaspiro[3.3]heptan-6-yl]cyclohexyl)oxy]-7-thia-9,1-
1-diazatricyclo[6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-3-yl]methyl
methanesulfonate (250 mg, 0.52 mmol, 1.00 equiv) and NaCN (153 mg,
3.12 mmol, 5.99 equiv) in DMSO (10 mL) was stirred for 3 h at
60.degree. C. After cooling, the reaction was quenched by the
addition of 30 mL of saturated aqueous sodium bicarbonate and
extracted with 3.times.50 mL of ethyl acetate. The combined organic
layers combined were washed with brine, dried over anhydrous sodium
sulfate and concentrated under vacuum. The residue was applied onto
a silica gel column with dichloromethane/methanol (10:1) to give
2-[(3R)-12-[(4-[2-oxa-6-azaspiro[3.3]heptan-6-yl]cyclohexyl)oxy]-7-thia-9-
,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-3-yl]acetoni-
trile (140 mg, 65%) as a colorless oil.
[1368] Synthesis of Compound I-156.
[1369] A solution of
2-[(3R)-12-[(4-[2-oxa-6-azaspiro[3.3]heptan-6-yl]cyclohexyl)oxy]-7-thia-9-
,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]acetonit-
rile (140 mg, 0.34 mmol, 1.00 equiv) in methanol (5 mL) was cooled
to 0.degree. C. This was followed by the addition of LiOH.H.sub.2O
(28 mg, 0.67 mmol, 2.00 equiv) and H.sub.2O.sub.2(30%, 0.5 mL) at
0.degree. C. under nitrogen. The resulting solution was stirred for
2 h at this temperature. The reaction was quenched with saturated
aqueous Na.sub.2SO.sub.3 and extracted with 3.times.50 mL of ethyl
acetate. The combined organic layers were concentrated under
vacuum. The crude product (100 mg) was purified by preparative HPLC
under the following conditions (Waters): column: XBridge Shield
RP18 OBD column: 5 um, 19*150 mm; mobile phase: water with 0.05%
NH.sub.4HCO.sub.3 and CH.sub.3CN (10% CH.sub.3CN up to 30% in 10
min, up to 95% in 2 min, down to 10% in 2 min); flow rate: 20
mL/min; UV detection at 254/220 nm. This afforded 43 mg (29%) of
2-[(3R)-12-[(4-[2-oxa-6-azaspiro[3.3]heptan-6-yl]cyclohexyl)oxy]-7-thia-9-
,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]acetamid-
e as a white solid. MS: m/z 429 (M+H).sup.+. .sup.1H NMR (300 MHz,
CD.sub.3OD): .delta. 8.45 (1H, s), 5.26-5.31 (1H, m), 4.75-4.87
(4H, s), 3.80-3.83 (1H, m), 3.45 (4H, m), 2.95-3.33 (3H, m),
2.71-2.77 (1H, m), 2.15-2.29 (5H, m), 1.90-1.95 (2H, m), 1.56-1.65
(2H, m), 1.18-1.27 (2H, m).
Example 167
Synthesis of Intermediates 167.3 and 167.4
##STR00540##
[1371] Synthesis of Compound 167.1.
[1372] Ammonia gas was introduced in 50 mL of CH.sub.3OH at
5.degree. C. for 15 min. To the above solution was added tert-butyl
N-methyl-N-(4-[[(3R)-3-(2-oxoethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6-
]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)carbamate (700
mg, 1.57 mmol, 1.00 equiv), NaCN (93.1 mg, 1.90 mmol, 1.20 equiv)
and NH.sub.4Cl (92.5 mg, 1.73 mmol, 1.10 equiv) successively. The
resulting mixture was stirred for 16 h at room temperature and
concentrated under reduced pressure. The residue was applied onto a
silica gel column with dichloromethane/methanol (1:30) to afford
tert-butyl
N-(4-[[(3R)-3-(2-amino-2-cyanoethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,-
6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)-N-methylcarbamate
(600 mg, 81%) as a yellow oil.
[1373] Synthesis of Compound 167.2.
[1374] To a solution of tert-butyl
N-(4-[[(3R)-3-(2-amino-2-cyanoethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,-
6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)-N-methylcarbamate
(800 mg, 1.70 mmol, 1.00 equiv) and triethylamine (340 mg, 3.36
mmol, 2.00 equiv) in dichloromethane (50 mL) was added dropwise a
solution of benzyl chloroformate (320 mg, 1.88 mmol, 1.10 equiv) in
10 mL of DCM at 0.degree. C. The resulting solution was stirred for
30 min at this temperature and then quenched with water. The
resulting solution was extracted with 3.times.50 mL of ethyl
acetate and the combined organic layers were washed with brine,
dried over sodium sulfate and concentrated under vacuum. The
residue was applied onto a silica gel column with ethyl
acetate/petroleum ether (1:10-1:5) to give benzyl
N-[2-[(3R)-12-[(4-[[(tert-butoxy)carbonyl](methyl)amino]cyclohexyl)oxy]-7-
-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]--
1-cyanoethyl]carbamate (0.5 g, 49%) as a white solid.
[1375] Synthesis of Intermediates 167.3 and 167.4.
[1376] To a 50-mL round-bottom flask containing a solution of
benzyl
N-[2-[(3R)-12-[(4-[[(tert-butoxy)carbonyl](methyl)amino]cyclohexyl)oxy]-7-
-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]--
1-cyanoethyl]carbamate (450 mg, 0.74 mmol, 1.00 equiv) in methanol
(20 mL) was added LiOH.H.sub.2O (94 mg, 2.24 mmol, 3.00 equiv) and
H.sub.2O.sub.2(30%, 2 mL) at 0.degree. C. The resulting solution
was stirred for 2 h at 0.degree. C. and quenched with saturated
aqueous Na.sub.2SO.sub.3 and extracted with 3.times.50 mL of ethyl
acetate. The combined organic layers were washed with brine, dried
over sodium sulfate and concentrated in vacuo. The residue was
applied onto a silica gel column with ethyl acetate/petroleum ether
(1:5-1:3) to afford the corresponding benzyl N-[(1
S)-2-[(3R)-12-[(4-[[(tert-butoxy)carbonyl](methyl)amino]cyclohexyl)oxy]-7-
-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]--
1-carbamoylethyl]carbamate (167.3, 230 mg) as a white solid and
benzyl
N-[(1R)-2-[(3R)-12-[(4-[[(tert-butoxy)carbonyl](methyl)amino]cyclohexyl)o-
xy]-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-
-yl]-1-carbamoylethyl]carbamate (167.4, 90 mg) as a white
solid.
Example 168
Synthesis of
(2S)-2-amino-3-[(3R)-12-[[4-(dimethylamino)cyclohexyl]oxy]-7-thia-9,11-di-
azatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]propanamide
(I-160)
##STR00541##
[1378] Synthesis of Compound 168.1.
[1379] To a solution of benzyl
N-[(1S)-2-[(3R)-12-[(4-[[(tert-butoxy)carbonyl](methyl)amino]cyclohexyl)o-
xy]-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-
-yl]-1-carbamoylethyl]carbamate (120 mg, 0.19 mmol, 1.00 equiv) in
dichloromethane (5 mL) was added hydrochloric acid (12 M, 1 mL) at
0.degree. C. The resulting solution was stirred for 1 h at this
temperature and concentrated under vacuum. This resulted in 100 mg
(crude) of benzyl
N-[(1S)-1-carbamoyl-2-[(3R)-12-[[4-(methylamino)cyclohexyl]oxy]-7-thia-9,-
11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]ethyl]car-
bamate hydrochloride as a yellow solid.
[1380] Synthesis of Compound 168.2.
[1381] A solution of benzyl
N-[(1S)-1-carbamoyl-2-[(3R)-12-[[4-(methylamino)cyclohexyl]oxy]-7-thia-9,-
11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]ethyl]car-
bamate hydrochloride (100 mg, 0.18 mmol, 1.00 equiv) in methanol
(10 mL) was added HCHO (37%, 2 mL) and stirred for 0.5 h at room
temperature. This was followed by the addition of NaBH.sub.3CN
(33.6 mg, 0.53 mmol, 2.99 equiv) at 0.degree. C. and the resulting
solution was allowed to react, with stirring, for an additional 2 h
at room temperature. The reaction was then quenched by the addition
of 20 mL of water and extracted with 3.times.50 mL of
dichloromethane and the combined organic layers were dried over
sodium sulfate and concentrated in vacuo. The residue was applied
onto a silica gel column with CH.sub.2Cl.sub.2: CH.sub.3OH (10:1)
to provide benzyl
N-[(1S)-1-carbamoyl-2-[(3R)-12-[[4-(dimethylamino)cyclohexyl]oxy]-7-thia--
9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]ethyl]c-
arbamate (50 mg, 52%) as a white solid.
[1382] Synthesis of Compound I-160.
[1383] To a solution of benzyl
N-[(1S)-1-carbamoyl-2-[(3R)-12-[[4-(dimethylamino)cyclohexyl]oxy]-7-thia--
9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]ethyl]c-
arbamate (40 mg, 0.07 mmol, 1.00 equiv) in dichloromethane (2 mL)
was added hydrochloric acid (conc., 1 mL) and the resulting
solution was stirred for 5 h at 30.degree. C. The resulting mixture
was concentrated under vacuum and the crude product was purified by
preparative HPLC under the following conditions (Waters): column:
XBridge Prep C18 OBD column: 5 um, 19*150 mm; Mobile phase: water
with 0.03% NH.sub.3.H.sub.2O and CH.sub.3CN (13.0% CH.sub.3CN up to
30.0% in 10 min, up to 100.0% in 2 min, down to 13.0% in 2 min);
flow rate: 20 mL/min; UV detection at 254/220 nm. The
product-containing fractions were collected and concentrated to
remove CH.sub.3CN and water under reduced pressure. The residue was
lyophilized overnight to give
(2S)-2-amino-3-[(3R)-12-[[4-(dimethylamino)cyclohexyl]oxy]-7-thia-9,11-di-
azatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]propanamide
(11.2 mg, 37%) as a white solid. MS: m/z 404 (M+H).sup.+. .sup.1H
NMR (300 MHz, CD.sub.3OD): .delta. 1.40-1.50 (m, 4H), 1.68-1.75 (m,
2H), 2.00-2.10 (m, 2H), 2.12-2.18 (m, 1H), 2.25-2.35 (m, 2H), 2.33
(s, 6H), 2.50-2.60 (m, 1H), 2.65-2.75 (m, 1H), 2.90-2.95 (m, 1H),
3.00-3.15 (m, 1H), 3.35-3.48 (m, 2H), 5.20-5.30 (m, 1H), 8.42 (s,
1H).
Example 169
Synthesis of
(5R)-5-[[(3R)-12-[[4-(methylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricyc-
lo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]methyl]imidazolidine-2,-
4-dione (I-159)
##STR00542##
[1385] Synthesis of Compound 169.1.
[1386] To a solution of benzyl
N-[(1R)-2-[(3R)-12-[(4-[[(tert-butoxy)carbonyl](methyl)amino]cyclohexyl)o-
xy]-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-
-yl]-1-carbamoylethyl]carbamate (80 mg, 0.15 mmol, 1.00 equiv) in
20 mL of THF was added TBAF hydrate (134 mg, 0.51 mmol, 4.00 equiv)
at room temperature. The resulting solution was stirred for 4 h at
70.degree. C. under nitrogen. After cooling down to room
temperature, the resulting solution was diluted with 50 mL of ethyl
acetate and washed with H.sub.2O and brine. The organic layer was
dried over anhydrous sodium sulfate and concentrated under vacuum.
The residue was applied onto a silica gel column with ethyl
acetate/petroleum ether (1:10) to yield 60 mg (94%) of tert-butyl
N-(4-[[(3R)-3-[[(4R)-2,5-dioxoimidazolidin-4-yl]methyl]-7-thia-9,11-diaza-
tricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)--
N-methylcarbamate as a white solid.
[1387] Synthesis of Compound I-159.
[1388] To a solution of tert-butyl
N-(4-[[(3R)-3-[[(4R)-2,5-dioxoimidazolidin-4-yl]methyl]-7-thia-9,11-diaza-
tricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)--
N-methylcarbamate (45 mg, 0.09 mmol, 1.00 equiv) in dichloromethane
(3 mL) was added hydrogen chloride (conc., 0.5 mL) at 0.degree. C.
under nitrogen. The resulting solution was stirred for 2 h at room
temperature and evaporated under reduced pressure. The crude
product (45 mg) was purified by preparative HPLC under the
following conditions (Waters): column: XBridge Shield RP18 OBD
column: 5 um, 19*150 mm; mobile phase: water with 0.03%
NH.sub.3.H.sub.2O and CH.sub.3CN (16% CH.sub.3CN up to 22% in 11
min, up to 100% in 2 min, down to 16% in 2 min); UV detection at
254 and 220 nm. The product-containing fractions were collected and
concentrated to remove CH.sub.3CN and water under reduced pressure.
The residue was lyophilized overnight to give
(5R)-5-[[(3R)-12-[[4-(methylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricyc-
lo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]methyl]imidazolidine-2,-
4-dione (16.5 mg) as a white solid. MS: m/z 416 (M+H).sup.+.
.sup.1H NMR (300 MHz, CD.sub.3OD): .delta. 1.20-1.40 (m, 2H),
1.50-1.65 (m, 2H), 1.72-1.95 (m, 1H), 2.00-2.37 (m, 6H), 2.45 (s,
3H), 2.56-2.68 (m, 2H), 2.98-3.05 (m, 1H), 3.08-3.15 (m, 1H), 3.50
(t, 1H, J=1.5 Hz), 4.19 (dd, 2H, J=11.7, 2.7 Hz), 5.20-5.30 (m,
1H), 8.42 (s, 1H).
Example 170
Synthesis of Intermediates 170.1 and 170.2
##STR00543##
[1390] The enantiomers of racemic ethyl
2-[3-chloro-8-thia-4,6-diazatricyclo[7.4.0.0[2,7]]trideca-1(9),2(7),3,5-t-
etraen-13-yl]acetate (1.4 g, 4.50 mmol, 1.00 equiv) in MeOH (10 mL)
were separated by preparative chiral HPLC under the following
conditions: column: Chiralpak IC 0.46*25 cm, 5 um; mobile phase,
Hex (0.1% TEA): EtOH=70:30; UV detection at 254 nm. The
product-containing fractions were collected and evaporated to
remove solvents under reduced pressure to give 520 mg (37%) of
ethyl
2-[(13R)-3-chloro-8-thia-4,6-diazatricyclo[7.4.0.0[2,7]]trideca-1(9),2(7)-
,3,5-tetraen-13-yl]acetate 170.1 (first peak) as a white solid and
520 mg (37%) of ethyl
2-[(13S)-3-chloro-8-thia-4,6-diazatricyclo[7.4.0.0[2,7]]trideca-1(9),2(7)-
,3,5-tetraen-13-yl]acetate 170.2 (second peak) as a white solid,
respectively.
Example 171
Synthesis of
3-((S)-4-(((1r,4S)-4-aminocyclohexyl)oxy)-5,6,7,8-tetrahydrobenzo[4,5]thi-
eno[2,3-d]pyrimidin-5-yl)propanamide (I-154)
##STR00544## ##STR00545##
[1392] Synthesis of Compound 171.1.
[1393] NaH (60% dispersion in mineral oil, 438 mg, 10.95 mmol, 4.00
equiv) was treated with tert-butyl N-(4-hydroxycyclohexyl)carbamate
(710 mg, 3.30 mmol, 1.20 equiv) in freshly distilled THF at
50.degree. C. for 30 min under nitrogen. Then a solution of ethyl
2-[(13
S)-3-chloro-8-thia-4,6-diazatricyclo[7.4.0.0[2,7]]trideca-1(9),2(7),3,5-t-
etraen-13-yl]acetate (850 mg, 2.73 mmol, 1.00 equiv) in THF (10 mL)
was added via syringe and stirred for 2 h at 60.degree. C. After
cooling, the reaction was quenched with brine, extracted with ethyl
acetate (80 mL), dried over anhydrous sodium sulfate and
concentrated under vacuum. The residue was applied onto a silica
gel column with ethyl acetate/petroleum ether (1:5) to give 800 mg
(60%) of ethyl 2-[(13
S)-3-[(4-[[(tert-butoxy)carbonyl]amino]cyclohexyl)oxy]-8-thia-4,6-diazatr-
icyclo[7.4.0.0[2,7]]trideca-1(9),2(7),3,5-tetraen-13-yl]acetate as
a colorless oil.
[1394] Synthesis of Compound 171.2.
[1395] To a solution of ethyl
2-[(13S)-3-[(4-[[(tert-butoxy)carbonyl]amino]cyclohexyl)oxy]-8-thia-4,
6-diazatricyclo[7.4.0.0[2,7]]trideca-1(9),2(7),3,5-tetraen-13-yl]acetate
(800 mg, 1.63 mmol, 1.00 equiv) in THF (30 mL) in an ice/water bath
under nitrogen was added LiAlH.sub.4 (121.2 mg, 3.20 mmol, 2.00
equiv). The resulting solution was stirred for 2 h at room
temperature and quenched with water, extracted with ethyl acetate
(80 mL), dried over anhydrous sodium sulfate and concentrated under
vacuum. The residue was applied onto a silica gel column with ethyl
acetate/petroleum ether (1:1) to give 490 mg (67%) of tert-butyl
N-(4-[[(13S)-13-(2-hydroxyethyl)-8-thia-4,6-diazatricyclo[7.4.0.0[2,7]]tr-
ideca-1(9),2(7),3,5-tetraen-3-yl]oxy]cyclohexyl)carbamate as a
colorless oil.
[1396] Synthesis of Compound 171.3.
[1397] To a solution of tert-butyl
N-(4-[[(13S)-13-(2-hydroxyethyl)-8-thia-4,6-diazatricyclo[7.4.0.0[2,7]]tr-
ideca-1(9),2(7),3,5-tetraen-3-yl]oxy]cyclohexyl)carbamate (490 mg,
1.09 mmol, 1.00 equiv) in DCM (20 mL) was added triethylamine (201
mg, 1.99 mmol, 1.80 equiv) and methanesulfonyl chloride (189 mg,
1.65 mmol, 1.50 equiv) at 0.degree. C. The resulting solution was
stirred for 2 h at room temperature and then washed with brine,
dried over anhydrous sodium sulfate and concentrated under vacuum.
The residue was applied onto a silica gel column with ethyl
acetate/petroleum ether (1:3) to provide 530 mg of tert-butyl
N-(4-[[(13S)-13-[2-(methanesulfonyloxy)ethyl]-8-thia-4,6-diazatricyclo[7.-
4.0.0[2,7]]trideca-1(9),2(7),3,5-tetraen-3-yl]oxy]cyclohexyl)carbamate
as a white solid.
[1398] Synthesis of Compound 171.4.
[1399] To a solution of tert-butyl
N-(4-[[(13S)-13-[2-(methanesulfonyloxy)ethyl]-8-thia-4,6-diazatricyclo[7.-
4.0.0[2,7]]trideca-1(9),2(7),3,5-tetraen-3-yl]oxy]cyclohexyl)carbamate
(525 mg, 1.00 mmol, 1.00 equiv) in DMSO (20 mL) was added NaCN (294
mg, 6.00 mmol, 6.00 equiv) and the resulting solution was stirred
for 2 h at 70.degree. C. under nitrogen. After cooling, the mixture
was diluted with DCM (80 mL), washed with brine, dried over
anhydrous sodium sulfate and concentrated under vacuum. The residue
was applied onto a silica gel column with ethyl acetate/petroleum
ether (1:3) to yield 380 mg (83%) of tert-butyl N-(4-[[(13
S)-13-(2-cyanoethyl)-8-thia-4,6-diazatricyclo[7.4.0.0[2,7]]trideca-1(9),2-
(7),3,5-tetraen-3-yl]oxy]cyclohexyl)carbamate as a white solid.
[1400] Synthesis of Compound 171.5.
[1401] To a solution of tert-butyl
N-(4-[[(13S)-13-(2-cyanoethyl)-8-thia-4,6-diazatricyclo[7.4.0.0[2,7]]trid-
eca-1(9),2(7),3,5-tetraen-3-yl]oxy]cyclohexyl)carbamate (300 mg,
0.66 mmol, 1.00 equiv) in methanol (15 mL) was added LiOH.H.sub.2O
(82 mg, 1.95 mmol, 3.00 equiv) and H.sub.2O.sub.2(30%, 0.5 mL) at
0.degree. C. and the resulting solution was stirred for 2 h at
30.degree. C. The reaction was quenched with saturated aqueous
sodium sulfite, extracted with DCM (30 mL), washed with brine,
dried over anhydrous sodium sulfate and concentrated under vacuum.
The residue was applied onto a silica gel column with
dichloromethane/methanol (20:1) to give 240 mg (77%) of tert-butyl
N-(4-[[(13S)-13-(2-carbamoylethyl)-8-thia-4,6-diazatricyclo[7.4.0.0[2,7]]-
trideca-1(9),2(7),3,5-tetraen-3-yl]oxy]cyclohexyl)carbamate as a
white solid.
[1402] Synthesis of Compound I-154.
[1403] To a solution of tert-butyl
N-(4-[[(13S)-13-(2-carbamoylethyl)-8-thia-4,6-diazatricyclo[7.4.0.0[2,7]]-
trideca-1(9),2(7),3,5-tetraen-3-yl]oxy]cyclohexyl)carbamate (240
mg, 0.51 mmol, 1.00 equiv) in dichloromethane (20 mL) was added
hydrogen chloride (12M) (0.5 mL). The resulting solution was
stirred for 2 h at room temperature. The pH value of the solution
was adjusted to 10 with sodium bicarbonate (aq) (20 mL), extracted
with dichloromethane (30 mL), dried over anhydrous sodium sulfate
and concentrated under vacuum. The residue was applied onto a
silica gel column with dichloromethane/methanol (2:1) to give 130
mg (69%) of the desired product I-154 as a white solid. MS: m/z 375
(M+H).sup.+. .sup.1H NMR (300 MHz, CD.sub.3OD): .delta. 8.46 (s,
1H), 5.35-5.27 (m, 1H), 3.19-3.16 (m, 1H), 2.98-2.75 (m, 3H),
2.61-2.42 (m, 1H), 2.39-2.15 (m, 3H), 2.14-1.87 (m, 6H), 1.86-1.65
(m, 4H), 1.45-1.32 (m, 2H).
Example 172
Synthesis of
3-((R)-4-(((1r,4R)-4-aminocyclohexyl)oxy)-5,6,7,8-tetrahydrobenzo[4,5]thi-
eno[2,3-d]pyrimidin-5-yl)propanamide (I-153)
##STR00546## ##STR00547##
[1405] Compound I-153 was synthesized in a manner consistent with
Example 171, except that intermediate 170.1 was used rather than
170.2. MS: m/z 375 (M+H).sup.+. .sup.1H NMR (300 MHz, CD.sub.3OD):
.delta. 8.47 (s, 1H), 5.38-5.29 (m, 1H), 3.25-3.17 (m, 2H),
2.98-2.78 (m, 2H), 2.61-2.20 (m, 4H), 2.19-2.08 (m, 3H), 2.05-1.95
(m, 3H), 1.93-1.75 (m, 4H), 1.74-1.57 (m, 2H).
Example 173
Synthesis of
3-((R)-4-(((1r,4R)-4-(methylamino)cyclohexyl)oxy)-5,6,7,8-tetrahydrobenzo-
[4,5]thieno[2,3-d]pyrimidin-5-yl)propanamide (I-162)
##STR00548## ##STR00549##
[1407] Compound I-162 was prepared in a manner consistent with
Example 171 except that tert-butyl
N-(4-hydroxycyclohexyl)-N-methylcarbamate was used rather than
tert-butyl N-(4-hydroxycyclohexyl)carbamate. MS: m/z 389
(M+H).sup.+. .sup.1H NMR (300 MHz, CD.sub.3OD): .delta. 8.46 (s,
1H), 5.37-5.27 (m, 1H), 3.25-3.17 (m, 1H), 2.98-2.78 (m, 2H),
2.61-2.46 (m, 2H), 2.45 (s, 3H), 2.44-2.20 (m, 3H), 2.18-1.90 (m,
6H), 1.93-1.75 (m, 4H), 1.74-1.57 (m, 2H).
Example 174
Synthesis of
3-((R)-4-(((1r,4R)-4-(dimethylamino)cyclohexyl)oxy)-5,6,7,8-tetrahydroben-
zo[4,5]thieno[2,3-d]pyrimidin-5-yl)propanamide (I-163)
##STR00550##
[1409] To a solution of
3-[(13R)-3-[[4-(methylamino)cyclohexyl]oxy]-8-thia-4,6-diazatricyclo[7.4.-
0.0[2,7]]trideca-1(9),2(7),3,5-tetraen-13-yl]propanamide (100 mg,
0.26 mmol, 1.00 equiv) in MeOH (15 mL) was added HCHO (37%, 1 mL)
and stirred for 1 h at room temperature. Then NaBH.sub.3CN (49 mg,
0.78 mmol, 3.00 equiv) was added and the resulting solution was
stirred overnight at room temperature. The mixture was then
quenched with water, extracted with dichloromethane (3.times.30
mL), dried over anhydrous sodium sulfate and concentrated under
vacuum. The residue (150 mg) was purified by preparative HPLC under
the following conditions (SHIMADZU): column: SunFire Prep C18,
19*150 mm 5 um; mobile phase: water with 0.1% NH.sub.4HCO.sub.3 and
CH.sub.3CN (6.0% CH.sub.3CN up to 60% in 20 min); flow rate: 20
mL/min; UV detection at 254/220 nm. The product-containing
fractions were collected and partially evaporated to remove water
and CH.sub.3CN under reduced pressure. The residue was lyophilized
overnight to give the desired product (63.2 mg) as a white solid.
MS: m/z 403 (M+H).sup.+. .sup.1H NMR (300 MHz, CD.sub.3OD): .delta.
8.46 (s, 1H), 5.32-5.26 (m, 1H), 3.25-3.17 (m, 1H), 2.98-2.78 (m,
2H), 2.61-2.46 (m, 2H), 2.45 (s, 6H), 2.44-2.24 (m, 3H), 2.18-1.90
(m, 6H), 1.93-1.65 (m, 4H), 1.74-1.47 (m, 2H).
Example 175
Synthesis of Intermediate 175.3
##STR00551##
[1411] Synthesis of Compound 175.1.
[1412] To a mixture of cyclohexanone (49 g, 0.5 mol, 1.0 equiv),
ethyl 2-cyanoacetate (56 g, 0.5 mol, 1.0 equiv) and sulphur (16 g,
0.5 mol, 1.0 equiv) in 150 mL of ethanol was added morpholine (44
g, 0.5 mol, 1.0 equiv). The mixture was stirred for 8 h at room
temperature. The reaction mixture was diluted with water and the
precipitate was collected by filtration and recrystallized from
ethanol to afford compound 175.1 as a yellow solid (62 g, 55%).
[1413] Synthesis of Compound 175.2.
[1414] A solution of compound 175.1 (35 g, 0.16 mol) in 150 mL of
formamide was heated at 180.degree. C. for 4 h. Upon cooling, the
mixture was poured into 200 mL of water and filtered. The solid was
collected and recrystallized from ethanol to afford compound 175.2
as a yellow solid (25 g, 75%). .sup.1H NMR (400 MHz, DMSO-d6):
.delta. 1.75-1.82 (m, 4H), 2.72-2.75 (m, 2H), 2.85-2.88 (m, 2H),
8.00 (s, 1H), 12.31 (br s, 1H). MS: m/z 207.0 (M+H).sup.+.
[1415] Synthesis of Compound 175.3.
[1416] To a 100-mL round-bottom flask containing a solution of
175.2 (450 mg, 2.2 mmol, 1.00 equiv) in 1,4-dioxane (30 mL) was
added POCl.sub.3 (5.1 g, 34.09 mmol, 15.25 equiv) at room
temperature under nitrogen. The resulting solution was stirred for
4 h at 90.degree. C. and concentrated under reduced pressure. The
residue was diluted with EtOAc and poured into 50 mL of cooled
saturated aqueous NaHCO.sub.3 and extracted with 3.times.80 mL of
dichloromethane. The combined organic layers were washed with
brine, dried over anhydrous sodium sulfate and concentrated under
vacuum. The residue was applied onto a silica gel column with ethyl
acetate/petroleum ether (1:7) to give
3-chloro-8-thia-4,6-diazatricyclo[7.4.0.0
[2,7]]trideca-1(9),2,4,6-tetraene (360 mg, 73%) as a yellow
solid.
Example 176
Synthesis of Intermediate 176.8
##STR00552##
[1418] Synthesis of Compound 176.2.
[1419] A solution of 4-aminobutan-1-ol (18 g, 201.94 mmol, 1.00
equiv), ethyl 1,3-dioxo-2,3-dihydro-1H-isoindole-2-carboxylate
(44.5 g, 203.02 mmol, 1.01 equiv) and TEA (28 g, 276.71 mmol, 1.37
equiv) in 500 mL of THF was heated to reflux overnight. The
reaction mixture was cooled to room temperature, quenched with
water and extracted with ethyl acetate. The combined organic layers
were washed with brine and dried over sodium sulfate. The solids
were filtered out and the filtrate was concentrated under vacuum.
The residue was applied onto a silica gel column with PE/EtOAc
(10:1 to 1:1) to give 30 g (68%) of
2-(4-hydroxybutyl)-2,3-dihydro-1H-isoindole-1,3-dione as a white
solid. MS (ES): m/z 220 (M+H).sup.+.
[1420] Synthesis of Compound 176.3.
[1421] To a 250-mL round-bottom flask, purged and maintained with
an inert atmosphere of nitrogen, was added a solution of oxalic
dichloride (2.52 g, 19.85 mmol, 1.98 equiv) in 40 mL of anhydrous
dichloromethane. This solution was cooled to -78.degree. C. under
nitrogen. A solution of DMSO (1.56 g, 19.97 mmol, 1.99 equiv) in
dichloromethane (10 mL) was added dropwise with stirring at
-78.degree. C. and the resulting solution was stirred for 20 min at
-78.degree. C. A solution of
2-(4-hydroxybutyl)-2,3-dihydro-1H-isoindole-1,3-dione (2.2 g, 10.03
mmol, 1.00 equiv) in 20 mL of dichloromethane was added dropwise
with stirring. Stirring was continued for 20 min at -78.degree. C.,
and then TEA (8.1 g, 80.20 mmol, 7.99 equiv) was added via syringe
at the same temperature. The resulting solution was allowed to
react, with stirring, for an additional 60 min at 0.degree. C.
After completion, the resulting mixture was diluted with 1 M
aqueous hydrochloric acid, extracted with DCM, washed with
3.times.100 mL of brine, dried over sodium sulfate and concentrated
under vacuum. The residue was purified by a silica gel column with
ethyl acetate/petroleum ether (1:1) to provide the desired
4-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)butanal (1.9 g, 87%) as a
white solid. MS (ES): m/z 218 (M+H).sup.+.
[1422] Synthesis of Compound 176.4.
[1423] A mixture of
4-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)butanal (2.2 g, 10.13
mmol, 1.00 equiv), TEA (2 g, 19.76 mmol, 1.95 equiv), S (340 mg,
10.61 mmol, 1.05 equiv) and ethyl 2-cyanoacetate (1.2 g, 10.61
mmol, 1.05 equiv) in 50 mL of ethanol was stirred for 20 hours at
65.degree. C. under nitrogen. The reaction mixture was cooled to
room temperature and concentrated in vacuo. The residue was diluted
with EtOAc, washed with brine, dried over anhydrous sodium sulfate
and concentrated under vacuum. The residue was applied onto a
silica gel column with ethyl acetate/petroleum ether (1:1) to
afford 2.4 g (69%) of ethyl
2-amino-5-[2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)ethyl]thiophene-3-ca-
rboxylate as an off-white solid. MS (ES): m/z 345 (M+H).sup.+.
[1424] Synthesis of Compound 176.5.
[1425] To a 250-mL round-bottom flask, purged and maintained with
an inert atmosphere of nitrogen, was added a solution of ethyl
2-amino-5-[2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)ethyl]thiophene-3-ca-
rboxylate (3.4 g, 9.87 mmol, 1.00 equiv) and formamidine acetate
(1.5 g, 14.41 mmol, 1.46 equiv) dissolved in 50 mL of
N,N-dimethylformamide. This solution was heated at 100.degree. C.
for 12 hrs. The reaction was cooled to room temperature and
quenched with water. The resulting mixture was extracted with
3.times.100 mL of ethyl acetate and the combined organic layers
were washed with brine, dried over sodium sulfate and concentrated
under vacuum. The residue was applied onto a silica gel column with
ethyl acetate/petroleum ether (1:1) to yield 1.76 g (55%) of
2-(2-[4-hydroxythieno[2,3-d]pyrimidin-6-yl]ethyl)-2,3-dihydro-1H-isoindol-
e-1,3-dione as an off-white solid. MS (ES): m/z 326
(M+H).sup.+.
[1426] Synthesis of Compound 176.6.
[1427] To a 250-mL round-bottom flask, purged and maintained with
an inert atmosphere of nitrogen, was added a solution of ethyl
2-amino-5-[2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)ethyl]thiophene-3-ca-
rboxylate (3.4 g, 9.87 mmol, 1.00 equiv) and formamidine acetate
(1.5 g, 14.41 mmol, 1.46 equiv) dissolved in 50 mL of
N,N-dimethylformamide. This solution was heated at 100.degree. C.
for 12 hrs. The reaction was cooled to room temperature and
quenched with water. The resulting mixture was extracted with
3.times.100 mL of ethyl acetate and the combined organic layers
were washed with brine, dried over sodium sulfate and concentrated
under vacuum. The residue was applied onto a silica gel column with
ethyl acetate/petroleum ether (1:1) to yield 1.76 g (55%) of
2-(2-[4-hydroxythieno[2,3-d]pyrimidin-6-yl]ethyl)-2,3-dihydro-1H-isoindol-
e-1,3-dione as an off-white solid. MS (ES): m/z 326
(M+H).sup.+.
[1428] Synthesis of Compound 176.7.
[1429] To a solution of 6-(2-aminoethyl)thieno[2,3-d]pyrimidin-4-ol
(2.0 g, 10.24 mmol, 1.00 equiv) and TEA (5 g, 49.41 mmol, 4.82
equiv) in 50 mL of THF was added Boc.sub.2O (7.0 g, 32.07 mmol,
3.13 equiv), in portions, at 0.degree. C. under nitrogen. The
resulting solution was warmed up to room temperature and stirred
for 12 h at 40 OC. TLC analysis indicated that the amine was
consumed completely and the resulting mixture was concentrated
under vacuum. The residue was diluted with 50 mL of ethyl acetate,
washed with brine, dried over Na.sub.2SO.sub.4 and concentrated
under reduced pressure. The residue was applied onto a silica gel
column with ethyl acetate/petroleum ether (1:4) to give 3.6 g (89%)
of
6-(2-[[(tert-butoxy)carbonyl]amino]ethyl)thieno[2,3-d]pyrimidin-4-yl
tert-butyl carbonate as a white solid. MS (ES): m/z 396
(M+H).sup.+.
[1430] Synthesis of Intermediate 176.8.
[1431] To a 25-mL round-bottom flask containing a solution of
6-(2-[[(tert-butoxy)carbonyl]amino]ethyl)thieno[2,3-d]pyrimidin-4-yl
tert-butyl carbonate (370 mg, 0.94 mmol, 1.00 equiv) in 10 mL of
methanol was added NH.sub.4OH (2.1 mL) at room temperature and the
resulting solution was stirred for 2 hours under N.sub.2. After
completion, the resulting mixture was concentrated under vacuum and
the residue was applied onto a silica gel column with ethyl
acetate/petroleum ether (1:1) to afford 252 mg (91%) of the desired
tert-butyl
N-(2-[4-hydroxythieno[2,3-d]pyrimidin-6-yl]ethyl)carbamate as a
white solid. MS (ES): m/z 296 (M+H).sup.+.
Example 177
Synthesis of Intermediate 177.1
##STR00553##
[1433] To a solution of tert-butyl
N-(2-[4-hydroxythieno[2,3-d]pyrimidin-6-yl]ethyl)carbamate (2.3 g,
7.79 mmol, 1.00 equiv) in DCE (300 mL) was added PPh.sub.3 (4.1 g,
15.63 mmol, 2.00 equiv). The solution was stirred for 1 h at room
temperature under nitrogen. Then CCl.sub.4 (3.6 g, 23.38 mmol, 3.00
equiv) was added and the resulting solution was stirred at
72.degree. C. overnight. After cooling, the resulting mixture was
concentrated under vacuum. The residue was applied onto a silica
gel column with ethyl acetate/petroleum ether (1:5 to 1:3) to give
tert-butyl
N-(2-[4-chlorothieno[2,3-d]pyrimidin-6-yl]ethyl)carbamate (1.0 g)
as a light yellow solid. MS (ES): m/z 314 and 316 (M+H).sup.+.
Example 178
Synthesis of Intermediate 178.3
##STR00554##
[1435] Synthesis of Compound 178.1.
[1436] Sodium hydride (80 mg, 2.00 mmol, 4.83 equiv, 60% dispersion
in mineral oil) was treated with
trans-4-(dimethylamino)cyclohexan-1-ol (80 mg, 0.56 mmol, 1.35
equiv) in 10 mL of distilled THF for 30 min at 0.degree. C. under
nitrogen. Then a solution of tert-butyl
N-(2-[4-chlorothieno[2,3-d]pyrimidin-6-yl]ethyl)carbamate (130 mg,
0.41 mmol, 1.00 equiv) in 3 mL of THF was added and stirred at room
temperature for 12 hours. After cooling to 0.degree. C., the
reaction was quenched with water and extracted with 3.times.30 mL
of ethyl acetate. The organic layers were combined, washed with
brine, dried over anhydrous sodium sulfate and concentrated under
vacuum. The residue was applied onto a silica gel column with
dichloromethane/methanol (4:1) to give 140 mg (80%) of tert-butyl
N-[2-(4-[[4-(dimethylamino)cyclohexyl]oxy]thieno[2,3-d]pyrimidin-6-yl)eth-
yl]carbamate as a white solid. MS (ES): m/z 421 (M+H).sup.+.
[1437] Synthesis of Compound 178.2.
[1438] To a solution of tert-butyl
N-[2-(4-[[4-(dimethylamino)cyclohexyl]oxy]thieno[2,3-d]pyrimidin-6-yl)eth-
yl]carbamate (140 mg, 0.33 mmol, 1.00 equiv) in 5 mL of DCM was
added CF.sub.3COOH (0.5 mL) at room temperature. The resulting
solution was stirred for 5 h at ambient temperature and then
concentrated under vacuum to give the desired
4-[[6-(2-aminoethyl)thieno[2,3-d]pyrimidin-4-yl]oxy]-N,N-dimethylcyclohex-
an-1-amine trifluoroacetate (100 mg) as a yellow oil which was used
directly without further purification. MS (ES): m/z 321
(M+H).sup.+.
[1439] Synthesis of Intermediate 178.3.
[1440] To a 25-mL round-bottom flask (1 atm), purged and maintained
with an inert atmosphere of nitrogen, was placed
4-[[6-(2-aminoethyl)thieno[2,3-d]pyrimidin-4-yl]oxy]-N,N-dimethylcyclohex-
an-1-amine (100 mg, 0.31 mmol, 1.00 equiv) in 25 mL of
1,2-dichloroethane. Then paraformaldehyde (80 mg, 2.67 mmol, 8.55
equiv) and CF.sub.3COOH (0.5 mL) were added simultaneously at
0.degree. C. and the resulting mixture was heated to 45.degree. C.
and stirred for 12 h. The reaction mixture was cooled to room
temperature with a water bath and concentrated under reduced
pressure. The crude product was purified by preparative HPLC under
the following conditions (Waters): Column: Xbridge Prep C18, 5 m,
19*50 mm; mobile phase: water with 0.01% TFA and CH.sub.3CN (10%
CH.sub.3CN up to 35% in 11 min, up to 95% in 1.5 min, down to 10%
in 1.5 min); flow rate: 20 mL/min; UV detection at 254/220 nm. This
resulted in 40 mg (39%) of
N,N-dimethyl-4-[8-thia-4,6,12-triazatricyclo[7.4.0.0-[2,7]]trideca-1(9),2-
(7),3,5-tetraen-3-yloxy]cyclohexan-1-amine trifluoroacetate as a
light yellow solid. MS (ES): m/z 333 (M+H).sup.+.
Example 179
Synthesis of
1-(13-[[4-(dimethylamino)cyclohexyl]oxy]-8-thia-4-azatricyclo[7.4.0.0-[2,-
7]]trideca-1(13),2(7),9,11-tetraen-4-yl)ethan-1-one (I-167)
##STR00555##
[1442] To a solution of
N,N-dimethyl-4-[8-thia-4-azatricyclo[7,4,0,0-[2,7]]trideca-1(13),2(7),9,1-
1-tetraen-13-yloxy]cyclohexan-1-amine trifluoroacetate (43 mg) and
TEA (50 mg, 0.49 mmol, 3.80 equiv) in 10 mL of dichloromethane at
0.degree. C. was added acetyl chloride (20 mg, 0.25 mmol, 1.96
equiv) at 0.degree. C. The resulting solution was stirred for 2
hours at this temperature under nitrogen. The reaction was then
quenched with CH.sub.3OH and concentrated under vacuum. The crude
product was purified by preparative HPLC under the following
conditions (Waters): Column: Xbridge Prep C18, 5 .mu.m, 19*50 mm;
mobile phase: water with 0.05% NH.sub.4HCO.sub.3 and CH.sub.3CN
(10% CH.sub.3CN up to 35% in 11 min, up to 95% in 1.5 min, down to
10% in 1.5 min); flow rate: 20 mL/min; UV detection at 254/220 nm.
This resulted in 12.6 mg (26%) of
1-(13-[[4-(dimethylamino)cyclohexyl]oxy]-8-thia-4-azatricyclo[7.4.0.0-[2,-
7]]trideca-1(13),2(7),9,11-tetraen-4-yl)ethan-1-one as a white
solid. MS (ES): m/z 375 (M+H).sup.+. .sup.1H NMR (400 MHz,
CD.sub.3OD): .delta. 1.30-1.65 (m, 4H), 1.94 (d, 2H), 2.13 (s, 3H),
2.20-2.32 (m, 9H), 2.81, 2.91 (t, t, 2H, J=5.7 Hz), 3.77, 3.84 (t,
t, 2H, J=5.7 Hz), 5.02-5.18 (m, 1H), 8.38, 8.39 (s, s, 1H).
Example 180
Synthesis of
4-([12-methanesulfonyl-8-thia-4,6,12-triazatricyclo[7.4.0.0-[2,7]]trideca-
-1(9),2(7),3,5-tetraen-3-yl]oxy)-N,N-dimethylcyclohexan-1-amine
(I-168)
##STR00556##
[1444] To a solution of
N,N-dimethyl-4-[8-thia-4,6,12-triazatricyclo[7.4.0.0-[2,7]]trideca-1(9),2-
(7),3,5-tetraen-3-yloxy]cyclohexan-1-amine trifluoroacetate (30 mg,
0.09 mmol, 1.00 equiv) in 5 mL of anhydrous dichloromethane was
added TEA (40 mg, 0.40 mmol, 4.38 equiv) and MsCl (14 mg, 0.12
mmol, 1.36 equiv) at 0.degree. C. under nitrogen. The resulting
solution was stirred for 2 h at room temperature. The reaction
mixture was concentrated under vacuum and the residue was purified
by preparative HPLC under the following conditions (Waters):
Column: XBridge Prep C18 OBD Column, 5 m, 19*150 mm; mobile phase:
water with 0.05% NH.sub.4HCO.sub.3 and CH.sub.3CN (16% CH.sub.3CN
increasing to 23% in 10 min, up to 100% in 2 min, down to 16% in 2
min); flow rate: 20 mL/min; UV Detection at 254/220 nm. This
resulted in 8.0 mg (22%) of
4-([12-methanesulfonyl-8-thia-4,6,12-triazatricyclo[7.4.0.0-[2,7]]trideca-
-1(9),2(7),3,5-tetraen-3-yl]oxy)-N,N-dimethylcyclohexan-1-amine as
a white solid. MS (ES): m/z 411 (M+H).sup.+; .sup.1H NMR (300 MHz,
CD.sub.3OD): .delta. 1.59-1.71 (m, 4H), 2.05-2.10 (d, 2H, J=15 Hz),
2.34-2.50 (m, 9H), 2.98 (s, 3H), 3.08 (t, 2H, J=5.7 Hz), 3.06 (t,
2H, J=5.7 Hz), 4.67 (t, 2H, J=1.8 Hz), 5.26 (m, 1H), 8.53 (s,
1H).
Example 181
Synthesis of
3-[[4-(dimethylamino)cyclohexyl]oxy]-N-methyl-8-thia-4,6,12-triazatricycl-
o[7.4.0.0[2,7]]trideca-1(9),2(7),3,5-tetraene-12-carboxamide
(I-169)
##STR00557##
[1446] To a 3-necked round-bottom flask containing a solution of
N,N-dimethyl-4-[8-thia-4,6,12-triazatricyclo[7.4.0.0[2,7]]trideca-1
(9),2(7),3,5-tetraen-3-yloxy]cyclohexan-1-amine trifluoroacetate
(300 mg, 1.00 equiv, 30% purity) in THF (50 mL) was added
triethylamine (0.4 mL). The solution was stirred at 0.degree. C.
for 10 min under nitrogen. Then triphosgene (300 mg, 1.0 mmol) in
10 mL of DCM was added via syringe at 0.degree. C. and stirred for
2 h at room temperature. Then methanamine-THF (2 M, 1.8 mL) was
added at 0.degree. C. and the resulting solution was stirred
overnight at room temperature. The reaction was quenched by the
addition of methanol and concentrated under vacuum. The residue was
pre-purified by a silica gel column with DCM/MeOH (30:1-10:1) to
give the crude product, which was purified by preparative HPLC
under the following conditions (Waters): Column: XBridge Shield
RP18 OBD Column, 5 .mu.m, 19*150 mm; mobile phase, water with 0.05%
NH.sub.4HCO.sub.3 and CH.sub.3CN (9% CH3CN up to 21% in 12 min, up
to 95% in 2 min, down to 9% in 2 min); flow rate: 20 mL/min; UV
detection at 254/220 nm. After concentration in vacuo and
lyophilization overnight, the corresponding
3-[[4-(dimethylamino)cyclohexyl]oxy]-N-methyl-8-thia-4,6,12-triazatricycl-
o[7.4.0.0[2,7]]trideca-1(9),2(7),3,5-tetraene-12-carboxamide (30
mg) was obtained as a white solid. MS (ES): m/z 390 (M+H).sup.+ and
412 (M+Na).sup.+. .sup.1H NMR (300 MHz, CD.sub.3OD): .delta. 8.50
(1H, s), 5.30-5.21 (1H, m), 4.78 (2H, s), 3.75 (2H, t), 2.95 (2H,
t), 2.78 (3H, s), 2.50-2.30 (9H, m), 2.07 (2H, d), 1.8-1.62 (2H,
m), 1.60-1.50 (2H, m).
Example 182
Synthesis of
2-cyclopropyl-1-(3-[[4-(dimethylamino)cyclohexyl]oxy]-8-thia-4,6,12-triaz-
atricyclo[7.4.0.0
[2,7]]trideca-1(9),2(7),3,5-tetraen-12-yl)ethan-1-one (I-170)
##STR00558##
[1448] Synthesis of Compound 182.1.
[1449] To a solution of tert-butyl
N-(2-[4-chlorothieno[2,3-d]pyrimidin-6-yl]ethyl)carbamate (100 mg,
0.32 mmol, 1.00 equiv) in freshly distilled THF (20 mL) was added
sodium hydride (64 mg, 1.6 mmol, 5.0 equiv, 60% dispersion in
mineral oil) at 0.degree. C. under nitrogen. After stirring for 30
min at room temperature, a solution of
4-(dimethylamino)cyclohexan-1-ol (50 mg, 0.35 mmol, 1.06 equiv) was
added and stirred overnight at room temperature. The reaction was
then quenched by the addition of brine and extracted with EtOAc.
The organic layers was combined and dried over anhydrous sodium
sulfate. After filtration and concentration, the residue was
applied onto a silica gel column with DCM/MeOH (50:1-30:1) to
provide 70 mg (52%) of tert-butyl
N-[2-(4-[[4-(dimethylamino)cyclohexyl]oxy]thieno[2,3-d]pyrimidin-6-yl)eth-
yl]carbamate as a light yellow solid. MS (ES): m/z 421
(M+H).sup.+.
[1450] Synthesis of Compound 182.2.
[1451] To a solution of tert-butyl
2-(4-((1r,4r)-4-(dimethylamino)cyclohexyloxy)thieno[2,3-d]pyrimidin-6-yl)-
ethylcarbamate (70 mg, 0.17 mmol, 1.0 equiv) in DCM (20 mL) was
added trifluoroacetic acid (1 mL) and stirred overnight at room
temperature. After concentration under vacuum, we obtained 70 mg of
(1r,4r)-4-(6-(2-aminoethyl)thieno[2,3-d]pyrimidin-4-yloxy)-N,N-dimethylcy-
clohexanamine trifluoroacetate as a light yellow oil and used it
directly without further purification. MS (ES): m/z 321
(M+H).sup.+.
[1452] Synthesis of Compound 182.3.
[1453] To a solution of 2-cyclopropylacetic acid (51 mg, 0.51 mmol,
3.0 equiv) in dry DMF (20 mL) was added DIEA (110 mg, 0.85 mmol,
5.0 equiv) followed by HATU (194 mg, 0.51 mmol, 3.0 equiv) at
0.degree. C. The resulting solution was stirred for 10 min at room
temperature. Then
(1r,4r)-4-(6-(2-aminoethyl)thieno[2,3-d]pyrimidin-4-yloxy)-N,N-dimethylcy-
clohexanamine trifluoroacetate (70 mg, 0.17 mmol, 1.0 equiv) in DMF
was added and stirred for 3 h at room temperature. The reaction was
then quenched by the addition of brine and extracted with EtOAC.
The organic layer was extracted with water thrice. The water layer
was collected and concentrated under vacuum and the residue was
dissolved in THF and stirred for 30 min. After filtration and
concentration, the residue was purified by flash preparative HPLC
under the following conditions: Column: C18 silica gel; mobile
phase: water then ramp up CH.sub.3CN to 80% within 30 min;
detector: UV 254 nm. After removed the eluting solvent, we obtained
40 mg (58%) of
2-cyclopropyl-N-[2-(4-[[4-(dimethylamino)cyclohexyl]oxy]thieno[2,3-d]pyri-
midin-6-yl)ethyl]acetamide as a yellow solid. MS (ES): m/z 403
(M+H).sup.+.
[1454] Synthesis of Compound I-170.
[1455] To a solution of
2-cyclopropyl-N-(2-(4-((1r,4r)-4-(dimethylamino)cyclohexyloxy)thieno[2,3--
d]pyrimidin-6-yl)ethyl)acetamide (40 mg, 1.0 mmol, 1.0 equiv) in
DCE (40 mL) was added paraformaldehyde (40 mg, 1.3 mmol, 13.0
equiv) followed by trifluoroacetic acid (0.6 mL). The resulting
solution was stirred overnight at room temperature. After
concentration under vacuum, the residue was purified by preparative
HPLC under the following conditions (1#-Pre-HPLC-016(Waters)):
Column: XBridge Shield RP18 OBD 5 m, 19*150 mm; mobile phase: water
(50 mM NH.sub.4HCO.sub.3) and CH.sub.3CN (5% CH.sub.3CN up to 30%
in 13 min, up to 95% in 2 min, down to 5% in 2 min); detector: UV
254, 220 nm. After concentration and re-lyophilization, we obtained
10.2 mg( ) of
2-cyclopropyl-1-(3-[[4-(dimethylamino)cyclohexyl]oxy]-8-thia-4,6,12-triaz-
atricyclo[7.4.0.0
[2,7]]trideca-1(9),2(7),3,5-tetraen-12-1)ethan-1-one as an
off-white solid. MS (ES): m/z 415 (M+H).sup.+, 437 (M+Na).sup.+;
.sup.1H NMR (300 MHz, CD.sub.3OD): .delta. 8.52 (1H, s), 5.28 (1H,
m), 4.92 (2H, s), 3.95 (2H, dt), 3.04-2.94 (2H, m), 2.69-2.54 (1H,
m), 2.52-2.43 (8H, m), 2.42-2.33 (2H, m), 2.12-2.08 (2H, m),
1.78-1.47 (4H, m), 1.10-1.02 (1H, m), 0.59-0.54 (2H, m), 0.27-0.21
(2H, m).
Example 183
Synthesis of
1-(3-[[4-(morpholin-4-yl)cyclohexyl]oxy]-8-thia-4,6,12-triazatricyclo[7.4-
.0.0[2,7]]trideca-1(9),2(7),3,5-tetraen-12-yl)ethan-1-one
(I-171)
##STR00559##
[1457] Synthesis of Compound 183.1.
[1458] To a solution of 4-(morpholin-4-yl)cyclohexan-1-ol (143 mg,
0.77 mmol, 1.10 equiv) in THF (20 mL) was added sodium hydride (140
mg, 3.50 mmol, 5.00 equiv, 60% dispersion in mineral oil) at
0.degree. C. The solution was stirred for 30 min at room
temperature under nitrogen. Then tert-butyl
N-(2-[4-chlorothieno[2,3-d]pyrimidin-6-yl]ethyl)carbamate (220 mg,
0.70 mmol, 1.00 equiv) in 5 mL of THF was added via syringe and the
resulting solution was stirred overnight at room temperature. The
reaction was then quenched by the addition of brine and extracted
with EtOAc. The organic layers were combined and dried over
anhydrous sodium sulfate. After filtration and concentration in
vacuo, the residue was purified by a silica gel column with
DCM/MeOH (30:1-10:1) to provide 127 mg (39%) of tert-butyl
N-[2-(4-[[4-(morpholin-4-yl)cyclohexyl]oxy]thieno[2,3-d]pyrimidin-6-yl)et-
hyl]carbamate as a white solid. MS (ES): m/z 463 (M+H).sup.+.
[1459] Synthesis of Compound 183.2.
[1460] To a solution of tert-butyl
N-[2-(4-[[4-(morpholin-4-yl)cyclohexyl]oxy]thieno[2,3-d]pyrimidin-6-yl)et-
hyl]carbamate (150 mg, 0.32 mmol, 1.00 equiv) in DCM/H.sub.2O
(10/0.5 mL) was added trifluoroacetic acid (0.8 mL) at 0.degree. C.
and stirred overnight at room temperature. After concentration
under vacuum, the residue was dissolved in DCE (30 mL) and
paraformaldehyde (180 mg) and trifluoroacetic acid (1 mL) were
added. The resulting solution was stirred overnight at 45.degree.
C. under nitrogen. After concentration under vacuum, the residue
was purified by preparative HPLC under the following conditions:
Column: XBridge Shield RP18 OBD, 5 m, 19*150 mm; mobile phase:
water (with 0.5% TFA) and CH.sub.3CN (0% CH.sub.3CN up to 21% in 12
min, up to 95% in 2 min, down to 0% in 2 min); flow rate: 20
mL/min; UV detection at 254/220 nm. After concentration under
vacuum, the desired
3-[[4-(morpholin-4-yl)cyclohexyl]oxy]-8-thia-4,6,12-triazatricycl-
o[7.4.0.0[2,7]]trideca-1(9),2(7),3,5-tetraene trifluoroacetate (100
mg, crude) was obtained as a light yellow solid. MS (ES): m/z 375
(M+H).sup.+.
[1461] Synthesis of Compound I-171.
[1462] To a solution of
3-[[4-(morpholin-4-yl)cyclohexyl]oxy]-8-thia-4,6,12-triazatricyclo[7.4.0.-
0[2,7]]trideca-1(9),2(7),3,5-tetraene trifluoroacetate (100 mg,
crude) in DCM (20 mL) was added TEA (108 mg, 1.07 mmol). The
solution was stirred for 10 min at 0.degree. C. under nitrogen.
Then acetyl chloride (41.9 mg, 0.53 mmol) was added to the reaction
solution at this temperature and the resulting solution was stirred
for 1.5 h at room temperature. The reaction was then quenched by
the addition of ethanol and concentrated under vacuum. The crude
product was purified by preparative HPLC under the following
conditions (Waters): Column: Xbridge Prep C18, 5 m, 19*50 mm;
mobile phase: water with 0.05% NH.sub.4HCO.sub.3 and CH.sub.3CN
(10% CH.sub.3CN up to 35% in 11 min, up to 95% in 1.5 min, down to
10% in 1.5 min); detector: UV 254/220 nm. After concentration in
vacuo and lyophilization overnight, the corresponding
1-(3-[[4-(morpholin-4-yl)cyclohexyl]oxy]-8-thia-4,6,12-triazatricyclo[7.4-
.0.0[2,7]]trideca-1 (9),2(7),3,5-tetraen-12-yl)ethan-1-one (22.1
mg) was obtained as a white solid. MS (ES): m/z 417 (M+H).sup.+ and
429 (M+Na).sup.+. .sup.1H NMR (300 MHz, CD.sub.3OD): .delta. 8.54
(1H, s), 5.33-5.23 (1H, m), 4.91 (2H, s), 3.97, 3.90 (2H, t, t),
3.76-3.69 (4H, m), 3.05, 2.95 (2H, t, t), 2.67-2.58 (4H, t),
2.34-2.25 (3H, m), 2.25, 2.23 (3H, s, s), 2.10 (2H, d), 1.74-1.45
(4H, m).
Example 184
Synthesis of Intermediate 184.4
##STR00560##
[1464] Synthesis of Compound 184.1.
[1465] A solution of tert-butyl
N-(2-[4-hydroxythieno[2,3-d]pyrimidin-6-yl]ethyl)carbamate (600 mg,
2.03 mmol, 1.00 equiv) in 25 mL of dichloromethane at 0.degree. C.
was added 4 mL of CF.sub.3COOH and the resulting solution was
stirred for 6 hours at room temperature. The resulting mixture was
concentrated under vacuum to give
6-(2-aminoethyl)thieno[2,3-d]pyrimidin-4-ol trifluoroacetate (570
mg, 91%) as a yellow oil which was used directly in the next step
without further purification. MS (ES): m/z 196 (M+H).sup.+.
[1466] Synthesis of Compound 184.2.
[1467] To a 25-mL round-bottom flask (1 atm) purged and maintained
with an inert atmosphere of nitrogen was added a solution of
6-(2-aminoethyl)thieno[2,3-d]pyrimidin-4-ol (570 mg, 2.92 mmol,
1.00 equiv) in 10 mL of dichloromethane. TEA (1.2 g, 11.86 mmol,
4.06 equiv) and acetyl chloride (460 mg, 5.86 mmol) were added at
0.degree. C. under nitrogen. The resulting solution was stirred for
2 h at room temperature and concentrated under vacuum. The residue
was applied onto a silica gel column with dichloromethane/methanol
(10:1) to give 400 mg (crude) of the desired
N-(2-[4-hydroxythieno[2,3-d]pyrimidin-6-yl]ethyl)acetamide as a
white solid. MS (ES): m/z 238 (M+H).sup.+.
[1468] Synthesis of Compound 184.3.
[1469] To a solution of
N-(2-[4-hydroxythieno[2,3-d]pyrimidin-6-yl]ethyl)acetamide (300 mg,
1.26 mmol, 1.00 equiv) and paraformaldehyde (300 mg, 10.00 mmol,
7.91 equiv) in 50 mL of 1,2-dichloroethane at 0.degree. C. was
added CF.sub.3COOH (6 mL). The solution was stirred for 12 h at
room temperature. The resulting mixture was concentrated under
vacuum. The residue was applied onto a silica gel column with
dichloromethane/methanol (10:1) to afford the desired
1-[3-hydroxy-8-thia-4,6,12-triazatricyclo[7.4.0.0-[2,7]]trideca-1-
(9),2,4,6-tetraen-12-yl]ethan-1-one (200 mg, 63%) as a light yellow
solid. MS (ES): m/z 250 (M+H).sup.+.
[1470] Synthesis of 184.4.
[1471] To a solution of
1-[3-hydroxy-8-thia-4,6,12-triazatricyclo[7.4.0.0-[2,7]]trideca-1(9),2(7)-
,3,5-tetraen-12-yl]ethan-1-one (250 mg, 1.00 mmol, 1.00 equiv) in
25 mL of anhydrous 1,4-dioxane was added POCl.sub.3 (1.53 g, 9.98
mmol, 9.95 equiv) and 4-dimethylaminopyridine (1.22 g, 9.99 mmol,
9.96 equiv) simultaneously at room temperature under nitrogen. The
resulting solution was heated to 100.degree. C. for 2 h. After
completion, the reaction mixture was cooled to room temperature and
concentrated under vacuum. The residue was diluted with EtOAc,
poured into cooled saturated aqueous sodium bicarbonate and
extracted with ethyl acetate. The combined organic layers were
washed with brine, dried over sodium sulfate and concentrated under
vacuum. The residue was applied onto a silica gel column with ethyl
acetate/petroleum ether (1:4) to give the corresponding
1-[3-chloro-8-thia-4,6,12-triazatricyclo[7.4.0.0-[2,7]]trideca-1(9),2(7),-
3,5-tetraen-12-yl]ethan-1-one (160 mg, 60%) as a yellow solid. MS
(ES): m/z 268 and 270 (M+H).sup.+.
Example 185
Synthesis of
1-(3-[[4-(morpholin-4-yl)cyclohexyl]amino]-8-thia-4,6,12-triazatricyclo[7-
.4.0.0-[2,7]]trideca-1(9),2(7),3,5-tetraen-12-yl)ethan-1-one
(I-172)
##STR00561##
[1473] To a solution of
1-[3-chloro-8-thia-4,6,12-triazatricyclo[7.4.0.0-[2,7]]trideca-1(9),2(7),-
3,5-tetraen-12-yl]ethan-1-one (100 mg, 0.37 mmol, 1.00 equiv) and
trans-4-(morpholin-4-yl)cyclohexan-1-amine dihydrochloride (412 mg,
1.61 mol, 4.32 equiv) in 10 mL of N,N-dimethylformamide was added
TEA (200 mg, 1.98 mmol, 5.29 equiv) and the resulting solution was
stirred for 12 h at 50.degree. C. under nitrogen. After
concentration in vacuo, the crude product was purified by
preparative HPLC under the following conditions (Waters): Column:
Xbridge Prep C18, 5 m, 19*50 mm; mobile phase: water with 0.05%
NH.sub.4HCO.sub.3 and CH.sub.3CN (10% CH.sub.3CN up to 35% in 11
min, up to 95% in 1.5 min, down to 10% in 1.5 min); detector: UV
254/220 nm. The product-containing fractions were collected and
partially evaporated under reduced pressure and lyophilized
overnight to give 76.9 mg (50%) of
1-(3-[[4-(morpholin-4-yl)cyclohexyl]amino]-8-thia-4,6,12-triazatricyclo[7-
.4.0.0-[2,7]]trideca-1(9),2(7),3,5-tetraen-12-yl)ethan-1-one as a
white solid. MS (ES): m/z 416 (M+H).sup.+. .sup.1H NMR (300 MHz,
CD.sub.3OD): .delta. 1.40-1.60 (m, 4H), 2.08 (d, 2H), 2.20-2.45 (m,
6H), 2.60-2.70 (m, 4H), 2.92, 3.02 (t, t, 2H), 3.70-3.80 (m, 4H),
3.89, 3.95 (t, t, 2H), 4.05-4.22 (m, 1H), 4.96, 5.00 (s, s, 2H),
8.29, 8.30 (s, s, 1H).
Example 186
Synthesis of
1-(3-[[4-(dimethylamino)cyclohexyl]amino]-8-thia-4,6,12-triazatricyclo[7.-
4.0.0-[2,7]]trideca-1(9),2(7),5-trien-12-yl)ethan-1-one (I-173)
##STR00562##
[1475] A 25-mL round-bottom flask (1.0 atm) purged and maintained
with an inert atmosphere of nitrogen was charged with a solution of
1-[3-chloro-8-thia-4,6,12-triazatricyclo[7.4.0.0-[2,7]]trideca-1(9),2(7),-
3,5-tetraen-12-yl]ethan-1-one (37 mg, 0.14 mmol, 1.00 equiv) and
trans-dimethylcyclohexane-1,4-diamine (37 mg, 0.26 mmol, 1.88
equiv) in 5 mL of DMF. TEA (0.2 mL) was added at room temperature.
The resulting solution was heated to 50.degree. C. for 12 hours.
After concentration in vacuo, the crude product was purified by
preparative HPLC under the following conditions (Waters): Column:
Xbridge Prep C18, 5 .mu.m, 19*50 mm; mobile phase: water with 0.05%
NH.sub.4HCO.sub.3 and CH.sub.3CN (10% CH.sub.3CN up to 35% in 11
min, up to 95% in 1.5 min, down to 10% in 1.5 min); detector: UV
254/220 nm. The product-containing fractions were collected and
partially evaporated under reduced pressure and lyophilized
overnight to give
1-(3-[[4-(dimethylamino)cyclohexyl]amino]-8-thia-4,6,12-triazatricyclo[7.-
4.0.0-[2,7]]trideca-1(9),2(7),5-trien-12-yl)ethan-1-one (76.9 mg,
50%) as a white solid. MS (ES): m/z 374 (M+H).sup.+; .sup.1H NMR
(300 MHz, CD.sub.3OD): .delta. 1.40-1.60 (m, 4H), 1.85-1.95 (m,
2H), 2.05-2.20 (m, 5H), 2.22-2.40 (m, 7H), 2.81, 2.91 (t, t, 2H),
3.78, 3.83 (t, t, 2H), 3.98-4.18 (m, 1H), 4.84, 4.88 (s, s, 2H),
8.18 (s, 1H).
Example 187
Synthesis of
2-[(12S)-3-[[4-(dimethylamino)cyclohexyl]oxy]-8-thia-4,6-diazatricyclo[7.-
4.0.0[2,7]]trideca-1(9),2(7),3,5-tetraen-12-yl]ethan-1-ol formate
(I-111)
##STR00563##
[1477] Synthesis of Compound 187.1.
[1478] To a solution of
2-[(12S)-3-chloro-8-thia-4,6-diazatricyclo[7.4.0.0[2,7]]trideca-1(9),2(7)-
,3,5-tetraen-12-yl]ethan-1-ol (300 mg, 1.12 mmol, 1.00 equiv) in 5
mL of distilled DMF was added TBSCl (252 mg, 1.50 equiv) and
imidazole (137 mg, 2.01 mmol, 1.80 equiv) at room temperature under
nitrogen. The resulting solution was stirred for 1 h at ambient
temperature, quenched with water and extracted with 3.times.50 mL
of ethyl acetate. The combined organic layers were washed with
brine, dried over anhydrous sodium sulfate and concentrated under
reduced pressure. The residue was applied onto a silica gel column
with ethyl acetate/petroleum ether (1:5) to provide
(12S)-12-[2-[(tert-butyldimethylsilyl)oxy]ethyl]-3-chloro-8-thia-4,6-diaz-
atricyclo[7.4.0.0[2,7]]trideca-1(9),2(7),3,5-tetraene (420 mg, 98%)
as a light yellow solid. MS (ES): m/z 384, 386 (M+H).sup.+.
[1479] Synthesis of Compound 187.2.
[1480] NaH (60% dispersion in mineral oil, 63 mg, 3.00 equiv) was
treated with trans-4-(dimethylamino)cyclohexan-1-ol (104 mg, 0.73
mmol, 1.40 equiv) in distilled tetrahydrofuran (8 mL) at room
temperature under nitrogen. After stirring for min,
(12S)-12-[2-[(tert-butyldimethylsilyl)oxy]ethyl]-3-chloro-8-thia-4,6-diaz-
atricyclo[7.4.0.0[2,7]]trideca-1(9),2(7),3,5-tetraene (200 mg, 0.52
mmol, 1.00 equiv) was added and the resulting solution was stirred
overnight at room temperature for 8 h. The reaction was then
quenched with saturated aqueous NH.sub.4Cl and extracted with
3.times.50 mL of ethyl acetate. The organic layers were combined,
washed with brine, dried over anhydrous sodium sulfate and
concentrated under vacuum. The residue was applied onto a silica
gel column with dichloromethane/methanol (4:1) to afford
4-[[(12S)-12-[2-[(tert-butyldimethylsilyl)oxy]ethyl]-8-thia-4,6-diazatric-
yclo[7.4.0.0[2,7]]trideca-1(9),2(7),3,5-tetraen-3-yl]oxy]-N,N-dimethylcycl-
ohexan-1-amine (110 mg, 43%) as a light yellow solid. MS (ES): m/z
490 (M+H).sup.+.
[1481] Synthesis of Compound I-111.
[1482] To a solution of
4-[[(12S)-12-[2-[(tert-butyldimethylsilyl)oxy]ethyl]-8-thia-4,6-diazatric-
yclo[7.4.0.0[2,7]]tri
deca-1(9),2(7),3,5-tetraen-3-yl]oxy]-N,N-dimethylcyclohexan-1-amine
(110 mg, 0.22 mmol, 1.00 equiv) in methanol (5 mL) was added
hydrochloric acid (12 M, 0.5 mL) at 0.degree. C. The resulting
solution was stirred for 1 h at room temperature. The solvent was
removed in vacuo and the crude product (80 mg) was purified by
preparative HPLC under the following conditions (SHIMADZU): Column:
SunFire Prep C18, 19*150 mm, 5 .mu.m; mobile phase: water (with
0.1% HCOOH) and CH.sub.3CN (6.0% CH.sub.3CN up to 53.0% in 16 min);
flow rate: 20 mL/min; UV detection at 254/220 nm. The
product-containing fractions were collected and partially
evaporated under reduced pressure to remove water and CH.sub.3CN.
The residue was lyophilized overnight to give the
2-[(12S)-3-[[4-(dimethylamino)cyclohexyl]oxy]-8-thia-4,6-diazatricyclo[7.-
4.0.0[2,7]]trideca-1(9),2(7),3,5-tetraen-12-yl]ethan-1-ol formate
(46 mg, 55%) as an off-white semi-solid. MS (ES): m/z 376
(M+H).sup.+. .sup.1H NMR (300 MHz, CDCl.sub.3): .delta. 8.49 (d,
2H), 5.22 (s, 1H), 3.82 (t, 2H), 3.16 (m, 2H), 2.88 (s, 2H), 2.66
(s, 6H), 2.48 (t, 3H), 2.19 (s, 2H), 2.05 (d, 2H), 1.70 (m,
7H).
Example 188
Synthesis of
2-[3-[[4-(dimethylamino)cyclohexyl]oxy]-8-thia-4,6-diazatricyclo[7.4.0.0[-
2,7]]trideca-1(9),2(7),3,5-tetraen-12-yl]ethan-1-ol formate
(I-108)
##STR00564##
[1484] Compound I-108 was prepared in a manner consistent with
Example 186, except that compound 153.7 was used rather than 154.1.
A white semi-solid was obtained (44% overall yield). MS (ES): m/z
376 (M-HCOOH+H).sup.+. .sup.1H NMR (400 MHz, CDCl.sub.3): .delta.
8.52 (s, 1H) 8.46 (d, 1H) 6.93 (m, 2H) 5.20 (d, 1H) 3.81 (t, 2H)
3.20 (dd, 2H) 2.86 (m, 2H) 2.65 (s, 6H) 2.46 (m, 3H) 2.18 (s, 2H)
2.04 (d, 2H) 1.65 (m, 7H).
Example 189
Synthesis of
2-[(12R)-3-[[4-(dimethylamino)cyclohexyl]oxy]-8-thia-4,6-diazatricyclo[7.-
4.0.0[2,7]]trideca-1(9),2(7),3,5-tetraen-12-yl]ethan-1-ol formate
(I-110)
##STR00565##
[1486] Compound I-110 was prepared in a manner consistent with
Example 186, except that compound 154.2 was used rather than 154.1.
A white semi-solid was obtained (23% overall yield). MS (ES): m/z
376 (M-HCOOH+H).sup.+. .sup.1H NMR (300 MHz, CDCl.sub.3): .delta.
8.49 (d, 2H) 5.22 (s, 1H), 3.83 (t, 2H), 3.15 (dd, 2H), 2.88 (s,
2H), 2.65 (s, 6H), 2.48 (t, 3H), 2.07 (t, 4H), 1.70 (m, 7H).
Example 190
Synthesis of
(2S)-2-hydroxy-3-[(3R)-12-[[4-(methylamino)cyclohexyl]oxy]-7-thia-9,11-di-
azatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]propanamide
(I-137)
##STR00566##
[1488] Synthesis of Compound 190.1.
[1489] A solution of tert-butyl
N-(4-[[(3R)-3-[2-[(tert-butyldimethylsilyl)oxy]-2-cyanoethyl]-7-thia-9,11-
-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cycloh-
exyl)-N-methylcarbamate (420 mg, 0.72 mmol, 1.00 equiv),
LiOH.H.sub.2O (60 mg, 1.43 mmol, 2.00 equiv) and
H.sub.2O.sub.2(30%) (0.5 mL) in methanol (20 mL) was stirred for 2
h at 0.degree. C. in a water/ice bath. The reaction was then
quenched by the addition of 30 mL of saturated Na.sub.2SO.sub.3.
The resulting solution was extracted with 3.times.40 mL of ethyl
acetate, concentrated under vacuum and purified by preparative TLC
(PE/EA=1:1). This resulted in tert-butyl
N-(4-[[(3R)-3-[(2S)-2-[(tert-butyldimethylsilyl)oxy]-2-carbamoylethyl]-7--
thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]o-
xy]cyclohexyl)-N-methylcarbamate (190.1, 180 mg) as a colorless oil
and tert-butyl
N-(4-[[(3R)-3-[(2R)-2-[(tert-butyldimethylsilyl)oxy]-2-carbamoylethyl]-7--
thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]o-
xy]cyclohexyl)-N-methylcarbamate (50.2, 160 mg) as a colorless
oil.
[1490] Synthesis of Compound I-137.
[1491] A solution of tert-butyl
N-(4-[[(3R)-3-[(2S)-2-[(tert-butyldimethylsilyl)oxy]-2-carbamoylethyl]-7--
thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]o-
xy]cyclohexyl)-N-methylcarbamate (160 mg, 0.26 mmol, 1.00 equiv)
and hydrogen chloride (conc.) (0.3 mL) in dichloromethane (10 mL)
was stirred for 2 h at 0.degree. C. in a water/ice bath. The pH
value of the solution was adjusted to 8 with NH.sub.4OH. The
resulting mixture was concentrated under vacuum. The crude product
(150 mg) was purified by preparative HPLC under the following
conditions (1#-Pre-HPLC-015(Waters)): Column, X-bridge C18, 19*150
mm, 5 m; mobile phase: water (50 mM NH.sub.4HCO.sub.3) and
CH.sub.3CN (10% CH.sub.3CN up to 21% in 15 min, up to 95% in 1.5
min, down to 10% in 1.5 min); UV detection at 254/220 nm. The
product was freeze-dried to afford
(2S)-2-hydroxy-3-[(3R)-12-[[4-(methylamino)cyclohexyl]oxy]-7-thia-9,11-di-
azatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]propanamide
(48.3 mg, 47%) as a white solid. .sup.1H NMR (400 MHz, CD.sub.3OD):
.delta. 8.46 (s, 1H), 5.30 (m, 1H), 4.16 (m, 1H), 3.59 (m, 1H),
3.16-2.94 (m, 2H), 2.77-2.68 (m, 1H), 2.58-2.52 (m, 6H), 2.48-2.10
(m, 4H), 1.75-1.72 (m, 3H), 1.66-1.34 (m, 2H). MS: m/z=391
(M+H).sup.+.
Example 191
Synthesis of
(2S)-2-amino-3-[(3R)-12-[[4-(methylamino)cyclohexyl]oxy]-7-thia-9,11-diaz-
atricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]propanamide
(I-146)
##STR00567##
[1493] To a solution of benzyl
N-[(1S)-2-[(3R)-12-[(4-[[(tert-butoxy)carbonyl](methyl)amino]cyclohexyl)o-
xy]-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-
-yl]-1-carbamoylethyl]carbamate (70 mg, 0.11 mmol, 1.00 equiv) in
dichloromethane (5 mL) was added hydrogen chloride (12 M, 2 mL).
The resulting solution was stirred for 5 h at 30.degree. C. and
then concentrated under vacuum. The crude product (70 mg) was
purified by preparative HPLC under the following conditions:
Column: SunFire Prep C18, 19*150 mm, 5 m; mobile phase: water (with
50 mL NH.sub.4HCO.sub.3) and CH.sub.3CN (5.0% CH.sub.3CN up to
43.0% in 12 min, up to 95.0% in 2 min, down to 5.0% in 2 min); UV
detection at 254/220 nm. This resulted in 28 mg (64%) of
(2S)-2-amino-3-[(3R)-12-[[4-(methylamino)cyclohexyl]oxy]-7-thia-9,11-diaz-
atricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]propanamide
as a white solid. MS (ES): m/z 390 (M+H).sup.+. .sup.1H NMR (300
MHz, CD.sub.3OD): .delta. 1.39-1.55 (m, 3H), 1.72-1.85 (m, 2H),
2.17-2.28 (m, 3H), 2.29-2.39 (m, 3H), 2.56 (s, 3H), 2.63-2.72 (m,
1H), 2.81-3.97 (m, 2H), 3.05-3.15 (m, 1H), 3.35-3.45 (m, 2H),
5.20-5.35 (m, 1H), 8.42 (s, 1H).
Example 192
Synthesis of
(1S)-2-[(3R)-12-[[4-(dimethylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricy-
clo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]-1-(1,3-oxazol-2-yl)et-
han-1-ol (I-62)
##STR00568##
[1495]
2-[(3R)-12-[[4-(dimethylamino)cyclohexyl]oxy]-7-thia-9,11-diazatric-
yclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]-1-(1,3-oxazol-2-yl)e-
than-1-ol (45 mg, 0.11 mmol, 1.00 equiv) was purified by chiral
preparative HPLC under the following conditions: Column: CHIRALPAK
IC; mobile phase: hexanes (0.1% TEA):EtOH=70:30; UV detection at
254 nm. This resulted in 31.6 mg (70%) of 192.1 as a white solid
and 12.7 mg (28%) of Compound I-62 as a white solid. Analytical
data for 1-62: MS: 429 (M+H).sup.+. .sup.1H NMR (300 MHz,
CDCl.sub.3): .delta. 8.49 (s, 1H), 7.64 (s, 1H), 7.28 (s, 1H),
5.22-5.27 (m, 1H), 4.97 (t, 1H), 3.10-3.12 (m, 1H), 2.94-3.09 (m,
2H), 2.62-2.72 (m, 2H), 2.21-2.37 (m, 10H), 1.95-2.03 (m, 3H),
1.40-1.58 (m, 4H).
Example 193
Synthesis of
2-[(4-[[(3R)-3-[(2R)-2-hydroxypropyl]-7-thia-9,11-diazatricyclo[6.4.0.0[2-
,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)(methyl)amino]-1-(p-
yrrolidin-1-yl)ethan-1-one (I-109)
##STR00569##
##STR00570##
[1497] Synthesis of Compound 193.1.
[1498] A 50-mL round-bottom flask containing a solution of
tert-butyl
N-methyl-N-(4-[[(3R)-3-(2-oxoethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6-
]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)carbamate (500
mg, 1.12 mmol, 1.00 equiv) in anhydrous THF (20 mL) was cooled down
to 0.degree. C. under nitrogen. Then CH.sub.3MgBr (1 M in THF, 3.36
mL) was added dropwise via syringe and the resulting solution was
stirred for 2 h at 0.degree. C. The reaction was then quenched with
saturated aqueous NH.sub.4Cl and extracted with 3.times.50 mL of
ethyl acetate. The combined organic layers were washed with brine,
dried (Na.sub.2SO.sub.4) and concentrated under reduced pressure.
The residue was applied onto a silica gel column with ethyl
acetate/petroleum ether (1:2) to give the desired tert-butyl
N-(4-[[(3R)-3-[(2R)-2-hydroxypropyl]-7-thia-9,11-diazatricyclo[6.4.0.0[2,-
6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)-N-methylcarbamate
(192.1, 170 mg, 33%) as a colorless oil and tert-butyl
N-(4-[[(3R)-3-[(2S)-2-hydroxypropyl]-7-thia-9,11-diazatricyclo[6.4.0.0[2,-
6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)-N-methylcarbamate
(130 mg, 25%) as a colorless oil, respectively.
[1499] Synthesis of Compound I-109.
[1500] A 50-mL round-bottom flask was charged with a solution of
tert-butyl
N-(4-[[(3R)-3-[(2R)-2-hydroxypropyl]-7-thia-9,11-diazatricyclo[6.4.0.0[2,-
6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)-N-methylcarbamate
(170 mg, 0.38 mmol, 1.0 equiv) in 5.5 mL of dichloromethane cooled
to 0.degree. C. Then hydrochloric acid (12 M, 0.5 mL) was added and
the resulting solution was stirred for 3 h at room temperature. The
reaction mixture was concentrated under reduced pressure to give
(2R)-1-[(3R)-12-[[4-(methylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricycl-
o[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]propan-2-ol
hydrochloride (130 mg, crude) as a light yellow oil. The resulting
hydrochloride (130 mg, crude) was dissolved in DMF (5 mL).
Potassium carbonate (359 mg) and
2-chloro-1-(pyrrolidin-1-yl)ethan-1-one (125 mg) were added at room
temperature and the resulting mixture was stirred for 14 h at
25.degree. C. After completion of the reaction, the product was
extracted with DCM, washed with brine and concentrated in vacuo.
The crude product (160 mg) was purified by preparative HPLC under
the following conditions (SHIMADZU): Column: SunFire Prep C18,
19*150 mm, 5 .mu.m; mobile phase: water (with 0.1% HCOOH) and
CH.sub.3CN (6.0% CH.sub.3CN up to 50.0% in 25 min); UV detection at
254/220 nm. The product containing fractions were collected and
evaporated to remove the water and CH.sub.3CN to give
2-[(4-[[(3R)-3-[(2R)-2-hydroxypropyl]-7-thia-9,11-diazatricyclo[6.4.0.0[2-
,6]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)(methyl)amino]-1-(p-
yrrolidin-1-yl)ethan-1-one (52.7 mg) as a white solid. MS (ES): m/z
473 (M+H).sup.+. .sup.1H NMR (400 MHz, CD.sub.3OD): .delta. 8.46
(1H, s), 5.32-5.18 (1H, m), 3.94-3.92 (1H, m), 3.57 (2H, t), 3.45
(2H, t), 3.36 (3H, m), 3.08-3.10 (1H, m), 2.96-2.98 (1H, m),
2.67-2.62 (2H, m), 2.41-2.29 (6H, m), 2.070-1.97 (5H, m), 1.95-1.87
(2H, m), 1.64-1.52 (5H, m), 1.30 (3H, d).
Example 194
Synthesis of
2-[(3R)-12-[[4-(dimethylamino)cyclohexyl]amino]-7-thia-9,11-diazatricyclo-
[6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-3-yl]acetamide
(I-99)
##STR00571##
[1502] Synthesis of Compound 194.1.
[1503] To a solution of
[(3S)-12-chloro-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9-
,11-tetraen-3-yl]methanol (300 mg, 1.25 mmol, 1.00 equiv) and
tert-butyl N-(4-aminocyclohexyl)carbamate (801 mg, 3.74 mmol, 3.00
equiv) in N,N-dimethylformamide (10 mL) was added triethylamine
(1.7 mL, 10.00 equiv). The resulting solution was stirred overnight
at 50.degree. C. The reaction was then quenched by the addition of
50 mL of water. The resulting solution was extracted with
2.times.50 mL of ethyl acetate and the organic layers combined and
concentrated under vacuum. The residue was applied onto a silica
gel column with ethyl acetate/petroleum ether (1:10-1:5). This
resulted in 400 mg (77%) of tert-butyl N-(4-[[(3
S)-3-(hydroxymethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(12),-
2(6),8,10-tetraen-12-yl]amino]cyclohexyl)carbamate as a light
yellow solid.
[1504] Synthesis of Compound 194.2.
[1505] To a solution of tert-butyl
N-(4-[[(3S)-3-(hydroxymethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dode-
ca-1(12),2(6),8,10-tetraen-12-yl]amino]cyclohexyl)carbamate (400
mg, 0.96 mmol, 1.00 equiv) and triethylamine (0.27 mL, 2.00 equiv)
in dichloromethane (20 mL) was added dropwise MsCl (164 mg, 1.43
mmol, 1.50 equiv). The resulting solution was stirred for 2 h at
room temperature. The reaction was then quenched by the addition of
50 mL of water. The resulting solution was extracted with
2.times.40 mL of ethyl acetate and the organic layers combined and
concentrated under vacuum. The residue was applied onto a silica
gel column with ethyl acetate/petroleum ether (1:10). Purification
afforded 379 mg (80%) of tert-butyl N-(4-[[(3
S)-3-[(methanesulfonyloxy)methyl]-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]-
dodeca-1(12),2(6),8,10-tetraen-12-yl]amino]cyclohexyl)carbamate as
a light yellow oil.
[1506] Synthesis of Compound 194.3.
[1507] To a solution of tert-butyl
N-(4-[[(3S)-3-[(methanesulfonyloxy)methyl]-7-thia-9,11-diazatricyclo[6.4.-
0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-12-yl]amino]cyclohexyl)carbamate
(379 mg, 0.76 mmol, 1.00 equiv) in DMSO (8 mL) was added NaCN
(112.2 mg, 2.29 mmol, 5.00 equiv). The resulting solution was
stirred for 5 h at 80.degree. C. The reaction was then quenched by
the addition of 50 mL of water. The resulting solution was
extracted with 2.times.40 mL of ethyl acetate and the organic
layers combined and concentrated under vacuum. The residue was
applied onto a silica gel column with ethyl acetate/petroleum ether
(1:10). This resulted in 260 mg (80%) of tert-butyl
N-(4-[[(3R)-3-(cyanomethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-
-1(12),2(6),8,10-tetraen-12-yl]amino]cyclohexyl)carbamate as a
yellow oil.
[1508] Synthesis of Compound 194.4.
[1509] To a solution of tert-butyl
N-(4-[[(3R)-3-(cyanomethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-
-1(12),2(6),8,10-tetraen-12-yl]amino]cyclohexyl)carbamate (260 mg,
0.61 mmol, 1.00 equiv) and LiOH.H.sub.2O (76.6 mg, 1.82 mmol, 3.00
equiv) in methanol (10 mL) was added H.sub.2O.sub.2(37%, 1 mL). The
resulting solution was stirred for 3 h at room temperature. The
reaction was then quenched by the addition of 50 mL of
Na.sub.2SO.sub.3 (aq.). The resulting solution was extracted with
3.times.40 mL of ethyl acetate and the organic layers combined and
concentrated under vacuum. The residue was applied onto a silica
gel column with dichloromethane/methanol (30:1). This resulted in
187 mg (69%) of tert-buty
N-(4-[[(3R)-3-(carbamoylmethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]do-
deca-1(12),2(6),8,10-tetraen-12-yl]amino]cyclohexyl)carbamate as a
light yellow solid.
[1510] Synthesis of Compound I-99.
[1511] To a solution of tert-butyl
N-(4-[[(3R)-3-(carbamoylmethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]do-
deca-1(12),2(6),8,10-tetraen-12-yl]amino]cyclohexyl)carbamate (187
mg, 0.42 mmol, 1.00 equiv) in dichloromethane (5 mL) was added
hydrogen chloride (12 M, 1 mL). The resulting solution was stirred
for 2 h at room temperature. After evaporation, the residue was
dissolved in CH.sub.3OH (10 mL) and HCHO (1.5 mL) was added. The
resulting solution was stirred for 1 h at room temperature. To the
above solution was added NaBH.sub.3CN (79 mg, 1.26 mmol, 3.00
equiv). The resulting solution was allowed to react, with stirring,
overnight at room temperature. The reaction was then quenched by
the addition of 10 mL of water. The resulting solution was
extracted with 2.times.50 mL of dichloromethane and the organic
layers combined. The crude product (100 mg) was purified by
preparative HPLC under the following conditions: Column: Xbridge
Prep C18, 5 m, 19*150 mm; mobile phase, water (with 50 mL
NH.sub.4CO.sub.3) and CH.sub.3CN (10.0% CH.sub.3CN up to 32.0% in
10 min, up to 95.0% in 1 min, down to 10.0% in 2 min); UV detection
at 254 nm. This procedure afforded 50 mg (32%) of
2-[(3R)-12-[[4-(dimethylamino)cyclohexyl]amino]-7-thia-9,11-diazatricyclo-
[6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-3-yl]acetamide as a
white solid. MS (ES): m/z 374 (M+H).sup.+. .sup.1H NMR (300 MHz,
CD.sub.3OD): .delta. 1.35-1.60 (m, 4H), 1.95-2.04 (m, 2H),
2.09-2.10 (m, 2H), 2.28-2.38 (m, 7H), 2.40-2.45 (m, 3H), 2.68-2.80
(m, 1H), 2.89-2.30 (m, 1H), 3.05-3.15 (m, 1H), 4.05-4.15 (m, 1H),
3.87 (dd, J=14.1, 6.3 Hz, 1H), 8.23 (s, 1H).
Example 195
Synthesis of
(2S)-1-[(3R)-12-[[4-(dimethylamino)cyclohexyl]oxyl-7-thia-9,11-diazatricy-
clo[6.4.0.0[2,6]]]dodeca-1(8),2(6),9,11-tetraen-3-yl]butan-2-ol
(I-107) and
Example 196
Synthesis of
(2R)-1-[(3R)-12-[[4-(dimethylamino)cyclohexyl]oxyl-7-thia-9,11-diazatricy-
clo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]butan-2-ol
(I-106)
##STR00572##
[1513] Synthesis of Compounds 195.1 and 196.1.
[1514] To a solution of tert-butyl
N-methyl-N-(4-[[(3R)-3-(2-oxoethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6-
]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)carbamate (370
mg, 0.83 mmol, 1.00 equiv) in freshly distilled THF (15 mL) was
added dropwise bromo(ethyl)magnesium (0.46 mL, 1.25 mmol, 1.50
equiv) at 0.degree. C. under nitrogen. The resulting solution was
stirred for 2 h at r.t and quenched by the addition of H.sub.2O.
The mixture was extracted with ethyl acetate, dried over anhydrous
sodium sulfate and evaporated in vacuo. The residue was applied
onto a silica gel column with ethyl acetate/petroleum ether
(1:10-1:5) to give 0.11 g (56%) of tert-butyl
N-(4-[[(3R)-3-[(2S)-2-hydroxybutyl]-7-thia-9,11-diazatricyclo[6.4.0.0[2,6-
]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)-N-methylcarbamate
(195.1) as a light yellow oil and 0.16 g (81%) of tert-butyl
N-(4-[[(3R)-3-[(2R)-2-hydroxybutyl]-7-thia-9,11-diazatricyclo[6.4.0.0[2,6-
]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)-N-methylcarbamate
(196.1) as a light yellow oil.
[1515] Synthesis of Compound I-107.
[1516] To a solution of tert-butyl
N-(4-[[(3R)-3-[(2S)-2-hydroxybutyl]-7-thia-9,11-diazatricyclo[6.4.0.0[2,6-
]]dodeca-1(8),2(6),9,11-tetraen-12-yl]oxy]cyclohexyl)-N-methylcarbamate
(110 mg, 0.23 mmol, 1.00 equiv) in dichloromethane (7 mL) was added
hydrochloric acid (12 M, 0.5 mL) at 0.degree. C. The resulting
solution was stirred for 2 h at room temperature. The solvent was
removed under reduced pressure to give
(2S)-1-[(3R)-12-[[4-(methylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricycl-
o[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]butan-2-ol
hydrochloride (90 mg, crude), which was used in the next step
directly without further purification. The hydrochloride salt thus
obtained (90 mg) was dissolved in methanol (8 mL). Then HCHO (37%,
1 mL) was added and the mixture was stirred at room temperature for
1 h. This was followed by the addition of NaBH.sub.3CN (41 mg, 0.65
mmol, 2.99 equiv). The resulting solution was stirred overnight at
room temperature and quenched by the addition of water. The mixture
was extracted with 3.times.10 mL of dichloromethane and the organic
layers combined and concentrated under vacuum. The crude product
(80 mg) was purified by preparative HPLC under the following
conditions (Waters): Column: SunFire Prep C18, 19*150 mm, 5 m;
mobile phase: water (with 0.05% NH.sub.4HCO.sub.3) and CH.sub.3CN
(7.0% CH.sub.3CN up to 60.0% in 14 min); flow rate: 20 mL/min; UV
detection at 254/220 nm. The product-containing fractions were
collected and partially evaporated to remove water and CH.sub.3CN
under reduced pressure. The residue was lyophilized overnight to
give the corresponding 48.4 mg (57%) of
(2S)-1-[(3R)-12-[[4-(dimethylamino)cyclohexyl]oxy]-7-thia-9,11-diazatr-
icyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]butan-2-ol
as a light yellow semi-solid. MS (ES): m/z 390 (M+H).sup.+. .sup.1H
NMR (400 MHz, CD.sub.3OD): .delta. 8.46 (1H, s), 5.26-5.31 (1H, m),
3.61-3.63 (2H, m), 3.05-3.15 (1H, m), 2.95-3.00 (1H, m), 2.60-2.71
(1H, m), 2.25-2.50 (10H, m), 2.10-2.20 (1H, m), 2.00-2.08 (2H, m),
1.65-1.75 (2H, m), 1.40-1.52 (5H, m), 0.97 (3H, t).
[1517] Synthesis of Compound I-106.
[1518] Compound I-106 was prepared in a manner consistent with
I-107, except that compound 196.1 was used rather than 195.1. 66.1
mg (58%) of I-106 were obtained as a light yellow semi-solid. MS
(ES): m/z 390 (M+H).sup.+. .sup.1H NMR (400 MHz, CD.sub.3OD):
.delta. 8.48 (1H, s), 5.23-5.35 (1H, m), 3.60-3.70 (1H, m),
3.35-3.40 (1H, m), 3.10-3.15 (1H, m), 2.90-3.00 (1H, m), 2.60-2.70
(1H, m), 2.30-2.50 (10H, m), 2.00-2.15 (3H, m), 1.30-1.75 (7H, m),
1.05 (3H, t).
Example 197
Synthesis of
(2S)-1-[(3R)-12-[[4-(dimethylamino)-4-ethylcyclohexyl]oxy]-7-thia-9,11-di-
azatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]butan-2-ol
(I-104)
##STR00573##
[1520] Compound I-104 was prepared in a manner consistent with
Compound I-101, except that compound 132.1 was used rather than
132.2. I-104 was obtained as an off-white solid (13.6 mg, 5.4%
overall yield). MS (ES): m/z 418 (M+H).sup.+. .sup.1H NMR (300 MHz,
CD.sub.3OD): .delta. 8.474 (1H, s), 333-5.42 (1H, m), 3.48-3.68
(2H, m), 3.00-3.14 (1H, m), 2.92-2.98 (1H, m), 2.70-2.73 (1H, m),
2.31-2.55 (6H, m), 2.06-2.11 (3H, m), 1.60-2.00 (8H, m), 1.26-1.58
(4H, m), 0.91-1.07 (6H, m).
Example 198
Synthesis of
2-[(3R)-12-[[4-(morpholin-4-yl)cyclohexyl]amino]-7-thia-9,11-diazatricycl-
o[6.4.0.0 [2,6]]dodeca-1(12),2(6),8,10-tetraen-3-yl]acetamide
(I-97)
##STR00574## ##STR00575##
[1522] Synthesis of Compound 198.2.
[1523] To a solution of tert-butyl N-(4-aminocyclohexyl)carbamate
(1.07 g, 4.99 mmol, 1.00 equiv) in DMF (10 mL) was added
triethylamine (1.26 g, 12.48 mmol, 2.50 equiv) and
1-bromo-2-(2-bromoethoxy)ethane (1.4 g, 6.04 mmol, 1.20 equiv). The
resulting solution was stirred overnight at 70.degree. C. The
resulting solution was diluted with ethyl acetate (100 mL), washed
with brine (100 mL), dried over anhydrous sodium sulfate and
concentrated under vacuum to give 1.2 g (crude) of tert-butyl
N-[4-(morpholin-4-yl)cyclohexyl]carbamate as a light yellow solid.
MS (ES): m/z 285 (M+H).sup.+.
[1524] Synthesis of Compound 198.3.
[1525] To a solution of tert-butyl
N-[4-(morpholin-4-yl)cyclohexyl]carbamate (1.0 g, 3.52 mmol, 1.00
equiv) in methanol (5 mL) was added concentrated hydrochloric acid
(1.5 mL) at 0.degree. C. The resulting solution was stirred
overnight at room temperature. To this mixture was slowly added
ether (50 mL). The precipitates were collected by filtration and
dried in an oven to give 4-(morpholin-4-yl)cyclohexan-1-amine
dihydrochloride (500 mg, 55%) as a white solid.
[1526] Synthesis of Compound 198.4.
[1527] To a 100 mL round-bottom flask containing a solution of
[(3S)-12-chloro-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(12),2(6),-
8,10-tetraen-3-yl]methanol (100 mg, 0.42 mmol, 1.00 equiv) in
anhydrous DMF (8 mL) was added triethylamine (372 mg, 3.68 mmol,
9.00 equiv) and 4-(morpholin-4-yl)cyclohexan-1-amine hydrochloride
(214 mg, 0.83 mmol, 2.00 equiv) at room temperature. The resulting
solution was stirred overnight at 80.degree. C. After cooling, the
resulting solution was diluted with DCM (50 mL), washed with brine,
dried over anhydrous sodium sulfate and concentrated under vacuum
to obtain 130 mg (81%) of
[(3S)-12-[[4-(morpholin-4-yl)cyclohexyl]amino]-7-thia-9,11-diazatricyclo[-
6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-3-yl]methanol as a
yellow oil. MS (ES): m/z 389 (M+H).sup.+.
[1528] Synthesis of Compound 198.5.
[1529] To a solution of
[(3S)-12-[[4-(morpholin-4-yl)cyclohexyl]amino]-7-thia-9,11-diazatricyclo[-
6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-3-yl]methanol (130 mg,
0.33 mmol, 1.00 equiv) in dichloromethane (5 mL) was added MsCl (57
mg, 0.50 mmol, 1.50 equiv) and triethylamine (100 mg, 0.99 mmol,
3.00 equiv) at 0.degree. C. The resulting solution was stirred for
2 h at room temperature and diluted with DCM (30 mL). the organic
layer was washed with brine, dried over anhydrous sodium sulfate
and concentrated under vacuum to obtain 140 mg (90%) of
[(3S)-12-[[4-(morpholin-4-yl)cyclohexyl]amino]-7-thia-9,11-diazatricyclo[-
6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-3-yl]methyl
methanesulfonate as a yellow oil. MS (ES): m/z 467 (M+H).sup.+.
[1530] Synthesis of Compound 198.6.
[1531] To a solution of
[(3S)-12-[[4-(morpholin-4-yl)cyclohexyl]amino]-7-thia-9,11-diazatricyclo[-
6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-3-yl]methyl
methanesulfonate (140 mg, 0.30 mmol, 1.00 equiv) in DMSO (5 mL) was
added NaCN (88 mg, 1.80 mmol, 6.00 equiv) at room temperature. The
resulting solution was stirred for 2 h at 80.degree. C. After
cooling, the resulting solution was diluted with DCM (30 mL),
washed with brine, dried over anhydrous sodium sulfate and
concentrated under vacuum to give
2-[(3R)-12-[[4-(morpholin-4-yl)cyclohexyl]amino]-7-thia-9,11-diazatricycl-
o[6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-3-yl]acetonitrile (90
mg, 84%) as a yellow oil. MS (ES): m/z 398 (M+H).sup.+.
[1532] Synthesis of Compound I-97.
[1533] To a solution of
2-[(3R)-12-[[4-(morpholin-4-yl)cyclohexyl]amino]-7-thia-9,11-diazatricycl-
o[6.4.0.0 [2,6]]dodeca-1(12),2(6),8,10-tetraen-3-yl]acetonitrile
(120 mg, 0.30 mmol, 1.00 equiv) in methanol (8 mL) was added
LiOH.H.sub.2O (37.8 mg, 0.90 mmol, 3.00 equiv) and
H.sub.2O.sub.2(30%, 0.5 mL) in an ice-water bath. The resulting
solution was stirred for 2 h at room temperature and diluted with
DCM (30 mL), washed with brine, dried over anhydrous sodium sulfate
and concentrated under vacuum. The residue was applied onto a
silica gel column with DCM/MeOH (20:1) to give 100 mg (80%) of
2-[(3R)-12-[[4-(morpholin-4-yl)cyclohexyl]amino]-7-thia-9,11-dia-
zatricyclo[6.4.0.0 [2,6]]dodeca-1(12),2(6),8,
10-tetraen-3-yl]acetamide as a white solid. MS (ES): m/z 416
(M+H).sup.+. .sup.1H NMR (400 MHz, CD.sub.3OD): .delta. 8.23 (s,
1H), 4.11-4.20 (m, 1H), 3.82-3.89 (m, 1H), 3.72 (s, 4H), 3.09-3.17
(m, 1H), 2.93-2.99 (m, 1H), 2.70-2.82 (m, 1H), 2.65 (s, 4H), 2.47
(s, 2H), 2.27-2.35 (m, 2H), 2.11-2.19 (m, 2H), 2.05-2.10 (m, 2H),
1.40-1.67 (m, 4H).
Example 199
Synthesis of
(2R)-1-[(3R)-12-[[4-(dimethylamino)-4-ethylcyclohexyl]oxy]-7-thia-9,11-di-
azatricyclo[6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-3-yl]propan-2-ol
(I-102)
##STR00576##
[1535] Synthesis of Compound 199.1 and 199.2.
[1536] Into a 100-mL round-bottom flask, purged and maintained
under an inert atmosphere of nitrogen, was placed a solution of
tert-butyl
N-(1-ethyl-4-[[(3R)-3-(2-oxoethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]-
]dodeca-1(12),2(6),8,10-tetraen-12-yl]oxy]cyclohexyl)carbamate (330
mg, 0.72 mmol, 1.00 equiv) in 10 mL of distilled tetrahydrofuran.
This solution was cooled to 0.degree. C. Then CH.sub.3MgBr-THF (1
M, 1.5 mL) was added dropwise via syringe. The resulting solution
was stirred for 2 h at this temperature. The reaction was then
quenched by the addition of 10 mL of NH.sub.4Cl (aq.) and extracted
with 3.times.50 mL of ethyl acetate. The combined organic layers
were washed with brine, dried over sodium sulfate and concentrated
under vacuum. The residue was applied onto a silica gel column with
ethyl acetate/petroleum ether (1:5) to give 160 mg (47%) of
tert-butyl
N-(1-ethyl-4-[[(3R)-3-[(2R)-2-hydroxypropyl]-7-thia-9,11-diazatricyclo[6.-
4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-12-yl]oxy]cyclohexyl)carbamate
199.2 as a white solid and 70 mg (20%) of tert-butyl
N-(1-ethyl-4-[[(3R)-3-[(2
S)-2-hydroxypropyl]-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(12),2-
(6),8,10-tetraen-12-yl]oxy]cyclohexyl)carbamate 199.1 as a white
solid.
[1537] Synthesis of Compound I-102.
[1538] A 50-mL round-bottom flask, purged and maintained with an
inert atmosphere of nitrogen, was charged with a solution of
tert-butyl
N-(1-ethyl-4-[[(3R)-3-[(2R)-2-hydroxypropyl]-7-thia-9,11-diazatricyclo[6.-
4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-12-yl]oxy]cyclohexyl)carbamate
(160 mg, 0.34 mmol, 1.00 equiv) in dichloromethane (6 mL) at
0.degree. C. Then hydrochloric acid (conc., 0.5 mL) was added at
this temperature and stirred for 2 h at room temperature. The
reaction solution was concentrated under vacuum to give 150 mg
(crude) of
(2R)-1-[(3R)-12-[(4-amino-4-ethylcyclohexyl)oxy]-7-thia-9,11-diazatricycl-
o[6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-3-yl]propan-2-ol
hydrochloride as a white solid.
[1539] This solid (150 mg, crude) was dissolved in methanol (6 mL)
and HCHO (37%, 1.0 mL) was added at room temperature. After
stirring for 30 min, NaBH.sub.3CN (61.8 mg, 0.98 mmol, 3.21 equiv)
was added and the resulting mixture was stirred for 5 h at room
temperature. The solution was then diluted with 10 mL of water,
extracted with 3.times.50 mL of CHCl.sub.3/i-PrOH (3/1) and the
combined organic layers were concentrated under vacuum. The crude
product (100 mg) was purified by preparative HPLC under the
following conditions (Waters): Column: SunFire Prep C18, 19*150 mm,
5 .mu.m; mobile phase, water (with 0.05% NH.sub.4HCO.sub.3) and
CH.sub.3CN (5.0% CH.sub.3CN up to 45.0% in 10 min, up to 95.0% in 2
min, down to 5.0% in 2 min); flow rate: 20 mL/min; UV detection at
254/220 nm. This resulted in 46.4 mg (38%) of
(2R)-1-[(3R)-12-[[4-(dimethylamino)-4-ethylcyclohexyl]oxy]-7-thia-9,11-di-
azatricyclo[6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-3-yl]propan-2-ol
as an off-white semi-solid. MS (ES): m/z 404 (M+H).sup.+. .sup.1H
NMR (300 MHz, CD.sub.3OD): .delta. 8.48 (1H, s), 5.41 (1H, m), 3.95
(1H, m), 3.33 (1H, m), 3.08 (1H, m), 2.97 (1H, m), 2.64 (1H, m),
2.49 (1H, m), 2.32 (6H, m), 2.18 (1H, m), 2.06 (2H, m), 1.60-1.85
(9H, m), 1.30 (3H, d), 0.95 (2H, m).
Example 200
Synthesis of
(2S)-1-[(3R)-12-[[4-(dimethylamino)-4-ethylcyclohexyl]oxy]-7-thia-9,11-di-
azatricyclo[6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-3-yl]propan-2-ol
(I-103)
##STR00577##
[1541] Into a 50-mL round-bottom flask containing a solution of
tert-butyl
N-(1-ethyl-4-[[(3R)-3-[(2S)-2-hydroxypropyl]-7-thia-9,11-diazatricyclo[6.-
4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-12-yl]oxy]cyclohexyl)carbamate
(70 mg, 0.15 mmol, 1.00 equiv) in dichloromethane (3 mL) was added
12 M hydrochloric acid (0.3 mL) at 0.degree. C. The resulting
solution was stirred for 2 h at room temperature and concentrated
under vacuum to give 60 mg (crude) of
(2S)-1-[(3R)-12-[(4-amino-4-ethylcyclohexyl)oxy]-7-thia-9,11-diazatricycl-
o[6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-3-yl]propan-2-ol
hydrochloride as a white solid.
[1542] This solid (60 mg, crude) was dissolved in 3 mL of methanol.
HCHO (37%, 0.5 mL) was added followed by stirring for 30 min at
room temperature. Then NaBH.sub.3CN (27 mg, 0.43 mmol, 3.54 equiv)
was added and stirring was continued for 5 h at ambient
temperature. The resulting solution was diluted with 10 mL of
water, extracted with 3.times.30 mL of trichloromethane/i-PrOH
(3/1) and the combined organic layers were concentrated under
vacuum. The crude product (50 mg) was purified by preparative HPLC
under the following conditions (Waters): Column: SunFire Prep C18,
19*150 mm, 5 m; mobile phase: water (with 0.05% NH.sub.4HCO.sub.3)
and CH.sub.3CN (5.0% CH.sub.3CN up to 45.0% in 10 min, up to 95.0%
in 2 min, down to 5.0% in 2 min); flow rate: 20 mL/min; UV
detection at 254/220 nm. This procedure resulted in 11.3 mg (23%)
of
(2S)-1-[(3R)-12-[[4-(dimethylamino)-4-ethylcyclohexyl]oxy]-7-thia-9,11-di-
azatricyclo[6.4.0.0[2,6]]dodeca-1(12),2(6),8,10-tetraen-3-yl]propan-2-ol
as a white solid. MS (ES): m/z 404 (M+H).sup.+. .sup.1H NMR (300
MHz, CD.sub.3OD): .delta. 8.48 (1H, s), 5.41 (1H, m), 3.95 (1H, m),
3.33 (1H, m), 3.08 (1H, m), 2.97 (1H, m), 2.64 (1H, m), 2.49 (1H,
m), 2.32 (6H, m), 2.18 (1H, m), 2.06 (2H, m), 1.60-1.85 (9H, m),
1.30 (3H, d), 0.95 (2H, m).
Example 201
Synthesis of
((R)-4-(((1r,4R)-4-(dimethylamino)cyclohexyl)oxy)-6,7-dihydro-5H-cyclopen-
ta[4,5]thieno[2,3-d]pyrimidin-5-yl)methanol (I-19) and
((S)-4-(((1r,4S)-4-(dimethylamino)cyclohexyl)oxy)-6,7-dihydro-5H-cyclopen-
ta[4,5]thieno[2,3-d]pyrimidin-5-yl)methanol (I-20), and Separation
of Chiral Compounds
##STR00578##
[1544] To a solution of I-4 (1.3 g, 3.3 mmol) in THF (30 mL) was
added LiAlH.sub.4 (508 mg, 13.3 mmol) in portions at 0.degree. C.
The mixture was allowed to warm to r.t. with stirring for 2 hours,
and then Na.sub.2SO.sub.4.10H.sub.2O (4.3 g, 13.3 mmol) was added.
The suspension was stirred for 2 hours and then filtrated and the
filtrate was purified by silica gel column chromatography with
MeOH/DCM=1:10 to give a white solid product (810 mg, 70%). The
product (550 mg) was resolved by Chiral-HPLC using the following
conditions: Instrument: Thar SFC Prep 80 (Thar Technologies,
Waters); Column: ChiralPak AD-H, 50 mm I.D..times.250 mm Length, 5
m (Daicel Chemical Industries Co., Ltd); Column Temperature:
35.degree. C.; Mobile Phase: CO.sub.2/MeOH/DEA=70/30/0.1; Flow
rate: 80 g/min; Back Pressure: 100 Bar; Wavelength: 214 nm; Cycle
time: 7.0 min; Injection Volume: 1.0 mL; Feed solution: 550 mg
dissolved in 14 mL MeOH. The solvent was concentrated under vacuum
to obtain 150 mg I-19 and 150 mg I-20.
Example 202
Synthesis of
(12S)-3-[[(1r,4r)-4-(morpholin-4-yl)cyclohexyl]oxy]-8-thia-4,6-diazatricy-
clo[7.4.0.0[2,7]]trideca-1(9),2(7),3,5-tetraene-12-carboxylic acid
(I-234)
##STR00579## ##STR00580##
[1546] Synthesis of Compound 202.6.
[1547] Compound 202.6 was prepared from 202.1 in a manner analogous
to the synthesis of 153.7 from 153.3. Isolated 954 mg of a
colorless oil in 61% overall yield.
[1548] Synthesis of Compound 202.7.
[1549] The enantiomers of 202.6 (1.25 g) were separated by
preparative chiral HPLC under the following conditions: Column:
Chiralpak IC, 2*25 cm, 5 .mu.m; mobile phase: hexane and EtOH
(85:15); flow rate: 20 mL/min; UV detection at 254/220 .mu.m. The
desired isomer-containing fractions were collected and evaporated
to remove solvent under reduced pressure to give 448 mg of 202.8
(tR=14.68 min) and 404 mg of 202.7 (tR=16.12 min) respectively. The
ee was found to be 98.7% ee for 202.7 (tR=7.71 min) and 100% ee for
202.8 (tR=9.59 min) as determined by analytical chiral HPLC under
the following conditions: Column: Lux Cellulose-4, 0.46*15 cm, 5
.mu.m, 4.6*250 mm, 5 m; mobile phase: Hex:IPA=80:20; flow rate: 1
mL/min; UV detection at 254 .mu.m.
[1550] Analytical data for 202.7: MS (ES): m/z 255 (M+H).sup.+.
1H-NMR (300 MHz, CDCl.sub.3): .delta. 8.75 (1H, s), 3.81-3.69 (2H,
m), 3.38 (1H, dd, J=16.8, 5.1 Hz), 3.05-2.82 (2H, m), 2.78-2.64
(1H, m), 2.20-2.07 (2H, m), 1.69-1.61 (1H, m).
[1551] Analytical data for 202.8: MS (ES): m/z 255 (M+H)+. 1H-NMR
(300 MHz, CDCl.sub.3): .delta. 8.75 (1H, s), 3.81-3.69 (2H, m),
3.38 (1H, dd, J=16.8, 5.1 Hz), 3.05-2.82 (2H, m), 2.78-2.64 (1H,
m), 2.20-2.07 (2H, m), 1.69-1.61 (1H, m).
[1552] Synthesis of Compound 202.9.
[1553] To a solution of 202.7 (253 mg, 0.99 mmol, 1.00 equiv) in
acetone (10 mL) was added dropwise Jones reagent (2 mL) at
0.degree. C. The resulting mixture was stirred for 20 min at this
temperature, quenched with aqueous saturated NaHSO.sub.3 and
extracted with EtOAc (2.times.100 mL). The combined organic layers
were washed with brine, dried over anhydrous sodium sulfate and
concentrated under vacuum to yield 247 mg (93%) of 201.9 as a white
solid.
[1554] Synthesis of Compound I-234.
[1555] Into a 50-mL 3-necked round-bottom flask purged and
maintained with an inert atmosphere of nitrogen, was placed a
solution of 4-(morpholin-4-yl)cyclohexan-1-ol (111 mg, 0.60 mmol,
1.20 equiv) in 5 mL of distilled THF at 0.degree. C. This was
followed by the addition of NaHMDS (0.75 mL, 2 M in THF) dropwise
via a syringe and stirring for 30 min. To a solution of 202.9 (135
mg, 0.50 mmol, 1.00 equiv) in 2 mL of THF was added and the
resulting solution was stirred for 2 h at 0.degree. C. The reaction
was then quenched by the addition of 5 mL of water and the pH value
of the solution was adjusted to 5 with 1 M hydrochloric acid and
extracted with 5.times.10 mL of chloroform/i-PrOH (3:1). The
combined organic layers were dried over anhydrous sodium sulfate
and concentrated under vacuum to give the resultant I-234 (200 mg,
crude) as a white solid. MS (ES): m/z 418 (M+H).sup.+. .sup.1H-NMR
(400 MHz, CDCl.sub.3): .delta. 8.48 (1H, s), 5.25-5.12 (1H, m),
3.87 (4H, brs), 3.30 (1H, dd), 3.08-2.74 (9H, m), 2.45-2.25 (3H,
m), 2.19-1.88 (3H, m), 1.80-1.50 (4H, m).
Example 203
Synthesis of
(12S)-3-[[4-(morpholin-4-yl)cyclohexyl]oxy]-8-thia-4,6-diazatricyclo[7.4.-
0.0[2,7]]trideca-1(9),2(7),3,5-tetraene-12-carboxamide (I-220)
##STR00581##
[1557] Synthesis of Compound I-220.
[1558] Compound I-220 was prepared from I-234 (Example 202) in a
manner consistent with the synthesis of I-13 from 4.1. Isolated
79.6 mg of a white solid in 38% yield. MS (ES): m/z 417
(M+H).sup.+. .sup.1H NMR (300 MHz, CD.sub.3OD): .delta. 8.45 (1H,
s), 5.30-5.22 (1H, m), 3.74-3.71 (4H, t), 3.33-3.26 (1H, m),
3.09-2.97 (3H, m), 2.87-2.70 (1H, m), 2.65-2.62 (4H, t), 2.45-2.30
(3H, m), 2.23-2.18 (1H, m), 2.11-2.07 (2H, m), 2.07-1.91 (1H, m),
1.64-1.44 (4H, m).
Example 204
Synthesis of
2-[(3S)-12-[[4-(dimethylamino)cyclohexyl]oxy]-10-[(1-methyl-1H-pyrazol-4--
yl)amino]-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tet-
raen-3-yl]acetamide (I-224)
##STR00582## ##STR00583##
[1560] Synthesis of Compound 204.1.
[1561] To a solution of triphosgene (2.205 g, 7.43 mmol, 1.0 equiv)
in 80 mL of anhydrous DCM was added a solution of 1.2 (4.455 g,
14.98 mmol, 2.00 equiv) in DCM (20 mL) dropwise with stirring at
0.degree. C., followed by addition of TEA (3.8 g, 37.43 mmol, 5.0
equiv) via syringe under nitrogen. The resulting solution was
stirred for 1 h at room temperature. To the mixture was added
(2,4-dimethoxyphenyl)methanamine (5.01 g, 29.96 mmol, 4.00 equiv)
and the resulting solution was allowed to react, with stirring, for
an additional 1 h at ambient temperature. The solids were filtered
out, washed with 2.times.100 mL of DCM and the filtrate was
concentrated under vacuum. The residue was applied onto a silica
gel column with ethyl acetate/petroleum ether (1:5) to give 204.1
(4.5 g, 61%) as a yellow solid.
[1562] Synthesis of Compound 204.2.
[1563] Sodium hydride (2.2 g, 55.00 mmol, 3.00 equiv, 60%) was
treated with 204.1 (9.0 g, 18.35 mmol, 1.00 equiv) in 100 mL of
dioxane overnight at 100.degree. C. under nitrogen. After cooling,
the reaction was then quenched with water and the pH value of the
solution was adjusted to 4 with 4 M hydrochloric acid. The solids
were collected by filtration and dried in an oven (45.degree. C.)
to yield 6.2 g (81%) of 204.2 as an off-white solid.
[1564] Synthesis of Compound 204.3.
[1565] To a solution of 204.2 (6.0 g, 14.41 mmol, 1.00 equiv),
ethanol (10 mL) and 4-methylbenzene-1-sulfonic acid (800 mg, 4.65
mmol, 0.32 equiv) in toluene (110 mL) was stirred overnight at
120.degree. C. After cooling, the reaction was quenched with
aqueous saturated sodium bicarbonate and extracted with 2.times.200
mL of ethyl acetate. The combined organic layers were dried over
sodium sulfate and concentrated under vacuum. The residue was
applied onto a silica gel column with ethyl acetate/petroleum ether
(1/2) to give 204.3 (6.0 g, 94%) as a yellow solid.
[1566] Synthesis of Compound 204.4.
[1567] To a solution of 204.3 (6.0 g, 13.4 mmol, 1.00 equiv) in 50
mL of trifluoroacetic acid was stirred for 4.5 h at 50.degree. C.
in an oil bath under nitrogen. After completion of the reaction,
the resulting mixture was concentrated under vacuum to give 204.4
(4.5 g, crude) as a white solid.
[1568] Synthesis of Compound 204.5.
[1569] Into a 250-mL round-bottom flask was placed 204.4 (4.0 g,
13.59 mmol, 1.00 equiv) in POCl.sub.3 (70 mL) under nitrogen and
the resulting mixture was stirred overnight at 105.degree. C. in an
oil bath. The resulting mixture was concentrated under vacuum and
the residue was diluted with 150 mL of EtOAc. The pH value of the
solution was adjusted to 7-8 with saturated sodium bicarbonate and
extracted with 2.times.150 mL of ethyl acetate. The organic layers
were washed with brine, dried over anhydrous sodium sulfate and
concentrated under vacuum. The residue was applied onto a silica
gel column with ethyl acetate/petroleum ether (1:10) to give the
desired 204.5 (1.95 g, 43%) as a light yellow solid.
[1570] Synthesis of Compound 204.6.
[1571] The enantiomers of 204.5 (2.3 g) were separated by
chiral-SFC under the following conditions: Column: Phenomenex Lux
5u Cellulose-3, 5*25 cm, 5 m; mobile phase: 75% CO.sub.2 and 25%
MeOH (0.01 DEA); flow rate: 200 g/min; UV detection at 220 .mu.m.
The first fraction to elute (tR=3.5 min) were collected and
evaporated to remove solvent under reduced pressure to give 900 mg
of 204.6. The second fraction to elute (tR=4.25 min) was collected
and evaporated to remove solvent under reduced pressure to give 900
mg of compound 204.9. The ee of 204.6 (98.5%) and of 204.9 were
determined by analytical chiral SFC under the following conditions:
Column: phenomenex Lux 5u Cellulose-3, 4.6*250 mm, 5 .mu.m; mobile
phase: 90% CO.sub.2 and 10% MeOH (0.01 DEA); flow rate: 4 mL/min;
UV detection at 254 .mu.m.
[1572] Synthesis of Compound 204.7.
[1573] Compound 204.7 was prepared from 204.6 in a manner analogous
to the synthesis of compound 16.4. Isolated 0.55 g of a light
yellow oil in 46% yield.
[1574] Synthesis of Compound 204.8.
[1575] A mixture of 204.7 (275 mg, 0.625 mmol, 1.00 equiv),
1-methyl-1H-pyrazol-4-amine (152 mg, 1.56 mmol, 2.50 equiv),
Pd.sub.2dba.sub.3 (28.6 mg, 0.03 mmol, 0.05 equiv), Xantphos (36.2
mg, 0.065 mmol, 0.10 equiv), NaOBu.sup.t (145 mg, 1.5 mmol, 2.5
equiv) in 30 mL of 1,4-dioxane was degassed three times with
nitrogen. The resulting mixture was stirred for 4 h at 100.degree.
C. The reaction mixture was concentrated under vacuum and the
residue was diluted with water. The pH value was adjusted to 5 with
1 M hydrochloric acid and extracted with 5.times.50 mL of
chloroform/iso-propanol (3:1). The combined organic layers were
dried over sodium sulfate and concentrated under vacuum.
Purification by chromatography on silica gel column with DCM/MeOH
(10:1 to 2:1) gave 204.8 (180 mg, 62%) as a grey solid.
[1576] Synthesis of Compound I-224.
[1577] Compound I-224 was prepared from 204.8 in a manner analogous
to the synthesis of Compound I-13. Isolated 35.9 mg of a white
solid in 20% yield. MS (ES): m/z 470 (M+H).sup.+. .sup.1H NMR (300
MHz, CD.sub.3OD): .delta. 7.89 (1H, br s), 7.59 (1H, s), 5.19 (1H,
m), 3.89 (3H, s), 3.66 (1H, m), 2.83-2.99 (4H, m), 2.70 (7H, m),
2.43 (2H, m), 2.14-2.39 (4H, m), 1.76-1.94 (4H, m).
Example 205
Synthesis of
2-[(3R)-12-[[4-(morpholin-4-yl)cyclohexyl]oxy](4,4,5,5-d4)-7-thia-9,
11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,
11-tetraen-3-yl]acetamide-d.sub.4 (I-188)
##STR00584## ##STR00585## ##STR00586##
[1579] Synthesis of Compound 205.2.
[1580] To a solution of (3,3,4,4-d.sub.4)cyclopentan-1-one (3.0 g,
34.0 mmol, 1.00 equiv) in 15 mL of distilled THF was added dropwise
2 M LiHMDS in THF (20.5 mL, 1.20 equiv) at -78.degree. C. under
nitrogen. After addition, the resulting solution was stirred for 1
h at -20.degree. C. Then ethyl cyanoformate (3.7 g, 37.4 mmol, 1.10
equiv) was added at -78.degree. C. and the resulting solution was
allowed to react, with stirring, for an additional 30 min at
-78.degree. C. The reaction was quenched with saturated NH.sub.4Cl
solution and extracted with 2.times.100 mL of ethyl acetate. The
combined organic layers were washed with brine, dried over sodium
sulfate and concentrated under vacuum. The residue was applied onto
a silica gel column with ethyl acetate/petroleum ether (1:20-1:10)
to give 3.5 g (64%) of 205.2.
[1581] Synthesis of Compound 205.3.
[1582] To a solution of 205.2 (3.5 g, 21.85 mmol, 1.00 equiv) in
ethanol (100 mL) was added S (784 mg, 1.10 equiv), ethyl
2-cyanoacetate (2.7 g, 24.03 mmol, 1.10 equiv) and Et.sub.2NH (3.19
g, 43.7 mmol, 2.00 equiv) subsequently under nitrogen. The
resulting mixture was stirred for 5 h at 45.degree. C. and cooled
to room temperature and quenched by the addition of 50 mL of water.
After extraction with 3.times.100 mL of ethyl acetate, the combined
organic layers were washed with brine and dried over sodium sulfate
and concentrated under vacuum. The residue was applied onto a
silica gel column with ethyl acetate/petroleum ether (1:10-1:5) to
give 205.3 (3.2 g, 51%) as a yellow solid.
[1583] Synthesis of Compound 205.4.
[1584] To a solution of 205.3 (3.2 g, 11.1 mmol, 1.00 equiv) in
formamide (10 mL) was added formamidine acetate (2.4 g) and the
resulting mixture was stirred for 5 h at 150.degree. C. under
nitrogen. After cooling to room temperature, the reaction was
quenched with water and extracted with 3.times.100 mL of ethyl
acetate. The organic layers were combined, washed with brine, dried
over sodium sulfate and concentrated under vacuum. The residue was
applied onto a silica gel column with ethyl acetate/petroleum ether
(1:10-1:5) to provide 1.6 g (54%) of 205.4 as a yellow solid.
[1585] Synthesis of Compound 205.5.
[1586] Into a 100-mL round-bottom flask containing a solution of
205.4 (1.6 g, 6.0 mmol, 1.00 equiv) in 20 mL of 1,4-dioxane was
added POCl.sub.3 (10 mL) under nitrogen. The resulting solution was
stirred for 3 h at reflux. After cooling down to room temperature
the excess of POCl.sub.3 was removed under reduced pressure and the
residue was dissolved in 50 mL of EtOAc and poured into water/ice.
The resulting solution was neutralized with saturated sodium
bicarbonate solution and extracted with 3.times.80 mL of ethyl
acetate. The combined organic layers was dried over sodium sulfate
and concentrated under vacuum. The residue was applied onto a
silica gel column with ethyl acetate/petroleum ether (1:10) to give
205.5 (950 mg, 55%) as a yellow solid.
[1587] Synthesis of Compound 205.6.
[1588] To a 100-mL 3-necked round-bottom flask was added a mixture
of 205.5 (900 mg, 3.14 mmol, 1.00 equiv) in 20 mL of freshly
distilled THF followed by DIBAL-H (895 mg, 6.30 mmol, 2.00 equiv)
at -78.degree. C. under nitrogen. The resulting solution was
stirred for 2 h at -78.degree. C., quenched by the addition of
aqueous saturated NH.sub.4Cl and extracted with 3.times.100 mL of
ethyl acetate. The organic layers were combined, washed with brine,
dried over sodium sulfate and concentrated under vacuum. The
residue was applied onto a silica gel column with ethyl
acetate/petroleum ether (1:1) to afford 205.6 (720 mg, 94%) as a
colorless oil.
[1589] Synthesis of Compound 205.7.
[1590] The enantiomers of 205.6 (720 mg) were resolved by
preparative SFC under the following conditions: Column: Chiralpak
AD-H, 2*25 cm; mobile phase: CO.sub.2 (60%) and methanol (40%);
flow rate: 40 g/min; UV detection at 254/220 nm. The
product-containing fractions were collected and evaporated to
remove methanol to afford 205.7 (tR=10 min, 320 mg, 89%) as a
colorless oil. A 100% ee value (tR=3.2 min) was measured by
analytical SFC under the following conditions: Column: CHIRALPAK
AD-H, 4.6*150 mm, 5 m Chiral-A(AD-H); mobile phase: CO.sub.2 (60%),
methanol (40%); flow rate: 4 mL/min; UV detection at 220 nm.
[1591] Synthesis of Compound 205.8.
[1592] To a solution of 205.7 (160 mg, 0.65 mmol, 1.00 equiv) in
anhydrous DCM (10 mL) was added 3,4-dihydro-2H-pyran (110 mg, 1.31
mmol, 2.00 equiv) and TsOH (56 mg, 0.33 mmol, 0.50 equiv). The
solution was stirred for 30 min at 0.degree. C. under nitrogen. The
resulting solution was diluted with water and extracted with
dichloromethane and the organic layers were combined, washed with
brine, dried over Na.sub.2SO.sub.4 and concentrated under vacuum.
The residue was applied onto a silica gel column with ethyl
acetate/petroleum ether (1:5) to give the desired 205.8 (170 mg,
79%) as a colorless oil.
[1593] Synthesis of Compound 205.9.
[1594] Sodium hydride (104 mg, 2.60 mmol, 5.03 equiv, 60%
dispersion in mineral oil) was treated with
trans-4-(morpholin-4-yl)cyclohexan-1-ol (143 mg, 0.77 mmol, 1.49
equiv) in 25 mL of distilled THF for 30 min at 0.degree. C. under
nitrogen. Then 205.8 (170 mg, 0.52 mmol, 1.00 equiv) in 5 mL of THF
was added via syringe and the resulting solution was allowed to
react, with stirring, for an additional 3 h while the temperature
was maintained at 55.degree. C. in an oil bath. The reaction was
then quenched by the addition of NH.sub.4Cl (aq.) and extracted
with ethyl acetate. The organic layers were combined, washed with
brine, dried over Na.sub.2SO.sub.4 and concentrated under vacuum.
The residue was applied onto a silica gel column with
dichloromethane/methanol (30:1) to afford 205.9 (110 mg, 45%) as a
colorless oil.
[1595] Synthesis of Compound 205.10.
[1596] To a solution of 205.9 (120 mg, 0.25 mmol, 1.00 equiv) and
conc. hydrochloric acid (0.5 mL) in methanol (15 mL) was stirred
for 30 min at 0.degree. C. in a water/ice bath. The reaction was
then quenched by the addition of sodium bicarbonate (sat.) and
extracted with 4.times.50 mL of DCM. The combined organic layers
were dried over sodium sulfate and concentrated under vacuum. The
residue was applied onto a silica gel column with
dichloromethane/methanol (25:1) to provide the 205.10 (85 mg, 86%)
as a colorless oil.
[1597] Synthesis of Compound 205.11.
[1598] To a solution of 205.10 (120 mg, 0.25 mmol, 1.00 equiv) and
conc. hydrochloric acid (0.5 mL) in methanol (15 mL) was stirred
for 30 min at 0.degree. C. in a water/ice bath. The reaction was
then quenched by the addition of sodium bicarbonate (sat.) and
extracted with 4.times.50 mL of DCM. The combined organic layers
were dried over sodium sulfate and concentrated under vacuum. The
residue was applied onto a silica gel column with
dichloromethane/methanol (25:1) to provide 205.11 (85 mg, 86%) as a
colorless oil.
[1599] Synthesis of Compound 205.12.
[1600] To a solution of 205.11 (95 mg, 0.20 mmol, 1.00 equiv), NaCN
(99 mg, 2.02 mmol, 10.03 equiv) and 4-dimethylaminopyridine (5 mg,
0.04 mmol, 0.20 equiv) in DMSO (5 mL) was stirred for 35 h at
60.degree. C. in an oil bath. The resulting solution was diluted
with 50 mL of water and extracted with 3.times.60 mL of DCM. The
combined organic layers were washed with brine, dried over sodium
sulfate and concentrated under vacuum. The residue was applied onto
a silica gel column with dichloromethane/methanol (30:1) to afford
205.12 (80 mg, 99%) as a colorless oil.
[1601] Synthesis of Compound I-188.
[1602] To a solution of 205.12 (80 mg, 0.20 mmol, 1.00 equiv),
LiOH.H.sub.2O (17 mg, 0.40 mmol, 2.04 equiv) and H.sub.2O.sub.2(0.5
mL, 30%) in methanol (10 mL) was stirred for 3 h at 0.degree. C.
The reaction was then quenched by the addition of saturated
Na.sub.2SO.sub.3 and extracted with 3.times.50 mL of DCM. The
organic layers were combined and concentrated under vacuum. The
residue was purified by preparative TLC with
dichloromethane/methanol (30:1) to give Compound I-188 (48.9 mg,
59%) as a white solid. MS (ES): m/z 421 (M+H).sup.+. .sup.1H NMR
(400 MHz, CD.sub.3OD): .delta. 8.49 (s, 1H), 5.33-5.25 (m, 1H),
3.82-3.72 (m, 5H), 3.03-2.99 (m, 1H), 2.67-2.63 (m, 4H), 2.41-2.27
(m, 4H), 2.12-2.09 (m, 2H), 1.71-1.47 (m, 4H).
Example 206
Synthesis of 12-[[4-(morpholin-4-yl)cyclohexyl]oxy]-7-thia-4,9,
11-triazatricyclo[6.4.0.0[2,6]]dodeca-1(12),2(6),8, 10-tetraene
(I-192)
##STR00587##
[1604] Synthesis of Compound 206.2.
[1605] To a solution of benzyl 3-oxopyrrolidine-1-carboxylate (4.5
g, 20.53 mmol, 1.00 equiv), ethyl 2-cyanoacetate (2.773 g, 24.51
mmol, 1.19 equiv), S (780 mg, 24.38 mmol, 1.19 equiv) and
diethylamine (1.791 g, 24.53 mmol, 1.20 equiv) in ethanol (40 mL)
was stirred for 5 h at 50.degree. C. The solids were collected by
filtration and dried in an oven at 45.degree. C. to give the
desired 206.2 (1.7 g, 24%) as a yellow solid.
[1606] Synthesis of Compound 206.3.
[1607] A mixture of 206.2 (1.5 g, 4.33 mmol, 1.00 equiv) and
formamidine acetate (4.582 g, 43.23 mmol, 9.98 equiv) in 50 mL of
formamide was stirred for 3 h at 180.degree. C. under nitrogen. The
reaction was then quenched by the addition of water and extracted
with 3.times.100 mL of ethyl acetate. The organic layers were
combined, washed with brine, dried over sodium sulfate and
concentrated under vacuum. The residue was applied onto a silica
gel column with dichloromethane/methanol (15:1) to provide 206.3
(1.2 g, 85%) as a white solid.
[1608] Synthesis of Compound 206.4.
[1609] To a solution of 206.3 (1.9 g, 5.80 mmol, 1.00 equiv) and
POCl.sub.3 (8.89 g, 57.98 mmol, 10.0 equiv) in 1,4-dioxane (50 mL)
was stirred for 3 h at 110.degree. C. under nitrogen. The resulting
mixture was concentrated under vacuum and the residue was dissolved
in EtOAc (100 mL) and poured into a cooled saturated sodium
bicarbonate and extracted with 3.times.80 mL of ethyl acetate. The
organic layers were combined, washed with brine, dried over sodium
sulfate and concentrated in vacuo. The residue was applied onto a
silica gel column with ethyl acetate/petroleum ether (1:1) to yield
206.4 (1.5 g, 75%) as a white solid.
[1610] Synthesis of Compound 206.5.
[1611] Sodium hydride (60%, 416 mg, 17.33 mmol, 6.66 equiv) was
treated with trans-4-(morpholin-4-yl)cyclohexan-1-ol (577 mg, 3.11
mmol, 1.20 equiv) in distilled THF (10 mL) at room temperature for
40 min under nitrogen. 206.4 (900 mg, 2.60 mmol, 1.00 equiv) was
added and the resulting solution was stirred for 4 h at 70.degree.
C. and cooled and quenched by the addition of NH.sub.4Cl (sat.) and
extracted with 3.times.50 mL of ethyl acetate. The organic layers
were combined, washed with brine, dried over sodium sulfate and
concentrated in vacuo. The residue was applied onto a silica gel
column with dichloromethane/methanol (15:1) to furnish 206.5 (900
mg, 70%) as colorless oil.
[1612] Synthesis of Compound I-192.
[1613] To a solution of 206.5 (200 mg, 0.40 mmol, 1.00 equiv) in 10
mL of DCM was added hydrochloric acid (12 M, 1 mL) followed by
stirring for 8 h at 25.degree. C. The pH value of the solution was
adjusted to 8 with ammonia and the resulting mixture was
concentrated under vacuum. The crude product (100 mg) was purified
by preparative HPLC under the following conditions (Waters):
Column: SunFire Prep C18 19*150 mm 5 m; mobile phase: water with
0.05% NH.sub.4HCO.sub.3 and CH.sub.3CN (50% CH.sub.3CN up to 85% in
10 min); flow rate: 20 mL/min; UV detection at 254 nm. This
resulted in Compound I-192 (7.6 mg, 5%) as a yellow solid. MS (ES):
m/z 361 (M+H).sup.+. .sup.1H NMR (400 MHz, CD.sub.3OD): .delta.
8.58 (s, 1H), 5.31-5.21 (m, 1H), 4.45-4.42 (m, 4H), 3.77-3.74 (m,
4H), 2.72-2.70 (m, 4H), 2.48-2.33 (m, 3H), 2.13-2.10 (m, 2H),
1.67-1.50 (m, 4H).
Example 207
Synthesis of 4-N-[12,
12-dimethyl-11-oxa-8-thia-4,6-diazatricyclo[7.4.0.0[2,7]]trideca-1(9),2(7-
),3,5-tetraen-3-yl]-1-N, 1-N-dimethylcyclohexane-1,4-diamine
(I-194)
##STR00588##
[1615] Synthesis of Compound 207.2.
[1616] To a solution of 2,2-dimethyloxane (2.5 g, 19.5 mmol, 1.00
equiv), ethyl 2-cyanoacetate (2.43 g, 21.45 mmol, 1.1 equiv) and
morpholine (2.55 g, 29.25 mmol, 1.5 equiv) in 80 mL of ethanol was
added S (0.69 g, 21.45 mmol, 1.1 equiv) at room temperature. The
resulting mixture was stirred overnight at 50.degree. C. in an oil
bath under nitrogen. After completion, the resulting mixture was
concentrated under vacuum and the residue was diluted with water
and extracted with 3.times.80 mL of ethyl acetate. The organic
layers were combined, washed with brine, dried over sodium sulfate
and concentrated under vacuum. The residue was applied onto a
silica gel column with ethyl acetate/petroleum ether (1:5) to give
the desired 207.2 (4.5 g, 90%) as a light yellow solid.
[1617] Synthesis of Compound 207.3.
[1618] Into a 50-mL round-bottom flask was placed 207.2 (2.2 g,
8.62 mmol, 1.00 equiv) and formamidine acetate (8.6 g, 82.69 mmol,
9.60 equiv) in 20 mL of formamide at room temperature. The
resulting solution was stirred for 3 h at 140.degree. C. in an oil
bath under nitrogen. The resulting solution was quenched with water
and extracted with ethyl acetate. The organic layers were washed
with brine, dried over sodium sulfate and concentrated in vacuo to
give 1.8 g (78%) of 207.3 as a white solid.
[1619] Synthesis of Compound 207.4.
[1620] 207.3 (1.8 g, 7.62 mmol, 1.00 equiv) in POCl.sub.3 (20 mL)
was stirred for 2 h at 110.degree. C. in an oil bath under
nitrogen. After completion, the reaction mixture was concentrated
in vacuo and the residue was diluted with EtOAc and poured into 100
g of water/ice. The solution was neutralized with saturated sodium
bicarbonate and extracted with 2.times.80 mL of ethyl acetate. The
combined organic layers were dried over sodium sulfate and
concentrated under vacuum. Purification by chromatography on silica
gel column with EtOAc/PE (1:30 to 1:10) to afford the 1.3 g (67%)
of 207.4 as a light yellow solid.
[1621] Synthesis of Compound I-194.
[1622] A mixture of 207.4 (196.8 mg, 0.77 mmol, 1.00 equiv),
potassium carbonate (533 mg, 5.04 equiv) and 1-N,
1-N-dimethylcyclohexane-1,4-diamine dihydrochloride (423.6 mg, 1.97
mmol, 2.57 equiv) in CH.sub.3CN (15 mL) was heated overnight at
70.degree. C. under nitrogen. The resulting mixture was
concentrated under vacuum and the residue was diluted with water
and extracted with 4.times.40 mL of DCM. The combined organic
layers were dried over sodium sulfate and concentrated under
vacuum. The residue was applied onto a silica gel column with
dichloromethane/methanol (15:1) to afford the desired I-194 (138.7
mg, 50%) as an off-white solid. MS (ES): m/z 361 (M+H).sup.+.
.sup.1H-NMR (300 MHz, CD.sub.3OD): .delta. 8.26 (1H, s), 4.83 (2H,
t), 2.96 (2H, s), 2.65-2.55 (1H, m), 2.40 (6H, s), 2.25-2.16 (2H,
m), 2.09-1.98 (2H, m), 1.55-1.45 (4H, m), 1.36 (6H, s).
Example 208
Synthesis of
12,12-dimethyl-3-[[4-(morpholin-4-yl)cyclohexyl]oxy]-11-oxa-8-thia-4,6-di-
azatricyclo[7.4.0.0[2,7]]trideca-1(9),2(7),3,5-tetraene (I-193)
##STR00589##
[1624] Sodium hydride (118.1 mg, 2.95 mmol, 5.01 equiv, 60%) was
treated with trans-4-(morpholin-4-yl)cyclohexan-1-ol (218.7 mg,
1.18 mmol, 2.00 equiv) in 10 mL of distilled THF for 30 min under
nitrogen. 207.4 (150.2 mg, 0.59 mmol, 1.00 equiv) was added and the
resulting solution was stirred for 3 h at 55.degree. C. After
cooled down to rt, the reaction was then quenched by the addition
of NH.sub.4Cl (aq.) and extracted with 3.times.60 mL of DCM. The
combined organic layers were dried over sodium sulfate and
concentrated under vacuum. The residue was applied onto a silica
gel column with dichloromethane/methanol (20:1) to provide the
desired 158.1 mg (66%) of I-193 as an off-white solid. MS (ES): m/z
404 (M+H).sup.+. .sup.1H-NMR (300 MHz, CD.sub.3OD): .delta. 8.49
(1H, s), 5.35-5.15 (1H, m), 3.72 (4H, t), 2.93 (2H, s), 2.63 (4H,
t), 2.45-2.25 (3H, m), 2.15-2.02 (2H, m), 1.69-1.40 (4H, m), 1.34
(6H, s).
Example 209
Synthesis of
4-methyl-12-[[4-(morpholin-4-yl)cyclohexyl]oxy]-7-thia-4,9,11-triazatricy-
clo[6.4.0.0[2,6]]dodeca-1(12),2(6),8, 10-tetraene (I-196)
##STR00590##
[1626] A solution of I-192 (Example 207; 200 mg, 0.55 mmol, 1.00
equiv), HCHO (37%, 0.2 mL) and NaBH.sub.3CN (104.9 mg, 1.67 mmol,
3.01 equiv) in methanol (5 mL) was stirred for 2 h at 25.degree. C.
The crude product (100 mg) was purified by preparative HPLC under
the following conditions (Waters): Column: SunFire Prep C18 19*150
mm 5 .mu.m; mobile phase: water with 0.05 NH.sub.4HCO.sub.3 and
CH.sub.3CN (50% CH.sub.3CN up to 85% in 10 min); flow rate: 20
mL/min; UV detection at 254 nm. This resulted in I-196 (4.7 mg, 2%)
as a white solid. MS (ES): m/z 375 (M+H).sup.+. .sup.1H NMR (400
MHz, d.sub.6-DMSO): .delta. 8.53 (s, 1H), 5.30-5.23 (m, 1H),
4.15-4.12 (m, 4H), 3.94-3.72 (m, 4H), 2.65 (s, 3H), 2.64-2.63 (m,
4H), 2.41-2.34 (m, 3H), 2.11-2.08 (m, 2H), 1.65-1.53 (m, 4H).
Example 210
Synthesis of
1-(12-[[4-(morpholin-4-yl)cyclohexyl]oxy]-7-thia-4,9,11-triazatricyclo[6.-
4.0.0[2,6]]dodeca-1(12),2(6),8, 10-tetraen-4-yl)ethan-1-one
(I-198)
##STR00591##
[1628] A solution of I-192 (Example 207; 150 mg, 0.42 mmol, 1.00
equiv), TEA (84.3 mg, 0.83 mmol, 2.00 equiv) and acetyl chloride
(65 mg, 0.83 mmol, 1.99 equiv) in dichloromethane (5 mL) was
stirred for 0.5 h room temperature. The resulting mixture was
concentrated under vacuum. The crude product (100 mg) was purified
by preparative HPLC under the following conditions (Waters):
Column: Xbridge Prep C18 5 .mu.m, 19*150 mm; mobile phase: water
with 0.05% NH.sub.4HCO.sub.3 and CH.sub.3CN (10.0% CH.sub.3CN up to
30.0% in 10 min, up to 100.0% in 5 min, down to 10.0% in 1 min);
flow rate: 20 mL/min; UV detection at 254 nm. This resulted in
I-198 (28.8 mg, 17%) as a white solid. MS (ES): m/z 403
(M+H).sup.+. .sup.1H NMR (300 MHz, CD.sub.3OD): .delta. 8.56 (s,
1H), 5.32-5.24 (m, 1H), 5.00-4.92 (m, 2H), 4.85-4.80 (m, 2H),
3.74-2.71 (m, 4H), 2.65-2.62 (m, 4H), 2.41-2.07 (m, 8H), 1.75-1.45
(m, 4H).
Example 211
Synthesis of methyl
12-[[4-(morpholin-4-yl)cyclohexyl]oxy]-7-thia-4,9,
11-triazatricyclo[6.4.0.0[2,6]]dodeca-1(12),2(6),8,
10-tetraene-4-carboxylate (I-199)
##STR00592##
[1630] Compound I-199 was prepared from I-192 in a manner analogous
to the synthesis of Compound I-198. Isolated a white oil in 4%
yield. MS (ES): m/z 419 (M+H).sup.+. .sup.1H NMR (300 MHz,
CDCl.sub.3): .delta. 8.56 (s, 1H), 5.12-5.23 (m, 1H), 4.82-4.77 (m,
4H), 3.82-3.49 (m, 7H), 2.60 (s, 4H), 2.28-2.01 (m, 5H), 1.61-1.36
(m, 4H).
Example 212
Synthesis of
N-methyl-12-[[4-(morpholin-4-yl)cyclohexyl]oxy]-7-thia-4,9,
11-triazatricyclo[6.4.0.0[2,6]]dodeca-1(8),9,
11-triene-4-carboxamide (I-200)
##STR00593##
[1632] A solution of I-192 (100 mg, 0.28 mmol, 1.00 equiv) in 3 mL
of DCM was added to a solution of triphosgene (40.8 mg, 0.14 mmol,
0.50 equiv) in DCM (7 mL) dropwise under nitrogen at 0.degree. C.
After 0.5 h, TEA (84 mg, 0.83 mmol, 3.01 equiv) and
CH.sub.3NH.sub.2-THF (0.5 mL) were added and the resulting solution
was stirred for 1.5 h at room temperature. The resulting mixture
was concentrated under vacuum. The crude product (100 mg) was
purified by preparative HPLC under the following conditions
(Waters): Column: SunFire Prep C18, 19*150 mm 5 .mu.m; mobile
phase: water with 0.05% NH.sub.4HCO.sub.3 and CH.sub.3CN (10.0%
CH.sub.3CN up to 30.0% in 10 min, up to 100.0% in 2 min, down to
10.0% in 1 min); flow rate: 20 mL/min; UV detection at 254 nm. This
resulted in I-200 (21 mg, 18%) as a white solid. MS (ES): m/z 418
(M+H).sup.+. .sup.1H NMR (300 MHz, CDCl.sub.3): .delta. 8.56 (s,
1H), 5.32-5.24 (m, 1H), 4.77 (d, J=6.3 Hz, 4H), 4.32-4.21 (m, 1H),
3.93-3.79 (m, 4H), 2.93 (d, J=4.5 Hz, 3H), 2.79-2.50 (m, 4H),
2.40-1.89 (m, 5H), 1.71-1.58 (m, 2H).
Example 213
Synthesis of
3-[[4-(morpholin-4-yl)cyclohexyl]amino]-8-thia-4,6-diazatricyclo[7.4.0.0[-
2,7]]trideca-1(9),2,4,6-tetraene-12-carboxamide (I-203)
##STR00594## ##STR00595##
[1634] Synthesis of Compound 213.5.
[1635] Compound 213.5 was prepared from methyl
3-oxocyclohexane-1-carboxylate in a manner analogous to the
synthesis of 207.4. Isolated 1.38 g of a white solid in 8% overall
yield. MS (ES): m/z 283 and 285 (M+H).sup.+.
[1636] Synthesis of Compound 213.6.
[1637] Into a 50-mL round-bottom flask containing a mixture of
213.5 (200 mg, 0.71 mmol, 1.00 equiv),
trans-4-(morpholin-4-yl)cyclohexan-1-amine dihydricholoride (269
mg, 1.05 mmol, 1.49 equiv), potassium carbonate (290 mg, 2.10 mmol,
2.97 equiv) in CH.sub.3CN (20 mL) was stirred for 14 h at
80.degree. C. under nitrogen. The reaction was then quenched by the
addition of 20 mL of water and extracted with 3.times.80 mL of DCM.
The combined organic layers were washed with brine, dried over
anhydrous sodium sulfate and concentrated under vacuum. The residue
was applied onto a silica gel column with dichloromethane/methanol
(15:1) to give 250 mg (82%) of 213.6 as a white solid.
[1638] Synthesis of Compound I-203.
[1639] NH.sub.3 (g) was introduced to methanol (35 mL) at 0.degree.
C. for 1 hr. Then 213.6 (250 mg, 0.58 mmol, 1.00 equiv) was added
and the resulting solution was stirred for 14 h at room
temperature. The resulting mixture was concentrated under vacuum
and the residue was applied onto a silica gel column with
dichloromethane/methanol (8:1) to give the desired Compound I-203
(170 mg, 70%) as a white solid. MS (ES): m/z 416 (M+H).sup.+.
.sup.1H-NMR (300 MHz, CD.sub.3OD): .delta. 8.25 (s, 1H), 4.15 (m,
1H), 3.75 (m, 4H), 3.15 (m, 2H), 2.92-2.61 (m, 7H), 2.39-1.82 (m,
7H), 1.62-1.47 (m, 4H).
Example 214
2-(12-[[4-(dimethylamino)cyclohexyl]oxy]-10-(phenylamino)-7-thia-9,
11-diazatricyclo[6.4.0.0 [2,6]]dodeca-1(12),2(6),8,
10-tetraen-3-yl)acetamide (I-204)
##STR00596##
[1641] Synthesis of Compound 214.1.
[1642] NaH (60% dispersion in mineral oil, 543.4 mg, 22.64 mmol,
5.00 equiv) was treated with trans-4-(dimethylamino)cyclohexan-1-ol
(428 mg, 2.99 mmol, 1.10 equiv) in freshly distilled THF (10 mL) at
room temperature for 1 h under nitrogen. To a solution of 204.5
(900 mg, 2.72 mmol, 1.00 equiv) in 10 mL of THF was added via
syringe and the resulting solution was stirred for 3 h at
60.degree. C. After completion of the reaction, the reaction was
cooled to room temperature and quenched with saturated NH.sub.4Cl
and extracted with 3.times.100 mL of DCM. The organic layers were
washed with brine, dried over anhydrous sodium sulfate and
concentrated under vacuum. The residue was applied onto a silica
gel column with dichloromethane/methanol (50:1 to 30:1) to give the
desired 214.1 (0.55 g, 46%) as a light yellow oil.
[1643] Synthesis of Compound 214.2.
[1644] To a 50 mL of dry round-bottom flask containing a solution
of 214.1 (270 mg, 0.62 mmol, 1.00 equiv) in 15 mL of dioxane was
added Pd.sub.2dba.sub.3 (31.9 mg, 0.03 mmol, 0.05 equiv), Xantphos
(35.6 mg, 0.06 mmol, 0.10 equiv), t-BuONa (142.9 mg, 1.49 mmol,
2.41 equiv) and aniline (142.9 mg, 1.54 mmol, 2.49 equiv)
sequentially at room temperature. Then the reaction mixture was
degassed three times with nitrogen and stirred for 4 h at
100.degree. C. The solids were filtered out by filtration and the
filtrate was neutralized with 1 M hydrochloric acid and extracted
with 3.times.50 mL of CHCl.sub.3/iso-propanol (3:1). The organic
layers were dried over sodium sulfate and concentrated under vacuum
to yield 214.2 (190 mg, crude) as a white solid.
[1645] Synthesis of Compound I-204.
[1646] Into a 50-mL round-bottom flask was placed a mixture of
214.2 (104 mg), NH.sub.4Cl (53 mg, 0.99 mmol, 4.58 equiv), HOBt (45
mg, 0.33 mmol, 1.54 equiv), EDCI (87 mg, 0.45 mmol, 2.10 equiv) and
4-dimethylaminopyridine (29 mg, 0.24 mmol, 1.10 equiv) in DMF (6
mL) under nitrogen. The resulting solution was stirred overnight at
room temperature. The reaction was quenched with water and
extracted with DCM and concentrated in vacuo. The residue was
purified by preparative HPLC under the following conditions
(Waters): Column: XBridge Shield RP18 OBD 5 m, 19*150 mm; mobile
phase: water with 0.01% NH.sub.4HCO.sub.3 and CH.sub.3CN (Gradient
B % 20%-24%, run time 10 min); flow rate: 15 ml/min; UV detection
at 254 nm. This resulted in 4.6 mg (5%) of I-204 as a solid. MS
(ES): m/z 466 (M+H).sup.+. .sup.1H-NMR (300 MHz,
CD.sub.3OD+CDCl.sub.3): .delta. 7.65 (2H, d), 7.43-7.31 (2H, m),
7.15-6.99 (1H, m), 5.25-5.05 (1H, m), 3.79-3.68 (1H, m), 3.08-2.82
(3H, m), 2.79-2.65 (1H, m), 2.61-2.31 (9H, m), 2.28-2.02 (4H, m),
1.75-1.39 (4H, m).
Example 215
Synthesis of
[(12S)-3-[[4-(morpholin-4-yl)cyclohexyl]amino]-8-thia-4,6-diazatricyclo[7-
.4.0.0[2,7]]trideca-2,4,6-trien-12-yl]methanol (I-210)
##STR00597##
[1648] A mixture of 202.7 (50 mg, 0.20 mmol, 1.00 equiv),
trans-4-(morpholin-4-yl)cyclohexan-1-amine dihydrochloride (109 mg,
0.59 mmol, 3.00 equiv), DIEA (51 mg, 0.39 mmol, 2.01 equiv) and
potassium carbonate (136 mg, 0.98 mmol, 5.01 equiv) in 25 mL of
CH.sub.3CN (25 mL) was stirred for 60 h at 80.degree. C. under
nitrogen. The reaction was then quenched by the addition of 30 mL
of water and extracted with 3.times.60 mL of
chloroform/iso-propanol (3:1). The combined organic layers were
concentrated under vacuum. The crude product (80 mg) was purified
by preparative HPLC under the following conditions (Waters):
Column: SunFire Prep C18, 19*150 mm 5 .mu.m; mobile phase: water
with 0.05% NH.sub.4HCO.sub.3 and CH.sub.3CN (10.0% CH.sub.3CN up to
30.0% in 9 min, up to 100.0% in 2 min, down to 10.0% in 1 min);
flow rate: 20 mL/min; UV detection at 220/254 nm. This resulted in
20.1 mg (25%) of I-201 as a white solid. MS (ES): m/z 403
(M+H).sup.+. .sup.1H NMR (300 MHz, CDCl.sub.3): .delta. 8.35 (1H,
s), 5.13-5.11 (1H, d),4.12-4.10 (1H, m), 3.73-3.68 (6H, s),
3.06-3.00 (1H, d), 2.87 (2H, s), 2.70-2.58 (5H, t), 2.30-2.27 (3H,
d), 2.10-1.96 (4H, m), 1.67-1.25 (5H, m).
Example 216
Synthesis of
[(12R)-3-[[4-(morpholin-4-yl)cyclohexyl]amino]-8-thia-4,6-diazatricyclo[7-
.4.0.0[2,7]]trideca-1(9),2,4,6-tetraen-12-yl]methanol (I-211)
##STR00598##
[1650] Compound I-211 was prepared from 202.8 in a manner analogous
to the synthesis of Compound I-210 from 202.7. Isolated 19.3 mg of
a white solid in 24% yield. MS (ES): m/z 403 (M+H).sup.+. .sup.1H
NMR (400 MHz, CDCl.sub.3): .delta. 8.38 (1H, s), 5.15-5.14 (1H,
d),4.17-4.14 (1H, m), 3.85-3.81 (4H, s), 3.79-3.71 (2H, m),
3.09-3.04 (1H, m), 2.90-2.86 (2H, s), 2.75-2.69 (5H, m), 2.65-2.34
(1H, s), 2.33-2.30 (2H, m), 2.14-2.07 (4H, m), 1.66-1.62 (5H,
m).
Example 217
Synthesis of
3-[(3R)-12-[[4-(morpholin-4-yl)cyclohexyl]oxy]-7-thia-9,
11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,
11-tetraen-3-yl]-2-oxopropanamide (I-213)
##STR00599##
[1652] Into a 500-mL round-bottom flask was placed a solution of
I-93 (8.5 g, 19.03 mmol, 1.00 equiv) in DMSO (300 mL) followed by
EDC (36.48 g, 10.00 equiv). This was followed by the addition of
2,2-dichloroacetic acid (9.8 g, 76.00 mmol, 4.00 equiv) dropwise
with stirring at 0.degree. C. The resulting solution was stirred
for 3 h at room temperature. The reaction was then quenched by the
addition of 120 mL of sodium bicarbonate (sat., aq.). The resulting
solution was extracted with 4.times.200 mL of ethyl acetate and the
organic layers combined. The resulting mixture was washed with
5.times.300 mL of brine. The mixture was dried over anhydrous
sodium sulfate and concentrated under vacuum. The residue was
applied onto a silica gel column with dichloromethane/methanol
(30:1) to give 7.8 g (92%) of I-213 as a white solid. MS (ES): m/z
445 (M+H).sup.+. .sup.1H NMR (300 MHz, CDCl.sub.3): .delta. 8.50
(1H, s), 6.82 (1H, s), 5.44 (1H, s), 5.23-5.20 (1H, m), 3.81-3.62
(6H, m), 3.20-2.93 (3H, m), 2.86-2.76 (1H, m), 2.60 (4H, s),
2.30-2.28 (3H, m), 2.15-1.98 (3H, m), 1.55-1.42 (4H, m).
Example 218
Synthesis of
2-[(3R)-12-[[4-(piperidin-1-yl)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo[-
6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]acetamide
(I-214)
##STR00600## ##STR00601##
[1654] Synthesis of Compound 218.1.
[1655] Sodium hydride (60%, 140 mg, 3.50 mmol, 5.00 equiv) was
treated with trans-4-(piperidin-1-yl)cyclohexan-1-ol (258 mg, 1.41
mmol, 2.00 equiv) in distilled tetrahydrofuran (10 mL) under
nitrogen for 1 h. Then a solution of 65.1 (250 mg, 0.70 mmol, 1.00
equiv) in tetrahydrofuran (5 mL) was added and stirred for 2 h at
room temperature. The reaction was then quenched by the addition of
20 mL of water and extracted with 3.times.100 mL of ethyl acetate.
The combined organic layers were dried over anhydrous sodium
sulfate and concentrated under vacuum. The residue was applied onto
a silica gel column with dichloromethane/methanol (100:1) to give
300 mg (85%) of 218.1 as a white solid.
[1656] Synthesis of Compound 218.2.
[1657] Into a 100-mL round-bottom flask was placed a solution of
219.1 (300 mg, 0.60 mmol, 1.00 equiv) in methanol (20 mL) followed
by cooling to 0.degree. C. Then 12 M hydrochloric acid (1 mL) was
added and the resulting solution was stirred for 2 h at room
temperature. The resulting mixture was concentrated under vacuum,
diluted with DCM, neutralized with saturated sodium bicarbonate,
washed with brine. The organic phase was dried over sodium sulfate
and concentrated in vacuo to give the desired 218.2 (250 mg, crude)
as a yellow oil.
[1658] Synthesis of Compound 218.3.
[1659] To a solution of 218.2 (170 mg, 0.44 mmol, 1.00 equiv) in
DCM (20 mL) was added methanesulfonyl chloride (94 mg, 0.82 mmol,
2.00 equiv) and TEA (127 mg, 1.26 mmol, 3.00 equiv) at 0.degree. C.
The resulting solution was stirred for 2 h at room temperature and
diluted with 100 mL of DCM, washed with brine, dried over anhydrous
sodium sulfate and concentrated under vacuum to afford 250 mg
(crude) of 218.3 as a yellow oil.
[1660] Synthesis of Compound 218.4.
[1661] Into a 25-mL round-bottom flask containing a solution of
218.3 (200 mg, 0.43 mmol, 1.00 equiv) in DMSO (10 mL) was added
sodiumcarbonitrile (105 mg, 2.14 mmol, 5.00 equiv). The resulting
solution was stirred for 2 h at 100.degree. C. in an oil bath.
After cooling, the reaction was then quenched by the addition of 50
mL of water and extracted with 3.times.100 mL of dichloromethane,
washed with brine, dried over anhydrous sodium sulfate and
concentrated under vacuum to provide 120 mg (crude) of 218.4 as a
yellow oil.
[1662] Synthesis of Compound I-214.
[1663] To a solution of 218.4 (120 mg, 0.30 mmol, 1.00 equiv) in
MeOH (5 mL) was added LiOH.H.sub.2O (25.2 mg, 0.60 mmol, 2.00
equiv) followed by cooling in an ice/water bath. Then hydrogen
peroxide (1 mL) was added slowly and the resulting solution was
stirred for 1 h at this temperature. The reaction was then quenched
with saturated NaHSO.sub.3 and extracted with 3.times.50 mL of
dichloromethane. The combined organic layers were dried over
anhydrous sodium sulfate and concentrated under vacuum. The crude
product (100 mg) was purified by preparative HPLC under the
following conditions ((Waters): Column: SunFire Prep C18, 19*150 mm
5 m; mobile phase: water with 0.05% NH.sub.4HCO.sub.3 and
CH.sub.3CN (40% CH.sub.3CN up to 70% in 10 min); flow rate: 20
mL/min; UV detection at 254 nm. This resulted in 22 mg (18%) of
I-214 as a white solid. MS (ES): m/z 415 (M+H).sup.+. .sup.1H NMR
(400 MHz, CD.sub.3OD): .delta. 8.49 (s, 1H), 5.29-5.24 (m, 1H),
3.81 (m, 1H), 3.33-3.25 (m, 1H), 3.03-2.98 (m, 2H), 2.85-2.68 (m,
5H), 2.53 (m, 1H), 2.33-2.25 (m, 4H), 2.09-2.06 (m, 2H), 1.68-1.31
(m, 10OH).
Example 219
Synthesis of
[(12R)-3-[[4-(morpholin-4-yl)cyclohexyl]oxy]-8-thia-4,6-diazatricyclo[7.4-
.0.0[2,7]]trideca-1(9),2(7),3,5-tetraen-12-yl]methanol (I-215)
##STR00602##
[1665] Synthesis of Compound 219.1.
[1666] To a solution of 202.8 (100 mg, 0.39 mmol, 1.00 equiv) in
dichloromethane (15 mL) was added DIEA (0.2 mL, 3.00 equiv) and
SEMCl (131 mg, 2.00 equiv) at 0.degree. C. under nitrogen. The
resulting solution was stirred for 2 h at room temperature and then
concentrated under vacuum. The residue was diluted with water and
extracted with EtOAc, washed with 1M aqueous HCl and brine, dried
over sodium sulfate and evaporated under reduced pressure. The
residue was applied onto a silica gel column with ethyl
acetate/petroleum ether (1:20) to give 100 mg (66%) of 219.1 as a
white solid.
[1667] Synthesis of Compound 219.2.
[1668] Sodium hydride (60%, 52 mg, 1.30 mmol, 5.00 equiv) was
treated with trans-4-(morpholin-4-yl)cyclohexan-1-ol (96 mg, 0.52
mmol, 2.00 equiv) in 3 mL of distilled THF at 0.degree. C. for 1 h
under nitrogen. A solution of 219.1 (100 mg, 0.26 mmol, 1.00 equiv)
in tetrahydrofuran (2 mL) was added at 45.degree. C. via syringe.
The resulting solution was stirred for 4 h at this temperature.
After cooling, the reaction was then quenched by the addition of 10
mL of water. The pH value of the solution was adjusted to 6 with 1
M aqueous hydrochloric acid followed by extraction with 3.times.50
mL of dichloromethane. The organic layers were combined and
concentrated under vacuum to give 90 mg (crude) of 219.2 as a white
solid.
[1669] Synthesis of Compound I-215.
[1670] To a solution of 219.2 (90 mg, 0.17 mmol, 1.00 equiv) in
methanol (5 mL) was added 12 M hydrochloric acid (0.2 mL) at
0.degree. C. The resulting solution was stirred for 2 h at room
temperature. The resulting solution was concentrated in vacuo and
the residue was diluted with DCM, washed with saturated aqueous
sodium bicarbonate and brine, dried over sodium sulfate and
evaporated under reduced pressure. Purification by chromatography
on silica gel with DCM/MeOH (1:50 to 1:30) yielded 19.7 mg of I-215
as a white solid. MS (ES): m/z 404 (M+H).sup.+. .sup.1H-NMR (400
MHz, CDCl.sub.3): .delta. 8.50 (s, 1H), 5.29-5.18 (m, 1H),
3.95-3.64 (m, 6H), 3.20 (dd, 1H), 2.98-2.80 (m, 2H), 2.78-2.45 (m,
5H), 2.38-2.25 (m, 3H), 2.18-1.95 (m, 4H), 1.45-1.25 (m, 5H).
Example 220
Synthesis of
[(12S)-3-[[4-(morpholin-4-yl)cyclohexyl]oxy]-8-thia-4,6-diazatricyclo[7.4-
.0.0[2,7]]trideca-1(9),2(7),3,5-tetraen-12-yl]methanol (I-216)
##STR00603##
[1672] Compound I-216 was prepared from 202.7 in a manner analogous
to the synthesis of Compound I-215 from 202.8. Isolated 24.3 mg of
a white solid in 15% overall yield from 202.7. MS (ES): m/z 404
(M+H).sup.+. .sup.1H-NMR (300 MHz, CDCl.sub.3): .delta. 8.49 (s,
1H), 5.30-5.15 (m, 1H), 3.78-3.64 (m, 6H), 3.18 (dd, 1H), 2.98-2.78
(m, 2H), 2.75-2.50 (m, 5H), 2.48-2.20 (m, 3H), 2.16-1.95 (m, 4H),
1.92-1.62 (m, 5H).
Example 221
Synthesis of
2-(3-[[4-(dimethylamino)cyclohexyl]oxy]-11-oxa-8-thia-4,6-diazatricyclo[7-
.4.0.0[2,7]]trideca-1(9),2(7),3,5-tetraen-12-yl)acetamide
(I-221)
##STR00604## ##STR00605##
[1674] Synthesis of Compound 221.2.
[1675] To a solution of ethyl prop-2-ynoate (6.2 g, 63.20 mmol,
1.07 equiv) in 80 mL of dry ether was added 4-methylmorpholine (6.3
g, 62.29 mmol, 1.06 equiv), pent-4-en-1-ol (4.25 g, 58.94 mmol,
1.00 equiv) successively. The resulting solution was stirred
overnight at room temperature under nitrogen. The resulting mixture
was poured into 150 mL of 0.5 M aqueous HOAc and extracted with
2.times.150 mL of ethyl acetate. The combined organic layers were
dried over sodium sulfate and concentrated under vacuum. The
residue was applied onto a silica gel column with ethyl
acetate/petroleum ether (1:30 to 1:10) to afford 9.6 g (96%) of
221.2 as a colorless oil.
[1676] Synthesis of Compound 221.3.
[1677] To a solution of 221.2 (9.8 g, 57.58 mmol, 1.00 equiv) in
150 mL of dry DCM at 0.degree. C. was added TFA (25 mL) dropwise
over 30 min. The resulting solution was stirred for 2 h at
0.degree. C. After completion, the reaction mixture was
concentrated in vacuo and diluted with 200 mL of EtOAc, washed with
a cold 1 M NaHCO.sub.3 solution. The organic layer was washed with
brine, dried over anhydrous sodium sulfate and concentrated under
vacuum to afford 14.1 g (crude) of 221.3 as a yellow oil which was
used for the next step without further purification.
[1678] Synthesis of Compound 221.4.
[1679] To a solution of 221.3 (14.1 g, crude) in 80 mL of methanol
(80 mL) was added potassium carbonate (0.3M, 200 mL) and the
resulting solution was stirred for 30 min at 25.degree. C. The pH
value of the solution was adjusted to 7 with AcOH. The resulting
solution was extracted with 3.times.100 mL of dichloromethane. The
organic layers were washed with brine, dried over anhydrous
magnesium sulfate and concentrated under vacuum to provide 8.2 g
(crude) of 221.4 as a colorless viscous liquid.
[1680] Synthesis of Compound 221.5.
[1681] To a solution of 221.4 (8.2 g, 43.57 mmol, 1.00 equiv) in
acetone (160 mL) at 0.degree. C. was added dropwise Jones reagent
(20 mL) and the resulting mixture was stirred for approx. 10 min.
The reaction was then quenched by the addition of saturated aqueous
NaHSO.sub.3 and extracted with 2.times.100 mL of ethyl acetate. The
combined organic layers were washed with brine, dried over
anhydrous sodium sulfate and concentrated under vacuum to provide
7.2 g (crude) of 221.5 as a light yellow oil.
[1682] Synthesis of Compound 221.6.
[1683] Into a 250-mL round-bottom flask containing a solution of
221.5 (7.2 g, 38.67 mmol, 1.00 equiv) in dry ethanol (85 mL) was
added S (1.2 g, 37.50 mmol, 0.97 equiv), ethyl 2-cyanoacetate (4.8
g, 42.43 mmol, 1.10 equiv) and morpholine (3.4 g, 39.03 mmol, 1.01
equiv) sequentially at room temperature. The resulting solution was
stirred overnight at 50.degree. C. in an oil bath under nitrogen.
The resulting mixture was concentrated under vacuum and the residue
was diluted with 100 mL of water and extracted with 2.times.150 mL
of ethyl acetate. The organic layers were combined, washed with
brine, dried over sodium sulfate and concentrated under vacuum. The
residue was applied onto a silica gel column with ethyl
acetate/petroleum ether (1:9) to give 11.5 g (95%) of 221.6 as a
yellow oil.
[1684] Synthesis of Compound 221.7.
[1685] To a solution of 221.6 (500 mg, 1.60 mmol, 1.00 equiv) in 15
mL of formamide (15 mL) was added formamidine acetate (830 mg, 7.97
mmol, 5.00 equiv) and the resulting mixture was stirred 5 h at
140.degree. C. in an oil bath under nitrogen. After cooling, the
resulting mixture was diluted with water and extracted with
3.times.60 mL of ethyl acetate. The combined organic layers were
washed with brine, dried over sodium sulfate and concentrated under
reduced pressure. The residue was applied onto a silica gel column
with ethyl acetate/petroleum ether (2:1) to give 283 mg (60%) of
221.7 as a white solid.
[1686] Synthesis of Compound 221.8.
[1687] To a solution of 221.7 (1.3 g, 4.42 mmol, 1.00 equiv) in 15
mL of dry 1,4-dioxane was added POCl.sub.3 (5 mL) at room
temperature under nitrogen. The resulting solution was stirred for
1 h at 100.degree. C. in an oil bath. The resulting mixture was
concentrated under vacuum and the residue was diluted with EtOAc
(150 mL), neutralized with saturated aqueous sodium bicarbonate,
washed with brine, dried over sodium sulfate and concentrated under
reduced pressure. The residue was applied onto a silica gel column
with ethyl acetate/petroleum ether (1:10) to provide 1 g (72%) of
221.8 as a white solid.
[1688] Synthesis of Compound 221.9.
[1689] To a solution of 221.8 (500 mg, 1.6 mmol, 1.0 equiv) in a
mixture of THF/water (6/6 mL) was added LiOH.H.sub.2O (202 mg, 4.8
mmol, 3.0 equiv) at 0.degree. C. The resultant solution was stirred
at room temperature for 3 h. The contents of the flask were
transferred to a separatory funnel, made acidic with 1M HCl and
then extracted with ethyl acetate (2.times.100 ml). Combined the
organics and washed 1.times. with brine before drying over sodium
sulfate, filtering and concentrating in vacuo. This afforded 342 mg
(crude) of compound 221.9 as a yellow solid that was used as is in
the next reaction.
[1690] Synthesis of Compound 221.10.
[1691] To a solution of compound 221.9 (100 mg, 0.35 mmol, 1.0
equiv) and trans-4-(dimethylamino)cyclohexanol (60 mg, 0.42 mmol,
1.2 equiv) in 3 mL of freshly distilled THF at 0.degree. C. was
added NaHMDS (2 M in THF, 0.5 mL, 1.05 mmol, 3.0 equiv) via syringe
under nitrogen. The resultant solution was stirred at this
temperature for 30 min and then diluted with water. The resultant
solution was acidified to pH 4-5 with 1M HCl solution and extracted
with CHCl.sub.3/iso-propanol (V/V=3/1), dried over sodium sulfate
and concentrated in vacuo. The residue was purified by
reverse-phase chromatography (water and CH.sub.3CN as eluent) to
give 30 mg (90% purity) of the desired compound 221.10 as a yellow
oil.
[1692] Synthesis of Compound I-221.
[1693] To a solution of 221.10 (25 mg, 0.06 mmol, 1.00 equiv) in
N,N-dimethylformamide (10 mL) was added NH.sub.4Cl (3.8 mg, 0.07
mmol, 1.20 equiv), HATU (27 mg, 0.07 mmol, 1.20 equiv) and DIEA (15
mg, 0.12 mmol, 2.00 equiv) successively at room temperature under
nitrogen. The resulting solution was stirred overnight at ambient
temperature, quenched with water and extracted with 4.times.20 mL
of dichloromethane. The combined organic layers were washed with
brine, dried over anhydrous sodium sulfate and concentrated under
vacuum. The crude product (40 mg) was purified by preparative HPLC
under the following conditions (Waters): Column: SunFire Prep C18,
19*150 mm 5 m; mobile phase: water with 0.05% NH.sub.4HCO.sub.3 and
CH.sub.3CN (10.0% CH.sub.3CN up to 36.0% in 10 min, up to 100.0% in
2 min, down to 10.0% in 1 min); flow rate: 20 mL/min; UV detection
at 220/254 nm. This resulted in 9.6 mg (38%) of I-221 as a white
solid. MS (ES): m/z 391 (M+H).sup.+. .sup.1H NMR (300 MHz,
CD.sub.3OD): .delta. 8.38 (1H, s), 5.17-5.10 (1H, m), 4.86-4.78
(2H, m), 4.08-4.02 (1H, m), 3.21 (1H, dd), 2.72-2.62 (1H, m),
2.57-2.48 (2H, m), 2.39-2.30 (1H, m), 2.30-2.20 (8H, m), 1.97-1.93
(2H, d), 1.57-1.38 (4H, m).
Example 222
Synthesis of
2-[(3R)-12-[[4-(pyrrolidin-1-yl)cyclohexyl]oxy]-7-thia-9,
11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,
11-tetraen-3-yl]acetamide (I-105)
##STR00606## ##STR00607##
[1695] Synthesis of Compound 222.2.
[1696] Into a 50-mL round-bottom flask purged and maintained with
an inert atmosphere of nitrogen was placed a mixture of
trans-4-aminocyclohexan-1-ol (1.0 g, 8.7 mmol, 1.00 equiv), KI
(1.87 g), potassium carbonate (0.3 g, 2.2 mmol, 0.25 equiv) and
1,4-dibromobutane (1.93 g, 8.9 mmol, 1.03 equiv) in CH.sub.3CN (30
mL). The resulting solution was heated to reflux for 2 hr and
filtered to remove the solids. The filtrate was concentrated in
vacuo and the residue was diluted with water and extracted with
3.times.50 mL of ethyl acetate. The combined organic layers were
dried over sodium sulfate and concentrated under vacuum. The
residue was applied onto a silica gel column with
dichloromethane/methanol (10/1) to give in 1.4 g (95%) of 222.2 as
a yellow solid.
[1697] Synthesis of Compound 222.3.
[1698] Sodium hydride (108 mg, 4.50 mmol, 4.0 equiv, 60% dispersion
in mineral oil) was treated with 222.2 (290 mg, 1.71 mmol, 1.52
equiv) in distilled tetrahydrofuran (10 mL) for 30 min at room
temperature under nitrogen. This was followed by the addition of
65.1 (400 mg, 1.13 mmol, 1.00 equiv) and the resulting solution was
allowed to react, with stirring, for an additional 1 h at
40.degree. C. The reaction was then quenched with saturated aqueous
NH.sub.4Cl and extracted with 4.times.30 mL of ethyl acetate. The
organic layers were combined, dried over sodium sulfate and
concentrated under vacuum. The residue was applied onto a silica
gel column with dichloromethane/methanol (30:1) to give the desired
222.3 (440 mg, 80%) as a yellow oil.
[1699] Synthesis of Compound 222.4.
[1700] To a solution of 222.3 (440 mg, 0.90 mmol, 1.00 equiv) in 10
mL of dichloromethane was added hydrochloric acid (conc., 0.5 mL)
at 0.degree. C. and the resulting solution was stirred for 4 h at
this temperature. The reaction was then quenched by the addition of
15 mL of sodium bicarbonate and extracted with 3.times.50 mL of
trichloromethane/i-PrOH (3:1). The combined organic layers were
dried over sodium sulfate and concentrated under vacuum. The
residue was applied onto a silica gel column with
dichloromethane/methanol (10:1) to give 250 mg (74%) of 222.4 as
yellow oil.
[1701] Synthesis of Compound 222.5.
[1702] Into a 50-mL round-bottom flask, purged and maintained with
an inert atmosphere of argon, was placed a solution of 222.4 (250
mg, 0.67 mmol, 1.00 equiv) in dichloromethane (8 mL) was added MsCl
(152 mg, 1.33 mmol, 1.99 equiv) and triethylamine (230 mg, 2.27
mmol, 3.40 equiv) at 0.degree. C. under nitrogen. The resulting
solution was stirred for 4 h at room temperature and diluted with
water and extracted with 3.times.50 mL of trichloromethane/i-PrOH
(3:1). The organic layers were dried over sodium sulfate and
concentrated under vacuum to give 222.5 (200 mg, crude) as a yellow
solid.
[1703] Synthesis of Compound 222.6.
[1704] To a solution of 222.5 (200 mg, 0.44 mmol, 1.00 equiv) in 5
mL of DMSO was added NaCN (103 mg, 2.10 mmol, 4.85 equiv) and
4-dimethylaminopyridine (10 mg, 0.08 mmol, 0.18 equiv) at room
temperature. The resulting solution was stirred for 5 h at
80.degree. C. After cooling, the reaction was quenched with sodium
bicarbonate (aq.) and extracted with 4.times.50 mL of ethyl acetate
and the organic layers were combined, dried over sodium sulfate and
concentrated under vacuum. 222.6 (160 mg, 94%) was obtained as a
yellow solid.
[1705] Synthesis of Compound I-105.
[1706] To a solution of 222.6 (160 mg, 0.42 mmol, 1.00 equiv) in
methanol (5 mL) was added LiOH.H.sub.2O (49 mg, 1.17 mmol, 2.79
equiv) and H.sub.2O.sub.2 (30%, 0.4 mL) at 0.degree. C. The
resulting solution was stirred for 5 h at this temperature and
quenched with Na.sub.2SO.sub.3 (aq.) and extracted with 3.times.50
mL of ethyl acetate. The organic layers were combined, washed with
brine, dried over sodium sulfate and concentrated under vacuum. The
crude product (150 mg) was purified by preparative HPLC under the
following conditions (Waters): Column: SunFire Prep C18, 19*150 mm
5 .mu.m; mobile phase: water with 0.05% NH.sub.4CO.sub.3 and
CH.sub.3CN (5.0% CH.sub.3CN up to 42.0% in 9 min, up to 95.0% in 2
min, down to 5.0% in 2 min); flow rate: 20 mL/min; UV detection at
254/220 nm. After evaporating the solvents and lyophilizing
overnight, the desired I-105 (116 mg, 69%) was obtained as a white
solid. MS (ES): m/z 401 (M+H).sup.+. .sup.1H-NMR (400 MHz,
CD.sub.3OD): .delta. 8.47 (1H, s), 5.31 (1H, m), 4.80 (1H, m), 3.14
(1H, m), 3.02 (2H, m), 2.70 (5H, m), 2.15-2.33 (7H, m), 1.84 (4H,
s), 1.68 (2H, m), 1.63 (2H, m).
Example 223
Synthesis of propyl
3-[[4-(dimethylamino)cyclohexyl]oxy]-8-thia-4,6,
12-triazatricyclo[7.4.0.0[2,7]]trideca-1(9),2(7),3,5-tetraene-12-carboxyl-
ate (I-184)
##STR00608##
[1708] Compound I-184 was prepared from 178.3 (free base) in a
manner analogous to the synthesis of Compound I-167. Isolated 11 mg
of a white solid in 15% yield. MS (ES): m/z 419 (M+H).sup.+.
.sup.1H NMR (400 MHz, CDCl.sub.3): .delta. 8.55 (1H, br s),
5.30-5.15 (1H, m), 4.84 (2H, s), 4.14 (2H, t), 3.86 (2H, brs), 2.95
(2H, brs), 2.65-2.25 (9H, m), 2.12-2.05 (2H, m), 1.72 (2H, sextet),
1.58-45 (4H, m), 1.03 (3H, t).
Example 224
Synthesis of
2-(3-[[4-(morpholin-4-yl)cyclohexyl]amino]-8-thia-4,6,12-triazatricyclo[7-
.4.0.0[2,7]]trideca-1(9),2(7),3,5-tetraene-12-sulfonyl)ethan-1-ol
(I-185)
##STR00609##
[1710] Synthesis of Compound 224.1.
[1711] To a solution of 225.10 (100 mg, 0.27 mmol, 1.00 equiv) in
10 mL of anhydrous DCM was added methyl 2-(chlorosulfonyl)acetate
(70 mg, 0.405 mmol, 1.50 equiv) at 0.degree. C., followed by
addition of TEA (82 mg, 0.81 mmol, 3.0 equiv) via syringe under
nitrogen. The resulting solution was stirred for 2 h at this
temperature and quenched with water and extracted with DCM, dried
over sodium sulfate and concentrated in vacuo. The residue was
purified with a silica gel column: eluting with DCM/MeOH (50:1 to
30:1), to give the desired compound 224.1 (100 mg, 90% purity) as a
light yellow solid.
[1712] Synthesis of Compound I-185.
[1713] To a solution of 224.1 (50 mg, 0.10 mmol, 1.00 equiv) in 8
mL of ethanol was added NaBH.sub.4 (50 mg, 1.32 mmol, 13.47 equiv)
at 0.degree. C. The resulting solution was stirred for 4 h at room
temperature and quenched by the addition of water and extracted
with DCM and concentrated under vacuum. The crude product (60 mg)
was purified by preparative HPLC under the following conditions
(Waters): Column: SunFire Prep C18, 19*150 mm 5 m; mobile phase:
water with 0.05% NH.sub.4HCO.sub.3 and CH.sub.3CN (15.0% CH.sub.3CN
up to 45.0% in 12 min, up to 100.0% in 2 min, down to 15.0% in 1
min); flow rate: 20 mL/min; UV detection at 220/254 nm. This
resulted in 5.7 mg (12%) of Compound I-185 as a white solid. MS
(ES): m/z 482 (M+H).sup.+. .sup.1H-NMR (400 MHz, DMSO): .delta.
1.23 (m, 4H), 1.82 (m, 2H), 1.97 (m, 2H), 2.08 (m, 1H), 2.50 (m,
4H), 2.95 (s, 2H), 3.44 (m, 2H), 3.58 (m, 6H), 3.79 (t, J=7.6 Hz,
2H), 4.11 (m, 1H), 4.71 (s, 2H), 5.07 (t, J=7.2 Hz, 1H), 5.93 (m,
1H), 8.33 (s, 1H).
Example 225
Synthesis of
12-(ethanesulfonyl)-N-[4-(morpholin-4-yl)cyclohexyl]-8-thia-4,6,
12-triazatricyclo[7.4.0.0[2,7]]trideca-1(9),2(7),3,5-tetraen-3-amine
(I-181)
##STR00610## ##STR00611##
[1715] Synthesis of Compound 225.2.
[1716] A mixture of 4-aminobutanoic acid (10.3 g, 100 mmol, 1.00
equiv) and 4.2 g (1.05 eq) of sodium hydroxide in THF/H.sub.2O
(200/250 mL) was added dropwise benzyl chloroformate (17.1 g, 100
mmol, 1.00 equiv) in THF (100 mL) at 0.degree. C. with the
additional of a solution of sodium hydroxide (4.0 g) in water (150
mL) at the same time. Then the resulting solution was stirred
overnight at room temperature. The pH value of the solution was
adjusted to 5 with 2 M aqueous hydrochloric acid followed by
extraction with ethyl acetate. The organic layers were dried over
anhydrous sodium sulfate and concentrated in vacuo, the residue was
applied onto a silica gel column with ethyl acetate/petroleum ether
(1:1 to 1:0) to provide 19.6 g (83%) of 225.2 as a white solid.
[1717] Synthesis of Compound 225.3.
[1718] A solution of 225.2 (23.7 g, 99.89 mmol, 1.00 equiv),
4-dimethylaminopyridine (13.4 g, 109.68 mmol, 1.11 equiv), DIEA
(25.8 g, 199.69 mmol, 2.01 equiv), EDCI (21.1 g, 110.07 mmol, 1.10
equiv) and methoxy(methyl)amine hydrochloride (10.7 g, 109.74 mmol,
1.10 equiv) in DCM (800 mL) was stirred 48 h at room temperature
under nitrogen. The reaction was quenched with water and extracted
with DCM. The organic layers were washed with 1 M aqueous HCl and
brine and then dried over sodium sulfate. After filtration and
concentration in vacuo, the residue was purified by a silica gel
column with EtOAc/petroleum ether (1:1 to 100% EtOAc) to provide 25
g (89%) of 225.3 as a colorless oil.
[1719] Synthesis of Compound 225.4.
[1720] To a solution of 225.3 (2.8 g, 10.0 mmol, 1.00 equiv) in THF
(150 mL) was added LiAlH.sub.4 (760 mg, 20.0 mmol, 2.00 equiv)
slowly at 0.degree. C. The resulting mixture was stirred for 1.5 h
at 0.degree. C. under nitrogen. The reaction was quenched with
Na.sub.2SO.sub.4.10H.sub.2O and filtered. The solids were washed
with THF (three times) and the filtrates were dried over anhydrous
sodium sulfate. After filtration, the solvent was removed to
provide 2.2 g of 225.4 as a colorless oil which was used directly
in the next step.
[1721] Synthesis of Compound 225.5.
[1722] To a solution of 225.4 (500 mg, 2.26 mmol, 1.00 equiv),
ethyl 2-cyanoacetate (306 mg, 2.71 mmol, 1.20 equiv) and S (87 mg,
2.72 mmol, 1.20 equiv) in ethanol (10 mL) was added Et.sub.2NH (198
mg, 2.71 mmol, 1.20 equiv) at room temperature under nitrogen. The
resulting mixture was stirred overnight at ambient temperature. The
reaction was then quenched by the addition of 20 mL of saturated
aqueous NH.sub.4Cl, followed by extraction with 3.times.80 mL of
ethyl acetate. The combined organic layers were washed with brine,
dried over sodium sulfate and concentrated under vacuum. The
residue was applied onto a silica gel column with ethyl
acetate/petroleum ether (1/5) to give 225.5 (0.3 g, 38%) as a
yellow oil.
[1723] Synthesis of Compound 225.6.
[1724] A solution of 225.5 (5.2 g, 14.92 mmol, 1.00 equiv) and
iminoformamide acetate (5.2 g, 49.95 mmol, 3.35 equiv) in formamide
(200 mL) was stirred for 2 h at 130.degree. C. and then heated to
160.degree. C. for 2 h under nitrogen. After cooling to room
temperature, the reaction was quenched with brine and extracted
with ethyl acetate. The organic layers were washed with brine and
dried over anhydrous sodium sulfate. After filtration and
concentration in vacuo, the residue was purified by a silica gel
column with EtOAc/petroleum ether (1:1 to 100% EA) to afford 2.6 g
(53%) of 225.6 as a white solid.
[1725] Synthesis of Compound 225.7.
[1726] To a mixture of 225.6 (2.0 g, 6.07 mmol, 1.00 equiv) and
paraformaldehyde (2.0 g, 66.67 mmol, 10.98 equiv) in 50 mL of DCE
was added F.sub.3CCOOH (4.0 mL) followed by stirring overnight at
room temperature under nitrogen. After concentration under vacuum,
the residue was applied onto a silica gel column with
EtOAc/petroleum ether (1:1-2:1) to afford 1.7 g (81%) of 225.7 as a
light yellow solid.
[1727] Synthesis of Compound 225.8.
[1728] To a solution of 225.7 (1.02 g, 2.99 mmol, 1.00 equiv) in
dioxane (50 mL) was added POCl.sub.3 (2.3 g, 15.00 mmol, 5.02
equiv) and the resulting mixture was stirred for 3 h at 100.degree.
C. After cooling and concentration in vacuo, the reaction mixture
was quenched with water/ice and the pH value of the solution was
adjusted to 7 with saturated aqueous sodium bicarbonate. After
extraction with ethyl acetate, the organic layer was washed with
brine and dried over anhydrous sodium sulfate. After filtration and
concentration in vacuo, the residue was applied onto a silica gel
column with EtOAc/petroleum ether (1:5-1:3) to provide 660 mg (61%)
of 225.8 as a light yellow solid.
[1729] Synthesis of Compound 225.9.
[1730] A mixture of 225.8 (194 mg, 0.54 mmol, 1.00 equiv),
trans-4-(morpholin-4-yl)cyclohexan-1-amine dihydrochloride (357 mg,
1.39 mmol, 3.00 equiv), potassium carbonate (745.2 mg, 5.39 mmol,
10.00 equiv) and triethylamine (163.7 mg, 1.62 mmol, 3.00 equiv) in
CH.sub.3CN (50 mL) was stirred for 48 h at 80.degree. C. under
nitrogen. After concentration under vacuum, the residue was applied
onto a silica gel column with DCM/MeOH (30:1-15:1) to provide 169.4
mg (62%) of 225.9 as a semi-solid.
[1731] Synthesis of Compound 225.10. A mixture of 225.9 (150 mg,
0.24 mmol, 1.00 equiv) and Pd/C (10%, 60 mg) was stirred for 48 h
at 40.degree. C. under H.sub.2. After completion, the solids were
filtered out and the filtrate was concentrated under vacuum to
provide 100 mg (crude) of 225.10 as a white solid.
[1732] Synthesis of Compound I-181.
[1733] To a solution of 225.10 (100 mg, 0.27 mmol, 1.00 equiv) in
DCE (20 mL) was added TEA (0.4 mL) and ethanesulfonyl chloride (0.2
mL) at 0 OC followed by stirring for 2 h. The reaction was then
quenched by the addition of methanol and then concentrated under
vacuum. The residue was purified by preparative HPLC under the
following conditions: Column: SunFire Prep C18, 19*150 mm 5 m;
mobile phase: water with 0.05% NH.sub.4HCO.sub.3 and CH.sub.3CN (5%
CH.sub.3CN up to 20% in 7 min, up to 25% in 52 min, hold at 25% for
2 min, up to 95% in 2 min, down to 5% in 2 min); flow rate: 20
mL/min; UV detection at 254/220 nm. The product-containing
fractions were collected and evaporated under reduced pressure to
remove the solvents. Overnight lyophilization afforded the desired
I-181 (26.5 mg) as a light yellow solid. LC-MS: (ES, m/z): 466
(M+H).sup.+. .sup.1H-NMR (400 MHz, CD.sub.3OD): .delta. 8.30 (1H,
s), 4.79 (2H, s), 4.21-4.13 (1H, m), 3.75-3.69 (6H, m), 3.26-3.19
(2H, dd), 3.07-3.00 (2H, m), 2.71-2.63 (4H, m), 2.42-2.33 (1H, m),
2.28-2.19 (2H, m), 2.13-2.07 (2H, m), 2.58-2.42 (4H, m), 1.37 (3H,
t).
Example 226
Synthesis of
12-methanesulfonyl-3-[[4-(morpholin-4-yl)cyclohexyl]oxy]-8-thia-4,6,
12-triazatricyclo[7.4.0.0[2,7]]trideca-1(9),2(7),3,5-tetraene
(I-187)
##STR00612##
[1735] Synthesis of Compound 226.1.
[1736] Sodium hydride (60%, 74 mg, 1.85 mmol, 5.00 equiv) was
treated with trans-4-morpholinocyclohexanol (104 mg, 0.56 mmol,
1.50 equiv) in 8 mL of distilled THF for 30 min at room temperature
under nitrogen. Then a solution of 225.8 (133 mg, 0.37 mmol, 1.00
equiv) in 5 mL of THF was added via syringe and the resulting
solution was stirred for 2 h at 70.degree. C. After cooling, the
reaction was then quenched with saturated aqueous NH.sub.4Cl and
extracted with 3.times.50 mL of DCM. The organic layers were
combined, washed with brine, dried over sodium sulfate and
concentrated under vacuum. The residue was applied onto a silica
gel column with dichloromethane/methanol (10/1) to provide 122 mg
(65%) of the desired product 226.1 as a white solid.
[1737] Synthesis of Compound I-187.
[1738] Compound I-187 was prepared from 226.1 in a manner analogous
to the synthesis of I-181 from 225.9. Isolated a white solid in 6%
overall yield from 226.1. MS 453 (M+H).sup.+. .sup.1H-NMR (400 MHz,
CD.sub.3OD): .delta. 8.54 (s, 1H), 5.32-5.25 (m, 1H), 4.68 (s, 2H),
3.74 (t, 4H), 3.69 (t, 2H), 3.14 (t, 2H), 2.97 (s, 3H), 2.65 (t,
4H), 2.45-2.30 (m, 3H), 2.10 (d, 2H), 1.72-1.62 (m, 2H), 1.60-1.45
(m, 2H).
Example 227
Synthesis of 1-(3-[[4-(dimethylamino)cyclohexyl]oxy]-8-thia-4,6,
12-triazatricyclo[7.4.0.0[2,7]]trideca-1(9),2,4,6-tetraen-12-yl)-4-hydrox-
ybutan-1-one (I-190)
##STR00613##
[1740] Synthesis of Compound 227.2.
[1741] To a solution of butane-1,4-diol (4.5 g, 50.0 mmol, 1.00
equiv) in 15 mL of dry DMF was added imidazole (6.8 g, 100.0 mmol,
2.00 equiv) followed by the addition of a solution of TBSCl (7.55
g, 50.00 mmol, 1.00 equiv) in DMF (5 mL) dropwise with stirring at
0.degree. C. under nitrogen. The resulting solution was stirred for
3 h at room temperature, quenched with water and extracted with
3.times.100 mL of ethyl acetate. The combined organic layers were
washed with brine, dried over sodium sulfate and concentrated under
vacuum. The residue was applied onto a silica gel column with ethyl
acetate/petroleum ether (1/5) to give 2.2 g (22%) of 227.2 as a
colorless oil.
[1742] Synthesis of Compound 227.3.
[1743] To a solution of 227.2 (2.2 g, 10.76 mmol, 1.00 equiv) in 20
mL of dry DMF was added PDC (20 g, 53.16 mmol, 4.94 equiv) at room
temperature. The resulting mixture was stirred overnight at ambient
temperature and quenched by the addition of 100 mL of water and
extracted with 3.times.200 mL of ethyl acetate. The combined
organic layers were washed with water, brine and dried over sodium
sulfate and concentrated under vacuum. The residue was applied onto
a silica gel column with ethyl acetate/petroleum ether (1/5-1/1) to
afford the desired 227.3 (700 mg, 30%) as a light yellow oil.
[1744] Synthesis of Compound 227.4.
[1745] Into a 50-mL round-bottom flask containing a solution of
178.3 (free base; 100 mg, 0.30 mmol, 1.00 equiv) in dry 5 mL of DMF
was added 227.3 (78 mg, 0.36 mmol, 1.19 equiv), HATU (114 mg, 0.30
mmol, 1.00 equiv) and DIEA (80 mg, 0.62 mmol, 2.06 equiv)
sequentially at room temperature under nitrogen. The resulting
solution was stirred overnight at ambient temperature, quenched
with saturated aqueous NH.sub.4Cl and extracted with 3.times.30 mL
of DCM. The combined organic layers were washed with brine, dried
over sodium sulfate and concentrated under vacuum. The residue was
applied onto a silica gel column with dichloromethane/methanol
(10/1) to provide 80 mg (50%) of 227.4 as a white solid.
[1746] Synthesis of Compound I-190.
[1747] To a solution of 227.4 (60 mg, 0.11 mmol, 1.00 equiv) in
methanol (5 mL) was added hydrochloric acid (conc., 0.1 mL) at
0.degree. C. followed by stirring for 5 h at room temperature. The
resulting mixture was concentrated under vacuum and the crude
product (60 mg) was purified by preparative HPLC under the
following conditions (Waters): Column: XBridge Shield RP18 OBD
Column: 5 .mu.m, 19*150 mm; mobile phase: water with 0.1%
NH.sub.4HCO.sub.3 and acetonitrile (10% to 36% in 10 min); flow
rate: 15 ml/min; UV detection at 254 nm. This resulted in 4.5 mg of
I-190 as a white solid. MS (ES): m/z 419 (M+H).sup.+. .sup.1H-NMR
(300 MHz, CD.sub.3OD): .delta. 8.51 (1H, s), 5.35-5.15 (1H, m),
4.97 (2H, t), 3.94 (2H, tt), 3.62 (2H, t), 3.03, 2.94 (2H, tt),
2.88-2.75 (1H, m), 2.62-2.49 (8H, m), 2.50-2.30 (2H, m), 2.13 (2H,
m), 1.85 (2H, quintet), 1.75-1.50 (4H, m).
Example 228
Synthesis of 1-[3-[(4-aminocyclohexyl)oxy]-8-thia-4,6,
12-triazatricyclo[7.4.0.0[2,7]]trideca-1(9),2,4,6-tetraen-12-yl]ethan-1-o-
ne (I-197)
##STR00614##
[1749] Synthesis of Compound 228.1.
[1750] Sodium hydride (60%, 74 mg, 1.85 mmol, 5.00 equiv) was
treated with tert-butyl N-(4-hydroxycyclohexyl)carbamate (120 mg,
0.56 mmol, 1.50 equiv) in 5 mL of distilled THF for 30 min at room
temperature under nitrogen. Then a solution of 184.4 (100 mg, 0.37
mmol, 1.00 equiv) in 5 mL of THF was added via syringe and the
resulting solution was stirred for 2 h at 70.degree. C. After
cooling, the reaction was then quenched with saturated aqueous
NH.sub.4Cl and extracted with 3.times.50 mL of DCM. The organic
layers were combined, washed with brine, dried over sodium sulfate
and concentrated under vacuum. The residue was applied onto a
silica gel column with dichloromethane/methanol (10/1) to provide
120 mg (72%) of 228.1 as a white solid.
[1751] Synthesis of Compound I-197.
[1752] To a solution of 228.1 (50 mg, 0.11 mmol, 1.00 equiv) in 5
mL of DCM was added hydrochloric acid (conc., 0.1 mL) at 0.degree.
C. and the resulting solution was stirred for 4 h at room
temperature. After completion, the resulting mixture was
concentrated under vacuum and the crude product (50 mg) was
purified by preparative HPLC under the following conditions
(Waters): Column: XBridge Shield RP18 OBD Column: 5 .mu.m, 19*150
mm; mobile phase: water with 0.1% NH.sub.4HCO.sub.3 and
acetonitrile (20% up to 24% in 10 min); flow rate: 15 mL/min; UV
detection at 254 nm. This resulted in 18.1 mg (47%) of I-197 as a
white solid. MS (ES): m/z 347 (M+H).sup.+. .sup.1H-NMR (400 MHz,
CD.sub.3OD): .delta. 8.54 (1H, s), 5.40-5.22 (1H, m), 4.92 (2H, s),
3.98, 3.91 (2H, tt), 3.09-3.02 (1H, m), 2.95-2.92 (2H, m),
2.48-2.30 (5H, m), 2.06 (2H, d), 1.80-1.60 (2H, m), 1.55-1.40 (2H,
m).
Example 229
Synthesis of
1-(3-[[4-(methylamino)cyclohexyl]oxy]-8-thia-4,6,12-triazatricyclo[7.4.0.-
0[2,7]]trideca-1 (9),2,4,6-tetraen-12-yl)ethan-1-one (I-202)
##STR00615##
[1754] Synthesis of Compound 229.1.
[1755] Into a 25-mL round-bottom flask containing a solution of
228.1 (70 mg, 0.16 mmol, 1.00 equiv) in anhydrous DMF (3 mL) was
added sodium hydride (60%, 30 mg, 0.75 mmol, 4.8 equiv) followed by
stirring for 30 min at 0.degree. C. under nitrogen. Then CH.sub.3I
(240 mg, 1.69 mmol, 10.79 equiv) was added and the resulting
solution was stirred for another 4 h at room temperature. The
reaction was then quenched by the addition of 10 mL of NH.sub.4Cl
(aq.) and extracted with 3.times.30 mL of DCM. The combined organic
layers were dried over sodium sulfate and concentrated under
vacuum. The residue was applied onto a silica gel column with
dichloromethane/methanol (20/1) to yield 50 mg (69%) of 229.1 as a
white solid.
[1756] Synthesis of Compound I-202.
[1757] Compound I-202 was prepared from 229.1 in a manner analogous
to the synthesis of Compound I-197. Isolated 6.6 mg of a white
solid in 17% yield. MS (ES): m/z 361 (M+H).sup.+. .sup.1H-NMR (300
MHz, CD.sub.3OD): .delta. 8.47 (1H, s), 5.26-5.10 (1H, m), 4.94
(2H, s), 3.86, 3.80 (2H, tt), 2.91-2.80 (3H, m), 2.66, 2.64 (3H,
ss), 2.40-2.22 (2H, m), 2.18-2.05 (5H, m), 1.75-1.55 (2H, m),
1.52-1.48 (2H, m).
Example 230
Synthesis of
2-(12-[[4-(dimethylamino)cyclohexyl]oxy]-10-[[4-(piperazin-1-yl)phenyl]am-
ino]-7-thia-9, 11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(12),2(6),8,
10-tetraen-3-yl)acetamide (I-205)
##STR00616##
[1759] Synthesis of Compound 230.2.
[1760] To a 100 mL of dry round-bottom flask containing a solution
of 230.1 (prepared using the same route as for 204.7 but omitting
the chiral separation; 200 mg, 0.46 mmol, 1.00 equiv) in 15 mL of
dioxane was added Pd.sub.2dba.sub.3 (25 mg, 0.023 mmol, 0.05
equiv), Xantphos (27 mg, 0.046 mmol, 0.10 equiv), t-BuONa (110 mg,
1.15 mmol, 2.50 equiv) and aniline (192 mg, 0.69 mmol, 1.50 equiv)
sequentially at room temperature. Then the reaction mixture was
degassed three times with nitrogen and stirred for 4 h at
100.degree. C. The solids were filtered out and the filtrate was
neutralized with 1 M hydrochloric acid and extracted with
4.times.50 mL of CHCl.sub.3/iso-propanol (3:1). The combined
organic layers were dried over sodium sulfate and concentrated in
vacuo. The residue was purified by chromatography on silica gel
with DCM/MeOH (20:1 to 10:1) to yield 100 mg of desired 230.2 as a
white solid.
[1761] Synthesis of Compound 230.3.
[1762] To a solution of 230.2 (100 mg, 0.15 mmol, 1.00 equiv) in
dry DMF (5 mL) was added HATU (70 mg, 0.18 mmol, 1.20 equiv), DIEA
(25 mg, 0.19 mmol, 1.26 equiv) and NH.sub.4Cl (25 mg, 0.47 mmol,
3.04 equiv) followed by stirring overnight at room temperature
under nitrogen. The reaction was then quenched by the addition of
20 mL of water and extracted with 5.times.50 mL of DCM. The
combined organic layers were dried over anhydrous sodium sulfate
and concentrated under vacuum. The residue was applied onto a
silica gel column with DCM/MeOH (20:1 to 10:1) to give 70 mg of
230.3 as an off-white solid.
[1763] Synthesis of Compound I-205.
[1764] To a solution of 230.3 (20 mg, 0.03 mmol, 1.00 equiv) in DCM
(5 mL) was added hydrochloric acid (37%, 0.2 0.2 mL) at 0.degree.
C. The resulting solution was stirred for 1 h at room temperature
and concentrated under vacuum. The crude product (20 mg) was
purified by preparative HPLC under the following conditions
(Waters): Column: XBridge Shield RP18 OBD 5 .mu.m, 19*150 mm;
mobile phase: water with 0.01% NH.sub.4HCO.sub.3 and CH.sub.3CN
(20%-24%, run time 10 min); flow rate: 20 mL/min; UV detection at
254 nm. This resulted in 10.2 mg (60%) of Compound I-205 as a white
solid. MS (ES): m/z 550 (M+H).sup.+. .sup.1H-NMR (300 MHz,
CD.sub.3OD): .delta. 7.57 (2H, J=8.1 Hz, d), 7.00 (2H, J=8.1 Hz,
d), 5.25-5.08 (1H, m), 3.78-3.65 (1H, m), 3.20-2.80 (11H, m),
2.75-2.65 (1H, m), 2.48-2.25 (9H, m), 2.24-2.02 (4H, m), 1.75-1.45
(4H, m).
Example 231
Synthesis of
(12R)-3-[[4-(morpholin-4-yl)cyclohexyl]amino]-8-thia-4,6-diazatricyclo[7.-
4.0.0[2,7]]trideca-1(9),2(7),3,5-tetraene-12-carboxamide (I-208)
and
Example 232
Synthesis of
(12S)-3-[[4-(morpholin-4-yl)cyclohexyl]amino]-8-thia-4,6-diazatricyclo[7.-
4.0.0[2,7]]trideca-1(9),2(7),3,5-tetraene-12-carboxamide
(I-207)
##STR00617##
[1766] The enantiomers of racemic I-203 (50 mg, 0.12 mmol, 1.00
equiv) were separated by chiral preparative HPLC under the
following conditions (Gilson G.times.281): Column: CHIRALPAK AD-H
SFC, 5*25 cm, 5 .mu.m; mobile phase: hexanes and IPA (30.0% IPA);
flow rate: 20 mL/min; UV detection at 254/220 nm. The
product-containing fractions were collected and evaporated in vacuo
to give 10.8 mg (tR=5 min 20 s) of I-208 as a white solid and 9.8
mg (tR=5 min 25 s) of I-207 as a white solid, respectively.
[1767] Analytical data for I-208: MS (ES): m/z 416 (M+H).sup.+.
.sup.1H-NMR (400 MHz, CD.sub.3OD): .delta. 8.24 (s, 1H), 4.19-4.06
(m, 1H), 3.76-3.74 (m, 4H), 3.16-3.10 (m, 2H), 2.98-2.94 (m, 2H),
2.80-2.69 (m, 1H), 2.68-2.65 (m, 4H), 2.45-2.38 (m, 1H), 2.25-2.20
(m, 3H), 2.10-2.08 (m, 2H), 1.99-1.90 (m, 1H), 1.64-1.55 (m,
5H).
[1768] Analytical data for I-207: MS (ES): m/z 416 (M+H).sup.+.
.sup.1H-NMR (400 MHz, CD.sub.3OD): .delta. 8.24 (s, 1H), 4.16-4.08
(m, 1H), 3.76-3.74 (m, 4H), 3.16-3.10 (m, 2H), 2.98-2.94 (m, 2H),
2.80-2.69 (m, 5H), 2.45-2.38 (m, 1H), 2.25-2.20 (m, 3H), 2.10-2.08
(m, 2H), 1.99-1.90 (m, 1H), 1.64-1.55 (m, 5H).
Example 233
Synthesis of 2-(3-[[4-(dimethylamino)cyclohexyl]oxy]-8-thia-4,6,
12-triazatricyclo[7.4.0.0[2,7]]trideca-1(9),2,4,6-tetraene-12-sulfonyl)et-
han-1-ol (I-209)
##STR00618##
[1770] Compound I-209 was prepared from 178.3 (free base) in a
manner analogous to the synthesis of Compound I-185 from 224.10.
Isolated 12.4 mg of a white solid in 19% yield from 178.3. MS (ES):
m/z 441 (M+H).sup.+. .sup.1H NMR (300 MHz, CD.sub.3OD): .delta.
8.47 (s, 1H), 5.35-5.15 (m, 1H), 4.72 (s, 2H), 3.98 (brs, 2H), 3.73
(br s, 2H), 3.06 (br s, 2H), 2.50-2.22 (m, 9H), 2.08 (d, 2H),
1.85-1.42 (m, 4H).
Example 234
Synthesis of
2-(12-[[4-(dimethylamino)cyclohexyl]oxy]-10-[(1-methyl-1H-pyrazol-4-yl)am-
ino]-7-thia-9, 11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,
11-tetraen-3-yl)acetamide (I-212)
##STR00619##
[1772] Compound I-212 was prepared from 230.1 in a manner analogous
to the synthesis of compound 230.3. Isolated 10.6 mg of a white
solid in 10% overall yield. MS (ES): m/z 470 (M+H).sup.+.
.sup.1H-NMR (300 MHz, CD.sub.3OD): .delta. 7.90 (1H, s), 7.56 (1H,
s), 5.21-5.08 (1H, m), 3.88 (3H, s), 3.75-3.60 (1H, m), 3.05-2.95
(3H, m), 2.95-2.78 (1H, m), 2.75-2.55 (1H, m), 2.54-2.30 (9H, m),
2.25-2.20 (4H, m), 1.75-1.45 (4H, m).
Example 235
(12R)-3-[[4-(morpholin-4-yl)cyclohexyl]oxy]-8-thia-4,6-diazatricyclo[7.4.0-
.0[2,7]]trideca-1(9),2(7),3,5-tetraene-12-carboxamide (I-240)
##STR00620##
[1774] Compound I-240 was prepared from 202.8 in a manner analogous
to the synthesis of Compound I-234 from 202.7. Isolated 84.3 mg of
a white solid in 19% overall yield from 202.8. MS (ES): m/z 417
(M+H).sup.+. .sup.1H-NMR (300 MHz, CD.sub.3OD): .delta. 8.47 (1H,
s), 5.30-5.24 (1H, m), 3.74-3.71 (4H, t, J=4.5 Hz), 3.27-3.25 (1H,
d, J=6.0 Hz), 3.09-2.95 (3H, m), 2.78-2.70 (1H, m), 2.70-2.63 (4H,
m), 2.38-2.30 (3H, m), 2.23-2.11 (1H, m), 2.11-2.07 (2H, d, J=12.0
Hz), 2.02-1.93 (1H, m), 1.68-1.44 (4H, m).
Example 236
Synthesis of
(S)-2-hydroxy-3-((R)-4-(((1r,4R)-4-(pyrrolidin-1-yl)cyclohexyl)oxy)-6,7-d-
ihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-5-yl)propanamide
(I-226) and
Example 237
Synthesis of
(R)-2-hydroxy-3-((R)-4-(((1r,4R)-4-(pyrrolidin-1-yl)cyclohexyl)oxy)-6,7-d-
ihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-5-yl)propanamide
(I-228)
##STR00621## ##STR00622## ##STR00623##
[1776] Synthesis of Compound 236.3.
[1777] Compound 236.3 was prepared from 25.1 in a manner analogous
to compound 98.3. Isolated 0.45 g of a white solid in 22% overall
yield from 25.1.
[1778] Synthesis of Compound 236.4.
[1779] Into a 100 mL round-bottom flask containing a solution of
236.3 (450 mg, 1.17 mmol, 1.00 equiv) in dichloromethane (20 mL)
was added trimethylsilanecarbonitrile (360 mg, 3.63 mmol, 3.00
equiv) and TEA (60 mg, 0.59 mmol, 0.50 equiv) and the resulting
solution was stirred for 2 h at room temperature under nitrogen.
The resulting solution was quenched with water and extracted with
3.times.50 mL of dichloromethane. The combined organic layers were
concentrated under vacuum to give 0.52 g (crude) of 236.4 as a
yellow oil.
[1780] Synthesis of Compound 236.5.
[1781] To a solution of 236.4 (520 mg, 1.07 mmol, 1.00 equiv) in 20
mL of MeOH was added acetic acid (1.0 mL) at 0.degree. C. and the
resulting solution was stirred for 1 h at room temperature. The pH
value of the solution was adjusted to 8 with saturated aqueous
sodium bicarbonate and extracted with 3.times.50 mL of
dichloromethane. The combined organic layers were dried over sodium
sulfate and concentrated under vacuum. The residue was applied onto
a silica gel column with dichloromethane/methanol (8/1). This
resulted in 0.37 g (84%) of 236.5 as a white solid.
[1782] Synthesis of Compound 236.6.
[1783] Into a 50-mL round-bottom flask containing a solution of
236.5 (370 mg, 0.90 mmol, 1.00 equiv) in dichloromethane (20 mL)
was added TBSCl (0.41 g, 3.00 equiv), imidazole (0.24 g, 4.00
equiv) and 4-dimethylaminopyridine (24 mg) sequentially at room
temperature. The resulting solution was stirred overnight at
ambient temperature and quenched with water and extracted with
3.times.50 mL of dichloromethane. The organic layers were combined,
dried over sodium sulfate and concentrated under reduced pressure.
The residue was purified by silica gel column with DCM/MeOH (30:1
to 10:1) to provide 0.33 g (70%) of 236.6 as a yellow oil.
[1784] Synthesis of Compound 236.7.
[1785] Tris(triphenylphosphine)rhodium(I) chloride (18.0 mg, 0.019
mmol) was added to a stirred solution of 236.6 (330 mg, 0.63 mmol)
and acetaldoxime (0.23 mL, 3.60 mmol) in toluene (5.0 mL) and the
reaction mixture heated at reflux overnight. Then
tris(triphenylphosphine)rhodium(I) chloride (4.6 mg, 0.005 mmol)
and acetaldoxime (62 .mu.L, 1.0 mmol) were again added and heating
continued for 2 h. After completion, the mixture was concentrated,
diluted with ethyl acetate, and the organic layer washed with
water, brine, dried, and concentrated in vacuo. The residue was
purified by chromatography on silica gel eluting with a gradient of
0-10% MeOH in DCM to give the desired product 236.7 (250 mg) as a
light yellow foam.
[1786] Synthesis of Compound 236.8.
[1787] Into a 100-mL round-bottom flask, a solution of material
236.7 (250 mg, 0.46 mmol, 1.00 equiv) in methanol (10 mL) was added
hydrochloric acid (2 M, 0.8 mL) and stirred for 2 hr in a water/ice
bath. After completion, the reaction was quenched with saturated
aqueous sodium bicarbonate and extracted with 3.times.30 mL of DCM.
The organic phase was dried over sodium sulfate and concentrated
under vacuum. The residue was purified by preparative TLC
(DCM/MeOH:10/1) to afford the desired product 236.8 (150 mg, 76%)
as a white solid.
[1788] Synthesis of Compound I-226 and I-228.
[1789] The enantiomers of racemic alcohol 236.8 (150 mg, 96%
purity) were separated by chiral HPLC under the following
conditions (Gilson G.times.281): Column: Chiralpak IA, 2*25 cm, 5
m; mobile Phase: Phase A: hexanes (0.1% IPA) (HPLC grade), Phase B:
EtOH (HPLC grade), gradient: 20% B in 7.6 min; flow rate: 20
mL/min; UV detection at 220/254 nm. The fractions of the first
enantiomer to elute were collected and evaporated under reduced
pressure and lyophilized overnight to afford I-226 (36.2 mg) with
100% ee as a white solid. The fractions of the second enantiomer to
elute were concentrated to give I-228 (40.0 mg) with 94.2% ee,
which was resubjected to the chiral HPLC conditions to give 30 mg
with 98.4% ee as a white solid. The ee values of the two isomers
were determined by chiral HPLC under the following conditions
(SHIMADZU-PDA): Column: Chiralpak IA-3, 0.46*15 cm, 3 m; mobile
phase: hexanes (0.2% IPA): EtOH=80:20; flow rate: 1.0 mL/min; UV
detection at 254 nm.
[1790] Analytical data for Compound I-226: MS (ES): m/z 431
(M+H).sup.+. .sup.1H-NMR (300 MHz, CD.sub.3OD): .delta. 8.45 (s,
1H), 5.31-5.24 (m, 1H), 4.06 (dd, J=10.8, 2.4 Hz, 1H), 3.72-3.61
(m, 1H), 3.22-3.08 (m, 1H), 3.05-2.89 (m, 1H), 2.80-2.60 (m, 5H),
2.50-2.09 (m, 7H), 1.95-1.62 (m, 7H), 1.56-1.40 (m, 2H).
[1791] Analytical data for Compound I-228: MS (ES): m/z 431
(M+H).sup.+. .sup.1H-NMR (300 MHz, CD.sub.3OD): .delta. 8.46 (s,
1H), 5.38-5.20 (m, 1H), 4.14 (dd, J=7.5, 5.7 Hz, 1H), 3.60-3.50 (m,
1H), 3.15-3.06 (m, 1H), 3.04-2.92 (m, 4H), 2.78-2.60 (m, 2H),
2.55-2.41 (m, 2H), 2.40-2.15 (m, 4H), 1.94 (brs, 4H), 1.85-1.45 (m,
5H).
Example 238
Synthesis of 1-(3-[[4-(dimethylamino)cyclohexyl]oxy]-8-thia-4,6,
12-triazatricyclo[7.4.0.0[2,7]]trideca-1(9),2,4,6-tetraen-12-yl)-3-hydrox-
ypropan-1-one (I-195)
##STR00624##
[1793] Compound I-195 was prepared from 238.1 and 178.3 (free base)
in a manner consistent with the synthesis of Compound I-190.
Isolated 49.1 mg of a white solid in 20% overall yield from 178.3.
MS (ES): m/z 405 (M+H).sup.+. .sup.1H-NMR (300 MHz, CD.sub.3OD):
.delta. 8.52 (1H, s), 5.32-5.18 (1H, m), 4.94 (2H, s), 4.02-3.80
(4H, m), 3.05, 2.96 (2H, tt), 2.80-2.70 (2H, m), 2.50-2.25 (9H, m),
2.07 (2H, d), 1.73-1.42 (4H, m).
Example 239
Synthesis of 3-[[4-(dimethylamino)cyclohexyl]oxy]-8-thia-4,6,
12-triazatricyclo[7.4.0.0[2,7]]trideca-1(9),2,4,6-tetraene-12-carboxamide
(I-201)
##STR00625##
[1795] A solution of 178.3 (free base) (100 mg, 0.30 mmol, 1.00
equiv) in 8 mL of distilled THF was added isocyanatotrimethylsilane
(35 mg, 0.30 mmol, 1.01 equiv), followed by addition of DIEA (77.4
mg, 0.60 mmol, 2.0 equiv) at room temperature under nitrogen. The
resulting solution was stirred overnight at this temperature and
concentrated under vacuum. The crude product (120 mg) was purified
by preparative HPLC under the following conditions (Waters):
Column: XBridge Shield RP18 OBD 5 .mu.m, 19*150 mm; mobile phase,
water with 0.01% NH.sub.4HCO.sub.3 and acetonitrile (15%-35% in 10
min); flow rate: 15 ml/min; UV detection at 254 nm. This resulted
in 22.8 mg (20%) of Compound I-201 as a white solid. MS (ES): m/z
376 (M+H).sup.+. .sup.1H NMR (300 MHz, CD.sub.3OD): .delta. 8.52
(1H, s), 5.31-5.18 (1H, m), 4.81 (3H, m), 3.79 (1H, t), 2.98 (2H,
brs), 2.45-2.25 (9H, m), 2.07 (2H, d), 1.78-1.60 (2H, m), 1.58-1.38
(2H, m).
Example 240
Synthesis of propyl
3-[[4-(morpholin-4-yl)cyclohexyl]amino]-8-thia-4,6,
12-triazatricyclo[7.4.0.0[2,7]]trideca-1(9),2(7),3,5-tetraene-12-carboxyl-
ate (I-186)
##STR00626##
[1797] Compound I-186 was prepared from 225.10 in a manner
consistent with the synthesis of Compound I-181, substituting
propyl chloroformate for ethanesulfonyl chloride. Isolated 14.5 mg
of a white solid in 22% yield. MS (ES): m/z 460 (M+H).sup.+.
.sup.1H-NMR (400 MHz, CD.sub.3OD): .delta. 8.32 (1H, s), 4.22-4.08
(3H, m), 3.90-3.80 (2H, m), 3.75-3.72 (4H, m), 2.98 (2H, t),
2.68-2.62 (4H, m), 2.45-2.32 (1H, m), 2.28-2.16 (2H, m), 2.15-2.05
(2H, m), 1.75 (2H, sextet), 1.58-1.39 (4H, m), 1.01 (3H, t).
Example 241
Synthesis of
1-((R)-4-(((1r,4R)-4-morpholinocyclohexyl)oxy)-5,6,7,8-tetrahydrobenzo[4,-
5]thieno[2,3-d]pyrimidin-6-yl)butan-2-ol (I-183)
##STR00627##
[1799] Synthesis of Compound 241.1.
[1800] To a solution of 155.2 (1.86 g, 3.50 mmol, 1.00 equiv) in
methanol (50 mL) was added hydrochloric acid (12 M, 1.5 mL)
followed by stirring for 2 h at room temperature. After evaporation
of the solvent, the pH value of the solution was adjusted to 8 with
saturated aqueous sodium bicarbonate and extracted with DCM. The
combined organic layers were washed with brine, dried over
anhydrous sodium sulfate and concentrated under reduced pressure.
The residue was applied onto a silica gel column with
dichloromethane/methanol (20:1-10:1) to give compound 241.1 (1.33
g, 91%) as a white solid.
[1801] Synthesis of Compound 241.2.
[1802] To a solution of 241.1 (700 mg, 1.68 mmol, 1.00 equiv) in
dry dichloromethane (50 mL) was added Dess-Martin periodinane (1.8
g, 4.24 mmol, 2.50 equiv) portionwise followed by stirring for 6
hours at room temperature under N.sub.2. The reaction was then
quenched with saturated aqueous sodium bicarbonate and extracted
with DCM. The organic layers were combined, washed with brine,
dried over sodium sulfate and concentrated under vacuum. The
residue was applied onto a silica gel column with DCM/MeOH (20:1)
to give compound 241.2 (540 mg, 78%) as a yellow solid.
[1803] Synthesis of Compound I-183.
[1804] To a solution of 241.2 (250 mg, 0.60 mmol, 1.00 equiv) in
distilled THF (5 mL) cooled to 0.degree. C. was added EtMgBr-THF (1
M, 4 mL) via syringe under N.sub.2. The resulting solution was
stirred for 5 h at room temperature. After completion, the reaction
was quenched with saturated aqueous NH.sub.4Cl and extracted with
3.times.60 mL of ethyl acetate and the organic layers combined. The
organic layer was washed with brine, dried over anhydrous sodium
sulfate and concentrated under vacuum. The residue was applied onto
a silica gel column with dichloromethane/methanol (20:1). The crude
product (150 mg) was purified by preparative HPLC under the
following conditions (Waters): Column: SunFire Prep C18, 19*150 mm
5 .mu.m; mobile phase: water with 0.05% NH.sub.4CO.sub.3 and
CH.sub.3CN (5.0% CH.sub.3CN up to 45.0% in 10 min, up to 95.0% in 2
min, down to 5.0% in 2 min); flow rate: 20 mL/min; UV detection at
254/220 nm. The product-containing fractions were collected and
partially evaporated to remove water and CH.sub.3CN under reduced
pressure. The residue was lyophilized overnight to give the desired
product I-183 (80 mg) as a yellow solid. MS (ES, m/z) 446
(M+H).sup.+. .sup.1H NMR (300 MHz, CD.sub.3OD): .delta. 8.44 (s,
1H), 5.28-5.22 (m, 1H), 3.74-3.67 (m, 5H), 3.25-3.19 (m, 1H),
3.08-2.77 (m, 2H), 2.64-2.52 (m, 4H), 2.49-2.21 (m, 4H), 2.16-1.94
(m, 4H), 1.67-1.58 (m, 10H), 0.99 (t, 3H).
Example 242
Synthesis of
1-((R)-4-(((1r,4R)-4-morpholinocyclohexyl)oxy)-5,6,7,8-tetrahydrobenzo[4,-
5]thieno[2,3-d]pyrimidin-6-yl)propan-2-ol (I-182)
##STR00628##
[1806] Compound I-182 was prepared from 241.2 in a manner analogous
to the synthesis of Compound I-183 from 241.2, substituting MeMgBr
for EtMgBr. Isolated 58.8 mg of a white solid in 19% yield. MS (ES,
m/z) 432 (M+H).sup.+. .sup.1H NMR (300 MHz, CD.sub.3OD): .delta.
8.44 (s, 1H), 5.28-5.18 (m, 1H), 3.98-3.91 (m, 1H), 3.74-3.71 (m,
4H), 2.99-2.90 (m, 2H), 2.65-2.62 (m, 4H), 2.50-2.41 (m, 4H),
2.20-1.90 (m, 4H), 1.89-1.53 (m, 8H), 1.26-1.19 (d, 3H).
Example 243
Synthesis of
2-[(3R)-12-[[4-(dimethylamino)cyclohexyl]oxy]-10-[(1-methyl-1H-pyrazol-4--
yl)amino]-7-thia-9,
11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,11-tetraen-3-yl]acetamid-
e (I-222)
##STR00629##
[1808] Compound I-222 was prepared from 204.9 in a manner analogous
to the synthesis of Compound I-224. Isolated 62.2 mg of a white
solid in 5% overall yield from 204.9. MS (ES): m/z 470 (M+H).sup.+.
.sup.1H-NMR (300 MHz, CD.sub.3OD): .delta. 7.90 (1H, br s), 7.56
(1H, s), 5.22-5.12 (1H, m), 3.92 (3H, s), 3.78-3.62 (1H, m),
3.08-2.80 (3H, m), 2.75-2.50 (2H, m), 2.44 (6H, s), 2.41-2.26 (2H,
m), 2.25-2.05 (4H, m), 1.70-1.46 (4H, m).
Example 244
Synthesis of
2-[(3R)-12-[[4-(4,4-difluoropiperidin-1-yl)cyclohexyl]oxy]-7-thia-9,11-di-
azatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,
11-tetraen-3-yl]acetamide (I-229)
##STR00630## ##STR00631##
[1810] Synthesis of Compound 244.2.
[1811] To a solution of 4,4-difluoropiperidine hydrochloride (1.58
g, 10.0 mmol, 1.00 equiv) in dichloromethane (75 mL) was added
1,4-dioxaspiro[4.5]decan-8-one (1.56 g, 10.0 mmol, 1.0 equiv),
acetic acid (0.5 mL, 2.00 equiv) and NaBH(OAc).sub.3 (4.24 g, 20
mmol, 2.0 equiv) at room temperature under nitrogen. The resulting
solution was stirred for 24 h at ambient temperature. The pH value
of the solution was adjusted to 12 with 1 M aqueous NaOH solution
and extracted with 3.times.50 mL of dichloromethane. The combined
organic layers were washed with brine, dried over sodium sulfate
and concentrated in vacuo. The residue was applied onto a silica
gel column with DCM/MeOH (80:1 to 50:1) to give the desired 244.2
(2.0 g) as a white solid.
[1812] Synthesis of Compound 244.3.
[1813] A mixture of 244.2 (200 mg, 0.77 mmol, 1.00 equiv) and
hydrochloric acid (4 M, 6 mL) in 30 mL of THF was stirred for 24 h
at 60.degree. C. The resulting mixture was concentrated under
vacuum. The pH value of the solution was adjusted to 8 with
saturated aqueous sodium bicarbonate and extracted with 5.times.50
mL of dichloromethane. The organic layers were combined, dried over
sodium sulfate and concentrated under vacuum to yield 150 mg (90%)
of 244.3 as a light yellow oil.
[1814] Synthesis of Compound 244.4.
[1815] To a solution of 244.3 (100 mg, 0.46 mmol, 1.00 equiv) in
methanol (10 mL) was added NaBH.sub.4 (53 mg, 1.40 mmol, 3.00
equiv) and the resulting solution was stirred for 3 h at room
temperature. The reaction was quenched with saturated aqueous
NH.sub.4Cl and extracted with 4.times.50 mL of dichloromethane. The
combined organic layers were washed with brine, dried over
anhydrous sodium sulfate and concentrated under vacuum to give 80
mg (79%) of 244.4 as a white solid.
[1816] Synthesis of Compound 244.5.
[1817] Into a 100-mL round-bottom flask containing a solution of
244.4 (100 mg, 0.46 mmol, 1.00 equiv) in dry dichloromethane (20
mL) was added 4-nitrobenzoyl chloride (170 mg, 0.92 mmol, 2.00
equiv), followed by addition of sodium bicarbonate (115 mg, 1.37
mmol, 3.00 equiv) and 4-dimethylaminopyridine (5 mg, 0.04 mmol,
0.10 equiv) at room temperature. The resulting mixture was stirred
4 h at ambient temperature. After completion, the resulting mixture
was diluted with water and extracted with DCM, dried and
concentrated under reduced pressure. The residue was purified by
chromatography on silica gel with DCM/MeOH (50:1 to 30:1) to afford
the corresponding 244.5 (120 mg) as a light yellow solid.
[1818] Synthesis of Compound 244.6.
[1819] The pure compound 244.5 (368 mg, 1.0 mmol, 1.0 equiv) in a
mixture of MeOH/THF/water (4 mL/4 mL/2 mL) was added LiOH.H.sub.2O
(126 mg, 3.0 mmol, 3.0 equiv) at room temperature and stirred for 1
h. After evaporation in vacuo, the residue was diluted with water
and acidified with 1 M hydrochloric acid to pH 6 and extracted with
DCM, washed with brine and dried, concentrated under reduced
pressure to give 244.6 (200 mg) as a light yellow solid.
[1820] Synthesis of Compound 244.7.
[1821] A solution of 21.3 (19.0 g, 74.59 mmol, 1.00 equiv) in
acetone (500 mL) cooled at 0.degree. C. was added dropwise Jones
reagent with stirring until the alcohol was consumed completely.
The resulting solution was diluted with water, washed with
saturated aqueous NaHSO3 and extracted with 3.times.800 mL of
EtOAC. The combined organic layers were washed with brine, dried
over sodium sulfate and concentrated under reduced pressure to give
18.0 g (crude) of 244.7 as a yellow solid. MS (ES): m/z 269 and 271
(M+H).sup.+.
[1822] Synthesis of Compound 244.8.
[1823] Into a 100-mL 3-necked round-bottom flask, purged and
maintained with an inert atmosphere of nitrogen, was placed a
solution of 244.6 (250 mg, 1.14 mmol, 1.20 equiv) in distilled THF
(10 mL) cooled to 0.degree. C. under nitrogen. This was followed by
the addition of NaHMDS (0.25 mL, 2 M in THF) dropwise with stirring
at this temperature. A solution of 244.7 (120 mg, 0.45 mmol, 1.00
equiv) in 5 mL of THF was added and the resulting solution was
stirred for 2 h at 0.degree. C. The formed solids were collected by
filtration and washed with THF then MTBE, followed by drying under
high vacuum to give 150 mg (crude) of 244.8 as a red solid.
[1824] Synthesis of Compound I-229.
[1825] To a solution of 244.8 (200 mg, crude) in distilled DMF (10
mL) was added HATU (98 mg, 0.26 mmol, 1.20 equiv), NH.sub.4Cl (29
mg, 0.54 mmol, 1.20 equiv) and DIEA (109 mg, 0.84 mmol, 2.00 equiv)
successively at room temperature under nitrogen. The resulting
mixture was stirred for 4 h at this temperature, diluted with water
and extracted with DCM. After concentration of the organic layers
in vacuo. The crude product (100 mg) was purified by preparative
HPLC under the following conditions (Waters): Column: Xbridge Prep
C18 5 .mu.m, 19*150 mm; mobile phase: water with 0.05%
NH.sub.3HCO.sub.3 and CH.sub.3CN (35% CH.sub.3CN up to 65% in 10
min); flow rate: 20 mL/min; UV detection at 254 nm. The
product-containing fractions were collected and evaporated under
reduced pressure and lyophilized overnight to afford 56 mg of I-229
as a white solid. MS (ES): m/z 451 (M+H).sup.+. .sup.1H-NMR (300
MHz, CD.sub.3OD): .delta. 8.37 (s, 1H), 5.22-5.08 (m, 1H),
3.77-3.65 (m, 1H), 3.09-2.84 (m, 3H), 2.72-2.62 (m, 5H), 2.52-2.45
(m, 1H), 2.32-2.13 (m, 4H), 1.90-1.81 (m, 6H), 1.60-1.45 (m,
4H).
Example 245
Synthesis of
(R)-2-hydroxy-3-((R)-4-(((1r,4R)-4-(piperidin-1-yl)cyclohexyl)oxy)-6,7-di-
hydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-5-yl)propanamide
(I-218) and
Example 246
Synthesis of
(S)-2-hydroxy-3-((R)-4-(((1r,4R)-4-(piperidin-1-yl)cyclohexyl)oxy)-6,7-di-
hydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-5-yl)propanamide
(I-217)
##STR00632## ##STR00633## ##STR00634##
[1827] Synthesis of Compound 245.3.
[1828] Compound 245.3 was prepared from 25.1 and
trans-4-(piperidin-1-yl)cyclohexan-1-ol in a manner analogous to
the synthesis of compound 236.4. Isolated 0.5 g of a yellow oil in
37% overall yield.
[1829] Synthesis of Compound 245.8.
[1830] Compound 245.8 was prepared from 245.3 in a manner analogous
to the synthesis of I-87 from 98.3. Isolated 0.1 g of a white solid
in 14% overall yield.
[1831] Synthesis of Compounds I-218 and I-217.
[1832] The enantiomers of 245.8 (100 mg, 0.22 mmol, 1.00 equiv)
were separated by preparative chiral HPLC under the following
conditions (Gilson): Column: CHIRALPAK OJ-H, 2*25 cm; mobile phase:
hexanes (0.1% DEA) and IPA (0.2% DEA), gradient: (hold at 10% IPA
in 23 min); flow rate: 20 mL/min; UV detection at 254/220 nm.
Isolated 20 mg of I-218 (tR=12.05 min, 100% ee, 2% overall yield)
and 22 mg of I-217 (tR=19.24 min, 100% ee, 2% overall yield), both
as white solids. The ee values of the two isomers were determined
by chiral HPLC under the following conditions (SHIMADZU): Column:
Chiralpak AD-3, 0.46*15 cm, 3 m (DAICEL); mobile phase: hexanes
(0.1% TEA): IPA=90:10; UV detection at 254 nm. flow rate: 1.0
mL/min.
Example 245
[1833] Analytical data for I-217: MS (ES): m/z 445 (M+H).sup.+.
.sup.1H-NMR (300 MHz, CD.sub.3OD): .delta. 8.45 (1H, s), 5.29-5.21
(1H, m), 4.14 (1H, dd), 3.65-3.50 (1H, m), 3.20-3.05 (1H, m),
3.02-2.89 (1H, m), 2.80-2.41 (8H, m), 2.40-2.20 (2H, m), 2.07 (2H,
d), 1.80-1.40 (10H, m).
Example 245
[1834] Analytical data for I-218: MS (ES): m/z 445 (M+H).sup.+.
.sup.1H-NMR (300 MHz, CD.sub.3OD): .delta. 8.45 (1H, s), 5.28-5.18
(1H, m), 4.06 (1H, dd, J=10.8, 2.4 Hz), 3.75-3.62 (1H, m),
3.20-3.05 (1H, m), 3.04-2.89 (1H, m), 2.75-2.60 (5H, m), 2.60-2.48
(1H, m), 2.45-2.25 (4H, m), 2.06 (2H, d), 1.80-1.45 (10H, m).
Example 247
Synthesis of
(12S)-3-[[4-(dimethylamino)cyclohexyl]oxy]-8-thia-4,6-diazatricyclo[7.4.0-
.0[2,7]]trideca-1(9),2(7),3,5-tetraene-12-carboxamide (I-233)
##STR00635##
[1836] Synthesis of Compound 247.1.
[1837] To a solution of 202.9 (134 mg, 0.50 mmol, 1.00 equiv) in
anhydrous DCM was added NH.sub.4Cl (160 mg, 3.0 mmol, 3.0 equiv),
HATU (228 mg, 0.6 mmol, 1.2 equiv) and DIEA (129 mg, 1.0 mmol, 2.0
equiv) at room temperature under nitrogen. The resulting solution
was stirred for 1 h at room temperature and diluted with water and
extracted with DCM. The combined organic layers were washed with
brine, dried and concentrated under vacuum. The residue was
purified by silica gel column with DCM/MeOH (80:1 to 50:1) to give
the desired 247.1 (120 mg, 90%) as a light yellow solid.
[1838] Synthesis of Compound I-233.
[1839] To a solution of 247.1 (75 mg, 0.20 mmol, 1.00 equiv) and
trans-4-(dimethylamino)cyclohexanol (32 mg, 0.22 mmol, 1.1 equiv)
in 5 mL of distilled THF was added NaHMDS (2 M in THF, 0.66 mmol,
0.33 mL) dropwise at 0.degree. C. under nitrogen. The resulting
solution was stirred for 30 min at this temperature and quenched
with water and extracted with 4.times.50 mL of dichloromethane. The
combined organic layers were concentrated under vacuum. The crude
product (70 mg) was purified by preparative HPLC under the
following conditions (Waters): Column: XBridge Shield RP18 OBD 5 m,
19*150 mm; mobile phase: water with 0.01% NH.sub.4HCO.sub.3 and
acetonitrile (10%-35% in 10 min); flow rate: 15 ml/min; UV
detection at 254 nm. This resulted in 8.5 mg of I-233 as a white
solid. MS (ES): m/z 375 (M+H).sup.+. .sup.1H-NMR (300 MHz,
CDCl.sub.3): .delta. 8.49 (1H, s), 5.66-5.58 (1H, m), 5.48-5.41
(1H, m), 5.25-5.21 (1H, m), 3.33-3.25 (1H, m), 3.15-2.91 (3H, m),
2.89-2.63 (2H, m), 2.55 (6H, s), 2.46-2.36 (2H, m), 2.26-2.10 (3H,
m), 2.10-1.98 (1H, m), 1.61-1.60 (4H, m).
Example 248
Synthesis of
(12S)-3-[[4-(4,4-difluoropiperidin-1-yl)cyclohexyl]oxy]-8-thia-4,6-diazat-
ricyclo[7.4.0.0[2,7]]trideca-1(9),2(7),3,5-tetraene-12-carboxamide
(I-236)
##STR00636##
[1841] Synthesis of Compound 248.1.
[1842] To a solution of
trans-4-(4,4-difluoropiperidin-1-yl)cyclohexan-1-ol (60 mg, 0.27
mmol, 1.11 equiv) in distilled THF (5 mL) was added NaHMDS (2 M in
THF, 0.37 mL, 3.00 equiv) dropwise with stirring at 0.degree. C.
under nitrogen. To this was added a solution of 202.9 (66 mg, 0.25
mmol, 1.00 equiv) in 2 mL of THF via syringe at this temperature.
The resulting solution was stirred for 5 min at 0.degree. C. The
reaction was then quenched with water and the pH value of the
solution was adjusted to .about.5.0 with 1 M hydrochloric acid and
extracted with 4.times.20 mL of dichloromethane. The combined
organic layers were dried over sodium sulfate and concentrated
under vacuum to give 100 mg (crude) of 252.1 as a light yellow
solid.
[1843] Synthesis of Compound 248.2.
[1844] To a solution of 248.1 (100 mg, crude) in 5 mL of DCM was
added oxalic dichloride (250 mg, 5.00 equiv) dropwise at 0.degree.
C., followed by addition of DMF (1 drop) under nitrogen. The
resulting solution was stirred for 1 h at room temperature and
concentrated under reduced pressure to give 110 mg (crude) of 248.2
as a light yellow solid.
[1845] Synthesis of Compound I-236.
[1846] To a solution of 248.2 (110 mg, crude) in 5 mL of DCM was
added dropwise 30 mL of ammonia solution. The solution was
extracted with 4.times.50 mL of dichloromethane and the organic
layers combined and dried over anhydrous sodium sulfate and
concentrated under vacuum. The crude product (60 mg) was purified
by preparative HPLC under the following conditions (Waters):
Column: XBridge Shield RP18 OBD 5 m, 19*150 mm; mobile phase: water
with 0.01% NH.sub.4HCO.sub.3 and acetonitrile (10%-33% in 12 min);
flow rate: 15 ml/min; UV detection at 254 nm. This resulted in 9.2
mg of I-236 as a white solid. MS (ES): m/z 451 (M+H).sup.+.
.sup.1H-NMR (300 MHz, CD.sub.3OD): .delta. 8.47 (1H, s), 5.35-5.15
(1H, m), 3.27-3.25 (1H, d, J=6.0 Hz), 3.05-2.97 (3H, m), 2.89-2.60
(6H, m), 2.33-2.22 (2H, m), 2.20 (1H, d), 2.19-1.85 (7H, m),
1.75-1.57 (4H, m).
Example 249
Synthesis of
2-[(3R)-10-(phenylamino)-12-[[(1r,4r)-4-(dimethylamino)cyclohexyl]oxy]-7--
thia-9, 11-diazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,
11-tetraen-3-yl]acetamide (I-232)
##STR00637##
[1848] Compound I-232 was prepared from 242.1 in a manner analogous
to the synthesis of Compound I-222. Isolated 27.8 mg of a white
solid in 13% overall yield from 242.1. MS (ES): m/z 466
(M+H).sup.+. .sup.1H-NMR (400 MHz, CD.sub.3OD): .delta. 7.70 (2H,
d), 7.32 (2H, t), 7.00 (1H, t), 5.18-5.05 (1H, m), 3.65-3.50 (1H,
m), 2.95-2.85 (2H, m), 2.82-2.71 (2H, m), 2.60-2.46 (7H, s),
2.38-2.28 (2H, m), 2.15-1.98 (4H, m), 1.62-1.40 (4H, m).
Example 250
Synthesis of
2-[(3R)-12-([4-[(3R)-3-methylmorpholin-4-yl]cyclohexyl]oxy)-7-thia-9,11-d-
iazatricyclo[6.4.0.0[2,6]]dodeca-1(8),2(6),9,
11-tetraen-3-yl]acetamide (I-227)
##STR00638## ##STR00639##
[1850] Synthesis of Compound 250.5.
[1851] Compound 250.5 was prepared from (R)-3-methylmorpholine in a
manner analogous to the synthesis of 243.5 from
4,4-difluoropiperidine hydrochloride. Isolated 350 mg of a light
yellow solid in 22% overall yield.
[1852] Synthesis of Compound 250.7.
[1853] The enantiomers of racemate 250.5 (350 mg) were separated by
chiral preparative HPLC under the following conditions (Gilson
G.times.281): Column: Chiralpak IC, 2*25 cm, 5 .mu.m; mobile phase:
hexane: EtOH=50:50; flow rate: 20 mL/min; UV detection at 254/220
nm. The second peak fractions were collected and evaporated under
reduced to give 200 mg of 250.7 with 99.7% ee as a light yellow
solid. The ee value was determined by chiral HPLC under the
following conditions: Column: Lux Cellulose-4, 0.46*15 cm, 5 .mu.m;
mobile phase: hexanes (0.1% TEA):EtOH=70:30; flow rate: 1.0 mL/min;
UV detection at 254 nm. .sup.1H NMR (300 MHz, CDCl.sub.3): .delta.
8.27 (d, 2H), 8.19 (d, 2H), 4.98-4.82 (m, 1H), 3.92-3.50 (m, 3H),
3.40-3.15 (m, 1H), 2.95-2.40 (m, 3H), 2.21 (br s, 2H), 1.98-1.75
(m, 2H), 1.68-1.30 (m, 5H), 0.95 (br s, 3H).
[1854] Synthesis of Compound 250.8.
[1855] Compound 250.8 was prepared from 250.7 in a manner analogous
to the synthesis of 244.6. Isolated 110 mg (96%) of a light yellow
solid.
[1856] Synthesis of Compound I-227.
[1857] Compound I-227 was prepared from 244.7 and 250.8 in a manner
analogous to the synthesis of Compound I-229. MS (ES): m/z 431
(M+H).sup.+. .sup.1H-NMR (400 MHz, CD.sub.3OD): .delta. 8.49 (1H,
s), 5.32-5.18 (1H, m), 3.88-3.76 (2H, m), 3.72-3.58 (2H, m),
3.30-3.28 (1H, m), 3.20-3.02 (1H, m), 3.02-2.65 (6H, m), 2.62-2.50
(1H, m), 2.40-2.19 (4H, m), 2.05-1.92 (1H, m), 1.90-1.40 (5H, m),
1.04 (3h, d).
Example 251
Synthesis of
(12S)-3-[[4-(dimethylamino)cyclohexyl]amino]-8-thia-4,6-diazatricyclo[7.4-
.0.0[2,7]]trideca-1(9),2(7),3,5-tetraene-12-carboxamide (I-230)
##STR00640##
[1859] A solution of 247.1 (50 mg, 0.19 mmol, 1.00 equiv) and
trans-1-N,1-N-dimethylcyclohexane-1,4-diamine dihydrochloride (80
mg, 0.37 mmol, 2.00 equiv) in CH.sub.3CN (10 mL) was added
potassium carbonate (79 mg, 0.57 mmol, 3.0 equiv) and the resulting
solution was stirred overnight at 80.degree. C. in an oil bath. The
solids were filtered out and washed with DCM. The filtrate was
concentrated under vacuum. The crude product (50 mg) was purified
by preparative HPLC under the following conditions (Waters):
Column: XBridge Shield RP18 OBD 5 .mu.m, 19*150 mm; mobile phase,
water with 0.05% NH.sub.4HCO.sub.3 and CH.sub.3CN (20% CH.sub.3CN
up to 40% in 10 min); flow rate: 15 mL/min; UV detection at 254 nm.
This resulted in 21.5 mg (31%) of I-230 as a white solid. MS (ES):
m/z 374 (M+H).sup.+. .sup.1H NMR (300 MHz, d.sub.6-DMSO): .delta.
8.26 (s, 1H), 7.45 (s, 1H), 6.97 (s, 1H), 5.98-5.96 (d, 2H),
4.05-4.01 (m, 1H), 3.08-3.06 (m, 2H), 2.85-2.82 (m, 2H), 5.59-2.51
(m, 1H), 2.17-2.13 (m, 6H), 2.05-2.03 (m, 3H), 1.84-1.76 (m, 3H),
1.49-1.26 (m, 4H).
Example 252
Synthesis of
(12S)-3-[[(1r,4r)-4-(morpholin-4-yl)cyclohexyl]oxy]-8-thia-4,6-diazatricy-
clo[7.4.0.0[2,7]]trideca-1(9),2(7),3,5-tetraene-12-carboxylic acid
(I-234)
##STR00641##
[1861] Synthesis of Compound 252.1.
[1862] A solution of trans-4-morpholinocyclohexanol (122.3 mg, 0.66
mmol, 1.1 equiv) in 5 mL of distilled THF was added NaHMDS (2 M in
THF, 0.33 mL, 1.1 equiv) dropwise via a syringe at 0.degree. C.
under nitrogen. Then 204.9 (200 mg, 0.6 mmol, 1.0 equiv) in 3 mL of
THF was added at this temperature and stirred for 30 min. After the
reaction was complete, the reaction mixture was diluted with
saturated aqueous NH.sub.4Cl and extracted with DCM, washed with
brine, dried and concentrated in vacuo. The residue was purified by
chromatography on silica gel with DCM/MeOH/NH.sub.4OH (80:1:0.01 to
50:1:0.01) to give the desired product 252.1 (140 mg) as a light
yellow oil.
[1863] Synthesis of Compound 252.2.
[1864] A mixture of compound 252.1 (140 mg, 0.292 mmol, 1.00
equiv), 1-methyl-1H-pyrazol-4-amine (42.5 mg, 0.437 mmol, 1.5
equiv), Pd.sub.2dba.sub.3 (14.3 mg, 0.015 mmol, 0.05 equiv),
Xantphos (18.1 mg, 0.030 mmol, 0.10 equiv), Cs.sub.2CO.sub.3 (286
mg, 0.876 mmol, 3.0 equiv) in 8 mL of dioxane was degassed three
times with nitrogen. The resulting mixture was stirred for 2 h at
100.degree. C. The reaction mixture was concentrated under vacuum
and the residue was diluted with water and extracted with DCM. The
combined organic layers were washed with brine, dried and
concentrated in vacuo. Purification by chromatography on silica gel
with DCM/MeOH/NH4OH (80:1 to 30:1:0.01) to give the desired 252.2
(130 mg, 90% purity) as a yellow semi-solid.
[1865] Synthesis of Compound 252.3.
[1866] To the compound 252.2 (130 mg, 90% purity) dissolved in a
mixture of THF/MeOH/water (3:3:1.5 mL) was added LiOH.H.sub.2O (40
mg) at room temperature followed by stirring for 4 h at this
temperature. The resulting solution was concentrated under reduced
pressure. The residue was diluted with 3 mL of water, acidified
with 1 M hydrochloric acid to pH 5 and extracted with
CHCl.sub.3/IPA (v/v: 3:1) four times. The combined organic layers
were dried and evaporated in vacuo to give 100 mg crude of 252.3 as
a yellow solid.
[1867] Synthesis of Compound I-234.
[1868] A mixture of 252.3 (60 mg, 0.12 mmol, 1.00 equiv) in
distilled DMF (5 mL) was added NH.sub.4Cl (19.08 mg, 0.36 mmol,
3.08 equiv), HATU (54.7 mg, 0.14 mmol, 1.23 equiv) and DIEA (33.4
mg, 0.26 mmol, 2.21 equiv) and stirred for 3 h at room temperature
under nitrogen. The resulting solution was diluted with 5 mL of
H.sub.2O and extracted with 3.times.20 mL of DCM and concentrated
under vacuum. The crude product (56 mg) was purified by preparative
HPLC under the following conditions (Waters): Column: XBridge
Shield RP18 OBD 5 m, 19*150 mm; mobile phase, water with 0.01%
NH.sub.4HCO.sub.3 and acetonitrile (10%-35% in 10 min); flow rate:
15 ml/min; UV detection at 254 nm. This resulted in 12.5 mg (21%)
of product I-234 as a white solid. MS (ES): m/z 512 (M+H).sup.+.
.sup.1H-NMR (400 MHz, CD.sub.3OD): .delta. 8.90 (s, 1H), 7.57 (s,
1H), 5.22-5.10 (m, 1H), 3.90 (s, 3H), 3.75-3.50 (m, 5H), 3.02-2.95
(m, 2H), 2.90-2.80 (m, 1H), 2.70-2.58 (m, 5H), 2.50-2.41 (m, 3H),
2.25-2.08 (m, 5H), 1.70-1.56 (m, 2H), 1.54-1.38 (m, 2H).
Example 253
Synthesis of 3-[[4-(dimethylamino)cyclohexyl]oxy]-8-thia-4,6,
12-triazatricyclo[7.4.0.0[2,7]]trideca-1(9),2(7),3,5-tetraene-12-sulfonam-
ide (I-238)
##STR00642##
[1870] Into a 50-mL round-bottom flask was placed a solution of
178.3 (HCl salt) (50 mg, .about.75 purity) in anhydrous DCM (5 mL)
cooled to 0.degree. C. Then sulfamoyl chloride (26 mg, 0.23 mmol,
1.50 equiv) was added, followed by addition of TEA (45 mg, 0.44
mmol, 2.96 equiv) and the resulting solution was stirred for 2 h at
this temperature under nitrogen. The resulting mixture was
concentrated under vacuum. The crude product (60 mg) was purified
by preparative HPLC under the following conditions (Waters):
Column: XBridge Shield RP18 OBD 5 m, 19*150 mm; mobile phase: water
with 0.01% NH.sub.4HCO.sub.3 and acetonitrile (gradient: 20%-24%
CH.sub.3CN in 10 min); flow rate: 15 ml/min; UV detection at 254
nm. This resulted in 10.7 mg (17%) of 1-238 as a white solid. MS
(ES): m/z 412 (M+H).sup.+. .sup.1H-NMR (300 MHz, CD.sub.3OD):
.delta. 8.47 (1H, s), 5.26-5.15 (1H, m), 4.51 (2H, s), 3.52 (2H,
t), 3.03 (2H, t), 2.43-2.25 (9H, m), 2.03 (2H, d), 1.67-1.45 (4H,
m).
Example 254
Synthesis of
12-methyl-3-[[(1r,4r)-4-(morpholin-4-yl)cyclohexyl]oxy]-8-thia-4,6-diazat-
ricyclo[7.4.0.0[2,7]]trideca-1(9),2,4,6-tetraene-12-carboxamide
(I-237)
##STR00643##
[1872] Synthesis of Compound 254.2.
[1873] To a solution of ethyl 3-oxocyclohexane-1-carboxylate (2.0
g, 11.75 mmol, 1.00 equiv) and ethane-1,2-diol (875 mg, 14.10 mmol,
1.20 equiv) in toluene (30 mL) was added TsOH (0.2 g) and the
resulting solution was stirred for 12 h at 110.degree. C. in an oil
bath. After cooling, the reaction was then quenched with water and
extracted with 3.times.60 mL of ethyl acetate. The combined organic
layers were washed with brine, dried over anhydrous sodium sulfate
and evaporated in vacuo. The residue was applied onto a silica gel
column with ethyl acetate/petroleum ether (1:30) to give 1.7 g
(68%) of 254.2 as a light yellow oil.
[1874] Synthesis of Compound 254.3.
[1875] To a solution of 254.2 (1.7 g, 7.93 mmol, 1.00 equiv) in
distilled THF (30 mL) cooled to -78.degree. C. was added newly
prepared LDA (1.02 g, 9.52 mmol, 1.20 equiv) under nitrogen via
syringe. After stirring for 30 min, CH.sub.3I (3.92 g, 27.62 mmol,
3.50 equiv) was added and the resulting solution was stirred for 2
h at -40.degree. C. The reaction was then quenched with water and
extracted with 3.times.60 mL of ethyl acetate. The organic layers
were combined, washed with brine and dried over anhydrous sodium
sulfate and concentrated under vacuum. The residue was applied onto
a silica gel column with ethyl acetate/petroleum ether (1:30) to
yield 1.7 g (94%) of 254.3 as a light yellow oil.
[1876] Synthesis of Compound 254.4.
[1877] Into a 100-mL round-bottom flask containing a solution of
254.3 (1.7 g, 7.45 mmol, 1.00 equiv) in acetone (30 mL) was added
hydrochloric acid (4 M, 5 mL) and the resulting solution was
stirred for 4 h at 70.degree. C. in an oil bath. After cooling to
room temperature, the reaction was then quenched with saturated
aqueous sodium bicarbonate and extracted with 3.times.60 mL of
ethyl acetate. The combined organic layers were washed with brine,
dried over anhydrous sodium sulfate and concentrated under vacuum.
The residue was applied onto a silica gel column with ethyl
acetate/petroleum ether (1:15) to afford 1.0 g (73%) of 254.4 as a
light yellow oil.
[1878] Synthesis of Compound 254.7.
[1879] Compound 254.7 was prepared from 254.4 in a manner analogous
to the synthesis of 207.4. Isolated 180 mg of a light yellow liquid
in 38% overall yield.
[1880] Synthesis of Compound 254.8.
[1881] trans-4-(Morpholin-4-yl)cyclohexan-1-ol (76 mg, 0.41 mmol,
1.20 equiv) was treated with NaHMDS (0.25 mL, 1.50 equiv) in 6 mL
of distilled THF for 20 min at 0.degree. C. under nitrogen. Then a
solution of 254.7 (100 mg, 0.32 mmol, 1.00 equiv) in dry THF (3 mL)
was added via syringe. After stirring for 1 h at this temperature,
the reaction was then quenched with water and extracted with
3.times.20 mL of ethyl acetate. The combined organic layers were
dried over anhydrous sodium sulfate and concentrated under vacuum.
The residue was applied onto a silica gel column with ethyl
acetate/petroleum ether (1:10) to give 45 mg (30%) of 254.8 as a
white solid. 76 mg of by-product 254.9 were also obtained as a
white solid.
[1882] Synthesis of 254.10.
[1883] A solution of 254.8 (40 mg, 0.09 mmol, 1.00 equiv) in
methanol/THF/water (3/3/3 mL) was added LiOH (8.4 mg, 0.35 mmol,
4.00 equiv) and the resulting solution was stirred overnight at
room temperature. The resulting solution was diluted with 10 mL of
water, acidified with 1 M hydrochloric acid and extracted with
3.times.20 mL of ethyl acetate. The organic layers were combined
and dried over anhydrous sodium sulfate and concentrated under
vacuum to give 30 mg (crude) of 254.10 as a white solid.
[1884] Synthesis of Compound I-237.
[1885] Compound I-237 was prepared from 254.10 in a manner
analogous to the synthesis of I-13. Isolated 12 mg of a white solid
in 57% yield. MS (ES): m/z 431 (M+H).sup.+. 1H-NMR: (300 MHz,
CD.sub.3OD): .delta. 8.47 (s, 1H), 5.32-5.15 (m, 1H), 3.80-3.68 (m,
4H), 3.50 (d, 1H), 3.02-2.89 (m, 2H), 2.82 (d, 1H), 2.71-2.69 (m,
4H), 2.49-2.18 (m, 4H), 2.10 (d, 2H), 1.98-1.85 (m, 1H), 1.75-1.40
(m, 4H), 1.31 (s, 3H).
Example 255
Synthesis of
2-(3-[[4-(dimethylamino)cyclohexyl]oxy]-1-oxa-8-thia-4,6-diazatricyclo[7.-
4.0.0[2,7]]trideca-1(9),2,4,6-tetraen-12-yl)ethan-1-ol (I-219)
##STR00644##
[1887] Synthesis of Compound 255.1.
[1888] A solution of 221.8 (260 mg, 0.83 mmol, 1.00 equiv) in
distilled THF (10 mL) cooled down to -78.degree. C. was added
DIBAL-H (25% in hexane, 2.0 g, 3.52 mmol, 4.24 equiv) dropwise
under nitrogen. The resulting solution was warmed up to -30.degree.
C. and stirred for 2 h. TLC analysis of the reaction indicated the
starting 1 consumed completely. The reaction was then quenched with
water and extracted with 3.times.50 mL of ethyl acetate. The
combined organic layers were dried over sodium sulfate and
concentrated under vacuum. The residue was applied onto a silica
gel column with ethyl acetate/petroleum ether (1/4) to afford 190
mg (84%) of 255.1 as a white solid.
[1889] Synthesis of Compound 255.2.
[1890] To a solution of 255.1 (190 mg, 0.70 mmol, 1.00 equiv) in
dichloromethane (5 mL) was added SEMCl (140 mg, 0.84 mmol, 1.32
equiv) and DIEA (180 mg, 1.39 mmol, 1.98 equiv) at 0.degree. C. The
resulting solution was stirred for 2.5 h at room temperature and
quenched by the addition of saturated aqueous NH.sub.4Cl and
extracted with 3.times.50 mL of ethyl acetate. The combined organic
layers were dried and concentrated under vacuum. The residue was
applied onto a silica gel column with ethyl acetate/petroleum ether
(1/10) to give 250 mg (89%) of the desired 255.2 as a colorless
oil.
[1891] Synthesis of Compound 255.3.
[1892] Sodium hydride (60%, 100 mg, 2.50 mmol, 5.0 equiv) was
treated with trans-4-(dimethylamino)cyclohexan-1-ol (143 mg, 1.00
mmol, 2.00 equiv) in distilled THF (8 mL) at 0.degree. C. under
nitrogen. Then 255.2 (200 mg, 0.50 mmol, 1.00 equiv) was added and
the resulting solution was stirred for another 1 h at 60.degree. C.
After cooling, the reaction was then quenched with saturated
aqueous NH.sub.4Cl and extracted with 3.times.60 mL of ethyl
acetate. The organic layers were combined, dried and concentrated
under vacuum. The residue was applied onto a silica gel column with
ethyl acetate/petroleum ether (1/5) to provide 190 mg (75%) of the
desired 255.3 as a white solid.
[1893] Synthesis of Compound I-219.
[1894] A solution of 255.3 (190 mg, 0.37 mmol, 1.00 equiv) in
methanol (6 mL) was added hydrochloric acid (37%, 0.5 mL) at
0.degree. C. The resulting solution was stirred for 3 h at room
temperature. After concentration under vacuum, the reaction mixture
was acidified by 1 M hydrochloric acid and extracted with DCM and
evaporated in vacuo. The crude product (190 mg) was purified by
preparative HPLC under the following conditions (Waters): Column:
XBridge Shield RP18 OBD 5 .mu.m, 19*150 mm; mobile phase: water
with 0.01% NH.sub.4HCO.sub.3 and acetonitrile (10%-33% CH.sub.3CN
in 10 min); flow rate: 15 ml/min; UV detection at 254 nm. This
resulted in 21.7 mg (15%) of I-219 as a white solid. MS (ES): m/z
378 (M+H).sup.+. 1H-NMR (300 MHz, CD.sub.3OD): .delta. 8.50 (1H,
s), 5.35-5.15 (1H, m), 4.92 (2H, s), 3.95-3.86 (1H, m), 3.82-3.72
(2H, m), 3.10 (1H, d), 2.80-2.70 (1H, m), 2.70-2.58 (1H, m), 2.47
(6H, s), 2.36 (2H, d), 2.10 (d, 2H), 1.98-1.82 (2H, m), 1.72-1.50
(4H, m).
Example 256
Synthesis of
2-((R)-4-(((1r,4R)-4-(dimethylamino)cyclohexyl)oxy)-2-((4-(4-methylpipera-
zin-1-yl)phenyl)amino)-6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidi-
n-5-yl)acetamide (I-231)
##STR00645##
[1896] Compound I-231 was prepared from 242.1 in a manner analogous
to the synthesis of Compound I-222, substituting
4-(4-methylpiperazin-1-yl)aniline for 1-methyl-1H-pyrazol-4-amine.
Isolated 5.4 mg of an off-white solid in 0.4% overall yield from
242.1. MS (ES): m/z 564 (M+H).sup.+. .sup.1H-NMR (300 MHz,
CD.sub.3OD): .delta. 8.40 (2.3H, brs), 7.58 (2H, d), 7.00 (2H, d),
5.25-5.08 (1H, m), 3.75-3.65 (1H, m), 3.10-2.82 (16H, m), 2.75-2.60
(5H, m), 2.52-2.48 (2H, m), 2.30-2.12 (5H, m), 1.80-1.60 (4H,
m).
Example 257
Synthesis of
2-(4-(((1r,4r)-4-(dimethylamino)cyclohexyl)oxy)-2-((4-(4-methylpiperazin--
1-yl)phenyl)amino)-6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-5--
yl)acetamide (I-206)
##STR00646##
[1898] Compound I-205 was prepared from 214.1 and
4-(4-methylpiperazin-1-yl)aniline in a manner analogous to the
synthesis of Compound I-231. Isolated 12.1 mg of an off-white solid
in 8% overall yield from 214.1. MS (ES): m/z 564 (M+H).sup.+.
.sup.1H NMR (300 MHz, CD.sub.3OD): .delta. 7.47 (2H, d), 7.60 (2H,
m), 6.90 (2H, d), 5.18-5.02 (1H, m), 3.70-3.45 (3H, m), 3.13-3.09
(4H, m), 3.05-2.70 (3H, m), 2.65-2.42 (6H, m), 2.37 (6H, s),
2.30-1.98 (9H, m), 1.65-1.30 (4H, m).
Example 258
Synthesis of
4-(((1r,4r)-4-morpholinocyclohexyl)amino)-6,8-dihydro-5H-pyrano[4',3':4,5-
]thieno[2,3-d]pyrimidine-6-carboxamide (I-241)
##STR00647##
[1900] Synthesis of Compound 258.2.
[1901] To a solution of 258.1 (5.0 g, 27.28 mmol, 1.00 equiv, 94%)
in freshly distilled benzene (30 mL) was added ethyl 2-oxoacetate
(6.13 g, 30.0 mmol, 1.1 equiv), followed by additional 0.7 M
ZnCl.sub.2-THF (16.40 mmol, 23.40 mL, 0.60 equiv) at 0.degree. C.
under nitrogen. The resulting solution was stirred for 72 h at room
temperature. After the starting diene was consumed completely, the
reaction solution was concentrated under reduced pressure, the
residue was washed with 1 M HCl solution and extracted with EtOAc,
dried over sodium sulfate and the solvents evaporated. The residue
was purified by silica gel column with EtOAc/PE (1:30 to 1:10) to
give 3.4 g (73%) of the desired 258.2 as a light yellow oil.
[1902] Synthesis of Compound 258.3.
[1903] Into a 100-mL round-bottom flask containing a solution of
258.2 (2.0 g, 11.75 mmol, 1.00 equiv) in ethyl acetate (50 mL) was
added palladium on activated carbon (10%, 200 mg) under nitrogen at
room temperature. Then H.sub.2 (g) was introduced in and degassed
three times. The resulting solution was stirred for 12 h at ambient
temperature. The solids were filtered out by filtration and washed
with EtOAc (3.times.). The filtrate was concentrated under reduced
pressure and the residue was purified by silica gel column with
EtOAc/PE (1:20) to give the desired 258.3 (1.62 g, 80%) as a light
yellow oil.
[1904] Synthesis of Compound 258.5.
[1905] To a solution of 258.3 (1.62 g, 9.4 mmol, 1.00 equiv) in
ethanol (60 mL) was added S (361 mg, 11.28 mmol, 1.20 equiv), ethyl
2-isocyanoacetate (1.28 g, 11.28 mmol, 1.20 equiv), morpholine
(1.23 g, 14.1 mmol, 1.50 equiv) sequentially under nitrogen. The
resulting mixture was stirred for 4 h at 50.degree. C. in an oil
bath. The resulting mixture was evaporated in vacuo, diluted with
water and extracted with 3.times.80 mL of ethyl acetate. The
combined organic layers were washed with brine, dried over
anhydrous sodium sulfate and concentrated under vacuum. The residue
was applied onto a silica gel column with ethyl acetate/petroleum
ether (1:30 to 1:15) to give 258.5 (1.3 g, 46%) as a light yellow
solid. The regioisomer 258.4 is a by-product of the reaction.
[1906] Synthesis of Compound 258.6.
[1907] A solution of 258.5 (800 mg, 2.67 mmol, 1.00 equiv) and
formamidine acetate (2.78 g, 26.7 mmol, 10.0 equiv) in formamide
(20 mL) was heated for 2 h at 140.degree. C. in an oil bath under
nitrogen. The resulting solution was cooled and diluted with water
and extracted with 3.times.50 mL of ethyl acetate. The combined
organic layers were washed with brine, dried over anhydrous sodium
sulfate and concentrated under vacuum. The residue was applied onto
a silica gel column with dichloromethane/methanol (100/1) to give
130 mg of 258.6 as a white solid. The aqueous phase was extracted
with 4.times.50 mL of CHCl.sub.3/IPA (v/v: 3:1), dried and
concentrated under reduced pressure to afford around 400 mg of
amide 258.7 as a brown solid.
[1908] Synthesis of Compound 258.8.
[1909] A mixture of 258.6 (130 mg, 0.46 mmol, 1.00 equiv) in dry
CH.sub.3CN (10 mL) was added POCl.sub.3 (355 mg, 2.32 mmol, 5.00
equiv) at room temperature and the resulting mixture was stirred
for 3 h at 85.degree. C. in an oil bath. The reaction mixture was
concentrated to remove the excess of POCl.sub.3 and diluted with
EtOAc. The mixture was poured into a cooled saturated aqueous
sodium dicarbonate and extracted with 3.times.50 mL of ethyl
acetate. The combined organic layers were dried and concentrated
under reduced pressure. The residue was applied onto a silica gel
column with ethyl acetate/petroleum ether (1:20) to give 90 mg
(65%) of 258.8 as a white solid.
[1910] Synthesis of Compound 258.9.
[1911] Into a 50-mL round-bottom flask was placed a mixture of
258.8 (90 mg, 0.30 mmol, 1.00 equiv) and
trans-4-(morpholin-4-yl)cyclohexan-1-amine dihydrochloride (92.6
mg, 0.36 mmol, 1.20 equiv) at room temperature. Then potassium
carbonate (124 mg, 0.90 mmol, 3.00 equiv) was added and the
resulting mixture was stirred for 12 h at 78.degree. C. in an oil
bath under nitrogen. After cooling, the resulting solution was
diluted with water and extracted with 3.times.50 mL of ethyl
acetate. The organic layers were combined, dried over anhydrous
sodium sulfate and concentrated under vacuum. The residue was
applied onto a silica gel column with dichloromethane/methanol
(1/10) to give 100 mg (74%) of 258.9 as a white solid.
[1912] Synthesis of Compound 258.10.
[1913] To a solution of 258.9 (100 mg, 0.224 mmol, 1.0 equiv) in a
mixture of THF/MeOH/water (4/4/2 mL) was added LiOH.H2O (38 mg,
0.896 mmol, 4.0 equiv) at room temperature. The resulting solution
was stirred at ambient temperature for 4 h and concentrated under
reduced pressure to give around 100 mg of 258.10 as a light yellow
solid.
[1914] Synthesis of Compound I-241.
[1915] The compound 258.10 (100 mg, crude) in 6 mL of distilled DMF
was added NH.sub.4Cl (20 mg, 0.372 mmol), HATU (128 mg, 0.336 mmol)
and DIEA (48 mg, 0.372 mmol) successively at room temperature and
stirred for 4 h under nitrogen. After completion, the reaction
mixture was diluted with water and extracted with DCM, dried over
sodium sulfate and concentrated in vacuo. The residue was purified
via a silica gel column with DCM/MeOH (50:1 to 30:1) to give the
desired product I-241 (45 mg) as a white solid. MS (ES): m/z 418
(M+H).sup.+. .sup.1H NMR (300 MHz, d.sub.6-DMSO): .delta. 8.29 (1H,
s), 7.40 (s, 2H), 6.10 (d, 1H), 4.90 (dd, 2H), 4.16 (dd, 1H),
4.10-3.90 (m, 1H), 3.56 (brs, 4H), 3.25-3.05 (m, 2H), 249 (brs,
4H), 2.30-2.12 (m, 1H), 2.00 (d, 2H), 1.86 (d, 2H), 1.55-1.20 (m,
4H).
Example 259
IRAK-4 Assay
Assay Materials
TABLE-US-00002 [1916] Material Vendor Catalog number HEPES Amresco
0511 Brij-35 Sigma B4184-100mL Coating Reagent #3 Caliper EDTA
Sigma E5134-1KG ATP Sigma A7699-1G MgCl.sub.2 Sigma 63068-250G
MnCl.sub.2 Sigma M8054-100G Peptide 8 GL bioscience 112396 IRAK4
CARNA Bioscience 09-145 384-well plate Corning 3573
[1917] A 1.times. kinase base buffer was prepared from 50 mM HEPES,
pH 7.5 and 0.0015% Brij-35. A stop buffer was prepared from 100 mM
HEPES, pH 7.5, 0.015% Brij-35, 0.2% Coating Reagent #3, and 50 mM
EDTA.
[1918] Test compound was diluted to 50.times. of the final desired
highest inhibitor concentration in reaction by 100% DMSO. 100 .mu.l
of this compound dilution was transferred to a well in a 96-well
plate. For example, if desired highest inhibitor concentration in
IC50 determination is 10 .mu.M, then prepare 500 .mu.M of compound
DMSO solution in this step.
[1919] Test compound was serially diluted by transferring 30 .mu.l
to 60 .mu.l of 100% DMSO in the next well and so forth for a total
of 10 concentrations. 100 .mu.l of 100% DMSO was added to two empty
wells for no compound control and no enzyme control in the same
96-well plate.
[1920] A new 96-well plate was marked as intermediate plate. 5
.mu.l of compound serial dilution was transferred from source plate
to the corresponding wells of the intermediate plate. 45 .mu.l of
1.times. kinase base buffer (KB buffer) was added to each well of
the intermediate plate. The intermediate plate was placed for 10
min on a shaker.
[1921] 5 .mu.l of each well was transferred from the 96-well
intermediate plate to a 384-well plate in duplicates. For example,
A1 of the 96-well plate is transferred to A1 and A2 of the 384-well
plate. A2 of the 96-well plate is transferred to A3 and A4 of the
384-well plate, and so on.
[1922] IRAK4 and DTT in 1.times. kinase base buffer was added. The
2.5.times. enzyme mix contained 8.8 nM IRAK4 and 5 mM DTT.
[1923] Peptide 8, ATP, MgCl.sub.2 and MnCl.sub.2 were added in the
1.times. kinase base buffer. The 2.5.times. peptide mix contained
3.75 .mu.M peptide 8, 92.5 .mu.M ATP, 12.5 mM MgCl.sub.2 and 2.5 mM
MnCl.sub.2.
[1924] Assay plate already contained 5 .mu.l of compound in 10%
DMSO. Added 10 .mu.l of 2.5.times. enzyme solution to each well of
the 384-well assay plate, except no enzyme control wells. The final
concentration of IRAK4 in reaction was 3.5 nM. Added 10 .mu.l of
1.times. kinase base buffer to no enzyme control wells in the assay
plate. Incubated at room temperature for 10 min.
[1925] Added 10 .mu.l of 2.5.times. peptide solution to each well
of the 384-well assay plate. The final concentration of Peptide 8
and ATP was 1.5 .mu.M and 37 .mu.M, respectively. Incubated at
28.degree. C. for 40 minutes. Added 25 .mu.l of stop buffer to stop
reaction. Collected data on Caliper.
[1926] Copied conversion % data from Caliper program. Converted
conversion % values to percent inhibition values. Percent
inhibition=(max-conversion %)/(max-min)*100, where "max" means the
conversion % of DMSO control and "min" means the conversion % of no
enzyme control.
[1927] Tables 3A, 3B and 3C show the activity of selected compounds
of this invention in the IRAK-4 activity inhibition assay. The
compound numbers correspond to the compound numbers in Table 1.
Compounds having an activity designated as "A" provided an
IC.sub.50.ltoreq.5 .mu.M; compounds having an activity designated
as "B" provided an IC.sub.50 of 5-20 .mu.M; compounds having an
activity designated as "C" provided an IC.sub.50 of 20-50 .mu.M;
and compounds having an activity designated as "D" provided an
IC.sub.50.gtoreq.50 .mu.M. "NA" stands for "not assayed."
TABLE-US-00003 TABLE 3A IRAK-4 Activity Inhibition Data Cpd #
IRAK-4 I-1 B I-2 C I-3 A I-4 C I-5 B I-6 B I-7 A I-8 D I-9 A I-10 C
I-11 B I-12 A I-13 A I-14 D I-15 D I-16 D I-17 A I-18 B I-19 A I-20
A I-21 A I-22 B I-23 B I-24 C I-25 C I-26 B I-27 B I-28 C I-29 D
I-30 C I-31 B I-32 A I-33 A I-34 A I-35 A I-36 D I-37 A I-38 C I-39
A I-40 A I-41 A I-42 A I-43 A I-44 A I-45 A I-46 A I-47 A I-48 A
I-49 A I-50 B I-51 A I-52 A I-53 A I-54 A I-55 A I-56 A I-57 A I-58
A I-59 A I-60 A I-61 A I-62 A I-63 A I-64 A I-65 A I-66 A I-67 A
I-68 A I-69 A I-70 A I-71 A I-72 A I-73 A I-74 A I-75 A I-76 A I-77
A I-78 A I-79 A I-80 A
TABLE-US-00004 TABLE 3B IRAK-4 Activity Inhibition Data Continued
Cpd # IRAK-4 I-81 B I-82 A I-83 A I-84 A I-85 A I-86 A I-87 A I-88
A I-89 A I-90 A I-91 A I-92 A I-93 A I-94 A I-95 A I-96 A I-97 A
I-98 A I-99 A I-100 A I-101 A I-102 A I-103 B I-104 B I-105 A I-106
A I-107 A I-108 A I-109 A I-110 A I-111 A I-112 A I-113 A I-114 NA
I-115 NA I-116 A I-117 A I-118 A I-119 A I-120 A I-121 A I-122 A
I-123 A I-124 B I-125 A I-126 A I-127 B I-128 A I-129 A I-130 A
I-131 A I-132 A I-133 A I-134 A I-135 A I-136 A I-137 A I-138 A
I-139 A I-140 A I-141 B I-142 A I-143 B I-144 A I-145 A I-146 A
I-147 A I-148 A I-149 A I-150 A I-151 B I-152 A I-153 A I-154 B
I-155 A I-156 A I-157 A I-158 C I-159 A I-160 A
TABLE-US-00005 TABLE 3C IRAK-4 Activity Inhibition Data Continued
Cpd # IRAK-4 I-161 B I-162 A I-163 A I-164 NA I-165 NA I-166 NA
I-167 A I-168 A I-169 A I-170 B I-171 B I-172 B I-173 B I-174 NA
I-175 NA I-176 NA I-177 NA I-178 NA I-179 NA I-181 B I-182 A I-183
A I-184 A I-185 A I-186 A I-187 A I-188 A I-190 C I-192 A I-193 A
I-194 A I-195 B I-196 B I-197 B I-198 C I-199 C I-200 A I-201 A
I-202 B I-203 A I-204 A I-205 A I-206 A I-207 A I-208 A I-209 A
I-210 A I-211 A I-212 A I-213 A I-214 A I-215 A I-216 A I-217 A
I-218 A I-219 A I-220 A I-221 A I-222 A I-224 A I-226 A I-227 A
I-228 A I-229 A I-230 A I-231 A I-232 A I-233 A I-234 A I-235 A
I-236 A I-237 A I-238 A
[1928] Provided compounds were also assayed as inhibitors of
IRAK-1. In certain embodiments, a provided compound inhibits IRAK-1
with an IC.sub.50.ltoreq.5 .mu.M. In some embodiments, a provided
compound inhibits IRAK-1 with an IC.sub.50 of 5-20 .mu.M. In other
embodiments, a provided compound inhibits IRAK-1 with an IC.sub.50
of 20-50 .mu.M.
[1929] Provided compounds were also assayed in a panel of 334
kinases and were found to be highly selective for IRAK4. Provided
compounds were also assayed for inhibition of IL-1-induced IRAK1
degradation in MRC5 cells, LPS- and R848 (TLR-7 agonist)-induced
cytokine expression in human whole blood, and found to be potent
inhibitors in those assays.
[1930] Provided compounds were also assayed to determine their Ki
versus IRAK-4 using a Reaction Biology radioactive kinase assay.
Certain compounds of the invention were found to have Ki values
ranging from about 1 nM to about 100 nM.
Example 260
Cytokine Production Assay
[1931] Provided compounds were also assayed in an LPS
(Lipopolysacharide) or R848 (TLR-7 agonist) induced cytokine
(TNF.alpha. and IL8) production assay in THP-1 cells, human
peripheral blood mononuclear cells (hPBMC), and whole blood. The
exemplary protocol for this assay in THP-1 cells was as follows
below.
[1932] THP-1 cells from ATCC (TIB-202) were cultured in RPMI Medium
1640 (Invitrogen, Cat No. A10491-01), 10% fetal bovine serum
(Invitrogen, Cat No. 10099141, Lot No. 8172882) containing 100 U/mL
Penicillin, 100 .mu.g/mL streptomycin (Invitrogen, Cat No.
15140-122), and 50 uM 2-Mercaptoethanol (Invitrogen, Cat No.
21985023). LPS-EK ultra pure (Invivogen, Cat No. tlrl-peklps) was
used to induce IL8 and TNF.alpha. production, that was detected in
the cell culture supernatant by IL8 HTRF kit (Cisbio, Cat No.
62IL8PEB) and TNF.alpha. HTRF kit (Cisbio, Cat No. 62TNFPEB), as
per manufacturer instructions. Cells were cultured in 96 well assay
plates at 100,000 cells per well, and compounds diluted in final
0.3% DMSO were pre-incubated with cells for 1 hour prior to
stimulation with 300 ng/mL LPS. Cytokine production in cell
supernatant was measured at 5 hours for TNF.alpha. and IL8
production, and for 16 hours for IL8 production and assessment of
cell viability.
[1933] Table 4 shows the activity of selected compounds of this
invention in the TNF.alpha. and IL8 production assay. The compound
numbers correspond to the compound numbers in Table 1. Compounds
having an activity designated as "A" provided an
IC.sub.50.ltoreq.0.5 .mu.M; compounds having an activity designated
as "B" provided an IC.sub.50 of 0.5-1.0 .mu.M; compounds having an
activity designated as "C" provided an IC.sub.50 of 1.0-5.0 .mu.M;
and compounds having an activity designated as "D" provided an
IC.sub.50.gtoreq.5 .mu.M. "NA" stands for "not assayed."
TABLE-US-00006 TABLE 4 TNF and IL8 Production Assay Cpd #
TNF.alpha. IL8 I-34 C C I-40 C C I-42 A A I-43 B B I-44 B C I-51 B
B I-57 A A I-65 B C I-67 B A I-68 B A I-71 B C I-73 C C I-77 C B
I-79 C B I-83 B NA I-85 B B I-86 C NA I-87 A A I-88 C C I-90 C NA
I-92 A A I-93 C C I-94 D NA I-100 C C I-105 B A I-106 B B I-108 C
NA I-109 B NA I-110 B A I-120 A A I-128 C B I-135 B B I-136 B A
I-137 B B I-142 A A I-144 A A I-149 C C I-168 D D I-188 B A I-194 D
C I-204 B C I-206 NA D I-207 C C I-214 A A I-215 B C I-217 A A
I-220 A A I-222 D D I-224 A A I-228 A A I-229 A B I-230 D D I-231 C
D I-233 A A I-235 A A
Example 261
In Vivo LPS-Induced Model of Cytokine Production
[1934] Compounds of the present invention were also evaluated in
rats in an in vivo efficacy model for inhibiting LPS-mediated
cytokine production. An exemplary protocol for this assay in
follows.
[1935] Drug to be tested was formulated in 10% HP-13-CD in saline
for i.p. injection. Male Wistar rats (180-220 g) were divided into
8 groups; every group except naive group had 10 rats at random as
follows, and the rats in all group (group A to H) were fasted
overnight.
TABLE-US-00007 Group number treatment Measurement A) Naive 5
Vehicle I.P. + 30 min later PBS i.v. + 1 h later Rat TNF-.alpha.
blood + 1 h later blood B) Model 10 Vehicle I.P. + 30 min later LPS
i.v. + 1 h later Rat TNF-.alpha. blood + 1 h later blood C)
dexamethasone 10 5 mg/kg dexamethasone I.P. + 30 min later Rat
TNF-.alpha. LPS i.v. + 1 h later blood + 1 h later blood D) 1 mg/kg
drug 10 1 mg/kg drug I.P. + 30 min later LPS i.v. + 1 h Rat
TNF-.alpha. later blood + 1 h later blood E) 3 mg/kg drug 10 3
mg/kg drug I.P. + 30 min later LPS i.v. + 1 h Rat TNF-.alpha. later
blood + 1 h later blood F) 10 mg/kg drug 10 10 mg/kg drug I.P. + 30
min later LPS i.v. + 1 h Rat TNF-.alpha. later blood + 1 h later
blood G) 30 mg/kg drug 10 30 mg/kg drug I.P. + 30 min later LPS
i.v. + 1 h Rat TNF-.alpha. later blood + 1 h later blood H) 100
mg/kg drug 10 100 mg/kg drug I.P. + 30 min later LPS i.v. + Rat
TNF-.alpha. 1 h later blood + 1 h later blood
[1936] Vehicle or drug were dosed i.p. 30 min prior to LPS/PBS
challenge. LPS or PBS was injected intravenously through the tail
vein as indicated. 1-2 mL of blood were collected at 1 h and 2 h
post LPS challenge by retro-orbital puncture by using 5 mL tube
coated with heparin saline (5 Uml/l). Collected plasma and freezed
it at -80.degree. C. until TNF-.alpha. is analyzed by ELISA. LC/MS
bioanalysis for drug exposure was performed for a total of 150
samples for each assay.
Example 262
In Vitro LPS/R848/CpG-Induced Cytokine Production Assays in hPBMC
or Whole Blood
[1937] Compounds of the present invention were also studied in in
vitro LPS/R848/CpG-induced cytokine production assays. Exemplary
protocols follow.
[1938] Whole Blood (LPS): 13 mL of whole blood solution was
prepared by combining whole blood in no serum medium with a ratio
of 1:1. Cells were seeded in a 96-well plate with 130 ul/well of
the cell suspension according to the plate map. 9 ul of 30 mM
compound solution was added into the wells in the assigned rows,
then serial solutions with 4.times. dilutions were made. That is,
add 9 uL of 100% DMSO into each of the rest wells and take 3 uL of
compound solution from the one-step higher concentration solution
and mix well with the DMSO. For the second compound master plate,
196 uL of the growth medium (no serum media) were added into each
of the wells and 4 uL of the compound solution from the first
compound master plate was added and mixed with the media. Cells
were treated for 0.5 h by adding 20 uL of the compound and the
control solutions prepared in the second master plate to each well
according to the plate map. Cells were stimulateds with a) 0.1
ug/mL of LPS overnight for whole blood assay; b) 0.01 ug/mL of LPS
overnight for PBMC assay. Plates were sealed with sealing films and
the plates were centrifuged at 3000 rpm at 4 degrees C. for 5 min.
The supernatants were transferred, and 100 ul of working Capture
antibody solution was added to each well. The plates were sealed
and incubated overnight at RT. IL-6, IFN-.alpha. or TNF-.alpha.
detection antibody labeled with biotin: Added 100 uL of the
Detection Antibody solution to each well. Covered the plate and
incubated for 2 h at RT. Added 100 uL of Streptavidin-HRP solution
to each well. Covered the plate and incubate for 20 min at RT in
dark. Added 100 uL of Substrate Solution to each well. Incubated
for 20 min at RT in dark. Added 50 uL of Stop Solution to each
well. Gently tapped the plate to ensure thorough mixing. Determined
the optical density of each well immediately, using a microplate
reader set to 450 nm and also read at 540 nm or 570 nm for
correction if wavelength correction is not available.
[1939] For R848-induced or CpG-induced assays, the same procedure
as above was followed except that 1 uM R848 for 20 h for
TNF-.alpha. production, and for 5 hr for INF-.alpha. production in
whole blood; 1 uM R848 for 5 h for PBMC cytokine production; or 0.5
uM or 0.1 uM CpG or 1 ng/mL IL-1.beta. overnight for PBMC cytokine
production were used as indicated in Table 5, instead of LPS. Data
from the whole blood and hPBMC cytokine production assays is shown
in Tables 5a and 5b.
TABLE-US-00008 TABLE 5a Results of in vitro cytokine production
assays Compounds having an activity designated as "A" provided an
IC.sub.50 .ltoreq. 0.25 .mu.M; compounds having an activity
designated as "B" provided an IC.sub.50 of 0.25-0.5 .mu.M;
compounds having an activity designated as "C" provided an
IC.sub.50 of 0.5-1.0 .mu.M; and compounds having an activity
designated as "D" provided an IC.sub.50 .gtoreq. 1.0 .mu.M. Stimu-
Test Compound Cells lant Conc. Cytokine I-67 I-92 I-73 I-85 I-105
I-79 Whole LPS 0.1 ug/mL TNF-.alpha. C D D D D Blood IL-6 A A ND ND
ND D R848 1 uM TNF-.alpha. C C ND ND ND ND IFN-.alpha. D C ND ND ND
ND hPBMC LPS 0.01 ug/mL TNF-.alpha. B A ND ND ND D IL-6 A A ND ND
ND D R848 1 uM TNF-.alpha. C A ND ND ND ND CpG 0.5 uM TNF-.alpha. B
A ND ND ND ND 0.1 uM IFN-.alpha. C B ND ND ND ND IL-1.beta. 1 ng/mL
IL-6 B A ND ND ND ND
TABLE-US-00009 TABLE 5b Results of in vitro cytokine production
assays continued Stimu- Test Compound Cells lant Conc. Cytokine
I-220 I-224 I-233 I-235 Whole LPS 0.1 ug/mL TNF-.alpha. D D D D
Blood R848 1 uM TNF-.alpha. D D D D IFN-.alpha. D D D D
Certain compounds of the invention inhibit .about.50% of the LPS
induced TNF production in vivo, at average drug concentrations
greater than 2 uM and higher.
Example 263
In Vitro Inhibition of Tumor Cell Proliferation Assays
[1940] Compounds of the present invention were also studied in in
vitro tumor cell proliferation inhibition assays. Exemplary
protocols were taken from Ngo et al. "Oncogenically active MYD88
mutations in human lymphoma" Nature (2011) vol. 470, 115-121, the
entirety of which is incorporated herein by reference. The
exemplary assay protocols follow.
[1941] Cell lines were cultured in RPMI 1640 medium supplemented
with penicillin/streptomycin and 10% fetal bovine serum or, for the
OCI series of cell lines, Iscove's medium with 20% fresh human
plasma. Cells were maintained in a humidified, 5% CO2 incubator at
37 uC. All cell lines were engineered to express an ecotropic
retroviral receptor and the bacterial tetracycline repressor.
[1942] DLBCL cell lines (GCB DLBCL: HT, OCI-LY8, OCI-LY19; ABC
DLBCL: HLY1, HBL1, TMD8, OCI-LY3, OCI-LY10, U2932, SUDHL2, DLBCL2)
were plated in duplicate at a density of 50,000 cells per well in
96-well plates along with DMSO as negative control, or different
concentrations of each compound of the invention. Cell viability at
1, 2 and 3 days after drug treatment was assayed by adding
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulphophenyl-
)-2H-tetrazolium and an electron coupling reagent (phenazine
methosulphate; Promega), incubated for 3 h and measured by the
amount of 490 nm absorbance using a 96-well plate reader. The
presented data were derived from 3 days of drug treatment. The
assay was performed twice. Results of the cell proliferation assay
are shown in FIGS. 1A, 1B, 2, 3, 4, and 5.
Example 264
In Vitro Inhibition of NF.kappa.B Activity in ABC DLBCL Cells
[1943] Compounds of the present invention were also assayed for
their ability to inhibit NF.kappa.B activity. The protocol of Ngo,
et al. (supra) was followed. HBL1 cells retrovirally expressing
MYD88-GFP constructs were transduced with lentiviral particles
containing a NF-kB firefly luciferase reporter construct by
following the manufacturer's instructions (SA Biosciences). Firefly
luciferase activity was measured using the Dual-Luciferase Reporter
Assay System (Promega) following the manufacturer's instructions.
Luminescence from equivalent amounts of lysate was read in
triplicate on a Microtiter Plate Luminometer (Dyn-Ex Technologies).
All readings were normalized to the mean fluorescence intensity of
MYD88-GFP expression for each MYD88 mutant as determined by FACS
analysis on a FACScalibur flow cytometer (Becton Dickinson).
Results of the NF.kappa.B activity inhibition assay are depicted in
FIG. 6.
Example 265
Inhibition of I.kappa.B.alpha. Phosphorylation & Degradation in
ABC DLBCL Cells
[1944] Compounds of the present invention were also assayed to
determine their ability to inhibit phosphorylation and degradation
of I.kappa.B.alpha.. An exemplary procedure follows. ABC DLBCL
(HBL1) cells were treated with 10 uM compounds of the invention for
3 hours, and cell lysates were separated by gel electrophoresis,
then subjected to Western blotting on nitrocellulose to determine
the degree of phosphorylation of I.kappa.B.alpha.. Results of this
assay are depicted in FIG. 7.
Example 266
Sensitization of ABC DLBCL and GCB DLBCL Cells to IRAK
Anti-Proliferative Effects Following BTK Knockdown
[1945] Compounds of the present invention were also assayed to
determine their ability to synergistically inhibit cell
proliferation in BTK knockdown cells. ABC DLBCL (HBL1, TMD8,
OCI-Ly10) and GCB DLBCL (OCI-Ly19, BJAB) cell lines were subjected
to a BTK shRNA knockdown per the procedure of Ngo, et al. (supra).
Following selection of transformed cells induction and regrowth,
each cell line was then treated with a 5 uM concentration of a
compound of the invention. The percentage of viable GFP+ cells was
plotted against the number of days post-shRNA induction to
determine the degree of synergistic effect of BTK knockdown and
IRAK inhibition present in each cell line. The results of the BTK
knockdown experiments are depicted in FIGS. 8, 9, and 10.
Example 267
In Vivo Murine IMQ-Induced Psoriasis Model
[1946] Compounds of the present invention were also evaluated in
mice in an in vivo efficacy model for inhibiting Imiquimod-induced
psoriasis. An exemplary protocol for this assay follows.
[1947] Psoriasis was induced in Balb/c mice by application of
imiquimod (IMQ). Dosing began on day 0 following IMQ application,
with the mice receiving an intraperitoneal injection of either I-67
or I-92 twice a day at the doses indicated in FIG. 11. The animals
were scored for clinical symptoms on day 1, and days 5 to 10.
[1948] IRAK4 inhibitors are efficacious in the Balb/c mouse model
of IMQ-induced psoriasis. Results of the study are presented in
FIG. 11, in which the degree of skin scaling is shown in
photographs of representative mice. IRAK4 inhibition helps to
resolve psoriatic skin with an efficaciousness comparable to
dexamethasone (`Dex` in FIG. 11). FIG. 12 presents the averages of
clinical scores for days 5, 8 and 10.
Example 268
In Vivo Murine Air Pouch Model of Human Gout
[1949] Compounds of the present invention were also evaluated in
mice in an in vivo efficacy model for inhibiting monosodium urate
(MSU) induced model of gout. An exemplary protocol for this assay
follows.
[1950] A sterile air pouch was created in Balb/c mice. I-67 was
administered orally to the mice twice a day for six days at doses
of either 10, 30 or 100 mg/kg. Following the last dose the mice
were anesthetized and the air pouch was injected with a suspension
of monosodium urate (MSU) to induce the inflammatory response. Four
hours after the injection the air pouch exudate was collected and
the number of white blood cells was measured.
[1951] An IRAK4 inhibitor is efficacious in the Balb/c mouse model
of MSU-induced gout. Results of the study are presented in FIG. 13,
which shows the distribution of white blood cell counts for mice
dosed with I-67 as described above.
Example 269
In Vivo Murine Collagen-Induced Arthritis Model
[1952] Compounds of the present invention were also evaluated in
mice in an in vivo efficacy model for inhibiting IRAK4-mediated
arthritis. An exemplary protocol for this assay follows.
[1953] Male DBA mice were immunized with collagen on day 0 and day
21 and randomly enrolled into groups upon onset of disease. The
groups consisted of a naive control group, a vehicle control group,
a group injected intraperitoneally with dexamethasone at 0.1 mg/kg
twice a day, a group injected intraperitoneally with I-92 at 30
mg/kg twice a day, a group injected intraperitoneally with I-67 at
30 mg/kg twice a day and two groups dosed orally with I-67 at 30
mg/kg, one once day and the other twice a day. Eight mice were
enrolled per group with the exception of the naive control group,
which contained four mice. Day 1 was designated as the first
treatment day, and mice were evaluated daily for clinical scores
until day 11. The mice were weighed on alternating days.
[1954] IRAK4 inhibitors are efficacious in the DBA mouse model of
collagen-induced arthritis. Results of the study are presented in
FIG. 14A-B. FIG. 14A presents the average clinical scores of the
groups dosed intraperitoneally. The left panels show the average
clinical scores for each group of mice up to day 11. The middle
panels show the average clinical scores calculated as the area
under the curve, and % inhibition relative to the vehicle is
indicated in the bar graph. The right panels show the average body
weight changes from day 1 to day 11. The clinical scores indicate
that I-67 and I-92 are efficacious compared to the vehicle. The
vehicle is an aqueous solution containing 10% HP.beta.CD. FIG. 14B
presents the average clinical scores of the groups dosed orally
with I-67. I-67 dosed orally twice a day was found to be
efficacious compared to the vehicle. The vehicle is 0.5%
methylcellulose in saline solution, and the dexamethasone and naive
control groups are the same as in A. All groups shown are part of
the same study.
Example 270
MyD88-L265P-Induced Phosphorylation Assay
[1955] Compounds of the present invention were also evaluated in
HBL1 cells for inhibition of MyD88-L265P-IRAK4-association-mediated
phosphorylation of IRAK1, and downstream signaling to TAK1,
i.kappa.b.alpha. and p38. A western blot indicating the degree of
phosphorylation of IRAK1, TAK1, i.kappa.b.alpha. and p38 in the
absence and presence of I-67 and I-92 was obtained using the method
described in Staudt et al. "Exploiting Synthetic Lethality for the
Therapy of ABC Diffuse Large B Cell Lymphoma," Cancer Cell 2012,
21: 723-737
[1956] Results of the study are presented in FIG. 15. IRAK4
inhibitors abrogate MyD88-L265P-induced IRAK1, TAK1,
i.kappa.b.alpha. and p38 phosphorylation.
Example 271
NF-.kappa..beta. Activity Inhibition Assay
[1957] Compounds of the present invention were also evaluated in
ABC DLBCL cell lines for inhibition of NF-.kappa..beta. activity.
An NF-.kappa..beta.-responsive luciferase reporter assay was used
following the method described and disclosed in Staudt et al.
(2012) and in Ngo et al. "Oncogenically active MYD88 mutations in
human lymphoma," Nature 2011, 470 (7332): 115-9, each of which is
herein incorporated by reference in its entirety. ABC DLBCL and GCB
DLBCL cell lines were created with an NF-.kappa..beta.
transcriptional reporter by transduction with lentiviral particles
containing an inducible NF-.kappa..beta.-responsive luciferase
reporter construct following the method of Staudt et al. (2012) and
Ngo et al. (2011). The readout of the results was measured as
luciferase activity.
[1958] Results of the study are presented in FIG. 16. IRAK4
inhibitors suppress NF-.kappa..beta. activity in Myd88L265P mut
HBL1, TMD8, OCI-Ly3, OCI-Ly10 and to a lesser extent Myd88WT U2932
ABC DLBCL cell lines. There was little to no effect of IRAK4
inhibition on GCB DLBCL cell lines.
Example 272
Cytokine Secretion Assay
[1959] Compounds of the present invention were also evaluated in
ABC DLBCL cell lines for inhibition of pro-inflammatory cytokine
secretion. IL-6- and IL-10-responsive ELISA assays were used
following the method described and disclosed in Ngo et al. (2011).
Cells transduced with inducible shRNAs were placed in medium
containing doxycycline and the concentrations of IL-6 and IL-10
were measured by ELISA, following the method of Ngo et al. (2011).
Alternatively, unmanipulated lymphoma cells were placed into fresh
media with the addition of I-67 or I-92 and assessed for cytokines
as above.
[1960] Results of the study are presented in FIG. 17. IRAK4
inhibitors suppress secretion of IL-6 HBL1, OCI-Ly3 and TMD8 ABC
DLBCL cell lines; and IL-10 in HBL1, OCI-Ly10 and TMD8 ABC DLBCL
cell lines.
Example 273
In Vivo Murine Tumor Model of Human ABC DLBCL Lymphoma
[1961] Compounds of the present invention were also evaluated in a
xenograft tumor model of human ABC DLBCL lymphoma first described
and disclosed in Staudt et al. (2012). The tumor was established by
subcutaneous injection of OCI-Ly10 cells into immunodeficient
(NOD/SCID) mice. Therapy was started with I-92 once tumors reached
200 mm.sup.3. Tumor growth was monitored by measuring tumor size in
two orthogonal directions. The tumor volume was calculated by using
the formula (1/2)(long dimension).times.(short
dimension).sup.2.
[1962] Results of the in vivo murine tumor model study are
presented in FIGS. 18A-B. Compound I-92 reduces ABC lymphoma growth
in the xenograft tumor model and is well tolerated by the
animals.
Example 274
Cell Viability Assay
[1963] Compounds of the present invention were also evaluated in a
cell viability assay. ABC DLBCL cell lines were treated with
ibrutinib, I-67, I-92 or a combination of ibrutinib with either
I-67 or I-92 according to the method reported in Staudt et al.
(2012).
[1964] Results of the cell viability assay are presented in FIG.
19. Synergistic killing of ABC DLBCL cells was observed with
ibrutinib and IRAK4 inhibitors (I-67 or I-92), by targeting B cell
receptor and Myd88-mediated signaling.
[1965] While we have described a number of embodiments of this
invention, it is apparent that our basic examples may be altered to
provide other embodiments that utilize the compounds and methods of
this invention. Therefore, it will be appreciated that the scope of
this invention is to be defined by the appended claims rather than
by the specific embodiments that have been represented by way of
example.
* * * * *